<!DOCTYPE html>
<html>
<head>
<title>Humira, INN-adalimumab;</title>
<meta http-equiv="X-UA-Compatible" content="IE=edge">
</head>
<body>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:301pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:282pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">ANNEX I</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:184pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">SUMMARY OF PRODUCT CHARACTERISTICS</span></b></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:301pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">1.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 20 mg solution for injection in pre-filled syringe</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">2.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each 0.2 ml single dose pre-filled syringe contains 20 mg of adalimumab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary cells.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For the full list of excipients, see section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">3.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL FORM </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Solution for injection. (injection)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clear, colourless solution. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CLINICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Therapeutic indications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Juvenile idiopathic arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Polyarticular juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira in combination with methotrexate is indicated for the treatment of active polyarticular juvenile </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more disease-modifying anti-rheumatic drugs (DMARDs). Humira can be given as monotherapy in case </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">efficacy in monotherapy see section 5.1). Humira has not been studied in patients aged less than 2 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Enthesitis-related arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric plaque psoriasis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and phototherapies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric Crohn&apos;s disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of moderately to severely active Crohn&apos;s disease in paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (from 6 years of age) who have had an inadequate response to conventional therapy including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have contraindications for such therapies.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:301pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric Uveitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">whom conventional therapy is inappropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Posology and method of administration  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treatment should be initiated and supervised by specialist physicians experienced in the diagnosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and treatment of conditions for which Humira is indicated. Ophthalmologists are advised to consult with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">an appropriate specialist before initiation of treatment with Humira (see section 4.4). Patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira should be given the Patient Reminder Card.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After proper training in injection technique, patients may self-inject with Humira if their physician </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">determines that it is appropriate and with medical follow-up as necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During treatment with Humira, other concomitant therapies (e.g., corticosteroids and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunomodulatory agents) should be optimised.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Posology</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Polyarticular juvenile idiopathic arthritis from 2 years of age</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for patients with polyarticular juvenile idiopathic arthritis from 2 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of age is based on body weight (Table 1). Humira is administered every other week via subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:112pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 1. Humira Dose for Patients with Polyarticular Juvenile Idiopathic Arthritis </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dosing Regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:185pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 kg to &lt; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Available data suggest that clinical response is usually achieved within 12 weeks of treatment. Continued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy should be carefully reconsidered in a patient not responding within this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in patients aged less than 2 years for this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Enthesitis-related arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for patients with enthesitis-related arthritis from 6 years of age is based </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">on body weight (Table 2). Humira is administered every other week via subcutaneous injection.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:301pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:147pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 2. Humira Dose for Patients with Enthesitis-Related Arthritis </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dosing Regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:185pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15 kg to &lt; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has not been studied in patients with enthesitis-related arthritis aged less than 6 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended Humira dose for patients with plaque psoriasis from 4 to 17 years of age is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body weight (Table 3). Humira is administered via subcutaneous injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:148pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 3. Humira Dose for Paediatric Patients with Plaque Psoriasis </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dosing Regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:185pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15 kg to &lt; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Initial dose of 20 mg, followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg given every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:318pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting one week after the initial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:367pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Initial dose of 40 mg, followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg given every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:318pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting one week after the initial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy beyond 16 weeks should be carefully considered in a patient not responding within this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If retreatment with Humira is indicated, the above guidance on dose and treatment duration should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">followed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety of Humira in paediatric patients with plaque psoriasis has been assessed for a mean of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 4 years for this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric Crohn&apos;s disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for patients with Crohn&#x2019;s disease from 6 to 17 years of age is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body weight (Table 4). Humira is administered via subcutaneous injection.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:301pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 4. Humira Dose for Paediatric Patients with Crohn&#x2019;s disease</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:78pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:78pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:254pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Induction Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:471pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maintenance </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:490pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:476pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Starting at</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:484pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:78pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:126pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 40 mg at week 0 and 20 mg at week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In case there is a need for a more rapid response to therapy with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">awareness that the risk for adverse events may be higher with use of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher induction dose, the following dose may be used:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:126pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 80 mg at week 0 and 40 mg at week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:474pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:478pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:78pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:126pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 80 mg at week 0 and 40 mg at week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In case there is a need for a more rapid response to therapy with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">awareness that the risk for adverse events may be higher with use of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher induction dose, the following dose may be used:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:126pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 160 mg at week 0 and 80 mg at week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:475pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:478pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who experience insufficient response may benefit from an increase in dosage:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg: 20 mg every week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 40 kg: 40 mg every week or 80 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy should be carefully considered in a subject not responding by week 12.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 6 years for this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric Uveitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for paediatric patients with uveitis from 2 years of age is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body weight (Table 5). Humira is administered via subcutaneous injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In paediatric uveitis, there is no experience in the treatment with Humira without concomitant treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:170pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 5. Humira Dose for Paediatric Patients with Uveitis</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dosing Regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:332pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg every other week in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:322pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination with methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:332pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:647pt;left:322pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination with methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">When Humira therapy is initiated, a loading dose of 40 mg for patients &lt; 30 kg or 80 mg for patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 30 kg may be administered one week prior to the start of maintenance therapy. No clinical data are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">available on the use of a Humira loading dose in children &lt; 6 years of age (see section 5.2).</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:301pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 2 years in this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">It is recommended that the benefit and risk of continued long-term treatment should be evaluated on a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">yearly basis (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal and/or hepatic impairment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has not been studied in these patient populations. No dose recommendations can be made.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Method of administration</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is administered by subcutaneous injection. Full instructions for use are provided in the package </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">leaflet.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is available in other strengths and presentations.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Contraindications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Active tuberculosis or other severe infections such as sepsis and opportunistic infections (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Moderate to severe heart failure (NYHA class III/IV) (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special warnings and precautions for use</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Traceability</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In order to improve traceability of biological medicinal products, the name and the batch number of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered product should be clearly recorded.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Infections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients taking TNF -antagonists are more susceptible to serious infections. Impaired lung function may </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increase the risk for developing infections. Patients must therefore be monitored closely for infections, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">including tuberculosis, before, during and after treatment with Humira. Because the elimination of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab may take up to four months, monitoring should be continued throughout this period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Humira should not be initiated in patients with active infections including chronic or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">localised infections until infections are controlled. In patients who have been exposed to tuberculosis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who have travelled in areas of high risk of tuberculosis or endemic mycoses, such as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">histoplasmosis, coccidioidomycosis, or blastomycosis, the risk and benefits of treatment with Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be considered prior to initiating therapy (see </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Other opportunistic infections</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who develop a new infection while undergoing treatment with Humira should be monitored </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">closely and undergo a complete diagnostic evaluation. Administration of Humira should be discontinued if </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a patient develops a new serious infection or sepsis and appropriate antimicrobial or antifungal therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be initiated until the infection is controlled. Physicians should exercise caution when considering </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the use of Humira in patients with a history of recurring infection or with underlying conditions which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">may predispose patients to infections, including the use of concomitant immunosuppressive medications.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:301pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Serious infections</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious infections, including sepsis, due to bacterial, mycobacterial, invasive fungal, parasitic, viral, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other opportunistic infections such as listeriosis, legionellosis and pneumocystis have been reported in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients receiving Humira.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Other serious infections seen in clinical trials include pneumonia, pyelonephritis, septic arthritis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">septicaemia. Hospitalisation or fatal outcomes associated with infections have been reported. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Tuberculosis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tuberculosis, including reactivation and new onset of tuberculosis, has been reported in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira. Reports included cases of pulmonary and extra-pulmonary (i.e. disseminated) tuberculosis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Before initiation of therapy with Humira, all patients must be evaluated for both active or inactive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&#x201c;latent&#x201d;) tuberculosis infection. This evaluation should include a detailed medical assessment of patient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">history of tuberculosis or possible previous exposure to people with active tuberculosis and previous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and/or current immunosuppressive therapy. Appropriate screening tests (i.e. tuberculin skin test and chest </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">X-ray) should be performed in all patients (local recommendations may apply). It is recommended that the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conduct and results of these tests are recorded in the Patient Reminder Card. Prescribers are reminded of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the risk of false negative tuberculin skin test results, especially in patients who are severely ill or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunocompromised. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If active tuberculosis is diagnosed, Humira therapy must not be initiated (see section 4.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In all situations described below, the benefit/risk balance of therapy should be very carefully considered.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">consulted.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosis prophylaxis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment before the initiation of Humira and in accordance with local recommendations. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Use of anti-tuberculosis prophylaxis treatment should also be considered before the initiation of Humira in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with several or significant risk factors for tuberculosis despite a negative test for tuberculosis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cannot be confirmed.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have occurred in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with Humira. Some patients who have been successfully treated for active tuberculosis have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">redeveloped tuberculosis while being treated with Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients should be instructed to seek medical advice if signs/symptoms suggestive of a tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infection (e.g., persistent cough, wasting/weight loss, low grade fever, listlessness) occur during or after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy with Humira. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Other opportunistic infections</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Opportunistic infections, including invasive fungal infections have been observed in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira. These infections have not consistently been recognised in patients taking TNF-antagonists and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">this has resulted in delays in appropriate treatment, sometimes resulting in fatal outcomes. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:301pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">8</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dyspnoea, and/or pulmonary infiltrates or other serious systemic illness with or without concomitant shock </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">an invasive fungal infection should be suspected and administration of Humira should be promptly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">discontinued. Diagnosis and administration of empiric antifungal therapy in these patients should be made </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in consultation with a physician with expertise in the care of patients with invasive fungal infections. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatitis B reactivation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reactivation of hepatitis B has occurred in patients receiving a TNF-antagonist including Humira, who are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chronic carriers of this virus (i.e. surface antigen positive). Some cases have had a fatal outcome. Patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be tested for HBV infection before initiating treatment with Humira. For patients who test positive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for hepatitis B infection, consultation with a physician with expertise in the treatment of hepatitis B is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recommended.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Carriers of HBV who require treatment with Humira should be closely monitored for signs and symptoms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of active HBV infection throughout therapy and for several months following termination of therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adequate data from treating patients who are carriers of HBV with anti-viral therapy in conjunction with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonist therapy to prevent HBV reactivation are not available. In patients who develop HBV </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactivation, Humira should be stopped and effective anti-viral therapy with appropriate supportive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment should be initiated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neurological events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonists including Humira have been associated in rare instances with new onset or exacerbation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">including multiple sclerosis and optic neuritis, and peripheral demyelinating disease, including Guillain-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Barr&#xe9; syndrome. Prescribers should exercise caution in considering the use of Humira in patients with pre-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">existing or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira should be considered if any of these disorders develop. There is a known association between </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intermediate uveitis and central demyelinating disorders. Neurologic evaluation should be performed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with non-infectious intermediate uveitis prior to the initiation of Humira therapy and regularly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">during treatment to assess for pre-existing or developing central demyelinating disorders. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Allergic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious allergic reactions associated with Humira were rare during clinical trials. Non-serious allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactions associated with Humira were uncommon during clinical trials. Reports of serious allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactions including anaphylaxis have been received following Humira administration. If an anaphylactic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reaction or other serious allergic reaction occurs, administration of Humira should be discontinued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immediately and appropriate therapy initiated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immunosuppression</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a study of 64 patients with rheumatoid arthritis that were treated with Humira, there was no evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enumeration of effector T-, B-, NK-cells, monocyte/macrophages, and neutrophils.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the controlled portions of clinical trials of TNF-antagonists, more cases of malignancies including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lymphoma have been observed among patients receiving a TNF-antagonist compared with control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients. However, the occurrence was rare. In the post marketing setting, cases of leukaemia have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reported in patients treated with a TNF-antagonist. There is an increased background risk for lymphoma </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:301pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">which complicates the risk estimation. With the current knowledge, a possible risk for the development of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lymphomas, leukaemia, and other malignancies in patients treated with a TNF-antagonist cannot be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">excluded.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22 years of age) treated with TNF-antagonists (initiation of therapy &#x2264; 18 years of age), including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab in the post marketing setting. Approximately half the cases were lymphomas. The other cases </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">represented a variety of different malignancies and included rare malignancies usually associated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunosuppression. A risk for the development of malignancies in children and adolescents treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonists cannot be excluded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare postmarketing cases of hepatosplenic T-cell lymphoma have been identified in patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab. This rare type of T-cell lymphoma has a very aggressive disease course and is usually fatal. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Some of these hepatosplenic T-cell lymphomas with Humira have occurred in young adult patients on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant treatment with azathioprine or 6-mercaptopurine used for inflammatory bowel disease. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">potential risk with the combination of azathioprine or 6-mercaptopurine and Humira should be carefully </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered. A risk for the development of hepatosplenic T-cell lymphoma in patients treated with Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cannot be excluded (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No studies have been conducted that include patients with a history of malignancy or in whom treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Humira is continued following development of malignancy. Thus, additional caution should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exercised in considering Humira treatment of these patients (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis patients with a history of PUVA treatment should be examined for the presence of non-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">melanoma skin cancer prior to and during treatment with Humira. Melanoma and Merkel cell carcinoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have also been reported in patients treated with TNF-antagonists including adalimumab (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an exploratory clinical trial evaluating the use of another TNF-antagonist, infliximab, in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies, mostly in the lung </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or head and neck, were reported in infliximab-treated patients compared with control patients. All patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had a history of heavy smoking. Therefore, caution should be exercised when using any TNF-antagonist in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">COPD patients, as well as in patients with increased risk for malignancy due to heavy smoking.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">With current data it is not known if adalimumab treatment influences the risk for developing dysplasia or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">colon cancer. All patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis), or who had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular intervals before </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy and throughout their disease course. This evaluation should include colonoscopy and biopsies per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">local recommendations.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Haematologic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare reports of pancytopenia including aplastic anaemia have been reported with TNF-antagonists.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adverse events of the haematologic system, including medically significant cytopenia (e.g. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">thrombocytopenia, leukopenia) have been reported with Humira. All patients should be advised to seek </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">persistent fever, bruising, bleeding, pallor) while on Humira. Discontinuation of Humira therapy should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered in patients with confirmed significant haematologic abnormalities.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">10</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vaccinations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Similar antibody responses to the standard 23-valent pneumococcal vaccine and the influenza trivalent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">virus vaccination were observed in a study in 226 adult subjects with rheumatoid arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with adalimumab or placebo. No data are available on the secondary transmission of infection by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">live vaccines in patients receiving Humira.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">agreement with current immunisation guidelines prior to initiating Humira therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients on Humira may receive concurrent vaccinations, except for live vaccines. Administration of live </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vaccines (e.g., BCG vaccine) to infants exposed to adalimumab in utero is not recommended for 5 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">following the mother&#x2019;s last adalimumab injection during pregnancy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Congestive heart failure</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a clinical trial with another TNF-antagonist worsening congestive heart failure and increased mortality </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">due to congestive heart failure have been observed. Cases of worsening congestive heart failure have also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been reported in patients receiving Humira. Humira should be used with caution in patients with mild </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">heart failure (NYHA class I/II). Humira is contraindicated in moderate to severe heart failure (see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.3). Treatment with Humira must be discontinued in patients who develop new or worsening symptoms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of congestive heart failure.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Autoimmune processes</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Humira may result in the formation of autoimmune antibodies. The impact of long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment with Humira on the development of autoimmune diseases is unknown. If a patient develops </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms suggestive of a lupus-like syndrome following treatment with Humira and is positive for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies against double-stranded DNA, further treatment with Humira should not be given (see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent administration of biologic DMARDS or TNF-antagonists</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious infections were seen in clinical studies with concurrent use of anakinra and another </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonist, etanercept, with no added clinical benefit compared to etanercept alone. Because of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">nature of the adverse events seen with the combination of etanercept and anakinra therapy, similar </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">toxicities may also result from the combination of anakinra and other TNF-antagonists. Therefore, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination of adalimumab and anakinra is not recommended. (See section 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concomitant administration of adalimumab with other biologic DMARDS (e.g, anakinra and abatacept) or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other TNF-antagonists is not recommended based upon the possible increased risk for infections, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">including serious infections and other potential pharmacological interactions. (See section 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Surgery</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is limited safety experience of surgical procedures in patients treated with Humira. The long half-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">life of adalimumab should be taken into consideration if a surgical procedure is planned. A patient who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requires surgery while on Humira should be closely monitored for infections, and appropriate actions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be taken. There is limited safety experience in patients undergoing arthroplasty while receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">11</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Small bowel obstruction</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Failure to respond to treatment for Crohn&#x2019;s disease may indicate the presence of fixed fibrotic stricture </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">that may require surgical treatment. Available data suggest that Humira does not worsen or cause </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">strictures.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elderly</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The frequency of serious infections among Humira treated subjects over 65 years of age (3.7%) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher than for those under 65 years of age (1.5%). Some of those had a fatal outcome. Particular attention </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">regarding the risk for infection should be paid when treating the elderly.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">See Vaccinations above.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has been studied in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients taking Humira as monotherapy and those taking concomitant methotrexate. Antibody </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">formation was lower when Humira was given together with methotrexate in comparison with use as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy. Administration of Humira without methotrexate resulted in increased formation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies, increased clearance and reduced efficacy of adalimumab (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The combination of Humira and anakinra is not recommended (see section 4.4 &#x201c;Concurrent administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of biologic DMARDS or TNF-antagonists&#x201d;). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The combination of Humira and abatacept is not recommended (see section 4.4 &#x201c;Concurrent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration of biologic DMARDS or TNF-antagonists&#x201d;).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Fertility, pregnancy and lactation</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential should consider the use of adequate contraception to prevent pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and continue its use for at least five months after the last Humira treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pregnancy</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A large number (approximately 2100) of prospectively collected pregnancies exposed to adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">resulting in live birth with known outcomes, including more than 1500 exposed during the first trimester, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">does not indicate an increase in the rate of malformation in the newborn.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a prospective cohort registry, 257 women with rheumatoid arthritis (RA) or Crohn&#x2019;s disease (CD)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with adalimumab at least during the first trimester and 120 women with RA or CD not treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab were enrolled.  The primary endpoint was the birth prevalence of major birth defects. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rate of pregnancies ending with at least one live born infant with a major birth defect was 6/69 (8.7%) in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the adalimumab-treated women with RA and 5/74 (6.8%) in the untreated women with RA (unadjusted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">OR 1.31, 95% CI 0.38-4.52) and 16/152 (10.5%) in the adalimumab-treated women with CD and 3/32 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(9.4%) in the untreated women with CD (unadjusted OR 1.14, 95% CI 0.31-4.16). The adjusted OR </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(accounting for baseline differences) was 1.10 (95% CI 0.45-2.73) with RA and CD combined. There were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">no distinct differences between adalimumab-treated and untreated women for the secondary endpoints </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spontaneous abortions, minor birth defects, preterm delivery, birth size and serious or opportunistic </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections and no stillbirths or malignancies were reported. The interpretation of data may be impacted due </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to methodological limitations of the study, including small sample size and non-randomized design.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a developmental toxicity study conducted in monkeys, there was no indication of maternal toxicity, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">embryotoxicity or teratogenicity. Preclinical data on postnatal toxicity of adalimumab are not available </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(see section 5.3).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Due to its inhibition of TNF</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf061;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">, adalimumab administered during pregnancy could affect normal immune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responses in the newborn. Adalimumab should only be used during pregnancy if clearly needed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab may cross the placenta into the serum of infants born to women treated with adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">during pregnancy. Consequently, these infants may be at increased risk for infection. Administration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">live vaccines (e.g., BCG vaccine) to infants exposed to adalimumab in utero is not recommended for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5 months following the mother&#x2019;s last adalimumab injection during pregnancy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Breast-feeding</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Limited information from the published literature indicates that adalimumab is excreted in breast milk at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">very low concentrations with the presence of adalimumab in human milk at concentrations of 0.1% to 1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of the maternal serum level. Given orally, immunoglobulin G proteins undergo intestinal proteolysis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have poor bioavailability. No effects on the breastfed newborns/infants are anticipated. Consequently, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira can be used during breastfeeding.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fertility</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Preclinical data on fertility effects of adalimumab are not available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.7</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Effects on ability to drive and use machines </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may have a minor influence on the ability to drive and use machines. Vertigo and visual </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">impairment may occur following administration of Humira (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Undesirable effects</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Summary of the safety profile</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira was studied in 9,506 patients in pivotal controlled and open label trials for up to 60 months or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more. These trials included rheumatoid arthritis patients with short term and long standing disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis) as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">well as axial spondyloarthritis (ankylosing spondylitis and axial spondyloarthritis without radiographic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">evidence of AS), psoriatic arthritis, Crohn&#x2019;s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and uveitis patients. The pivotal controlled studies involved 6,089 patients receiving Humira and 3,801</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients receiving placebo or active comparator during the controlled period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The proportion of patients who discontinued treatment due to adverse events during the double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">controlled portion of pivotal studies was 5.9% for patients taking Humira and 5.4% for control treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The most commonly reported adverse reactions are infections (such as nasopharyngitis, upper respiratory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tract infection and sinusitis), injection site reactions (erythema, itching, haemorrhage, pain or swelling), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">headache and musculoskeletal pain.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">13</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious adverse reactions have been reported for Humira. TNF-antagonists, such as Humira affect the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immune system and their use may affect the body&#x2019;s defence against infection and cancer.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fatal and life-threatening infections (including sepsis, opportunistic infections and TB), HBV reactivation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and various malignancies (including leukaemia, lymphoma and HSTCL) have also been reported with use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious haematological, neurological and autoimmune reactions have also been reported. These include </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rare reports of pancytopenia, aplastic anaemia, central and peripheral demyelinating events and reports of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lupus, lupus-related conditions and Stevens-Johnson syndrome.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In general, the adverse events in paediatric patients were similar in frequency and type to those seen in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adult patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tabulated list of adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The following list of adverse reactions is based on experience from clinical trials and on postmarketing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experience and are displayed by system organ class and frequency in Table 6 below: very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1/10); common (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1/100 to &lt; 1/10); uncommon (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1/1,000 to &lt; 1/100); rare (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1/10,000 to &lt; 1/1,000); </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and not known (cannot be estimated from the available data). Within each frequency grouping, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">undesirable effects are presented in order of decreasing seriousness. The highest frequency seen among the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">various indications has been included. An asterisk (*) appears in the SOC column if further information is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">found elsewhere in sections 4.3, 4.4 and 4.8.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:288pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:259pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Undesirable Effects</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Infections and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infestations*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Respiratory tract infections (including lower and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">upper respiratory tract infection, pneumonia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sinusitis, pharyngitis, nasopharyngitis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pneumonia herpes viral)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Systemic infections (including sepsis, candidiasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and influenza),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intestinal infections (including gastroenteritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">viral),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">skin and soft tissue infections (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paronychia, cellulitis, impetigo, necrotising </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fasciitis and herpes zoster),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ear infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">oral infections (including herpes simplex, oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:621pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">herpes and tooth infections), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reproductive tract infections (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vulvovaginal mycotic infection), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">urinary tract infections (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pyelonephritis),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fungal infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joint infections</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">14</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neurological infections (including viral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">meningitis),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">opportunistic infections and tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(including coccidioidomycosis, histoplasmosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and mycobacterium avium complex infection), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bacterial infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">eye infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">diverticulitis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neoplasms benign, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">malignant and unspecified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(including cysts and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">polyps)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Skin cancer excluding melanoma (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">basal cell carcinoma and squamous cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">carcinoma),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">benign neoplasm</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Lymphoma**, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">solid organ neoplasm (including breast cancer, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lung neoplasm and thyroid neoplasm), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">melanoma**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Leukaemia</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:367pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatosplenic T-cell lymphoma</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Merkel cell carcinoma (neuroendocrine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">carcinoma of the skin)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Kaposi&#x2019;s sarcoma</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Blood and the lymphatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">system disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Leukopenia (including neutropenia and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">agranulocytosis), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anaemia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Leucocytosis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">thrombocytopenia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Idiopathic thrombocytopenic purpura</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pancytopenia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immune system disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypersensitivity,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:610pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">allergies (including seasonal allergy)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sarcoidosis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vasculitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Anaphylaxis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Metabolism and nutrition </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Lipids increased</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">15</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypokalaemia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">uric acid increased, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blood sodium abnormal,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hypocalcaemia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:164pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hyperglycaemia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:180pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hypophosphatemia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dehydration</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psychiatric disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mood alterations (including depression), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anxiety,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">insomnia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Nervous system disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Headache</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paraesthesias (including hypoesthesia),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">migraine,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">nerve root compression</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cerebrovascular accident</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tremor,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">neuropathy  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Multiple sclerosis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demyelinating disorders (e.g. optic neuritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Guillain-Barr&#xe9; syndrome)</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Eye disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Visual impairment,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conjunctivitis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blepharitis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">eye swelling</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Diplopia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ear and labyrinth </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vertigo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Deafness, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tinnitus</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cardiac disorders* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tachycardia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Myocardial infarction</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">16</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arrhythmia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">congestive heart failure</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:130pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:130pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cardiac arrest</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vascular disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypertension, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">flushing, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">haematoma</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Aortic aneurysm,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:231pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vascular arterial occlusion,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:244pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">thrombophlebitis   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Respiratory, thoracic and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mediastinal disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Asthma,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dyspnoea,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cough</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pulmonary embolism</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interstitial lung disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chronic obstructive pulmonary disease,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pneumonitis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pleural effusion</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pulmonary fibrosis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Gastrointestinal disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Abdominal pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">nausea and vomiting</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">GI haemorrhage, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dyspepsia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">gastroesophageal reflux disease,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sicca syndrome</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pancreatitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:559pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dysphagia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">face oedema</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Intestinal perforation</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepato-biliary disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elevated liver enzymes</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cholecystitis and cholelithiasis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hepatic steatosis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bilirubin increased</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatitis</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">17</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactivation of hepatitis B</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1) </span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:100pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoimmune hepatitis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:130pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:129pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Liver failure</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Skin and subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tissue disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rash (including exfoliative rash)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Worsening or new onset of psoriasis(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">palmoplantar pustular psoriasis)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">urticaria,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bruising (including purpura), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dermatitis (including eczema),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">onychoclasis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:266pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hyperhidrosis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">alopecia</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pruritus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Night sweats,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">scar</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erythema multiforme</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Stevens-Johnson syndrome</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">angioedema</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cutaneous vasculitis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:420pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lichenoid skin reaction</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Worsening of symptoms of dermatomyositis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Musculoskeletal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">connective tissue disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Musculoskeletal pain</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Muscle spasms (including blood creatine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">phosphokinase increased)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rhabdomyolysis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:571pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">systemic lupus erythematosus</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Lupus-like syndrome</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal and urinary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal impairment,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">haematuria</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Nocturia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reproductive system and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">breast disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erectile dysfunction</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">18</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">General disorders and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:98pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration site </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:111pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conditions*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Injection site reaction (including injection site </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:98pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">erythema)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Chest pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:140pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">oedema,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:151pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pyrexia</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:178pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:178pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Inflammation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Investigations*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Coagulation and bleeding disorders (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">activated partial thromboplastin time prolonged), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoantibody test positive (including double </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">stranded DNA antibody), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blood lactate dehydrogenase increased</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Weight increased</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Injury, poisoning and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">procedural complications</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Impaired healing</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">* further information is found elsewhere in sections 4.3, 4.4 and 4.8</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">** including open label extension studies</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> including spontaneous reporting data</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2)</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> The mean weight change from baseline for adalimumab ranged from 0.3 kg to 1.0 kg across adult </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">indications compared to (minus) -0.4 kg to 0.4 kg for placebo over a treatment period of 4-6 months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Weight increase of 5-6 kg has also been observed in long-term extension studies with mean exposures of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 1-2 years without control group, particularly in patients with Crohn&#x2019;s disease and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ulcerative colitis. The mechanism behind this effect is unclear but could be associated with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anti-inflammatory effect of adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uveitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety profile for patients with uveitis treated with Humira every other week was consistent with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">known safety profile of Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Description of selected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Injection site reactions</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the pivotal controlled trials in adults and children, 12.9% of patients treated with Humira developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection site reactions (erythema and/or itching, haemorrhage, pain or swelling), compared to 7.2% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients receiving placebo or active control. Injection site reactions generally did not necessitate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">discontinuation of the medicinal product.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Infections </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the pivotal controlled trials in adults and children, the rate of infection was 1.51 per patient year in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treated patients and 1.46 per patient year in the placebo and active control-treated patients. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections consisted primarily of nasopharyngitis, upper respiratory tract infection, and sinusitis. Most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients continued on Humira after the infection resolved.  </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">19</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The incidence of serious infections was 0.04 per patient year in Humira treated patients and 0.03 per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient year in placebo and active control &#x2212; treated patients.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled and open label adult and paediatric studies with Humira, serious infections (including fatal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections, which occurred rarely) have been reported, which include reports of tuberculosis (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extrapulmonary histoplasmosis, blastomycosis, coccidioidomycosis, pneumocystis, candidiasis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">aspergillosis and listeriosis). Most of the cases of tuberculosis occurred within the first eight months after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initiation of therapy and may reflect recrudescence of latent disease.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No malignancies were observed in 249 paediatric patients with an exposure of 655.6 patient years during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira trials in patients with juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enthesitis-related arthritis). In addition, no malignancies were observed in 192 paediatric patients with an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exposure of 498.1 patient years during Humira trials in paediatric patients with Crohn&#x2019;s disease. No </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">malignancies were observed in 77 paediatric patients with an exposure of 80.0 patient years during a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira trial in paediatric patients with chronic plaque psoriasis. No malignancies were observed in 60 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients with an exposure of 58.4 patient years during a Humira trial in paediatric patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">uveitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During the controlled portions of pivotal Humira trials in adults of at least 12 weeks in duration in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">without radiographic evidence of AS, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease, ulcerative colitis and uveitis, malignancies, other than lymphoma and non-melanoma skin cancer, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were observed at a rate (95% confidence interval) of 6.8 (4.4, 10.5) per 1,000 patient-years among 5,291</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treated patients </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a rate of 6.3 (3.4, 11.8) per 1,000 patient-years among 3,444 control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (median duration of treatment was 4.0 months for Humira and 3.8 months for control-treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients). The rate (95% confidence interval) of non-melanoma skin cancers was 8.8 (6.0, 13.0) per 1,000 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient-years among Humira-treated patients and 3.2 (1.3, 7.6) per 1,000 patient-years among control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients. Of these skin cancers, squamous cell carcinomas occurred at rates (95% confidence interval) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.7 (1.4, 5.4) per 1,000 patient-years among Humira-treated patients and 0.6 (0.1, 4.5) per 1,000 patient-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">years among control patients. The rate (95% confidence interval) of lymphomas was 0.7 (0.2, 2.7) per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1,000 patient-years among Humira-treated patients and 0.6 (0.1, 4.5) per 1,000 patient-years among </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">control patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">When combining controlled portions of these trials and ongoing and completed open label extension </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies with a median duration of approximately 3.3 years including 6,427 patients and over 26,439</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient-years of therapy, the observed rate of malignancies, other than lymphoma and non-melanoma skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cancers is approximately 8.5 per 1,000 patient years. The observed rate of non-melanoma skin cancers is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 9.6 per 1,000 patient years, and the observed rate of lymphomas is approximately 1.3 per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1,000 patient years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In post-marketing experience from January 2003 to December 2010, predominantly in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rheumatoid arthritis, the reported rate of malignancies is approximately 2.7 per 1,000 patient treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">years. The reported rates for non-melanoma skin cancers and lymphomas are approximately 0.2 and 0.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">per 1,000 patient treatment years, respectively (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare post-marketing cases of hepatosplenic T-cell lymphoma have been reported in patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Autoantibodies </span></i></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients had serum samples tested for autoantibodies at multiple time points in rheumatoid arthritis studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">I &#x2212; V. In these trials, 11.9% of patients treated with Humira and 8.1% of placebo and active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">control &#x2212; treated patients that had negative baseline anti-nuclear antibody titres reported positive titres at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24. Two patients out of 3,441 treated with Humira in all rheumatoid arthritis and psoriatic arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies developed clinical signs suggestive of new-onset lupus-like syndrome. The patients improved </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">following discontinuation of therapy. No patients developed lupus nephritis or central nervous system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Hepato-biliary events</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled Phase 3 trials of Humira in patients with rheumatoid arthritis and psoriatic arthritis with a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">control period duration ranging from 4 to 104 weeks, ALT elevations &#x2265; 3 x ULN occurred in 3.7% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira-treated patients and 1.6% of control-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled Phase 3 trials of Humira in patients with polyarticular juvenile idiopathic arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 to 17 years and enthesitis-related arthritis who were 6 to 17 years, ALT elevations &#x2265; 3 x ULN occurred </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in 6.1% of Humira-treated patients and 1.3% of control-treated patients. Most ALT elevations occurred </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with concomitant methotrexate use. No ALT elevations &#x2265; 3 x ULN occurred in the Phase 3 trial of Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients with polyarticular juvenile idiopathic arthritis who were 2 to &lt; 4 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled Phase 3 trials of Humira in patients with Crohn&#x2019;s disease and ulcerative colitis with a control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">period ranging from 4 to 52 weeks. ALT elevations &#x2265; 3 x ULN occurred in 0.9% of Humira-treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients and 0.9% of controlled-treated patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the Phase 3 trial of Humira in patients with paediatric Crohn&#x2019;s disease which evaluated efficacy and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">safety of two body weight adjusted maintenance dose regimens following body weight adjusted induction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy up to 52 weeks of treatment, ALT elevations &#x2265; 3 x ULN occurred in 2.6% (5/192) of patients of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">whom 4 were receiving concomitant immunosuppressants at baseline.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled Phase 3 trials of Humira in patients with plaque psoriasis with a control period duration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ranging from 12 to 24 weeks, ALT elevations &#x2265; 3 x ULN occurred in 1.8% of Humira-treated patients and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.8% of control-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No ALT elevations &#x2265; 3 x ULN occurred in the Phase 3 trial of Humira in paediatric patients with plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled trials of Humira (initial doses of 80 mg at Week 0 followed by 40 mg every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting at Week 1) in adult patients with uveitis up to 80 weeks with a median exposure of 166.5 days and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">105.0 days in Humira-treated and control-treated patients, respectively, ALT elevations &#x2265; 3 x ULN </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurred in 2.4% of Humira-treated patients and 2.4% of control-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Across all indications in clinical trials patients with raised ALT were asymptomatic and in most cases </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">elevations were transient and resolved on continued treatment. However, there have also been post-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">marketing reports of liver failure as well as less severe liver disorders that may precede liver failure, such </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as hepatitis including autoimmune hepatitis in patients receiving adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with azathioprine/6-mercaptopurine</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult Crohn&#x2019;s disease studies, higher incidences of malignant and serious infection-related adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">events were seen with the combination of Humira and azathioprine/6-mercaptopurine compared with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira alone.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">21</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting of suspected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">asked to report any suspected adverse reactions via the national reporting system listed in </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000ff">Appendix V.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Overdose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose-limiting toxicity was observed during clinical trials. The highest dose level evaluated has been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">multiple intravenous doses of 10 mg/kg, which is approximately 15 times the recommended dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacodynamic properties</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-&#x3b1;) inhibitors. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ATC code: L04AB04</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mechanism of action</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab binds specifically to TNF and neutralises the biological function of TNF by blocking its </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interaction with the p55 and p75 cell surface TNF receptors.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with an IC</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> of 0.1-0.2 nM). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharmacodynamic effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After treatment with Humira, a rapid decrease in levels of acute phase reactants of inflammation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and serum cytokines (IL-6) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed, compared to baseline in patients with rheumatoid arthritis. Serum levels of matrix </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">destruction were also decreased after Humira administration. Patients treated with Humira usually </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced improvement in haematological signs of chronic inflammation.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A rapid decrease in CRP levels was also observed in patients with polyarticular juvenile idiopathic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis, Crohn&#x2019;s disease, ulcerative colitis and hidradenitis suppurativa after treatment with Humira. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with Crohn&#x2019;s disease, a reduction of the number of cells expressing inflammatory markers in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">colon including a significant reduction of expression of TNF&#x3b1; was seen. Endoscopic studies in intestinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mucosa have shown evidence of mucosal healing in adalimumab treated patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical efficacy and safety</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adults with rheumatoid arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira was evaluated in over 3,000 patients in all rheumatoid arthritis clinical trials. The efficacy and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">safety of Humira were assessed in five randomised, double-blind and well-controlled studies. Some </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients were treated for up to 120 months duration. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study I evaluated 271 patients with moderately to severely active rheumatoid arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 years old, had failed therapy with at least one disease-modifying, anti rheumatic drug and had </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">22</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">insufficient efficacy with methotrexate at doses of 12.5 to 25 mg (10 mg if methotrexate-intolerant) every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">week and whose methotrexate dose remained constant at 10 to 25 mg every week. Doses of 20, 40 or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg of Humira or placebo were given every other week for 24 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study II evaluated 544 patients with moderately to severely active rheumatoid arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 years old and had failed therapy with at least one disease-modifying, anti-rheumatic drugs. Doses of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 or 40 mg of Humira were given by subcutaneous injection every other week with placebo on alternative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks or every week for 26 weeks; placebo was given every week for the same duration. No other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease-modifying anti-rheumatic drugs were allowed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study III evaluated 619 patients with moderately to severely active rheumatoid arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 years old, and who had an ineffective response to methotrexate at doses of 12.5 to 25 mg or have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been intolerant to 10 mg of methotrexate every week. There were three groups in this study. The first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received placebo injections every week for 52 weeks. The second received 20 mg of Humira every week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for 52 weeks. The third group received 40 mg of Humira every other week with placebo injections on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">alternate weeks. Upon completion of the first 52 weeks, 457 patients enrolled in an open-label extension </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">phase in which 40 mg of Humira/MTX was administered every other week up to 10 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study IV primarily assessed safety in 636 patients with moderately to severely active rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis who were </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 years old. Patients were permitted to be either disease-modifying, anti-rheumatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">drug-na&#xef;ve or to remain on their pre-existing rheumatologic therapy provided that therapy was stable for a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">minimum of 28 days. These therapies include methotrexate, leflunomide, hydroxychloroquine, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sulfasalazine and/or gold salts. Patients were randomised to 40 mg of Humira or placebo every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for 24 weeks.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study V evaluated 799 methotrexate-na&#xef;ve, adult patients with moderate to severely active early </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rheumatoid arthritis (mean disease duration less than 9 months). This study evaluated the efficacy of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg every other week/methotrexate combination therapy, Humira 40 mg every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and methotrexate monotherapy in reducing the signs and symptoms and rate of progression </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of joint damage in rheumatoid arthritis for 104 weeks. Upon completion of the first 104 weeks, 497 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients enrolled in an open-label extension phase in which 40 mg of Humira was administered every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week up to 10 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary end point in RA studies I, II and III and the secondary endpoint in RA study IV was the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">percent of patients who achieved an ACR 20 response at Week 24 or 26. The primary endpoint in RA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study V was the percent of patients who achieved an ACR 50 response at Week 52. RA studies III and V </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had an additional primary endpoint at 52 weeks of retardation of disease progression (as detected by X-ray </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">results). RA study III also had a primary endpoint of changes in quality of life. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">ACR response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The percent of Humira-treated patients achieving ACR 20, 50 and 70 responses was consistent across RA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies I, II and III. The results for the 40 mg every other week dose are summarised in Table 7. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">23</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 7</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:197pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">ACR Responses in Placebo-Controlled Trials</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:255pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(Percent of Patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:169pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA Study I</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:298pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA Study II</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:428pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA Study III</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:144pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:149pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:151pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=60</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:194pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">/ MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:218pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=63</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:287pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=110</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:346pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:350pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=113</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=200</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:460pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">/ MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=207</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:149pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:215pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:287pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">19.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:350pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">63.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:222pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:293pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:356pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:151pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:215pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:350pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:222pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:293pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:356pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:151pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:215pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:350pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:222pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:293pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:356pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> RA study I at 24 weeks, RA study II at 26 weeks , and RA study III at 24 and 52 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 40 mg Humira administered every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> MTX = methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**p &lt; 0.01, Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA studies I-IV, all individual components of the ACR response criteria (number of tender and swollen </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joints, physician and patient assessment of disease activity and pain, disability index (HAQ) scores and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">CRP (mg/dl) values) improved at 24 or 26 weeks compared to placebo. In RA study III, these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvements were maintained throughout 52 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension for RA study III, most patients who were ACR responders maintained </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response when followed for up to 10 years. Of 207 patients who were randomised to Humira 40 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week, 114 patients continued on Humira 40 mg every other week for 5 years. Among those, 86 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (75.4%) had ACR 20 responses; 72 patients (63.2%) had ACR 50 responses; and 41 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(36%) had ACR 70 responses. Of 207 patients, 81 patients continued on Humira 40 mg every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for 10 years. Among those, 64 patients (79.0%) had ACR 20 responses; 56 patients (69.1%) had ACR 50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responses; and 43 patients (53.1%) had ACR 70 responses.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study IV, the ACR 20 response of patients treated with Humira plus standard of care was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">statistically significantly better than patients treated with placebo plus standard of care (p &lt; 0.001).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA studies I-IV, Humira-treated patients achieved statistically significant ACR 20 and 50 responses </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared to placebo as early as one to two weeks after initiation of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study V with early rheumatoid arthritis patients who were methotrexate na&#xef;ve, combination therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Humira and methotrexate led to faster and significantly greater ACR responses than methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and Humira monotherapy at Week 52 and responses were sustained at Week 104 (see Table </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8).</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">24</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:288pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:233pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">ACR Responses in RA Study V</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:258pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(percent of patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:79pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:172pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:170pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n=257</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:232pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:236pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n=274</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:290pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira/MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:308pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n=268</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:371pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">p-value</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:427pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">p-value</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:487pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">p-value</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">c</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">62.6%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">54.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">72.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:377pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.013</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.043</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">56.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">69.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:377pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.002</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.140</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">61.6%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.317</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">42.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">27.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.656</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46.6%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.864</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:80pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a. p-value is from the pairwise comparison of methotrexate monotherapy and Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy using the Mann-Whitney U test.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:80pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b. p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy using the Mann-Whitney U test</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:80pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">c.   p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using the Mann-Whitney U test</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension for RA study V, ACR response rates were maintained when followed for up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 years. Of 542 patients who were randomised to Humira 40 mg every other week, 170 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued on Humira 40 mg every other week for 10 years. Among those, 154 patients (90.6%) had ACR </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 responses; 127 patients (74.7%) had ACR 50 responses; and 102 patients (60.0%) had ACR 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responses.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 52, 42.9% of patients who received Humira/methotrexate combination therapy achieved clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission (DAS28 (CRP) &lt; 2.6) compared to 20.6% of patients receiving methotrexate monotherapy and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.4% of patients receiving Humira monotherapy. Humira/methotrexate combination therapy was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinically and statistically superior to methotrexate (p &lt; 0.001) and Humira monotherapy (p &lt; 0.001) in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">achieving a low disease state in patients with recently diagnosed moderate to severe rheumatoid arthritis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The response for the two monotherapy arms was similar (p = 0.447). Of 342 subjects originally </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomized to Humira monotherapy or Humira/methotrexate combination therapy who entered the open-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">label extension study, 171 subjects completed 10 years of Humira treatment. Among those, 109 subjects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(63.7%) were reported to be in remission at 10 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Radiographic response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study III, where Humira treated patients had a mean duration of rheumatoid arthritis of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 11 years, structural joint damage was assessed radiographically and expressed as change in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">modified Total Sharp Score (TSS) and its components, the erosion score and joint space narrowing score. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira/methotrexate patients demonstrated significantly less radiographic progression than patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving methotrexate alone at 6 and 12 months (see Table 9).  </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">25</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension of RA Study III, the reduction in rate of progression of structural damage is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintained for 8 and 10 years in a subset of patients. At 8 years, 81 of 207 patients originally treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg Humira every other week were evaluated radiographically. Among those, 48 patients showed no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">progression of structural damage defined by a change from baseline in the mTSS of 0.5 or less. At </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 years, 79 of 207 patients originally treated with 40 mg Humira every other week were evaluated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">radiographically. Among those, 40 patients showed no progression of structural damage defined by a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">change from baseline in the mTSS of 0.5 or less.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:274pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:147pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Radiographic Mean Changes Over 12 Months in RA Study III</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:180pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo/</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:180pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:260pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira/MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:263pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:266pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:352pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo/MTX-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:342pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira/MTX (95% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:360pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:365pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Interval</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:458pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Sharp Score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:284pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:357pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.6 (1.4, 3.8) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:456pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:92pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erosion score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:284pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:357pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.6 (0.9, 2.2)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:457pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">JSN</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:284pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:357pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.9 (0.3, 1.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:459pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  0.002</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">95% confidence intervals for the differences in change scores between methotrexate and Humira. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Based on rank analysis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Joint Space Narrowing</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study V, structural joint damage was assessed radiographically and expressed as change in modified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Sharp Score (see Table 10).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:278pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:164pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  Radiographic Mean Changes at Week 52 in RA Study V</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:173pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=257</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(95% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:162pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:167pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interval)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:244pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:247pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=274</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:249pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(95% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:237pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:242pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interval)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:305pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira/MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=268</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(95% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:311pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:317pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interval)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:379pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:428pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:478pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:85pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Sharp </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:158pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.7 (4.2-7.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0 (1.7-4.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.3 (0.5-2.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0020</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:479pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erosion score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:158pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.7 (2.7-4.7)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.7 (1.0-2.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.8 (0.4-1.2)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0082</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:479pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:89pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">JSN score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:158pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.0 (1.2-2.8)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.3 (0.5-2.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:312pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.5 (0-1.0)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0037</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:484pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.151</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value is from the pairwise comparison of methotrexate monotherapy and Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy using the Mann-Whitney U test.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy using the Mann-Whitney U test </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using the Mann-Whitney U test</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following 52 weeks and 104 weeks of treatment, the percentage of patients without progression (change </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">from baseline in modified Total Sharp Score </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.5) was significantly higher with Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy (63.8% and 61.2% respectively) compared to methotrexate monotherapy (37.4% and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33.5% respectively, p &lt; 0.001) and Humira monotherapy (50.7%, p &lt; 0.002 and 44.5%, p &lt; 0.001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension of RA study V, the mean change from baseline at Year 10 in the modified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Sharp Score was 10.8, 9.2 and 3.9 in patients originally randomized to methotrexate monotherapy, </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">26</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira monotherapy and Humira/methotrexate combination therapy, respectively. The corresponding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">proportions of patients with no radiographic progression were 31.3%, 23.7% and 36.7% respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of life and physical function </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Health-related quality of life and physical function were assessed using the disability index of the Health </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Assessment Questionnaire (HAQ) in the four original adequate and well-controlled trials, which was a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pre-specified primary endpoint at Week 52 in RA study III. All doses/schedules of Humira in all four </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies showed statistically significantly greater improvement in the disability index of the HAQ from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">baseline to Month 6 compared to placebo and in RA study III the same was seen at Week 52. Results from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the Short Form Health Survey (SF 36) for all doses/schedules of Humira in all four studies support these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">findings, with statistically significant physical component summary (PCS) scores, as well as statistically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significant pain and vitality domain scores for the 40 mg every other week dose. A statistically significant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">decrease in fatigue as measured by functional assessment of chronic illness therapy (FACIT) scores was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">seen in all three studies in which it was assessed (RA studies I, III, IV).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study III, most subjects who achieved improvement in physical function and continued treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintained improvement through Week 520 (120 months) of open-label treatment. Improvement in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">quality of life was measured up to Week 156 (36 months) and improvement was maintained through that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">time.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study V, the improvement in the HAQ disability index and the physical component of the SF 36 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">showed greater improvement (p &lt; 0.001) for Humira/methotrexate combination therapy </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate monotherapy and Humira monotherapy at Week 52, which was maintained through </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 104. Among the 250 subjects who completed the open-label extension study, improvements in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">physical function were maintained through 10 years of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult plaque psoriasis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were studied in adult patients with chronic plaque psoriasis (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 10% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BSA involvement and PASI </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 12 or </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 10) who were candidates for systemic therapy or phototherapy in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised, double-blind studies. 73% of patients enrolled in Psoriasis Studies I and II had received prior </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">systemic therapy or phototherapy. The safety and efficacy of Humira were also studied in adult patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with moderate to severe chronic plaque psoriasis with concomitant hand and/or foot psoriasis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">candidates for systemic therapy in a randomised double-blind study (Psoriasis Study III).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Study I (REVEAL) evaluated 1,212 patients within three treatment periods. In period A, patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received placebo or Humira at an initial dose of 80 mg followed by 40 mg every other week starting one </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">week after the initial dose. After 16 weeks of therapy, patients who achieved at least a PASI 75 response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(PASI score improvement of at least 75% relative to baseline), entered period B and received open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg Humira every other week. Patients who maintained </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75 response at Week 33 and were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">originally randomised to active therapy in Period A, were re-randomised in period C to receive 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira every other week or placebo for an additional 19 weeks. Across all treatment groups, the mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">baseline PASI score was 18.9 and the baseline PGA score ranged from &#x201c;moderate&#x201d; (53% of subjects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">included) to &#x201c;severe&#x201d; (41%) to &#x201c;very severe&#x201d; (6%).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Study II (CHAMPION) compared the efficacy and safety of Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> methotrexate and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo in 271 patients. Patients received placebo, an initial dose of MTX 7.5 mg and thereafter dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increases up to Week 12, with a maximum dose of 25 mg or an initial dose of 80 mg Humira followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week (starting one week after the initial dose) for 16 weeks. There are no data available </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparing Humira and MTX beyond 16 weeks of therapy. Patients receiving MTX who achieved a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 50 response at Week 8 and/or 12 did not receive further dose increases. Across all treatment </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">27</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">groups, the mean baseline PASI score was 19.7 and the baseline PGA score ranged from &#x201c;mild&#x201d; (&lt;1%) to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x201c;moderate&#x201d; (48%) to &#x201c;severe&#x201d; (46%) to &#x201c;very severe&#x201d; (6%).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients participating in all Phase 2 and Phase 3 psoriasis studies were eligible to enrol into an open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension trial, where Humira was given for at least an additional 108 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Psoriasis Studies I and II, a primary endpoint was the proportion of patients who achieved a PASI 75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response from baseline at Week 16 (see Tables 11 and 12).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 11</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:180pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Ps Study I (REVEAL)  - Efficacy Results at 16 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:303pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:306pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=398</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:307pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:376pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:405pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=814</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    </span></b><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> PASI 75</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:304pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">26 (6.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">578 (70.9)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    PASI 100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 (0.8)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">163 (20.0)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    PGA: Clear/minimal</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:304pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17 (4.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">506 (62.2)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Percent of patients achieving PASI75 response was calculated as centre-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adjusted rate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p &lt; 0.001, Humira vs. Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 12</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:176pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Ps Study II (CHAMPION) Efficacy Results at 16 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:235pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:240pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=53</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:240pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:315pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:313pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=110</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:315pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:406pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=108</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:408pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:135pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    </span></b><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> PASI 75</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:233pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 (18.9)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39 (35.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">86 (79.6)</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a, b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:135pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    PASI 100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:238pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 (1.9)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:314pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8 (7.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18 (16.7)</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c, d</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:135pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    PGA: </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:135pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Clear/minimal</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 (11.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33 (30.0)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">79 (73.1)</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a, b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:135pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p &lt; 0.001 Humira vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:135pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p &lt; 0.001 Humira vs. methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:135pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p &lt; 0.01 Humira vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:135pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p &lt; 0.05 Humira vs. methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Psoriasis Study I, 28% of patients who were PASI 75 responders and were re-randomised to placebo at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 33 compared to 5% continuing on Humira, p &lt; 0.001, experienced &#x201c;loss of adequate response&#x201d;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(PASI score after Week 33 and on or before Week 52 that resulted in a &lt;PASI 50 response relative to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">baseline with a minimum of a 6-point increase in PASI score relative to Week 33). Of the patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lost adequate response after re-randomisation to placebo who then enrolled into the open-label extension </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trial, 38% (25/66) and 55% (36/66) regained PASI 75 response after 12 and 24 weeks of re-treatment, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A total of 233 PASI 75 responders at Week 16 and Week 33 received continuous Humira therapy for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52 weeks in Psoriasis Study I, and continued Humira in the open-label extension trial. PASI 75 and PGA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of clear or minimal response rates in these patients were 74.7% and 59.0%, respectively, after an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">additional 108 weeks of open-label therapy (total of 160 weeks). In an analysis in which all patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dropped out of the study for adverse events or lack of efficacy, or who dose-escalated, were considered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">non-responders, PASI 75 and PGA of clear or minimal response rates in these patients were 69.6% and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">55.7%, respectively, after an additional 108 weeks of open-label therapy (total of 160 weeks).</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">28</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A total of 347 stable responders participated in a withdrawal and retreatment evaluation in an open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension study. During the withdrawal period, symptoms of psoriasis returned over time with a median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">time to relapse (decline to PGA &#x201c;moderate&#x201d; or worse) of approximately 5 months. None of these patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced rebound during the withdrawal period. A total of 76.5% (218/285) of patients who entered the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">retreatment period had a response of PGA &#x201c;clear&#x201d; or &#x201c;minimal&#x201d; after 16 weeks of retreatment, irrespective </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of whether they relapsed during withdrawal (69.1%[123/178] and 88.8% [95/107] for patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">relapsed and who did not relapse during the withdrawal period, respectively). A similar safety profile was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed during retreatment as before withdrawal.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Significant improvements at Week 16 from baseline compared to placebo (Studies I and II) and MTX </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(Study II) were demonstrated in the DLQI (Dermatology Life Quality Index). In Study I, improvements in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the physical and mental component summary scores of the SF-36 were also significant compared to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an open-label extension study, for patients who dose escalated from 40 mg every other week to 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly due to a PASI response below 50%, 26.4% (92/349) and 37.8% (132/349) of patients achieved </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75 response at Week 12 and 24, respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Study III (REACH) compared the efficacy and safety of Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo in 72 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with moderate to severe chronic plaque psoriasis and hand and/or foot psoriasis. Patients received an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initial dose of 80 mg Humira followed by 40 mg every other week (starting one week after the initial dose) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or placebo for 16 weeks. At Week 16, a statistically significantly greater proportion of patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received Humira achieved PGA of &apos;clear&apos; or &apos;almost clear&apos; for the hands and/or feet compared to patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who received placebo (30.6% versus 4.3%, respectively [P = 0.014]).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Study IV compared efficacy and safety of Humira versus placebo in 217 adult patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">moderate to severe nail psoriasis. Patients received an initial dose of 80 mg Humira followed by 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every other week (starting one week after the initial dose) or placebo for 26 weeks followed by open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treatment for an additional 26 weeks. Nail psoriasis assessments included the Modified Nail </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Severity Index (mNAPSI), the Physician&#x2019;s Global Assessment of Fingernail Psoriasis (PGA-F)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and the Nail Psoriasis Severity Index (NAPSI) (see Table 13). Humira demonstrated a treatment benefit in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">nail psoriasis patients with different extents of skin involvement (BSA&#x2265;10% (60% of patients) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BSA&lt;10% and &#x2265;5% (40% of patients)).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 13</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:183pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Ps Study IV Efficacy Results at 16, 26 and 52 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Endpoint</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:218pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 16</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:195pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo-Controlled</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 26</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:310pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo-Controlled</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:446pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:441pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Open-label</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:191pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=108</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:248pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:240pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg eow </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:249pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=109</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:304pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=108</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:360pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:353pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg eow </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:362pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=109</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:449pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:441pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg eow </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:453pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=80</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; mNAPSI 75 (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:199pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:254pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">26.0</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:314pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:366pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46.6</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:456pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PGA-F </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clear/minimal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265;2-grade </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:199pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:254pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29.7</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:314pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:366pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">48.9</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:456pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">61.3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Percent Change in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Fingernail </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NAPSI (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:198pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-7.8</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:251pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-44.2</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:310pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-11.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:364pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-56.2</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:454pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-72.2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p&lt;0.001, Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">vs.</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treated patients showed statistically significant improvements at Week 26 compared with placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in the DLQI. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">29</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult Crohn&#x2019;s disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in over 1500 patients with moderately to severely active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Crohn&#x2019;s disease (Crohn&#x2019;s Disease Activity Index (CDAI) </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 220 and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 450) in randomised, double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo-controlled studies. Concomitant stable doses of aminosalicylates, corticosteroids, and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunomodulatory agents were permitted and 80% of patients continued to receive at least one of these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">medications. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Induction of clinical remission (defined as CDAI &lt; 150) was evaluated in two studies, CD Study I </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(CLASSIC I) and CD Study II (GAIN). In CD Study I, 299 TNF-antagonist naive patients were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised to one of four treatment groups; placebo at Weeks 0 and 2, 160 mg Humira at Week 0 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg at Week 2, 80 mg at Week 0 and 40 mg at Week 2, and 40 mg at Week 0 and 20 mg at Week 2. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">CD Study II, 325 patients who had lost response or were intolerant to infliximab were randomised to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receive either 160 mg Humira at Week 0 and 80 mg at Week 2 or placebo at Weeks 0 and 2. The primary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">non-responders were excluded from the studies and therefore these patients were not further evaluated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Maintenance of clinical remission was evaluated in CD study III (CHARM). In CD Study III, 854 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received open-label 80 mg at Week 0 and 40 mg at Week 2. At Week 4 patients were randomised to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week, 40 mg every week, or placebo with a total study duration of 56 weeks. Patients in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical response (decrease in CDAI &#x2265; 70) at Week 4 were stratified and analysed separately from those </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">not in clinical response at Week 4. Corticosteroid taper was permitted after Week 8. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">CD study I and CD study II induction of remission and response rates are presented in Table 14.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:281pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 14</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:193pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Induction of Clinical Remission and Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(Percent of Patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:191pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CD Study I: Infliximab Naive </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:191pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patients</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:372pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CD Study II: Infliximab </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:372pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Experienced Patients</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:197pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:203pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=74</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:258pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:255pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">80/40 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:261pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 75</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:318pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:313pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">160/80 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:324pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=76</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:385pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:388pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=166</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:468pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:462pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">160/80 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:471pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=159</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:205pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:266pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:325pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:475pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">21%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response (CR-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">100)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:205pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:266pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">37%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">**</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:394pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:473pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">**</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All p-values are pairwise comparisons of proportions for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.01</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Similar remission rates were observed for the 160/80 mg and 80/40 mg induction regimens by Week 8 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adverse events were more frequently noted in the 160/80 mg group.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In CD Study III, at Week 4, 58% (499/854) of patients were in clinical response and were assessed in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">primary analysis. Of those in clinical response at Week 4, 48% had been previously exposed to other TNF-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antagonists. Maintenance of remission and response rates are presented in Table 15. Clinical remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">results remained relatively constant irrespective of previous TNF-antagonist exposure.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">30</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Disease-related hospitalisations and surgeries were statistically significantly reduced with adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared with placebo at Week 56.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:281pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 15</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maintenance of Clinical Remission and Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(Percent of Patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:141pt;left:283pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:141pt;left:359pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">40 mg Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:153pt;left:353pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">every other week</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:141pt;left:450pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">40 mg Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:153pt;left:458pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">every week</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 26</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:286pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=170</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:378pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=172</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:468pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=157</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:291pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">47%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response (CR-100)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:291pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">27%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in steroid-free remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:230pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for &gt;=90 days</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:279pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3% (2/66)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:360pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">19% (11/58)**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15% (11/74)**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 56</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:286pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=170</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:378pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=172</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:468pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=157</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:291pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response (CR-100)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:291pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">48%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in steroid-free remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for &gt; = 90 days</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:279pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5% (3/66)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:363pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29% (17/58)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20% (15/74)**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.001 for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo pairwise comparisons of proportions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">** p &lt; 0.02 for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo pairwise comparisons of proportions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of those receiving corticosteroids at baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients who were not in response at Week 4, 43% of Humira maintenance patients responded by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 12 compared to 30% of placebo maintenance patients. These results suggest that some patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have not responded by Week 4 benefit from continued maintenance therapy through Week 12. Therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued beyond 12 weeks did not result in significantly more responses (see section 4.2).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">117/276 patients from CD study I and 272/777 patients from CD studies II and III were followed through </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at least 3 years of open-label adalimumab therapy. 88 and 189 patients, respectively, continued to be in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical remission. Clinical response (CR-100) was maintained in 102 and 233 patients, respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of life</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In CD Study I and CD Study II, statistically significant improvement in the disease-specific inflammatory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bowel disease questionnaire (IBDQ) total score was achieved at Week 4 in patients randomised to Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80/40 mg and 160/80 mg compared to placebo and was seen at Weeks 26 and 56 in CD Study III as well </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">among the adalimumab treatment groups compared to the placebo group.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult Uveitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in adult patients with non-infectious intermediate, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:621pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">posterior, and panuveitis, excluding patients with isolated anterior uveitis, in two randomised, double-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">masked, placebo-controlled studies (UV I and II). Patients received placebo or Humira at an initial dose of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg followed by 40 mg every other week starting one week after the initial dose. Concomitant stable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">doses of one non-biologic immunosuppressant were permitted. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV I evaluated 217 patients with active uveitis despite treatment with corticosteroids (oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">prednisone at a dose of 10 to 60 mg/day). All patients received a 2-week standardised dose of prednisone </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60 mg/day at study entry followed by a mandatory taper schedule, with complete corticosteroid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:722pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">discontinuation by Week 15. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV II evaluated 226 patients with inactive uveitis requiring chronic corticosteroid treatment (oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">prednisone 10 to 35 mg/day) at baseline to control their disease. Patients subsequently underwent a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mandatory taper schedule, with complete corticosteroid discontinuation by Week 19. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary efficacy endpoint in both studies was &#xb4;time to treatment failure&#xb4;. Treatment failure was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined by a multi-component outcome based on inflammatory chorioretinal and/or inflammatory retinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vascular lesions, anterior chamber (AC) cell grade, vitreous haze (VH) grade and best corrected visual </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">acuity (BCVA). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who completed Studies UV I and UV II were eligible to enroll in an uncontrolled long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension study with an originally planned duration of 78 weeks. Patients were allowed to continue on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study medication beyond Week 78 until they had access to Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Clinical Response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with Humira versus patients receiving placebo (See Table 16). Both studies demonstrated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">an early and sustained effect of Humira on the treatment failure rate versus placebo (see Figure 1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 16</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:180pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Time to Treatment Failure in Studies UV I and UV II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:75pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Analysis</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:103pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Treatment</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:189pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:225pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Failure</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:225pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:283pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Median Time to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:283pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Failure (months)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:378pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HR</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:414pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CI 95% </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:414pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">for HR</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:472pt"><b><i><span style="font-family:TimesNewRoman,BoldItalic,serif;font-size:11.04pt">P</span></i></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> Value</span></b><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:75pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Time to Treatment Failure At or After Week 6 in Study UV I  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Primary analysis (ITT)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">107</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">84 (78.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:472pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">110</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60 (54.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.36, 0.70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:472pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:75pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Time to Treatment Failure At or After Week 2 in Study UV II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Primary analysis (ITT)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">111</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">61 (55.0)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8.3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:472pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">115</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45 (39.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NE</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.57</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.39, 0.84</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:472pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.004</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note: Treatment failure at or after Week 6 (Study UV I), or at or after Week 2 (Study UV II), was counted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as event. Drop outs due to reasons other than treatment failure were censored at the time of dropping out.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">a</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HR of adalimumab vs placebo from proportional hazards regression with treatment as factor.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">b</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2-sided </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">P</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> value from log rank test.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">c</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NE = not estimable. Fewer than half of at-risk subjects had an event. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">32</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Figure 1: Kaplan-Meier Curves Summarizing Time to Treatment Failure on or after Week 6 (Study </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:233pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">UV I) or Week 2 (Study UV II) </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TREATMENT FAILURE RATE (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TIME (MONTHS)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:100pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV I                        Treatment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:445pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TREATMENT FAILURE RATE (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TIME (MONTHS)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:100pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV II                       Treatment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:445pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note: P# = Placebo (Number of Events/Number at Risk); A# = HUMIRA (Number of</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Events/Number at Risk).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Study UV I statistically significant differences in favour of adalimumab versus placebo were observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for each component of treatment failure. In Study UV II, statistically significant differences were observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for visual acuity only, but the other components were numerically in favour of adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of the 424 subjects included in the uncontrolled long-term extension of Studies UV I and UV II, 60</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subjects were regarded ineligible (e.g. due to deviations or due to complications secondary to diabetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">retinopathy, due to cataract surgery or vitrectomy) and were excluded from the primary analysis of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">efficacy. Of the 364 remaining patients, 269 evaluable patients (74%) reached 78 weeks of open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab treatment. Based on the observed data approach, 216 (80.3%) were in quiescence (no active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inflammatory lesions, AC cell grade  &#x2264; 0.5+, VH grade &#x2264; 0.5+) with a concomitant steroid dose &#x2264; 7.5 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">per day, and 178 (66.2%) were in steroid-free quiescence. BCVA was either improved or maintained (&lt; 5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">letters deterioration) in 88.6% of the eyes at week 78. Data beyond Week 78 were generally consistent </span></p>
<img style="position:absolute;top:111pt;left:100pt;width:432pt;height:174pt" src="data:image/png;base64,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">
<img style="position:absolute;top:297pt;left:291pt;width:31pt;height:14pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABcAAAAICAAAAAA3wTsyAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAR0lEQVR4nGP8z4AVMGKK/2eEioMZaDIg8X8fGRmAFEyWiYEPov75
fqAwTPQ/8z8+n39MEPP//2dk/A+V+8+EsBfDBmzuAQMAmYsaASeQxO8AAAAASUVO
RK5CYII=">
<img style="position:absolute;top:297pt;left:401pt;width:43pt;height:14pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABcAAAAGCAIAAACnwpLJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAqElEQVR4nGP8//8/A8WAEW4KkMHIyEhQA1ZlCFN+//79/ft3Pj6+
9+/f83Bzs7Cyfvz4kZ+fHygI1MTKxvblyxcBAQEgyczExMnF9eHDByAX3ZSbN2/e
vn3b29t7+fLlFhYWQON27twZHR29Y8cOUVFROTm5vXv3RkREbNu2DWi0qanJ+vUb
/Hx9gcahmAJxLUgIycHI7v/37x8TExNWKUaSQhctUOBcAGVhWfUkQWeYAAAAAElF
TkSuQmCC">
<img style="position:absolute;top:334pt;left:100pt;width:432pt;height:171pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAA2MAAAFUCAIAAAAms3NiAAAACXBIWXMAAA7EAAAO
xAGVKw4bAABW6UlEQVR4nO2dIWAazdb351MPruu6V5Wq4EpVeVV4VKkKVSXqISpE
hahS1VSVqlJVokpUibpEXaK+jXqpKnFElai7cRu3Vd93dg8Mw+5C0oRl2eX/E3TZ
EpjZmTnznzMzZ/7P//t//08AAAAAAADg4/+EpxR///5tGEZIXw4AAAAAAMJD07QX
L148VCmSHPzrr78C/+v6+rrVahUKhYd8PwAAAAAAWD7tdufjx/d/oBTniMJArq9v
Ot3O7j//3Ct5AAAAAAAgMj59+lStVidK8dOnL81Gg7Tds2fP+M7FxUWj0TS63Wwu
Vy6Xt7Zeeu7n8rlSaXLfw/X1dafbhVIEAAAAAIgdHz59ev/27UQp/v33q+Fg0O0Z
G0+eCFfnFQoFy7Q0XaNXutNqtzY3N5X7umWa8r7/B6AUAQAAAABiykQpkqRrNput
ZovuSqV4dHRUP6wXS8XPnz/zdb5Y+Pb1a8D9QuHbt6/+H8DsMwAAAABATBkpxVa7
fVirCVuIlKBXqRR3dvYMo9toNLe2XpKUzOVy9L+//vtr1n35vRcXF6bra7Rsmy72
d3cjyyIAAAAAALgXI6VoGEan0yGd2Gm3heJTfP78uWVa8u3Tp09ZR5aKRcuyul1j
Y2PqPn+MOD8/HwyHzpVNiP19KEUAAAAAgJjhXafo0XxP//VUpMREEdJbV0cW8nnv
x8SUUpRgnSIAAAAAQEzxKUXWfMZIGr569WrQH8i3I+FoGNVKxbkPpQgAAAAAkFxm
KEW5TnFvz+h0G01lPaIQv3656xS70/en1ylKoBQBAAAAAGJK0Owz+xTl3ud6vVgc
73Guu3ucJ3ufS/X6YavVmrv3GUoRAAAAACCW3LJO8fr6plDIW5alaRq90n/54ilO
3ff/AJQiAAAAAEBM8SpFXpgYfEZLPlcuTZ/R0nTvZ7PlSmXrJc5oAQAAAABIFF6l
uHAQeRsAAAAAIKaEqBR///79119/QSkCAAAAAMSUJfgUMfsMAAAAABBLwlWKx8cn
pmmmUmJ/fz+M7wcAAAAAAOERrlJ0T3+2hsPBLs59BgAAAACIG9jRAgAAAAAAgsE6
RQAAAAAAEAyUIgAAAAAACAZKEQAAAAAABLOEeIpQigAAAAAAsSRcnyKJRcuyoBQB
AAAAAOIIZp8BAAAAAEAwiJIDAAAAAACCCVcpXl1fW6bV6/V2d6EUAQAAAABiRrhK
8ejoyDnNT9Pe4jQ/AAAAAIC4gXWKAAAAAAAgGChFAAAAAAAQDJQiAAAAAAAIBkoR
AAAAAAAEA6UIAAAAAACCCUsp8lF+AkoRAAAAACC2wKcIAAAAAACCWcoZLZ0OIm8D
AAAAAMQO+BQBAAAAAEAw4SrFL1++DE1T1/S3b3FGCwAAAABAzAj53Oera8vCuc8A
AAAAALEEs88AAAAAACAYKEUAAAAAABAMlCIAAAAAAAgGShEAAAAAAAQDpQgAAAAA
AIKBUgQAAAAAAMFAKQIAAAAAgGCgFAEAAAAAQDBQigAAAAAAIJhwlSJ9uzkcptMZ
nOYHAAAAABA74FMEAAAAAADBQCkCAAAAAIBgoBQBAAAAAEAw4SrF379/W5YFpQgA
AAAAEEeW4FO86XQ7UIoAAAAAALEDs88AAAAAACCY25Xi6elZp9MZ9Pt6Jl3I53d3
d/n+xcVFo9E0ut1cPlcqlbe2Xgb+OXyKAAAAAAAx5RaleHR0VD+sa7qezWb7/Z5l
WZVK9e3b/evr60KhYJkW/ZdlmvTJVru1ubnp/wb4FAEAAAAAYsotSvHVq1eD/oBV
4OXlZSFfoJu//vuLFWSxVKrXD1utFl3nC4Vv376qf/v79++//voLShEAAAAAIKbc
ohRfb2/3ew6PHz+mt0//9VSkxK9fv3Z29oxut9Fsbm29JC2Yy+b4Pv8VaUTbRYiU
bVvdrrG7C6UIAAAAABAzblGK5+fn1Wq1Uqns7u6enp7RZa1Wo+vnz59bltU1jI0n
T8RYQcq3xNHxcb/fF6QVhY3T/AAAAAAA4sgtSvH45OSwWqMLTdcs0+KLVqtVLBTp
uttTlKLyVgWzzwAAAAAAMeUWpej4Dk0rncnk8jnbsg2jS2/zhYJpDgf9wRylyIsU
BfY+AwAAAADElnlK8fLyqpDPi5SQ6xTPz8/LpTJdkFicWqeYy9HNX79+sUCUMlHA
pwgAAAAAEFvmKcXRVhXFWciT0dl8jhRkvV4vFm/Z+0yvOM0PAAAAACCm3DL7/OnT
l2ajQRf5YsG2rJ7RE27oxEwmM46n6K5fTAnSi2o8RWX2GT5FAAAAAIBYcvsZLccn
J0bXGA6HqZQggVgul+mVVKA8oyWbz5V9Z7TIaWj4FAEAAAAAYsqCz33mGWdCXafY
7Xb/gVIEAAAAAIgbD1WK6uYV9Q5LxtEZLZ0uIm8DAAAAAMSO25WiXwvOR93+jNln
AAAAAID4EuLsM1036w1n10ta23/7diHfDwAAAAAAlsaClaKYnn3utjumadkpe38f
p/kBAAAAAMSMcJXiaJ0iZp8BAAAAAGLI4mef1UWNo3WK2NECAAAAABBDwlKKiLwN
AAAAABB3Fj/7LMb7WiZKET5FAAAAAIAYEsreZ3UCGj5FAAAAAICYEopPUWD2GQAA
AAAg/oQ4+8wg8jYAAAAAQEwJd++zgE8RAAAAACC2hKIUpU/RNE3Lsnq93u7u7kK+
HwAAAAAALI0QI2/T67u9A9KKmWy6Wqv90eHRAAAAAAAgcsJbp2j/9dcjRN4GAAAA
AIgvIc4+Y+8zAAAAAECsCSueIqLkAAAAAADEncXPPt/8/v1ovCRxNPsMpQgAAAAA
EENC8SmKsVtRIJ4iAAAAAEBsCWudol8pqqEW/Yf+AQAAAACAVSMsn6IYuxXhUwQA
AAAAiClh7WgRY/+i3NHi+S8BnyIAAAAAwGoTbpQc+BQBAAAAAOJLGD5Fjrl9Q68f
9t6ZlpXOpKu1Kt0XIiWUzS7wKQIAAAAArDKh+BTl9fjc5z7OaAEAAAAAiB3hneY3
Qt37LLBOEQAAAAAgPixeKaoyUbBSxLnPAAAAAAAxZGFK0X+OH98xLavb7ZZLJQRT
BAAAAACIF4v0KapiUd5kn2K5XBKYegYAAAAAiBVh7WgZiUVbWLY3Sg6UIgAAgMi5
vr5utztuXA4AwiM1jv3i1LRcLvfixYuok/RnLH6d4s3v3yn3YlY8RShFAAAAS0YN
zcGcn/8wDCNfyDtvIBfBUkin9SdPnkSdij8jpL3PNxw6kRqfZdn+HS3+FgsAAAAs
k/MfPwaDAQ6GAGA+YZ3RIlcrYu8zAACAFeT8/MdgCKUIwC0seEeLeuKz59xngXln
AAAAS4Q6nV6/P1kkNprrGv0vyUS68Q+UIgBzCStKDp/mt7ezY5pWLputHtbUD0Ms
AgAACJuLi4tGo5HNZt13qbFInFzk87lnz55Flj4A4kAo6xRVVJ8iAAAAsDRIKRqG
sb+/H3VCAIgxUIoAAACSCZQiAA8HShEAAEAycZVib39/N+qEABBjoBQBAAAsm/Pz
82azqWm63GWSSglbLiNcCO635Qv5N1tbfAMB2gC4B1CKAAAAls3Z2dnQNKlr8ATN
iDpdAAAv91GKf9SeoRQBAAB4Og6pFCNMEgDgLtyuFKl5NxpNw+imNK2Qz+/ujhZ8
uNEHmka3m83lyuXy1tbLQAUJpQgAAAng6urKsqwHfEFKPTLPCXMoRKhdA5yUACyE
25XiwcFBp93J5nPDwcAyrcNG/Z83b0j/FQoFshqapjm2wxatdmtzc9P/51CKAACQ
ALa3tzOjwIT3xVbWINqiWCwgliEAq88tSvH8/LxcLudyue/fv19cXBQLxUw285//
/Ofo6Kh+WC+Wip8/f+brfLHw7etX/zdAKQIAQNz5/ft3pVL59u1b1AkBACybW5Ti
hw8fWs1W7bDGk86np2ealtrc3NzZ2zO63UajubX1krRgLpuj//3131/yDy8vL03T
maewbXs4HMg5awAAAHFkZ2cHShGANeQWpfh6e7tv9CrVaq/Xs20rny+8feuEMH3+
/LllWt2ekdb1v/766+nTp8IW9HbjyRP+w4uLC9M0BStF09yHUgQAgEUQ1fI7KEUA
1pNblOLTfz3li3yhYJrDQX/AM87O/ZTodo2NjSfyY6pSlGD2GQAAIkFqylevXum6
/sBvS6VSX4OWGAEAks0tSpF9h5Vq9e3b/cvLy0K+IJw9a71yuUyqkaUhGaNMOuMI
R2OiFKWFglIEAIDlo7oe9w4Ovn7+HG16AAAx5RaluLPjrkdsOusRxdh32Ol2OD4O
3/evU1Qt1PXNTafTgVIEAICogFIEANybW5Sis6+5Xi8WnRlnZx90qazp2s+fPwP2
PhcK375h7zMAAITL9fWNbd8S19CePhKv3mhAKQIA7sctSnEUN9G0SCBy3ETeB63E
U9Qt0ySb1GrNiKcInyIAACyOd+8+0GtK+4PTkTPpzJs3W6GlCACQZG6PvH15dVU/
rPf7PV3XS+XyP2/e8H3njJZm0+h0c/lcqVTa2poyQ1inCAAAYfDu3btKpfLEt30Q
AADC4D7nPt8RFotQigAAsECgFAEAy2TxSpEEIl+QTKRry7KgFAEA4N5cXV33ej35
ttPp1OuHUIoAgOWwYKXIMlFufIZSBACAB3Jyctrv97PyzOWUKOTzjx49ijRRAIB1
IRSfoutNvPnrr0cHO3umaWazubcf3y7q+wEAYK0gpSiE/Wa8RhwAAJZJiLPPDHyK
AIClEdVJd6FycnIiRAqblwEAkbD42WdensivgpVip7u7C6UIAFgGFxcXNDodvfHE
FYwnw+GwkC9AKQIAImHxPsWb378fjcWi8EXJ8SxkBACAxXJycmrZVk6u6ksE6XQa
CxMBAJGwSKWouhKnfIrdbrlUgjoEACwBUoqalnr58mXUCQEAgCQQyt5nF2fWR42n
qHoT4VkEAITEycmJpmlQigAAsBDCWqco77jrFDu7u7sL+X4AAJgPfIoAALBAwoqn
SBe2EI+mfYqqEzGRWxQBAJEDpQgAAAskrNnnsWfRtiyb9z5j9hkAsASgFAEAYIGE
cu6zd/Z5xo4WuBUBAAsHShEAABZIiLPP9Prp3QfLtPSMXqlW5R4XAZ8iACA0oBQB
AGCBhHWaH18fHx0PzaGW0vbf7s/6DAAALBAoRQAAWCChzD6reCJvAwCAh8urK9uy
FvVthtHLZNJQigAAsBDCOvdZzjJ7zn2GNxEA4OHVq1e5XH5y7N6Dj+ArFYsbGxsP
ThcAAIClK0UAAPCws7Pz7du3qFMBAAAgAMw+AwAiBkoRAABWFihFAECUnJ2dt1qt
79+hFAEAYBVZ6uyzPOsPSxUBAMzr19vVanVz80XUCQEAABAAfIoAgChRp54xjAQA
gFUjXKU48im6p/mF8f0AgGVyc3Nj28LdnLwwarUaFikCAMDKEta5z4w5HFqW3ev3
dnd3F/L9AIAI2d7eSad19zK1IL2Y0nTt7f7+7R8EAAAQBWGtU2Rq1Zplmpls5u37
94v6fgBAVCx8kzKmmwEAYMUJa/ZZ7mu5vr7pdDtYpwhAAkA4GwAAWDewowWAVeHH
xUWr2XQmdh92Qkl4mEPz3//+HnUqAEgsd/SyL9MZH2vH/2ITH+tH8RBCWacoQ+TQ
K85oAeCOnJ2dWZb95s1W1AkBIOGsbZe/fCJ81LN+OvD+3W+uISHOPvPzdXyK2PsM
wB1wlaL15s2bqBMCAAiLW8XHmquTNc/+arKUKDnwKQIwl3cfPgyHQ2GLSqW8ubkZ
dXK8wHYDEDvQbMGiCGXvs6ydUIoA3IW9g4PD2uHjx4+iTsg80PGARHJzc9NqtZby
U6lyufToUUAzP//xo9/rqZ+UUagymczLly8Dv+7o6Mi27ek/Ga1xTqXEw0Kfym+z
0+n01lbwkpjT09PBYJhKCX/YrGKp9OTxY+GzGxcXF4ZhzPldN+W2mgAxtXD7rjnS
9fSslTzHxyekTAK/qlgsPnnyxH//6uqKlIyTGjs4AXOeUgIIxaeorlZ09j53Oph9
BmAOrlKsPXYNKwBgmVCH1ev1l/NbuVw2cLhFQmQ4NKdujTWSrmmkQgL/6sePHyPd
sqjwpr5fJzRNe7axwbd9su/SsszJJjwlDdlsJlATX11fDwfDeT8qFpMdTUs9e/Ys
8L9IrVqW8gOKKM1k0oF2mJTMYDAISNj4jqZPnlLyWIJSxN5nkGR+/LjodNoP+ALH
0vR6PRpQBRpWAABYMnMmEDC3sIYsUilyBZLVCHufwTpwcnJqCzufy93vz0fj9lRK
1zTYXwDmAI0CQCQsTClKP6LUi/TW6HRN07SEvY/TukDi4KpOSlHTUrMWEgEQazzi
7OTkxJhaTjehkM/PWqe1d3Dg/ONZb/bnaJomXO9D4AK2XDZbKpUCpeTZ2Vmn2w1M
A1Z9AHArC1aKjPQpNg7r1Kq1tF6tVjEWBIkEShGsA/DnAbC2LHj2WV5Lm4J4iiDZ
nJycaJoGpQhAfIEOBmAOiz+jRQ2R4577fO3ufd4VaI0gibBSzOfzqNtgxSELTNbY
mhHmQxK48bRYLD6O244r9DgALATsfQbAYW9vb1agrPnQX1WrtRcvgsMxALA6XFxc
tFqtQqEw5zOzFhPmcrm47M2HQARgsYR7RouAUgQxYWdn59u3b1GnAqw7oaocUopk
jcnih/T9AIBEAqUI1oubmxs3Ov8I6UGp1Wrfv3+PKlVgfbi6upq+kXryJHjvraeu
CiUssaZpgR4+/5+oDAbDXq/3/j2UIgDgD7irUiTBVy6XB/1Bp9vhuOc0PG00mka3
m83nyqXy1lbwin4oRRAVge6Z4+NjwzB0XR/fGC3Koq73LXwtIGR+/PjRbLZ0XXPf
jY5K42XcfsjGtttt+UnlwjkUbiPoQIjLy8s5B9PZbiwb7L4CAPwRd1WKBwfvOq7N
6vaMjSdPSP8VCgUnAo6mWaYzhG21W5ubm/4/hFIE0eLRi0fHx2ld584S65nAkjk7
OyOz+ebNm6gTAgAAd+VOSvH09KxarThX9kgpHh0d1Q/rxVLx8+fPfJ0vFL59++r/
WyhFsAqQKBwMhzSqMQwjl8uSUoRMBMvHVYr2mzfBEaoBAGAFuV0psvtQ13XTtCzT
ZKW4s7NndLuNZnNr6yV9IJfLkYj89d9fQX9+0+l2oBRB5Ozt7WXdM/cK+fyTJ0+i
Tg5IMmRYh4OB/75t25VqdfPFi+UnCQAA7sftSvHg4KDT7rTarXK5LH2Kz58/t0yr
axgbG06P+/RfT0VKOG/HHfDV1RUvrLZse9Dvz1qIA8DS2Ds4+Pr5c9SpAGtBJJUN
bnIAQBjcohTPz3+US6Vypfz+/fuRHOw66vDp06dSNQpWimLyVriTLAN3SG3bIpUS
OPcZRMjNzQ3V206njd3NYDns7R18/RqgFCHmAACxY55S5P3OdNFqtR4/fqw6Dl+9
ejXoD9inSLYvk8k4wnHsYvR8SafbJbkplCP+AFgmbsDhdrFYCNx0BWIHSX9nU3Aq
FXiayByymeysGOlHx8ez/mrW4pkfPy76g37gf/WMXuC6bQAAiB3zlOLl1VUhlx+F
mxvbY03XS6XSYDgwOso6xayz/GvGOkXsaAERQ0rRMAw4thPDycnJcGg6y6NT45CY
dxGMKZHW9VlLVM/Pf3g+LOPSzFpWeHV1RckI+BMhdF0LjGIDAACxY55SpP61WChO
3Uo5YedKpbKmpdy9z6XPnz86e5/r9Xx+9t7nTnd3d6QUMfkClsOXL0eW7YYgtgVd
pPX0/j4WyyaEk5NTesUOYgAAWAJ/cEaLuhjR3RBdtExT03V6JQXZaiGeIlgSdxlv
7OzsjUI7uei6/vhx8EkYYAW5urpuNOru9LLKyIVommapVEQEaQAAWAJ/oBR5beLU
GS3NptHBGS1gedzdJ42dzrGG7MZwSANRLaWcuMjwW5L+mJ0AAIAlsJRzn93ZZ8w7
g2Uya/MpSADSmMCqAABA2CxPKYb0/QAEAqUYFz58+GBalrBFqVTE5nQAAFg17q8U
A0fz/pusFMvlEob+4N5cXl72+/3pSchbMIzu168IUxIDdnZ2vn37FnUqAAAABBOK
T5H1Ir3StWVZ8CmCB/LlyxeSibqu+xatzYQ+vLmJM9NiAJQiAACsMgtWiq46dPpy
7s8r5YplmtlcrnZYg08R3BtSivl8PpPJoBatDienp3xi510oFYuPHj0K/K/t7Z3v
36EUAQBgRQl3nSIJR8eniL3P4AEcHR/3DKNarfKme7Ai7Ozs8RlOXjxxsF0XcC6b
naXyr66uZkXDBgAAEDmL9ykGrFOEUgQPYHt7u1arwaG4amDPEAAArANhzD4LuUiR
LqAUwQPBOrYlc3R0PBwOlBszj8z7+PHjMhMGAABg+cCnCFYdKMUl8+nTl3K5NEMg
Tt6mUqlZSw8liHcIAABxZynxFKEUwQOAUowj0IgAAJAMwvUpjna0IEoOuI3z8x+2
HbyRttVqY28sAAAAEAlh+RSlZLy+vu52u//Apwjm8vr161KpPH1vFDpR1zUc3QEA
AABEAqLkgKUya1ISU8yrwM3NjW3bjx8/jjohAAAAVoUQZ5/5GusUgeTi4sIweoE7
JHq93vfv36NK2Hpyfn7ebLU0TZMH35BMLBWLL1++jDppAAAAVoXF+xTlUX70+uHg
nWma6Uzm7fu3i/p+EF+Ojo9ty85ms84bdU9tSpBeebaxEV3SQmcFd3hcXl7S60ai
HzsAAIAHEopSFG4kRXq9vLi0LLM/GOzu7i7q+0F8IaWY1nW4rAAAAIC4sPDZ5xue
x5LBt7FOEUikUlxBBxsAAAAA/ISyo8XViKOlT4iSAyTwKQIAAADxIsTZZ+xoAR7g
UxRuAzEMgy7S6czGxhP/B25ubnq93pxvGO8/eRDD4RBrQgAAANzKUk7zg08RuMCn
6MrEXrfbyWSzuWz22bNn/s9c39x0Op3AP0+JlO07fPl+rHlBAAAAuCM4zQ8sjzVX
ijyOOjs7G5omWgQAAIBYsASleNPpdtAvgu3tHSHsaq32IsiRFmuurq66XUNOCfvV
sPS1n5yc9AeDTDqNU4sAAADEgrDiKcq38CkCJsGnsBwdHZNMzKQz/FbXtXQ6HbgQ
88ePC9u2c7ns2i7TBAAAEC8w+wwWzM3NjWVZwrfxolY7/P49UUpRDoqOjo9JJm5u
vog6RQAAAMCCCVcpsmjoGgaU4vpwfHxsGD1d15RjWJwLXdf39/cjTlwIXF5e1uv1
arUauD0FAAAAiDXhKkX6dnM4TKczb98mUCIAFdXBtlbbVk5OTkgO//Pmjef+OkcC
AgAAkBgw+wwWycXFRafTzeWy66QUTzUtdWt+IRwBAADEEShFsEheb28XiHz+yZOA
mNKJ5OTkRNO09VHGAAAA1gooRbBIErzBeRZ39CkCAAAAcQRKEdyJT1++DAcDkbrl
GDn678+fPyd7pvXi8lI9bW8wGBTyeShFAAAAiQRKEdwCy7537z5UKuV4zSmHJFgP
Dt5lc1ld0+QdyEQAAABJBUoReGGBRa9uWMSUG+LGrtcb1WrlLkoxvg7FO6b83bt3
5UplI1aiGQAAALgfS1GKne7uLpRizDg9PW212npa5wjaJBcPDw8fPXoUdboeyunZ
Wb/fFzLYoxIfvFqpzMrghw+f5MfM4bBWq8XLvQoAAADcj7CUouKXsnHucxw5OTml
1zdvtqJOyIKhoYttT0lEeaHreqBPkaqxaZqKpEw9efJ4OakFAAAAogWzz2sNC/qD
d+9sy1aP3qPL4dAsl0tbWzFWildXV+12u1QqzxJ28Z0oBwAAAJZDKEpROhR7Rs+y
LNM0d/d3F/j9YLEkNbTN9vZ2Pp8vlUoJmDQHAAAAImHBSpHUofq2cVi3TEvPpPdx
mt8Kk1SlmNR8AQAAAEsjXJ8ivWL2efVJpKL68eNHo9H4/v171AkBAAAAYsxilKJc
76Uu/BorxRvsaFlxEqkUX79+fXhYf/ZsI+qEAAAAADFm8T5Fj2qET3GVuby8NHq9
nmEkTykmUv4CAAAAS2bx6xTlvDO/tSwLSnFlOTk5NU2zUMhvbMTS93Z8fGJZpnJj
FCSR6A8G375+5WvscQYAAADuR4g+RQGluEpcXV1LFSXGQQS7XSOd1qM9jO4hMm57
e7tWqwX+l67rjx8j6iEAAADwIG5XihcXF41m0+h0M9lMsVjc3d313M/lc6VSeWtr
Sm3I7h+zzyvC33//ncvlpu85HrhSufxsBRyKHBB71sEn/L/+WNm1w8PvmGIGAAAA
QuMWpXh5dVXI5elC03XLdKb5SpXyx/fvqecuFAqWaWm6Rq90v9VubW5u+r8BSnFF
WPF1ezs7e9lsdn9G3M3T09N+fzA+g3pyWEomnX7z5s3yUgkAAACsGbcoxYODg067
U66U379/f35+Xi6XhS16/V6n06nX68Vi6fPnj0dHR3Sdzxe+ffvq/wYoxRVh5ZXi
TrPZxGpCAAAAYKW4RSm+evVq0B9If+HTfz0VKdE1jPph3eh2G83m1tZL0oK5rDOt
+eu/v/zfAKW4IqymUjw9O+u023Shadrnz5+jTg4AAAAAprhFKR6fnNiWVSwWHz9+
fHFxQRfUo//8+fP58/+xLLPbNTY2nIVlUkFujNeZHR0d9Xo94c4VZrOZt2/fLi1L
IJAIlaJnRzwAAAAA4sLtO1q4gyeZWKvVBv1BpVp9+3bfkYZCdHsjaSjfpnVdagIZ
T7Hb7f4Dn2J0nJ2dtdvtdDr9/v37qNMCAAAAgDhxpyg5zkrEw7pIiVLZ2c4ixrPS
U0px2qcocWafO93dXSjF5eHx3p2cnGpaKtpQOCocOwkhbAAAAIDV53al+OHDh1ar
pWlatVb7Z7zPdGdnzzC6jUazUMhTrz93nSJO81sq5+fnRq8nbJFKjbYJD4fDUrG4
OkqRBg+NRuPjx49RJwQAAAAAt3CLUuR9zSQTSSw+e/Zs6v5hvVga730+rOeLBXkk
hgp2tCwZKtFsJpNOp9Wb9PbRo0d8HeF6wYuLS6pITrCbVOojpsIBAACAlecWpcgL
EEeMT0rrdDu6rk/iKVoW3ef90aRC5Md5qSLOaFkyVKLFQkGV9avD0dFxSkvlczka
e0jlCgAAAICVZZ5SlGG3ldN0HUgpkhAZndHS7WazuXJ56owWnPscFe/evev3+41G
YzXPcT46Pk7rER8eCAAAAIC7s+Bzn0ka8gkaUIqRsHdw8HWFoxJCKQIAAADxYvFK
kS946pkuoBQfgrqm8Pr6ut/vz/98p9P5GrRadEWAUgQAAADihVcpPny7gwymyM5F
RykiSs4iODs76xoGbzOfha5rgadvrwJUJVrtNpQiAAAAECNC9CkKzD4vFFKKQ9OM
9ZOETxEAAACIFwtWisJRhzd//fWIX9/tHZC4yWSz79/jNL8Hsbe3Z9t2qVR++XJF
XYbzub6+EcLudDrpdBpKEQAAAIgLYfkUxditiHiKCyHCU5sfzsXlZaNeT2masO1a
rfbEd5APAAAAAFaTxfsUxVgvTpQi1inei5ubGydWpQsJrO/fv0ebnntz/uPHYDDA
aAEAAACIHaEoRRX4FO/Nly9HQ3OoaZpw9gal3r7djzpFt0ODhP5g0Go2NU23bFfm
2sK2rUKh8GZ8FCQAAAAA4sISlCLOfb4nX758yefzq3nayhyOjo9J3eZz6h7t1OPH
OJEFAAAAiB9hzT6rUQDhU7wHZ2dnzWazXq9vbGyoZ95EdWTzfKZK/OYmJYT/sL6V
TTwAAAAAZgGluKIcHR9n0pnNzRdRJ8Th4vKSZGvgf5VL5RcvJl5PyEEAAAAgSSx+
7zOH3ZavUIr3Y6WU4q1AIAIAAACJJMR1ijjN74/wiC1HKWYyuWx21RTYfFEIyQgA
AAAkiVB8iuod+BT/FOcgRNtut9uZTDZCn+L5+Q96jYtTEwAAAABhEMoZLe6Bz048
xS/vPgxNU8+k377FGS1/wOvtbV3Xq5XKxsZGJAm4vrnptDuapr15sxVJAgAAAACw
CoQ1+zxapHh1bVmW0TN2d3cX+/3JZu/g4OvnzxEm4ODggF6r1SrOUwEAAADWmXDP
aKELrFO8I1dXV/JElmaz+fXr1wgTE+vDAwEAAACwKMKYfR5tfBauWMQ6xTuyd3CQ
1tOpVEoIW9f1ZZ5o8u7dO9M0U5pmj6WqSKW+RSpVAQAAALAKhKUU5TV8ineElOJh
rfb48ePl//RdPIjY1AwAAACsIeGuU4RS9KNKrpPT00677foRnXBCrVbLf7TJEsBc
MwAAAAACCTFKDiJv30pgeO1leu/Of/xoNZuZTKZarcJlCAAAAAAPOM0vMo6PT3o9
o1Qub76ILGbhycmppqVevnwZVQIAAAAAsMqE5VOUF1CKs9je3q5Uq9lMJpIZZ+HI
xBPDMEql0ubmZiQJAAAAAMCKs3ilKNwtz/It1imqkG62bNvZ3izEYe3w+/coVwdu
b+/UatVnz55FmAYAAAAArDLh+hSvLi8ty+71e4i8zTgRrXkDixC6nt7fv/9jmb+c
kSTprG3UV1dXfFGLWqoCAAAAYMUJxacoXLfize/frcM6TvNTIaVY+/NQOH+6x4W0
YKPR/Pz5Y+D/Hh0dm6YpUkLX9N1d+HoBAAAAMJNwz2gRWKfoPoHBcOjMN6dEs9Fs
NOp3V4r32wdNSrHZbH78GKwUF/hDAAAAAEg2oUTeFsL+669HrBeddYqd7jr7ro6O
j82hqad14WhFUSqV7q3J5ui5m5ubarXK17Ytcrns/v7+Hf8WAAAAACCQMGafJzJR
sFJcb59iYNDExQIVCAAAAIAwCMmn6LBWZ7ScnJ52O92UlvL/l21Z1Wotk0k/UMzR
w2y12kL5hUI+/+TJk4d8JwAAAADAHMJSiiwTxdr4FJfgODw7OzOMXj6fE4IXPYps
NhvJOdEAAAAAWBPC3dGyJj5Fx9vXboeqFG9ubgzDMC0r2U8SAAAAACtFiEqRsSy7
0+0kXt+E7VM8ODiwbbtSqT57thHSTwAAAAAAeAhl9lkNvp3UKDmUu8Fg6M4DO3S7
3Vw+H94Jzjs7O9++TUXJxi4WAAAAAIRNiGe08J2kRsm5uLg4PDzM5nLyTrlUWuD+
kh8/frRaLeGe56KlNNMcNptNSEMAAAAALJOwfIqsFPtGz7SsoTn0xPZLAKQUSQG/
fx/W2TNL2CIDAAAAADCfUE7zY6VIr8dfjkzTTGna/tuEKMWdvT0nsLUT3drO5fP7
oZ1nDaUIAAAAgMgJ8dxnvnDWKSZo9nnv4ODr589L+CFHKWYy4S18BAAAAAC4lVD2
PkuSFCWHvaSBSjGMzSXwKQIAAAAgcsJVioJ9iolQisxSfYpQigAAAACIFCjFP2Nv
7+DrVyhFAAAAAKwFC1OKs2Zg46gUP3z4wLtWxjdS8tqyrK9fv4bxo/IB8ql9pmlW
q5Vnz56F8VsAAAAAAHfh/krx4uKi0WwanW42lyuXy1tbLwM/FkeluL29Xa/X7bFC
TLk3+SKVSoV91DI9MdsVqguMzggAAAAAcA/uqRRJzRQKRcs0NV2zTIvutNqtzc3N
wE/GQileXl6abkaIVqvpORAl8GNeXF2paalZjkDS1pZlT8tPepvSUt4/wfkrAAAA
AFgF7qkUj46O6of1Yqn4+fNnvs4XC9+CpmXjohT39vYymYx7mUqn07NcpDs7O9ls
VrkhJ6ZHF5qm//PPm8C/PTk5NU1zrBPlq9B1/c2b4D8BAAAAAIiQeyrFnZ09w+g2
Gk1SVKQFc7kcaZ5f//3l/2RslOLdNjUvbe8zAAAAAEDk3FMpPn/+3DKtbs/YcNfS
PX36lJSifCsc/9lJv98XrtNM1/W3oZ3mt7e31+v1Av9r2vk3gZI0HAx4LeBdPq+S
yWTevg3rBD8AAAAAgJXinkrx6b+eipTodo2NjSejt0J0jdFboWzLsCyblFxizmgB
AAAAAFgf7qkUX716NegPJj7FaeGoEpfZZwAAAAAA4OG+6xT39oxOt9FMzjpFAAAA
QAVhKECMCK+6PmDvc71eLI73Ptfr+UK89z4DABbF2vava5txAECC+fDh0/v394yn
WLAsS9M0ehX2kuIpwhCDOIJ6u1aguEG8QI0F83nYGS2NpmG4Z7SUZp7RcnNzc3hY
T6f1BydVZRLFcDgcpNPpoP9NKcfx/dF3LvzDD8T5reFw6GbzflmLDZZlO4HInUt5
Mk6SGBUcb/ZKcUYTS8q2LdOy0vpi2/7qMGqMNr3a9rg0E9ZCp5rh0DTd0kxM7oJR
rFCSWQMrlBrn0k50NkdQvdW0VEjNkyz5x/fvF3Duc1SsSYDDnZ2dWcfGJIkPHz4V
i4XEn3Z9cnJKTfrly+DBVWKgwWSn232f9KhSV1dXrVb7/Xsnm8n2zayJsSUrVC6X
En+YKlkhen3zZivqhITL+fmPwXCQ+PVv19fXjUbz48f3of4KlOKqsy5K8dOnYgFK
MQmQZhoMBuuiFNvtZGeTFfCaGFuyQuXSmihFO/HHg62NUrxpNOofP34M9VegFFcd
KMVkwD3uOihFsTY+xcurq3bSlSKzt3fw9Wvyje2nT59K66IUJz7FpLrD10YpXjca
DSjFmayJ8YJSTBJQikliHXyKzMHBwec1GJZ/+PCpVC5trJlSTCpQigskzkoRPsUE
gXWKSWKNlOJ4nWKyWZNh+dr4FE+ESCVVKUoXKZTiAoFSXHXWRSn6fIqJnBMhG61p
GpRiMlgfn+KaGNsPrlKETzEZrI1SxDrFufy4uHiRdBcU8ePHjxcvXkSditA5Oz/P
ZjKPHz+OOiFhwcKXJFQqldrY2Ig6OeFCw1zTtJ49S342+/1+4nW/cDvdzc31skKJ
HKkyZIXoNfETOJdXV5ZpvXiR8Gze3Nz0er2wrVCMlSIAAAAAAAgVKMUVJcEjWgAS
A9opACDxQCkCAAAAIPZg5BYSUIoAAABAkoGEAg8BShEAAMBdgeYAYAUJtWFCKYII
QGcDEkbyqjTnKHn5AslgTs1EpV04UIqxAbUfxIikVtek5gsAkCQWa6nipxQvLi4a
jaZhdLO5XLlU3toahRFKngU/Pjnpdjo9o+fktDzJaSI5Pz+n0sxkM//5z3+iTktY
HB0ddbvGcDhwq25pc3Mz6hSFgpNNwxgOhtlstlgsJq/ebm9vm6b1f//vqKJeXl41
mw3DMOg6ny9UqpVYh26WhvT19rZtWWp7lBYpl8+VSjG2SGpn8fr1tm1bfrMjLVKn
04lvzyJz+unTl2aj0el21DCKdJN6Uk3T8vn87u5udMlcGNQ2relKOzZHg2w2lwxz
NJJA3S5VTsqRLDh5P5ufkkYLIWZK8fr6ulAoUFXQNN0yTZESrVYrkT0uGeXDam30
JiWELRrNZgJqeSBUrNTxkISibP7676+okxMK7z58aDdb1LZ1PU2NmcqUeqDkBb/l
bGq6Rmq43+tRU63VasnohJjLq6tCLk8XXFFHFsm0NF2nVkoX6Uym3W7FKIZ84Bj7
8vKS8qW2x4lFcs0RkQCLRCq/UMj7zQ4VKw3OB/0BZfbXryRYpL//fkUGljSTHMYc
HBx02h1SFeZgaJrmYaP+z5s30Sbygahtk2v1hw8fWmyOsrl+v0+aoXYYb3Mk80gG
x5FAQpQr5ffv36uGiO+32ouURjFTijQ+qNfrpKM/f/7M1zSI//bta9TpWjyvXr0i
O8Wt18npYZ3G8d+/f486XaHgtOdWy+l+kmKXPUj/BGWTNASP77mFR520BfP06VMq
x27P6ZCS5ycmM00t0TC6dD0YDKgrYitE/dC//+20zdfb232jl4DeiDJldJzxDGdT
BFkkEhn/jrNFmmRTeJUiKwzWxHEfu5KGaDabbGC5YQq2SOUy19uLi4tioRj3dqq2
TdmJPP3XU3pNkjk6OHjXabe57+Ac0c1ev9fpdCj7xdJYGh3W84VFSqOYKcWdnT2q
Co2GM5alBpDL5hKpLTx+i1kD32TA1Z16Hepihc9kJwPueKSAoKrb6/U1LZU8d/jz
589pXCv9bdRC464nJOyDkW85j6pForenp2fVSmWxNnrJTLKp6CSvRZp+G0e4x5X+
UTUjIxWVcy1SzPuXqbkpMVGKHotE9TbW5iiw0grHHP2PZZoTc5QjgxRvc8QDNukv
dKRwSnQNw1HJ3S67+UfSaKHNM2ZKkQteVnd1xBB10hYJlTQNEVKaxtMBoyFCsfDt
a1y7nzlQ1TdNs9FoOMOjmNvlWTiupl6vVqv1+n2j46wjKRaLcZ/rCYS6nMPD2uFh
nQwW9VLtVqterydjkp2a4WAwsCzb8VuMeyNWxnL5VwLcM6Ns2jb7FLk9Blgkdz6n
2WzEdA3fpDS7E58iT1n+/fcry7IajTo7bOKrhoWreqng6IKFlOwr2fldqVZ7vZ5t
W1SUb9/uR5zWBxBYmiKJ5ohyYVsWdR+PHz9ma6Pp2s+fP4OlkWFsbCxGGsVMKTpz
W5x/fhzKVFfUSQsLOShc7LKDVYDscoMGQU1Sic1MJuP4TUUylSLXW6qrpBG1lMbm
LAELgzxcXl2RGmZPjKZpJKFE4rLpcad5BqsJcLYxTkbywfMYSbJIznQNZVMpL2dl
CFukbCYZRcl4Kiq/JfKFgmkOB/1BsVT6/PljlEl8MKPWNx7eTMyRs6pPI/VP9Tkx
5ohkIuWOCo7kPqn8kXOxO5KG664U2fU6Vd1TQl2lmzDkcpnDekLqt4ozJCoWeaVp
smfY2fPEi0jEuK9NZzJy/2wycKZiu10yylSs9LbX61Fr1XT958//jTppC4AdTh4J
xRZpyqdYLKbTsS/ZWZKXdyyJpAwAPEqRnTS8eGCOVo4jHicLWyQWGfIh9Pq9GO3E
8uOptGNzpBeKhRSbo8GARrA/f/6MOKEPhp36VDlLlfJHd7F7gDQSwugZTxYkjWKm
FLns50zGJyZWDuWOmjGNh2hoG3eH+Sx4Vl3XddM0nTGfafEqkwT4Kjzwaja5C3g8
a5AQCSVh8ySLT7bQJHn9PX4L1SIJuU4x/gtF/DqJSrNarfaSZZE8pckdMAfWGO0h
TYpF8vgU1fW11GlmMhm6GfdoDF5/vyuOZXSUxJgjuaG7WqvJ0drO3p7RIUPU2Nra
wjpF397n5K7e45acy+UajUasx3lzcFxrtRpveR6FPXJJgF32IPeKNt3S5L3eydu2
v729TUpCeptGasMdzSemDnt6I88uYLkgNdZ7n4VPQolxVyTrcLTJWwikkIamqZbm
yclJbbz/YzR2FSIZsdg8SpHrLc9y8J5CXu4WdTIfhMdDzGsxJ+ZoPG0Va9cpFxwV
FtVJlvXsHRsXqLOEQEojaqqLcpzFTCkqQYNGLqgEtGE/ckAvV1cQsV4mfyuJWeAV
iBowUsa78kTBTQCjqA0pkc3mNE3r93tyhivqpC2MUW+kbPVwAu+5s1r0lvIrYyFF
ndIH4V/yNbFIY99/AiySEzYyXwjcSOd5AnGfrRovXOtubGxQXqhbGUcmHgniuId2
Er4ik0FkeHV4MswRr7hjSTC6SIl2p5PW9VClUcyUolACkcf9nIA58ByWp0IkwC7P
IQGbRudDVqzdavHSvXyhUK1W1BFh1KlbGLzXkpQTXet6OhmHIqj4VyLyGS09o2cL
2zmjpVJZ1CryCPG0x5FFEpOw2yIRY9c5ZicxFklu6B4OBurolAMQkn7SNL1cKSdg
1SkXmbr+2zVH3cGgL6bNUUytrhywqc1QjJ0OOKMFAAAAAGCtYY27fKW71koxpgOL
BBBVdQcAAADAH7EMpQhBoIKnMZ91eD4eobwOWQYJA5U2LsSlpOKSzvVkST5FVAIm
8Dkk+OEkOGse1iens5j/BPB8Ys0qF5+aNk86755szHKsOatf9NGmcKVnn/2PZvWL
81YSkIVAFpKvuD+cP+2Z/uhP4sIDc7TMBzLnt5JXLpIEZ41ZnwwmPqfLYR0e4wPz
uNJKEdyPBNf71c/aPVK4yplamqcQTp3lANcvWEHuUvHWqnKuWmaXrRT/KP/rNuK/
NVOJzHWSWLfVBUziM3gXEvwQEpy1deaOxYrSjzWLKr7QlaI8Tt4h5bxkc95gPzt7
e8IW3759ffXqVT5f4MCY5+fnzWazZ/Ry+VylUlFjSLrxt4vZbFY94uL1623btvyx
r15vb9vWH9wPD+fs+UbDE9GK7gwGg5TmHJWrRrTiGOPZbI7zeHR01DWM4WBAT69Y
GAWFGsVPMrrpdIaeUrVSiTbeL5V1p93p93qeeE7+YGwybv6MbA6pcMvlkix090FR
Tg3P/WhxIruWy5nMJOIaF6hh9PzpHOU0l/v29avzQKoVNSAWP5BJQCxqI+VViRXq
z+aooPs9aq3B2RwXqJBRx6djuTHLb4MeZLx3iTybmwlMvJpHejitVpvbYKlUlLGL
R/e73Uw2Q0072pjGU/FZ3VfZANUW5wl+qZpZWTP92SGzRtnXNC2fz0ceupkboHvk
IDXA8ubmC/V/t7e3TdPyHMl9x2yKIAMeFbLjoMdemO44xIx0+humCOo0nabd6fSN
Xr7gNO1cLheVTBzbUrL5Ob/Np6K0fKZjVJS5rDy2zfMo+HBkzw+tyJEtJOlarRbl
l4rVzbK39gZaS48tYsmUdcXAYnvJ0JUiHywj38ojkhrNZqGQ51r499+vstlMrVbL
ZXMcKV4e9iB7U/WEN1af6hH1/rOn5tyfHOIUFJo/PEZneBsGB+aVpztQd8vh4ylH
pWKRn4max3cfPrTdcx6pQvAn6SlRS+YsjILspwS16u/ukWLLh2u5U9BKkcmg/9xc
R+fNiKmOyp/NdCaTTqfJWItxQNHRg3IDVqv3I8mpRKbKe1wHp9Nw06mco6rm1Hkg
zYZ6gOFhvU7NwXNqwiqcajjJ5vj4nNHYT6l4TpUen6PKJzRSdmTbPDh412m3he+4
1VU4lYclu3zgwqcUDw4OSBMLIWSzFUoe07rOZkp+A5+mJc2XfETFonN/6fkbMWmA
42xyPZQHyLqGpU+1UT2oQ2aTDMv4gJZRjS1Xyu/fvxf8fDod+vPhcMAWLMIAzlLW
BzZAz+E6EtkwlWyOHpTMJjMy4FGfGjyxM8UCDcudx07N7Z/JY/d0NExAp3l5SQZH
PdpbHq8qz7xWm/YymSpKsvmpPytKmUdPkfFJ0J7I1ZEXKMPdHw1RdD3t1F5beJxK
gdZyyhaVyxPvQ+zOaJFKUebQOdHYDSP+77Gsef78f0o0Hi8V6VmQgqRxLZ96zMen
jg4xLEwOyaX/JcHU7XZ5KED1pt6oG52umH6OM++7sem5/i1HKVK9J7FPRllte5wv
NkbctajnAYzzaDx+/Eg9slN+kqDGw0dgy8PiDg+nTMYyef78Oakcrp3cYmV2uMTV
ei9d4m42+/SfpJg5X3wSGvdt/HD4mk9h4oO/qUmoFjwS+Oxm52psauenU620/gci
pk9i9df5qGD7xdecTTa+3E45y6q68rTNiTt52iLPaptLhp/zLH0zK/Eyj2SiqRxZ
XUlTTp9k8+K/H1WHxOZU7WsZPhmMLRIbFvV8C5nNer1BWn9iqdwOqdfvcZtlS74K
J5p4G+DYuoq59W1mNt2D4NjhNDHgKyAs5nQcc9JJ2Rz0+2RzvJ2m0gnOb9rLhMfS
lUpQUcrue3ZRcpFRRtrTfS7dlB9utdoRZtADN6t0OtNue7s/IbPsDn48iiXQFslz
n6Vv9eFEoBS5E+X+lexLr9fjk601LUVVnJ5OqVxmbxn9Fxd5LpuT38CWVxYwD2rl
KEH+yp/eDw85UONf5AZMUqlQKJK2k+abuiV6AjwI8OTREWGmxUl1nkaOnkfOtixq
1dLtpOqMsHPkh1JFDY8ueOUAdxu5/MjHyQbI7+Tns4lY7LJ7Q7o06At7vT4/EHVc
qN5ffjYlbKCpFGhML9yaSQVKGaG+k62SJ52eAg18ICwf2Ux76nxUsP1yHE7jbPJo
XtO1nz9/inFBi/ETYFe9zCZPBum6ZpomjSJo2MNOjkkbdIkwj+zvDPTdcuIdpyC1
PdOS/e64KB0fITU6y7LpEdFwTrgjXss0qVgpd4H3lzPJ5V+ZNKsBeg0LVWi3zTpF
OTQLhTy7Qp0/Hwyki0IOXNt0S2mzqgWLBE6nvwFKrzbj8RrIGuucdzeczqYrMqgb
Gi2gYgM+7atbPpxOf8cxtdDLMzDzd5qup5xRO9appl10m/YSp90ks2z+HYtyzqMY
ffjyqlRycifHtNEyp/sbFZa7cs+jWNQsc6uUA5uFdx/LVoqUB0f8Gs5KLBqJUok2
6nWecaP/ZZ8/DfG5mGU+R43W7WlYbqsKiawD2WWPj/CW+7btGU6FB5+ES2ZGnYNj
wUcFT5XD/V8hF2iK8eCY8sjLRMgWHB7WDg/rpCF4HQlJT+qH6HFNKcV6XV1MFiGU
/na73WjUKW2cU81diEkp13WdRgLswuGBI5vm16+3SY7Q0+j1+1Q01GPx+htZ6eWD
kn8eIWSsSUA0aNjnOh6ooo7SmRK12iSdci2BmtPr65tcNksWmTLY7XTkoavslJVy
SnUkR5VNstck8tRssjT0KsXxoG5cb9u8woZtHFVR/nOZl6m2GZFSZDnl1Lp+j5pS
z5XCVFGlD3hW4j32R34VOyA985ViPMFNleFjRF5wrpmarheLBU8D9BgWUn5kQ1h/
qNmk/6JxKbVfKuJxBdB//vxffnqVStVZEmNZqgWLKptibChsW8izjN36NqQU+r0y
asMMyqZTzwMNeES5nMpmu91JpYS6sp8tz2i9hJLOu3Sa85v2ErImRzj+PMoaO+m+
u12PbFLzyMc9k7DyPwr+IarnqjKLnO3t7Z7hdn+9PmVNdn9CLayA2vvJcSG3Wrqe
dqbjhRgMB/wMnXl2e5F1dbnrFJUl1ew7EWOXG3WQNLanik7VdHQMtvJQRr2mO5ij
3ouuPXroj9YpCnnS9nIHTGrfLxNGEmq0SMgy2bsm3B6aLB1PA9EnSXz0jd5o2ZOr
qqly8F4WHvRT06pUq85novZCkX1xJKxlURHzNJB0O2XzOS2lsW3idWykt+g+Z5Mf
jnA3PJG14nmi0eIhd/LOWU3l+vAiXw7FJokqMOnyQiHPBktOMlJPnMlm5cJTTqda
aUeDdVt5IO46Reqz1bat1vmIs5nNqEtk2BE1WXDZaIhxraYCJbPO2WS3KyunQNW7
CusU2dvHa4O4yHiAPifxgfZHrpSnWkptU07yKvf1Zqv5YrmLa7nrnWqA2qhl1Rt1
MjuOYXElMlVa012AGFhjJfRV9CeUI27ass3mCwXTHNJ9drUuM48SueqOHnXWaYCO
RZXrZSdr05X6xvMAYpxNqVQom9VqbTgc8Oyn/Ale5SbHcpEgW804m5NKO0mn4ljh
O/M6TeWBcHPg5fJOy+emvXQTJJchqp2juvQ50HSoxkcyx/LQA+yO5+Ijh4ts1Clw
Ix33klwtA7MsdYL/f/114IEsRSm6c80OTtnr6rZQkokG1UR3fp1yNRwODw8PPT2T
UASyORySBWc7pf7KSPn5ZpP/9H6oqH2/NN+smGVJu6t/KI8lmUeelGQXVMpdo02m
gTemsbeD11+PX52xPv9cJNENqJGTgaExEHeQVGT0kKmAqSeeDAyqNdJ81aqzzqBS
q77dd7LJ+oN7Gkp5u9Ohj6UzmUajzkPbyQrIWi1C1ykXHK8gVNun1H/SDcPpp2bM
skMWKP0VFaj3geRHywm8SjEiB4Y3m0pjkWO/0RYld+xHtdppmySu3M6VF90LZzGQ
s+wmUPWO+oOo1ymmNI17ILUNTiVeGZ3zdLxHQAh3cE/NlkW/urrUuT8csjhb5qpT
te0H1LdaLZt1x2PdLjv7qQxJMlL1YwPiqbGMtOTSb8ptlj+mPr1Iel9pUScN0DUU
ZDD5Ufh705nZdHfm+RdDr4KbP6DjcNsmPXYqykB/kqfSyrrh7wSnmra7E2uxfqk/
zaNqS9UlsMFFGdQwA11r0a7UCoQ1ukzSzCwrPq9R7XU7UP//qkuQF5LCZfkUZ8zz
OksuBlO71vPFAg1lqIXT9WSdojtRS9WCp4QClh3M8E/86f2Fo8YT9hgaz1uefCS7
Rv2Tk0djahZSThzIFeWsTkhe02ieHhd1eFS3otoD4VmnKJQNLmS/hkPHbcPZlJMa
zmS0UpTqHiYxmQpx+i1u7WwKHcdAPk8XPEWyfLg+syUdeWJce+pMU45W+vcfP36k
LvrhZXlyeEdZC3ggrpKYWqc4rvMRZ1PZiy31+unpmQyMQtZqks1xgUrLNZpDEIK3
lJZKZVlDIvcpUgIcbaQsrWPpQ1kYhc4Zp1yIUeKpuDvttjoTTa80ZmNtxPadPxl4
P5JKG1zfxns/pWGRU35Gz2g0Gh4zK3dJV2s16drZ2dsjESxnh9hSRRiXgHtH7jU8
C2pF0MjE0zDFjGx6vj9an6KY3XHIx+4ZmHHDpGJ9codOM7BpLyljCtLmO0U5vYAy
MOWBwoC6XUdI+JQir3SKdmLKA/uD5Gw4+x3Ubs6vBT21V31isV2nON6/EviB19vb
WkojfUNZlWMC9cHJfaD1+qE/IhSzskpRxdOA2c5yHmW0jm636wkVSc/Hqdb1qbAy
2byzq6Xf75XGYQvVjy3fmyirJnc80sFG3QZVZZL+uXyOuh+qxGyLqTQp8RxckL+B
S1l+jLfcsvANqAwL3dX1R8gYMWo0DZZQHFdvsmG/Xs/nAyrtpy9fmvUGlWBTPpBW
iz5JJcpbu+hPOORQhHuf1SXhE9+hW76UTcu2KHlUjTmbVNaUa5lNqn6DwYDl7wR3
LmmllCIPuihV7XaH8nJ6elqtVnlph6qlGLnOT620vLpI+ti4blPJ0p8G3v93FEGs
eIUA1zfKHa/QohZEZaoaFtkVkdLy1Fg5bFAn1sW0b4Y9HFEJC0a1qH5D4alv/qC8
/Ce6u04gUOwufO3X/VDtIa+OVaeSxLSUDIw9zPh9ivTNTtOu1+kPx4XrmKPlz03N
t/ke0T8nj343sOyqIi9HFc7jVKcw7v74A06WC5PC8kfHDLuXjNinKFy/K5lg6kKo
7KXMD4ynODRNT7QkSZyU4riCSmeSdPVTd8uuQTWP8lE4C/jGy9roadArzz6PFgm5
Qbkj6YoYuWRNwl0IPepSscgZ5AiCZNcqlTLZI3XpiRqeUDqx2D8hI1ZIH88qxFMU
vlo0SSfjxgDrDwb+2J/KAxmtHHBXJetOPMXxQgKxGvEUha9HGQeDdJaNUsdMqW13
Orw/dNYwfWXXKfKeDH8IdPUzMvH+PMoSp7Kzhc1l2mg0NS01jqeoC+X+kkOpyxVO
Tn1ztb50ElN9owtOfNbdcMbxFCvVajqt18bZVCdDRoxtMrVBt8YW3RY9GktEu0Vg
qgG6tmIqCN90ffPH3mMh6IFNTeCkUFQEdhzqY1fT6c+mxO+mknE3SYK4S570drsd
iQN1yuaP69tUPEVFNs3Jo7/I5DdHu6Dfw/X1TalU4vlVaf/nxFOUWZabJqck03ia
K07xFHm9SDqd8UTGZ3gfKGWYY9iqeaOcN5rNvtHjNW103xOqTYWdWP7la/PuLz36
FwdxIONF6ZGlywc5yL1OMo+86IQtFG9qG7jVKJNxVnlyBXL+vN3u93rpTKawAgck
yKM7KIPqCQfyRAGOSk2lSb2mvyjpY20nSH1vOHSikdPHZDsZVYaeWxkWHX3+3nAt
UkPQTdKZVStt37N0euqBFAuUI86pPHTHf45RhPgbCw3/+CwBKqZKpUJ9SWA2Jbyx
w6PvVyECH6+aoAdOyfMcLCSRiXcrrTePXGSO3BydPjVaga3cT0V+sBAfceTUtnED
lAZEGhZdT9PQbuvlS2+0WnUhAZOajNY40hs9Fl3XViEogdMAG00+JspjKDz1zR+U
l8WHg5JZtdJKAx75MFWeDORs+POd0aI2t1s6zWnzJZTDwJymXa1EqIn9tlT+V1BR
ThqmOqXmtzzshY3W7PjhHVfU/dFwlO2q2v0JJcu87jbQ3k4qf877xB7O8s59njUl
uuSpUpxiuZqgXGLBnxZTrIv1LonHWe1rAsoRxJHYnPs8HzS/teV+Rb+CFeaPkrSC
6V8siSlW8EdEVYKoOX7wTACzwJoQsVJk1qdmPzCn6/Ogkkciyy6MTCXyQYF4EVgJ
UTPjAkpKkhCfIgCBxL2pxz399ybWGY914pfJagqpxSYg8uyAdWMhy11CYk2VYhyt
QCzSvJBExiKnf8q9MxW7pxG7BN+DtVqveT+Wk+WlPdhVK8Hw0rNqOV04ic9gGCRB
Ka7IXhkwHxTHLPBkAAgVLPsB8WLVqtzylKI8KcgfDG9nZ49ev337+urVK3ne+Shi
SLfrj17hDzsp3NDTtmX5t7577l9dXeX5AIYxYZ9VKsPRyXCA6i8GRg31pJmPyDMM
g67V4AW84X/0N25kh2jjzssiy2SnouTImA6e6DlCFuU4mrGM0UCFS5+Uhe7E3+l0
eP//KoSPmZWe0X2jl8vnSt5Ke1Mo5GWl/fTpCz2QVEqjm/xARmcEKwGx5IETkeRR
yLBHbswRmU15lrGKPMNNbZscT34qWmG9/s8/o2PvAws6KmQ4T2md5gTpUCvtqA0q
cVU8bXCWXYoEDrrmCYwi73tCh3japgh6SjKuk79pLx/ZuXqy6Q304x4QJU9yU2us
DFumWrCpCj/+kqgOLVQhk1Iul9TimOoRXGRtVDuaOQaZCawPkcDh8WWUvUlnyjhF
6elMp4vS6NLflkqTPM7RFSuC5+HP7+XVRjoJLOgLEfVwlqcU5cF9/lObqSlSla3V
arlsjmO3Uv6LhaLJMV19UYjVSJtzzs8WQcFFx0HtJ8dOhH3+4+QXx+d5qHbKHzVU
zQvljtIpAzLTTbqgOsQn0o4DpTrhrPmb1VjWS0Y5ut59tmJ0cKqMdCqfgPrA1ezL
o7TcU+F79GGuDOqxKJzN5QcxVpFjHklAOt1XedCZmM4pH8RE2RwOh5ZlcqlNAv8q
siPCML+zsjkVoHicVHnykJpNb/0c91t8LI0Tu5sL2rI8oYOXD58GJjMiz8x08IWx
9ebRjUMuW7d6TtIqRBeXTILbT6dndJ+M8/RJWsfHTihc1TTJp8RHw001eTf7pUr5
4/RZycvHn80pC5zisfrIBMkj5mVM31E8fLd34I9NBR4Xo/rgOcQ8EiaVVjlekkNn
y95NFh8HNqbKOSub8mtn1ZPlox7HwD347Z3p3DyyrlrB0w0k/ixPlamL2stLWzTK
sgJnLWY7WiYBxIVzboF69JBwT64slcpU5DRc4M5VPSdKHk1Dz4vz7Ak7ydFf+fAS
tWYH3udvW6bvbf4v+uPcetIsj7n77p6/4pzaZ/S4z+YDfAIPLFm+75rNFp9gJjta
GnlTy5WnDMmuRT3uWRalGk9fHVfxGIMfIB8fF+1pNHw68OT0+lqNQ7uz72FWOmVB
U5dMD4f/Sw0hSzZC/gSNhqm2R3uG/axsKulMkeDzpFMt0Fn101/Qfi/XMlFH7ayB
Ak8TVQ/Okm12ThucZZeigkdifK2mZ9b9nb29fm9iZlXvKZddQJMXEXvBhcyOm07V
hN5qgWuHh/IwQHleHOVUS6Xkh1ehYTKqw141p7Nq4ySbHoPsuuj8Z3zzdbT11p+S
+xSl7HQMostHFH7+/NHfrlcBf+11ytTozor37jZSb7GGkbUlKUV5jqE8jE6eZECW
hUVhStParRaZm1K57FhYo8uuI89x19yG5QTuwcG7Trs9+pmUoG6YFZIcb/F9z7na
1MMtbSTBKQwcu3AllnZnKs3j/PJhptI7xfaaj3RkCRX5PAirUj7AQD5Yx/NEjdNp
nV3LsqlUOZGsP9Sj32X2+b/kuZY5Fxo/qV4Z/1mlS4ZP9aALuUaCpB7JvnrDl07F
mT3OqVNpuS3Ic8+oQDUtpdYNPn5NOE8v4GSF8FBHF8HZnD65eJzOlDpmUwuUpbO/
fjoFbVn8ZLh1y4HQ8uFZOV3XTNOk6se+ItaynPKR/QkqSjE7j7PsUlSwkqMnTeNM
oSgAVur0/HvT9z3ZZGeMruv0kCzTZGHh2J+h0uTdh8ZSO5I8yuxQRXWyOS4ytqsz
LTD1JsWRS2KWpZIf9lT4qOClLJ7iELNro9ppzs/m1AOMVCmen/8ol0pOSno9afDn
dN9qjZ2VR1aQ3Jl6dMUqENgYZ5UpH+sis8xTPROTlcsttpdchlIcuXwti3p9gyxx
tyv7kuOTk0a9TqWoHpxK9aBarakNQHVC8HSPrCtUJ8gKU7VwNKiiCEf3bZtqhlBq
g3PSa69H42BSqMI9gCvs6RLHC0i/WB79IhXh+/EvsmNZmjA3zUN6UKofgrtVOaSQ
Xih6Ajn3wFYyc/S/9ACjPU2LitK2LEoM1VROpKZrP3/+ZP3Br6SKDg+ptdZZ9crs
U0ac/z07c+YO3P/lFXL0YcoX5Y6y+ebNaH3b6gwEqWLX6w3THNZqo3TSaOefoHSq
lZZrYKVapfpg25ZcmMvQg6rX66qUXL572POLnM2hOaTSUce1PImsThyr9ZkNMdUB
f/1UqwGv7PR88zKRAzmeuyEjQ6+eJSte+xOcx656ot0suxQV1N+QFG40Gp5Db0nt
kdbw3/eYJim2Rk/J1dPeJl8s+ueLloybHavRqPOcBmdne3ubut5Am+/JpsRjqRh/
hWeimsAZFUfKGVJubGywPqAiKBYLnhbn6TQl7JjkZUJ8Z6qeRFpvJzVTKUpP9z2n
M5WoRcmdqVN7fbpi2dkLYlJ7xw9/bGECylQoxaqn0wEmKyVkTh/OMpSinNzp9fud
Tpt6ULKt0l/CE1vdrkHmmp4FaQvhK8JRtruOeaKqTHc8K23nrVOcdkHx8IKUlq6n
eY2UuiQ2DPgX05lMOp0e9PvUDqVQppqRSt2SFx4ryEchnVX0rIqu5ynr6kVHEEe6
TlFCfQYZUxoGyQWp6mpLoSxUVYuS8lWr1pxzcu3Rsid6pTbAAoJt8Wgh4GosLpEO
YDWdjFywKE2zWtBy2VO+WBgOhsPBQJ3M4vJVG0gkyM5vlE13xY+aTW5ZdJNa5ePH
j/imWqAsHag0aYicSmk8+Dls1B0/ca3Wc10+vLzP/wCXBg/ief501NDcfWM88yiN
hsf+2LbguXIeEdFFNj9ug9M7WiJcp6jKF+5EG80m2T11DbRzy/2PjHtwvNrTqDV2
6ikFda70HGhsT1W5UvGuQV8m3HE62VGyKRwL/D+WaU5svmnNscDSr0HXanZWpGGK
sbONl4SqxTFVG6nFGV25+yGw0+RZICEmTfvTly/N+rieRDp1M6vG5nJ5ko/ptNqZ
Trz7Qsmj2+nYhUJeLUpPZ+p5Gy2BWfaWaXfKwsgs+3WOnNMjk7WQkcwylCLPn/KE
qcwSe4CPj0/cxQPO/DrlajgcHh4e0n2uxDxUEopwNIdDsln+PTF3V4o01peOH/lX
oU7gTv0in0PvruZx1qvdIS88xaxuNmSfIj1Aem40yNja2hJjdeKZH1wmXB3lNgjq
V0gvygpKmaJmQFnmhdL+ouQVNjx4orekg8mgq75DuYBjFdSwcBs25YY9Rvn8dDpb
LWmj6bH0XI+y7HV45MAZ99dAdYVudJkbwWLCyabb63BxqAWtppP1hCxQyppbP9Ps
lZH1k+0d9bgFnmHvdKkXj8RJzIvHhbP4rKUuk6WcBihFtdLWqm/3Z+cxl/v3v0dt
cBV2tLDFmJjf6U6In7wnnWpR0lMqlcqp1NRTUqeYeUkuPTSWkhFnMyg7Xpvv9gjU
4gItsBtoounYqbGlYhmxIg0zoNKOXUezWly1UpHZ9IwfBsMBD2/ouVWrlUk9GS/T
jKTeThUlp2Q8hnGKMqVx/ITLy0vS9G5R9qm8VBvLcMwQtdOhR0HXgR4o/pOoYtPw
uJr7kZFIcEWLt0zdTWbcy6uN1POURAju0tCVolwN4DAOEyPEqNfxRwbh+6wb/OsJ
2MPhz/+s5Wsek0EPlKqNuizM445eOJQAyiD/ItdCFgqUhWaj2em05U/LOjpqAGJU
6uqjEOP5AqpS9DocOgNl/nPpwomwT3r34UPb3bxcrdVkaAZ1uZtQ9kmQFlSLkmu2
dBbKLVDsgScT0O/1KLPUJ0U1TcmQeRXOtu7SxCNerZHA/fnzf510Vqt9w5tOT6X1
FCgP/uTqAp4pizbakQjMZq2maRq7/MV4Z1W9UX8zvTFW7gmlChlYPz1bieXW+OXX
W2kc1M3mVJSlUolGNcKzTnFkf5ypalmUAXl0HQBTq/0i9c2IscThvZOjPdpufmlw
PnWfd8u6irDjIvXHJMjXeDM4fZ7kIzVquY1dNvmos+lstJ/sjXUdMDQ48dp8aYHH
pelYqnabMijlFHsiZUXlRUSBw9Rlygvpa1A35lN+qTjofmBtJHXrlOZYD82wYFql
UhnVB94aPN49vfwJnOmi1C3LlPu4fUXplBFVVBL3U0U5o9PhuDmB+x+iZdJI5b5s
Vyy565rS3jJ1u0VPtxKwtHqhWQtdKfpjbcgHwbvkqAVS8ZM6pKzK4d14ADe1R6le
P/TE95Lc0afI3RJVvnanTc9XbrmX/d/CGf+i1u50lF/Uu92OPyRkYF48e59ZSZCV
tyyb+jMaXtArPUZWaTwiDCkv85F1XZ1JlFWWzY2UC51ux1lfr2SflcdUTIexe4Z9
0jKnkeROwumU7hPnsbdavJGZJaAnnf6gdKpzQlYProHycUUeg8OTTXboykooV0zL
dPpDnPJkird+FgqWbXkLulaLZDP7RLyKiQziTpfdqLwibY794elOusN5lPv25ENY
BZ+iXLMhlHA2wu13lfuTSEY0hjk8rMmilJ2TGheTnxL12f4mHxXB2XSFL5ka0hcT
C1ytuKsmumqNDbBUrsziyZxJw4x6plImbHp44xQHXTi1MZujV7XF9ft9NV7vrKZd
KBYD68nylWJAUY6Hl0Gd6bgoxw1TWid/Ucrts6OYKvW6Oh0UIbMaKW8tmrKirRal
eWSLFHvrDddQd1fJL04MhK4UeSimBj2S1pNzRXqf/peHRHLEFhj3aGiantCDEn/c
xFn3uZ2onwnbf8Pazrkat236Red1fl7GvYsMsOSJp2jZdqlY5IcjHQMRmuxRmL3p
HoUaJ41l2UMjoYZKrdqTfRlYZ7Lky7Xyo7W60+0nwpCwanhIeuVFMJOVXr50lspl
T06n6rb753KNfIQONg/ebLo5kn5QGRJFNqvAsKCB9ZMu+JtHBd3teqIVRoU6kTeJ
6jWuzIH2x5tHp0z1Vqs5tZozyC4tgUBH1y1xZ937/qJUUWe1+Imp7V0EHaywfDzZ
DLT5wmeBeWyjfkzONa9Ow/SgFseoNrq+QOmdYk+h19J6mrYvQu0qjHACUzIpSk9n
6oZRvLUo5SJU6URfBcvjQZ36D7IwjhXtDwYBHajPZC0wa+EqRVnMnkSz4zRfLNQP
D2msJuNGqh/zx1L3hB5UUePSzb/PrmnD6JL2Wk6U9sBflGGQ7pIXXuTnntGSyudz
lWpV7m5pNkZLanihSVQ2OnAij7fdUJLkiSbySIDAoqS6Th/jRdb0SdIi9Lf+UwdE
pEpRjGsmjdQpq+4ZLSWqtP5I+gRvY/LnlCPt0TeQwaLBvWzt/CWrcDSCmGTT3S6a
zZXLJdk2/ekMLNBZ9dMt6C7dF0pBLzt7PnglzNQZLW725Rkt4zxOdvCIcdvs9wfD
QUAbnGWXooLT449eqaZzjpkVyrLplKYVpg+7YlZBKXoe+90tsDyUyHPKFFf4aKN+
BuKptOpycK6NXIc92VSadiqbzapNW35gReqtp8byIgFSBbIoC4W8szbJl8dZRbn6
Z7R4Hn6ghfGElGYSckYLAGAWq3bK55JZ8+wnDJQmAAnj/wNQ4Tn0CQt9wQAAAABJ
RU5ErkJggg==">
<img style="position:absolute;top:519pt;left:291pt;width:31pt;height:14pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABcAAAAICAAAAAA3wTsyAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAR0lEQVR4nGP8z4AVMGKK/2eEioMZaDIg8X8fGRmAFEyWiYEPov75
fqAwTPQ/8z8+n39MEPP//2dk/A+V+8+EsBfDBmzuAQMAmYsaASeQxO8AAAAASUVO
RK5CYII=">
<img style="position:absolute;top:519pt;left:401pt;width:43pt;height:14pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABcAAAAGCAIAAACnwpLJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAqElEQVR4nGP8//8/A8WAEW4KkMHIyEhQA1ZlCFN+//79/ft3Pj6+
9+/f83Bzs7Cyfvz4kZ+fHygI1MTKxvblyxcBAQEgyczExMnF9eHDByAX3ZSbN2/e
vn3b29t7+fLlFhYWQON27twZHR29Y8cOUVFROTm5vXv3RkREbNu2DWi0qanJ+vUb
/Hx9gcahmAJxLUgIycHI7v/37x8TExNWKUaSQhctUOBcAGVhWfUkQWeYAAAAAElF
TkSuQmCC">
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">33</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with these results but the number of enrolled subjects declined after this time. Overall, among the patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who discontinued the study, 18% discontinued due to adverse events, and 8% due to insufficient response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to adalimumab treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of Life</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patient reported outcomes regarding vision-related functioning were measured in both clinical studies, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using the NEI VFQ-25. Humira was numerically favoured for the majority of subscores with statistically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significant mean differences for general vision, ocular pain, near vision, mental health, and total score in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV I, and for general vision and mental health in Study UV II. Vision related effects were not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">numerically in favour of Humira for colour vision in Study UVI and for colour vision, peripheral vision </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and near vision in Study UV II.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immunogenicity</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Formation of anti-adalimumab antibodies is associated with increased clearance and reduced efficacy of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab. There is no apparent correlation between the presence of anti-adalimumab antibodies and the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurrence of adverse events.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with polyarticular juvenile idiopathic arthritis who were 4 to 17 years, anti-adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies were identified in 15.8% (27/171) of patients treated with adalimumab. In patients not given </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant methotrexate, the incidence was 25.6% (22/86) compared to 5.9% (5/85) when adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was used as add-on to methotrexate. In patients with polyarticular juvenile idiopathic arthritis who were</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 to &lt; 4 years old or aged 4 and above weighing &lt;15 kg, anti-adalimumab antibodies were identified in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7% (1/15) of patients, and the one patient was receiving concomitant methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with enthesitis-related arthritis, anti-adalimumab antibodies were identified in 10.9% (5/46) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with adalimumab. In patients not given concomitant methotrexate, the incidence was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13.6% (3/22), compared to 8.3% (2/24) when adalimumab was used as add-on to methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in rheumatoid arthritis studies I, II and III were tested at multiple time points for anti-adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies during the 6 to 12 month period. In the pivotal trials, anti-adalimumab antibodies were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">identified in 5.5% (58/1053) of patients treated with adalimumab, compared to 0.5% (2/370) on placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients not given concomitant methotrexate, the incidence was 12.4%, compared to 0.6% when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab was used as add-on to methotrexate.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with paediatric psoriasis, anti-adalimumab antibodies were identified in 5/38 subjects (13%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with 0.8 mg/kg adalimumab monotherapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with psoriasis, anti-adalimumab antibodies were identified in 77/920 subjects (8.4%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with adalimumab monotherapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult plaque psoriasis patients on long term adalimumab monotherapy who participated in a withdrawal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and retreatment study, the rate of antibodies to adalimumab after retreatment (11 of 482 subjects, 2.3%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was similar to the rate observed prior to withdrawal (11 of 590 subjects, 1.9%).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with moderately to severely active paediatric Crohn&#x2019;s disease, the rate of anti-adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibody development in patients receiving adalimumab was 3.3%. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with Crohn&#x2019;s disease, anti-adalimumab antibodies were identified in 7/269 subjects (2.6%).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with non-infectious uveitis, anti-adalimumab antibodies were identified in 4.8% (12/249) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of patients treated with adalimumab.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">34</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Because immunogenicity analyses are product-specific, comparison of antibody rates with those from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other products is not appropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Juvenile idiopathic arthritis (JIA)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Polyarticular juvenile idiopathic arthritis (pJIA)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira was assessed in two studies (pJIA I and II) in children with active</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">polyarticular or polyarticular course juvenile idiopathic arthritis, who had a variety of JIA onset types </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(most frequently rheumatoid-factor negative or positive polyarthritis and extended oligoarthritis).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pJIA I</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:256pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in a multicentre, randomised, double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">parallel &#x2212; group study in 171 children (4-17 years old) with polyarticular JIA. In the open-label lead in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">phase (OL LI) patients were stratified into two groups, MTX (methotrexate)-treated or non-MTX-treated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who were in the non-MTX stratum were either na&#xef;ve to or had been withdrawn from MTX at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:306pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">least two weeks prior to study drug administration. Patients remained on stable doses of non-steroidal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anti-inflammatory drugs (NSAIDs) and or prednisone (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.2 mg/kg/day or 10 mg/day maximum). In the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">OL LI phase all patients received 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2 </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">up to a maximum of 40 mg Humira every other week for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16 weeks. The distribution of patients by age and minimum, median and maximum dose received during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the OL LI phase is presented in Table 17.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:287pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 17</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:104pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Distribution of patients by age and adalimumab dose received during the OL LI phase</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Age Group</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Number of patients at Baseline </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Minimum, median and maximum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 to 7 years</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">31 (18.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10, 20 and 25 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8 to 12 years</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">71 (41.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20, 25 and 40 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13 to 17 years</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">69 (40.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25, 40 and 40 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients demonstrating a Paediatric ACR 30 response at Week 16 were eligible to be randomised into the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">double blind (DB) phase and received either Humira 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2 </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">up to a maximum of 40 mg, or placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every other week for an additional 32 weeks or until disease flare. Disease flare criteria were defined as a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">worsening of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% from baseline in </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 3 of 6 Paediatric ACR core criteria, </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 2 active joints, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf03e;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% in no more than 1 of the 6 criteria. After 32 weeks or at disease flare, patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were eligible to enrol into the open label extension phase. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">35</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:287pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 18</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:213pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Ped ACR 30 Responses in the JIA study</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Stratum</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:270pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:419pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Without MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Phase</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">OL-LI 16 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ped ACR 30 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response (n/N)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:252pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">94.1% (80/85)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">74.4% (64/86)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">                                                           Efficacy Outcomes</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Double Blind 32 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira /MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N = 38)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo / MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N = 37)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N = 30)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:461pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:461pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N = 28)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Disease flares at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the end of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">32 weeks</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n/N)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36.8% (14/38)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64.9% (24/37)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">43.3% (13/30)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:461pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">71.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:461pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(20/28)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Median time to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease flare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&gt;32 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&gt;32 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:461pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ped ACR 30/50/70 responses Week 48 significantly greater than those of placebo treated patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p = 0.015</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p = 0.031</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Amongst those who responded at Week 16 (n=144), the Paediatric ACR 30/50/70/90 responses were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintained for up to six years in the OLE phase in patients who received Humira throughout the study.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Over all 19 subjects, of which 11 of the baseline age group 4 to 12 and 8 of the baseline age group 13 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17 years were treated 6 years or longer.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Overall responses were generally better and, fewer patients developed antibodies when treated with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination of Humira and MTX compared to Humira alone. Taking these results into consideration, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is recommended for use in combination with MTX and for use as monotherapy in patients for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">whom MTX use is not appropriate (see section 4.2).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pJIA II</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira was assessed in an open-label, multicentre study in 32 children </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(2 - &lt; 4 years old or aged 4 and above weighing &lt; 15 kg) with moderately to severely active polyarticular </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">JIA. The patients received 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body surface area (BSA) of Humira up to a maximum of 20 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every other week as a single dose via SC injection for at least 24 weeks. During the study, most subjects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">used concomitant MTX, with fewer reporting use of corticosteroids or NSAIDs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 12 and Week 24, PedACR30 response was 93.5% and 90.0%, respectively, using the observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">data approach. The proportions of subjects with PedACR50/70/90 at Week 12 and Week 24 were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">90.3%/61.3%/38.7% and 83.3%/73.3%/36.7%, respectively. Amongst those who responded (Paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 30) at Week 24 (n=27 out of 30 patients), the Paediatric ACR 30 responses were maintained for up </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 60 weeks in the OLE phase in patients who received Humira throughout this time period. Overall, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 subjects were treated for 60 weeks or longer.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Enthesitis-related arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in a multicentre, randomised, double-blind study in 46 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients (6 to 17 years old) with moderate enthesitis-related arthritis. Patients were randomised </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to receive either 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body surface area (BSA) of Humira up to a maximum of 40 mg, or placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every other week for 12 weeks. The double-blind period is followed by an open-label (OL) period during </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">36</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:52pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">which patients received 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BSA of Humira up to a maximum of 40 mg every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneously for up to an additional 192 weeks. The primary endpoint was the percent change from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline to Week 12 in the number of active joints with arthritis (swelling not due to deformity or joints </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with loss of motion plus pain and/or tenderness), which was achieved with mean percent decrease of -</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">62.6% (median percent change -88.9%) in patients in the Humira group compared to -11.6% (median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">percent change -50.0%) in patients in the placebo group. Improvement in number of active joints with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis was maintained during the OL period through Week 156 for the 26 of 31 (84%) patients in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira group who remained in the study. Although not statistically significant, the majority of patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demonstrated clinical improvement in secondary endpoints such as number of sites of enthesitis, tender </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joint count (TJC), swollen joint count (SJC), Paediatric ACR 50 response, and Paediatric ACR 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric plaque psoriasis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Humira was assessed in a randomised, double-blind, controlled study of 114 paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients from 4 years of age with severe chronic plaque psoriasis (as defined by a Physician&#x2019;s Global </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Assessment (PGA) &#x2265; 4 or &gt; 20% BSA involvement or &gt; 10% BSA involvement with very thick lesions or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Area and Severity Index (PASI) &#x2265; 20 or &#x2265; 10 with clinically relevant facial, genital, or hand/ foot </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">involvement) who were inadequately controlled with topical therapy and heliotherapy or phototherapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients received Humira 0.8 mg/kg eow (up to 40 mg), 0.4 mg/kg eow (up to 20 mg), or methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.1-0.4 mg/kg weekly (up to 25 mg). At Week 16, more patients randomised to Humira 0.8 mg/kg had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">positive efficacy responses (e.g., PASI 75) than those randomised to 0.4 mg/kg eow or MTX.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:367pt;left:147pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 19: Paediatric Plaque Psoriasis Efficacy Results at 16 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:300pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:301pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=37 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:385pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 0.8 mg/kg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:423pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=38 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:289pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 (32.4%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22 (57.9%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PGA: Clear/minimal</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:289pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15 (40.5%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23 (60.5%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX = methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> P=0.027, Humira 0.8 mg/kg versus MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> P=0.083, Humira 0.8 mg/kg versus MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who achieved PASI 75 and PGA clear or minimal were withdrawn from treatment for up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36 weeks and monitored for loss of disease control (i.e. a worsening of PGA by at least 2 grades). Patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were then re-treated with adalimumab 0.8 mg/kg eow for an additional 16 weeks and response rates </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed during retreatment were similar to the previous double-blind period: PASI 75 response of 78.9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(15 of 19 subjects) and PGA clear or minimal of 52.6% (10 of 19 subjects).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open label period of the study, PASI 75 and PGA clear or minimal responses were maintained for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">up to an additional 52 weeks with no new safety findings.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric Crohn&#x2019;s disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira was assessed in a multicentre, randomised, double-blind clinical trial designed to evaluate the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">efficacy and safety of induction and maintenance treatment with doses dependent on body weight (&lt; 40 kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or &#x2265; 40 kg) in 192 paediatric subjects between the ages of 6 and 17 (inclusive) years, with moderate to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">severe Crohn&#xb4;s disease (CD) defined as Paediatric Crohn&apos;s Disease Activity Index (PCDAI) score &gt; 30. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Subjects had to have failed conventional therapy (including a corticosteroid and/or an immunomodulator) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for CD. Subjects may also have previously lost response or been intolerant to infliximab. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">37</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All subjects received open-label induction therapy at a dose based on their Baseline body weight: 160 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at Week 0 and 80 mg at Week 2 for subjects &#x2265; 40 kg, and 80 mg and 40 mg, respectively, for subjects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 4, subjects were randomised 1:1 based on their body weight at the time to either the Low Dose or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Standard Dose maintenance regimens as shown in Table 20.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 20</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:254pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maintenance regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:226pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:226pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:275pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Low dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:336pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Standard </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:336pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:275pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 mg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:275pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Efficacy results</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary endpoint of the study was clinical remission at Week 26, defined as PCDAI score </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 10.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline) rates are presented in Table 21. Rates of discontinuation of corticosteroids or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunomodulators are presented in Table 22.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 21</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:257pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Paediatric CD Study</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:210pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PCDAI Clinical Remission and Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:261pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Standard Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:264pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">40/20 mg eow </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:280pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 93</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Low Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:344pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">20/10 mg eow </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:360pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 95</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:424pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">P value</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 26</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:361pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.075</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   Clinical response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:361pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">48.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.073</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 52</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:471pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:471pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:471pt;left:361pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:471pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.100</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:484pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   Clinical response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:484pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:484pt;left:361pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:484pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.038</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">* p value for Standard Dose </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Low Dose comparison.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 22</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:257pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Paediatric CD Study</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:116pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Discontinuation of Corticosteroids or Immunomodulators and Fistula Remission</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:303pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Standard Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:306pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">40/20 mg eow </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:396pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Low Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:388pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">20/10 mg eow </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:469pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">P value</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">1</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:95pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Discontinued corticosteroids</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:324pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N= 33</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=38</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 26</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">84.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.066</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">69.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.420</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:95pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Discontinuation of Immunomodulators</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">2</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:325pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=60</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=57</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">30.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.983</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:95pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Fistula remission</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">3</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:325pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=15</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=21</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 26</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.608</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.303</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  p value for Standard Dose </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Low Dose comparison.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Immunosuppressant therapy could only be discontinued at or after Week 26 at the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">investigator&apos;s discretion if the subject met the clinical response criterion </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">38</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:53pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">3</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> defined as a closure of all fistulas that were draining at Baseline for at least 2 consecutive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">post-Baseline visits</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Statistically significant increases (improvement) from Baseline to Week 26 and 52 in Body Mass Index </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and height velocity were observed for both treatment groups.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Statistically and clinically significant improvements from Baseline were also observed in both treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">groups for quality of life parameters (including IMPACT III).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">One hundred patients (n=100) from the Paediatric CD Study continued in an open-label long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension study. After 5 years of adalimumab therapy, 74.0% (37/50) of the 50 patients remaining in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study continued to be in clinical remission, and 92.0% (46/50) of patients continued to be in clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response per PCDAI.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric Uveitis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira was assessed in a randomized, double-masked, controlled study of 90 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients from 2 to &lt; 18 years of age with active JIA-associated noninfectious anterior uveitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who were refractory to at least 12 weeks of methotrexate treatment. Patients received either placebo or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg adalimumab (if &lt; 30 kg) or 40 mg adalimumab (if &#x2265; 30 kg) every other week in combination with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">their baseline dose of methotrexate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary endpoint was &#x2018;time to treatment failure&#x2019;. The criteria determining treatment failure were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">worsening or sustained non-improvement in ocular inflammation, partial improvement with development </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of sustained ocular co-morbidities or worsening of ocular co-morbidities, non-permitted use of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant medications, and suspension of treatment for an extended period of time.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Clinical Response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab significantly delayed the time to treatment failure, as compared to placebo (See Figure 2, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">P &lt; 0.0001 from log rank test).The median time to treatment failure was 24.1 weeks for subjects treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with placebo, whereas the median time to treatment failure was not estimable for subjects treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab because less than one-half of these subjects experienced treatment failure. Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significantly decreased the risk of treatment failure by 75% relative to placebo, as shown by the hazard </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ratio (HR = 0.25 [95% CI: 0.12, 0.49]).</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">39</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Figure 2: Kaplan-Meier Curves Summarizing Time to Treatment Failure in the Paediatric Uveitis </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Study</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:180pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PROBABILITY OF FAILING TREATMENT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:274pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TIME (WEEKS)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:445pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note: P = Placebo (Number at Risk); H = HUMIRA (Number at Risk).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacokinetic properties</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Absorption and distribution</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following the administration of 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(maximum of 40 mg) subcutaneously every other week to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with polyarticular juvenile idiopathic arthritis (JIA) who were 4 to 17 years the mean trough </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">steady-state (values measured from Week 20 to 48) serum adalimumab concentration was 5.6 &#xb1; 5.6 &#xb5;g/ml </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:621pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(102% CV) for adalimumab without concomitant methotrexate and 10.9 &#xb1; 5.2 &#xb5;g/ml (47.7% CV) with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with polyarticular JIA who were 2 to &lt; 4 years old or aged 4 and above weighing &lt; 15 kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dosed with adalimumab 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">, the mean trough steady-state serum adalimumab concentrations was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.0 &#xb1; 6.1 &#xb5;g/ml (101% CV) for adalimumab without concomitant methotrexate and 7.9 &#xb1; 5.6 &#xb5;g/ml </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(71.2% CV) with concomitant methotrexate.</span></p>
<img style="position:absolute;top:110pt;left:99pt;width:432pt;height:358pt" src="data:image/png;base64,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">
<img style="position:absolute;top:485pt;left:280pt;width:36pt;height:9pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAEwAAAAMCAAAAADtpASbAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAA2UlEQVR4nI2SPQ7CMAyF7bCzICYkJBaExMghkLgA5+BKcJDeoBsS
B+jUzoiJmDglrknSEk/x36f36iKBC0KYjN++y/pCvIb2DyfDGJKIhiXKCHlADVmT
7XlYwiJANZ28HACE4RNRxm+9EaMV49u1OHwynxtlk9qGxPd6yfT7S0SaAyOeD2vC
0GLD3Ka1gQbbeVCGUFeiA497t4XXTgp0QQfrboR29kb2tzvxUlV7knE1OK8wKJuO
6HBiLvKYg+X/oNxMmo0oUweBHDe9f6HN/sLK2KjwIlhpfAC8cXABl3kQ5QAAAABJ
RU5ErkJggg==">
<img style="position:absolute;top:487pt;left:401pt;width:35pt;height:6pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAFIAAAANCAIAAAC1lq7uAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAApElEQVR4nOWVzRGEIAxGE4qgDVy7oirdZmjAtQa6AHXirBHRkz9j
eAcmcsqbLwaMMQLAeCIiLySxlULSFk9ivmjLy/mvtvXCZMjFwI2o5jerIQ8hKKUe
6PEy9nZWfshFhk8FeaUrjT699333u7+5c5lnG0FrbYzJpw0sZOfct2nvb/QKRqmq
/lhr+e9dygPGmeTL0d7d5HD41r2U7HouKG1OodoDHdh+5CqIp8EAAAAASUVORK5CYII=">
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">40</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:52pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following the administration of 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(maximum of 40 mg) subcutaneously every other week to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with enthesitis-related arthritis who were 6 to 17 years, the mean trough steady-state (values </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">measured at Week 24) serum adalimumab concentrations were 8.8 &#xb1; 6.6 &#x3bc;g/ml for adalimumab without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant methotrexate and 11.8 &#xb1; 4.3 &#x3bc;g/ml with concomitant methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following the administration of 0.8 mg/kg (maximum of 40 mg) subcutaneously every other week to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients with chronic plaque psoriasis, the mean &#xb1; SD steady-state adalimumab trough </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentration was approximately 7.4 &#xb1; 5.8 &#xb5;g/ml (79% CV).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In paediatric patients with moderate to severe CD, the open-label adalimumab induction dose was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">160/80 mg or 80/40 mg at Weeks 0 and 2, respectively, dependent on a body weight cut-off of 40 kg. At </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 4, patients were randomised 1:1 to either the Standard Dose (40/20 mg eow) or Low Dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(20/10 mg eow) maintenance treatment groups based on their body weight. The mean (&#xb1;SD) serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab trough concentrations achieved at Week 4 were 15.7 &#xb1; 6.6</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml for patients &#x2265; 40 kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(160/80 mg) and 10.6 &#xb1; 6.1</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml for patients &lt; 40 kg (80/40 mg). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For patients who stayed on their randomised therapy, the mean (&#xb1;SD) adalimumab trough concentrations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at Week 52 were 9.5 &#xb1; 5.6</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml for the Standard Dose group and 3.5 &#xb1; 2.2</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml for the Low Dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">group. The mean trough concentrations were maintained in patients who continued to receive adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment eow for 52 weeks. For patients who dose escalated from eow to weekly regimen, the mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&#xb1;SD) serum concentrations of adalimumab at Week 52 were 15.3 &#xb1; 11.4 &#x3bc;g/ml (40/20 mg, weekly) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.7 &#xb1; 3.5 &#x3bc;g/ml (20/10 mg, weekly).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab exposure in paediatric uveitis patients was predicted using population pharmacokinetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">modelling and simulation based on cross-indication pharmacokinetics in other paediatric patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn&#x2019;s disease, and enthesitis-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis). No clinical exposure data are available on the use of a loading dose in children &lt; 6 years. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">predicted exposures indicate that in the absence of methotrexate, a loading dose may lead to an initial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increase in systemic exposure.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Exposure-response relationship in paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">On the basis of clinical trial data in patients with JIA (pJIA and ERA), an exposure-response relationship </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was established between plasma concentrations and PedACR 50 response. The apparent adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">plasma concentration that produces half the maximum probability of PedACR 50 response (EC50) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 &#x3bc;g/ml (95% CI: 1-6 &#x3bc;g/ml).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Exposure-response relationships between adalimumab concentration and efficacy in paediatric patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with severe chronic plaque psoriasis were established for PASI 75 and PGA clear or minimal, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively. PASI 75 and PGA clear or minimal increased with increasing adalimumab concentrations, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">both with a similar apparent EC50 of approximately 4.5 &#x3bc;g/ml (95% CI 0.4-47.6 and 1.9-10.5, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adults</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After subcutaneous administration of a single 40 mg dose, absorption and distribution of adalimumab was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">slow, with peak serum concentrations being reached about 5 days after administration. The average </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">absolute bioavailability of adalimumab estimated from three studies following a single 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous dose was 64%. After single intravenous doses ranging from 0.25 to 10 mg/kg, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentrations were dose proportional. After doses of 0.5 mg/kg (~40 mg), clearances ranged from 11 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15 ml/hour, the distribution volume (V</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">ss</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">) ranged from 5 to 6 litres and the mean terminal phase half-life </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was approximately two weeks. Adalimumab concentrations in the synovial fluid from several rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients ranged from 31-96% of those in serum.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">41</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following subcutaneous administration of 40 mg of adalimumab every other week in adult rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis (RA) patients the mean steady-state trough concentrations were approximately 5</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml (without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant methotrexate) and 8 to 9</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml (with concomitant methotrexate), respectively. The serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab trough levels at steady-state increased roughly proportionally with dose following 20, 40 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg subcutaneous dosing every other week and every week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with psoriasis, the mean steady-state trough concentration was 5</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab 40 mg every other week monotherapy treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with Crohn&#x2019;s disease, the loading dose of 80 mg Humira on Week 0 followed by 40 mg Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">on Week 2 achieves serum adalimumab trough concentrations of approximately 5.5</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">induction period. A loading dose of 160 mg Humira on Week 0 followed by 80 mg Humira on Week 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">achieves serum adalimumab trough concentrations of approximately 12</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml during the induction period. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mean steady-state trough levels of approximately 7</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml were observed in Crohn&#x2019;s disease patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received a maintenance dose of 40 mg Humira every other week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with uveitis, a loading dose of 80 mg adalimumab on Week 0 followed by 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab every other week starting at Week 1, resulted in mean steady-state concentrations of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 8 to 10</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Population pharmacokinetic and pharmacokinetic/pharmacodynamic modelling and simulation predicted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparable adalimumab exposure and efficacy in patients treated with 80 mg every other week when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared with 40 mg every week (including adult patients with RA, HS, UC, CD or Ps, patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adolescent HS, and paediatric patients &#x2265; 40 kg with CD).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elimination</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Population pharmacokinetic analyses with data from over 1,300 RA patients revealed a trend toward </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher apparent clearance of adalimumab with increasing body weight. After adjustment for weight </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">differences, gender and age appeared to have a minimal effect on adalimumab clearance. The serum levels </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of free adalimumab (not bound to anti-adalimumab antibodies, AAA) were observed to be lower in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with measurable AAA.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatic or renal impairment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has not been studied in patients with hepatic or renal impairment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Preclinical safety data </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Non-clinical data reveal no special hazard for humans based on studies of single dose toxicity, repeated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose toxicity, and genotoxicity.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">An embryo-foetal developmental toxicity/perinatal developmental study has been performed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cynomolgus monkeys at 0, 30 and 100 mg/kg (9-17 monkeys/group) and has revealed no evidence of harm </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to the foetuses due to adalimumab. Neither carcinogenicity studies, nor a standard assessment of fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibody with limited cross-reactivity to rodent TNF and to the development of neutralising antibodies in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rodents. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">42</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">List of excipients </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mannitol</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Polysorbate 80</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Water for injections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Incompatibilities </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">products.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Shelf life </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 years</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for storage </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Store in a refrigerator (2</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C &#x2013; 8</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C). Do not freeze. Keep the pre-filled syringe in its outer carton in order to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">protect from light.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A single Humira pre-filled syringe may be stored at temperatures up to a maximum of 25&#xb0;C for a period of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">up to 14 days. The syringe must be protected from light, and discarded if not used within the 14-day </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Nature and contents of container  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 20 mg solution for injection in single-use pre-filled syringe (type I glass) with a plunger stopper </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(bromobutyl rubber) and a needle with a needle shield (thermoplastic elastomer). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Packs of:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 pre-filled syringes (0.2 ml sterile solution), each with 1 alcohol pad, in a blister. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for disposal</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requirements.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">7.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">AbbVie Deutschland GmbH &amp; Co. KG</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Knollstrasse</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">67061 Ludwigshafen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Germany</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">8.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBERS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/022</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">43</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">9.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of first authorisation: 08 September 2003</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of latest renewal: 08 September 2008 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">10.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Agency </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000ff">http://www.ema.europa.eu</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">44</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">1.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg/0.8 ml solution for injection</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">2.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each 0.8 ml single dose vial contains 40 mg of adalimumab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary cells.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For the full list of excipients, see section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">3.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL FORM </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Solution for injection. (injection)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clear, colourless solution.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CLINICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Therapeutic indications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Juvenile idiopathic arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Polyarticular juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira in combination with methotrexate is indicated for the treatment of active polyarticular juvenile </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more disease-modifying anti-rheumatic drugs (DMARDs). Humira can be given as monotherapy in case </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">efficacy in monotherapy see section 5.1). Humira has not been studied in patients aged less than 2 years. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Enthesitis-related arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric plaque psoriasis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and phototherapies.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">45</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adolescent hidradenitis suppurativa</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sections 5.1 and 5.2).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric Crohn&apos;s disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of moderately to severely active Crohn&apos;s disease in paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (from 6 years of age) who have had an inadequate response to conventional therapy including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have contraindications for such therapies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric ulcerative colitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (from 6 years of age) who have had an inadequate response to conventional therapy including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">medical contraindications for such therapies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric Uveitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">whom conventional therapy is inappropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Posology and method of administration  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treatment should be initiated and supervised by specialist physicians experienced in the diagnosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and treatment of conditions for which Humira is indicated. Ophthalmologists are advised to consult with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">an appropriate specialist before initiation of treatment with Humira (see section 4.4). Patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira should be given the Patient Reminder Card.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After proper training in injection technique, patients may self-inject with Humira if their physician </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">determines that it is appropriate and with medical follow-up as necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During treatment with Humira, other concomitant therapies (e.g., corticosteroids and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunomodulatory agents) should be optimised.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Posology</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Polyarticular juvenile idiopathic arthritis from 2 years of age</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for patients with polyarticular juvenile idiopathic arthritis from 2 years</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of age is based on body weight (Table 1). Humira is administered every other week via subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:112pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 1. Humira Dose for Patients with Polyarticular Juvenile Idiopathic Arthritis </span></b></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">46</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:59pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:59pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dosing Regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:75pt;left:185pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 kg to &lt; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:75pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Available data suggest that clinical response is usually achieved within 12 weeks of treatment. Continued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy should be carefully reconsidered in a patient not responding within this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in patients aged less than 2 years for this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Enthesitis-related arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for patients with enthesitis-related arthritis from 6 years of age is based </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">on body weight (Table 2).  Humira is administered every other week via subcutaneous injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:147pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 2. Humira Dose for Patients with Enthesitis-Related Arthritis </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dosing Regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:185pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15 kg to &lt; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has not been studied in patients with enthesitis-related arthritis aged less than 6 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended Humira dose for patients with plaque psoriasis from 4 to 17 years of age is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body weight (Table 3). Humira is administered via subcutaneous injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:148pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 3. Humira Dose for Paediatric Patients with Plaque Psoriasis </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dosing Regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:185pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15 kg to &lt; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Initial dose of 20 mg, followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg given every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:318pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting one week after the initial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Initial dose of 40 mg, followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg given every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:318pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting one week after the initial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy beyond 16 weeks should be carefully considered in a patient not responding within this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If retreatment with Humira is indicated, the above guidance on dose and treatment duration should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">followed.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">47</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety of Humira in paediatric patients with plaque psoriasis has been assessed for a mean of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 4 years for this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adolescent hidradenitis suppurativa (from 12 years of age, weighing at least 30 kg)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There are no clinical trials with Humira in adolescent patients with HS.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The posology of Humira in these patients has been determined from pharmacokinetic modelling and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">simulation (see section 5.2).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended Humira dose is 80 mg at Week 0 followed by 40 mg every other week starting at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 1 via subcutaneous injection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adolescent patients with inadequate response to Humira 40 mg every other week, an increase in dosage</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 40 mg every week or 80 mg every other week may be considered.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Antibiotics may be continued during treatment with Humira if necessary. It is recommended that the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient should use a topical antiseptic wash on their HS lesions on a daily basis during treatment with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy beyond 12 weeks should be carefully reconsidered in a patient with no improvement </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">within this time period.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Should treatment be interrupted, Humira may be re-introduced as appropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The benefit and risk of continued long-term treatment should be periodically evaluated (see adult data in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 12 years in this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric Crohn&apos;s disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for patients with Crohn&#x2019;s disease from 6 to 17 years of age is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body weight (Table 4). Humira is administered via subcutaneous injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 4. Humira Dose for Paediatric Patients with Crohn&#x2019;s disease</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:78pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:78pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:255pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Induction Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:471pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maintenance </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:490pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:476pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Starting at </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:484pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:78pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:126pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 40 mg at week 0 and 20 mg at week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:474pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:477pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">48</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:78pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:78pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:255pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Induction Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:471pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maintenance </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:490pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:476pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Starting at </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:484pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:111pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In case there is a need for a more rapid response to therapy with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">awareness that the risk for adverse events may be higher with use of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher induction dose, the following dose may be used:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:126pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 80 mg at week 0 and 40 mg at week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:78pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:164pt;left:126pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 80 mg at week 0 and 40 mg at week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In case there is a need for a more rapid response to therapy with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:204pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">awareness that the risk for adverse events may be higher with use of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher induction dose, the following dose may be used:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:126pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 160 mg at week 0 and 80 mg at week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:474pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:177pt;left:477pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:256pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who experience insufficient response may benefit from an increase in dosage:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg: 20 mg every week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 40 kg: 40 mg every week or 80 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy should be carefully considered in a subject not responding by week 12.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 6 years for this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric ulcerative colitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for patients from 6 to 17 years of age with ulcerative colitis is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body weight (Table 5). Humira is administered via subcutaneous injection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:146pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 5. Humira Dose for Paediatric Patients with Ulcerative Colitis </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:102pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:234pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Induction Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:395pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maintenance Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:392pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Starting at Week 4*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:120pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:192pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 80 mg at Week 0 (given as two 40 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg injections in one day) and</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:192pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 40 mg at Week 2 (given as one 40 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg injection)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:365pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 40 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:120pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:192pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 160 mg at Week 0 (given as four </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg injections in one day or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">two 40 mg injections per day for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">two consecutive days) and</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:192pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 80 mg at Week 2 (given as two 40 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg injections in one day)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:365pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 80 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:91pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">* </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric patients who turn 18 years of age while on Humira should continue their prescribed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:91pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintenance dose.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy beyond 8 weeks should be carefully considered in patients not showing signs of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response within this time period.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">49</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 6 years in this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in different strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric Uveitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for paediatric patients with uveitis from 2 years of age is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body weight (Table 6). Humira is administered via subcutaneous injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In paediatric uveitis, there is no experience in the treatment with Humira without concomitant treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:170pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 6. Humira Dose for Paediatric Patients with Uveitis</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dosing Regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:332pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg every other week in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:322pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination with methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:332pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:306pt;left:322pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination with methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">When Humira therapy is initiated, a loading dose of 40 mg for patients &lt; 30 kg or 80 mg for patients &#x2265; 30 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">kg may be administered one week prior to the start of maintenance therapy. No clinical data are available </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">on the use of a Humira loading dose in children &lt; 6 years of age (see section 5.2).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 2 years in this indication. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">It is recommended that the benefit and risk of continued long-term treatment should be evaluated on a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">yearly basis (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Renal and/or hepatic impairment</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has not been studied in these patient populations. No dose recommendations can be made.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Method of administration</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is administered by subcutaneous injection. Full instructions for use are provided in the package </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">leaflet.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is available in other strengths and presentations.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Contraindications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Active tuberculosis or other severe infections such as sepsis, and opportunistic infections (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Moderate to severe heart failure (NYHA class III/IV) (see section 4.4).</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special warnings and precautions for use  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Traceability</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In order to improve traceability of biological medicinal products, the name and the batch number of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered product should be clearly recorded.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Infections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients taking TNF-antagonists are more susceptible to serious infections. Impaired lung function may </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increase the risk for developing infections. Patients must therefore be monitored closely for infections, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">including tuberculosis, before, during and after treatment with Humira. Because the elimination of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab may take up to four months, monitoring should be continued throughout this period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Humira should not be initiated in patients with active infections including chronic or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">localised infections until infections are controlled. In patients who have been exposed to tuberculosis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who have travelled in areas of high risk of tuberculosis or endemic mycoses, such as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">histoplasmosis, coccidioidomycosis, or blastomycosis, the risk and benefits of treatment with Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be considered prior to initiating therapy (see </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Other opportunistic infections</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who develop a new infection while undergoing treatment with Humira should be monitored </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">closely and undergo a complete diagnostic evaluation. Administration of Humira should be discontinued if </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be initiated until the infection is controlled. Physicians should exercise caution when considering </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the use of Humira in patients with a history of recurring infection or with underlying conditions which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">may predispose patients to infections, including the use of concomitant immunosuppressive medications.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Serious infections</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious infections, including sepsis, due to bacterial, mycobacterial, invasive fungal, parasitic, viral, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other opportunistic infections such as listeriosis, legionellosis and pneumocystis have been reported in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients receiving Humira.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Other serious infections seen in clinical trials include pneumonia, pyelonephritis, septic arthritis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">septicaemia. Hospitalisation or fatal outcomes associated with infections have been reported. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Tuberculosis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tuberculosis, including reactivation and new onset of tuberculosis, has been reported in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira. Reports included cases of pulmonary and extra-pulmonary (i.e. disseminated) tuberculosis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Before initiation of therapy with Humira, all patients must be evaluated for both active or inactive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&#x201c;latent&#x201d;) tuberculosis infection. This evaluation should include a detailed medical assessment of patient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">history of tuberculosis or possible previous exposure to people with active tuberculosis and previous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and/or current immunosuppressive therapy. Appropriate screening tests (i.e. tuberculin skin test and chest </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">X-ray) should be performed in all patients (local recommendations may apply). It is recommended that the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conduct and results of these tests are recorded in the Patient Reminder Card. Prescribers are reminded of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the risk of false negative tuberculin skin test results, especially in patients who are severely ill or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunocompromised. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If active tuberculosis is diagnosed, Humira therapy must not be initiated (see section 4.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In all situations described below, the benefit/risk balance of therapy should be very carefully considered.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">51</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">consulted.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosis prophylaxis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment before the initiation of Humira, and in accordance with local recommendations. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Use of anti-tuberculosis prophylaxis treatment should also be considered before the initiation of Humira in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with several or significant risk factors for tuberculosis despite a negative test for tuberculosis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cannot be confirmed.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have occurred in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with Humira. Some patients who have been successfully treated for active tuberculosis have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">redeveloped tuberculosis while being treated with Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients should be instructed to seek medical advice if signs/symptoms suggestive of a tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infection (e.g., persistent cough, wasting/weight loss, low grade fever, listlessness) occur during or after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy with Humira. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Other opportunistic infections</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Opportunistic infections, including invasive fungal infections have been observed in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira. These infections have not consistently been recognised in patients taking TNF-antagonists and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">this has resulted in delays in appropriate treatment, sometimes resulting in fatal outcomes. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dyspnoea, and/or pulmonary infiltrates or other serious systemic illness with or without concomitant shock </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">an invasive fungal infection should be suspected and administration of Humira should be promptly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">discontinued. Diagnosis and administration of empiric antifungal therapy in these patients should be made </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in consultation with a physician with expertise in the care of patients with invasive fungal infections.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatitis B reactivation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reactivation of hepatitis B has occurred in patients receiving a TNF-antagonist including Humira, who are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chronic carriers of this virus (i.e. surface antigen positive). Some cases have had a fatal outcome. Patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be tested for HBV infection before initiating treatment with Humira. For patients who test positive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for hepatitis B infection, consultation with a physician with expertise in the treatment of hepatitis B is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recommended.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Carriers of HBV who require treatment with Humira should be closely monitored for signs and symptoms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of active HBV infection throughout therapy and for several months following termination of therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adequate data from treating patients who are carriers of HBV with anti-viral therapy in conjunction with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonist therapy to prevent HBV reactivation are not available. In patients who develop HBV </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactivation, Humira should be stopped and effective anti-viral therapy with appropriate supportive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment should be initiated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neurological events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonists including Humira have been associated in rare instances with new onset or exacerbation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">including multiple sclerosis and optic neuritis, and peripheral demyelinating disease, including Guillain-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Barr&#xe9; syndrome. Prescribers should exercise caution in considering the use of Humira in patients with pre-</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">existing or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira should be considered if any of these disorders develop. There is a known association between </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intermediate uveitis and central demyelinating disorders. Neurologic evaluation should be performed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with non-infectious intermediate uveitis prior to the initiation of Humira therapy and regularly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">during treatment to assess for pre-existing or developing central demyelinating disorders. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Allergic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious allergic reactions associated with Humira were rare during clinical trials. Non-serious allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactions associated with Humira were uncommon during clinical trials. Reports of serious allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactions including anaphylaxis have been received following Humira administration. If an anaphylactic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reaction or other serious allergic reaction occurs, administration of Humira should be discontinued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immediately and appropriate therapy initiated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immunosuppression</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a study of 64 patients with rheumatoid arthritis that were treated with Humira, there was no evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enumeration of effector T-, B-, NK-cells, monocyte/macrophages, and neutrophils.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the controlled portions of clinical trials of TNF-antagonists, more cases of malignancies including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lymphoma have been observed among patients receiving a TNF-antagonist compared with control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients. However, the occurrence was rare. In the post marketing setting, cases of leukaemia have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reported in patients treated with a TNF-antagonist. There is an increased background risk for lymphoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">which complicates the risk estimation. With the current knowledge, a possible risk for the development of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lymphomas, leukaemia, and other malignancies in patients treated with a TNF-antagonist cannot be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">excluded.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22 years of age) treated with TNF-antagonists (initiation of therapy &#x2264; 18 years of age), including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab in the post marketing setting. Approximately half the cases were lymphomas. The other cases </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">represented a variety of different malignancies and included rare malignancies usually associated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunosuppression. A risk for the development of malignancies in children and adolescents treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonists cannot be excluded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare postmarketing cases of hepatosplenic T-cell lymphoma have been identified in patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab. This rare type of T-cell lymphoma has a very aggressive disease course and is usually fatal. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Some of these hepatosplenic T-cell lymphomas with Humira have occurred in young adult patients on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant treatment with azathioprine or 6-mercaptopurine used for inflammatory bowel disease. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">potential risk with the combination of azathioprine or 6-mercaptopurine and Humira should be carefully </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered. A risk for the development of hepatosplenic T-cell lymphoma in patients treated with Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cannot be excluded (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No studies have been conducted that include patients with a history of malignancy or in whom treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Humira is continued following development of malignancy. Thus, additional caution should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exercised in considering Humira treatment of these patients (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis patients with a history of PUVA treatment should be examined for the presence of non-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">melanoma skin cancer prior to and during treatment with Humira. Melanoma and Merkel cell carcinoma </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">53</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have also been reported in patients treated with TNF-antagonists including adalimumab (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an exploratory clinical trial evaluating the use of another TNF-antagonist, infliximab, in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies, mostly in the lung </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or head and neck, were reported in infliximab-treated patients compared with control patients. All patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had a history of heavy smoking. Therefore, caution should be exercised when using any TNF-antagonist in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">COPD patients, as well as in patients with increased risk for malignancy due to heavy smoking.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">With current data it is not known if adalimumab treatment influences the risk for developing dysplasia or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">colon cancer. All patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis), or who had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular intervals before </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy and throughout their disease course. This evaluation should include colonoscopy and biopsies per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">local recommendations.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Haematologic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare reports of pancytopenia including aplastic anaemia have been reported with TNF-antagonists. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adverse events of the haematologic system, including medically significant cytopenia (e.g. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">thrombocytopenia, leukopenia) have been reported with Humira. All patients should be advised to seek </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">persistent fever, bruising, bleeding, pallor) while on Humira. Discontinuation of Humira therapy should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered in patients with confirmed significant haematologic abnormalities.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vaccinations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Similar antibody responses to the standard 23-valent pneumococcal vaccine and the influenza trivalent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">virus vaccination were observed in a study in 226 adult subjects with rheumatoid arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with adalimumab or placebo. No data are available on the secondary transmission of infection by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">live vaccines in patients receiving Humira.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">agreement with current immunisation guidelines prior to initiating Humira therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients on Humira may receive concurrent vaccinations, except for live vaccines. Administration of live </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vaccines (e.g., BCG vaccine) to infants exposed to adalimumab in utero is not recommended for 5 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">following the mother&#x2019;s last adalimumab injection during pregnancy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Congestive heart failure</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a clinical trial with another TNF-antagonist worsening congestive heart failure and increased mortality </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">due to congestive heart failure have been observed. Cases of worsening congestive heart failure have also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been reported in patients receiving Humira. Humira should be used with caution in patients with mild </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">heart failure (NYHA class I/II). Humira is contraindicated in moderate to severe heart failure (see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.3). Treatment with Humira must be discontinued in patients who develop new or worsening symptoms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of congestive heart failure.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Autoimmune processes</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Humira may result in the formation of autoimmune antibodies. The impact of long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment with Humira on the development of autoimmune diseases is unknown. If a patient develops </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms suggestive of a lupus-like syndrome following treatment with Humira and is positive for </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">54</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies against double-stranded DNA, further treatment with Humira should not be given (see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent administration of biologic DMARDS or TNF-antagonists</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious infections were seen in clinical studies with concurrent use of anakinra and another </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonist, etanercept, with no added clinical benefit compared to etanercept alone. Because of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">nature of the adverse events seen with the combination of etanercept and anakinra therapy, similar </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">toxicities may also result from the combination of anakinra and other TNF-antagonists. Therefore, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination of adalimumab and anakinra is not recommended. (See section 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concomitant administration of adalimumab with other biologic DMARDS (e.g, anakinra and abatacept) or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other TNF-antagonists is not recommended based upon the possible increased risk for infections, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">including serious infections and other potential pharmacological interactions. (See section 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Surgery</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is limited safety experience of surgical procedures in patients treated with Humira. The long half-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">life of adalimumab should be taken into consideration if a surgical procedure is planned. A patient who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requires surgery while on Humira should be closely monitored for infections, and appropriate actions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be taken. There is limited safety experience in patients undergoing arthroplasty while receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Small bowel obstruction</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Failure to respond to treatment for Crohn&#x2019;s disease may indicate the presence of fixed fibrotic stricture </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">that may require surgical treatment. Available data suggest that Humira does not worsen or cause </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">strictures.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elderly</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The frequency of serious infections among Humira treated subjects over 65 years of age (3.7%) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher than for those under 65 years of age (1.5%). Some of those had a fatal outcome. Particular attention </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">regarding the risk for infection should be paid when treating the elderly.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">See Vaccinations above.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Excipients with known effects</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This medicinal product contains less than 1 mmol of sodium (23 mg) per 0.8 ml dose, i.e. essentially </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2018;sodium-free&#x2019;.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has been studied in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients taking Humira as monotherapy and those taking concomitant methotrexate. Antibody </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">formation was lower when Humira was given together with methotrexate in comparison with use as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy. Administration of Humira without methotrexate resulted in increased formation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies, increased clearance and reduced efficacy of adalimumab (see section 5.1). </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">55</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The combination of Humira and anakinra is not recommended (see section 4.4 &#x201c;Concurrent administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of biologic DMARDS or TNF-antagonists&#x201d;). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The combination of Humira and abatacept is not recommended (see section 4.4 &#x201c;Concurrent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration of biologic DMARDS or TNF-antagonists&#x201d;).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Fertility, pregnancy and lactation</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential should consider the use of adequate contraception to prevent pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and continue its use for at least five months after the last Humira treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pregnancy</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A large number (approximately 2100) of prospectively collected pregnancies exposed to adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">resulting in live birth with known outcomes, including more than 1500 exposed during the first trimester, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">does not indicate an increase in the rate of malformation in the newborn.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a prospective cohort registry, 257 women with rheumatoid arthritis (RA) or Crohn&#x2019;s disease (CD)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with adalimumab at least during the first trimester and 120 women with RA or CD not treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab were enrolled.  The primary endpoint was the birth prevalence of major birth defects. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rate of pregnancies ending with at least one live born infant with a major birth defect was 6/69 (8.7%) in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the adalimumab-treated women with RA and 5/74 (6.8%) in the untreated women with RA (unadjusted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">OR 1.31, 95% CI 0.38-4.52) and 16/152 (10.5%) in the adalimumab-treated women with CD and 3/32 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(9.4%) in the untreated women with CD (unadjusted OR 1.14, 95% CI 0.31-4.16). The adjusted OR </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(accounting for baseline differences) was 1.10 (95% CI 0.45-2.73) with RA and CD combined. There were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">no distinct differences between adalimumab-treated and untreated women for the secondary endpoints </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spontaneous abortions, minor birth defects, preterm delivery, birth size and serious or opportunistic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections and no stillbirths or malignancies were reported. The interpretation of data may be impacted due </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to methodological limitations of the study, including small sample size and non-randomized design.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a developmental toxicity study conducted in monkeys, there was no indication of maternal toxicity, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">embryotoxicity or teratogenicity. Preclinical data on postnatal toxicity of adalimumab are not available </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(see section 5.3).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Due to its inhibition of TNF</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf061;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">, adalimumab administered during pregnancy could affect normal immune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responses in the newborn. Adalimumab should only be used during pregnancy if clearly needed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab may cross the placenta into the serum of infants born to women treated with adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">during pregnancy. Consequently, these infants may be at increased risk for infection. Administration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">live vaccines (e.g., BCG vaccine) to infants exposed to adalimumab in utero is not recommended for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5 months following the mother&#x2019;s last adalimumab injection during pregnancy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Breast-feeding</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Limited information from the published literature indicates that adalimumab is excreted in breast milk at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">very low concentrations with the presence of adalimumab in human milk at concentrations of 0.1% to 1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of the maternal serum level. Given orally, immunoglobulin G proteins undergo intestinal proteolysis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have poor bioavailability. No effects on the breastfed newborns/infants are anticipated. Consequently, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira can be used during breastfeeding.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fertility</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">56</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Preclinical data on fertility effects of adalimumab are not available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.7</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Effects on ability to drive and use machines </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may have a minor influence on the ability to drive and use machines. Vertigo and visual </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">impairment may occur following administration of Humira (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Undesirable effects</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Summary of the safety profile</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira was studied in 9,506 patients in pivotal controlled and open label trials for up to 60 months or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more. These trials included rheumatoid arthritis patients with short term and long standing disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis) as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">well as axial spondyloarthritis (ankylosing spondylitis and axial spondyloarthritis without radiographic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">evidence of AS), psoriatic arthritis, Crohn&#x2019;s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and uveitis patients. The pivotal controlled studies involved 6,089 patients receiving Humira and 3,801 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients receiving placebo or active comparator during the controlled period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The proportion of patients who discontinued treatment due to adverse events during the double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">controlled portion of pivotal studies was 5.9% for patients taking Humira and 5.4% for control treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The most commonly reported adverse reactions are infections (such as nasopharyngitis, upper respiratory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tract infection and sinusitis), injection site reactions (erythema, itching, haemorrhage, pain or swelling), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">headache and musculoskeletal pain.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious adverse reactions have been reported for Humira. TNF-antagonists, such as Humira affect the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immune system and their use may affect the body&#x2019;s defence against infection and cancer.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fatal and life-threatening infections (including sepsis, opportunistic infections and TB), HBV reactivation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and various malignancies (including leukaemia, lymphoma and HSTCL) have also been reported with use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious haematological, neurological and autoimmune reactions have also been reported. These include </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rare reports of pancytopenia, aplastic anaemia, central and peripheral demyelinating events and reports of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lupus, lupus-related conditions and Stevens-Johnson syndrome.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In general, the adverse events in paediatric patients were similar in frequency and type to those seen in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adult patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tabulated list of adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The following list of adverse reactions is based on experience from clinical trials and on postmarketing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experience and are displayed by system organ class and frequency in Table 7 below: very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1/10); common (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1/100 to &lt; 1/10); uncommon (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1/1,000 to&lt; 1/100); rare (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1/10,000 to &lt; 1/1,000); </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and not known (cannot be estimated from the available data). Within each frequency grouping, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">undesirable effects are presented in order of decreasing seriousness. The highest frequency seen among the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">various indications has been included. An asterisk (*) appears in the SOC column if further information is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">found elsewhere in sections 4.3, 4.4 and 4.8.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">57</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:288pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 7</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:259pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Undesirable Effects</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Infections and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infestations*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Respiratory tract infections (including lower and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">upper respiratory tract infection, pneumonia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sinusitis, pharyngitis, nasopharyngitis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pneumonia herpes viral)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:193pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Systemic infections (including sepsis, candidiasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and influenza),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intestinal infections (including gastroenteritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">viral),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">skin and soft tissue infections (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paronychia, cellulitis, impetigo, necrotising </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:266pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fasciitis and herpes zoster),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ear infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">oral infections (including herpes simplex, oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">herpes and tooth infections), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reproductive tract infections (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vulvovaginal mycotic infection), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">urinary tract infections (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pyelonephritis),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fungal infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joint infections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neurological infections (including viral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">meningitis),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">opportunistic infections and tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(including coccidioidomycosis, histoplasmosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and mycobacterium avium complex infection), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bacterial infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">eye infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">diverticulitis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neoplasms benign, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">malignant and unspecified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(including cysts and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">polyps)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Skin cancer excluding melanoma (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">basal cell carcinoma and squamous cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">carcinoma),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">benign neoplasm</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Lymphoma**, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">solid organ neoplasm (including breast cancer, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lung neoplasm and thyroid neoplasm),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">melanoma**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Leukaemia</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">58</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatosplenic T-cell lymphoma</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Merkel cell carcinoma (neuroendocrine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:113pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">carcinoma of the skin)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:129pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Kaposi&#x2019;s sarcoma</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Blood and the lymphatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">system disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Leukopenia (including neutropenia and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">agranulocytosis), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anaemia </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Leucocytosis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:231pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">thrombocytopenia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Idiopathic thrombocytopenic purpura</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pancytopenia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immune system disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypersensitivity,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">allergies (including seasonal allergy)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sarcoidosis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vasculitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Anaphylaxis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Metabolism and nutrition </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Lipids increased</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypokalaemia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">uric acid increased, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blood sodium abnormal,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hypocalcaemia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hyperglycaemia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hypophosphatemia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dehydration</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psychiatric disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mood alterations (including depression), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anxiety,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">insomnia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Nervous system disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Headache</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">59</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paraesthesias (including hypoesthesia),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">migraine,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">nerve root compression</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cerebrovascular accident</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tremor,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">neuropathy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Multiple sclerosis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demyelinating disorders (e.g. optic neuritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Guillain-Barr&#xe9; syndrome)</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Eye disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Visual impairment,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conjunctivitis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blepharitis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">eye swelling</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Diplopia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ear and labyrinth </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vertigo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Deafness, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tinnitus</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cardiac disorders* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tachycardia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Myocardial infarction</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arrhythmia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">congestive heart failure</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cardiac arrest</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vascular disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypertension, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">flushing, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">haematoma</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Aortic aneurysm,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vascular arterial occlusion,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">thrombophlebitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Respiratory, thoracic and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mediastinal disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Asthma,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dyspnoea,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cough</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">60</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pulmonary embolism</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:98pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interstitial lung disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:111pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chronic obstructive pulmonary disease,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pneumonitis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pleural effusion</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:164pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pulmonary fibrosis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Gastrointestinal disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Abdominal pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">nausea and vomiting</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">GI haemorrhage, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dyspepsia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:266pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">gastroesophageal reflux disease,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sicca syndrome</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pancreatitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dysphagia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">face oedema</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Intestinal perforation</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepato-biliary disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elevated liver enzymes</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:420pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:420pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cholecystitis and cholelithiasis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hepatic steatosis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:445pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bilirubin increased</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactivation of hepatitis B</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1) </span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoimmune hepatitis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Liver failure</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Skin and subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tissue disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rash (including exfoliative rash)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Worsening or new onset of psoriasis (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">palmoplantar pustular psoriasis)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">urticaria,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bruising (including purpura), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dermatitis (including eczema),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">onychoclasis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hyperhidrosis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">alopecia</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pruritus</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">61</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Night sweats,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">scar</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erythema multiforme</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:138pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Stevens-Johnson syndrome</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:154pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">angioedema</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cutaneous vasculitis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lichenoid skin reaction</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:217pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Worsening of symptoms of dermatomyositis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Musculoskeletal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">connective tissue disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Musculoskeletal pain</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Muscle spasms (including blood creatine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">phosphokinase increased)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rhabdomyolysis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">systemic lupus erythematosus</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Lupus-like syndrome</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal and urinary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal impairment,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">haematuria</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Nocturia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reproductive system and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">breast disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erectile dysfunction</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:496pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">General disorders and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration site </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conditions*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:496pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:496pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Injection site reaction (including injection site </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">erythema)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Chest pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">oedema,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pyrexia</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Inflammation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Investigations*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Coagulation and bleeding disorders (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">activated partial thromboplastin time prolonged), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoantibody test positive (including double </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">stranded DNA antibody), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blood lactate dehydrogenase increased</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Weight increased</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2)</span></sup></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">62</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Injury, poisoning and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:98pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">procedural complications</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Impaired healing</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">* further information is found elsewhere in sections 4.3, 4.4 and 4.8</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:138pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">** including open label extension studies</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> including spontaneous reporting data</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2)</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> The mean weight change from baseline for adalimumab ranged from 0.3 kg to 1.0 kg across adult </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">indications compared to (minus) -0.4 kg to 0.4 kg for placebo over a treatment period of 4-6 months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Weight increase of 5-6 kg has also been observed in long-term extension studies with mean exposures of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 1-2 years without control group, particularly in patients with Crohn&#x2019;s disease and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:214pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ulcerative colitis. The mechanism behind this effect is unclear but could be associated with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:227pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anti-inflammatory effect of adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hidradenitis suppurativa</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety profile for patients with HS treated with Humira weekly was consistent with the known safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">profile of Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uveitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety profile for patients with uveitis treated with Humira every other week was consistent with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">known safety profile of Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Description of selected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Injection site reactions</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the pivotal controlled trials in adults and children, 12.9% of patients treated with Humira developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection site reactions (erythema and/or itching, haemorrhage, pain or swelling), compared to 7.2% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients receiving placebo or active control. Injection site reactions generally did not necessitate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">discontinuation of the medicinal product. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Infections</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the pivotal controlled trials in adults and children, the rate of infection was 1.51 per patient year in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treated patients and 1.46 per patient year in the placebo and active control-treated patients. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections consisted primarily of nasopharyngitis, upper respiratory tract infection, and sinusitis. Most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients continued on Humira after the infection resolved.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The incidence of serious infections was 0.04 per patient year in Humira treated patients and 0.03 per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient year in placebo and active control &#x2212; treated patients.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled and open label adult and paediatric studies with Humira, serious infections (including fatal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections, which occurred rarely) have been reported, which include reports of tuberculosis (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extrapulmonary histoplasmosis, blastomycosis, coccidioidomycosis, pneumocystis, candidiasis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">aspergillosis and listeriosis). Most of the cases of tuberculosis occurred within the first eight months after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initiation of therapy and may reflect recrudescence of latent disease.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></i></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">63</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No malignancies were observed in 249 paediatric patients with an exposure of 655.6 patient years during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira trials in patients with juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enthesitis-related arthritis). In addition, no malignancies were observed in 192 paediatric patients with an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exposure of 498.1 patient years during Humira trials in paediatric patients with Crohn&#x2019;s disease. No </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">malignancies were observed in 77 paediatric patients with an exposure of 80.0 patient years during a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira trial in paediatric patients with chronic plaque psoriasis. No malignancies were observed in 93 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients with an exposure of 65.3 patient years during a Humira trial in paediatric patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ulcerative colitis. No malignancies were observed in 60 paediatric patients with an exposure of 58.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient years during a Humira trial in paediatric patients with uveitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During the controlled portions of pivotal Humira trials in adults of at least 12 weeks in duration in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">without radiographic evidence of AS, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease, ulcerative colitis and uveitis, malignancies, other than lymphoma and non-melanoma skin cancer, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were observed at a rate (95% confidence interval) of 6.8 (4.4, 10.5)  per 1,000 patient-years among 5,291 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treated patients </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a rate of 6.3 (3.4, 11.8) per 1,000 patient-years among 3,444 control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (median duration of treatment was 4.0 months for Humira and 3.8 months for control-treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients). The rate (95% confidence interval) of non-melanoma skin cancers was 8.8 (6.0, 13.0) per 1,000 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient-years among Humira-treated patients and 3.2 (1.3, 7.6) per 1,000 patient-years among control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients. Of these skin cancers, squamous cell carcinomas occurred at rates (95% confidence interval) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.7 (1.4, 5.4) per 1,000 patient-years among Humira-treated patients and 0.6 (0.1, 4.5) per 1,000 patient-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">years among control patients. The rate (95% confidence interval) of lymphomas was 0.7 (0.2, 2.7) per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1,000 patient-years among Humira-treated patients and 0.6 (0.1, 4.5) per 1,000 patient-years among </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">control patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">When combining controlled portions of these trials and ongoing and completed open label extension </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies with a median duration of approximately 3.3 years including 6,427 patients and over 26,439 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient-years of therapy, the observed rate of malignancies, other than lymphoma and non-melanoma skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cancers is approximately 8.5 per 1,000 patient years. The observed rate of non-melanoma skin cancers is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 9.6 per 1,000 patient years, and the observed rate of lymphomas is approximately 1.3 per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1,000 patient years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In post-marketing experience from January 2003 to December 2010, predominantly in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rheumatoid arthritis, the reported rate of malignancies is approximately 2.7 per 1,000 patient treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">years. The reported rates for non-melanoma skin cancers and lymphomas are approximately 0.2 and 0.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">per 1,000 patient treatment years, respectively (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare post-marketing cases of hepatosplenic T-cell lymphoma have been reported in patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Autoantibodies</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients had serum samples tested for autoantibodies at multiple time points in rheumatoid arthritis studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">I &#x2212; V. In these trials, 11.9% of patients treated with Humira and 8.1% of placebo and active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">control &#x2212; treated patients that had negative baseline anti-nuclear antibody titres reported positive titres at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24. Two patients out of 3,441 treated with Humira in all rheumatoid arthritis and psoriatic arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies developed clinical signs suggestive of new-onset lupus-like syndrome. The patients improved </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">following discontinuation of therapy. No patients developed lupus nephritis or central nervous system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">64</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Hepato-biliary events</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled Phase 3 trials of Humira in patients with rheumatoid arthritis and psoriatic arthritis with a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">control period duration ranging from 4 to 104 weeks, ALT elevations &#x2265; 3 x ULN occurred in 3.7% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira-treated patients and 1.6% of control-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled Phase 3 trials of Humira in patients with polyarticular juvenile idiopathic arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 to 17 years and enthesitis-related arthritis who were 6 to 17 years, ALT elevations &#x2265; 3 x ULN occurred </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in 6.1% of Humira-treated patients and 1.3% of control-treated patients. Most ALT elevations occurred </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with concomitant methotrexate use. No ALT elevations &#x2265; 3 x ULN occurred in the Phase 3 trial of Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients with polyarticular juvenile idiopathic arthritis who were 2 to &lt;4 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled Phase 3 trials of Humira in patients with Crohn&#x2019;s disease and ulcerative colitis with a control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">period ranging from 4 to 52 weeks. ALT elevations &#x2265; 3 x ULN occurred in 0.9% of Humira-treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients and 0.9% of controlled-treated patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the Phase 3 trial of Humira in patients with paediatric Crohn&#x2019;s disease which evaluated efficacy and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">safety of two body weight adjusted maintenance dose regimens following body weight adjusted induction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy up to 52 weeks of treatment, ALT elevations &#x2265; 3 x ULN occurred in 2.6% (5/192) of patients of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">whom 4 were receiving concomitant immunosuppressants at baseline.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled Phase 3 trials of Humira in patients with plaque psoriasis with a control period duration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ranging from 12 to 24 weeks, ALT elevations &#x2265; 3 x ULN occurred in 1.8% of Humira-treated patients and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.8% of control-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No ALT elevations &#x2265; 3 X ULN occurred in the Phase 3 trial of Humira in paediatric patients with plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled trials of Humira (initial doses of 160 mg at Week 0 and 80 mg at Week 2, followed by 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every week starting at Week 4), in patients with hidradenitis suppurativa with a control period duration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ranging from 12 to 16 weeks, ALT elevations &#x2265; 3 x ULN occurred in 0.3% of Humira-treated patients and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.6% of control-treated patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled trials of Humira (initial doses of 80 mg at Week 0 followed by 40 mg every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting at Week 1) in adult patients with uveitis up to 80 weeks with a median exposure of 166.5 days and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">105.0 days in Humira-treated and control-treated patients, respectively, ALT elevations &#x2265; 3 x ULN </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurred in 2.4% of Humira-treated patients and 2.4% of control-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the controlled Phase 3 trial of Humira in patients with paediatric ulcerative colitis (N=93) which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">evaluated efficacy and safety of a maintenance dose of 0.6 mg/kg (maximum of 40 mg) every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N=31) and a maintenance dose of 0.6 mg/kg (maximum of 40 mg) every Week (N=32), following body </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weight adjusted induction dosing of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2 (N=63), or an induction dose of 2.4 mg/kg (maximum of 160 mg) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at Week 0, placebo at Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2 (N=30), ALT elevations &#x2265; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 X ULN occurred in 1.1% (1/93) of patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Across all indications in clinical trials patients with raised ALT were asymptomatic and in most cases </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">elevations were transient and resolved on continued treatment. However, there have also been post-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">marketing reports of liver failure as well as less severe liver disorders that may precede liver failure, such </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as hepatitis including autoimmune hepatitis in patients receiving adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with azathioprine/6-mercaptopurine</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">65</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult Crohn&#x2019;s disease studies, higher incidences of malignant and serious infection-related adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">events were seen with the combination of Humira and azathioprine/6-mercaptopurine compared with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira alone.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting of suspected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">asked to report any suspected adverse reactions via the national reporting system listed in </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000ff">Appendix V.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Overdose </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose-limiting toxicity was observed during clinical trials. The highest dose level evaluated has been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">multiple intravenous doses of 10 mg/kg, which is approximately 15 times the recommended dose.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacodynamic properties</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-&#x3b1;) inhibitors. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ATC code: L04AB04</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mechanism of action</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab binds specifically to TNF and neutralises the biological function of TNF by blocking its </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interaction with the p55 and p75 cell surface TNF receptors.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with an IC</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> of 0.1-0.2 nM). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharmacodynamic effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After treatment with Humira, a rapid decrease in levels of acute phase reactants of inflammation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and serum cytokines (IL-6) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed, compared to baseline in patients with rheumatoid arthritis. Serum levels of matrix </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">destruction were also decreased after Humira administration. Patients treated with Humira usually </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced improvement in haematological signs of chronic inflammation.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A rapid decrease in CRP levels was also observed in patients with polyarticular juvenile idiopathic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis, Crohn&apos;s disease, ulcerative colitis and hidradenitis suppurativa after treatment with Humira. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with Crohn&#x2019;s disease, a reduction of the number of cells expressing inflammatory markers in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">colon including a significant reduction of expression of TNF&#x3b1; was seen. Endoscopic studies in intestinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mucosa have shown evidence of mucosal healing in adalimumab treated patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical efficacy and safety</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adults with rheumatoid arthritis</span></i></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">66</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira was evaluated in over 3,000 patients in all rheumatoid arthritis clinical trials. The efficacy and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">safety of Humira were assessed in five randomised, double-blind and well-controlled studies. Some </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients were treated for up to 120 months duration. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study I evaluated 271 patients with moderately to severely active rheumatoid arthritis who were </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">years old, had failed therapy with at least one disease-modifying, anti rheumatic drug and had insufficient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">efficacy with methotrexate at doses of 12.5 to 25 mg (10 mg if methotrexate-intolerant) every week and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">whose methotrexate dose remained constant at 10 to 25 mg every week. Doses of 20, 40 or 80 mg of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira or placebo were given every other week for 24 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study II evaluated 544 patients with moderately to severely active rheumatoid arthritis who were </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">years old and had failed therapy with at least one disease-modifying, anti-rheumatic drugs. Doses of 20 or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg of Humira were given by subcutaneous injection every other week with placebo on alternative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks or every week for 26 weeks; placebo was given every week for the same duration. No other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease-modifying anti-rheumatic drugs were allowed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study III evaluated 619 patients with moderately to severely active rheumatoid arthritis who were </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">years old, and who had an ineffective response to methotrexate at doses of 12.5 to 25 mg or have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intolerant to 10 mg of methotrexate every week. There were three groups in this study. The first received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo injections every week for 52 weeks. The second received 20 mg of Humira every week for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52 weeks. The third group received 40 mg of Humira every other week with placebo injections on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">alternate weeks. Upon completion of the first 52 weeks, 457 patients enrolled in an open-label extension </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">phase in which 40 mg of Humira/MTX was administered every other week up to 10 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study IV primarily assessed safety in 636 patients with moderately to severely active rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis who were </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 years old. Patients were permitted to be either disease-modifying, anti-rheumatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">drug-na&#xef;ve or to remain on their pre-existing rheumatologic therapy provided that therapy was stable for a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">minimum of 28 days. These therapies include methotrexate, leflunomide, hydroxychloroquine, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sulfasalazine and/or gold salts. Patients were randomised to 40 mg of Humira or placebo every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for 24 weeks.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study V evaluated 799 methotrexate-na&#xef;ve, adult patients with moderate to severely active early </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rheumatoid arthritis (mean disease duration less than 9 months). This study evaluated the efficacy of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg every other week/methotrexate combination therapy, Humira 40 mg every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and methotrexate monotherapy in reducing the signs and symptoms and rate of progression </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of joint damage in rheumatoid arthritis for 104 weeks. Upon completion of the first 104 weeks, 497 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients enrolled in an open-label extension phase in which 40 mg of Humira was administered every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week up to 10 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary end point in RA studies I, II and III and the secondary endpoint in RA study IV was the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">percent of patients who achieved an ACR 20 response at Week 24 or 26. The primary endpoint in RA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study V was the percent of patients who achieved an ACR 50 response at Week 52. RA studies III and V </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had an additional primary endpoint at 52 weeks of retardation of disease progression (as detected by X-ray </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">results). RA study III also had a primary endpoint of changes in quality of life. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">ACR response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The percent of Humira-treated patients achieving ACR 20, 50 and 70 responses was consistent across RA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies I, II and III. The results for the 40 mg every other week dose are summarised in Table 8. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">67</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:178pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 8 ACR Responses in Placebo-Controlled Trials</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:255pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(Percent of Patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:169pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA Study I</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:298pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA Study II</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:428pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA Study III</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:144pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:149pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:151pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=60</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:194pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">/ MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:218pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=63</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:287pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=110</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:346pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:350pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=113</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=200</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:460pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">/ MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=207</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:149pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:215pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:287pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">19.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:350pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">63.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:222pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:293pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:356pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:151pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:215pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:350pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:222pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:293pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:356pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:151pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:215pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:350pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:222pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:293pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:356pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> RA  study I at 24 weeks, RA study II at 26 weeks , and RA study III at 24 and 52 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 40 mg Humira administered every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> MTX = methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**p &lt; 0.01, Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA studies I-IV, all individual components of the ACR response criteria (number of tender and swollen </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joints, physician and patient assessment of disease activity and pain, disability index (HAQ) scores and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">CRP (mg/dl) values) improved at 24 or 26 weeks compared to placebo. In RA study III, these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvements were maintained throughout 52 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension for RA study III, most patients who were ACR responders maintained </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response when followed for up to 10 years. Of 207 patients who were randomised to Humira 40 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week, 114 patients continued on Humira 40 mg every other week for 5 years. Among those, 86 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (75.4%) had ACR 20 responses; 72 patients (63.2%) had ACR 50 responses; and 41 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(36%) had ACR 70 responses. Of 207 patients, 81 patients continued on Humira 40 mg every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for 10 years. Among those, 64 patients (79.0%) had ACR 20 responses; 56 patients (69.1%) had ACR 50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responses; and 43 patients (53.1%) had ACR 70 responses.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study IV, the ACR 20 response of patients treated with Humira plus standard of care was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">statistically significantly better than patients treated with placebo plus standard of care (p &lt; 0.001).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA studies I-IV, Humira-treated patients achieved statistically significant ACR 20 and 50 responses </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared to placebo as early as one to two weeks after initiation of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study V with early rheumatoid arthritis patients who were methotrexate na&#xef;ve, combination therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Humira and methotrexate led to faster and significantly greater ACR responses than methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and Humira monotherapy at Week 52 and responses were sustained at Week 104 (see Table </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9).</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">68</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:213pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 9 ACR Responses in RA Study V</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:258pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(percent of patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:75pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:176pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:174pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n=257</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:236pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:240pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n=274</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:294pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira/MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:313pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n=268</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:113pt;left:375pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">p-value</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:113pt;left:432pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">p-value</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:113pt;left:492pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">p-value</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">c</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:175pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">62.6%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:241pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">54.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:313pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">72.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:382pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.013</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:434pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:498pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.043</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:175pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">56.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:241pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:313pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">69.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:382pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.002</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:434pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:498pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.140</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:175pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:241pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:313pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">61.6%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:377pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:434pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:498pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.317</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:175pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">42.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:241pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:313pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:377pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:434pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:498pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:175pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">27.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:241pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:313pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:377pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:434pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:498pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.656</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:175pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:241pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:313pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46.6%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:377pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:434pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:498pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.864</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value is from the pairwise comparison of methotrexate monotherapy and Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy using the Mann-Whitney U test.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:92pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy using the Mann-Whitney U test</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy using </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:92pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the Mann-Whitney U test</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension for RA study V, ACR response rates were maintained when followed for up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 years. Of 542 patients who were randomised to Humira 40 mg every other week, 170 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued on Humira 40 mg every other week for 10 years. Among those, 154 patients (90.6%) had ACR </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 responses; 127 patients (74.7%) had ACR 50 responses; and 102 patients (60.0%) had ACR 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responses.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 52, 42.9% of patients who received Humira/methotrexate combination therapy achieved clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission (DAS28 (CRP) &lt; 2.6) compared to 20.6% of patients receiving methotrexate monotherapy and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.4% of patients receiving Humira monotherapy. Humira/methotrexate combination therapy was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinically and statistically superior to methotrexate (p &lt; 0.001) and Humira monotherapy (p &lt; 0.001) in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">achieving a low disease state in patients with recently diagnosed moderate to severe rheumatoid arthritis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The response for the two monotherapy arms was similar (p = 0.447). Of 342 subjects originally </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:493pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomized to Humira monotherapy or Humira/methotrexate combination therapy who entered the open-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">label extension study, 171 subjects completed 10 years of Humira treatment. Among those, 109 subjects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(63.7%) were reported to be in remission at 10 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Radiographic response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study III, where Humira treated patients had a mean duration of rheumatoid arthritis of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 11 years, structural joint damage was assessed radiographically and expressed as change in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">modified Total Sharp Score (TSS) and its components, the erosion score and joint space narrowing score. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira/methotrexate patients demonstrated significantly less radiographic progression than patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving methotrexate alone at 6 and 12 months (see Table 10). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension of RA Study III, the reduction in rate of progression of structural damage is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintained for 8 and 10 years in a subset of patients. At 8 years, 81 of 207 patients originally treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg Humira every other week were evaluated radiographically. Among those, 48 patients showed no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">progression of structural damage defined by a change from baseline in the mTSS of 0.5 or less. At </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 years, 79 of 207 patients originally treated with 40 mg Humira every other week were evaluated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">radiographically. Among those, 40 patients showed no progression of structural damage defined by a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">change from baseline in the mTSS of 0.5 or less.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">69</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:123pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 10 Radiographic Mean Changes Over 12 Months in RA Study III</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:180pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo/</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:180pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:260pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira/MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:263pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:266pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:352pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo/MTX-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:342pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira/MTX (95% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:360pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:365pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Interval</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:458pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Sharp Score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:284pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:357pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.6 (1.4, 3.8) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:456pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:92pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erosion score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:284pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:357pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.6 (0.9, 2.2)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:457pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:168pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">JSN</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:284pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:357pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.9 (0.3, 1.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:459pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  0.002</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">95% confidence intervals for the differences in change scores between methotrexate and Humira. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Based on rank analysis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Joint Space Narrowing</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study V, structural joint damage was assessed radiographically and expressed as change in modified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Sharp Score (see Table 11).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:144pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 11 Radiographic Mean Changes at Week 52 in RA Study V</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:173pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=257</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(95% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:162pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:167pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interval)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:244pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:247pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=274</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:249pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(95%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:237pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:242pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interval)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:305pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira/MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=268</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(95% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:311pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:317pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interval)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:379pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:428pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:478pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:85pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Sharp </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:158pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.7 (4.2-7.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0 (1.7-4.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.3 (0.5-2.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0020</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:479pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erosion score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:158pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.7 (2.7-4.7)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.7 (1.0-2.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.8 (0.4-1.2)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0082</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:479pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:89pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">JSN score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:158pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.0 (1.2-2.8)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.3 (0.5-2.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:312pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.5 (0-1.0)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0037</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:484pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.151</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p-value is from the pairwise comparison of methotrexate monotherapy and Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy using the Mann-Whitney U test.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy using the Mann-Whitney U test </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using the Mann-Whitney U test</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following 52 weeks and 104 weeks of treatment, the percentage of patients without progression (change </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">from baseline in modified Total Sharp Score </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.5) was significantly higher with Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy (63.8% and 61.2% respectively) compared to methotrexate monotherapy (37.4% and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33.5% respectively, p &lt; 0.001) and Humira monotherapy (50.7%, p &lt; 0.002 and 44.5%, p &lt; 0.001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension of RA study V, the mean change from baseline at Year 10 in the modified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Sharp Score was 10.8, 9.2 and 3.9 in patients originally randomized to methotrexate monotherapy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira monotherapy and Humira/methotrexate combination therapy, respectively. The corresponding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">proportions of patients with no radiographic progression were 31.3%, 23.7% and 36.7% respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of life and physical function</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Health-related quality of life and physical function were assessed using the disability index of the Health </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Assessment Questionnaire (HAQ) in the four original adequate and well-controlled trials, which was a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pre-specified primary endpoint at Week 52 in RA study III. All doses/schedules of Humira in all four </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies showed statistically significantly greater improvement in the disability index of the HAQ from </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">baseline to Month 6 compared to placebo and in RA study III the same was seen at Week 52. Results from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the Short Form Health Survey (SF 36) for all doses/schedules of Humira in all four studies support these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">findings, with statistically significant physical component summary (PCS) scores, as well as statistically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significant pain and vitality domain scores for the 40 mg every other week dose. A statistically significant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">decrease in fatigue as measured by functional assessment of chronic illness therapy (FACIT) scores was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">seen in all three studies in which it was assessed (RA studies I, III, IV).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study III, most subjects who achieved improvement in physical function and continued treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintained improvement through Week 520 (120 months) of open-label treatment. Improvement in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">quality of life was measured up to Week 156 (36 months) and improvement was maintained through that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">time.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study V, the improvement in the HAQ disability index and the physical component of the SF 36 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">showed greater improvement (p &lt; 0.001) for Humira/methotrexate combination therapy </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate monotherapy and Humira monotherapy at Week 52, which was maintained through </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 104. Among the 250 subjects who completed the open-label extension study, improvements in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">physical function were maintained through 10 years of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were studied in adult patients with chronic plaque psoriasis (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 10% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BSA involvement and PASI </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 12 or </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 10) who were candidates for systemic therapy or phototherapy in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised, double-blind studies. 73% of patients enrolled in Psoriasis Studies I and II had received prior </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">systemic therapy or phototherapy. The safety and efficacy of Humira were also studied in adult patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with moderate to severe chronic plaque psoriasis with concomitant hand and/or foot psoriasis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">candidates for systemic therapy in a randomised double-blind study (Psoriasis Study III).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Study I (REVEAL) evaluated 1,212 patients within three treatment periods. In period A, patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received placebo or Humira at an initial dose of 80 mg followed by 40 mg every other week starting one </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">week after the initial dose. After 16weeks of therapy, patients who achieved at least a PASI 75 response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(PASI score improvement of at least 75% relative to baseline), entered period B and received open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg Humira every other week. Patients who maintained </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75 response at Week 33 and were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">originally randomised to active therapy in Period A, were re-randomised in period C to receive 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira every other week or placebo for an additional 19 weeks. Across all treatment groups, the mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">baseline PASI score was 18.9 and the baseline PGA score ranged from &#x201c;moderate&#x201d; (53% of subjects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">included) to &#x201c;severe&#x201d; (41%) to &#x201c;very severe&#x201d; (6%).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Study II (CHAMPION) compared the efficacy and safety of Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> methotrexate and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo in 271 patients. Patients received placebo, an initial dose of MTX 7.5 mg and thereafter dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increases up to Week 12, with a maximum dose of 25 mg or an initial dose of 80 mg Humira followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week (starting one week after the initial dose) for 16 weeks. There are no data available </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparing Humira and MTX beyond 16 weeks of therapy. Patients receiving MTX who achieved a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 50 response at Week 8 and/or 12 did not receive further dose increases. Across all treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">groups, the mean baseline PASI score was 19.7 and the baseline PGA score ranged from &#x201c;mild&#x201d; (&lt;1%) to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x201c;moderate&#x201d; (48%) to &#x201c;severe&#x201d; (46%) to &#x201c;very severe&#x201d; (6%).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients participating in all Phase 2 and Phase 3 psoriasis studies were eligible to enrol into an open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension trial, where Humira was given for at least an additional 108 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Psoriasis Studies I and II, a primary endpoint was the proportion of patients who achieved a PASI 75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response from baseline at Week 16 (see Tables 12 and 13).</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">71</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 12</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:180pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Ps Study I (REVEAL)  - Efficacy Results at 16 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:303pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:306pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=398</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:307pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:376pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:405pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=814</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    </span></b><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PASI 75</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:304pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">26 (6.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">578 (70.9)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    PASI 100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 (0.8)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">163 (20.0)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    PGA: Clear/minimal</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:304pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17 (4.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">506 (62.2)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Percent of patients achieving PASI75 response was calculated as centre-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adjusted rate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p&lt;0.001, Humira vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 13</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:176pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Ps Study II (CHAMPION) Efficacy Results at 16 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:235pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:240pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=53</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:240pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:315pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:313pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=110</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:315pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:406pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=108</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:408pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:135pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    </span></b><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PASI 75</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:233pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 (18.9)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39 (35.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">86 (79.6)</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a, b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:135pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    PASI 100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:238pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 (1.9)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:314pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8 (7.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18 (16.7)</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c, d</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:135pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    PGA: </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:135pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Clear/minimal</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 (11.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33 (30.0)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">79 (73.1)</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a, b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:135pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p&lt;0.001 Humira vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:135pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p&lt;0.001 Humira vs. methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:135pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p&lt;0.01 Humira vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:135pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p&lt;0.05 Humira vs. methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Psoriasis Study I, 28% of patients who were PASI 75 responders and were re-randomised to placebo at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 33 compared to 5% continuing on Humira, p&lt;0.001, experienced &#x201c;loss of adequate response&#x201d; (PASI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score after Week 33 and on or before Week 52 that resulted in a &lt;PASI 50 response relative to baseline </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with a minimum of a 6-point increase in PASI score relative to Week 33). Of the patients who lost </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adequate response after re-randomisation to placebo who then enrolled into the open-label extension trial, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38% (25/66) and 55% (36/66) regained PASI 75 response after 12 and 24 weeks of re-treatment, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A total of 233 PASI 75 responders at Week 16 and Week 33 received continuous Humira therapy for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52 weeks in Psoriasis Study I, and continued Humira in the open-label extension trial. PASI 75 and PGA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of clear or minimal response rates in these patients were 74.7% and 59.0%, respectively, after an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">additional 108 weeks of open-label therapy (total of 160 weeks). In an analysis in which all patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dropped out of the study for adverse events or lack of efficacy, or who dose-escalated, were considered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">non-responders, PASI 75 and PGA of clear or minimal response rates in these patients were 69.6% and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">55.7%, respectively, after an additional 108 weeks of open-label therapy (total of 160 weeks).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A total of 347 stable responders participated in a withdrawal and retreatment evaluation in an open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension study. During the withdrawal period, symptoms of psoriasis returned over time with a median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">time to relapse (decline to PGA &#x201c;moderate&#x201d; or worse) of approximately 5 months. None of these patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced rebound during the withdrawal period. A total of 76.5% (218/285) of patients who entered the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">retreatment period had a response of PGA &#x201c;clear&#x201d; or &#x201c;minimal&#x201d; after 16 weeks of retreatment, irrespective </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of whether they relapsed during withdrawal (69.1%[123/178] and 88.8% [95/107] for patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">relapsed and who did not relapse during the withdrawal period, respectively). A similar safety profile was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed during retreatment as before withdrawal.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">72</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Significant improvements at Week 16 from baseline compared to placebo (Studies I and II) and MTX </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(Study II) were demonstrated in the DLQI (Dermatology Life Quality Index). In Study I, improvements in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the physical and mental component summary scores of the SF-36 were also significant compared to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an open-label extension study, for patients who dose escalated from 40 mg every other week to 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly due to a PASI response below 50%, 26.4% (92/349) and 37.8% (132/349) of patients achieved </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75 response at Week 12 and 24, respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Study III (REACH) compared the efficacy and safety of Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo in 72 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with moderate to severe chronic plaque psoriasis and hand and/or foot psoriasis. Patients received an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initial dose of 80 mg Humira followed by 40 mg every other week (starting one week after the initial dose) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or placebo for 16 weeks. At Week 16, a statistically significantly greater proportion of patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received Humira achieved PGA of &apos;clear&apos; or &apos;almost clear&apos; for the hands and/or feet compared to patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who received placebo (30.6% versus 4.3%, respectively [P = 0.014]).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Study IV compared efficacy and safety of Humira versus placebo in 217 adult patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">moderate to severe nail psoriasis. Patients received an initial dose of 80 mg Humira followed by 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every other week (starting one week after the initial dose) or placebo for 26 weeks followed by open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treatment for an additional 26 weeks. Nail psoriasis assessments included the Modified Nail </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Severity Index (mNAPSI), the Physician&#x2019;s Global Assessment of Fingernail Psoriasis (PGA-F) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and the Nail Psoriasis Severity Index (NAPSI) (see Table 14). Humira demonstrated a treatment benefit in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">nail psoriasis patients with different extents of skin involvement (BSA&#x2265;10% (60% of patients) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BSA&lt;10% and &#x2265;5% (40% of patients)).    </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 14</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:183pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Ps Study IV Efficacy Results at 16, 26 and 52 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Endpoint</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:245pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 16</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:222pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo-Controlled</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:360pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 26</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo-Controlled</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:473pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Open-label</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:216pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:218pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=108</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:275pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:267pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg eow </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:276pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=109</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:332pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=108</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:387pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg eow </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:389pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=109</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg eow </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:480pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=80</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; mNAPSI 75 (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">26.0</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:341pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:393pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46.6</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:483pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PGA-F clear/minimal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265;2-grade improvement (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29.7</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:341pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:393pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">48.9</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:483pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">61.3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Percent Change in Total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fingernail NAPSI (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:224pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-7.8</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:278pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-44.2</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-11.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-56.2</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:481pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-72.2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p&lt;0.001, Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">vs.</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treated patients showed statistically significant improvements at Week 26 compared with placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in the DLQI. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult hidradenitis suppurativa</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in randomised, double-blind, placebo-controlled studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and an open-label extension study in adult patients with moderate to severe hidradenitis suppurativa (HS) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who were intolerant, had a contraindication or an inadequate response to at least a 3-month trial of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">systemic antibiotic therapy. The patients in HS-I and HS-II had Hurley Stage II or III disease with at least </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 abscesses or inflammatory nodules.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study HS-I (PIONEER I) evaluated 307 patients with 2 treatment periods. In Period A, patients received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo or Humira at an initial dose of 160 mg at Week 0, 80 mg at Week 2, and 40 mg every week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting at Week 4 to Week 11. Concomitant antibiotic use was not allowed during the study. After </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">73</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 weeks of therapy, patients who had received Humira in Period A were re-randomised in Period B to 1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of 3 treatment groups (Humira 40 mg every week, Humira 40 mg every other week, or placebo from Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 to Week 35). Patients who had been randomised to placebo in Period A were assigned to receive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg every week in Period B.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study HS-II (PIONEER II) evaluated 326 patients with 2 treatment periods. In Period A, patients received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo or Humira at an initial dose of 160 mg at Week 0 and 80 mg at Week 2 and 40 mg every week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting at Week 4 to Week 11. 19.3% of patients had continued baseline oral antibiotic therapy during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study.  After 12 weeks of therapy, patients who had received Humira in Period A were re-randomised in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Period B to 1 of 3 treatment groups (Humira 40 mg every week, Humira 40 mg every other week, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo from Week 12 to Week 35). Patients who had been randomised to placebo in Period A were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assigned to receive placebo in Period B.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients participating in Studies HS-I and HS-II were eligible to enrol into an open-label extension study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in which Humira 40mg was administered every week. Mean exposure in all adalimumab population was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">762 days. Throughout all 3 studies patients used topical antiseptic wash daily.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Clinical Response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reduction of inflammatory lesions and prevention of worsening of abscesses and draining fistulas was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assessed using Hidradenitis Suppurativa Clinical Response (HiSCR; at least a 50% reduction in total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">abscess and inflammatory nodule count with no increase in abscess count and no increase in draining </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fistula count relative to Baseline). Reduction in HS-related skin pain was assessed using a Numeric Rating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Scale in patients who entered the study with an initial baseline score of 3 or greater on a 11 point scale. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 12, a significantly higher proportion of patients treated with Humira versus placebo achieved </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HiSCR.   At Week 12, a significantly higher proportion of patients in Study HS-II experienced a clinically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">relevant decrease in HS-related skin pain (see Table 15). Patients treated with Humira had significantly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reduced risk of disease flare during the initial 12 weeks of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:174pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 15:  Efficacy Results at 12 Weeks, HS Studies I and II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:269pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HS Study I</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:428pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HS Study II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:233pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:297pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:313pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weekly</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:392pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:457pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:474pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weekly</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hidradenitis Suppurativa </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical Response (HiSCR)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:233pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 154</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:227pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 (26.0%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:313pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 153</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:303pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64 (41.8%) </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:395pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=163</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:385pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45 (27.6%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=163</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:460pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">96 (58.9%) </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265;30% Reduction in Skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pain</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:233pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 109</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:227pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">27 (24.8%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:313pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 122</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34 (27.9%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:395pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=111</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:385pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23 (20.7%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=105</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:460pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">48 (45.7%) </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">* </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">P</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> &lt; 0.05, ***</span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">P </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001, Humira versus placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">a</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among all randomised patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">b</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients with baseline HS-related skin pain assessment &#x2265; 3, based on Numeric Rating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Scale 0 &#x2013; 10; 0 = no skin pain, 10 = skin pain as bad as you can imagine.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Humira 40 mg every week significantly reduced the risk of worsening of abscesses and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">draining fistulas. Approximately twice the proportion of patients in the placebo group in the first 12 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of Studies HS-I and HS-II, compared with those in the Humira group experienced worsening of abscesses </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(23.0% vs 11.4%, respectively) and draining fistulas (30.0% vs 13.9%, respectively).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Greater improvements at Week 12 from baseline compared to placebo were demonstrated in skin-specific </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">health-related quality of life, as measured by the Dermatology Life Quality Index (DLQI; Studies HS-I </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:719pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and HS-II), patient global satisfaction with medication treatment as measured by the Treatment </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">74</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Satisfaction Questionnaire - medication (TSQM; Studies HS-I and HS-II), and physical health as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">measured by the physical component summary score of the SF-36 (Study HS-I).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with at least a partial response to Humira 40 mg weekly at Week 12, the HiSCR rate at Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36 was higher in patients who continued weekly Humira than in patients in whom dosing frequency was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reduced to every other week, or in whom treatment was withdrawn (see Table 16).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:109pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 16:</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:140pt;left:184pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Proportion of Patients</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Achieving HiSCR</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b </span></b></sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">at Weeks 24 and 36 After </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:181pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Treatment Reassignment from Weekly Humira at Week 12</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:220pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(treatment </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:217pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">withdrawal)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:230pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 73</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:310pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:305pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">every other week</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:329pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 70</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:406pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:424pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">weekly</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:425pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 70</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:130pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:221pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 (32.9%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36 (51.4%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 (57.1%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:244pt;left:130pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 36</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:244pt;left:221pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22 (30.1%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:244pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28 (40.0%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:244pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39 (55.7%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:133pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">a</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:146pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients with at least a partial response to Humira 40 mg weekly after 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:146pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:133pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">b</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:146pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients meeting protocol-specified criteria for loss of response or no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:146pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement were required to discontinue from the studies and were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:146pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">counted as nonresponders.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients who were at least partial responders at Week 12, and who received continuous weekly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira therapy, the HiSCR rate at Week 48 was 68.3% and at Week 96 was 65.1%. Longer term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment with Humira 40 mg weekly for 96 weeks identified no new safety findings.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients whose Humira treatment was withdrawn at Week 12 in Studies HS-I and HS-II, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HiSCR rate 12 weeks after re-introduction of Humira 40 mg weekly returned to levels similar to that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed before withdrawal (56.0 %).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult Crohn&#x2019;s disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in over 1500 patients with moderately to severely active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Crohn&#x2019;s disease (Crohn&#x2019;s Disease Activity Index (CDAI) </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 220 and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 450) in randomised, double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo-controlled studies. Concomitant stable doses of aminosalicylates, corticosteroids, and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunomodulatory agents were permitted and 80% of patients continued to receive at least one of these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">medications. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Induction of clinical remission (defined as CDAI &lt; 150) was evaluated in two studies, CD Study I </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(CLASSIC I) and CD Study II (GAIN). In CD Study I, 299 TNF-antagonist naive patients were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised to one of four treatment groups; placebo at Weeks 0 and 2, 160 mg Humira at Week 0 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:571pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg at Week 2, 80 mg at Week 0 and 40 mg at Week 2, and 40 mg at Week 0 and 20 mg at Week 2. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">CD Study II, 325 patients who had lost response or were intolerant to infliximab were randomised to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receive either 160 mg Humira at Week 0 and 80 mg at Week 2 or placebo at Weeks 0 and 2. The primary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">non-responders were excluded from the studies and therefore these patients were not further evaluated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Maintenance of clinical remission was evaluated in CD study III (CHARM). In CD Study III, 854 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:647pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received open-label 80 mg at Week 0 and 40 mg at Week 2. At Week 4 patients were randomised to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week, 40 mg every week, or placebo with a total study duration of 56 weeks. Patients in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical response (decrease in CDAI &#x2265; 70) at Week 4 were stratified and analysed separately from those </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">not in clinical response at Week 4. Corticosteroid taper was permitted after Week 8. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">CD study I and CD study II induction of remission and response rates are presented in Table 17.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">75</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:281pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 17</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:193pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Induction of Clinical Remission and Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:99pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(Percent of Patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:115pt;left:191pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CD Study I: Infliximab Naive </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:191pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patients</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:115pt;left:372pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CD Study II: Infliximab </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:372pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Experienced Patients</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:197pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:203pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=74</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:258pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:255pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">80/40 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:261pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 75</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:318pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:313pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">160/80 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:324pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=76</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:385pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:388pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=166</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:468pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:462pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">160/80 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:471pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=159</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:205pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:205pt;left:205pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:205pt;left:266pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:204pt;left:325pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:205pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:204pt;left:475pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">21%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response (CR-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">100)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:205pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:266pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">37%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">**</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:394pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:473pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">**</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All p-values are pairwise comparisons of proportions for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.01</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Similar remission rates were observed for the 160/80 mg and 80/40 mg induction regimens by Week 8 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adverse events were more frequently noted in the 160/80 mg group.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In CD Study III, at Week 4, 58% (499/854) of patients were in clinical response and were assessed in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">primary analysis. Of those in clinical response at Week 4, 48% had been previously exposed to other TNF-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antagonists. Maintenance of remission and response rates are presented in Table 18. Clinical remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">results remained relatively constant irrespective of previous TNF-antagonist exposure.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Disease-related hospitalisations and surgeries were statistically significantly reduced with adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared with placebo at Week 56.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:281pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 18</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maintenance of Clinical Remission and Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(Percent of Patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:283pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:359pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">40 mg Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:353pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">every other week</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:450pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">40 mg Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:458pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">every week</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 26</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:286pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=170</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:378pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=172</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:468pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=157</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:291pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">47%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response (CR-100)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:291pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">27%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in steroid-free remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for &gt;=90 days</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:279pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3% (2/66)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:360pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">19% (11/58)**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15% (11/74)**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 56</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:286pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=170</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:378pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=172</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:468pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=157</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:291pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response (CR-100)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:291pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">48%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in steroid-free remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for &gt;=90 days</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:279pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5% (3/66)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:363pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29% (17/58)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20% (15/74)**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.001 for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo pairwise comparisons of proportions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">** p &lt; 0.02 for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo pairwise comparisons of proportions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of those receiving corticosteroids at baseline</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">76</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients who were not in response at Week 4, 43% of Humira maintenance patients responded by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 12 compared to 30% of placebo maintenance patients. These results suggest that some patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have not responded by Week 4 benefit from continued maintenance therapy through Week 12. Therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued beyond 12 weeks did not result in significantly more responses (see section 4.2).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">117/276 patients from CD study I and 272/777 patients from CD studies II and III were followed through </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at least 3 years of open-label adalimumab therapy. 88 and 189 patients, respectively, continued to be in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical remission. Clinical response (CR-100) was maintained in 102 and 233 patients, respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of life</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In CD Study I and CD Study II, statistically significant improvement in the disease-specific inflammatory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bowel disease questionnaire (IBDQ) total score was achieved at Week 4 in patients randomised to Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80/40 mg and 160/80 mg compared to placebo and was seen at Weeks 26 and 56 in CD Study III as well </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">among the adalimumab treatment groups compared to the placebo group.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adult Uveitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in adult patients with non-infectious intermediate, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">posterior, and panuveitis, excluding patients with isolated anterior uveitis, in two randomised, double-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">masked, placebo-controlled studies (UV I and II). Patients received placebo or Humira at an initial dose of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg followed by 40 mg every other week starting one week after the initial dose. Concomitant stable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">doses of one non-biologic immunosuppressant were permitted. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV I evaluated 217 patients with active uveitis despite treatment with corticosteroids (oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">prednisone at a dose of 10 to 60 mg/day). All patients received a 2-week standardised dose of prednisone </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60 mg/day at study entry followed by a mandatory taper schedule, with complete corticosteroid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">discontinuation by Week 15. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV II evaluated 226 patients with inactive uveitis requiring chronic corticosteroid treatment (oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">prednisone 10 to 35 mg/day) at baseline to control their disease. Patients subsequently underwent a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mandatory taper schedule, with complete corticosteroid discontinuation by Week 19. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary efficacy endpoint in both studies was &#xb4;time to treatment failure&#xb4;. Treatment failure was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined by a multi-component outcome based on inflammatory chorioretinal and/or inflammatory retinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vascular lesions, anterior chamber (AC) cell grade, vitreous haze (VH) grade and best corrected visual </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">acuity (BCVA).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who completed Studies UV I and UV II were eligible to enroll in an uncontrolled long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension study with an originally planned duration of 78 weeks. Patients were allowed to continue on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study medication beyond Week 78 until they had access to Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Clinical Response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with Humira versus patients receiving placebo (See Table 19). Both studies demonstrated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">an early and sustained effect of Humira on the treatment failure rate versus placebo (see Figure 1). </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">77</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 19</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:180pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Time to Treatment Failure in Studies UV I and UV II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:75pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Analysis</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:103pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Treatment</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:189pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:225pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Failure</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:225pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:283pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Median Time to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:283pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Failure (months)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:378pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HR</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:414pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CI 95% </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:414pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">for HR</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:472pt"><b><i><span style="font-family:TimesNewRoman,BoldItalic,serif;font-size:11.04pt">P</span></i></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> Value</span></b><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:75pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Time to Treatment Failure At or After Week 6 in Study UV I  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Primary analysis (ITT)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">107</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">84 (78.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:472pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">110</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60 (54.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.36, 0.70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:472pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:75pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Time to Treatment Failure At or After Week 2 in Study UV II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Primary analysis (ITT)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">111</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">61 (55.0)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8.3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:472pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">115</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45 (39.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NE</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.57</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.39, 0.84</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:472pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.004</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note: Treatment failure at or after Week 6 (Study UV I), or at or after Week 2 (Study UV II), was counted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as event. Drop outs due to reasons other than treatment failure were censored at the time of dropping out.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">a</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HR of adalimumab vs placebo from proportional hazards regression with treatment as factor.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">b</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2-sided </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">P</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> value from log rank test.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">c</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NE = not estimable. Fewer than half of at-risk subjects had an event. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Figure 1: Kaplan-Meier Curves Summarizing Time to Treatment Failure on or after Week 6 (Study </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:233pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">UV I) or Week 2 (Study UV II)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TREATMENT FAILURE RATE (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TIME (MONTHS)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:100pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV I                        Treatment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:445pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<img style="position:absolute;top:353pt;left:100pt;width:432pt;height:174pt" src="data:image/png;base64,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">
<img style="position:absolute;top:540pt;left:291pt;width:31pt;height:14pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABcAAAAICAAAAAA3wTsyAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAR0lEQVR4nGP8z4AVMGKK/2eEioMZaDIg8X8fGRmAFEyWiYEPov75
fqAwTPQ/8z8+n39MEPP//2dk/A+V+8+EsBfDBmzuAQMAmYsaASeQxO8AAAAASUVO
RK5CYII=">
<img style="position:absolute;top:540pt;left:401pt;width:43pt;height:14pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABcAAAAGCAIAAACnwpLJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAqElEQVR4nGP8//8/A8WAEW4KkMHIyEhQA1ZlCFN+//79/ft3Pj6+
9+/f83Bzs7Cyfvz4kZ+fHygI1MTKxvblyxcBAQEgyczExMnF9eHDByAX3ZSbN2/e
vn3b29t7+fLlFhYWQON27twZHR29Y8cOUVFROTm5vXv3RkREbNu2DWi0qanJ+vUb
/Hx9gcahmAJxLUgIycHI7v/37x8TExNWKUaSQhctUOBcAGVhWfUkQWeYAAAAAElF
TkSuQmCC">
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">78</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:64pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TREATMENT FAILURE RATE (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:273pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TIME (MONTHS)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:100pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV II                       Treatment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:445pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note: P# = Placebo (Number of Events/Number at Risk); A# = HUMIRA (Number of</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Events/Number at Risk).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Study UV I statistically significant differences in favour of adalimumab versus placebo were observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for each component of treatment failure. In Study UV II, statistically significant differences were observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for visual acuity only, but the other components were numerically in favour of adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of the 424 subjects included in the uncontrolled long-term extension of Studies UV I and UV II, 60</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subjects were regarded ineligible (e.g. due to deviations or due to complications secondary to diabetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">retinopathy, due to cataract surgery or vitrectomy) and were excluded from the primary analysis of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">efficacy. Of the 364 remaining patients, 269 evaluable patients (74%) reached 78 weeks of open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab treatment. Based on the observed data approach, 216 (80.3%) were in quiescence (no active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inflammatory lesions, AC cell grade  &#x2264; 0.5+, VH grade &#x2264; 0.5+) with a concomitant steroid dose &#x2264; 7.5 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">per day, and 178 (66.2%) were in steroid-free quiescence. BCVA was either improved or maintained (&lt; 5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">letters deterioration) in 88.6% of the eyes at week 78. Data beyond Week 78 were generally consistent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with these results but the number of enrolled subjects declined after this time. Overall, among the patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who discontinued the study, 18% discontinued due to adverse events, and 8% due to insufficient response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to adalimumab treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of Life</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patient reported outcomes regarding vision-related functioning were measured in both clinical studies, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using the NEI VFQ-25. Humira was numerically favoured for the majority of subscores with statistically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significant mean differences for general vision, ocular pain, near vision, mental health, and total score in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV I, and for general vision and mental health in Study UV II. Vision related effects were not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">numerically in favour of Humira for colour vision in Study UVI and for colour vision, peripheral vision </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and near vision in Study UV II.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immunogenicity</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Formation of anti-adalimumab antibodies is associated with increased clearance and reduced efficacy of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab. There is no apparent correlation between the presence of anti-adalimumab antibodies and the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurrence of adverse events.</span></p>
<img style="position:absolute;top:78pt;left:100pt;width:432pt;height:171pt" src="data:image/png;base64,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">
<img style="position:absolute;top:263pt;left:291pt;width:31pt;height:14pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABcAAAAICAAAAAA3wTsyAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAR0lEQVR4nGP8z4AVMGKK/2eEioMZaDIg8X8fGRmAFEyWiYEPov75
fqAwTPQ/8z8+n39MEPP//2dk/A+V+8+EsBfDBmzuAQMAmYsaASeQxO8AAAAASUVO
RK5CYII=">
<img style="position:absolute;top:263pt;left:401pt;width:43pt;height:14pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABcAAAAGCAIAAACnwpLJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAqElEQVR4nGP8//8/A8WAEW4KkMHIyEhQA1ZlCFN+//79/ft3Pj6+
9+/f83Bzs7Cyfvz4kZ+fHygI1MTKxvblyxcBAQEgyczExMnF9eHDByAX3ZSbN2/e
vn3b29t7+fLlFhYWQON27twZHR29Y8cOUVFROTm5vXv3RkREbNu2DWi0qanJ+vUb
/Hx9gcahmAJxLUgIycHI7v/37x8TExNWKUaSQhctUOBcAGVhWfUkQWeYAAAAAElF
TkSuQmCC">
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">79</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with polyarticular juvenile idiopathic arthritis who were 4 to 17 years, anti- adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies were identified in 15.8% (27/171) of patients treated with adalimumab. In patients not given </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant methotrexate, the incidence was 25.6% (22/86) compared to 5.9% (5/85) when adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was used as add-on to methotrexate. In patients with polyarticular juvenile idiopathic arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 to &lt; 4 years old or aged 4 and above weighing &lt;15 kg, anti-adalimumab antibodies were identified in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7% (1/15) of patients, and the one patient was receiving concomitant methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with enthesitis-related arthritis, anti-adalimumab antibodies were identified in 10.9% (5/46) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with adalimumab. In patients not given concomitant methotrexate, the incidence was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13.6% (3/22), compared to 8.3% (2/24) when adalimumab was used as add-on to methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in rheumatoid arthritis studies I, II and III were tested at multiple time points for anti-adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies during the 6 to 12 month period. In the pivotal trials, anti-adalimumab antibodies were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">identified in 5.5% (58/1053) of patients treated with adalimumab, compared to 0.5% (2/370) on placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients not given concomitant methotrexate, the incidence was 12.4%, compared to 0.6% when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab was used as add-on to methotrexate.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with paediatric psoriasis, anti-adalimumab antibodies were identified in 5/38 subjects (13%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with 0.8 mg/kg adalimumab monotherapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with psoriasis, anti-adalimumab antibodies were identified in 77/920 subjects (8.4%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with adalimumab monotherapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult plaque psoriasis patients on long term adalimumab monotherapy who participated in a withdrawal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and retreatment study, the rate of antibodies to adalimumab after retreatment (11 of 482 subjects, 2.3%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was similar to the rate observed prior to withdrawal (11 of 590 subjects, 1.9%).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with moderately to severely active paediatric Crohn&#x2019;s disease, the rate of anti-adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibody development in patients receiving adalimumab was 3.3%. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with Crohn&#x2019;s disease, anti-adalimumab antibodies were identified in 7/269 subjects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(2.6%).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with non-infectious uveitis, anti-adalimumab antibodies were identified in 4.8% (12/249) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of patients treated with adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with moderately to severely active paediatric ulcerative colitis, the rate of anti-adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibody development in patients receiving adalimumab was 3%.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Because immunogenicity analyses are product-specific, comparison of antibody rates with those from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other products is not appropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Juvenile idiopathic arthritis (JIA)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Polyarticular juvenile idiopathic arthritis (pJIA)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira was assessed in two studies (pJIA I and II) in children with active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">polyarticular or polyarticular course juvenile idiopathic arthritis, who had a variety of JIA onset types </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(most frequently rheumatoid-factor negative or positive polyarthritis and extended oligoarthritis).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pJIA I</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">80</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:66pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in a multicentre, randomised, double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:79pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">parallel &#x2212; group study in 171 children (4-17 years old) with polyarticular JIA. In the open-label lead in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:91pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">phase (OL LI) patients were stratified into two groups, MTX (methotrexate)-treated or non- MTX-treated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:104pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who were in the non-MTX stratum were either na&#xef;ve to or had been withdrawn from MTX at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">least two weeks prior to study drug administration. Patients remained on stable doses of non-steroidal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:129pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anti-inflammatory drugs (NSAIDs) and or prednisone (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.2 mg /kg/day or 10 mg/day maximum). In the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:142pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">OL LI phase all patients received 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2 </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">up to a maximum of 40 mg Humira every other week for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16 weeks. The distribution of patients by age and minimum, median and maximum dose received during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:168pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the OL LI phase is presented in Table 20.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:193pt;left:287pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 20</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:104pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Distribution of patients by age and adalimumab dose received during the OL LI phase</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Age Group</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:202pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Number of patients at Baseline </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:202pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:378pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Minimum, median and </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:378pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">maximum dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 to 7 years</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">31 (18.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10, 20 and 25 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8 to 12 years</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">71 (41.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20, 25 and 40 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13 to 17 years</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">69 (40.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25, 40 and 40 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients demonstrating a Paediatric ACR 30 response at Week 16 were eligible to be randomised into the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">double blind (DB) phase and received either Humira 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2 </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">up to a maximum of 40 mg, or placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every other week for an additional 32 weeks or until disease flare. Disease flare criteria were defined as a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">worsening of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% from baseline in </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 3 of 6 Paediatric ACR core criteria, </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 2 active joints, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf03e;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% in no more than 1 of the 6 criteria. After 32 weeks or at disease flare, patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were eligible to enrol into the open label extension phase. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:287pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 21</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:213pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Ped ACR 30 Responses in the JIA study</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Stratum</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:270pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:419pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Without MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Phase</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">OL-LI 16 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ped ACR 30 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:493pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response (n/N)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:252pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">94.1% (80/85)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">74.4% (64/86)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">                                                          Efficacy Outcomes</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Double Blind 32 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira / MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N = 38)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo / MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N = 37)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N = 30)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:461pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:461pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N = 28)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Disease flares at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the end of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">32weeks</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n/N)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36.8% (14/38)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64.9% (24/37)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">43.3% (13/30)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:461pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">71.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:461pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(20/28)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Median time to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease flare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&gt;32 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&gt;32 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:461pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ped ACR 30/50/70 responses Week 48 significantly greater than those of placebo treated patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p = 0.015</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p = 0.031</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Amongst those who responded at Week 16 (n=144), the Paediatric ACR 30/50/70/90 responses were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintained for up to six years in the OLE phase in patients who received Humira throughout the study.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">81</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Over all 19 subjects, of which 11 of the baseline age group 4 to 12 and 8 of the baseline age group 13 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17 years were treated 6 years or longer.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Overall responses were generally better and, fewer patients developed antibodies when treated with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination of Humira and MTX compared to Humira alone. Taking these results into consideration, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is recommended for use in combination with MTX and for use as monotherapy in patients for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">whom MTX use is not appropriate (see section 4.2). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pJIA II</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira was assessed in an open-label, multicentre study in 32 children (2 -</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt;4 years old or aged 4 and above weighing &lt; 15 kg) with moderately to severely active polyarticular JIA. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:204pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The patients received 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body surface area (BSA) of Humira up to a maximum of 20 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week as a single dose via SC injection for at least 24 weeks. During the study, most subjects used </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant MTX, with fewer reporting use of corticosteroids or NSAIDs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 12 and Week 24, PedACR30 response was 93.5% and 90.0%, respectively, using the observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">data approach. The proportions of subjects with PedACR50/70/90 at Week 12 and Week 24 were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">90.3%/61.3%/38.7% and 83.3%/73.3%/36.7%, respectively. Amongst those who responded (Paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 30) at Week 24 (n=27 out of 30 patients), the Paediatric ACR 30 responses were maintained for up </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 60 weeks in the OLE phase in patients who received Humira throughout this time period. Overall, 20 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subjects were treated for 60 weeks or longer.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Enthesitis-related arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in a multicentre, randomised, double-blind study in 46 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients (6 to 17 years old) with moderate enthesitis-related arthritis. Patients were randomised </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to receive either 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body surface area (BSA) of Humira up to a maximum of 40 mg, or placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every other week for 12 weeks. The double-blind period is followed by an open-label (OL) period during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">which patients received 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BSA of Humira up to a maximum of 40 mg every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneously for up to an additional 192 weeks. The primary endpoint was the percent change from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline to Week 12 in the number of active joints with arthritis (swelling not due to deformity or joints </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with loss of motion plus pain and/or tenderness), which was achieved with mean percent decrease of -</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">62.6% (median percent change -88.9%) in patients in the Humira group compared to -11.6% (median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">percent change -50.0%) in patients in the placebo group. Improvement in number of active joints with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis was maintained during the OL period through Week 156 for the 26 of 31 (84%) patients in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira group who remained in the study. Although not statistically significant, the majority of patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demonstrated clinical improvement in secondary endpoints such as number of sites of enthesitis, tender </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joint count (TJC), swollen joint count (SJC), Paediatric ACR 50 response, and Paediatric ACR 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Humira was assessed in a randomised, double-blind, controlled study of 114 paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients from 4 years of age with severe chronic plaque psoriasis (as defined by a Physician&#x2019;s Global </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Assessment (PGA) &#x2265; 4 or &gt; 20% BSA involvement or &gt; 10% BSA involvement with very thick lesions or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Area and Severity Index (PASI) &#x2265; 20 or &#x2265; 10 with clinically relevant facial, genital, or hand/ foot </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">involvement) who were inadequately controlled with topical therapy and heliotherapy or phototherapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients received Humira 0.8 mg/kg eow (up to 40 mg), 0.4 mg/kg eow (up to 20 mg), or methotrexate 0.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2013; 0.4 mg/kg weekly (up to 25 mg). At week 16, more patients randomised to Humira 0.8 mg/kg had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">positive efficacy responses (e.g., PASI 75) than those randomised to 0.4 mg/kg eow or MTX.  </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">82</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:149pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 22: Paediatric Plaque Psoriasis Efficacy Results at 16 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:300pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:301pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=37 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:98pt;left:385pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 0.8 mg/kg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:423pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=38 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:124pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:289pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 (32.4%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22 (57.9%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:139pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PGA: Clear/minimal</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:140pt;left:289pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15 (40.5%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:140pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23 (60.5%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:154pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX = methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> P=0.027, Humira 0.8 mg/kg versus MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> P=0.083, Humira 0.8 mg/kg versus MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who achieved PASI 75 and PGA clear or minimal were withdrawn from treatment for up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36 weeks and monitored for loss of disease control (i.e. a worsening of PGA by at least 2 grades). Patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were then re-treated with adalimumab 0.8 mg/kg eow for an additional 16 weeks and response rates </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed during retreatment were similar to the previous double-blind period:  PASI 75 response of 78.9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(15 of 19 subjects) and PGA clear or minimal of 52.6% (10 of 19 subjects).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open label period of the study, PASI 75 and PGA clear or minimal responses were maintained for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">up to an additional 52 weeks with no new safety findings.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adolescent hidradenitis suppurativa</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There are no clinical trials with Humira in adolescent patients with HS. Efficacy of adalimumab for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment of adolescent patients with HS is predicted based on the demonstrated efficacy and exposure-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response relationship in adult HS patients and the likelihood that the disease course, pathophysiology, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">drug effects are substantially similar to that of adults at the same exposure levels. Safety of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recommended adalimumab dose in the adolescent HS population is based on cross-indication safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">profile of adalimumab in both adults and paediatric patients at similar or more frequent doses (see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.2).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric Crohn&#x2019;s disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira was assessed in a multicentre, randomised, double-blind clinical trial designed to evaluate the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">efficacy and safety of induction and maintenance treatment with doses dependent on body weight </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&lt; 40 kg or &#x2265; 40 kg) in 192 paediatric subjects between the ages of 6 and 17 (inclusive) years, with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">moderate to severe Crohn&#xb4;s disease (CD) defined as Paediatric Crohn&apos;s Disease Activity Index (PCDAI) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score &gt; 30. Subjects had to have failed conventional therapy (including a corticosteroid and/or an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunomodulator) for CD. Subjects may also have previously lost response or been intolerant to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infliximab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All subjects received open-label induction therapy at a dose based on their Baseline body weight: 160 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at Week 0 and 80 mg at Week 2 for subjects &#x2265; 40 kg, and 80 mg and 40 mg, respectively, for subjects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 4, subjects were randomised 1:1 based on their body weight at the time to either the Low Dose or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Standard Dose maintenance regimens as shown in Table 23.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">83</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 23</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:254pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maintenance regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:226pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:226pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:275pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Low dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:336pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Standard </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:336pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:275pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 mg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:275pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Efficacy results</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary endpoint of the study was clinical remission at Week 26, defined as PCDAI score </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 10.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline) rates are presented in Table 24. Rates of discontinuation of corticosteroids or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunomodulators are presented in Table 25.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 24</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:257pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Paediatric CD Study</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:210pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PCDAI Clinical Remission and Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:261pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Standard Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:264pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">40/20 mg eow </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:280pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 93</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Low Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:344pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">20/10 mg eow </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:360pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 95</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:424pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">P value</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 26</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:361pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.075</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   Clinical response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:361pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">48.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.073</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 52</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:361pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:395pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.100</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   Clinical response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:361pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.038</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">* p value for Standard Dose </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Low Dose comparison.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 25</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:257pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Paediatric CD Study</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:116pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Discontinuation of Corticosteroids or Immunomodulators and Fistula Remission</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:303pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Standard Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:306pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">40/20 mg eow </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:396pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Low Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:388pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">20/10 mg eow </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:469pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">P value</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">1</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:95pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Discontinued corticosteroids</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:324pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N= 33</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=38</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 26</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">84.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.066</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">69.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.420</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:95pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Discontinuation of Immunomodulators</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">2</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:325pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=60</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=57</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">30.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.983</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:95pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Fistula remission</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">3</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:325pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=15</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=21</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 26</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.608</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.303</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  p value for Standard Dose </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Low Dose comparison.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Immunosuppressant therapy could only be discontinued at or after Week 26 at the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">investigator&apos;s discretion if the subject met the clinical response criterion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">3</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  defined as a closure of all fistulas that were draining at Baseline for at least 2 consecutive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">post-Baseline visits</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Statistically significant increases (improvement) from Baseline to Week 26 and 52 in Body Mass Index </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and height velocity were observed for both treatment groups.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">84</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Statistically and clinically significant improvements from Baseline were also observed in both treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">groups for quality of life parameters (including IMPACT III).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">One hundred patients (n=100) from the Paediatric CD Study continued in an open-label long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension study. After 5 years of adalimumab therapy, 74.0% (37/50) of the 50 patients remaining in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study continued to be in clinical remission, and 92.0% (46/50) of patients continued to be in clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response per PCDAI.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric ulcerative colitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira was assessed in a multicenter, randomized, double-blind, trial in 93 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients from 5 to 17 years of age with moderate to severe ulcerative colitis (Mayo score 6 to 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with endoscopy subscore of 2 to 3 points, confirmed by centrally read endoscopy) who had an inadequate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response or intolerance to conventional therapy. Approximately 16% of patients in the study had failed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">prior anti-TNF treatment. Patients who received corticosteroids at enrollment were allowed to taper their </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">corticosteroid therapy after Week 4.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the induction period of the study, 77 patients were randomized 3:2 to receive double-blind treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Humira at an induction dose of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2; or an induction dose of 2.4 mg/kg (maximum of 160 mg) at Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0, placebo at Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2. Both groups received 0.6 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(maximum of 40 mg) at Week 4 and Week 6. Following an amendment to the study design, the remaining </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16 patients who enrolled in the induction period received open-label treatment with Humira at the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">induction dose of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 mg/kg (maximum of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg) at Week 2.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 8, 62 patients who demonstrated clinical response per Partial Mayo Score (PMS; defined as a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">decrease in PMS &#x2265; 2 points and &#x2265; 30% from Baseline) were randomized equally to receive double-blind </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintenance treatment with Humira at a dose of 0.6 mg/kg (maximum of 40 mg) every week (ew), or a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintenance dose of 0.6 mg/kg (maximum of 40 mg) every other week (eow). Prior to an amendment to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the study design, 12 additional patients who demonstrated clinical response per PMS were randomized to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receive placebo but were not included in the confirmatory analysis of efficacy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Disease flare was defined as an increase in PMS of at least 3 points (for patients with PMS of 0 to 2 at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 8), at least 2 points (for patients with PMS of 3 to 4 at Week 8), or at least 1 point (for patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PMS of 5 to 6 at Week 8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who met criteria for disease flare at or after Week 12 were randomized to receive a re-induction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose of 2.4 mg/kg (maximum of 160 mg) or a dose of 0.6 mg/kg (maximum of 40 mg) and continued to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receive their respective maintenance dose regimen afterwards.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Efficacy Results</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:610pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The co-primary endpoints of the study were clinical remission per PMS (defined as PMS &#x2264; 2 and no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">individual subscore &gt; 1) at Week 8, and clinical remission per FMS (Full Mayo Score) (defined as a Mayo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Score &#x2264; 2 and no individual subscore &gt; 1) at Week 52 in patients who achieved clinical response per PMS </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:648pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at Week 8.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission rates per PMS at Week 8 for patients in each of the Humira double-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blind induction groups are presented in Table 26.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">85</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:189pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 26: Clinical Remission per PMS at 8 Weeks </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:257pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:210pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 160 mg at Week </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:115pt;left:228pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">0 / Placebo at Week 1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:130pt;left:266pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=30</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:404pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b, c</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:360pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 160 mg at Week </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:115pt;left:396pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">0 and Week 1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:130pt;left:417pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=47</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:247pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13/30 (43.3%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:397pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28/47 (59.6%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 2.4 mg/kg (maximum of 160 mg) at Week 0, placebo at Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:178pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:192pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:217pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Not including open-label Induction dose of Humira 2.4 mg/kg (maximum of 160 mg) at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 0 and Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note 1: Both induction groups received 0.6 mg/kg (maximum of 40 mg) at Week 4 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note 2: Patients with missing values at Week 8 were considered as not having met the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endpoint</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 52, clinical remission per FMS in Week 8 responders, clinical response per FMS (defined as a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">decrease in Mayo Score &#x2265; 3 points and &#x2265; 30% from Baseline) in Week 8 responders, mucosal healing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(defined as Mayo endoscopy subscore &#x2264; 1) in Week 8 responders, clinical remission per FMS in Week 8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remitters, and the proportion of subjects in corticosteroid-free remission per FMS in Week 8 responders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were assessed in patients who received Humira at the double-blind maximum 40 mg eow (0.6 mg/kg) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum 40 mg ew (0.6 mg/kg) maintenance doses (Table 27).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:213pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 27: Efficacy Results at 52 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:279pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:245pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 40 mg eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:405pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:373pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 40 mg ew</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:416pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission in Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8 PMS responders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:272pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9/31 (29.0%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:397pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14/31 (45.2%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response in Week 8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PMS responders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:269pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">19/31 (61.3%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:395pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">21/31 (67.7%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mucosal healing in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 8 PMS responders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:269pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12/31 (38.7%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:395pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16/31 (51.6%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission in Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8 PMS remitters</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:272pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9/21 (42.9%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:395pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10/22 (45.5%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Corticosteroid-free </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission in Week 8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PMS responders</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:272pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4/13 (30.8%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:398pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5/16 (31.3%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 0.6 mg/kg (maximum of 40 mg) every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 0.6 mg/kg (maximum of 40 mg) every week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> In patients receiving concomitant corticosteroids at baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note: Patients with missing values at Week 52 or who were randomized to receive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">re-induction or maintenance treatment were considered non-responders for Week 52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endpoints</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">86</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Additional exploratory efficacy endpoints included clinical response per the Paediatric Ulcerative Colitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Activity Index (PUCAI) (defined as a decrease in PUCAI &#x2265; 20 points from Baseline) and clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission per PUCAI (defined as PUCAI &lt; 10) at Week 8 and Week 52 (Table 28). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:181pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 28: Exploratory Endpoints Results per PUCAI</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:361pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:298pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:153pt;left:264pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 160 mg at </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:167pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 0 / Placebo at Week 1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=30</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:428pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b,c</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:153pt;left:397pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 160 mg at </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:167pt;left:404pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 0 and Week 1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:439pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=47</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission per PUCAI</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:286pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10/30 (33.3%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22/47 (46.8%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response per PUCAI</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:286pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15/30 (50.0%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">32/47 (68.1%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:359pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 52</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:297pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">d</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:262pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 40 mg eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:431pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">e</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:397pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 40 mg ew</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:439pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission per PUCAI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in Week 8 PMS responders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:286pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14/31 (45.2%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18/31 (58.1%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response per PUCAI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in Week 8 PMS responders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:286pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18/31 (58.1%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16/31 (51.6%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Humira 2.4 mg/kg (maximum of 160 mg) at Week 0, placebo at Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Not including open-label Induction dose of Humira 2.4 mg/kg (maximum of 160 mg) at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 0 and Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Humira 0.6 mg/kg (maximum of 40 mg) every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">e</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Humira 0.6 mg/kg (maximum of 40 mg) every week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note 1: Both induction groups received 0.6 mg/kg (maximum of 40 mg) at Week 4 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note 2: Patients with missing values at Week 8 were considered as not having met the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endpoints</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note 3: Patients with missing values at Week 52 or who were randomized to receive re-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">induction or maintenance treatment were considered non-responders for Week 52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endpoints</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of the Humira-treated patients who received re-induction treatment during the maintenance period, 2/6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(33%) achieved clinical response per FMS at Week 52.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of life</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinically meaningful improvements from Baseline were observed in IMPACT III and the caregiver Work </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Productivity and Activity Impairment (WPAI) scores for the groups treated with Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinically meaningful increases (improvement) from Baseline in height velocity were observed for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">groups treated with adalimumab, and clinically meaningful increases (improvement) from Baseline in </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">87</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Body Mass Index were observed for subjects on the high maintenance dose of maximum 40 mg (0.6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg) ew. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric Uveitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira was assessed in a randomized, double-masked, controlled study of 90 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients from 2 to &lt; 18 years of age with active JIA-associated noninfectious anterior uveitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who were refractory to at least 12 weeks of methotrexate treatment. Patients received either placebo or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg adalimumab (if &lt; 30 kg) or 40 mg adalimumab (if &#x2265; 30 kg) every other week in combination with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">their baseline dose of methotrexate. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary endpoint was &#x2018;time to treatment failure&#x2019;. The criteria determining treatment failure were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">worsening or sustained non-improvement in ocular inflammation, partial improvement with development </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of sustained ocular co-morbidities or worsening of ocular co-morbidities, non-permitted use of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant medications, and suspension of treatment for an extended period of time.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Clinical Response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab significantly delayed the time to treatment failure, as compared to placebo (See Figure 2, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">P &lt; 0.0001 from log rank test).The median time to treatment failure was 24.1 weeks for subjects treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with placebo, whereas the median time to treatment failure was not estimable for subjects treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab because less than one-half of these subjects experienced treatment failure.  Adalimumab </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">88</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significantly decreased the risk of treatment failure by 75% relative to placebo, as shown by the hazard </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ratio (HR = 0.25 [95% CI: 0.12, 0.49]).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Figure 2: Kaplan-Meier Curves Summarizing Time to Treatment Failure in the Paediatric Uveitis </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:111pt;left:292pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Study</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PROBABILITY OF FAILING TREATMENT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:274pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TIME (WEEKS)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:445pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note: P = Placebo (Number at Risk); H = HUMIRA (Number at Risk).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacokinetic properties</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Absorption and distribution</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:610pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following the administration of 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(maximum of 40 mg) subcutaneously every other week to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with polyarticular juvenile idiopathic arthritis (JIA) who were 4 to 17 years the mean trough </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">steady-state (values measured from Week 20 to 48) serum adalimumab concentration was 5.6 &#xb1; 5.6 &#xb5;g/ml </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(102% CV) for adalimumab without concomitant methotrexate and 10.9 &#xb1; 5.2 &#xb5;g/ml (47.7% CV) with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with polyarticular JIA who were 2 to &lt;4 years old or aged 4 and above weighing &lt;15 kg dosed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with adalimumab 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">, the mean trough steady-state serum adalimumab concentrations was </span></p>
<img style="position:absolute;top:142pt;left:99pt;width:432pt;height:358pt" src="data:image/png;base64,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">
<img style="position:absolute;top:516pt;left:280pt;width:36pt;height:9pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAEwAAAAMCAAAAADtpASbAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAA2UlEQVR4nI2SPQ7CMAyF7bCzICYkJBaExMghkLgA5+BKcJDeoBsS
B+jUzoiJmDglrknSEk/x36f36iKBC0KYjN++y/pCvIb2DyfDGJKIhiXKCHlADVmT
7XlYwiJANZ28HACE4RNRxm+9EaMV49u1OHwynxtlk9qGxPd6yfT7S0SaAyOeD2vC
0GLD3Ka1gQbbeVCGUFeiA497t4XXTgp0QQfrboR29kb2tzvxUlV7knE1OK8wKJuO
6HBiLvKYg+X/oNxMmo0oUweBHDe9f6HN/sLK2KjwIlhpfAC8cXABl3kQ5QAAAABJ
RU5ErkJggg==">
<img style="position:absolute;top:518pt;left:401pt;width:35pt;height:6pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAFIAAAANCAIAAAC1lq7uAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAApElEQVR4nOWVzRGEIAxGE4qgDVy7oirdZmjAtQa6AHXirBHRkz9j
eAcmcsqbLwaMMQLAeCIiLySxlULSFk9ivmjLy/mvtvXCZMjFwI2o5jerIQ8hKKUe
6PEy9nZWfshFhk8FeaUrjT699333u7+5c5lnG0FrbYzJpw0sZOfct2nvb/QKRqmq
/lhr+e9dygPGmeTL0d7d5HD41r2U7HouKG1OodoDHdh+5CqIp8EAAAAASUVORK5CYII=">
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">89</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.0 &#xb1; 6.1 &#xb5;g/ml (101% CV) for adalimumab without concomitant methotrexate and 7.9 &#xb1; 5.6 &#xb5;g/ml </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(71.2% CV) with concomitant methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:91pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following the administration of 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(maximum of 40 mg) subcutaneously every other week to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with enthesitis-related arthritis who were 6 to 17 years, the mean trough steady-state (values </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">measured at Week 24) serum adalimumab concentrations were 8.8 &#xb1; 6.6 &#x3bc;g/ml for adalimumab without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant methotrexate and 11.8 &#xb1; 4.3 &#x3bc;g/ml with concomitant methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:163pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following the administration of 0.8 mg/kg (maximum of 40 mg) subcutaneously every other week to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients with chronic plaque psoriasis, the mean &#xb1; SD steady-state adalimumab trough </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentration was approximately 7.4 &#xb1; 5.8 &#xb5;g/ml (79% CV).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab exposure in adolescent HS patients was predicted using population pharmacokinetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">modelling and simulation based on cross-indication pharmacokinetics in other paediatric patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn&#x2019;s disease, and enthesitis-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis). The recommended adolescent HS dosing schedule is 40 mg every other week. Since exposure to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab can be affected by body size, adolescents with higher body weight and inadequate response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">may benefit from receiving the recommended adult dose of 40 mg every week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In paediatric patients with moderate to severe CD, the open-label adalimumab induction dose was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">160/80 mg or 80/40 mg at Weeks 0 and 2, respectively, dependent on a body weight cut-off of 40 kg. At </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 4, patients were randomised 1:1 to either the Standard Dose (40/20 mg eow) or Low Dose (20/10 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg eow) maintenance treatment groups based on their body weight. The mean (&#xb1;SD) serum adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trough concentrations achieved at Week 4 were 15.7 &#xb1; 6.6</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml for patients </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 40 kg (160/80 mg) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10.6 &#xb1; 6.1</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml for patients &lt; 40 kg (80/40 mg).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For patients who stayed on their randomised therapy, the mean (&#xb1;SD) adalimumab trough concentrations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at Week 52 were 9.5 &#xb1; 5.6</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml for the Standard Dose group and 3.5 &#xb1; 2.2</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml for the Low Dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">group. The mean trough concentrations were maintained in patients who continued to receive adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment eow for 52 weeks. For patients who dose escalated from eow to weekly regimen, the mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&#xb1;SD) serum concentrations of adalimumab at Week 52 were 15.3 &#xb1; 11.4 &#x3bc;g/ml (40/20 mg, weekly) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.7 &#xb1; 3.5 &#x3bc;g/ml (20/10 mg, weekly).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab exposure in paediatric uveitis patients was predicted using population pharmacokinetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">modelling and simulation based on cross-indication pharmacokinetics in other paediatric patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn&#x2019;s disease, and enthesitis-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis). No clinical exposure data are available on the use of a loading dose in children &lt; 6 years. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">predicted exposures indicate that in the absence of methotrexate, a loading dose may lead to an initial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increase in systemic exposure.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Exposure-response relationship in paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">On the basis of clinical trial data in patients with JIA (pJIA and ERA), an exposure-response relationship </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was established between plasma concentrations and PedACR 50 response. The apparent adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">plasma concentration that produces half the maximum probability of PedACR 50 response (EC50) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 &#x3bc;g/ml (95% CI: 1-6 &#x3bc;g/ml). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Exposure-response relationships between adalimumab concentration and efficacy in paediatric patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:658pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with severe chronic plaque psoriasis were established for PASI 75 and PGA clear or minimal, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively. PASI 75 and PGA clear or minimal increased with increasing adalimumab concentrations, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">both with a similar apparent EC50 of approximately 4.5 &#x3bc;g/ml (95% CI 0.4-47.6 and 1.9-10.5, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:722pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adults</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">90</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After subcutaneous administration of a single 40 mg dose, absorption and distribution of adalimumab was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">slow, with peak serum concentrations being reached about 5 days after administration. The average </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">absolute bioavailability of adalimumab estimated from three studies following a single 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous dose was 64%. After single intravenous doses ranging from 0.25 to 10 mg/kg, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentrations were dose proportional. After doses of 0.5 mg/kg (~40 mg), clearances ranged from 11 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15 ml/hour, the distribution volume (V</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">ss</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">) ranged from 5 to 6 litres and the mean terminal phase half-life </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was approximately two weeks. Adalimumab concentrations in the synovial fluid from several rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients ranged from 31-96% of those in serum.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following subcutaneous administration of 40 mg of adalimumab every other week in adult rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis (RA) patients the mean steady-state trough concentrations were approximately 5</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml (without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant methotrexate) and 8 to 9</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml (with concomitant methotrexate), respectively. The serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab trough levels at steady-state increased roughly proportionally with dose following 20, 40 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg subcutaneous dosing every other week and every week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with psoriasis, the mean steady-state trough concentration was 5 &#x3bc;g/ml during</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab 40 mg every other week monotherapy treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with hidradenitis suppurativa, a dose of 160 mg Humira on Week 0 followed by 80 mg on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 2 achieved serum adalimumab trough concentrations of approximately 7 to 8 &#x3bc;g/ml at Week 2 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 4.  The mean steady-state trough concentration at Week 12 through Week 36 were approximately 8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 10 &#x3bc;g/ml during adalimumab 40 mg every week treatment.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with Crohn&#x2019;s disease, the loading dose of 80 mg Humira on Week 0 followed by 40 mg Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">on Week 2 achieves serum adalimumab trough concentrations of approximately 5.5</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">induction period. A loading dose of 160 mg Humira on Week 0 followed by 80 mg Humira on Week 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">achieves serum adalimumab trough concentrations of approximately 12</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml during the induction period. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mean steady-state trough levels of approximately 7</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml were observed in Crohn&#x2019;s disease patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received a maintenance dose of 40 mg Humira every other week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following the subcutaneous administration of body weight-based dosing of 0.6 mg/kg (maximum of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg) every other week to paediatric patients with ulcerative colitis, the mean trough steady-state serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab concentration was 5.01&#xb1;3.28 &#xb5;g/ml at Week 52. For patients who received 0.6 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(maximum of 40 mg) every week, the mean (&#xb1;SD) trough steady-state serum adalimumab concentration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was 15.7&#xb1;5.60 &#x3bc;g/ml at Week 52.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with uveitis, a loading dose of 80 mg adalimumab on Week 0 followed by 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab every other week starting at Week 1, resulted in mean steady-state concentrations of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 8 to 10</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Population pharmacokinetic and pharmacokinetic/pharmacodynamic modelling and simulation predicted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparable adalimumab exposure and efficacy in patients treated with 80 mg every other week when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared with 40 mg every week (including adult patients with RA, HS, UC, CD or Ps, patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adolescent HS, and paediatric patients &#x2265; 40 kg with CD and UC).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elimination</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Population pharmacokinetic analyses with data from over 1,300 RA patients revealed a trend toward </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher apparent clearance of adalimumab with increasing body weight. After adjustment for weight </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">differences, gender and age appeared to have a minimal effect on adalimumab clearance. The serum levels </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of free adalimumab (not bound to anti-adalimumab antibodies, AAA) were observed to be lower in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with measurable AAA. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">91</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatic or renal impairment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has not been studied in patients with hepatic or renal impairment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Preclinical safety data </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Non-clinical data reveal no special hazard for humans based on studies of single dose toxicity, repeated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose toxicity, and genotoxicity.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">An embryo-foetal developmental toxicity/perinatal developmental study has been performed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cynomolgus monkeys at 0, 30 and 100 mg/kg (9-17 monkeys/group) and has revealed no evidence of harm </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to the foetuses due to adalimumab. Neither carcinogenicity studies, nor a standard assessment of fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibody with limited cross-reactivity to rodent TNF and to the development of neutralising antibodies in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rodents.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">List of excipients </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mannitol</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Citric acid monohydrate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium citrate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium dihydrogen phosphate dihydrate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Disodium phosphate dihydrate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium chloride</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Polysorbate 80</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium hydroxide</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Water for injections.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Incompatibilities </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">products.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Shelf life </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for storage </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Store in a refrigerator (2</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C &#x2013; 8</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C). Do not freeze. Keep the vial in the outer carton in order to protect from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">light.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Nature and contents of container  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in single-use vial (type I glass), fitted with rubber stoppers, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">aluminium crimps and flip-off seals. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 Pack of 2 boxes each containing:</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">92</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 vial (0.8 ml sterile solution), 1 empty sterile injection syringe, 1 needle, 1 vial adapter and 2 alcohol </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pads.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for disposal</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requirements.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">7.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">AbbVie Deutschland GmbH &amp; Co. KG</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Knollstrasse</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">67061 Ludwigshafen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Germany</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">8.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBER </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">9.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of first authorisation:  8 September 2003</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of latest renewal: 8 September 2008</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">10.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Agency </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000ff">http://www.ema.europa.eu</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">93</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">1.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in pre-filled syringe</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in pre-filled pen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">2.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in pre-filled syringe </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each 0.8 ml single dose pre-filled syringe contains 40 mg of adalimumab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in pre-filled pen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each 0.8 ml single dose pre-filled pen contains 40 mg of adalimumab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary cells.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For the full list of excipients, see section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">3.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL FORM </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Solution for injection. (injection)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clear, colourless solution. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CLINICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Therapeutic indications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rheumatoid arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira in combination with methotrexate, is indicated for:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:Wingdings,sans-serif;font-size:11.04pt">&#xf0a7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:Wingdings,sans-serif;font-size:11.04pt">&#xf0a7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with methotrexate is inappropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has been shown to reduce the rate of progression of joint damage as measured by X-ray and to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improve physical function, when given in combination with methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Juvenile idiopathic arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Polyarticular juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira in combination with methotrexate is indicated for the treatment of active polyarticular juvenile </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more disease-modifying anti-rheumatic drugs (DMARDs). Humira can be given as monotherapy in case </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">94</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">efficacy in monotherapy see section 5.1). Humira has not been studied in patients aged less than 2 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Enthesitis-related arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Axial spondyloarthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Ankylosing spondylitis (AS)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inadequate response to conventional therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Axial spondyloarthritis without radiographic evidence of AS</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">evidence of AS but with objective signs of inflammation by elevated CRP and / or MRI, who have had an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriatic arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of active and progressive psoriatic arthritis in adults when the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. Humira has </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with polyarticular symmetrical subtypes of the disease (see Section 5.1) and to improve physical function.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are candidates for systemic therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric plaque psoriasis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and phototherapies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hidradenitis suppurativa (HS)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy (see sections 5.1 and 5.2).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Crohn&#x2019;s disease</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for treatment of moderately to severely active Crohn&#x2019;s disease, in adult patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have not responded despite a full and adequate course of therapy with a corticosteroid and/or an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">95</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric Crohn&apos;s disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of moderately to severely active Crohn&apos;s disease in paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (from 6 years of age) who have had an inadequate response to conventional therapy including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have contraindications for such therapies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ulcerative colitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric ulcerative colitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (from 6 years of age) who have had an inadequate response to conventional therapy including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">medical contraindications for such therapies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uveitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sparing, or in whom corticosteroid treatment is inappropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric Uveitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">whom conventional therapy is inappropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Posology and method of administration  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treatment should be initiated and supervised by specialist physicians experienced in the diagnosis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and treatment of conditions for which Humira is indicated. Ophthalmologists are advised to consult with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">an appropriate specialist before initiation of treatment with Humira (see section 4.4). Patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira should be given the Patient Reminder Card.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After proper training in injection technique, patients may self-inject with Humira if their physician </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">determines that it is appropriate and with medical follow-up as necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During treatment with Humira, other concomitant therapies (e.g., corticosteroids and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunomodulatory agents) should be optimised.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Posology</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Rheumatoid arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for adult patients with rheumatoid arthritis is 40 mg adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered every other week as a single dose via subcutaneous injection. Methotrexate should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued during treatment with Humira.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">96</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Glucocorticoids, salicylates, non-steroidal anti-inflammatory drugs, or analgesics can be continued during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment with Humira. Regarding combination with disease modifying anti-rheumatic drugs other than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate see sections 4.4 and 5.1.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In monotherapy, some patients who experience a decrease in their response to Humira 40 mg every other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">week may benefit from an increase in dosage to 40 mg adalimumab every week or 80 mg every other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">week. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Available data suggest that the clinical response is usually achieved within 12 weeks of treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy should be reconsidered in a patient not responding within this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Dose interruption</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There may be a need for dose interruption, for instance before surgery or if a serious infection occurs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Available data suggest that re-introduction of Humira after discontinuation for 70 days or longer resulted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in the same magnitudes of clinical response and similar safety profile as before dose interruption.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS and psoriatic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for patients with ankylosing spondylitis, axial spondyloarthritis without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">radiographic evidence of AS and for patients with psoriatic arthritis is 40 mg adalimumab administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every other week as a single dose via subcutaneous injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Available data suggest that the clinical response is usually achieved within 12 weeks of treatment. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy should be reconsidered in a patient not responding within this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for adult patients is an initial dose of 80 mg administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneously, followed by 40 mg subcutaneously given every other week starting one week after the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initial dose.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy beyond 16 weeks should be carefully reconsidered in a patient not responding within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Beyond 16 weeks, patients with inadequate response to Humira 40 mg every other week may benefit from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">an increase in dosage to 40 mg every week or 80 mg every other week. The benefits and risks of continued</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg weekly or 80 mg every other week therapy should be carefully reconsidered in a patient with an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inadequate response after the increase in dosage (see section 5.1). If adequate response is achieved with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every week or 80 mg every other week, the dosage may subsequently be reduced to 40 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Hidradenitis suppurativa</span></i></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">97</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended Humira dose regimen for adult patients with hidradenitis suppurativa (HS) is 160 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initially at Day 1 (given as four 40 mg injections in one day or as two 40 mg injections per day for two </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">consecutive days), followed by 80 mg two weeks later at Day 15 (given as two 40 mg injections in one </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">day). Two weeks later (Day 29) continue with a dose of 40 mg every week or 80 mg every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(given as two 40 mg injections in one day). Antibiotics may be continued during treatment with Humira if </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">necessary. It is recommended that the patient should use a topical antiseptic wash on their HS lesions on a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">daily basis during treatment with Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy beyond 12 weeks should be carefully reconsidered in a patient with no improvement </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">within this time period.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Should treatment be interrupted, Humira 40 mg every week or 80 mg every other week may be re-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">introduced (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The benefit and risk of continued long-term treatment should be periodically evaluated (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Crohn&#x2019;s disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended Humira induction dose regimen for adult patients with moderately to severely active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Crohn&#x2019;s disease is 80 mg at Week 0 followed by 40 mg at Week 2. In case there is a need for a more rapid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response to therapy, the regimen 160 mg at Week 0 (given as four 40 mg injections in one day or as two </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg injections per day for two consecutive days), followed by 80 mg at Week 2 (given as two 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injections in one day), can be used with the awareness that the risk for adverse events is higher during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">induction.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After induction treatment, the recommended dose is 40 mg every other week via subcutaneous injection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Alternatively, if a patient has stopped Humira and signs and symptoms of disease recur, Humira may be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">re-administered. There is little experience from re-administration after more than 8 weeks since the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">previous dose.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During maintenance treatment, corticosteroids may be tapered in accordance with clinical practice </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">guidelines.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Some patients who experience decrease in their response to Humira 40 mg every other week may benefit </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">from an increase in dosage to 40 mg Humira every week or 80 mg every other week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Some patients who have not responded by Week 4 may benefit from continued maintenance therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">through Week 12. Continued therapy should be carefully reconsidered in a patient not responding within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Ulcerative colitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended Humira induction dose regimen for adult patients with moderate to severe ulcerative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">colitis is 160 mg at Week 0 (given as four 40 mg injections in one day or as two 40 mg injections per day </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">98</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for two consecutive days) and 80 mg at Week 2 (given as two 40 mg injections in one day). After </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">induction treatment, the recommended dose is 40 mg every other week via subcutaneous injection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During maintenance treatment, corticosteroids may be tapered in accordance with clinical practice </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">guidelines. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Some patients who experience decrease in their response to Humira 40 mg every other week may benefit </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">from an increase in dosage to 40 mg Humira every week or 80 mg every other week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Available data suggest that clinical response is usually achieved within 2-8 weeks of treatment. Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy should not be continued in patients failing to respond within this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Uveitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for adult patients with uveitis is an initial dose of 80 mg, followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg given every other week starting one week after the initial dose. There is limited experience in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initiation of treatment with Humira alone. Treatment with Humira can be initiated in combination with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">corticosteroids and/or with other non-biologic immunomodulatory agents. Concomitant corticosteroids </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">may be tapered in accordance with clinical practice starting two weeks after initiating treatment with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira.   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">It is recommended that the benefit and risk of continued long-term treatment should be evaluated on a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">yearly basis (see section 5.1).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Special populations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elderly</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose adjustment is required.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal and/or hepatic impairment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has not been studied in these patient populations. No dose recommendations can be made.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Polyarticular juvenile idiopathic arthritis from 2 years of age</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for patients with polyarticular juvenile idiopathic arthritis from 2 years</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of age is based on body weight (Table 1). Humira is administered every other week via subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:112pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 1. Humira Dose for Patients with Polyarticular Juvenile Idiopathic Arthritis </span></b></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:299pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">99</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:59pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:59pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dosing Regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:75pt;left:185pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 kg to &lt; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:75pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Available data suggest that clinical response is usually achieved within 12 weeks of treatment. Continued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy should be carefully reconsidered in a patient not responding within this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in patients aged less than 2 years for this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Enthesitis-related arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for patients with enthesitis-related arthritis from 6 years of age is based </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">on body weight (Table 2). Humira is administered every other week via subcutaneous injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:147pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 2. Humira Dose for Patients with Enthesitis-Related Arthritis</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dosing Regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:185pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15 kg to &lt; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has not been studied in patients with enthesitis-related arthritis aged less than 6 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Psoriatic arthritis and axial spondyloarthritis including ankylosing spondyliti</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">s</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in the paediatric population for the indications of ankylosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spondylitis and psoriatic arthritis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended Humira dose for patients with plaque psoriasis from 4 to 17 years of age is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body weight (Table 3). Humira is administered via subcutaneous injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:148pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 3. Humira Dose for Paediatric Patients with Plaque Psoriasis</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dosing Regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:185pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15 kg to &lt; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Initial dose of 20 mg, followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg given every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:318pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting one week after the initial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Initial dose of 40 mg, followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg given every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:318pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting one week after the initial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">100</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy beyond 16 weeks should be carefully considered in a patient not responding within this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If retreatment with Humira is indicated, the above guidance on dose and treatment duration should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">followed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety of Humira in paediatric patients with plaque psoriasis has been assessed for a mean of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 4 years for this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adolescent hidradenitis suppurativa (from 12 years of age, weighing at least 30 kg)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There are no clinical trials with Humira in adolescent patients with HS.  The posology of Humira in these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients has been determined from pharmacokinetic modelling and simulation (see section 5.2).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended Humira dose is 80 mg at Week 0 followed by 40 mg every other week starting at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 1 via subcutaneous injection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adolescent patients with inadequate response to Humira 40 mg every other week, an increase in dosage</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 40 mg every week or 80 mg every other week may be considered.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Antibiotics may be continued during treatment with Humira if necessary.  It is recommended that the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient should use a topical antiseptic wash on their HS lesions on a daily basis during treatment with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy beyond 12 weeks should be carefully reconsidered in a patient with no improvement </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">within this time period.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Should treatment be interrupted, Humira may be re-introduced as appropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The benefit and risk of continued long-term treatment should be periodically evaluated (see adult data in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">section 5.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 12 years in this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric Crohn&apos;s disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for patients with Crohn&#x2019;s disease from 6 to 17 years of age is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body weight (Table 4). Humira is administered via subcutaneous injection.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">101</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 4. Humira Dose for Paediatric Patients with Crohn&#x2019;s disease</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:78pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:78pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:255pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Induction Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:470pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maintenance </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:490pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:476pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Starting at </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:483pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:78pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:126pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 40 mg at Week 0 and 20 mg at week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In case there is a need for a more rapid response to therapy with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">awareness that the risk for adverse events may be higher with use of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher induction dose, the following dose may be used:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:126pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 80 mg at week 0 and 40 mg at week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:474pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:477pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:78pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:126pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 80 mg at week 0 and 40 mg at week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In case there is a need for a more rapid response to therapy with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">awareness that the risk for adverse events may be higher with use of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher induction dose, the following dose may be used:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:126pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 160 mg at week 0 and 80 mg at week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:474pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:477pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who experience insufficient response may benefit from an increase in dosage:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg: 20 mg every week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 40 kg: 40 mg every week or 80 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy should be carefully considered in a subject not responding by week 12.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 6 years for this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric ulcerative colitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for patients from 6 to 17 years of age with ulcerative colitis is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body weight (Table 5). Humira is administered via subcutaneous injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:146pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 5. Humira Dose for Paediatric Patients with Ulcerative Colitis </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:102pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:234pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Induction Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:395pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maintenance Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:392pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Starting at Week 4*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:120pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:192pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 80 mg at Week 0 (given as two 40 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg injections in one day) and</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:192pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 40 mg at Week 2 (given as one 40 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg injection)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:365pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 40 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:120pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:192pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 160 mg at Week 0 (given as four </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg injections in one day or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">two 40 mg injections per day for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">two consecutive days) and</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:192pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 80 mg at Week 2 (given as two 40 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg injections in one day)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:365pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 80 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:91pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">* </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric patients who turn 18 years of age while on Humira should continue their prescribed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:91pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintenance dose.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">102</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy beyond 8 weeks should be carefully considered in patients not showing signs of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response within this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 6 years in this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in different strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric Uveitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for paediatric patients with uveitis from 2 years of age is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body weight (Table 6). Humira is administered via subcutaneous injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In paediatric uveitis, there is no experience in the treatment with Humira without concomitant treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:170pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 6. Humira Dose for Paediatric Patients with Uveitis</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dosing Regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:332pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg every other week in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:322pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination with methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:332pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:322pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination with methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">When Humira therapy is initiated, a loading dose of 40 mg for patients &lt; 30 kg or 80 mg for patients &#x2265; 30 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">kg may be administered one week prior to the start of maintenance therapy. No clinical data are available </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">on the use of a Humira loading dose in children &lt; 6 years of age (see section 5.2).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 2 years in this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">It is recommended that the benefit and risk of continued long-term treatment should be evaluated on a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">yearly basis (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Method of administration</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is administered by subcutaneous injection. Full instructions for use are provided in the package </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">leaflet.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is available in other strengths and presentations.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Contraindications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Active tuberculosis or other severe infections such as sepsis, and opportunistic infections (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Moderate to severe heart failure (NYHA class III/IV) (see section 4.4).</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">103</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special warnings and precautions for use  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Traceability </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In order to improve traceability of biological medicinal products, the name and the batch number of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered product should be clearly recorded.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Infections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients taking TNF-antagonists are more susceptible to serious infections. Impaired lung function may </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increase the risk for developing infections. Patients must therefore be monitored closely for infections, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">including tuberculosis, before, during and after treatment with Humira. Because the elimination of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab may take up to four months, monitoring should be continued throughout this period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Humira should not be initiated in patients with active infections including chronic or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">localised infections until infections are controlled. In patients who have been exposed to tuberculosis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who have travelled in areas of high risk of tuberculosis or endemic mycoses, such as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">histoplasmosis, coccidioidomycosis, or blastomycosis, the risk and benefits of treatment with Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be considered prior to initiating therapy (see </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Other opportunistic infections</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who develop a new infection while undergoing treatment with Humira should be monitored </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">closely and undergo a complete diagnostic evaluation. Administration of Humira should be discontinued if </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be initiated until the infection is controlled. Physicians should exercise caution when considering </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the use of Humira in patients with a history of recurring infection or with underlying conditions which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">may predispose patients to infections, including the use of concomitant immunosuppressive medications.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Serious infections</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious infections, including sepsis, due to bacterial, mycobacterial, invasive fungal, parasitic, viral, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other opportunistic infections such as listeriosis, legionellosis and pneumocystis have been reported in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients receiving Humira.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Other serious infections seen in clinical trials include pneumonia, pyelonephritis, septic arthritis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">septicaemia. Hospitalisation or fatal outcomes associated with infections have been reported. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Tuberculosis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tuberculosis, including reactivation and new onset of tuberculosis, has been reported in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira.  Reports included cases of pulmonary and extra-pulmonary (i.e. disseminated) tuberculosis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Before initiation of therapy with Humira, all patients must be evaluated for both active or inactive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&#x201c;latent&#x201d;) tuberculosis infection.  This evaluation should include a detailed medical assessment of patient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">history of tuberculosis or possible previous exposure to people with active tuberculosis and previous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and/or current immunosuppressive therapy.  Appropriate screening tests (i.e. tuberculin skin test and chest </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">X-ray) should be performed in all patients (local recommendations may apply).  It is recommended that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the conduct and results of these tests are recorded in the Patient Reminder Card.  Prescribers are reminded </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunocompromised. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If active tuberculosis is diagnosed, Humira therapy must not be initiated (see section 4.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In all situations described below, the benefit/risk balance of therapy should be very carefully considered.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">consulted.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosis prophylaxis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment before the initiation of Humira, and in accordance with local recommendations. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Use of anti-tuberculosis prophylaxis treatment should also be considered before the initiation of Humira in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with several or significant risk factors for tuberculosis despite a negative test for tuberculosis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cannot be confirmed.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have occurred in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with Humira. Some patients who have been successfully treated for active tuberculosis have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">redeveloped tuberculosis while being treated with Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients should be instructed to seek medical advice if signs/symptoms suggestive of a tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infection (e.g., persistent cough, wasting/weight loss, low grade fever, listlessness) occur during or after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy with Humira. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Other opportunistic infections</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Opportunistic infections, including invasive fungal infections have been observed in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira. These infections have not consistently been recognised in patients taking TNF-antagonists and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">this has resulted in delays in appropriate treatment, sometimes resulting in fatal outcomes. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dyspnoea, and/or pulmonary infiltrates or other serious systemic illness with or without concomitant shock </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">an invasive fungal infection should be suspected and administration of Humira should be promptly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">discontinued.  Diagnosis and administration of empiric antifungal therapy in these patients should be made </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in consultation with a physician with expertise in the care of patients with invasive fungal infections. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatitis B reactivation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reactivation of hepatitis B has occurred in patients receiving a TNF-antagonist including Humira, who are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chronic carriers of this virus (i.e. surface antigen positive).  Some cases have had a fatal outcome. Patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be tested for HBV infection before initiating treatment with Humira. For patients who test positive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for hepatitis B infection, consultation with a physician with expertise in the treatment of hepatitis B is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recommended.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Carriers of HBV who require treatment with Humira should be closely monitored for signs and symptoms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of active HBV infection throughout therapy and for several months following termination of therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adequate data from treating patients who are carriers of HBV with anti-viral therapy in conjunction with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonist therapy to prevent HBV reactivation are not available. In patients who develop HBV </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactivation, Humira should be stopped and effective anti-viral therapy with appropriate supportive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment should be initiated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neurological events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonists including Humira have been associated in rare instances with new onset or exacerbation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">including multiple sclerosis and optic neuritis, and peripheral demyelinating disease, including Guillain-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Barr&#xe9; syndrome. Prescribers should exercise caution in considering the use of Humira in patients with pre-</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">105</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">existing or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira should be considered if any of these disorders develop. There is a known association between </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intermediate uveitis and central demyelinating disorders. Neurologic evaluation should be performed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with non-infectious intermediate uveitis prior to the initiation of Humira therapy and regularly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">during treatment to assess for pre-existing or developing central demyelinating disorders. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Allergic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious allergic reactions associated with Humira were rare during clinical trials. Non-serious allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactions associated with Humira were uncommon during clinical trials. Reports of serious allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactions including anaphylaxis have been received following Humira administration. If an anaphylactic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reaction or other serious allergic reaction occurs, administration of Humira should be discontinued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immediately and appropriate therapy initiated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immunosuppression</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a study of 64 patients with rheumatoid arthritis that were treated with Humira, there was no evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enumeration of effector T-, B-, NK-cells, monocyte/macrophages, and neutrophils.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the controlled portions of clinical trials of TNF-antagonists, more cases of malignancies including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lymphoma have been observed among patients receiving a TNF-antagonist compared with control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients. However, the occurrence was rare. In the post marketing setting, cases of leukaemia have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reported in patients treated with a TNF-antagonist. There is an increased background risk for lymphoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">which complicates the risk estimation. With the current knowledge, a possible risk for the development of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lymphomas, leukaemia, and other malignancies in patients treated with a TNF-antagonist cannot be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">excluded.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to 22 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">years of age) treated with TNF-antagonists (initiation of therapy &#x2264; 18 years of age), including adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in the post marketing setting. Approximately half the cases were lymphomas. The other cases represented </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a variety of different malignancies and included rare malignancies usually associated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunosuppression. A risk for the development of malignancies in children and adolescents treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonists cannot be excluded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare postmarketing cases of hepatosplenic T-cell lymphoma have been identified in patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab. This rare type of T-cell lymphoma has a very aggressive disease course and is usually fatal. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Some of these hepatosplenic T-cell lymphomas with Humira have occurred in young adult patients on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant treatment with azathioprine or 6-mercaptopurine used for inflammatory bowel disease. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">potential risk with the combination of azathioprine or 6-mercaptopurine and Humira should be carefully </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered. A risk for the development of hepatosplenic T-cell lymphoma in patients treated with Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cannot be excluded (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No studies have been conducted that include patients with a history of malignancy or in whom treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Humira is continued following development of malignancy.  Thus, additional caution should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exercised in considering Humira treatment of these patients (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis patients with a history of PUVA treatment should be examined for the presence of non-</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">106</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">melanoma skin cancer prior to and during treatment with Humira.  Melanoma and Merkel cell carcinoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have also been reported in patients treated with TNF-antagonists including adalimumab (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an exploratory clinical trial evaluating the use of another TNF-antagonist, infliximab, in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies, mostly in the lung </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or head and neck, were reported in infliximab-treated patients compared with control patients. All patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had a history of heavy smoking. Therefore, caution should be exercised when using any TNF-antagonist in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">COPD patients, as well as in patients with increased risk for malignancy due to heavy smoking.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">With current data it is not known if adalimumab treatment influences the risk for developing dysplasia or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">colon cancer.  All patients with ulcerative colitis who are at increased risk for dysplasia or colon </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">carcinoma (for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or who had a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intervals before therapy and throughout their disease course. This evaluation should include colonoscopy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and biopsies per local recommendations.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Haematologic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare reports of pancytopenia including aplastic anaemia have been reported with TNF-antagonists.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adverse events of the haematologic system, including medically significant cytopenia (e.g. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">thrombocytopenia, leukopenia) have been reported with Humira. All patients should be advised to seek </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">persistent fever, bruising, bleeding, pallor) while on Humira. Discontinuation of Humira therapy should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered in patients with confirmed significant haematologic abnormalities.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vaccinations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Similar antibody responses to the standard 23-valent pneumococcal vaccine and the influenza trivalent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">virus vaccination were observed in a study in 226 adult subjects with rheumatoid arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with adalimumab or placebo. No data are available on the secondary transmission of infection by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">live vaccines in patients receiving Humira.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">agreement with current immunisation guidelines prior to initiating Humira therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients on Humira may receive concurrent vaccinations, except for live vaccines. Administration of live </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vaccines (e.g., BCG vaccine) to infants exposed to adalimumab in utero is not recommended for 5 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">following the mother&#x2019;s last adalimumab injection during pregnancy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Congestive heart failure</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a clinical trial with another TNF-antagonist worsening congestive heart failure and increased mortality </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">due to congestive heart failure have been observed. Cases of worsening congestive heart failure have also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been reported in patients receiving Humira. Humira should be used with caution in patients with mild </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">heart failure (NYHA class I/II). Humira is contraindicated in moderate to severe heart failure (see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.3). Treatment with Humira must be discontinued in patients who develop new or worsening symptoms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of congestive heart failure.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Autoimmune processes</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Humira may result in the formation of autoimmune antibodies. The impact of long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment with Humira on the development of autoimmune diseases is unknown. If a patient develops </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms suggestive of a lupus-like syndrome following treatment with Humira and is positive for </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">107</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies against double-stranded DNA, further treatment with Humira should not be given (see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent administration of biologic DMARDS or TNF-antagonists</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious infections were seen in clinical studies with concurrent use of anakinra and another </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonist, etanercept, with no added clinical benefit compared to etanercept alone. Because of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">nature of the adverse events seen with the combination of etanercept and anakinra therapy, similar </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">toxicities may also result from the combination of anakinra and other TNF-antagonists. Therefore, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination of adalimumab and anakinra is not recommended. (See section 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concomitant administration of adalimumab with other biologic DMARDS (e.g, anakinra and abatacept) or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other TNF-antagonists is not recommended based upon the possible increased risk for infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">including serious infections and other potential pharmacological interactions. (See section 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Surgery</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is limited safety experience of surgical procedures in patients treated with Humira. The long half-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">life of adalimumab should be taken into consideration if a surgical procedure is planned.  A patient who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requires surgery while on Humira should be closely monitored for infections, and appropriate actions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be taken. There is limited safety experience in patients undergoing arthroplasty while receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Small bowel obstruction</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Failure to respond to treatment for Crohn&#x2019;s disease may indicate the presence of fixed fibrotic stricture </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">that may require surgical treatment. Available data suggest that Humira does not worsen or cause </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">strictures.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elderly</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The frequency of serious infections among Humira treated subjects over 65 years of age (3.7%) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher than for those under 65 years of age (1.5%). Some of those had a fatal outcome. Particular attention </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">regarding the risk for infection should be paid when treating the elderly.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">See Vaccinations above.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Excipients with known effects</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">This medicinal product contains less than 1 mmol of sodium (23 mg) per 0.8 ml dose, i.e. essentially </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2018;sodium-free&#x2019;.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has been studied in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients taking Humira as monotherapy and those taking concomitant methotrexate.  Antibody </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">formation was lower when Humira was given together with methotrexate in comparison with use as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy. Administration of Humira without methotrexate resulted in increased formation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies, increased clearance and reduced efficacy of adalimumab (see section 5.1). </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">108</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The combination of Humira and anakinra is not recommended (see section 4.4 &#x201c;Concurrent administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of biologic DMARDS or TNF-antagonists&#x201d;). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The combination of Humira and abatacept is not recommended (see section 4.4 &#x201c;Concurrent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration of biologic DMARDS or TNF-antagonists&#x201d;).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Fertility, pregnancy and lactation</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential should consider the use of adequate contraception to prevent pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and continue its use for at least five months after the last Humira treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pregnancy</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A large number (approximately 2100) of prospectively collected pregnancies exposed to adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">resulting in live birth with known outcomes, including more than 1500 exposed during the first trimester, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">does not indicate an increase in the rate of malformation in the newborn.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a prospective cohort registry, 257 women with rheumatoid arthritis (RA) or Crohn&#x2019;s disease (CD) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with adalimumab at least during the first trimester and 120 women with RA or CD not treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab were enrolled.  The primary endpoint was the birth prevalence of major birth defects. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rate of pregnancies ending with at least one live born infant with a major birth defect was 6/69 (8.7%) in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the adalimumab-treated women with RA and 5/74 (6.8%) in the untreated women with RA (unadjusted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">OR 1.31, 95% CI 0.38-4.52) and 16/152 (10.5%) in the adalimumab-treated women with CD and 3/32 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(9.4%) in the untreated women with CD (unadjusted OR 1.14, 95% CI 0.31-4.16). The adjusted OR </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(accounting for baseline differences) was 1.10 (95% CI 0.45-2.73) with RA and CD combined. There were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">no distinct differences between adalimumab-treated and untreated women for the secondary endpoints </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spontaneous abortions, minor birth defects, preterm delivery, birth size and serious or opportunistic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections and no stillbirths or malignancies were reported. The interpretation of data may be impacted due </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to methodological limitations of the study, including small sample size and non-randomized design.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a developmental toxicity study conducted in monkeys, there was no indication of maternal toxicity, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">embryotoxicity or teratogenicity. Preclinical data on postnatal toxicity of adalimumab are not available </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(see section 5.3).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Due to its inhibition of TNF</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf061;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">, adalimumab administered during pregnancy could affect normal immune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responses in the newborn. Adalimumab should only be used during pregnancy if clearly needed.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab may cross the placenta into the serum of infants born to women treated with adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">during pregnancy. Consequently, these infants may be at increased risk for infection. Administration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">live vaccines (e.g., BCG vaccine) to infants exposed to adalimumab in utero is not recommended for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5 months following the mother&#x2019;s last adalimumab injection during pregnancy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Breast-feeding</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Limited information from the published literature indicates that adalimumab is excreted in breast milk at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">very low concentrations with the presence of adalimumab in human milk at concentrations of 0.1% to 1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of the maternal serum level. Given orally, immunoglobulin G proteins undergo intestinal proteolysis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have poor bioavailability. No effects on the breastfed newborns/infants are anticipated. Consequently, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira can be used during breastfeeding.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fertility</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">109</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Preclinical data on fertility effects of adalimumab are not available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.7</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Effects on ability to drive and use machines </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may have a minor influence on the ability to drive and use machines. Vertigo and visual </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">impairment may occur following administration of Humira (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Undesirable effects</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Summary of the safety profile</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira was studied in 9,506 patients in pivotal controlled and open label trials for up to 60 months or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more. These trials included rheumatoid arthritis patients with short term and long standing disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis) as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">well as axial spondyloarthritis (ankylosing spondylitis and axial spondyloarthritis without radiographic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">evidence of AS), psoriatic arthritis, Crohn&#x2019;s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and uveitis patients. The pivotal controlled studies involved 6,089 patients receiving Humira and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3,801 patients receiving placebo or active comparator during the controlled period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The proportion of patients who discontinued treatment due to adverse events during the double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">controlled portion of pivotal studies was 5.9% for patients taking Humira and 5.4% for control treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The most commonly reported adverse reactions are infections (such as nasopharyngitis, upper respiratory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tract infection and sinusitis), injection site reactions (erythema, itching, haemorrhage, pain or swelling), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">headache and musculoskeletal pain.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious adverse reactions have been reported for Humira. TNF-antagonists, such as Humira affect the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immune system and their use may affect the body&#x2019;s defence against infection and cancer.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fatal and life-threatening infections (including sepsis, opportunistic infections and TB), HBV reactivation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and various malignancies (including leukaemia, lymphoma and HSTCL) have also been reported with use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious haematological, neurological and autoimmune reactions have also been reported. These include </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rare reports of pancytopenia, aplastic anaemia, central and peripheral demyelinating events and reports of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lupus, lupus-related conditions and Stevens-Johnson syndrome.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In general, the adverse events in paediatric patients were similar in frequency and type to those seen in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adult patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tabulated list of adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The following list of adverse reactions is based on experience from clinical trials and on postmarketing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experience and are displayed by system organ class and frequency in Table 7 below: very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1/10); common (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1/100 to &lt; 1/10); uncommon (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1/1,000 to &lt; 1/100); rare (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1/10,000 to &lt; 1/1,000); </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and not known (cannot be estimated from the available data). Within each frequency grouping, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">undesirable effects are presented in order of decreasing seriousness. The highest frequency seen among the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">various indications has been included. An asterisk (*) appears in the SOC column if further information is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">found elsewhere in sections 4.3, 4.4 and 4.8.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">110</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:288pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 7</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:259pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Undesirable Effects</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Infections and</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infestations*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Respiratory tract infections (including lower and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">upper respiratory tract infection, pneumonia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sinusitis, pharyngitis, nasopharyngitis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pneumonia herpes viral)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:193pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Systemic infections (including sepsis, candidiasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and influenza),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intestinal infections (including gastroenteritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">viral),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">skin and soft tissue infections (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paronychia, cellulitis, impetigo, necrotising </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:266pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fasciitis and herpes zoster),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ear infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">oral infections (including herpes simplex, oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">herpes and tooth infections), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reproductive tract infections (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vulvovaginal mycotic infection), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">urinary tract infections (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pyelonephritis),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fungal infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joint infections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neurological infections (including viral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">meningitis),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">opportunistic infections and tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(including coccidioidomycosis, histoplasmosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and mycobacterium avium complex infection), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bacterial infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">eye infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">diverticulitis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neoplasms benign, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">malignant and unspecified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(including cysts and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">polyps)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Skin cancer excluding melanoma (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">basal cell carcinoma and squamous cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">carcinoma),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">benign neoplasm</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Lymphoma**, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">solid organ neoplasm (including breast cancer, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lung neoplasm and thyroid neoplasm), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">melanoma**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Leukaemia</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatosplenic T-cell lymphoma</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">111</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Merkel cell carcinoma (neuroendocrine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">carcinoma of the skin)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Kaposi&#x2019;s sarcoma</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Blood and the lymphatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">system disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Leukopenia (including neutropenia and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">agranulocytosis), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anaemia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Leucocytosis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">thrombocytopenia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Idiopathic thrombocytopenic purpura</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pancytopenia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immune system disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypersensitivity,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">allergies (including seasonal allergy)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sarcoidosis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vasculitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Anaphylaxis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Metabolism and nutrition </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Lipids increased</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypokalaemia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">uric acid increased, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blood sodium abnormal,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hypocalcaemia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hyperglycaemia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hypophosphatemia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dehydration</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psychiatric disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mood alterations (including depression), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anxiety,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">insomnia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Nervous system disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Headache</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paraesthesias (including hypoesthesia),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">migraine,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">nerve root compression</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">112</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cerebrovascular accident</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tremor,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">neuropathy  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Multiple sclerosis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demyelinating disorders (e.g. optic neuritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Guillain-Barr&#xe9; syndrome)</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Eye disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Visual impairment,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conjunctivitis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blepharitis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">eye swelling</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Diplopia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ear and labyrinth </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vertigo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Deafness, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tinnitus</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cardiac disorders* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tachycardia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Myocardial infarction</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arrhythmia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">congestive heart failure</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cardiac arrest</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vascular disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypertension, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">flushing, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">haematoma</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Aortic aneurysm,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vascular arterial occlusion,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">thrombophlebitis   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Respiratory, thoracic and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mediastinal disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Asthma,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dyspnoea,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cough</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pulmonary embolism</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interstitial lung disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chronic obstructive pulmonary disease,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pneumonitis,</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">113</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pleural effusion</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:111pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pulmonary fibrosis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Gastrointestinal disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Abdominal pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:153pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">nausea and vomiting</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">GI haemorrhage, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:194pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dyspepsia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">gastroesophageal reflux disease,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sicca syndrome</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pancreatitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dysphagia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">face oedema</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Intestinal perforation</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepato-biliary disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elevated liver enzymes</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cholecystitis and cholelithiasis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hepatic steatosis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bilirubin increased</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactivation of hepatitis B</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1) </span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoimmune hepatitis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Liver failure</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:509pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Skin and subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tissue disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:509pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:509pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rash (including exfoliative rash)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Worsening or new onset of psoriasis(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">palmoplantar pustular psoriasis)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">urticaria,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bruising (including purpura), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dermatitis (including eczema),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">onychoclasis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hyperhidrosis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">alopecia</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pruritus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Night sweats,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">scar</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">114</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erythema multiforme</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:100pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Stevens-Johnson syndrome</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:116pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">angioedema</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cutaneous vasculitis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lichenoid skin reaction</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:180pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:179pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Worsening of symptoms of dermatomyositis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Musculoskeletal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">connective tissue disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Musculoskeletal pain</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:243pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:243pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Muscle spasms (including blood creatine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:256pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">phosphokinase increased)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rhabdomyolysis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">systemic lupus erythematosus</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Lupus-like syndrome</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal and urinary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal impairment,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">haematuria</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Nocturia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reproductive system and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">breast disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erectile dysfunction</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">General disorders and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration site </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conditions*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Injection site reaction (including injection site </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">erythema)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Chest pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">oedema,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pyrexia</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Inflammation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Investigations*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Coagulation and bleeding disorders (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">activated partial thromboplastin time prolonged), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoantibody test positive (including double </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">stranded DNA antibody), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blood lactate dehydrogenase increased</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Weight increased</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Injury, poisoning and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">procedural complications</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Impaired healing</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">115</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">* further information is found elsewhere in sections 4.3, 4.4 and 4.8</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">** including open label extension studies</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:78pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> including spontaneous reporting data</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:90pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2)</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> The mean weight change from baseline for adalimumab ranged from 0.3 kg to 1.0 kg across adult </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">indications compared to (minus) -0.4 kg to 0.4 kg for placebo over a treatment period of 4-6 months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Weight increase of 5-6 kg has also been observed in long-term extension studies with mean exposures of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 1-2 years without control group, particularly in patients with Crohn&#x2019;s disease and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ulcerative colitis. The mechanism behind this effect is unclear but could be associated with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anti-inflammatory effect of adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hidradenitis suppurativa</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety profile for patients with HS treated with Humira weekly was consistent with the known safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">profile of Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uveitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety profile for patients with uveitis treated with Humira every other week was consistent with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">known safety profile of Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Description of selected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Injection site reactions</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the pivotal controlled trials in adults and children, 12.9% of patients treated with Humira developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection site reactions (erythema and/or itching, haemorrhage, pain or swelling), compared to 7.2% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients receiving placebo or active control. Injection site reactions generally did not necessitate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">discontinuation of the medicinal product. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Infections</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the pivotal controlled trials in adults and children, the rate of infection was 1.51 per patient year in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treated patients and 1.46 per patient year in the placebo and active control-treated patients. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections consisted primarily of nasopharyngitis, upper respiratory tract infection, and sinusitis. Most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients continued on Humira after the infection resolved.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The incidence of serious infections was 0.04 per patient year in Humira treated patients and 0.03 per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient year in placebo and active control &#x2212; treated patients.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled and open label adult and paediatric studies with Humira, serious infections (including fatal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections, which occurred rarely) have been reported, which include reports of tuberculosis (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extrapulmonary  histoplasmosis,  blastomycosis, coccidioidomycosis, pneumocystis,  candidiasis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">aspergillosis and listeriosis). Most of the cases of tuberculosis occurred within the first eight months after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initiation of therapy and may reflect recrudescence of latent disease.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No malignancies were observed in 249 paediatric patients with an exposure of 655.6 patient years during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira trials in patients with juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enthesitis-related arthritis). In addition, no malignancies were observed in 192 paediatric patients with an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exposure of 498.1 patient years during Humira trials in paediatric patients with Crohn&#x2019;s disease. No </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">malignancies were observed in 77 paediatric patients with an exposure of 80.0 patient years during a </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">116</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira trial in paediatric patients with chronic plaque psoriasis. No malignancies were observed in 93 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients with an exposure of 65.3 patient years during a Humira trial in paediatric patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ulcerative colitis. No malignancies were observed in 60 paediatric patients with an exposure of 58.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient years during a Humira trial in paediatric patients with uveitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During the controlled portions of pivotal Humira trials in adults of at least 12 weeks in duration in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">without radiographic evidence of AS,  psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease, ulcerative colitis and uveitis, malignancies, other than lymphoma and non-melanoma skin cancer, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were observed at a rate (95% confidence interval) of 6.8 (4.4, 10.5) per 1,000 patient-years among 5,291 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treated patients </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a rate of 6.3 (3.4, 11.8) per 1,000 patient-years among 3,444 control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (median duration of treatment was 4.0 months for Humira and 3.8 months for control-treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients). The rate (95% confidence interval) of non-melanoma skin cancers was 8.8 (6.0, 13.0) per 1,000 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient-years among Humira-treated patients and 3.2 (1.3, 7.6) per 1,000 patient-years among control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients. Of these skin cancers, squamous cell carcinomas occurred at rates (95% confidence interval) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.7 (1.4, 5.4) per 1,000 patient-years among Humira-treated patients and 0.6 (0.1, 4.5) per 1,000 patient-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">years among control patients. The rate (95% confidence interval) of lymphomas was 0.7 (0.2, 2.7) per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1,000 patient-years among Humira-treated patients and 0.6 (0.1, 4.5) per 1,000 patient-years among </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">control patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">When combining controlled portions of these trials and ongoing and completed open label extension </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies with a median duration of approximately 3.3 years including 6,427 patients and over </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">26,439 patient-years of therapy, the observed rate of malignancies, other than lymphoma and non-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">melanoma skin cancers is approximately 8.5 per 1,000 patient years. The observed rate of non-melanoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">skin cancers is approximately 9.6 per 1,000 patient years, and the observed rate of lymphomas is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 1.3 per 1,000 patient years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In post-marketing experience from January 2003 to December 2010, predominantly in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rheumatoid arthritis, the reported rate of malignancies is approximately 2.7 per 1,000 patient treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">years. The reported rates for non-melanoma skin cancers and lymphomas are approximately 0.2 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.3 per 1,000 patient treatment years, respectively (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare post-marketing cases of hepatosplenic T-cell lymphoma have been reported in patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Autoantibodies</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients had serum samples tested for autoantibodies at multiple time points in rheumatoid arthritis studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">I &#x2212; V. In these trials, 11.9% of patients treated with Humira and 8.1% of placebo and active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">control &#x2212; treated patients that had negative baseline anti-nuclear antibody titres reported positive titres at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24. Two patients out of 3,441 treated with Humira in all rheumatoid arthritis and psoriatic arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies developed clinical signs suggestive of new-onset lupus-like syndrome. The patients improved </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">following discontinuation of therapy. No patients developed lupus nephritis or central nervous system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Hepato-biliary events</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled Phase 3 trials of Humira in patients with rheumatoid arthritis and psoriatic arthritis with a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">control period duration ranging from 4 to 104 weeks, ALT elevations &#x2265; 3 x ULN occurred in 3.7% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira-treated patients and 1.6% of control-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled Phase 3 trials of Humira in patients with polyarticular juvenile idiopathic arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 to 17 years and enthesitis-related arthritis who were 6 to 17 years, ALT elevations &#x2265; 3 x ULN occurred </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">117</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in 6.1% of Humira-treated patients and 1.3% of control-treated patients. Most ALT elevations occurred </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with concomitant methotrexate use. No ALT elevations &#x2265; 3 x ULN occurred in the Phase 3 trial of Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients with polyarticular juvenile idiopathic arthritis who were 2 to &lt;4 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled Phase 3 trials of Humira in patients with Crohn&#x2019;s disease and ulcerative colitis with a control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">period ranging from 4 to 52 weeks. ALT elevations &#x2265; 3 x ULN occurred in 0.9% of Humira-treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients and 0.9% of controlled-treated patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the Phase 3 trial of Humira in patients with paediatric Crohn&#x2019;s disease which evaluated efficacy and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">safety of two body weight adjusted maintenance dose regimens following body weight adjusted induction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy up to 52 weeks of treatment, ALT elevations &#x2265; 3 x ULN occurred in 2.6% (5/192) of patients of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">whom 4 were receiving concomitant immunosuppressants at baseline.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled Phase 3 trials of Humira in patients with plaque Psoriasis with a control period duration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ranging from 12 to 24 weeks, ALT elevations &#x2265; 3 x ULN occurred in 1.8% of Humira-treated patients and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.8% of control-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No ALT elevations &#x2265;3 X ULN occurred in the Phase 3 trial of Humira in paediatric patients with plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled trials of Humira (initial doses of 160 mg at Week 0 and 80 mg at Week 2, followed by 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every week starting at Week 4), in patients with hidradenitis suppurativa with a control period duration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ranging from 12 to 16 weeks, ALT elevations &#x2265; 3 x ULN occurred in 0.3% of Humira-treated patients and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.6% of control-treated patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled trials of Humira (initial doses of 80 mg at Week 0 followed by 40 mg every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting at Week 1) in adult patients with uveitis up to 80 weeks with a median exposure of 166.5 days and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">105.0 days in Humira-treated and control-treated patients, respectively, ALT elevations &#x2265; 3 x ULN </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurred in 2.4% of Humira-treated patients and 2.4% of control-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the controlled Phase 3 trial of Humira in patients with paediatric ulcerative colitis (N=93) which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">evaluated efficacy and safety of a maintenance dose of 0.6 mg/kg (maximum of 40 mg) every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N=31) and a maintenance dose of 0.6 mg/kg (maximum of 40 mg) every Week (N=32), following body </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weight adjusted induction dosing of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2 (N=63), or an induction dose of 2.4 mg/kg (maximum of 160 mg) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at Week 0, placebo at Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2 (N=30), ALT elevations &#x2265; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 X ULN occurred in 1.1% (1/93) of patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Across all indications in clinical trials patients with raised ALT were asymptomatic and in most cases </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">elevations were transient and resolved on continued treatment.  However, there have also been post-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">marketing reports of liver failure as well as less severe liver disorders that may precede liver failure, such </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as hepatitis including autoimmune hepatitis in patients receiving adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with azathioprine/6-mercaptopurine</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult Crohn&#x2019;s disease studies, higher incidences of malignant and serious infection-related adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">events were seen with the combination of Humira and azathioprine/6-mercaptopurine compared with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira alone.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting of suspected adverse reactions</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">118</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important.  It allows </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued monitoring of the benefit/risk balance of the medicinal product.  Healthcare professionals are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">asked to report any suspected adverse reactions via the national reporting system listed in </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000ff">Appendix V.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Overdose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose-limiting toxicity was observed during clinical trials. The highest dose level evaluated has been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">multiple intravenous doses of 10 mg/kg, which is approximately 15 times the recommended dose.    </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacodynamic properties</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-&#x3b1;) inhibitors. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ATC code: L04AB04</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mechanism of action</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab binds specifically to TNF and neutralises the biological function of TNF by blocking its </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interaction with the p55 and p75 cell surface TNF receptors.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with an IC</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> of 0.1-0.2 nM). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharmacodynamic effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After treatment with Humira, a rapid decrease in levels of acute phase reactants of inflammation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and serum cytokines (IL-6) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed, compared to baseline in patients with rheumatoid arthritis. Serum levels of matrix </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">destruction were also decreased after Humira administration. Patients treated with Humira usually </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced improvement in haematological signs of chronic inflammation.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A rapid decrease in CRP levels was also observed in patients with polyarticular juvenile idiopathic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis, Crohn&#x2019;s disease, ulcerative colitis and hidradenitis suppurativa after treatment with Humira. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with Crohn&#x2019;s disease, a reduction of the number of cells expressing inflammatory markers in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">colon including a significant reduction of expression of TNF&#x3b1; was seen. Endoscopic studies in intestinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mucosa have shown evidence of mucosal healing in adalimumab treated patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical efficacy and safety</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Rheumatoid arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira was evaluated in over 3,000 patients in all rheumatoid arthritis clinical trials. The efficacy and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">safety of Humira were assessed in five randomised, double-blind and well-controlled studies. Some </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients were treated for up to 120 months duration. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study I evaluated 271 patients with moderately to severely active rheumatoid arthritis who were </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">years old, had failed therapy with at least one disease-modifying, anti rheumatic drug and had insufficient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">efficacy with methotrexate at doses of 12.5 to 25 mg (10 mg if methotrexate-intolerant) every week and </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">119</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">whose methotrexate dose remained constant at 10 to 25 mg every week. Doses of 20, 40 or 80 mg of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira or placebo were given every other week for 24 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study II evaluated 544 patients with moderately to severely active rheumatoid arthritis who were </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">years old and had failed therapy with at least one disease-modifying, anti-rheumatic drugs.  Doses of 20 or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg of Humira were given by subcutaneous injection every other week with placebo on alternative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks or every week for 26 weeks; placebo was given every week for the same duration.  No other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease-modifying anti-rheumatic drugs were allowed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study III evaluated 619 patients with moderately to severely active rheumatoid arthritis who were </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">years old, and who had an ineffective response to methotrexate at doses of 12.5 to 25 mg or have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intolerant to 10 mg of methotrexate every week. There were three groups in this study.  The first received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo injections every week for 52 weeks. The second received 20 mg of Humira every week for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52 weeks. The third group received 40 mg of Humira every other week with placebo injections on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">alternate weeks. Upon completion of the first 52 weeks, 457 patients enrolled in an open-label extension </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">phase in which 40 mg of Humira/MTX was administered every other week up to 10 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study IV primarily assessed safety in 636 patients with moderately to severely active rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis who were </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 years old. Patients were permitted to be either disease-modifying, anti-rheumatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">drug-na&#xef;ve or to remain on their pre-existing rheumatologic therapy provided that therapy was stable for a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">minimum of 28 days. These therapies include methotrexate, leflunomide, hydroxychloroquine, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sulfasalazine and/or gold salts. Patients were randomised to 40 mg of Humira or placebo every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for 24 weeks.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study V evaluated 799 methotrexate-na&#xef;ve, adult patients with moderate to severely active early </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rheumatoid arthritis (mean disease duration less than 9 months). This study evaluated the efficacy of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg every other week/methotrexate combination therapy, Humira 40 mg every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and methotrexate monotherapy in reducing the signs and symptoms and rate of progression </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of joint damage in rheumatoid arthritis for 104 weeks. Upon completion of the first 104 weeks, 497 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients enrolled in an open-label extension phase in which 40 mg of Humira was administered every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week up to 10 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary end point in RA studies I, II and III and the secondary endpoint in RA study IV was the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">percent of patients who achieved an ACR 20 response at Week 24 or 26. The primary endpoint in RA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study V was the percent of patients who achieved an ACR 50 response at Week 52. RA studies III and V </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had an additional primary endpoint at 52 weeks of retardation of disease progression (as detected by X-ray </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">results). RA study III also had a primary endpoint of changes in quality of life.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">ACR response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The percent of Humira-treated patients achieving ACR 20, 50 and 70 responses was consistent across RA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies I, II and III. The results for the 40 mg every other week dose are summarised in Table 8. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">120</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:197pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">ACR Responses in Placebo-Controlled Trials</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:255pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(Percent of Patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:169pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA Study I</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:298pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA Study II</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:428pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA Study III</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:144pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:149pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:151pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=60</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:194pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">/ MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:218pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=63</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:287pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=110</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:346pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:350pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=113</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=200</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:460pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">/ MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=207</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:149pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:215pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:287pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">19.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:350pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">63.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:222pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:293pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:356pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:151pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:215pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:350pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:222pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:293pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:356pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:151pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:215pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:350pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:222pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:293pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:356pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> RA study I at 24 weeks, RA study II at 26 weeks , and RA study III at 24 and 52 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 40 mg Humira administered every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> MTX = methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**p &lt; 0.01, Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA studies I-IV, all individual components of the ACR response criteria (number of tender and swollen </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joints, physician and patient assessment of disease activity and pain, disability index (HAQ) scores and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">CRP (mg/dl) values) improved at 24 or 26 weeks compared to placebo. In RA study III, these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvements were maintained throughout 52 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension for RA study III, most patients who were ACR responders maintained </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response when followed for up to 10 years. Of 207 patients who were randomised to Humira 40 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week, 114 patients continued on Humira 40 mg every other week for 5 years. Among those, 86 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (75.4%) had ACR 20 responses; 72 patients (63.2%) had ACR 50 responses; and 41 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(36%) had ACR 70 responses. Of 207 patients, 81 patients continued on Humira 40 mg every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for 10 years. Among those, 64 patients (79.0%) had ACR 20 responses; 56 patients (69.1%) had ACR 50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responses; and 43 patients (53.1%) had ACR 70 responses.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study IV, the ACR 20 response of patients treated with Humira plus standard of care was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">statistically significantly better than patients treated with placebo plus standard of care (p &lt; 0.001).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA studies I-IV, Humira-treated patients achieved statistically significant ACR 20 and 50 responses </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared to placebo as early as one to two weeks after initiation of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study V with early rheumatoid arthritis patients who were methotrexate na&#xef;ve, combination therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Humira and methotrexate led to faster and significantly greater ACR responses than methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and Humira monotherapy at Week 52 and responses were sustained at Week 104 (see Table </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9).</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">121</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:288pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:233pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">ACR Responses in RA Study V</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:258pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(percent of patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:79pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:172pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:170pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n=257</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:232pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:236pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n=274</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:290pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira/MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:308pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n=268</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:113pt;left:371pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">p-value</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:113pt;left:427pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">p-value</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:113pt;left:487pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">p-value</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">c</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">62.6%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">54.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">72.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:377pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.013</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.043</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">56.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">69.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:377pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.002</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.140</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">61.6%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.317</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">42.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">27.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.656</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46.6%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.864</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:80pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a. p-value is from the pairwise comparison of methotrexate monotherapy and Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy using the Mann-Whitney U test.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:80pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b. p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy using the Mann-Whitney U test</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:80pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">c.   p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using the Mann-Whitney U test</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension for RA study V, ACR response rates were maintained when followed for up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 years. Of 542 patients who were randomised to Humira 40 mg every other week, 170 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued on Humira 40 mg every other week for 10 years. Among those, 154 patients (90.6%) had ACR </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 responses; 127 patients (74.7%) had ACR 50 responses; and 102 patients (60.0%) had ACR 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responses.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:493pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 52, 42.9% of patients who received Humira/methotrexate combination therapy achieved clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission (DAS28 (CRP) &lt; 2.6) compared to 20.6% of patients receiving methotrexate monotherapy and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.4% of patients receiving Humira monotherapy. Humira/methotrexate combination therapy was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinically and statistically superior to methotrexate (p &lt; 0.001) and Humira monotherapy (p &lt; 0.001) in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">achieving a low disease state in patients with recently diagnosed moderate to severe rheumatoid arthritis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The response for the two monotherapy arms was similar (p = 0.447).  Of 342 subjects originally </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomized to Humira monotherapy or Humira/methotrexate combination therapy who entered the open-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">label extension study, 171 subjects completed 10 years of Humira treatment. Among those, 109 subjects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(63.7%) were reported to be in remission at 10 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Radiographic response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study III, where Humira treated patients had a mean duration of rheumatoid arthritis of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 11 years, structural joint damage was assessed radiographically and expressed as change in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">modified Total Sharp Score (TSS) and its components, the erosion score and joint space narrowing score.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira/methotrexate patients demonstrated significantly less radiographic progression than patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving methotrexate alone at 6 and 12 months (see Table 10).  </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">122</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension of RA Study III, the reduction in rate of progression of structural damage is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintained for 8 and 10 years in a subset of patients. At 8 years, 81 of 207 patients originally treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg Humira every other week were evaluated radiographically. Among those, 48 patients showed no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">progression of structural damage defined by a change from baseline in the mTSS of 0.5 or less. At </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 years, 79 of 207 patients originally treated with 40 mg Humira every other week were evaluated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">radiographically. Among those, 40 patients showed no progression of structural damage defined by a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">change from baseline in the mTSS of 0.5 or less.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:271pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:147pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Radiographic Mean Changes Over 12 Months in RA Study III</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:180pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo/</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:180pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:260pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira/MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:263pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:266pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:352pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo/MTX-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:342pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira/MTX (95% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:360pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:365pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Interval</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:458pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Sharp Score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:284pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:357pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.6 (1.4, 3.8) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:456pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:92pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erosion score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:284pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:357pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.6 (0.9, 2.2)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:457pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">JSN</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:284pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:357pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.9 (0.3, 1.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:459pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  0.002</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">95% confidence intervals for the differences in change scores between methotrexate and Humira. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Based on rank analysis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Joint Space Narrowing</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study V, structural joint damage was assessed radiographically and expressed as change in modified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Sharp Score (see Table 11).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:278pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 11</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:163pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  Radiographic Mean Changes at Week 52 in RA Study V</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:173pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=257</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(95% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:162pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:167pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interval)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:244pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:247pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=274</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:249pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(95% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:237pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:242pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interval)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:305pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira/MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=268</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(95% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:311pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:317pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interval)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:379pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:428pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:478pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:85pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Sharp </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:158pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.7 (4.2-7.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0 (1.7-4.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.3 (0.5-2.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0020</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:479pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erosion score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:158pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.7 (2.7-4.7)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.7 (1.0-2.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.8 (0.4-1.2)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0082</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:479pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:89pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">JSN score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:158pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.0 (1.2-2.8)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.3 (0.5-2.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:312pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.5 (0-1.0)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0037</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:484pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.151</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value is from the pairwise comparison of methotrexate monotherapy and Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy using the Mann-Whitney U test.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy using the Mann-Whitney U test </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using the Mann-Whitney U test</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following 52 weeks and 104 weeks of treatment, the percentage of patients without progression (change </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">from baseline in modified Total Sharp Score </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.5) was significantly higher with Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy (63.8% and 61.2% respectively) compared to methotrexate monotherapy (37.4% and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33.5% respectively, p &lt; 0.001) and Humira monotherapy (50.7%, p &lt; 0.002 and 44.5%, p &lt; 0.001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively). </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">123</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension of RA study V, the mean change from baseline at Year 10 in the modified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Sharp Score was 10.8, 9.2 and 3.9 in patients originally randomized to methotrexate monotherapy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira monotherapy and Humira/methotrexate combination therapy, respectively. The corresponding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">proportions of patients with no radiographic progression were 31.3%, 23.7% and 36.7% respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of life and physical function</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Health-related quality of life and physical function were assessed using the disability index of the Health </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Assessment Questionnaire (HAQ) in the four original adequate and well-controlled trials, which was a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pre-specified primary endpoint at Week 52 in RA study III. All doses/schedules of Humira in all four </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies showed statistically significantly greater improvement in the disability index of the HAQ from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">baseline to Month 6 compared to placebo and in RA study III the same was seen at Week 52. Results from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the Short Form Health Survey (SF 36) for all doses/schedules of Humira in all four studies support these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">findings, with statistically significant physical component summary (PCS) scores, as well as statistically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significant pain and vitality domain scores for the 40 mg every other week dose. A statistically significant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">decrease in fatigue as measured by functional assessment of chronic illness therapy (FACIT) scores was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">seen in all three studies in which it was assessed (RA studies I, III, IV).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study III, most subjects who achieved improvement in physical function and continued treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintained improvement through Week 520 (120 months) of open-label treatment. Improvement in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">quality of life was measured up to Week 156 (36 months) and improvement was maintained through that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">time.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study V, the improvement in the HAQ disability index and the physical component of the SF 36 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">showed greater improvement (p &lt; 0.001) for Humira/methotrexate combination therapy </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate monotherapy and Humira monotherapy at Week 52, which was maintained through </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 104.  Among the 250 subjects who completed the open-label extension study, improvements in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">physical function were maintained through 10 years of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Axial spondyloarthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Ankylosing spondylitis (AS)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg every other week was assessed in 393 patients in two randomised, 24 week double &#x2212; blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo &#x2212; controlled studies in patients with active ankylosing spondylitis (mean baseline score of disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.3 in all groups) who have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had an inadequate response to conventional therapy. Seventy-nine (20.1%) patients were treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitantly with disease modifying anti &#x2212; rheumatic drugs, and 37 (9.4%) patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">glucocorticoids. The blinded period was followed by an open &#x2212; label period during which patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received Humira 40 mg every other week subcutaneously for up to an additional 28 weeks. Subjects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n=215, 54.7%) who failed to achieve ASAS 20 at Weeks 12, or 16 or 20 received early escape open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab 40 mg every other week subcutaneously and were subsequently treated as non-responders in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the double-blind statistical analyses.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the larger AS study I with 315 patients, results showed statistically significant improvement of the signs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and symptoms of ankylosing spondylitis in patients treated with Humira compared to placebo.  Significant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response was first observed at Week 2 and maintained through 24 weeks (Table 12). </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">124</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 12</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:163pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Efficacy Responses in Placebo-Controlled AS Study &#x2013; Study I</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:225pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Reduction of Signs and Symptoms</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:127pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:294pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:298pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=107</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:404pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:408pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=208</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:129pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">             Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:303pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">42%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:303pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">21%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:303pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">19%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">51%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">             Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:303pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:303pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">11%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">35%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">             Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7%**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BASDAI</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">             Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:303pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:303pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">42%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:120pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">***,** Statistically significant at p &lt; 0.001, &lt; 0.01 for all comparisons between Humira and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:370pt;left:120pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo at Weeks 2, 12 and  24</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:120pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Assessments in Ankylosing Spondylitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:120pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Bath Ankylosing Spondylitis Disease Activity Index</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:420pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treated patients had significantly greater improvement at Week 12 which was maintained through </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:433pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24 in both the SF36 and Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Similar trends (not all statistically significant) were seen in the smaller randomised, double &#x2212; blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:471pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo controlled AS study II of 82 adult patients with active ankylosing spondylitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Axial spondyloarthritis without radiographic evidence of AS</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in two randomized, double-blind placebo-controlled </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies in patients with non-radiographic axial spondyloarthritis (nr-axSpA). Study nr-axSpA I evaluated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:547pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with active nr-axSpA. Study nr-axSpA II was a treatment withdrawal study in active nr-axSpA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who achieved remission during open-label treatment with Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study nr-axSpA I</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:610pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Study nr-axSpA I, Humira 40 mg every other week was assessed in 185 patients in a randomised, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 week double - blind, placebo - controlled study in patients with active nr-axSpA (mean baseline score </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.4 for patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:648pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with Humira and 6.5 for those on placebo) who have had an inadequate response to or intolerance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1 NSAIDs, or a contraindication for NSAIDs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Thirty-three (18%) patients were treated concomitantly with disease modifying anti-rheumatic drugs, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">146 (79%) patients with NSAIDs at baseline. The double-blind period was followed by an open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">period during which patients receive Humira 40 mg every other week subcutaneously for up to an </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">125</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">additional 144 weeks. Week 12 results showed statistically significant improvement of the signs and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms of active nr-axSpA in patients treated with Humira compared to placebo (Table 13).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 13</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:167pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Efficacy Response in Placebo-Controlled Study nr-axSpA I</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:74pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Double-Blind</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:74pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Response at Week 12</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:381pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:10.08pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:386pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:10.08pt">N=94</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:474pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:10.08pt">Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:480pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:10.08pt">N=91</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:473pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">31%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:475pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52%**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 5/6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:473pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">31%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS Partial Remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:475pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  16%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BASDAI</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   35%**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASDAS</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c,d,e</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:389pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-0.3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:474pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-1.0***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASDAS Inactive Disease</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:473pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hs-CRP</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d,f,g</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:389pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-0.3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:474pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-4.7***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">SPARCC</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">h</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MRI Sacroiliac Joints</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d,i</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:389pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-0.6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:477pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-3.2**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">SPARCC MRI Spine</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d,j</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:389pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-0.2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:477pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-1.8**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Assessment of SpondyloArthritis international Society</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Bath Ankylosing Spondylitis Disease Activity Index</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Ankylosing Spondylitis Disease Activity Score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> mean change from baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">e</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> n=91 placebo and n=87 Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">f</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> high sensitivity C-Reactive Protein (mg/L)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">g</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> n=73 placebo and n=70 Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">h</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Spondyloarthritis Research Consortium of Canada</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">i</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> n=84 placebo and Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">j</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> n=82 placebo and n=85 Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">***, **, * Statistically significant at p &lt; 0.001, &lt; 0.01, and &lt; 0.05, respectively, for all comparisons </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">between Humira and placebo.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension, improvement in the signs and symptoms was maintained with Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy through Week 156.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:493pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Inhibition of inflammation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#221e1f">Significant improvement of signs of inflammation as measured by hs-CRP and MRI of both Sacroiliac </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#221e1f">Joints and the Spine was maintained in Humira-treated patients through Week 156 and Week 104, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#221e1f">respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Quality of life and physical function</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Health-related quality of life and physical function were assessed using the HAQ-S and the SF-36 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">questionnaires. Humira showed statistically significantly greater improvement in the HAQ-S total score </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:621pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and the SF-36 Physical Component Score (PCS) from baseline to Week 12 compared to placebo. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Improvement in health-related quality of life and physical function was maintained during the open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension through Week 156.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study nr-axSpA II</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">673 patients with active nr-axSpA (mean baseline disease activity [BASDAI] was 7.0) who had an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inadequate response to </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 2 NSAIDs, or an intolerance to or a contraindication for NSAIDs enrolled into </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">126</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the open-label period of Study nr-axSpA II during which they received Humira 40 mg eow for 28 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These patients also had objective evidence of inflammation in the sacroiliac joints or spine on MRI or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">elevated hs-CRP. Patients who achieved sustained remission for at least 12 weeks (N=305) (ASDAS &lt; 1.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at Weeks 16, 20, 24, and 28) during the open-label period were then randomized to receive either </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued treatment with Humira 40 mg eow (N=152) or placebo (N=153) for an additional 40 weeks in a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">double-blind, placebo-controlled period (total study duration 68 weeks). Subjects who flared during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">double-blind period were allowed Humira 40 mg eow rescue therapy for at least 12 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary efficacy endpoint was the proportion of patients with no flare by Week 68 of the study. Flare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was defined as ASDAS &#x2265; 2.1 at two consecutive visits four weeks apart. A greater proportion of patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">on Humira had no disease flare during the double-blind period, when compared with those on placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(70.4% vs. 47.1%, p&lt;0.001) (Figure 1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:159pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Figure 1: Kaplan-Meier Curves Summarizing Time to Flare in </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:262pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Study nr-axSpA II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:10.08pt">                   PROBABILITY OF NO FLARE</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:281pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:10.08pt">TIME (WEEKS)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:10.08pt">                                  Treatment      </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:252pt"><span style="font-family:TimesNewRoman,serif;font-size:10.08pt">Placebo     </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:10.08pt">Humira     &#x2206; Censored</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note: P = Placebo (Number at Risk (flared)); A = HUMIRA (Number at Risk (flared)).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among the 68 patients who flared in the group allocated to treatment withdrawal, 65 completed 12 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of rescue therapy with Humira, out of which 37 (56.9%) had regained remission (ASDAS &lt; 1.3) after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 weeks of restarting the open-label treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">By Week 68, patients receiving continuous Humira treatment showed statistically significant greater</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement of the signs and symptoms of active nr-axSpA as compared to patients allocated to treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">withdrawal during the double-blind period of the study (Table 14).</span></p>
<img style="position:absolute;top:246pt;left:98pt;width:442pt;height:118pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAABvgAAAHeCAAAAAB7jVMLAAAACXBIWXMAAA7EAAAO
xAGVKw4bAADCvUlEQVR4nOy96XMcyX33+cvMuqvvAzcB8JxbMyPLkiw9tmyHH8c6
YmMjdl/s2/0Dd9/uPhsb9lp61pZlWdbMSHNwOCQI4kbfXV13VWZuZnU3yCGHQ5AE
QFLIz5BDoLo6q7uO/OYv83cgDgqFQqFQXB6QEj6FQqFQXCaU8CkUCoXiUqGET6FQ
KBSXCiV8CoVCobhUKOFTKBQKxaVCCZ9CoVAoLhVK+BQKhUJxqTgj4WMUuAGcY8gQ
wuhM2lQoFAqF4gWYmMawDpn+lJfPQPgYQsAZARhrLsTWS7enUCgUCsXLwNGgkepP
M8JeXvgYLyy8SVkcCTLCQfwn/pCXbVehUCgUihdgUoscIU74aa+fgcXHC1HNdHGQ
zK+/dHMKhUKhULwEDIeaAakh5yO/i7OY6hSNMGrCCGpAIQeEkYC9dLsKhUKhUDw/
GPqokZiQP8Xl5KWFj1PKkfjfsOXm/QWUS+cWLI6lvEUVCoVC8SoY11Id7ba6i5jI
6U7+uPq9tPBRyoS6Mup22uiBsey7oHw6FQqFQvHqyHTgyd33ISKaFL4nFvvOwOLj
SBP6d+d/2KkHaX140vBLtqtQKBQKxYuAtBT0W//nRkg06Wf5/cIn7MEnTMJvwRgz
vmMjL5b1mv1WDwh9+c+sUCgUCsWLU56YyfJuv10IGmWPx/OdCJ+QRP5dZhr/lvH2
XbvQQvgwakx0pwdPCxhUKBQKheIiwAk4LB5WUkyExSdTq3ybE+GjgJ4a8yD5TlWU
MCbfikg1i+AHd+KX/8gKhUKhULw4rV51LJOreETTvium/OFUJ5vGnPPTLM89shNn
lAFC2GtC2/ktqimLT6FQKBSvEhb3fhYO+ZErhO+7LLqHwpdTEyglQtEeC/njRSoW
TUojFGZh8ZbHhU+zEjNhTCVsUSgUCsUrhWGhSpyPrWk4wxM8FL4wt7Uo1wyQ4ecP
d8iE6gnAAZ4XCve4Ms6nOjXqhFxOmSoUCoVC8erAQqbKEx4Z0xW87/HqnORlLcl0
XGReebgDFarHxF+X5VLgMAP8WCz83LlFIwlPuXmOX0ahUCgUimcRAbYqXminmCCY
FlH4Fg+Fz6dV4FRL0RN1hQrhQ4wxIBoWr5Nvvz4PZ7DynIPK2KJQKBSKVwqSoXw0
xyEmBH+fV6fv4NxnjZ5ZFr882HgYz5dNtAp8uVbJ9MjEMNCJrqFHTUchi9JIFIfJ
Rfsok1Oq3x8NeLnJtUyflOflm8QZK84VR/urkDw0lznFQTkwdIYpAjyq5VMznBf7
yynnJ88w54+vzioUCsVlRCiRiSkPLbk09x2vnwhf4G5diyx07PhNrKVG4M62R/bx
YvSHH6ODpR7b/fP9VZ9oSvhegl6LZ+Sh3X0SJRLZcLCEd1v2bDuCUW1vQcuN+1e/
9X5aiJs6vwqFQvE0Ti18HPl5rbf/IRysyN74RLpEh/zZShu6k2sgp0PjMtaKSdOT
xpTwPR++ZokBxqT0xCmSBvXDUxdgXZP/jqvgVXq2Sbi8Ukher6ntN3uXOtMKhULx
bU4tfOBpjrAnGl7lXgNLuZuTJSXofnRMl46A91p9FxerhY8cgTHASvhOQWHd8cgB
nhnweJ0onzBhZHtpY7Y9y21xGg9q3D3mCwilxmyAwfm08O+87NPc8p6dcnXmFQrF
pef0wge+H220hiXnOE/NqDTfmibuH96pE78xgJVh+GAje9z3RQnfKZmvwclZ5FHt
kTpRUtGKV/p17+H2xGQpFbt2W6jINT6HcoyLxqacxFPO1gC/N/2OQqFQXAJOLXw0
Rg4YGUwn0QLtkbAE3hg5OePvfyZ+zBF6rCU11XlKigECPPgv/WHQSI3sJGqEihOI
0d77cHcRYG9xvj02ETB8+8OUf/pule2XpDYKc8+iFGvA8vky4YnFV+gnBiV8CoXi
snNq4UtMoqVgwsZet193H+46rP/uLyud6gjuX0UbB2xQLt716BGU8J0OWbhQyFUl
OFwQ5rVelOsFOZagTJy/coopHC1BMt8OqZb3878IRnJVzwkGWCNAc9agGdJxms7n
oudnGlFKgRCizrxCobjsnH6qc1K1ItsnpTSRM2teZb4905Ed8TCvANVq6dbi49k8
lfCdklwInwaoqiWjQ20pQbO1UpbnQviwxUn7N5uhnc62M3xMamL3dLXLbHFJPGJo
kKe0TFOkozSZe93OLTxE0xw0QwmfQqG49Jxe+I5v0jxGSM94rvGHXp0Uj1ei9rbz
5bsHrbUuJKiYihMKxzkRrafS9XDqYY/4mQpfpiGYpM15CrQ3fQoPeZUAOZFd2i5X
ZQmLVBdnkYqTmQW1DKiFfG2po3OWG+Lc5Rx0hoW1LfbxKwzleSXxS4fLsUX7bRQ6
fFSHg3qvapip+em1ykHLgM8+7OeLsUnzogzHwyswjZfgYtQilNeYj1oe1tp4atWN
U7yqUCgUryOnX+MjlGQ6PCF8EKzByHc7C/ur3fRtv9qdCR+GDA9aKJcZXWQbrNwM
Iw4xOSPh6zkm/CllvE4RSSxxDWrftBAMa1mq64gzYSnnMTjDJpIag7N+e2Ba06/N
hVTKy9P9+TfAU3PxuOx9srAauOIyBg5MKte/ThxhQ05cnJjw9VvQfSsZsd5q/Jjw
zaEEKNfmAfMPnWAel7a5dyh7fC1XoVAo3hBOb/HFVmz9/t0KPCZ8oaktdLjoW/da
R5vL4SQ5Eb7Ymmcaka711ECuLwwLdnZTnYnJEjqf0mPfu+vrT2aNvPAWXrhbGdYX
jweTqqYL1SMIWDRaFddhu+G3rxwcZ6ZuGtJtE3INjpbXP2nA7jr/arWCYPHX16K7
Hxw1q629rWbFTEYV9OkP0rQCA7HPFUgsXOpv3Xqa8PFCWr9D+NAT+xX/qAhBhULx
pvIc4QxjWjLAyafC90g261JQ6gdOXGV4sJxa3kz48lQXsne8mEhffCy2EeaEOYGz
W+PLmdFvnkE7rwtHSwBGxmFSRnC8kOGTsIWk773j+pTpwvwjOZ6e+VHt0w8R2iNL
fO2g/enKcOkHv0Msu39NQ3qnzvP12zfif11qi91Ghp46aHL4c7rniov5NOGbwfjM
O/RPyZpWKBSKRzm18G1vhvagGTn6E8KHwA6PmjkxxI9Gms6ET/Scx2Un11KAol7D
lz8bl4TFd2bCxxOMtcC9/dbJp3izGZYYPsI//9w5wCvZ9Z0TSY+oDJlcvl0NU92t
jYb1+Rv6dng9yCHOm8k7/xwvuMWCKoLBlaEhLgPw++9GufbFQrvnOH5a90i5024O
8sPWTPjmzaBZmEMx0SlDKmbCpz38aN+qr/gonDPQvmO7QqFQvM48h8UnbI9J2c0e
m+r0KmZqxOMaeBlvWZVBNBO+2Nn7cFDzc5vLsg2Abt4Wv5zhGh/ISO/o8Bd7Z9HS
a8CCB3GluusGHz8YmMm1LY1Oz3wziAFWDq7ef/vAM5ONBw8vSIMP3Tw127sAFZ9U
czQUEtV5J9htH22kfFzFPNXlRYuYFZVA06Pbm3YcWY8LHyviBzEk3ESQMTKb6vyW
8In/yKO/y2SsQvWKclTnfmYUCoXibDm98I0ZqYwr+AnnlsiBlX02dsxcO3xvCHOL
D3BsA6oNzaJ/lAtIegackrOy+NKgPqiS0NWfvesbQQZ16kEjhcrB299UB3WWpcKq
LsYM7U7TPFjdh7/7x6v3azRNOdYQ10LM3GDjAcCPvhnDjbuiiXKwtwz1IfTHf+nv
jNdje1AhoyrycsuB3/3Dr94FcIk3n+o8ua6siB/EKGQuZgnXZxbfw/MqnXHhoRDO
MvHExS8IVH1FhULxpnFq4QsdYT1g3WKPCV9skXpf2Bc812HrQ39le+7ckpjllTuG
lspkWaKj3DgcGVpwsHJma3yDBk3B/vjTl2/ptcAJ4a2v68NSnDcHi0dg6GlWnH2i
882vQXPHYCaaFkM1mUpOmYbLh1ZiZeICQgKkHiX5O1+Nr3g8NDQspCpwUdkbG/Z+
pTxojNc9nul3byD+uPBxWggfQT4vERoLs++7hI+fTGmymVDKuBWM3/QJZoVCcRk5
vcVHSeByRGTBdVwI17DOYztADrrS2WvduapDriFwvXlDPM5loQYyz0GJNMrPcI0P
shzpKM+sN9wZYxqvRxAVX6A07C3HFniV2BLn3av0ymasF9v7SyfbOw2tVx42jMgV
p3NslKPcBu/mMVroGAnymumoRrVSWBrzXhul+ta1/QV9woyV4bAOqYGg10xMmjji
EkSaMM/jBs+oUFe0e2U0uZLtXvMNI0/cBxswqjExeEk1qgPFUz/dQQ3zyMkiRytq
IR2X3DE1NR0XKop9KD3ryyoUCsVrwPMIn19iWBarLYRvUhb9KNy9wXObAg/cHIne
FL3zFZ03RDMuK/MVVQakMJ218DFhqiBNgz+VqgOJKdQly6jm0+qB+7/8W2QxLM9y
6IjtcQaz7b9NyE5Ty5Cbf/R5L19yIg7RZHHxeOVgiez/9DfyglnW/miV7zgthNvh
ZP1BvylOUhqXD9ctf2Hfa+y7tf22wYRNx/y8OssRiuyo+VVbXEeNQTxZy6H8TVOL
rVwDfvdv98QJ9rKmEOdRLTVGtXEZqH7/amqMq76pT2NUpLvTKKnYz/6mCoVC8Up5
YeGTFsqw3muJXUpsr/7NTYAg//DB6s6sIU4pwtI+lO73LKf2WQufkIoEOYTNnDHO
osFXAWIciZPKNI4q3lFwHeR4gqPb7/BktAhhUgeojTrh5sPtnQV4cAXLmDv5dp5/
9p6lJXoj80rGoDqGkl+Ks6hUGYorhHS5wnrkxItcKJh/80hYj3/cnB9ZvFle+Cmt
zBcNTrI6GunuLHtLCCaJkLw1TBzO9ssiO3Ni60Bv9xqT6m66bJIi5QuMiTL4FArF
G8HpC9FSbSKFD82nOrOgNqyDh22C2uF2C/7x7wAtH3I2b4gJnWN5XoNiXYifg/DJ
yU6SzKY631TlM8W30DDN/QXxNfZX0wySxqQUushIxqgCSdAQ248XWTTfvnrbr5uw
s65/sWITIwvDJiPo/o/91k6zD9CwDkEbBy1A3VZnoTG04pU/NqDqJcbddhXBz36t
ZeMq278yru7/+BAv/botl+rEBeI2EPu+7cKwQiDufZCz1DMIpISwjC7QPI80LdNC
U/NLwzrVGn16cAXxcRUyGQoxrRchPmuxFKzC2xUKxWvNqYWPUX1SouSh8MU80GoH
KwB3/sw3jmvFzmAdl06Ej3GgWdaQJQMQwWc+1Vnk86L5PO7szfUuzEBD0jWovWNi
2JKF7MdVYdWJbZkZuQzXd0xC7tyabQ9K8opkSK92R21GuDC7o9LEkRcqHn+IDyF4
/z6HPntruLvmwdvb1IZeS9taB/GPTOaJ7L06gsQECgEWFzTGhfAxi5Jey9OCdkZD
7GANRjWfVUJnklb0nVVh3mexYcq4eTiIrosT32+L035/JapmVNMB8n7NhDg1sf49
cX8KhULxOvA8wucJi4/MhU9IXrx5zNDeMkGwGB6UttmNehKcWHycyUlOLnMfZ5zo
+MydWzgTvTETPfmbXmA1l7O1XEet41EDulo9htHSYe323/cyce56S6hxNGqQY2O2
PVuMo+NyA979pwWcmdZ+uAZo/Rtj9y8f7K4hWO0ub8tL9mDD2/zdNegsup9vbl0T
zXsxacKd1aQBdoj2o3qTBbKAVGjg2fmjcRlkdHyxfVIeQCPXAI4ahrxaCYgBhgO7
KwT+7Qdud8VYu8O3r7Z6FEdaDroGPLFyr4Zzv1as8SrVUygUrzGnT1JNjXGZygiy
uVfnpALVMZcKKH5rd9/vHUH9TuvhVKdcuyreOa0zd/ZTnTAz+4ofzqjBCwdxmstC
eXR5z4VBgyV2rtHCRdUeZcdXjHRlzxKmHkSz7blmDcE+XIFxZZz+4l/rELhXdv3S
KFvgX/3DA10PHau/Yyx9XVrb/HfcApSTnXVE8RfvwU5+TVys2x/rW01h8pHQTDU7
Mh56wzI8KGV5FcDXiAxmiFGEy2jCKpEz/UD774/EiT5uY8MjRrLS586ERLFpYS4u
cW8lHS3kO22zyNPzas6lQqFQnIbnEj5h8Z0IX64Fq1G68ElVur6b6Vo3wTL5VWSe
NESF8jGuzdd7zkH4cq4DnVksb2o4g4CnXBdmsxATBlaOUzMRI4raSBeGliw8hM1H
t4v9S7dXBzeijFa8UsiIrMtU8Zp9O210l44Wh+m4crTUbUN3IT9aPb7FOjbC9MFG
pucapwki2OD3rn/+Ph80Uw1PyvMPEVsp0ouYFem3dO86HC8Czc1RbViRSQcmFsmz
NgVjtxY7ODCrIWWZ0fq8dVh3IYuJ1f7lB33XCp0YiUMo4VMoFK8xp/fqzLgROnv/
0yfNHUcu9filSf+vdlMd+s1ci6qWv76z8pvVBxvTRthDITopRCu6aKF8uSpE+21m
hWa1nBEdZZkzTYFZBD/K5UtEhapAHjmzjCk4BIcH4EhxEZaiTA/AY2tsWpzrDNwA
Vv5jBbpN7FVQqyvMwcpXTZvfXqzHs8NlZY1SHFkpeVaWTa98+53tNitDmNYGjTRn
JWRnOe8sVL5aZX5VGtmNe3W4/bbnkKzGkjTS714tqRp9CoXidefUwpdlxAwd+Me/
++MH2aQhE2UCDPZ+ELg+617FX1/DJOqvgczu8lg+jxPhw0wJ33fBci4UjQBDwHNa
FO6d/ZXagnlRMYjzWSIAg3LCUq6Jn5kYXhCMV/dGaTXO7ZYxXt2Hq/ervc6KZ1hf
vIdobnC85PsMPSzbhAd6hQduFmCtsN6f9qmsiaOFzrAO0XBlerVhfLNLqO/KOIpJ
+e2ve83hW11+uAx+Cf7w8d2bMWEY7dcNTWmfQqF4rTm9xRclNZ9WAQ5WZKhyr8Vj
b1H6GZaoIRRxYvs17oVLPsJE+9a0oxK+ZyDdXzHKiJA+hlCCpsiMN0yeLwtDQmU8
3dR71RZjEIpZZmPE5NpgfO3XV8iQVACubgOUJ60dh8OnH7FRI/rBXT4xTLR8AF+8
J4zEKZYGC+gwE5dBw98X/4j9UmKG2Prk49TYrtZ50lmHI7cMMTSOhhvhQlA5srda
9XC4BA/c5mKXu+GktxlqXsmSTqeqaINCoXhtOb3w5UPX8bmpRaaWUjswNHRU0e7e
pMgAtnXzaKlbNWILIkBF/YVHjjCdolPC9xRkhXqhaUPTJAzJdb0iQAO0aW5oSCwC
KTPwPOxAKJ/PbB5UpcssyFoKH3/S7IOM4VsydgxzIsQPNnekJeeEUPLhyi7oS7sn
uTZzsNz+4rH8sUhE9rSPJUYr3I4wbn5Vh5jofikiaUkMfwbvjzi8/XW7K3bpNdb3
+Tc6vwp6sHPDSCHRiGcZUviIusIKheJ15fTOLSSjFni6TEkljL8ivyTI3NWDRpRn
DdGBDzRHG0Srj/uyK+H7Xmax92hgmpgjvdhSzGrOBDDDCElhLArTinOZOBAiBwXa
zOLDaOtaQKzUgOUjXvatxQfX72m5RXFOUvjRHyyv3dWh3rHma3ytHlTa99DaHpp6
BT3tc1EzcWNdvGuS1WECelYG5nGtDGhU3V9zA0ydraV87+//tQ0QVCk/XpSB9pWg
VdRwZ2+ys5FCofgT53mqM4h+NnSO6qGM9ood6lf7vAVwuAyhFUdmaWIaMjB63u7J
EdRU52mQ3q6cTdVInidZEbawnBmVwSB0HraR6YgWdWOnFh/O+bg1rAOLTJ375fVj
YTE2SFeoXaZnK53cjqyEg5mAMTtO2tCPpRX4TIS5x8p1ss3Aq0SanpiUTEpeFVUP
7WzjsBYPrhgHRx/0SpOd9VGTJmZOVn95S9j8PJfmHntz4yoVCsWfOqef6kxM5tth
VZgARloO3MLdIXAzPSXg1WV8mehp9bnwPRJQroTvOaB0LlCFGTjdhqaJAGZbHnMc
mZRlqrC9VVT1pPML1z/8HZgZd/23u30wyuIvz8SZN9LZ/k64viOsvtaYPyPBSg4l
baTVep22/C0xaKdq44j99L/TmriE9fGgav3ufcMWR2V1jw/rkd3qp9G4QTSsAtgV
CsXrzOmFb28FMxzZMpY50/tN8X+/Dn4pcENHWhU2jUrC8gicmcmihO90sJmNhygl
BHhqPHIZ5CzovHgenp/HHDRIucln4Qxw0DL6zYMqsfnuFRpUYFhDiOSUdOsaBFkN
Mg1NE2hOia2RaTKN4WKK9enXAXsVuPfX/QiubQl7Ucsxx8zMEOX1YalXTns1jRE3
0ozS0dIfl7OddRhpVsUK2Va5jDlVvi0KheL15fTC98JHeFT4zjpziyLTOwts6NjI
Dg4XgmoG+s66X8tTw3NJTih+4SlHSgYN3eDR/PeSb0flCchp07W9LE3jJa9qTEzj
6tetHh86Jtyzf7ava54QTPmpeB4Z1sOpb4VCoXhtUML3pkOjcdOCoMQgcpLb75O9
Na9SCphfhuilauMNStwk7KGHLtdi22GBgSbLhxx4bEvvG9bqw8ef8AkZYrQEZmrF
fH81xgbAo1amQqFQvE4o4XvDybXI9pFrOYOvbkWlIqnmlxsujo5rFZA1H14cnw3+
5oE59waVkRHXupOKB6tRctTb/Ob69rXFTmSbun/tV6uouKImz8re/aviM8HREvAg
rpNR7aW/oUKhUJwtFyF8j4QzKOE7c0JnZ31YRxQwPFjLu2j1aOnOLSvh/ZI5yev+
i1aH7bUyHcaG9lA6Mz0ovXW7MSz5aeKiQQPQlWiYYqpZ0b3rv/zr+1cZcTTr+GAl
88ua3F3+SY3vOYZCoVC8CpTwveEI6+rT9wlePPr9Dw+bhtQ5rzKm0Oy2AmJJX5YX
bDfTQz11H9mwt4qijX+/isqT0kSWBvQqVhDWaGxv5r+SRQRl/tbeT4+HowVHVovv
W650AFZrfAqF4rVDTXW+4aTapArZ8q5cz8u02OgtZoOGDkZzH3fbfFJ54YbZpMpR
rtHZr1EJvKqeTmpODrG4lBpjuu1BCU94tboDMpMLoa3A2q5kcdb44j0hwH6NR45a
6lMoFK8bSvjedLzKvrZKMcNsoQONQT2KN7cBKului6PC7HpBUqxRHDoPExH89idW
YqStHqzuY+KMAZy8NTTG0I5TsnIXFju8MQCofua0o8n17PZmvn1D2qMKhULxmqGE
7w1n0PAqEGk6RLZXiUwMh+1AcymZlL1KnMvQyheDYci8JiTzNbrEChExhnW0clDK
GaQAq/1Yf/cz4mZYpjPIEzNxwo8+xRRY5CJo/N9/HrjQbZ/V91QoFIqz4gKFT8uB
i8Mp4TtjZMpOoVIptmVwO5tdSP54IoEzOA6XibKBjaLVBExxZ6TGnZ+MsjBZhFFF
WJ6AdGfshDJZZ32A2JF/E/oVRrFVJJ85CzjI75PpvdYTKdGmOd04I1J3X03GtMxz
7Jyc+XlXKBRnjRK+Nx2eC+HTUJYJgRHCl8PsSs4zwpzZgSgV1xFPHA1ge3Nn49pv
apNGfO0g0+Gb9zxx7HGzMoHa/beO8/Sd37XLfspyf3Hi5MiAjOsvex/N3x8jJ3Ri
iz4tCXbIXYCIX/zS4rBcTOue/YBDoVCcNUr43nA4pbJIA8kpNmQOswymIoERPtuT
zCnjQvgi95hrZnlc79cB0vF6DHq2EfbEIWsjEFLIe8PBu/YDM/3Jr037uDb16jx7
Hfiu+PhpFtO0KHFx8YuLuZYw7WCdz4peqDtcoXh9ucBwBiV85wFjxfnFwhwjSJxf
Nq3WLoXvTMWGy+sozMhRK9Q0PPrFH9JOnfY3OwsQWx1rKYyt0dXaNmAmPsPS57bL
rz64Xata39zIkSYsvpfWoWnVXA5kr83w9wdJJGlZ5u6GYgRwUXeaUOKeVcr0s5rV
VSgU54cSvjedmUWdycWlohwQnyrfmQufbBWBFkS2M66hxBhFyyDzu1QiWxh09OCt
EErgO+HRDzp7qw8qpstDpw/1HJ+Z8SXr8JoZ0jKSmY/fl7ks3gSURY4GCTNk+u5n
lJ84Y1JDaF/EzLO2tBUKxZmjpjrffIp5tVwDMcCYT/Fx6U9yxie5qI8LgQ004m+P
k0FjVI07GyCTvMBoNRC3yvoed7yNPRQ4fHedOzH/fKMcUWLiXBaUfzmoGEAxyvnR
2+KX8EmbL8XixmKUmeA5WuS3qbyhL/I2i3Uy9lp2roRPoXjtUcL3J8JM+LJ5ijF2
5s4tRXNysa7fBHS8sHVtWBfySvUdo6UV907iGDQlje4GPChliZbffGB5mAEQVHib
vhzz97/z/2i1lLjweHtCFwsrd+tmMFmCbjs9+1XO7yUDagXY3l84Y0tboVCcPUr4
/kSQwscJpNq33DnP3KuEJ8jslm1oDEoszWXq6vrI1HzAZsQzAzYOU6LH7T7TVnbE
3iYqkrxw+sx2TwESdxFCibghY26Hj6diw3mSgW5qS/96PcDapBEjRC5S+Cg5WKK6
vzDCSvgUitcdFcCueC64n9n2I4LaWQidyIas4QsbU2iN4ddGYEfQ7q7u//DztOyM
USRkEr+sxefiCUAtC0gOo9ojKUjZLHwj0//4ASVUc4N714J//9uJifCF6B5FmDMh
yok+qmr3/7zfbwD4JZWcW6F4nVHCp3g+MqYjWkxdFhcRyfCBkRW0eDR+f1AdAZCr
Rz7Aohc1+6X6rjAKWc5yO3nJwzJN5839mnk8KYXcmsTV2XYbGM0p5bV+MwUj2ryz
ORzW4eu3LnytLbb21jLDcDp6ZE+sl6kHpVAozhklfIrnQ1zNLMF2XMwkcp5b0K0a
ydKIw/GiV8JltFOvH+WOLNZQan1dI16F5QblTws4Py0IaJQsMOP6f9sofp9bkHPL
88t3j5ZgVAdKCm/Ojo0Jlo6uL2tpPgs+vZn5aIGj6Mefi+dJg3zYVnV4FYrXGFWW
SPF8pBzTFBkp0TUkrq0uru5nH376c69nZyUzier83nVx0+ysQ4KR3u6IdyRB4wym
/njKLXnbaLnBM8Dz+1L+K/1JFvYBrNpRjSx/zvdqpTPLknZqsoBp1f0VJ6Ipt0+c
ixQKxWuIEj7F8xGlhsFzYVnpMlSOxYiWB43GkHfb0MeOXbm9mFoLxzByDJiUUTdd
JEUasZe1vCKX3b3VsA9++tWYaAk6sSANXoTwCz28tmXFTgjiDw8MEmNcOLect8WH
OZMSS2WteeT6kY24EPk/vH2xPqUKheJ5UFOdiucjSWxd6EleTCTKK5nev4YrA2N3
/fP3Aar7wtjq3Zhsb+baiMBffMEhcCHDLzvTWSiYP1/YQ/XB4y+LG3XjAXaR5tz5
q1+Bc/fK1Lnl3O80llGsYZrZQTmx+PbG8U8f9E1XnCYZV6judIXitUQJn+L5oLkh
rx5DU+8WltgQuvLKMtxtIyPxoQTow18fL2+/Db6//Pl7Q96A/KXj+LBH69/89cHi
MVp/gLiezdPB5AhrhBA0rERZqdaPizW37AIzdWYZMRBNo0a/tbG9t9axqjz64ke3
N4gmhe+VlIlQKBTfjxI+xfNBxYXMsF6kBAWE0ORow0C8U9aF2NBSFDoDN6qh0J6U
b2+Ku6r9ZYuSM+j+/VJsUJ0mzqQ8qoXOt5xbitykx4uAWb/V6rmBg6LC6bRY/3vp
I38/ZsrAIFkOP/odZnYElTTP6yPfCYkmrVwlfArFa8j5C19qTMqhw5ESvj9NEhNQ
qWPDiNc/+5F+XCG1Pk+s2k5ZhrPdv+p8uQn0aLXTfEFnE5mDTUbmU5Lsb+LEfDww
PzawjLDAGSaoNAG01k3aXYzzBdYD8cO5r/ERCisHUMGj+lCr9ZCBUtbMPJ6cdZJw
hUJxdijhU7wkCf1ga/EYSr6MW1/U9iuegco9kFldYIXscu/g7YeZ1J4beb9QRjAl
qQH58ep3ZaRhlDENRc3bLV4DaMU+bDwA0DOhSHDeAXUZgBPK8Pz3vrDiUmL6Rgqw
9J8tpIRPoXhtUcKneCnG1cPloyUZtsaPFjGM6j/9Dclhe1OaamOo7i14LYDD5Ree
8pNvZBwj6OKmjNSrPFHvTgYuxBFv6Lnv+hubt7FvLj241Y2skXhRaPE5o2MC1zvB
+pcLzvZCxwkrlpeXj3WVrFqheH1Rwqd4SSg1YG9NCl2cmUa/SQl8+e4EnGEz10Ni
wpA6jld+2Ss+aMDxIlDyeHwep0zDkCXmYInDOK52tBUI0eo2niyLu+yphdrPkgmr
euD/1WdGrxQsAXT/yx3gX95SwqdQvLYo4VO8FEL2uF++vZFTk9Iq+CXGmOFVYitm
zvFiCPaw8ZIOHtKJhnONj3jNr/zxnccEJUUYc864RrQEchkmPynnGrLCjAjRG1XP
+06jqT2krpFbsL8ifvWHV8Rz9MF/qoK0CsVrjBI+xcsxriZ+c/pjpsOkJG8jNmL0
Z1sAn3wEMWK5FR0ulF/QAmJMVtajzM6RHu3egsenEHmxxCd2sTgcrMAwW5AFAkfX
PtnIpPepdSaFIb6HmUn5+T/sQpCmrVFlWhMi0Z6YklUoFK8LSvgUL0dRKIEGZmrp
MDRcgJ10UwudyAGz3IW7y+4x/rNtvNPQ9Bdz76dU1tfNs7qx8N+v/Xaj8bjTCE1A
I5y2wxwyNliWShwTXb/yG7P6lBbPGEaDkfG3X7MdmUR0XO1Z6xMj5OdUFkqhUJwB
SvgUL0ViQmLEBqFEhrIL7THHVSmGh3817NeG+6u334baGDrtoW7qckXu+UPLZX1d
mkNegoW75RQer3cXBqRKgGoTG6NxNTWy4YKvc0vcuDyg1XMPZfeqiawGLw43KWf3
2xWcstWgjLtMCZ9C8dryTOFjT4kBlkHDcjZnNpnDxVj+uzNEqQD2SwVNc2ySPLW2
N7RM/92PILJX/+1//h1K4mpkg1eZJ2+mPHFTIzWA9hZDB1Kke5XUYJSZEDqxNazL
iVOvIn4RWpY5/SYqj7HvPtj4Zt3cWS+amDYVGzg5Xjev/tNq1y6JMZaeJ4bZ3/1F
wFPKnYvwbhlXR3Xg8fGG9MDpVXXU6nGURFWZmXt8QWbnSbwik3GPjMwfMPWkKRTf
wWmE71svMJiuXcxHspkw5aZJMmapG584ghK+S0WeY6FmmabdX88scb13f+b7aGF/
9yr4pYOWQVExXOLSD4WmSRVBrqUGHRslOWeaa5TRzBUv9ktEK6LXYaKhyLIBB9ki
i7BXibkNQ16bFZpPTenBQrUH6/F4UcgkwzyxpBihOzdlmdzz/rr8sBK3Dn68N6yK
+3piZu5opTZo78lHZFTrnP9065PZafijG9STplB8B6cSvuKH+Rse+50CQo9I3pNr
OEr4Lhc8R5oQPgMP61lQCiuAAic1D5bhuKY9NL94ZgygIX/KMx62QN45ISGISEMv
JokmVTCQsjGxMO4ky4YRi3solGUXjGi4ArTwIWEUNHSwAuO/OAhyqA9BywkFsEmE
cwb3r57/102NIamgZh+IGYKeabyk9QH08oDniUVk9przhaLpGJTBvA4SLRxu1COm
UDydZ6/x8ULsTtYqnvY8FQVAEc+fyJShyhJdLoQWYU7zPl3ThTm0snW9Ouq1SgH/
5GPotij7dl2+fFIr7qyjupba4t80JElLrhtCenRF3CR56kQaE4J5uMLjo01UuVfv
lEsQW15ldjQ8qg0acXa3vmhDCoac2oyZhWFSjuI6wLB+3t93e7NnlYpP0q+LDzO8
2V/JeM9I9v23YJot+0Ju9ofCN433V/UAFYqncxrhk3/gESeBYlkvQWTuV86onF3R
Ied64eDw2BGU8F0uhIUvrrkVT471FTeXCawXYNhIkL51DWSNIpAznRwnFhxXrcI7
Ro6astBNheUnJzeHeRMXk5yMcy3DOEM0uBHFID1J+M46DFyS6dp8JuG4kdsjTUoP
9atFa5CJzbEjDtstW+f9baXuwjBrEr+UI3K4nLkpAjMktCjSt3tFWGTnLUHiTHA+
H1DIir8pN58I+1AoFA85hVeneKpYEUVcoLNCyHCINW1qBeY5lV2QDTE3WVh54ghq
qvMSwkd1Oes9evtYTw+WUfedyXiwQsnRUgbFWIi7X78FW9f2Ju8MUk3H5XvX4WCl
Y9nduhw59d00bQFlfmGv9ZvQWe2YJB5c/eCL/H61FToTlzLKENFIlpm5Jb1gUqwl
WE8pIUXdCKPX4gerZ1D5/VkMGn5JlhwMq0m34UDZ53p+7d4C+tcbg7yFezW5FHCO
t7t4OGWqUj5TeA46hpRqeiaeOfWUKRTfzWmETw4o+TwQWDreASY4nZZd4YjnogfC
OHEhYDabxzI/cgQlfJeRXDsC1CJOVL0frvarWr2jZ4aOkmzaVzPvhx2wR1gr3B5H
3p/1oH1HA3eEav3MfO+YNf/fG45opNeC//h5LgvejQwHgrgV3Dhcnvzb1UyXdxTG
KCyx3IC8Wye69LR6ODFx55bMn+2c+xcVsvzpR3x/TRy9uwK/+Qtxt5uJ2L762xW4
v4aKm/8cb3cq7GLxHxB5WoXiu4xjwpPUwliZfArFUzid8Iknaj5nxGbCR4ui2pwR
sQUIAq8EPnOY94QbnRK+S4W084q58MNlOFjurOXit+PF/VWEKSyO0owUwke53RxU
x/y4iswhM0oINeOAp50VPK4e1w0EWp7qnjlpJWEdMIf1+2h0uF7y/bfHoGfyPvKJ
XogcJTlOsJzgpH65KM6XIXEMlFjpaOHcXUtktpo4rQwaQmQjO2js/Pkw7X001Ozj
xoAf56uhnQl77zwViE8ji6RDizSkuRknpgXBsI0wUU+ZQvHdPFP4chg1J+XI3nPr
/VaJjO1oYmlby3ak6UUPl5hbm/if/tcxLU8ovn8Veo7zqLBRAjkVY1Ax6tUoV8J3
ifj9zbJ07KA4C/bep4TQQdNIeYiKqT+kOZGecaCp0VkOHUAVTwjiqA6QEipGWbUR
B9bXa+IGim1Y6By30gwZGqOWpU+Ae5YBW4tOQomBkFzbSzFoAbZPwkpfReB4iMBc
2TbDNRgBtLtcaP8kaxSLniepzc6DKKmK8adXCR/cIvfWE4JQhh0YWvYEu+d31GeR
gwYZvogk4QrFc3MKi29S9h2/3FkM3VYP7OiHd7eMMox1fSp8XiXPboRhClAfOmOt
70rTUAz7haE3S7GRcqKJ4yjhu1QIYysJw7WN9F/WQQsdT5ghbLGr7ZewJhOxMHf5
CBpbpaNViK27Ov6LfWjdM5Hh5y7K+IdbbPFf2nIS9Hhx0NB1e8ATqWaIkHfu1Ear
n9S1wO03xd1ErYgYDAd2YeydpFC4eOGLmBtbk4qeQmctg3e+IvUeh6/fCjS5PC5s
vuCcjqsntA0B8y1UJgzvrUG7x8X4c+CvvuKgBpmlW2XqVrymnEL4EjPSQ8v44n/c
htpYh5xZET24Es6ED0Jndx1WOmvbpdoeJJNq4Y4nxvScomK4xzPQZctK+C4ZRxVh
yPG7NyDSNaGDwwZ/sDF0qaYhyNKs9ocfQLcN/ZyVpW/IveswrB8b9UkZ/Lx2uAyj
GsMZ19Gwfmj+5C7PUl2jGTf07s//ZQHEO4f1SN+6lhAr9RtiT51PcMnTzJkP5atI
Dn2PbMrHJdOPlmDnRvbBH3m+v7G9zuFcnVtYMl6K9m7mk7rnovT2R6jkf/LRl+ul
QSMdtyEm512I9+kfTPYBKmOb4vXkFFOdTM8Rxf/5d76VZ1+9A8ihCYf7i3Ph44Nb
HuaRVwe0lAwDpOnC2jtZ1aBFmo5ijU8J32Wi34xN/8e3OYssMewPey3bIB4alHS5
9JTnzIktNhxfkxVsadciuZWXo8GCDqnRyVrMDh2ZoAUo4YyELmc0J4QxTrS4wWMI
nJ0rBz8Y6rfXUFIK9KQsjzhoyNvqVRkZX7yXGv5SkGSDK8COmh+Q2wTlDf14+io6
SQRx5tgRoQtf9W9CxP26Hrr5rS0+nWN88bL3ZwaTyqcedsVrxymED6caI5Ss5H2e
mJ7b3Sz3eLd9YvHla8dgh6LD6jZWmf0gxWSWxVO2HqeaRVhMTUMJ3yVDCF7Q3FmI
txdtZo+ZUCVhDvVadDrzhwKKketV9jWr1LFruUaLAPYomSyGNfFDMu6/JW6ULCmN
qwgSA3LKiIYYJaSYfe+2uVk4ueyvUgID2/jm7cRkGBh7VfFrrLsIZgeXJw6BNKkA
rHVxhNsDGcd6jp2/AQnimIJMmeYR5NY6Gg6yapZ5SxDk1fMP53gq0txjmXb+cYwK
xXNzmuoMEzsR/0nTrXv7L/0Sapu77KAxEz5KZN1NznM316yk8eu3ilb59G+eZLYQ
vijXLayE71IxcgxwaN/SOEo9Q7cnxDEyPqoKaeJIK64/ha/flf/KKLjM4TwwdWkg
MOpjU64URwlUeJw0MNtb69czqhnAEmLoeRiXg6C0mflhProCETv+xV7pg/+jXD4y
WOOVCR9060a1x8dN4F6J1sMru+BAeOWATSNgz8sORRTXKttDXu9kFVZNatHemrVy
L9E0n+mRbXSXzum4zybPNJ3FxjnHMSoUL8JphK9bj8qpid0jVuKjeq9V1GSYW3zD
umsNZPWxfjOMro9/9B/zdvNczvIzWwYBMsZcJXyXja3rXjl+sFDWhMaFZUiielR4
PsmZP/ARtYzEjJgZ6RbQjDmRLV9Lklrx5qHhhs6wnkQ11OjDnRs5IDHEYgz3F7TQ
OFwWrcPSp4uQjhrCFAQ961exV81k4PYrmesc1SC1KYSEJqwJ+z/ZByj5P7zjm0U4
PULpuR158bgUMBilNQO8q4NRNTFRZwV/ef0CMnR/L3GiOSwyzzmOUaF4EZ6dpDoz
DhZSByyWcRhXuxUzuI4PU/1kqhOQHYUmhsMl0cLaXsZED1V0PRElhowuiokBcdBU
wne5GNuVJCdjXouZjCKPbOavpf5BUVFIjISK9adMTw0IHRiXcWRPypSw3IjsSOd6
bAGPHBkfd/juf9wYo0pg6EAp1nINUPnOUocJUybieVJC1qCBdC3iMNAqoZU/Xq/v
ohjVamMxAJwgh6aDK0KyRZcPmZZJ2TvHWHIxEvjRNmTUhNgSksciJzr82TFA45P1
zkJ2/9Z5HffZhKFegtA85zhGheJFOIXFN656lUx38zTJrXGFUK5rpSGLESmSdSbY
gPUHYwf1liC11nbprCGOxKg8oU4qE5vJDLrIzrPESLASvksBJYDGlUciyPmwcff9
eKRjXVpu/FkBXtkscUIZ1R5UvMq4NHNaSY1JvhrurflYI9JtUOZ22flph+JEk+Xw
7l8dVyFwn7/Q+8vy8PtyBuLBkDnb+qvHNf6UB+sMQeA+aA6FYZ2UUaCFqb+2+SB0
ePzVWlsMDrA+j/S4YELHqwTO8dLI1eWY5sIPb2hi7DH1eJrDxXlIzYmtBS54pikG
UdETuYUVl4JTCF9k9+qZpTOWMUN0KRQMMDxmzDqiwLVL/eP21gbZXxUtkHTW0KQM
+62QUJdgnlOEJu915I0XGEr4LgUeCVY++IzjuTdjY5JVKsf9clgI1rOFT+bJk3+T
n955f3940ozM21IfdVqQSDNqulQ4bHz5Pp3UfvNT2N5A8McPGNNmybAvkMe/ryNM
0M39Xat8zsI3cfsfHjqlzuJxuwuNsZ0li6MEFjolX5iaBys9m2jTKeJz/AzfBYuT
WuyODzb9kj2uTsqPlzM7d2QfExUpfR7ZJo4vpc7vbk4qqhu6zJwmZRnqONghiHKG
pfe52E+fIH2+d+QQIwptoCyqwluDo3lDaedH49hMxH657AyWD43SIMSmmuq8NAzS
+sNcmaMK4MDQJ7rM4lOkuvt+iuTonIMxpHUyrXc8nUiI7HC0ArtLMieCkL7D5WJ3
YedlcRn6v/jiyl0j0PCr8OQvvu+0HBDnQTnXaFj+5vp5W3wBCCtzfQdK/q37GeJO
CO99Aabp4SNDHyxpKdae3cY5kOncL3/1Z7f+ryXMeg3tpI4n/953nSGyMhUdutKi
k91NUUBbXohuRZ+Ourwy8gabF/VxFK8Xz17jQzIvIjEMnLJcG1QQAY3qgZZLZy3R
O3l1cPHH/1/I95c+vK8745OpzszQcbp86CBGc9BIYsRIjOGxEr5LQrZzPTG9dD6V
5ELYResQ42LB69mRzYXwif+PWxBzPc/Ks+2UJObWApQSYQ8igjGBXtOzJkAqJLZA
Fl9PdSE5Fx/NN/u+rZMNudYvmUWHe653+8jd8CdvH6YVP/jgj2UWNOgYNh5Ux+0u
P1qCb67IZNX84gP6E28xC2qLnVJXZzrjwbxqy0UJn7gT5tOYRQrvWb+ExA0UJA2I
0qoYi2G4+ClYxWvBs4WPEYY5ogbJeEJG1ciwZCVsks+yv6dWtORBdWyZ9lHFc3/w
L7OG8twSRuJCpxjeY02P9EQ8f+JwSvguBYHrVYQRZs/tjc5CnFZYfLQxC+t61h1A
Z8mXdXGv+A4Gv/CK52DiL97zSzKriwzZE8LHO4uDRqbLBb4Y+u+PXpHwzb9vLJ1P
OeXawTWAuNs2znuqswwswG6vrPffHvB713stqtWHVrz6dalTNV7lozZyJq3SBB0v
QKdOz70u4hMELgyhXrgYUE5OEgj0KyZkmZ0ZYpjUd+xJ+XsbUfyp8mzhS8zYFv2M
IaftDb860UwChg8yG4u0+MjdWguVA3cCYCRIz+YWH7Duj0Z+yQfRBXGsaU5HLw9i
rCvhuxwcL0pHTgwP13Zo4oxqcNq1nqIMlthZO6xbEBjRSZ1HGRkBWVgpcmAiJEux
j6s9mwhzb7C89Tc7r2iqc/59T/AqRZX487b4GH6wAUdLcmyg/9NfQRw2/FufL2LL
85vOVq1rzeeaL3ogcLiEWbCya9ngu+L6aXPhuagnHzMW0AbsLOiyfozMejCdQ9Bh
d4Uk3IIRrojBu/QbVlxCnr3GF1uD+rhGNUJZZIblHDSkm8PcKJzSKWe6HMwRBldu
/u9GGfR41hAlMKwnhJLZkP/o/b7syJRX5+UhsEjuzwULU8Lw2I1LUxeDZ755JpAI
Zin+E4SKgkdaYvoZOZFBOWfqhUvihvKC5ciGO7dekXMLzL5vmU8FWXzmRMcTcM9Z
+MRzFjq//7jfOlxZPNoqLcRQovFNfwiGmS/dxwzz6fm+6CeOLR7DQvrlMrhfleuH
pj3PIJNf0PHjSo8v+N7KWB6ZYjQtA8l5f3VIW15gDq/DfoP4ddUTXU6eLXyZflga
rGo2ifNAD2s5RSYyekmdc5pnlJrVY8ZXhEkY9zfDteH+0qyhDB0uayEt+5oGQh+R
oRksz4V6KuG7HAgTaFiH/MS1YlTj2bT3O5Xwzem2peOKb89jwbhXlYs3E1uG63HK
da+SIzKuxhZHgzIz4RWFMzzyfYsFNRmiGFv95vlbfP3m4XKmh44RUEvoPcdiMKDl
730BtVE7npzjob+X6hgqnsxzUVn7b+XFz96/8LW0/PDK4cf9wJPuLVOPo6JS/eqn
G2M7FcOvbNTuXEkvzNdG8XrxTOGjGdKFiumZsXTUl0Ex41opyiHP7NAkEUn9pSPS
/v0PRb82QWXp7jmP1uU0yZBpoiJvC+eOKkSrOFemhbBiTF5xPZ6LRRozLE2z8sbR
4dKgkbEF/2ARmdwZ6WU20vLFMYqg2cfnliT7u0HAhVl+HJfv3kBjhErhfAA0H5E8
/nnOarshA2HE8UdmKY9vHlH85buwsy6nw8fV3SXs4tzPja8WFof1SPRJVz+pihfv
3MqYCc8LAzz1mxGDHFkiS/Em8WyLj4pLK4tKYq5lkR2P7I+2tYzh0bDUPlwWI9yv
3gGIyZ33ktyuZzFLH6apyDLQ9ZxPeyFdCZ/iHGFyIgtr+LIJn4RnOS0jDg82stRF
W1dzfeWgeOGdwzQEk4lnUKcX9FmkEMkAy/yDP7qjUUtYXrqWpaN7P76g45Oi7i9C
fnmr9nbiud8sJxqJTMCf29dDp9+6+04KLLEHjX6TY8DGUbUoqf0CgexsloltYqTl
VzGzrngZni18MtY4BW3/g7GZDG0TULMPcUiEeec3091mz0ItmdAzDjd8QvlR46Hw
caGPOBfNSqdzUMKnOE9kFQRx61024aOcF1N47x4MnPzoulet9sfThauKB5URhnGF
5WbOLyqaLy1ypXK4PvR0K8Ki56j1oNW7cfeCjj8FIc6XJoE4MIfDVuHyC/DJx70r
Mcc8O14F2KlVZJAympQgdHqomc3fecojTIdZwLr1sC79/pxnv0XxGnGKNT5OeMo1
c+d/+6UbcnGvCHlLja/fgknNiFv3KhC1A8R1eeOUtS+XHrH4GKWM60LsCocWJXyK
84RRLkNn8ksmfDnPmVxHLMPqfntke1ZJiEx9KF8qTVDhI5SGtQutzSejloDg6984
CXWDxWNDC410fj2e5tV7ptsRRozzVuOOrXu9ktlZOFiJrXtXO0uNQeDqMRm7iakd
Ldful/TKXcflaFR7ge95QpS81NsVr4BnC18uhC/hGrMBWRlQWPD2G3fxNcZHLSdc
v99vdn76wDGHjYFlD5Ow9ojwiVFRzhzRIYFMHKyET3GOsJwClvX6LpnwycV0KLLa
DOswdtf6vtlrFb49fun+1eZeZ8kEj1fzi/L2wSzLgOikWrjVfPDF8j6pDCu1TnxB
xy8Q5wOna3tijA4k94NFcTLcUR1212GEy2I0cLgcsPK05FqFs5S6D71NT3uesHTe
5VluR6aWUlvNdb5hnCplmVzjY3xSe+/LzR228oWpawCxBX4jO2gLSRsf/P3eta3G
KInKkH47FT2nGlAqU2wgJXyKcyVHBGgGl0/4irrPsfVgAxgm9M4t8IdXJgaYEGDH
jMGrQHKBcY0so1gnUEnraQSRnAlyg+pYz579zjMEIVYWyotcpyeX/EakHBLzm5v1
A1ucKO3Bol8b0+b13993btrx/U2AsTE/Qaf1PuWyXZpmzYMVOczotZ79FsVrxGnq
8c0ctHvW0Q1KQmwB7Dfzkqc5O+viqbq9YUNqHKxAt4SGyxPziRosQviwrMOshE9x
nkz9Gy+b8NEiOkQwrHu4hEq7NUi3byUmZ3717o3Q/fKdMasLRbwor85panEAx+kz
J9Mjg6QGM7PhfDLw8SlPOPPtc+cWxD76Q8WblIfO2OxeOb4SGAakx0tRGS0epcwC
zRc9WbfUiGDojtsv9GUhzdw/fpBNVBT8G8fpvDoZ4HF165qQuaMlMTwqkXE110Jd
Tw0emXRSMvvNTsn2o4VJ+WSqk1E0XVDPRQuaWuNTnCti8I11lMTlSyZ8D/nVL7xK
6cgmsbC3Ygso+eK9cRU1vlxMzFS/0NNB4zh7e3S8KMtDyEJSoftQn857jQ9m4QwE
1TrGxj7jzZ508wGksdqEkrTkw9KRnRo0vbabwULHtgfQ7pITp9fTniguy46yHKC5
4xRliBVvFKez+GDqvMsLF89ZEmo2zZXoORrzc8fKspyYOE0csZ9MinviRSbnBOQa
hBI+xTlS1Fbj+bU98KyZF5/k8txpkR24yP1iUZs+eYlGIGMaQZnmG+P2Ba5BHdo1
7lf0fnliMTMxGdPuXUecUT0xLyChTmoA/P6HeW6hEbl5ZNvWgYGykreYDcSLtZEb
OIwEbgCg5YS+dTTGyElQTpcTL8foOWI+bBxYpR7Uh7JTk2WTZ9uRzGRAw/KkLKsR
osABDmdagT4yUVCCYT0yscyWIL4p+CXw/SUZS8iSvAziPIs/aVyWa1SjlngWfFrl
Z/053nBOLXzTXHdy8Xe2I88oJzJEBvOYmrq4AtgAJuSPfFvalPApLgBK4Di9kprY
9id5neWzFFmX504TmpJc6dZGs19tLCORELb++YYtRgXS/LoQeHcBWFgy99pbq6YY
FR+0DOgsIDisITPV2DPLUb0s3aV+A+2uMOPGLxcMNzTjlQMjLb37W4CffFb2y526
nzXdbqTduA0yxELLG4MmTd/5z4af6Thn2mlTuWRF39isDP0seTT4fX9VLvkxvyLT
h59HmVvZvE/sjjsfQwwaUZFrW3yMYV0oP7OKv/LO318Spzsixvc2eDk5tfABp2wa
mnoifDnHGqHSlQ4IQeJW0GVGKWJ8e15FCZ/iIthesrzKnV8kw8AR/U1iXLZbLOLg
dNvpvJPLiiAHyiKhQ3xygTNxwtAJ26gyhu1muVvOS+BxVt/7swPSaXgN6J93NQSD
j2xh4k0qk1KutwZMy5cMvA2ktPEH8erqvqwQXE5SzGQJQ/dYawxclPuV0sFzH0hP
crJ4gDgPdW0yTR4rLAPRuw1RBQsjMLBxhPOzNnEZ5l6VDRxHXGINJYmtw6iWxrYe
YTPIamPLb8LQdJhXi0hvRb5GrchRzjeP8xzCl1M5rX2S8JYJQKanlm7kwC2WCgMQ
8YlmfNuDbBZYrIRPca7srqFu2ZI5hg6XRe/LLtm8TmQQ+Vj9/oqmE/GciqdMnoos
c+ipyh+eGRSnh5uM8C/ek7Ny+KgWu3ocppvJ1hWth7TqeXt3pv4i+ExfD7Zamvjq
kYUOV4p5yMOPjiGh2II8IJ3/unXjC2Nia4PGoAHNARcCwTh+zjuGx3b6N/9WGwgF
mpxkTU89ITFZSgYrMqAkPXNjK7Z4NA2WH0J9mrpWzrTKxOzSf7eoFJ7oWBzYq2R6
4CYmR35JdbiPc3rhg5xyTDCfJ6GW9S3zjDo0F3LImUlzJotrJzKfwdQgnx1BCZ/i
/JFrfMjKNYbvXYc4dxh63n7sTafjgPRb1GZPXp4hgrJMP96Q9ceTc5h0+27SzDl8
z/jV2ywzOSORHY8Xtlvlnb/eShPNFgOScz485uj+1W6T5GQc1YYNU5g6wc0vdXfn
3SAxRE+UpRYR5pr9+6sY7rWqlPB4snmvOReo0/dMQk04FoJnbC8hEPo6fTugwBUW
r2yIJvSheXt2PZ4vbehqjMxhHQI304f1PopWExPioI4jm7OOI9O0Q2p027JyuBaD
BSe5RFXPO+M5hI8VU51z4Uul81wR+zm1+GS92Wmp0KICCD+Zy1dTnYoLIeRu2sMV
Z9DYYjcgk/UiX/VHulD2lwjzKzlBQMUjOXMukwNQelL+/CIQ5sdv/tJy9CPpKYIZ
MWLEdEZhIOwTWWvjnBGmjpAGZER86tzL8GHLAJ7pwviD/dWBbcMerMl+6mAlssFD
5UnZSrivm6KDw8JgPeVxCCUygAat7jf7ABp6aMkaafOfPwC4s5mWMuLbRVGtM+3x
wrQG25tAyXi8DrC9Ebp3r/q21+q2e/HqsAGjMsmxVyuKWOZR2ty9Ap6unf3neKN5
DuGDwod4Lnx8tuHJG2XqAvPwVyV8iguA4Ry+eQfKHfvLd2HSWcOPx5P+qRPoRqYX
j5ZMGVGYMOKXfkkjIA3hi/oYSVYC+HSDNaWPC8CwgvyKsEP3r7BY16UsnjORHWET
cRa5o/3r3IZRtMzs4O67nAdubHmmGQ+X7950g/srhATDhVgMCg7e9iJaenSa6tnw
XE+zyWIpBGzV+tZYK4IpEQoNlJQ71s66V4E//ACyDBdutmfW4/3/7L1Xk2RHlud3
3K8WoUXKytIKDdVoNd2jltyxnTXu0kja2PKBxk/FZ5KPfKHRyAdyOcvZGdrM7Oxy
MN0AuoEuFEpnpYrI0HHjahd0vxGRVUiggCqgBDLTf9ZdmRF540Yg0/38/bgfMWgk
xB8EF2bWpNarm5/e1O/VzNKkImNbPnzb1GHbb8yoP2xOfY0+8NcYNeCjD0B8zJf7
OU46LyZ88zIRiwtlTAueTzTQnvqNUg7aU7dSwqd4HcTaYA0yC+DxuWG2+nAdYe0s
jbLIQZBGtcBbGG9ZnJNy+SsQrsnEf23t8IT93d2MHZJzE3R55MTZoH3/nAliOTIy
X32jxNTK716qZHmW1GWoY+hBGDd9MrEzQzweVyFNKmwlHF6+XZr3h8xQf600472y
JT/yVxLinwXKdGIm9sWeNhWP1jtFVwrpAfYDZMQ4272UT//wb53yVDNksN9LtHgz
f/9GkBni68zu/tGHnuaRD38+LaFZ9v7vqnlUrdxp769osCcbzZuI4ti49terdvDS
P8fJ5kWF7zu8gxI+xavjqKttsnc5NajZvXzr3NTlqDC6c/djTmpl3MqWrXA5MYUV
DJEMjkO5I1bMk0piyTtRYMbTI3TxuuX7EB1I5gb2ayz6fNLIE26bR2d5skVRlpD2
63pzg6aGydly69GKsmpq1catjzc6bjkA3RF/Yp2HPvBBQ/w14+mKGCj2VH/RhsFZ
ZppAZWJiEekuBgwlYODDy5Xy5+NK6PWbBhDeXcmIwzRgaLFf9n1XIEFJOM2m9Oln
Pjy+khNwKC1idLrncj3veqXmI1u8y6hWH8U28g5dQF7I982m+M8NNNVEYoESPsWJ
Ro5POZrS0eqkMjxv90pZCvfWvN9dLEEI9pGdkVGPwuSRJzlXNH1iBQjKubNU0czM
tKNt0uXrljk6aMBakIzWFkNYjeSvwlJuaenykSxQz+l3aPT6HXm8oZUDfvvG4mFk
Y4gnbw86zaFdgs6qcJQOr055Zup3Lk0n54TosRlN1pvdFxU+Rtm8SNVTA0HGNvgh
eH/9C544v/s3n1o8DnkL+Nj+3rFFy3Euq8QgKAX8H38B3ZXLD4DVx3a8v/7worDV
tX/3c6RRMzD3gyvpz/fGwv2u3x6/kyAmlXmCS3D4uhYgP3SU8ClONE+VrjpsTyuc
xWuf2W1ZK0vuZEV55ejKLEXWEz9N+oMRM4Q9TlmcN4MqiEU0Fa+wtEkltJ5qX/fl
14l1tswIlit9/mKW8sxAMzD0pceXAS5m/+v8VSF968Hye92Iwdv6vApxCm4ERn5+
G0pbt2l9WAqqlW0zExbOfPc3ssXFC/05hQlLE+wjtsjvYkVcA8l3r0GJ63wC3Eke
bxXDc2y6kMifInj+kmjHORqQu9qaPwMzg7EdtIE3Zsakul0HuHO9OhLOtZsG527z
NfjihpgPvt31D//lP8SO+Bx7G0Epjyrf9B5nidchfCqdQfHq4Ms9pOn99pU0m9Zt
HEGmxS7OzHkpqflgix2CceQ+GXrjkgZ0Avbc77u/NWrLsBANtKKu1vHXfek9J0/s
x1nLF/w2KOKECLlZnuUx2SZX6N7rSqcY1eTR3rC+tFu5OUgdolUeXAU6akLCLRzo
oef0y2YKFtGlLZqFNZO9oPAxDHkCPkphXtKDC7tGKQerwu0oBLN+uyY0URvtXH5Z
4Tx8rqJ18WahK2RXtrzhdGUgUyl4p43RzBOfJ+l4jjxXbQl1dMwPr7f64mqo7pGs
RWNHW97qzK/ZlPApTjZFJT0OugxUr+5lNQj9ydRuUuG9JbouDPHC2wi9HGvTo8yq
cQUXB3YCNqVluRXHcKbP1+06C/xjr5tHMnNh3GbNiPlEW7QDomcuX/CbocWEl/m+
c3QgsvLFaxM+4WMGjfsr5jIxr9eUndG0Isan+HMfrMna2Xsb2057CmWA4k8bei8q
fHxep+VI+KiJ8piZthgNOtnc4zbF9+ONWsphWNHSSZvOjwLhe+Qxyq4XXNOIwSeV
/grNTHTl7mgzmpTATid5ywtQZ00eJnZX+cEagnxWA04ztzqa+bIHYb6Vx2W5ZJv3
6v3un+NUoLY6FSccYQ/kyDKpJqb3YfvWWy6ewb0rE8Pd3YTDehFmLu3e0NVjX0x8
Xkhl6kOvta+3Ij1xsTZodMY3IkRKMEsd93c3zBwde50v30e+lR+5vRb8p/eLpFXO
MZYDWo3opyj8iaWBx8IAiLn/2t68u1IEjqbLv4cJaYbyGtFDw2QEk/5mP1sXPv20
nMyaRXFL/nDTHDReWPiYjFPhmbHY6qQYsoRZ1qObphEjXDnY+qQG+cEH/3QRdtoW
ZLBId/iu9nT52cQoLz1oyscc6sPf/8ht7M6yjTg1V7etgef4n1zeOXftbug6gZ7/
eHvGwwrNogq0/+1PH16E/uhqsaWrBqsSPsVJp2gAx6dukr3bCTbixq0W+vBnZKjV
RpsJFJ2Ri4k+3ZpA+/MKli1GxCsudaH+qASjsIWNYPhOYDRuy/1LYRIDtIEmX3nd
XPU4NFLrrgYNa6bpGlBCNe1YpSLFG2aMs2aSL137NLcLt146ejBv3iDZqzDh7QXI
n9eR5sBfVPiKFGaeG8tX8ZwLn5L4++u88+MugPeocmCsoWv/67uTaV3TZXWP77M3
kEMxbsHltWno/fY9QFRzDipm3vkv/++Kbk0cyPXHWwiqjypw992711KaWcDrt9bq
2mftndH7lT330436pJzPz1zPPEr4FCecuZDZoYdRaCPAwwrSSN+g8jDETtKFwclM
ZBgR76zIflqU8zbVcAdr1MEzYfyKjczcGFcLyygeWdNjr1uF4m24i+uHmRFzrMuA
l5zIDiWghO8JnBfrhaXH94Kxkt+f7grsbj5lYMQftN+U0Uoz5JHMhZ1zIbGLGNNe
Q9aSzqbNkeUm5osHtxRQWB7yxaYO+cgpJUELgU8Sm+b+rDEoBbAWzJp9ebFYSr1A
56MvYRTjT3zNYbWjmxGYmY+C8rQy0fTUSs3m/vq+gTKNQqtntcOhTqDN+lcfo0Q4
hlALiPZoMxxthhpCmhI+JXyKEw7Vbm35wtg9bsSXH9WYZmY7m2LUxs7+erI6gUrR
pkeMO6Yh4aFJ7WIcabKrpOfeN8WiGHVWp2WkybMpLP29EhAhaW547HW02PjkfH3A
eI+sAQk8syhCLDPFj+meKoV/BuG0qGU81P29rdUR5wQ0G2cp4l6ytre0ohiT73p/
MyuZA6F79s2Pwdx8xMQTv/iQN7PWfSMvBbXAKnXWs77vHkI7DHXiRlDlEz+qTBm/
1J9aqT0dlQ5qJT1HOmTclKUeZLXJRZmtM2eRlfApTjSTCkcsqHRXeCmMjeF1IxtJ
B45PHJMZzMjZ4niEj98aQ/X3VTEauTxrufoA2p+2+d0LwsPLuu9MUO3zmlG00mad
X3UTOP66ZK57fHVWH8Djqp2WOtWdqzG19s8zhPbXOVrmN8iyj4ozB6dyRYXR4y04
uJBtxITqwgNL/alXfWiZSRHzI3cRvuPtc7C8Brrz/ifi+5UutIJct2bsZ/8kDLS3
fnfrMYA/g+tfADSjCGTLXd18+0NYmeZk07kLjUAnaZQ4zt5ajo2i1BYUeYhLW3zm
LLISPsXJJnC1LC2xnvnjz/w0hdSoimfsqWzLErmQaYuz/Myc2jyqRuaiiLolNXPm
aFmkTTZQv2IM6yAbvoy4Zz1aN4+iQZevk2ImvUVHaONhWziG3S3txn9wi94zyPhS
+5nMLOrzK84WUvgw6q51Sh669MDMZZUWoTCW1KF//teYfz9LWpaV0Vp9DissCZo0
KI1gY89wmg8A3v4MrlLYyWsj8K5sj+HKHmof1IcZpj/5TXW8dgCVSTWuHJamB2tB
KafaIilVDNszvEWv0hkUJ5sZ5pod6bpmHx5elpuM++u3rliQ9DfGpZDWCCy6NCR2
xPxJJUMy+4kyh2t0xh2x/IUUh1UI8Uwvy8MPXjQJT/RjrxOrN3k6yO2UgIkyNzcQ
1B5U85nMG0vso17bvQpxZUtuld931pDda4RH110ZGiWU65zKPXJiTVsp8FH9+95d
yhRJPQf33Cgxu5eHDY6afb7TtvJHvxy4H18vTTUtu3eOOYhnVujBxl9fh/7lz34E
U2HYicMu3uPT8qCRw6JNw1EFPnjSrvEM5fcp4VOcaHot2GvYfWyWxOB6vMUS5g/r
SXi5Z0j5gQdbCwFLMxnnN9BdGVLOKHN54M5KaY/7uD6jlUVK+jRaldU5KSL4+Otg
3nu5JJ07+nglrSHQ7m5wIYI6koaDUaQDp7pQQeE8TjwVO3fGkGl2gB40bfuLv/g9
XzpToefxf/uHk1ou65t9r8VQonEz9g8bxe7CrZ9Cj5VXD+S+Oh+vGCE0BuiwxdFB
sxJvGf/XdRltI7f8x+1H62APVmfyE8ZOqhWd5cRA1jUu/FEk+8lRrh813Dkrg1Zt
dSpONFSLTH1q2mht92ADoKv59ifvQ+QBf7w1RR4+SmCHPOOGgWmx1cnEFTrERWRm
5HbqJk+cQ8NBFhSeXWYgOPa6osqw8PjiKuxUZH+73rWs/TcXoR+fi8HZc8qEYAMT
IlZ53sNVDVOV33fmKBLMBw2GUVz82YvOWD27zFBiz7CmFb0yvuO9iSUWcnEj5tBx
cVpJfeG/+SHRAuPgohirA7MEiHLMggrY6f0LuD7i6ezthzY4+q1zSKOr2eHmDuxc
FMs0wjWWC280zY2SnomhSpCJzlp+nxI+xclmOLos3L5bPxuZsLceu7Jk526LeKVD
ufl4b809tojl8+AW+W1uEJZwW5uXQeSLrR+qydY6z971SdMyjNLVzIzt2zczk+ih
x4XraGQEm5jkLpJtebJKrPL7zh7C6Ru04c51iBwiH8wzB1YOeWp9/4HAqPEPf7Gj
jetwsEob+WT/nz0CPi2hqbOGsl3Twoxkbmd11L1Z7GM2d2yNcTbz/LjfRHbqfXoR
ONFCC+Vg8rSwy5qpx7omhM9B2RnL71PCpzjRsCwv7ZwDzQ1mljGqwaSSWrubwEuh
rMs7TzYoVCyxCdKEpEl7JNuSi2W5U4RiIvHkpCKLPDpI4yhmnuzaZh173eLMjhMj
sYOS+HmoWeNaYma2fJ7OyjTXDOCZLRMjpB+q8vvOHrI7A+Vw468anlY0LMVaZo6r
0ohmSJN77Py7tiVCM/9O6e0h4XHRVRAFhlV69Ce3OHz6DtMSnwSNDPh2pcoG1Rs7
2d57e+d61IwJONMK8OGffZ7YMegPVxLi4BzbkMbYEivDNNQMnRLsouSM5fcp4VOc
aDga5CUPEFnkEecLT01HRJv58KVwy5eLkE6giUOLbqZyw0iGDXAddMJDw8yKyHXO
9W+9j+J0cetfPRpXYKKbYgjmNG2MHr9f35Z1Yr4Xyz6DeKcJh+eRf8/3zz1+9F99
SLz+ysU7YS2yONqrOcHDd5FenWbF6ITdjanLM1+o4595D4UZbn7epJpYDrK9cxnW
R5Y7jVYHtA3Q10oaKsJxzgpK+BQnmkQWv89Hbw0Wj4u0A5B9FnJ9pr3C0sg8RzrK
Mw9MClomnhDCh4F7MRiZLOkiFtBnaQWtmLO7CfU9Bw6axRGv8PjvXIOgnHa2vu+N
l30G+0YF7v3J329afv+3v0DA/vEP8DRYq4SUo7c/7Tfh7//rQVB2Q8is8w/wzrmI
+Xbabxikdnd0BfGZnxH3sD0ZXRArRe2wDfcv91o914OpYWL+nf3Rk4cSPsXJZhqB
4xrCvMyh82LSYBfFqvj0lTUgoxnXMSO8aPVCY49R2ZOA+7F27f88r0GENO3smBHF
EzprXugak2LngYPJc7ATPnkZ47DoM+i1HsHVu14IlhbBOby9kg9l4rp18xMzk9l+
P/8QYQrghTrOoB64E5nnB4CtWFZ/4UFNC6m12t2v1NMErM7a0Ha2/vd3SGw6Z2pz
QqUzKE42iZkjA0G02OpcVk3JzH2+QcjLaob2VVjK5damWWTwxQ6lTAaHMzMLaQty
kGUx1Pne2UOGV/7+R9BryvNh2fDI1mTtUP59x8KyzyDsN7TEl5X1Bo3Umm3/KDNS
W3aZ2NsQ/+ycE5+g8dTLPtmqZ9ShGtJJEa61W/Wv3N1uu7C62x5aD6oVyxpIgQ6f
aqF4JlDCpzjR5FJ9UMddnqEsq9izIvNuf/0VvjNDYiwH5cMGDNpTVxasAsZMMbSH
nolYUbiYqTO+M8cElZ8eeN2VyM3u3fz+Fm/eZxAZoQeH6bnMQONSbgOND86b8MXW
4+vw4NL+eqRrWhRbftrfiAwDfv1TiLDNMHiREwXllT5167vA1zpcLBeZzOibloP1
ae03l/iie9RZscxqq1NxouGQpTLrnCzykOaxlxzwpBznr2yfc/EmRaSnTAFGy/IX
VBgoZ6dBsqJONWPceJUfQfGDY3cTqDamMsay6MAXVGf0ZQzDZZ/BSRtibEFuTKE8
82VjJTH6KDOAT4XgRq4sxTL29cI5nGruLK9PKgOrBEZpTN2DSnMw8xAv7Y7+qJcC
qk6M4P27pVtrkFgk5/KM+qzUmVXCpzjxxA4MyzBvcb0cWZGNeWC8+r7fk8rjLXi8
tTzDEdYpk7ufsoP7PLz9lX8CxQ+KmJS6K08eMtxrwQDM0rNf8Zws+gwO9Irw+WIn
11HXFqMuwixqMjSpQjZYE+8VkopMRx3VQOii/ADDZsTe64aAmd01XDecVkqBMMl+
BzzZSvnWr3Z8jCYOZVhHlL76GfPDQAmf4mTD+u1xFRJzMX5lZYxCc7TcgGk5f1Ue
F12GbCY2l8l+8zZ0nBIbeGjlafn71adSnFQGDSBIy/GiDwMlVqfsvoT7LvoMRm6g
O3D/8rQsy+P1m9Kzy8yMGzgozZN3puXQkestsSCT+alCJZMSAXz+IfBh3U4Z6rd4
PvgXn1rdCt78TbM6BR6U7SFgMYVY9uoOxX9YKOFTKF4iuS6mlHnQ1JTuKd4gTyoP
DetBOfT9YO2Ag4HNWXS+Jwxwo2OQ7WurD3SNe2Fio9DNudmvzTcozkDZBSV8CsXL
ZOolXmcVcqSCOhVvnplPyPqoe2N06XAGQYmnpQzxUoAen/NTopdGLj+s8UebDty6
eP+cuQjKOQOtRZTwKRQvkUklXp2WdrKSrAClhrniDRMZRlaJAZ3bgTVIRud2mviw
NoI13rn4sH0I2tbD9a7jdbVqkMFB1YahYWj4O7fLPTmodAaF4qUSVs2IR4C0M1X7
UPEDZeyVkzS+drg+SEFDxMjBSs9lXdOZlAIbR9b5e+zKPXmh3tof5q1ACN/XS8Hp
QgmfQvFSUcKn+GEgKxgdbIIwvJlVsbvQ5llgI1aJJ7DSBT+6uJNd/wKgNipD6OtB
xiFOavKFZyANR211KhQvEbXVqfhBwIFJ4TOFWQ+nq7UxnN9uJjMAjQK0o7BqoC64
a/fNzHecx4aWwEbSp5kTGqZUzFM/dJXwKRQvExXcovgBIFVPml57+6KwuonjH5qb
HY741g6teQeZl4vvJ1VZdoF/8j4ghr3ywfbGEEeWa2lnYOQq4VMoXiLH0hnUSFe8
EWihe5xbrSk9cCvWTjvyeNTSAoqnzX6JtwfCMmvnf1dGlbEw8xvBFKF+7bCRmrq0
2XDaCy88r/Axajy6ABDrRuykxHtqQg/rRfeXFBtEnxgOWt736B2U8CnODgwX5UND
WyWwK94kHI2TOnGlBc/v/zxIjFLEZSv2frJqzw5bjSGHW7+cBj6gPDN11A7D0nRc
lRYeig7up5znEL4iqYNqQQmG4TnWrTIPDttPXXL7Bi02dwaOZlHt6L5H76CET3F2
kMKHdBq5SvgUbxCSOzFF3sFG60O94iNOcu8LfPlwBXiycefilBjX/qc/QlZanvQ3
YXvlzgeh1l77aJw0U0MJnwTxRS0mNNPtaRkeXgQ+qj+V21+UYKUITyqQGoC/qmlK
+BRnCk4Ak8RXwqd4g8QO5FHWyk0O6cGPYkLN+iAn6zQIa5kwv+Nq09pFoYs6JQen
B+ehMgVwQ2CJEr4C4fHNVUp4wULuiLm7KTQv1Z50WyEkCzYeXOKIIA1yah6f7yqd
QXGmYBR4npeU8CneJDRJGvHjG81PiUxoyHjzb38sjPC4SYQVHvy427rrytKyW8Ht
9Zu3M2NS1XynA5/9KFLCV4A45cJf41TPjbtXA1cDuHcF7l8+kq69DUjs7gqPvHG1
3xzVCDqWvaSET3GW4BQByany+BRvktyAu2uJ++6Hddj5z+7/7p2Lj/ikgoQF9qJu
G8pB5KDNB8Yg3eBw/9qoDE6ydjA5NwElfHNQzqiYwpSxQb38u3eBTXbeDeNmzyof
XcIeXt6rOXla6qyOS4GHjqUvqa1OxVmCMh0yAiq4RfEm4ZwM1vitP8YDK4VSUJm4
EYChxwCtHrhRfQjiX7h6j5eCc9GgMvMnjSyAu1eU8M1BnMhGL5RGK3DnupkZ+do9
9+7VxxtH4a7p7z8YVnSEKYaP3oPtVYyxEj7FmYVwA3KCdSV8ijeIDMKINXOIanCw
BjxxxlVILYjc4ieBafHc5ONkbVwdNDorU/1KF8pfrMBuXQlfgTzjE/8j1M0mP9IP
/Nn6funA+/VPo6daTO3ob42t9MZtt/zv2qspwpoSPsWZhTATCNWQEj7Fm2RqmxAN
2+agAUHczrXUSeycm3BYNftN8XPZp0823+uuZHsXIfRrIyPLU195fHNQLtMgxc/+
8U8QNITbbKMYEpq5OZbFTBnXxC8JbfR5BpqRQK5Huo7l7y2xMzP0cmpDIXzCzcaZ
EFBdCZ/iVBMf/HTCSDbcmJjC1My7YCsUrx1KQdMg0nRNxlk8q/ZmgnWcpbqDALMk
s42ZYb3WT/mm+Fbho0y6bAC2+CkiQWVWevsz4I82M6wXwkfAasTnb4tLDq6z6t6w
KHIqlY9kbsaLX3rh8c1Kjh4HSVUJn+I0smhhxoPywTpc+cdqZx16rbPQ0VPxw4RT
BlhDRFbOo5Saz7iMICl8hm2behDPTCvTT3t56jnfvtXJBOKb4N2+EDlB4mJ6CK0E
y+LznGnduqmzAZ7S84B0Qoqzv6WrXPzWufQJZT9gjXIITSV8ilNMbkC7B8Patf/5
lxqZ+XHpTX8gxZmEc2FtkYYyecwkTPizS5BpWp5pNrKtOI0NXZrsM7DT+VyVW6iQ
LrBQecrh43e766hqbtsgfqFS+DhC8Z/82n3ckMepCH75P15YbHUerHEW+xDZ85pn
CGtMCuLEVcKnOM2keYuWDiww0xwzQx5rq8GueO2wxU7bBGu6rBvLnnEdYppGM2wV
fkmOQCZo01NfqfP5glsKj88sRzm99Q7AqIbMjO+vwHxv53Aldi1zjLNDtlXzd/ny
jE+enh6sZRqd35UHK8iIY5twJXyKUwkrtjYyGyp3txIvRDw0zJkvxr+KclG8dqhc
cgk7HCGtaAz5LOEDinSWI9PLCPA8jlfkU1w79UP2uYRPfEG41ZO/yQRZoyZ3Z7Ds
2oAys8qnnLPUFTfQ94oqnsICkHh8Toa3HN1pYx/XH9nAlPApTiGMUcoRQvaoXgxv
jhr9T97urRFQ8Z2K189S6L71kDkHQ/7fSYWlhzzxsFzCnf4Wyt8qfEUOgvhlVCft
7rikTSp7G60+kGkNFrs4vVZuuhEPSvsb1SnNikPUucu3X4pW8hQVR4G8+8cH0Oji
HCnhU5xGGCFC+LAlU18f/Pf/x/qgyWmWp1U4XtFBoXjNfNN+uxQ+AjqaXwa5/O4M
HPJ9e1Sn/EfGppzbEQsCahM9cW5+znNj8esk+r0rqGJ3rRSLixMKR1ud++8HydW7
QjWl8EFt1Oyjmavy+BSnFE4YwjjzUT66NDa7ldaAJ/ZuW/h7p3/9rPihkgN889JL
FlygXMO6EaepbSSGPN87/cr3PFudeY5MHWmU80k1nTVAp+XdEpEvEL9PqrG4fx6t
dIVbSFnqTDTDwJwzfWY4a/vISpZ38kLwZoOGEj7FqSQz99xarwVo5o3qYStMTZyC
OdQqVBaAcIpr+HxCya/HwgfUjFC8IYpsNaTJRjwULbZGGT/t4S3fKnwEI7GUxbof
YQq5MWhwhAx9NiojmapQTNigDB4raWGaVu+wMtbkyShP7cwCXJoc3UkHeXpqKOFT
nEbG1fjRzQRN227INCdC7sPWSjaik0amJV6R5QDHtpyKSbCcCWpGKN4QXxY+dkb2
J75V+DK550s4MqDezakPfc+xU40UbaZltkgAFbT1uDqkunh9ZRJZC686KHV/PCxN
8uXK4ScfcSNRJcsUpxShbGOsu/lbn1m9jX7ZTt/7bWqJ8Z7OGqmVfV36cJHcfvr3
lBQ/cL4sfKQIwjj9fHtwi3TfGICbyfXqbLZKhBIa0cFmIV/yJag8db9gW/DF9YuP
zIw/kbWdUpVqdHGjj/5sWk5S4EQJn+I0clD2GB5eGfHUrozHa0ZQG9ZH+bAdeCxj
3qSycPaOu3hMRb4o3ijzkpRL4aPznbxTz3Oc8VEq++nh8jSDaQMetr3qRJdHpoRy
TYhg7K51Om2I770DezeTnBVJ7WLlECMfoLO6FD6t1bd5AiqPT3EqoRqE+d7G+b6x
eyUZlzXwwvzeX/x9HchYlgSWKUFfmmCyQHBOTfyV/pUKxWvly8I3H6Wcn3b1+3bh
4xnFmgYa1L5oBZYufiGo2R+iKs8JYF1L8cV94Afjm9Ct2O3e5oMi5EWGgaYWfeqE
lDQncmMnU+kMitNJGuhVJ5GdPuVR3moHeLY5npBSlGnZrFKCeTofKbqdFKWQICam
latsB8Ub5WuCWzhXwS2c5KBhxuytnXO/Ljlx5HgrXZ6ZOS9+P3z3GmpOe2XYX++x
clmjE00GtxRVqvVRDSJ9caPZGhb+nqbO+BSnkmEdYK/qc9i5seObB2tw8G7v481z
nbRsfPZ+oDtkkceecVn9lvMyl/8ybhzvX6lQvFa+LHyLlPdTb6G/PbiFMaxDlpfR
xh6NDAvCVrx638iYrms8z0ktXAkd95OqH9CqxqC8p88TQRAhds4sshQ+0KnmdpCj
hE9xOgltDbl7nolYZzVwqVks/1w88+Is9gMHjjy7QvnsPEY2jsPq8f6VCsVrRQW3
PKNyCyMUdOnGtYf57esIXb0LfFxNrf11BJEz8w9X7JTzA7OB1veBq0a0irPJ5zcT
h08di40rqXa4AXtXvnCa2Eov30/T0sw0YwvPWBkosbbPw2fnKneujbyoOikjGd/5
NXGfRdjLk4XjMY4yI4IS8GFDNUBSfEe+LHz8jBTYe44zPiZWqJTd+oX8cbMv/0c0
6Kzev9wYbj3urAD/ycdw+T5cuwPtcamfHt+6UcKnOAtMKsOGd6vprX68Kh7ouWui
84+gNrn4oD6AaVjrXBjJMn8c9dqyzh9odtghm9s1H3OmLfL8nqKo98mfbYTmJYjl
9CKyc2jRTFuheHGU8D2rHx/CJE7au5vo+nYC1bGYc/c2xTxLbTuBkX/7sn5xD8rl
XWPrPkxcfvywXgmf4izQaWOU61B74OWJMTqfG6mFkqCJZ25HN11NnnkHJTEFtE7J
G/SvFxURZy5OrSKj7yszQiohfWbfbDgqEp9Z8OgCzIvBq2mleHGU8D0juIVggydx
sgGDZnX83m+B77k12G74AHYqf2eDBs+t2kjonng0qBwPz5ZdjbASPsXpJnJj98on
HoJo9ypAn5S4n17u//5yZcqFO0bZSKwcYYzLHCVTL69OV2abnVH1sGI+YyqwZV2k
Z8Hn/9Mi5Ny9guSVTDVAUrw4X05nUMI3Rwhfgi2NZk7oou7KjBjew4vwcF2sUz/+
8WHN6LU++mAbbUG/yfDtG6S7/pXdGSV8irNAbPhTc1bptGJHSFxmPrrQw01OUn9i
cW3UYmIGSbdsZLmQBZ5jZKkXOLKdkZgdXJ6lzzk6qqMM6cDps874oEiK4JC6uY7Z
qCE3RpXwKV4cJXxfL3w0A0PMvoO1zIyzCmEH0tcbW+ZYzDWgc/fuwK5BBqY8if+K
pqmtTsUZYPs8XLu7GY4qE7ATcGJYGzgTuHy/pB/qY4841cmF0WSGNGtsT/hqvNan
hmd9YXk0B0sjT+q3WIuvPMuxgfOs/Mx35JyLGTVpzZImdNvkSe1cheIFUFudz6jc
sphM4t/EBnlAv31+Frc4Yv32pIQjt9c6bMlfWAg2Rgdry/sevYMSPsUZYGfz4ZZ+
2IZxFXIjMnU4bCdktjo2Mdh5ULt6H8APDv08a8HIq4exDfd+fr+WkxS5RpqjpWd3
JHxM+IKccv+ZbygmlsAKehvrf/mz/YpuSOFTwZ2KF0QJ37OEr5hjem4kdgxOxF0U
O1IDM5PMqpPKsN5ryTYWuSGm+lHHdSV8ijNFZ3V/neHdzb0N2F+HXisz00W0Zb5z
iVMd2TjivdYw8xx9fx3xUS0zkRaNqyn2gKVHgve0cGUE68/c6pQTS0hfXhLztrRT
mRiWzJ9Vwqd4QZTwPVv4vtc7KOFTnH6oBnnIXYsde/4pIcpTbhopG55jmpgJRdnq
zEg12t+AW28NXTsPq48uQL85s7Ji/TjzYbp/3o7d3HgqnS+1Ml60e7i/7gyqWjfb
vPT//Lcfp9bY8AaNxTXf1HFboTiGLKjQnM2PjXfOy2fk4JyTY21a/lI+6fxwWe83
ISalyEInc6mlhE+heDmwlBkmOf7k4qvJciZjvHS4sA2Nfj/lmx3jxiQz7cT5281m
Lrt/pdPzOTEP6mJ+TDQfUhsgsAuL8yS/PTalY0fJrBF6kOV6XNWpmE78sN11SwDd
FXmREj7Fc8LmNam5Zbrmg6kYQjnOnCyoHcmZzLWZeEflXJZDi+hk5yKk1tfd8ySg
hE+heDkwKob68eK+RwYkI9jSGSG0XCUzIi5LJ+3euUhzIzktxBJbuGxiCjoxpwNb
rLHDh2+j9X0ultu5kfOnCrtkKbLm+X291sixiymKDuvEioRrGDuv479UcWogCNCy
J0NnBfbXh44j3LvIPbqCcg3B0bha5swwXBjxr+00eRJ4HcKn0hkUpx5OqRjhaVY9
9vxS+FIxC4QBYb2N+uhc2oU757JKQH52vzwFeLg6Wpu6GOXDGxEnkbAxIZgGdDZY
qYs0nEojdOTExQ7BOHL5SLf764m9fQF2nbob8//4qySuZaZy9hQvQpETI7SsESeb
2zj0PvogyaF0sPZkvNko6tkrR9fDomJQ6APJnacE8mShhE+heAlwQjWNJ0nj2PPZ
4mtuGjQlhqlFtgZ8b0Me1o1qiTfxAUZVNKmwPDVlj75JM2HutFxEqcQIZCkyqvGp
jxZL7dCTxy4l1G+K5flupVTM0HEz1WS1l5HpPGMiKxRfDy8S+Qx/BpOyHENFM7mD
9mK8hR70G095fIugKkjLB6tMe3jxjX3s74na6lQoXgaciUFOsuMr4OUZX+oAD3Lb
g8ixso8+OGgPG511OLwyYwdrGTIiI6zKGNB+TUstjmRwwZ7rdc9BOqlYd85bVC7L
pSWi2tDVY39SzQ3YdhvMgP213U1w6XivXKEuUDgjYXmKlwWR25fGRi/jvNfOh75H
f/8ukMV4GzTg03eimV4/upxTGQxjELfXIOaodEIbKSvhUyheHs9MJxDraJIwywpK
6NyHLWomYA9KyIBS1+032cEGpFqkY3t+uEIwLqpOy4KdPJm+H5I4g0UR3OnWBNqf
V2ZZa6/mwq1frNwHPvYM/XdvAfSaozJSwqd4ERjlSEN+BH7f8YZiRMKD1u1mZTne
OqvAtEb/yfVFI0meVD+/dPOvVyf+vA3diUujUcKnULwECJo38Xx2OgMhTDMwm/zp
//L2YR10FhrE4mkZsgDVohlpyYCVB5eEoeEZWKkVO8M68NhO5ealTUKhZ3JtnZnI
MCIuzBF0V1jnF7tQH/LDNvXSR+fFkx9+AKqju+IFEA4cwhroVqmbO6XHhoVs3q1A
thhvEJQiF3ndowTtIp9B/COPr+yYjw0ZafUNpfV+oCjhUyheA/MYuCyvISBav7kP
ZR/yTDMxitPKgy2G5iXHvkJQAiIsixsWNwFIHGSjmCd6ymk5p43ED4BA4oHWryHc
CgOZ0EBzW/bFDT35coXiG4jg82sloWMARl73dnIDhhf7E8vCRXwy4xpJfVjf5zMf
djfFMB3xOoxR5XBws/npn9zlozrvt57c7cRYdiV8CsVrQOZL0Tyn+b/6OyvevQ4Z
RjxPM+Ld6PAubkH+DOETr+z8qptIT7KYNHl+LgPzsWFGiLpySY6Z96BBLPFTXgML
f+HocnblYMDXJFcoFMcRy6NhmZXTy/dXOts/7SE+vDrkIWg6xpxywLuNDz72EN+W
me2yZTKzeAI2BlS7fX2csbFVhb2N5VbnibHsSvgUitcAlfUxGOOtjAszke9dgiJn
PbFH9XEFJsHqM4IERtyzHq2bQBdRdql1WOeD1Rmpzlw8n56Pt2BU0mHlH66CdArD
YFX4eYMG0RDsecfTKxSKp3l48VGlViyq6kN4zC9wbc81HJZgvMhZ58jMuXAIeXdl
Ub+FMh1yU4693Zt3V1OL6MIRPGkmXaUzKBSvAc4olblRzciLGZQC+Zxtszy+spOK
1XSiPys6TvZnFwKpPzm7i5ibW/vrcO9iqXIvaQDlmWF0m25l1wT4/KaYXZkZO8CJ
Lu2VyutTfCN7G9B3qnzroWUE46ovT/MQjCwhfIXy7fFrgRa5JfGzmQ97q8CIrBT0
4A/CmW7ZzujzG9O0HTvshJ0sK+FTKF4LhHGEhTHprELoZTqbJx7gsWeF3hfX6bNr
HqYWRQQvhC/FMggmJBWACa+JCUWCErHjUcvorvKeYTl5r2UA1ZK8BH2zfOQpKhRf
Rx+hOvmnP4suPQCxHEstE7qT8w9uZORoIYYan3gl3SAcprqDIOQehMgDNBZDMHbF
8gruXMsS94SlNaitToXitcCZmAMwLeexk5lFzTHKNPkEJGy4OV8x869MQvEMZ5lR
VJWa/2ym8bwCkbu34V746OBixi2GZUHr8XrCIOxdAPhPv5wG9dxlUZXfvgoqv0Hx
jeyvizGGmlky8YnTuXq/BODHMphKDjrz1n/eEd/OzKv/b9O0GWYTXkFTXEbv/f2o
5Rz+6Z1ZrxbWLHlGfaKGmRI+heL1sBz1vRYQPdE1GTKHhvWIyHKci6aX/Ct+H9WK
UsDLLcviOo7YsCmeoJndsWoQxQ0YVYiJdjfkVRwGG+juZnzvkiejXE6YRVK8VmTJ
hbSa8NUugJsRaPXq3g6AlcHc8psZlKfy/A+gPdMC0BmTmoCdEN7a/X2T+rk+qUA2
qmJ8olw+JXwKxWuALeZXYk99DHQRb8mYPmgk9rA+KT9L+GLmjauLMvhFEtWi0Xqv
2gg4wzlxciMzOYqdsKwlONzQetNqY7jxt5dnPvn8naN8LIXi6+DBbB1xppWnK124
/jDzUqKT1QGWlcnkj6/cg/YhnN/G9T5Y1SAtsSk4EPuzC48gseDK/b31IGt0akiW
oj05KOFTKE4gRM+snBtHjxlmeH+D59U8r392PeAozHpXZUJ8xgvNpIX6FXXVgDL8
rDyHr5mZVCVFnEKeBKMEJR0S7hKAH3/shbg28GdbkzzSiZHXMmqkGTgx2Nga/eo/
QgnMAeLv38pWOz6eIhYjwzn0aeJr33BG/YNECZ9CcQKZWYeX3v31l59r9TID7a+h
qBHt/KTHYWCWYocyQzqSizPEuUc5n9RfnYSc86XI8aMLCNKeKkmlokRPB7Q4MuaQ
oLHZnJSFsiWlKWhGpQtQHVeYOYALOwhncJFtF9vn7tp9ff2x0MBSAHqLdcHgq5/q
vvhZao5q8WJf4aml2A8bJXwKxUmE4X6ymvhPnohixwU7XenChUehu31jYsIX6yUg
zJR6t5hyHHH+7CO/p1SNokW1tXm8DVVe3+liadcRR5Y72tsUT3z830XbQuLSy9O/
e3+/cvnhx7+CnX8z/B/+pbxMLHzS5oyPajCsAwx/9r+9Dyx69PaI16P3/7/IrccG
Qos9+JOBSmdQKE4is7QxqnVrgabrmFPmDxqQG/ubmLZz8jhZhXLwyFyDWzcybj89
2+T8ezp29LgHdzwfazFVv1KEWHl+p4PQYxrNO39++2Ct35qwanlKmMVDL/L8vgWD
Jodx2LABJmk9eH8bEn3YvnXuWocnvGhUlPXXkZ6ho/60JwYlfArFCUQW0YjcwzZd
RK6EHsCnF9+b9i/fB7jwcOzriN+92o/P5cxEjGmLiYxCW4OMmXjegrToQbowWYzL
wBn2JBRGNmrjsoCx/G4pfPgrr1OcTMQfVdp8jDTC1rss6/xiEsvVzKCOnOF4ddZM
bt9AMKxgWc/TBRhXERysylcOG7KDXwJ0tiLGWVaJu7CSFMHDHE5KsWq11alQnECG
dal1DGfzYDoxo1IgHgr8z28aOTq047aVM0aYzamGMoJNXqgVik2dZVw3c3mgJ54y
l33+GC0S7Pm8VBWXC1bKGNeF8LGn3EB87HWKk0lRSUj8BY1J+9FG5NFMKAAf1lOr
FEwtm/da4ysDXpj/EWvAaNKmtgHv/Hsz2NrbEAK3v4YoI7oR6GbqebOimUMhfCcl
xEUJn0JxIpEtGGAoa3HK2YR68Va6MZAyB/ziIz41HYCZbkHODEwYRjI6HYtJSCjS
MSGuUC/p0ZmLPD8mDSHGmGi6tF1i0rIioF3D4iWg6WTxrvqx1ylOKJzIfkQoO5f3
2OaYQ++dbuBuX7x/TdY2l03Zk1aAzOTztyAnuo5y4gx9C8UWwMH73dDbsxootVhQ
wkBWPt4SbuKb/g96MZTwKRQnkdDSM7NoO1SEq8jMvhbioTut8nj281/71qVuRDSI
M+TK7ad8ceRghKFR0qNgZbGVCUd5fsLjE8IXaXrRWBQt+q4hDJSAgZd9BvFXXqc4
oUjhw6M//C0YiFIjbu+XYOKY8aUDGF7vzWgFwfp9QwN5middfsKoI4bBb34iG2tF
wtGDQaNILx3VS9vIWWx1npQgKCV8CsUJZrkLKfvWotK0V/dSDoljf3YZWfjeehT6
2NrBG8M6TZmuAzc4x2OTpC3Z6I9aA8+OnZkfuTILPnKFlMJyerK5SeBZLhXTpaOd
91FnFR5vJdqonWce9Kt60Sd+jrgfHzZOXivuMwtNU2RbrcHQcfwgS8uV+43ba5UZ
boc8bGmj3Ln3B+SLlRxpi4pBU1dP2gFDuRkY1rygAshz5mn5dz9Luz42xIWMK+E7
egclfArFq2KZj4VzA9yxKZw/WTZYzNtoYwzVf6o1yMR+/16xswUaYiQ2c7cwWoeN
XlXKVogd8dPYlTnuNLZhXnlKzNAMcWbNS2mLp7bXzNyYYbdIbJiWhdBFwmkMnGUw
A2dE3vYpJVT8oOGEEKTrFjNyxA0G1KLEr+04KSus/rnpZKULV+4dXV+Zcmgfrt/J
4pvnP31yGy/LPa8/KkdYV8L35XdQwqdQvCqO8rF2NxHwxLRzfs8ul1v9mPgPPxjl
BskdMdvsQGgj5jlxMPRa07Dizvzt8/BJu3bnPZhUiJ7GWUVucs40U9ouOq31m7C/
vlfV9Lm2kX7d3D4/cY1O1WKH5QfvcLTXMo8+h3ABHl0oYkvV9D4RyC5ZiHN5TlzP
Qs+Qu+VxXM/HreKv2C89uGjLdn2Ly0c1+a/4K0fuZLjBjtY3Yx9jsXaKEdaEkZ/3
0DoJqHQGheJ0YM0M+O37PCgBm5EGH7GGbCLDfUArfWMmr+CceRT8Ax+SNG0nZv+9
mOkdM3aK/PTOe4cAMdbnicjDy2Pw765m84Iv3IHSX73NSiPTC/xg+18H6KGrD+uQ
LqUPRci5e6XoR3ricrrOJIRiHUhm7a6bY9eMbDyZbUAHeT4f18LB1qBBEOu39CkW
Xouw2w5MDSd2ds6NSbPfPCxFy/xRmIVsjaMMSSP/NbVmf6Ao4VMoTjTzfKxZCUNg
mlaWPbqaYJy8vZ3lLljpcLY1vDlJxdSjskQnXut6odDG3c00d2NPzsNYrt5TyGX1
qQqZLe4auagEAY8dlhOGEPZcawAJ2r8488VbYkCsswokKtPF9Ymb65iNGrBI8lP8
wCFM04reDFKsAjuswjRq4+6KGEwR92iuGTCNm9Pa8nIguXX/Zs4sjiJ3f32ZPzqu
xrqRplFr8Uc/KX95tdWpUJxglvlYubG2XQJiEGHN7l3D8ezGAG7f0BjfX4epJncg
ZSKDiXVaH8665wdtiMUC3ss9vQeJhnSYsirSEOGLoixsftQHQAkBTQYuwMiwUFTq
ruQGVLQkolM7E0q5+Byj1ixpQrdNED5RpavOKsKJF39hRoXgCfmbrsJu0y56gIws
l4jRUD5o6aGDO835GTJn0rV/vDWL2jBoiLHzJH+UE0M8c7Tl/gb/m14EJXwKxUlm
kY9lunHgf/7nvfiLS0Zq3bsklI3kNjEih1Odi1W5sHKE69pqFzY+rcEgdoT56rw/
BeveWmoDzkyYXu5Ddbg0A+ObHVi5VSfSgcMY1Yj7d9cBDmrc4aN7f5rAwwszQ9d6
1cXHMILexvpf/my/ohtFHuBJ2fI6q8g/EJPJKZN4NXJB/PlZBjbfd+rA0IyXhcsv
5E3WbC10j+skJI1clqBOZk1IcxfmIifcRYanfuSfsCp2SvgUipNNkY/16F/cKRL5
Mm5FeSV2UguNqp++rdufXSxEKNfl+h603kqeebzfgtx4sOY8uASfvsNnwlUEfadS
hthINbMQrsTdXWV7Fwe+nLuMM0LiNXh0QdyrXzZhWO+uCJM4qufLD5GUhP0o7VQm
hlXkASrh+2EjT3UJN8RXogelzMwNyvVC/6i00FRjKLMgspbBKvNEl1i4/rEjQ37N
Zf5o5OXiby85ncJHZEka/pwlaZ7+FWRmUIpc8TtSwqdQvHzm+Vg645m5fhBr4gEk
3DIA2SMbiMGFqA3bYq2eMh1zYnOKNOH8Jbqpi4lIi5BNPm/cXqTtLRriLs3BDAHG
mlYUNQOsASHIKi5K7Ng5bAubOViTGX0d1699+t/8vTlpiB9OHYMuC5o9PdeF50Bl
+Rg1/RVvmOcWvmVF9/lX/pWLv9SIUAmfQvF6WORjlVmto+H8n/9dLoQp5UbeGBhi
zZ41/+aKLeZbr8GpzOTTTEK5Jr43ZU1OxuTRzWIyyorUCC0S4hfTXsxzcY2s2mKw
QvgwIWAiiowcrNgJSjCpiEVxQOsh2pxw5Afw4NKY14SDeWz5v5zyX7UcCsXr56Vt
dT4zhlkJn0Lx6jjKx+J3rjN8f5MgA3KuW8M6PKqXJ8mKELnYlXuPLOGGKcSOI86o
I2tuMs6tp7szyHm59Md4UY0aDGBUSB53uHwfDXEinsrF/2fyEYSWP9Tylsz8Enft
bk4tjKk289mi4S1fRroowVP8kHgR4Su+XV50vG/XUxd9+QdK+BSKV8ciH4vbOtV+
8xNZU6VAFhWuoX4TEuGhoXkfWcJ1xOYnM1znUs8Q6LCsNT337NA8KhMKIWTyOuBF
5f3FWT0ioPOcG4kL06uHUN9xqZZaj/TkvWhUlRumM1vnkft0IrMsdQ0n7AhIccp5
fuGT60MxRfTFBCCLleGTMFYKGAixjt9ICZ9C8eo4yscKvX/4Q4DZPA2BDc4nYYPt
b4b98+JxRlxKhIfGaJFoLP8vty6Rhtm3CB8qnpFNj+b5ebrwJnkGujELW2Y5pIkF
8GjFKSzFyPC9YFyHB5fEPId5EWvp+lEuzwgZnd9NtTNSvHleQPjknopMzp9vebBl
367lhTkR6zoi02CREj6F4vWwzMfCkzob10dQ0otdRaLDvl9exFYOfVOm8QnPELJc
BqogTYiR0D0svn7bVueiE8NRWyIyFz4ZFIM0Kjw8bnTq5YNNI7l7FQ7egtHYM+5c
yoqqFUJDc0P28yuCYwgt7o6wCm5RvGleYKuTFvlCxcIQY5wv+nYd3Sgn2NTy3Dq+
oFPCp1C8Mo7yscbVzOy1llOL79Y9yIM6GZfFPM2Mo1JSyzwDORnnrUO/Obhl3qod
vhzNLV4a4qzSb8K89Xuar6dZYJoPL84NBnL4cNGjPXJMWf5a3JQQuXDWji+MFYo3
wAsIHycyXwgDEfNMh2XfrqMf58SQ68onWycLlPApFK+MZT5W6OVcQ1gW35ChJ+IL
CWpFzKVQpshBmcxgZ3KnZn4s+HSM9iKdgaOvSWdYns0ViczieY2ALrP+Zj48unAY
XRCGgFlBBa3vM9RZ7Vdb48x49OMxoot+fiPPmQcECPPBi0LGCsWb5zmEb568F3rJ
0K0mI7Oem9MyBDrSFlsWvSbKzMjSZHTzTO/VfEJ1jeJF2oNMFEqpYagEdoXi9MAo
BQ1zZg4qUbAqtzJ5lA0uoeGF6fZ5VJ7yw3bX9yAo5Qbkxq23ckD6uJQltVCX7YuI
DkdJwXPFfRpedMItns1U3p/iFfD8Ht/eBsycYYsctqmm39rwiuHIeeJmZpogn3CL
wrS2aEzydL6frFIt1E4Jn0JxelgInx6Uwgm6npj1W74sXoVLwDu/3GEs5i7EWQVm
WR0gLnodjX0c+YkNjJjsS1m/zzIHX4ojVyheHs8rfJxpaaZjq6s3svH++zCsF08z
ntuDBkB3ZaqHLYZ3tJozX7AtBzZiy5NwJXwKxamBy8a2QsNY5FlgZtPu1djOTeHf
NQaHrYTtXRskjWE7TloAnTaWLeL3GybqVTMPcnrUzo0jZQ0Ub4DnFD7OcXjvvZXD
2gjc/3DT/vRCaX4IzgB3r0/ATspux0rrw8pkbJmIFTcrTrkBUcKwPA5UwqdQnB4W
wjcrA+xeoNtbQKhF8rie2jCow8yH3JhdHPC3/nITxdiKrDB+b1T69+8keUnLtGWW
n2yJ82WHjy0MkWrqp3iVPJ/wMbkfL7c2y34ez5Lczx9vYJkPJEsaaZqbMgJgoxRR
SLG+uPM83y/VMcmRpbY6FYrThKxghoVd2B+/xTYO4d5mb8WkCdE8VBsFvHyIPBeQ
YQexNa0UZ3rSviQWjUwzN4vC/4VdKXaG8JMouXl6RWGMig5JVOX9KV4BzyF8jMm4
rsRHJq50AcyssTNdgQhpRYhWEN+ME14fOjFgf6q7k+KuHC/THkJb4zGzVHCLQnGa
oBRJ4cttjky+B23ICaW+RjPHD3lxFDK0vbUDI4NhmWfeIbRRCW1rpRxDZvHe6sKu
FPtCGEO6uC1bZLhrMn5G2BBd5f0pXgHfLnycECYEzEDl6bz07NoBHlZAVoCQwxbB
qIpSKze2z4e0TQnNwEIZN9GiqG1s6JyIOWIo4VMoTg+cyvA22dJo0IwcGOjSr5MZ
65FjMRQ79yqtfC2ONv/mqpj0k6qwHK2+duua8P1oaGnD9sKuyA7ucvMoW9w2L3Lc
hdoV+fOyVqhy+BQvn+cQvjRnmi7T1e04xvvOKjL1vrN9vvgx4zjymFjDmQx/9EFj
6I1pgj3MiwpFhfDlABpmWVZWwqdQnCIWZ3Njpx7xBENvI5EhK6EHqW0e4Cobl/WH
F1Ndk53eZfMk9+F5wPu+7rKpbUfuwq7kskraU+l9Myl84mGCsDavkaFQvHy+VfgS
GZiSJ3kdYfMhW2d4sG7RkHzxo8Xrc5MSixETDtuANg/CVDeMIggUxtVt06Omy2ep
obOy5k9rw91NJXwKxemB6JmVc+PocW7Ezu9+lk7KaVHJKS0tni+mPKXU6rdHNeC/
3yxpKTLz4UpqQaeOJyWc+DBlWim0tfvGVpzYNprZUbQqe6LiYR0mlcSS95j5i4jy
J7dVKF6UbxU+4aZx4bzxtcAaurBvT6o1dH4715dFqjOT5A7N7diZNYiWkFQrGlyy
jo+LMR9bKGEmpua8di5WwqdQnB5m1uGld3/95HElTXxvMPZoTrCFSe4++VHRB4m6
VGa7T13ZVIJntPtnD8C9fU6smw9KpNr/81tJ+/N65ArHkcGwgWDCDF9mRyXcWRaR
iTWGjHnbI8614x9oUUx7GSyjfEbF1/EcwS05YUjTjOqYR9yT4ViaFR+WuazcAnKF
l+cuzZzY2bnkBL1mqMmsvSJa6/cblXGNaKiQuY//9bixwyE0lfApFKcHhvvJqvDW
FkwdMFJsBA6hmqGxHGGtWPKiotcDIGMMVV3LOMgE95R4pDZrDGiWmO7M7zcBmVkR
zYnGqJKZAA8vCo8vj2W5bcoRNeHxmo5A1l+TfG2no0Un+cUjZWkUX8dzCF9WJOJV
3cNu+96VyMh1y2MTTBfBVsKHIw5P7ZDeODAiTgDPa3jisPfHMerXh+IB1nK4+Tm0
DxniRAmfQnF6mKWNUa1bC8SCF3PKfBikVoOlGuNYuGU0XdT0lT+TBXtTN3IRMqdm
Sm2cMjNbH+PGIcShRqsP1/Cf/rpc+pSVprie9S8n5ofv7WkVB6blsLM1asu9UhNm
wsJo+XJz9Vl9QZeoLoCKr+PbhU/ucwIGqzbLUnEdgTLSyZNmRQgIsSE1kfDxyndW
Yg1py6bLXmRmlYhww+AZhdoIVHCLQnG6kAl6kXvYpov4lHF5attsOtjiXDZAOipm
L4WviFs5FPrVWZ2UMI+xDYm9uwl7a4mlCZ9O3KuzCrkh/pF1tZFDRkUBRNltsLhH
psOooucG1ableXIxsGOVPGUkqAwEXW51cqQy4RVf5VuFL5935oIWSydRbVoD0r8x
WX3AliU5kWxyCYkeXRq4IcDv3loMxESntdjUm50MdHkTOD+a+kHoKeFTKE4Pw7oM
5BSatNzShBSscRUIzBPPsydbnXyemv7bdzslv7gQmbKLBA2qso499zq+32/SYUtI
4IFtZxUE9siOWFTC1t5GZ3wjQqQEEKeeATtkSy7IZSYhPlpoF5BiR/WJ2GmgEuAV
X+VbhY/wok8XrA5Ln23NvL3NXgthxmPraDRFpMxDzUFOPKhzoi3HXDb+Lz4yU3Bz
0GmGnK3bANbA0pXwKRSnCZrbQv+EeM0NiGyCOynJ/cwvFSM7+l72UQpKSwsgS55F
7qQsH+aGNAy5MarNf3b5Af74XZkjkR28naDG7Yp4LkxLxudvQbWrM0o5xpgs+oIu
g1g4Y0Vm/JM4U4SV8CmO8+1bnZQwrmkaNui41GvN/GnZyoAPXTxfyjE8pWU+0+oE
eGLvnDsa4NNyz/HFio4hxFJT2/vxkNoDN8VK+BSK00No6ZkppGzZXih20rg6/9HT
/YaOlGlajmhJuojcKk5JhO4Jh0/TSFQRd5lpTmJo4m556n+xpZkDDw+bkW3J9mi5
MZa+ITZsHGcGCI9PCN/RVuqTT8So8PmsxYNMJsMrc6M4xvPU6qQ5N/TNveZH43do
OFsfXuYTLhZmYVoPPbF+yzWiaWktdqLHW5ETP9nTp3IboujHhw1VpFqhULwYwoZo
NMEuM6HIhZI9z6blYNUMM5kvKGwQLmp+ykIaC4dzWB/WZRmpwM8/+2BUy/RnGDbF
2eb5hA90HV25x+FxQx7tlTOW7lfTuljoiSUYnZC6fvBu/8Zf1TzY86zl1kMRxaXh
wNHiDBvYVsKnUCieEzrP+5vHEuz8rItqn9fE8nkMVRivpkbXdHMwZarDfCezaG8k
7QsmYQXVOwaqjv7/9u7sR5LkzhP7z8xv97ivvLOy7uru6uY1MxzNcDSzxACLBRa7
WEgCVk960Jv+IT3qH5D0JAgQZsRdQsMZkktySHZXdVV1HXmfkXH77WYmM4/IrK6L
GZyt6ozO+H3IqoyMdPeIygZ+3zBzO3qV9MF3OQYfeoupgi8DTXOjwoEZVLpFjZDi
UEByvAqHNTOyBwd3Afb+NOiLF6upC/H5zeb85jMJHRolmk5MDD6E0NTyW3VAYx42
SKdKOjUQoQvQP7jne/KbJDGTAoh4Mp94TIgn92Qdqz1fqu4LCA1KMfjQ20wRfPk4
ZKLXOyCOn/0wM0nN2YUDr6h2G4E08eA316uffwaF/SLE2+zWeY865/ngKgo806ma
woPBhxCakpCNvrw1Fxj9Bvh0pJdkaRmU5E/8JFkEOPisDSSi9NXFWZLhnVMCxtHt
0027Yu0uY/Cht5hikWo1PFiI8GbHSNSIrNOGG2T7a7Ih+OwOPLsJyeYdGH3/KWQ0
1rXAfTmhdDyjhuuQcJ1yHYMPITQlzvN5f/QIFrmxv9wbj5cZBIswCpsAvkhqQPRS
5I8PV3MlxgWsX4F97WYW9pYDCLTd6xh86C2mmcAOqtsyql3bgoEw7dvtnvlsNe0V
HLFwIobt63sro6Qur5QkhdhqN75+cdXrrkEiDJLhtkQIoWnlH5vHWxIF1mmLJc6x
4ZB8rGZgD8uDUpp4xEjHS5PJg9Px3D2SuoWBGlEnwMgC5jGKwYfeYorpDIxQyDLv
wX2TGa1tO2q0RTdrQrtsgmEfeJ1ar7J8ADur6ob0a0vGjheRzUAHpmHwIYT+SH1R
GU9VGNeMLM7UHRZI1eSHe/uwuKXmp+fDWnjeOXX6F71NvmjTvcrzz0Yn0MR7fOht
Lg6+jKndJVNWAfUBy4r1TPzsXr2bLATe9RfF5yXzwSdP/txP+aDUrcJkm77zqwsh
8y4hpkgtDD6E0JSy/NZdvtj9ePR4tzp0iCZIpjMQYRGg7Vra0A0ozRcN1mXyZYzz
okzBo7/8TY0dLBKIzUd3MPjQW1wYfGyyoexJK8taUVYIPvs/4MYwqREI43tHYpTU
TpoEqnt0sgz7m6/AhVo8AefxIYTen/Hy05n+9Nazm89qttVuQWwNaxknxBt1F5Kj
hdaXdd/bb2bEHhYvvt77eVMcF0j7Vrh4P75J8JHQgaMFecLBcq/C/eIX91Mje3YX
smH7hgYnw5XxB6+3vAIGH0LofcuXUiTtxkA0ReYajxbzoS+F/RKxo9DWmdhdq+7b
auVrQYaO/qHfDRm/J/r1b9HMmiL4uAw+GWqDUs/sL53WE/PIrPpebLGDVXh0Tx6z
u0wIZ+9aEg+DDyH03nGVfJDakUMKoc3CE1qH3oI5hOIIhsQj+0uCikicLPOwDGrJ
zw/q1ZJ2HoBoRl0cfONV1cl+odytbl2DU7MIndrBYjRsJaNivzIqUegKWsnetSKe
yIMTgw8h9B6pT+QABgFhMNBYqKJN2DH4hYUjASd3u//5rz/a3FzoF+mooPbP/kZh
hZtxU8zjGw8rTg0YFtuZ7ZoA7UanBrtNK7bgqOkf3wTwdeNdXdsYfAih924cfOyY
rcee2hstYBy+szXSl+JuwiK7TATsrzAWliCf9f6hTXq21EoyWN1m3zRLluW6JZ7v
9DEyB41BSSVX1zCGtdAD6EVO+d1Zhl2dCKH3btzVKQxIzL5lw0i3086i8D2ytZRv
ZUv0jPLWERyXrW+g3rDx/oAkoxom37fA1MGnJtOkI8fQ8j2XWdxeHz8fOmq4sdpQ
cnK9N14Bgw8h9L6NB7cA97MqiNTMaPL8Pz7zoWg/qnerX957+Amxo2r3pJF3c374
YZ1qMgXIOkdfX0MNzaKpgw98z/dkxKXGeIFO8N0s8Xhmyh9EdqCbZ9d74xUw+BBC
79t4tz9VSvqu0ITOUpuI/UVrcwW6ptrUgYCRlrS//z5Ar/xNFJyU55vefm26PZpZ
0wffv/gVMPgQQh/Y8xvR2nDkV/Q0MTu1xDheGBV//JPFQwGjgvr/a7J8xRcBX2ud
qarEX2+tCbW5mvxbe/d5Y2FY81lJ9bHKtsEbl0EzBoMPIfStF7iBawycdlNkD+9a
vQp/egc0vvTzDfHgY8j0bvW148Wk3L2sb2qVqZcB9/JpTsnXKtab5433AdQgPVyz
kpB5eyvQC5fOfo6VbjZh8CGEroBhyYwHywHfWQN4alyDTXtJK/TCe1ujwYKWvWsC
+/kYBkJBjU55yxEE3lKxvhZsauC70Agcr2qRejq25JXeCFA0U76J4MPpDAihDyro
rqzvaK6/cGDbPagWt2EjjU6h1meqgvW1N/o6J9n1SiVibxuPKcsXvNISfOM8FXwj
Apb75K/3xN//7WF5PODv7GAsdjMIgw8h9O2XZUmJPb0LW9eOyvZBtgaJZZyUia9H
RlBX8TV23qSTdUmNjjlvCWZEg5Tobxynyhcwbr3jPD7ZQcmIwW4dHS7l8+j7Wf3s
cEYAF++cQdjViRD61jtagM2NTB8ZFoO8w9IXRQHJwoAJIvy4Hk+OexlgTLYFX7bw
dJ+7NOYmf/04tR8uMOa+47x08qi9BuQXfwaWNXi4PvJs4+z1NLXsFZa7mYPBhxC6
AhIz80kJ0kF9cLzcb9Cy+GoZOvWTxtY1GA7PmmDngSbDjMu6xM6e7yYlO0o1/fXj
BMt343becV5KcmACsSKZvXbXgVGBHZ8NptHgXYsYo8uEwYcQ+vbr1Hy1ilQlNY5b
aoBJtyY2jRUokcd1vnvz4b3JYS9Hr4hMBhg9CzCjG1XtNKLOG8flC6Mx+x3nMdn6
U3dyOkVTfLXqyCJ6ULXidNA6O1umIq7kMnsw+BBCV4fvjSgvPFm6fSSC7XuDEjlY
fFxagtBSUZYRMil0WVhMuN22CyxjoOna8xuD7jXYWxmZZhZ7spHYbowstVBHpgPj
BvB3nLe58dXtTO9pp39yKuDBJ/L19peeVWvDrAr98kDzGGBP5yzC4EMIXRkjTzBj
EDeB+EllqBandtpumjwtLttb/+oFNI4mhY77q0PhbruOyPcbJaTarX2x1C9nOodo
uJqBeVCTdapfBnj+4y3Vsnv7eQ73fnVDPPwEyO7KyNN5acQzoUOWOrvXOKw+0t+1
Tym6VBh8CKErI7L7UD44vU9ksfE9omdr/admebxUp6o67LzQ5dPzUprPTiBQgZE6
I2iQnuHJ751QsFO7BCPqyu8KtPuO83So/OKmFrjy9WTYETdgVkj8YcHrNp1YXHuS
aIa6bYgVb8bgdAaE0BXSjlYBTlpiUDqorZ14fsn8nJZE6mlZKXS8sxYf7P5oTyz/
f8upqk2yRsmwM7crJnRLGkTtT7MoCxwAHzzIWJOlKXvHebW4vm+GztaGOG4m+3/7
fPnRStwdtSAxuVHsAxvqpgHwlhVh0KXC4EMIXRkDR62in3o0sIaksLeSZ2C3mhph
f3FUgHbtvNCJAGwNAioLEmfcVduMDmhvNWUBdame9hsRdwclPynq2yva+T2+188T
Xmw9u6YX0yiQRz+91a0OykJtWrO15OvFhAa6qavJgO9aOQZdDuzqRAhdHaGz51aD
O1u760yTZWZnrffdvVNW7VaBaenLQSpCqMEuHDhRbTEmgFnQqal7eEW1iVGnrMXW
+BafPC+jTHvHeXrYXuTWl//mcbdq5ccClIZs59qgpPax6ZdDTdMw+GYPBh9C6Mpg
QRFYb2MkIs04LggPMj3wVBETYljmUVyeFDqm+QZk7vk2Clxm22mdxbLlN9I1AwI1
Yz2jNGDF/CF/x3ntBojQvftEnNQpP1yG7XU4XE9kdHZFTQbp41v5oE7+5m4O6FJh
8CGEro6EHqwB6esu7K7KWGKg9W90IjhympCm7ssuy0kNEuMCR2KbJWqJTd9TrbZn
N+FwUSRgxfJ/agnPlwXytfOIz+3MIT1WS3tNtd/tUZOUhwK2rYXEzLTxKYALds4a
DD6E0NXRL4dOwRc9ouYoANgdYjtEyBCED7Ni9OT1/HyiOoVR2ff8etQvy+ZeZDN+
sKZeUbYL+2UYFWL9bFaf77Xr5PR8Sc/ztUQJyXc+EmTyZmWUygN5Yp/viJSOKiQx
1fzCyIZeJeFqbv1BUx8VOJUvEjqZPihxmkRFAplqa+IE+rfA4EMIXRmqX3Jv1U8M
QqnqXgyLAIOlQHyoXRLOXq9y/gw7ba3s77coGSTRsnwLB3V1l0/thatuAPKzOiuj
WA22abzWHuQ07xfl4+Aj+ba2KuFgEtujpEIhiUodNcswBLXQTOio7W/l21iR/9QS
yCfjsJLX2L1FTWBb860w+BBCV8gRX7bDwD5bL6XbuTmIvrcjPtguCePXGy9GTUhg
bN1+snDrxPdGUWNY/Plt14GuqRZTK2bcUoNkFFkST5rwtQbfu/W1gmzfqWgTKsRI
RNWOR0w7IQ35b/JZKdSNuLeQcTMxZbtvoDmjUmzJpmCotZfllw/yb/72w+kMCKEr
Q43DJOvbpcHke8+H1vHdx5DCh1kr+pXXk6/gjryIre7KUjfIanvsrzc//n8XeWKr
wTCygZe333J7KyNdFkXzD1w6pxp7MXfG27xPBpb6BQiJra6lxqGqTk95WAY6MLWb
LoWua8mWnxpXqpYvRW+DwYcQujJSo1tVGZOo5pdMC2bJvNlbUUXogwTf2eudr+Wp
y1bWo3sZU5l20pRPhYFKp6eVRr/MThYnXWAyoVRetQ2P5BPhzyuiloIhU9rg6maf
YEJYkUmHwUJM8rWw86Zf3G9xFjswKpHE3F09qQcF34o9EWpWbI14KS+wiXnSzPRO
keC2SG+DXZ0IoaukW42tdmPyjQwmR90h+4Abwuavd9ZrOSgft2Ir04OorHo1STWI
RoUsdQB2PxnAjf+0zGUGy3q4c5cBfLVuBkSTCcfEWUtQ3aJTfzKV24xxT4dO0ehl
Lh0P1iGwuarvVlzVaTow7ZS8uEkPS3s3tIMFCvsLg6N74rihHSz1Kr4ZlkAGMMHF
Qt8Cgw8hdGWEUZUdLY/3yROSQdQ4knxf9A9SdM5e79yw2KnICFqGTilK23+zX3i0
ojorI880M2HGGVfb+WlU0xxzlEDfUGNwZBie9XkKtUqa/JPIpwXLWNq/oR/oTYhV
g1XW0kffeV5o9W16UurUvcGDT0wrapdLT+7w4Ojmlx/Jf2qvcyM0TgvuoKCx54Ul
3B3i7TD4EEJXBtMyXTbzsslKKYJEIi2p/dnz795/+p29nja+PFCI7MB9cid0RlZm
0aOF1FA391J1Q8/hsQDOBJE18Nm/flap/7bAM6reaXa+sgsZQQHknzz4soyVi4Wf
X+t5vRpR2+Fm/MbjWqarIStk/ZfHn8r6HOhLB/54nTRy6jhAjAQCNzX2lrVYmP/1
9fuKwuBDCKH3j6fc0FNCJ4u28Lzl1S4YqWak3WLCDFeTublpLvvWqKJKokg4OBBb
PTUZoVPrVR7fTUwnEu2Cvb0OgVpo2/Z6Yq/qyjakbUWRbbKHd+nCAcTF1AnI8n6m
+Rv9rSX5WpEo1J+WSaWbT4Xoln1XS0w4bgFPhK3mAc45DD6EEHrP8sEpahreWfBx
BhoRArT86cjOuKZBHJegUztY4tQXQlcbGLUbm6uHq9B10qQe6EmBWCk/WBwVfv+R
f3QXDpaPrred/s4nQeH6CztMTbj/0zpYD24SQfq1ROvHrZKebVYfLRuOmYJotvVn
YrGrpvn1Su1kFQ6EW4GeZ/B5X0INgw8hhN4zIYQaU8LEZN0UwTJQvZVOmumECWqq
1a55EDb3r8ONn7ZARDGxDGAO9468QHjxoAnRnzyA1lHmpO1wTQ3TiS0vCJ3SUd/z
mBF0VtXyLk5066vCabny+OOD4taft9sbm0eLm9cAhiVVZRcPmpsexMzt2cSCcdol
ab4q25zD6QwIIfS+cSYrXhSXzxYMyzJBCOfekLnE55bOQdNEmjoGFcXtSmSLlKve
Tqc06JUTppnHrmVCYxirNWieXgf40rpx0pTluFd9dFfdqlSz2Z3g+Fb08IZ29/H2
2mlDwBd/EtMD/bv7p+X8UPKn/3uhXtgfrKh6y06hlfnllHQrxr7Z+FAr2XxbYPAh
hND7Ngm+Cpl0KopMNdC4HQsb4sSkjIGmExI7BOydxpDZNiRc14nnn9YCbhyuhgWi
McJ7FTDSX93V/QZ0ayBGBeIePP2+rMubG6T0rCGv2W6Qz34HpBY9axS1LtGBxNu3
SO0UiH5cff7ffFWCw2aQb0GfaUB6ekE2/Ybuh5ve8a2AXZ0IIfSenXV1jicTqOYZ
l09wrudjXFJhgko+DWBrA679dImFBROCWLdNcA7KbVo7acKz/+5h2thySKdeOnRS
40FpjfhaWkg/fQRk4wXA6UrcqZLxxcVovUN8lxDfeUi+03pAFofdhmfwrapJX9S6
i/Ci0IROSX+0UD1MVkNTZuh8T2zH4EMIoffsbHDLuNSpG3rj5aIFEZksgfmwyvE4
z251byW21FpmQUKN9uru0tZN6LOCGXhW+Victu/KKrx59EM4+fRIxAbN925IjM8/
JY57rNkhSbz02ue1TBRHojawOyaI5V+t1j5fVscFzu4Pnhvm4aBVOSGNNqkHzosb
0K7tL6iiPMdlGIMPIYTeP54IQ389+KSQWpM6qJwYlVQflhL5UE3pUwHYLslYjHXK
dStSMxFtsnqaZnxQHbm9yl65oLOCz0hm9MsOiwcLsbi2ZZYfNIfN2AopODt1YhkP
Fw1jSIsklm+g9chyjaEdpbeOe2VS7oU2IXG+jdIl/WZmwIXBx99xE1Qtmvq1Twzj
/75ckDeGyWLwIYTQ22VM00HEdv5QBhITukGSpEoCd1g6bgbuyGI2FYv950uQ6nBS
C/Q6jbPtteKIgbb2lUWW92VBlREZrXdC3cwgssANZdG1jsoFv/S80BiN257i9381
zJJW69nP/1wjfY+Nyimd29Gd0wTfKz/g4wY7nAWcGhgruEw1lXlv2/wJgw8hhN4u
y6gJIjHUCmX57gqyUgLj9knFqMa9fnNYINnBesvYE5UO52zUZGklXiw9Tqye7jn0
2Pubn0Lr17ftXQ/I8t99XIi8TqdQD2PdTvLKLcCr7wgiSKfqpKyVdvObgvX0p9+V
Lz7VxkhX0lTBlz84O+G179XaQFxoZ3dx3/IKGHwIIfRWLCG6zhlQKpigFNScB/lN
xN3dNdnC448/OmZLC8cAt54Gzhf34dG93/0wXjyU7QwG5MZzP6q7Zm95v7bfXSTW
ys+WYOEQjExPr233tAJplv+vv+jIUwtDUhyUtitqGsTq//Pv94K/+Kd+eWct3ypp
Ll18j0/kYSfOWnhvadK98tQb80NwOgNCCL0dS4SuEUi0fOt1LdIoz4hFTqBZId3P
P33wyXHFjI/+lf/cE/n2e9vrpPSsKfo328dNKsjKrpHm/W0givXHtiq/v/0Oiauh
LNxb106aGreiojMcab1m5o2ArO68+MsDEL3q8s/XIHD5vE5qmCb41P9B/9o56siY
aON7oyymNuSjlBJujhdjfTUJMfgQQuiteCqITiHW1J0ijQx1TTBVUYdFEjhw0mSa
rKDGsGSSwwqc0OHG0aIqwLbzj/eI3XHKAxgUrYxlS3vW7grRTqquMSgO/EXuM2bC
726XOCNqCRd5Dtu6rnEBp58c8/Gwxa2Gl83pEJcpRnUKIbgKvzGD50FGA6rr4xVw
QmLraWIbfMhsEhVfnx+CXZ0IIfR2qj5SQlSLTwgNIrUrA9FlS6LgC9/xi3x/Nd2+
CToTPNj+GOBn/8vvfbdfocd1MNIsKuptp30vOyqS0kAMuj9+1tHvtPfSVSo6nhk6
EN3Z2bzWOoFENKMYNG44fSCl/sBfhrbjwtCk+fDSuavI0wQfV/tasckTJmeqRU4T
Tc934iCcZUw+wZ2szwskLLw+PwSDDyGE3k3Ww3yQYD4YRd1YYgyyxuYSbF2D2Eqo
fgLXQhH3FjoANSJ4ryZbbsPSwtOCCrHw5kF+h0mcNIGYewXnxlNCKlHIOm5aKY4q
e3UzLp0yAp/9r38ptr+7VSppHU7B6niDEoRa3n6Zu0Wrpws+GX325Ak+CT6Wj4QV
XP09yhwrsnkfSlqgvz4/BIMPIYTe6pVSmH/DgLAwahEte9EstLd+sL/MIi+x1Hx3
mWxZORCxJWv1UXF5W0vLhEJsCDfMJyw8qbRIvo5L79qLu+3dFUgNktTjBNxAY/U2
0etPSsT0ulDsH5ZuHYpjsxKMGzAYfK8hGfTqw2Lo7HrV00ZB6zvh0NafLzmhbow/
ogyhCMfyP5M3gHI/zdQCdCoeJ80+ddNV/peUv1sMPoQQ+sM4o5RHUV0mWLc6CLxi
P9LLOjHCctsG307cXrnPa/mhYuRRI5GFlUceJ4IctNSyLlQtCQqRRTiJLaJGXSwd
uIVjEJFz4wsntlfZyahw4LpZsyvrsG+Y+fpq8zahb4oW37A4ckfF44XAa7TBCb//
9LlZhL5hjIOvW+3u3V3sVHpmsrZTjsPxaZxr51fL7wli8CGE0IVSNYOMu5BpPSjL
Qpn4flT629+3myu/p5XdNa9zcI3d/KJA6s/czFnZ3fuff9Ipgiacxxs//N/uRLZJ
YrBEAt1a4/fx8rWDw4YhqzbUT2WxdjuDppXI+tvqZPv1apgdLXZM2yBzWI+nCL7Y
Co3ANh/8202o9A3IuB2y/bVgEnzDIqSNESd/8TO49VTPJmNgvj6TnXNCMPgQQuhi
WcI0S7PIwjYAVcMvTZ4uHsrkguYJNNo3n8HKHrjB6m7FT+XhdgRWDLYxtFLeOHWC
yVUM9bPvPR1CfbD+zNPNwIf9NWckuLbQq+89/3irYg3KAp5VTUvH4HsTyYAbGWH0
1387srP0y4/kxwYWC3ixMAk+gEGJ6DZ7vgg7a54P6vdNv3aTTw2MweBDCKFp8CTV
XNhdDgoAhxU7dCb1MjW61c0NeN7SDq9D4AoxLOcLZ8UWgO9BRKx8oc9JVT6ty+f3
bgfQqQsmazwIlydHrXR05/NFGBRJtc0MjYvjihrbokr0Jf+rv2lTBB9NdK4xbTk7
FbE18E42im1x0jxr8QGnxPH+uWFDGNZgx63lv8XJyp1qz+HxlHY15AWDDyGE/gCZ
ZDwDM38cJVFLfgmyYre85zbkD3tFMzFlyU0H9UGpWz3Umqd1eHF9b6XjODL9OrXT
+oiXYEALvhuxQpHup58cDrzEHI95AcPyjgXUd8Al3UrXWe50S/kYRTFvY1um2p1h
6MSO2i8RxMmjvxoVSNPa4fu1s+DbX3RvPhRpe8n3ghefqM8nk5ulLJ+goqZlym/B
wOBDCKE/iJ/NqjtsMm6HQRkYZJ76CWOmatzBVr3QrcaWrLSdGhw5pf2GsGSz78gz
rPGpDDT1JWU2+epWan51C1ITonTJ2h2Mvt9X7ZD7v6O6EYvFQxC+rtOXKy/Pj2mC
76QaFhOLeoe8IHrVdiNf+fS8xed78qNEmrrbnlrw9Cd/RTT5veC6yBgnlJiq5Scz
0MHgQwihC4zHR6gADO3xDn69Coz8BaYNKXhs+zoMSv0y9Gxb9W7mXlwHmYP8YKXt
aSZkoEMSsHq+P219/de6q+7mgZMypkZ87tl1Il5cd8OidmKxUNcIBt+bCE/N/Vbi
gs1TAf3yScnyb9KDxDgLPk5J63jkESs20r5lsWPdstRK44RnmQw+tfWUYIxzD4MP
IYQuwMR4eciB5nWroXD8wknBkTnYp8V8T4BTvQyQaJpsciTmoLS/rHpHCdcCN185
Um01xLi62bd3Iz5ukW7leeNmv21eP2RO3F0vPTi9GXiG32vd/5KFlTgfjcjn7hbf
NC2+fnlQSg0vS+LM7pc0Jgy90OUR0fLFOgWRP8nb58WhFYtnN8+vy7IC7NrqvwCV
YLlT68caZxh8CCH0YYnRqh9rxIx3taXWz2qylSd0but0IDI9sxiQ1V0QmSF8UZAp
mpiX/X6/YVMEX+i0q6ltcJ5y0/c4AxPMATcnW87GYC8cVWAouLa0+3LXIgFs+J2d
fEytugolRD1MjExg8CGE0AcVj+r65mpnvXe0otb5TCpht5Kqjf8++j9v+fVWJ3DI
2jawlaNuZViM7IsveMVMs2QZOXapqxEmOFXNaXmcMSTG2dHhR8NOq3dcPmmS4hDS
s4nrsk3uRMSKTBmFlFAa/OBoG45a2NWJEEIfWOgIur4NRmvU11i1K4twox+v9Hwr
vu4fN09a8g+oeYJ2CJF9UtUvvOAVc/E9PvnsSNNMkyY80zsloskPEIavZ2oTBpmK
PquBkfbK0G5Aixw7o7Pu4sPefcErIlSjiGSLT02sXNgLCxh8CCH0YaWGmvfXL2in
dXh8Vz6xv3CwergIiZk9v5Nu3oa8DZPpo4Is3J3aeAbgHLk4+LjGqSDM1FIRa71y
aNryyEDL6GSaOi2O7n++vxxbPY0WHDF8uUR1pmfawMnn8VGS3toD4L0qBh9CCH1g
oQOfL1tmWI7AhsdNUoWdNej2zaahhoyGxO7316NBC3oVOFhSf8+Xi4MvtiKH01RN
S4jMUXmoWxqYI3kizVt82pf/Zqt8YrRdcGFUvv04mexKFLi7TRGXzy8UukahK/q6
icGHEEIfVN9OC+orpzwzQtm6Oyy5mxuymdc2ysMitBtPb3WH60MrDBfTuDAqXPb7
/aZdfI8vsjvVfoXpGuOhFRQz0IlhdTMz31udif4ysaMT3lKjbYclq7QzaQnKVrWU
ysDMF3AhesEHnM6AEEIfHqe+d1zuLaSGjLlIG9QBntyJEjDVOJaAwfFN4Dw0LUhl
QYejhct+v9+0i4MvNQ4KnRXd0aLMN4JKxohFzHZcFYJlKWOtoGKxnp6GFfkrNEuD
iNCz8S1DV3s5XGh0d9+mPouwxYcQQh9YtwoQ2bFBR3l7blCKLfk1I1rb8dTDgyW1
wmfPtlNDZAbe43sNYSkxQP5JzcXD05pMLNlsbmxaWuCpYEsi81j/8RPRK2h7KzvF
+4NhRl5bBQA3okUIoZmQjtdSJv3Dj18snTVL8uWU58vFLT618ptaBIcK2axzIu3F
j07kL6onuovus5sgPy5wQ/zZL9QNUpDxqI3Gg1vE+ScIDD6EEJoNauFkmGwjkI16
G2oXgflbuGWK4ONCgwT0vU/7Vtx1LCBOwsTBgl+EdpNs1X/zoxc3Gm3tyHETC1rW
Ez3fg+hr0YbBhxBCMyIvyCBCA7Y2DJrkk83mrx5PcY9PaCIRurX9P/1nLxBELJ4w
kQ7MImQGEZXt4ojqzepeZmqR2Bg8rb6x7JvId2DH4EMIocumdgyQdfiL/2HTrPxs
jYx3T52/enxx8GUy+GKhcweInQKrDoz98otlByJW0EljH/7hR7C/snQgj/3oSxCn
Xv75QcD5UgAYfAghNBsmwWcT0DP5leUddKpbb75MtWSZusfHxbDyycONbVo6GNUA
Il2Hbg221nrVZPcGPP4fH4Xl/t5y4Kbqzil8baML7OpECKEZMe7qJJpFokPXGd+Z
4nze1iybZj++yRZRbfvwFtNeXJffP7GuQbtsPL/B4gycoQzCr8qtQLPSA1h7/SoY
fAghNBsmg1v8HzyBu/9kWQnVNWzxvWk8qpMD7Zef34BB6XBR5lu3qubnpcwWqQmb
G753RFrw6B4cLWR6POnqPP9FYvAhhNBMOJvOoEXCiex2o6cZhiafm7etaKdr8cF4
r0KRD/GcHCgSQQ2i5kmONAcyPU2IpWWpSV4b3YLBhxBCM0LEwtleh71lMqR6v0Io
ncdqPHXwqekeqpFMz4MvFVQjIvBISC1gkGSaqaWpjcGHEEIzKdR0WYAf3YO91du/
9IxQw+D7w8GnRgOpnfXI2YGcyRDkTFMdxvIZxkDXgac6Bh9CCM0kzhKDGL3KoERU
a2Z7EYPvouDLGBCVWuMDheoq5mlWULtehOAEQA0NWGq8GXw4nQEhhGZCNHQ9GBXI
6m+v7WmFBIPvguCDjAmqUXEefKCCLy1EwoEA3B7VdF2w7C1dnRh8CCE0A/LSm0C3
UBBQ6/rCwOC7KPh43tUpzu/xqS9Z6qRgyF+kmVCaL1XGsasTIYRm06BAYW8FzMX/
+37knDSwxXdh8EG+ivd58I3Ti2ni1fMYBh9CCM2mCIjVqX3+p0MD+vfM3xQx+KYI
vnEP59eD7zzDBBFC9Wli8CGE0GwKXLVH+KN/1/6Hjw+dMokIBt9UwfcveAUMPoQQ
ukyq5Kpp6ixx4Dhek3U9zjzQWY8WuF9Su9bOFww+hBCaF720eVov+Dtrapudz38Y
sEEVkkHjst/WNw2DDyGE5sbOmizrkeVElV6/VPBlTQ51I8NFql/1PoIPpzMghNCl
youuOGklZmIVngb3Y7HyS6ukB8RMhw1VmueqKGPwIYTQVSeYmm/GtOB40SZiVEhH
1d1VyNzrvywD+MIhMFf7sGNXJ0IIXXUZIwbh6d6NXoVAaJHATTsLOyVSFt2je/LH
QF4fj3+lYfAhhNAVJ5KMqk0ENKs7Wme0Y3kPrhV8T1b4hQdV+qxchnw/ubmBwYcQ
QlccT1K1e05yIO7o9nYNVGFWKy0nJSJOGqNiItt78zShD4MPIYSuuNhizEwD0+kk
f/Pzg4/65UzfXe1VTutqN/bdDYO/IwCuKgw+hBC64hKTpXYa2mbsMaG2D99Z2yuU
u7V8zS2AkYvB9woMPoQQ+pZjWpbaWeJsXS8dG2lUebqhP/gEhiXH+v06BMfXsMX3
KpzOgBBC33KCyNRjqSMKgecv9cLKoJglaVGsPlrpBgKeb2DwvQKDDyGEvvVYavPU
irti6cChJRgWw1Gzt+qD6JcDunUbg+8V2NWJEELfcpyK1ITUkLX3aAEGJd53bPlk
v9ytygzkFLs6X4XBhxBC33KZDkyTwdcvf/lRrwI9XoNeJRnVQqdfTridahh8r8Dg
Qwihb7m8rafiLzUiG/rl0JGtPpC1uF8OTBmKBIPvFRh8CCF01WR6yi1IElGEbjV0
LvvtfNMw+BBCaM4MsipRkxwAfGdUSox5q8gYfAghNH84jTOvUzuty6qceJf9br5h
OJ0BIYTmTGQHgwWiKjGnMH89nRh8CCE0b06akQ1MG1KHcQuD7w3Y1YkQQleOTLvN
Dcgn8QGMCpf9dr5hGHwIITRvRp31UDd+/YOHH/PD5ct+M988DD6EEJo7I8cvHd8c
GQd130vAvOy38w3D4EMIoXnjexAOy7aeCRgVIvuy3843DYMPIYTmTJiUh0WAsm+E
EFv+vM1mwOBDCKH5IzbrwdFf+s3/skYh0+atIuN0BoQQmjORMHT5pd1IjdRIXt7h
kyV6LoozBh9CCM2dNPK2GjYDyhxBorPok6WZzEN1xq5OhBCaM/kWDfkj0YuzVYgn
z2sy9+Yh+TD4EEJo/sQWiCCyCpDFWnS2dgtVxXoOyjMGH0IIzZuRZUASlmFkaL0G
AJ88ncn2Hp2D8jxt8HFmqPVtQt0InTjzvh5dnGZ6pue/OkLeHBeLwYcQQrMlcAGS
qBTZW9VSlJS2asavftR2HT4XHZ1TBR8n+cZNwyJ0/DV+VOEeHLfOD+iVMj3RE5cJ
ojFC3/IKGHwIITRLIlt1dcovey390Voh3L0tc9BIe3UMvhwRQqjfhCAj3R6U4MV1
EN2aauZNDkhM+TMGmnrGZxZ/Y51vDD6EEJopsm6rwS2J3mnsrWSJC+Fv71XbDWAY
fDnZ4hunVK8i/+KZubsqEy7W9JcXEIEnf1sifMfkf5zOgBBCs4ZpnZosxY/v6hmI
o//+4X+5eVSIyxh8OSKYkO01wfTU+Or20NUAnt6CZzdfRlcmdKbnWxnKBmGPlN94
BQw+hBCaKYxmRuA+WDUd4vliy12PhgWAR7cx+HIk5arxyzg/rZV+/xnw/s5nftg4
sUqTA7J+WX++QeXHB765TJ5+8uYrYFcnQgjNmP0lPvzxbvbF/Q7JtNLQtB54tVjH
4MsRkTH5hbFgAZ7cNRMjXXrqfnV7e0U7OyINut8ZqrGflK/3tL///huvgMGHEEIz
hWkHjuEvaGZkjUps9+4XS8R3M0Ex+HLqHp/8f8bcpP+JflAYLe8XD7xf/YkaDJtj
iSNPrPGhztNGG96c9ofBhxBCs+VwESLmLcY9PfVdL0tllXaH1Lcx+HIklcGl1m/7
xX9LoH5qxTYJ5S8scVNqaAS40NpZsQDgpqk8usyOzXxKgxC0W42N7OXip2ljoFf2
U5th8CGE0KXiMStAf7SmpyuPCmBk3cppnSRGanRdixOSGpf9Bj+wC4OPcdVkA7Dl
T0k2LI+K978AsbmaUH0cfIkJdnz/J83NDTUxJNLpOPiyRMYhT0dVIVuM8lNEZsur
ZBq2+BBC6NKFAtLyab3ch01vwQqHUXNjK+otqKrNtSu/IfvFXZ1ckg+Gn7VFpp6J
XMqOoRlRjRIQPLSZRaAwjGw48rprW8s0X/BGJuLkQ8Mk+MAuDjKWUIHBhxBClyox
j6om+B6BtL2oSj+jLHMy+sUdyFxIuXXZb/ADm2blFiajCyxSGgj458+OlknF3LIh
ISrhhKDyV2i29iKwgsEi03hKVbKp4DuuymYesPMWn3q12MIWH0IIXa7QgXCYLaem
yLiuwf1N63FFu76pOvciXb/6+/JNM7glb/GZpSBlDz8F6FaJmYj9hcm2TXzQu65W
duGdBkA/rcdU0+As2oKwaJ61+HSmWtcOBh9CCF0y35JtkdAFkZinN3sEtDBJh//+
PzmjGpyyFrArvi/fVMGnVp+mzZP80wCxug3hjs6Hb6qTPHf0u9sEnt2EFy2S3/sD
ERn6r28Sw43zdb8p7P95EBon1MXgQwihSyabfKlx+P3907q/2hOk1hFwsESMbrdU
4hROqld8X74Lgy+fgyCzqtJvHfWKWr+8t9JsQzaoTlrDg1LSXSz3Nzar3aV/3JAf
JGTw5dHG2x8lUXa2vQP56CFAsW1meI8PIYQum4jtZ98bJtz6/V8fJEsQLO0/WnfJ
yINn6wan6RXfl+/iUZ3qLzWic21HQMrsTI+cj74UauTKuBs4Y5YlRMFP9awWbxlU
03QVbbGuE23hODPVDUJ5BaY5fbPnBAYGH0IIXapBKY2KSSXYXz75jz85bh63gPiu
7xHrt/eOFuDx3eSK78s3TVdnmhJTphgTol+JR3XQWWm3eLZxIe3UgBipHQHceK4x
xojq6eQ8U1dsnTLZWuRgEMZKWQCJwTgGH0IIXbLdlkkWNoHs3hIi0GyuLf/TkiEL
/pOWcGxIVYNPFv+3bDR3JVwYfBklIuNULwSUQWqc1gUhhj7qViYHaIHbWQ3v/t2a
av7pJInzUZ1qtOfxbS580HUhc5NklWMoGW3RLWLwIYTQpcraNW46B7XYIubDm/KJ
UUHmXDxswsih2SBduOw3+IFdGHyJrrozBTGgdpSyArQ9x4617OURLCyo9W/CSC86
xhACLR/VqXYu+vmnbv6BQe3WJ07+ZFeAT20c3IIQQpfPgJRpg2vbRTjWzOJpo/mo
lukksvbDDS0bd3Re2Up98eCWfK4CgJuoe3qj0aL81YARHKxNDjhchH8u3sofPrlD
WtXfUP18rz7gfVqWsQk6ZDqVp4tRAYMPIYQuF2dRuCAg9avlL3mpCJCqbs5+2a+m
x8kKfHFn0tWpXXypb6Up7vExpvbTo6VBAoM6vGh5lb6eQjw5IJ/hn8aHt766Ddt/
dqRGdebBFzqnJcFtSHWeCEOGnwvgjSJCMfgQQuiSZQt0+6vPgLZrMPAoeXqzc/9w
t64ZC1t2ZA9KF1/gW+3i4BMJU3PSNag+bg4tNWKTNNodUpgckA5qxmjvLkC70ecb
aXjW1ZnJ+ONqmz75RU2HAMft4O4MCCF0+QalxPrqlhq8MhTFTg0CN3Dbi9lR1SSL
L47Xvrp1lecywFT78aWgUc7t9Z21XxWdMHC8hSORmGejOk+aQWEQ1gZGqVfp3lx6
GE0Gt3Cm2oL8tKZBCgaIbl3PSscWBh9CCF2yQenhX5VfgJu00hPKy30ghNc6UOlV
u852QS1JqeavC5jbrs6Ec6pDkpbIyh4LDAv8Zrj4zEjOVm6h7va62tiJnzZf3GaE
hpPpDPppvVOSrb5Uh5So5aqLUdZ8UKcYfAghdMlkre5W4bRo+h4PCoF73HpyR/XT
tRuhZu6uXO2VOqdauYVnDHRNxlmrkz66G3q3noJoN0AkFimcmjxtDQh/cR2OW1Sz
fBETqr1yIdyIFiGEZoxMPhBZviSnrNEmcMZkqTbyO1Wc8dfr+BUzxT0+Lrj8PTz8
ofpxo12KUn17EX63Uo7KZeiduMZCnCXFIawPu/JyX96glGLwIYTQ7OJqqRFgzMhX
5BRCG28mAKHKO1nvjdfr+BUzzX58hGZh1NpdJXe3IgC1O9EuWQEICrXT+otiJFyn
eAx2BE12elA2Xl/iDYMPIYRmC1djDjkX+fZysjJPdtHh6oF8qF/tpTqnGdySUUNE
YbQCp41K7zu/A3GSLcGz9a1b8oRUGNCtAinHjd2NzVNR9Iuvr/CmdjWiGHwIITQ7
1CgNITIZfGrQfd6tJ5/ygMmCTa74Sp1TBV9ELY0lju+So4VRVtAPlqK9G1yD7fXU
yPTQor53CnXoOaM69Mv89c8JGHwIITRTUlC7hcuaP+nSlGWaq+BzecZkDafGlW7v
TRN8LAFDBzhYSswwKWfdcpxV4atbHUd48gODD8WBq3ZX75d9byg8rr9+FezqRAih
mSLDTTBBKCN5gw+YLMokf6S6P6/2XnzKFCu3TGJK/h3Zql8T+k7myifkdztrqTDz
2Y/HVnmU1NQ0hrPrnr8CBh9CCM2iSQ9dvnncW3ZiuLKVeprgy8NLT43IDsHpl+Wn
A43FtlAz0zVmDFxmHSyBDD8hmMG0s+uevwIGH0IIzRIuy7DaI27SqhFUrcgsyGST
VYA36vgVM13w/Ve9AgYfQgih2YHBhxBCaK5g8CGEEJor30Tw4XQGhBBCMwODDyGE
0FzBrk6EEEJzBYMPIYTQXMHgQwghNFcw+BBCCM0VDD6EEEJzBYMPIYTQXMHpDAgh
hOYKBh9CCKG5gl2dCCGE5goGH0IIobmCwYcQQmiuYPAhhBCaKxh8CCGE5goGH0II
obmC0xkQQgjNFQw+hBBCcwW7OhFCCM0VDD6EEEJzBYMPIYTQXMHgQwghNFcw+BBC
CM0VDD6EEEJzBaczIIQQmisYfAghhOYKdnUihBCaKxh8CCGE5goGH0IIobkydfBx
oOOvNP+GkLPzv34xMTnolVfA4EMIITQ7/qgWn1DJRsannZ//6tXe8goYfAghhGbH
H9fVKTNMOz9x2lfA4EMIITQ7/gX3+HjezcnJa4cL8bKbU550/lOczoAQQmiGTB18
DMZHEJ4RQ36fEfrq8ZxTGWlMy2MPgw8hhNBsmjr4hAwwxrkopSkxNRAq+F45QQai
TrLUVBd6ZcQLdnUihBCaHdN3dQqZe4yLYpwQ2wCWUfpqk4+lYEAaO0BfbQti8CGE
EJoh07f48h5MmWFRTG0TGCNUezX4EtAhiV1CNAw+hBBCs2qa4Mtn7aXGiLq7qztO
46jOzb/7fv2VESxSbJ3aHohhkQimAx9fTqi/M0Z0isGHEEJoFlwYfPws3k6aO8Zi
4KqH3eH6ayNYpMAdFuHLj4YeFVx7LfjAwOBDCCE0Ey4MvoyMZymIpLOUH0BfNB2A
F+vk1TMGpc0NAmbs25qa2MDPfjQOPl3D4EMIITQLLm7xjVdqEYSMis2TTx64adov
bcWLDpmMYRGyVUc41yG2wQlFqOvjaX55m5CojOMZaBrB4EMIITQDphrcIjgXWtSq
7mmy7ZaBnvpeltHJ4BbBQAPGrMON+7+uD9sWUD3v4pwMamEyFZlQB2PwIYQQunxT
BJ9gXD4wC4V+2h8tCAqNtjhYCqiugk8Q2Z5T8/fiKiFW1NwjGbHydV14PnGdppRy
xinVMfgQQgjNgIu7OlnGQdPz2eoCTpoAlb6WBe5Iy/s0OWUp0UmaFAksd689Gngx
OACMyhNl8Gk0oZp8RKiBwYcQQmgGXBh8sQw+alpwuPTxQxGGZmFULBt7XWprxiT4
EmKQJFmIyscW0ft2CO7Xgy+WQZfJBqCJwYcQQmgGXBh8TPCMUVNvjiIx8hILZOsN
aGhmNN+Yj+tb18An2adBW4w24igAQieLVQ9KB8m1L+4DxCEzTFsrDKqd3VUMPoQQ
Qpfp4nt8gjMZfHlPZ6KdigUAA2igJfmgTiEGNejb1sEyrD43iHH7F/ZksOehmzTk
l15RDY2hagK7ejVOMfgQQghdpmlGdWacGFD0Zci5kSWEqREYmtr54ce0cbyw4Pxj
g9UhEJPtilS0HcbXfIcLoGoPv3/+t736jgDfxOBDCCF0iaYJPsZk8C31Q94vC+qD
YxAx0LVJj+bhIsDpguBPbgeuLnhoTSb3UfHkP2wZ/Wp3cqGPvoTWMSciw+BDCCF0
iS6+x0eAM9CpxkGkxoBaRC8Q0dd6uqETlrECPI6+Q6DS7Q3WiWUMxfmEd7BjgNqQ
CU0X8pGKQBzcghBC6JJdGHwpJWr6uiZTTAy8yOTEdCgMtKGma8BSVupVgJT5k7IF
O3fd7nlX56iYmgCVxlNQXZ2Mw7XuoDD0PQw+hBBCl+niFp/aVh0oWewmwbBGqQ+2
QcnQpEJwtVpZUO5XNg4OS3RYBGLUf1s/341v899t90HP8gVeCL32CMA6tXQMPoQQ
Qpdpuv34ZFCZKYjQCQ0mLIPSkQ4QJVwzdH1QvvksNuHJnaNKM41EOpnOkJjQce3U
SHUCqWwx7n2vw+xTN6YYfAghhC7RFMHHooS6Rr5wy9HCb77fqZlpcafMdjYgdMDv
reisfkpXt8FMzER3h7IZ2Kv4HgjGhJrALsOvX44MXKsTIYTQLLg4+HiUUcMk9a4Q
u4vchO11N1x6GmulsLv85A70LQeqQaxxRxuqFaxb4QCYFtlqiU9BNDosBe5JY6S5
GHwIIYRmwMXBl4ZgWQC//d7aju/uawtAajf+4bQkSAECk2iw86Nt0Bg4IZQGN54T
uvCTVQ94aoEKPkoiNzV65YhaGHwIIYRmwMXBxxJhGOoREP7wI7K3cu9xvtVeuHNn
e93vVrx2U35j+iUQblTqQ2ok+qgEajkzUDv16cBjWwjs6kQIITQLphncwjNh0JNP
jwD63WtQ6S8cDQtp2luOXedFUwYdHC6OCrHoeUu+NzqyC6BlunxWCKFGheokIMTM
cJFqhBBCs2CqUZ0pMzR4+h/6OxubAEsHMIrMYuD6BQDKuoNrwGmXm0WAKhttrkOc
WtwaX1yA0AB8J7E5xeBDCCE0A6abziC1G93rcUScwAtjvVPcXu6sNNulUWimxgBK
+SG7a2CHQ5AJCPxkIb+6UME3KkS2msqHwYcQQujSTTGqk493Wh8WR0VoHdf8hxv5
LTyWUHv1l0u7dkPt26BrvQr88Hn7pKEm8NXOri4Eycx2rV9NsKsTIYTQLJi6xQeQ
MdB0+TVflIxPNt2DQC1dpr7nCTGJWtCanK/dMn4FLkA9g8GHEEJoBkwffELtqE5p
yNQkBc49ocg2nabnO9KSPOE0mqqUw+BDCCE0o6YOPpVxedJNgs8U+WKdwszXIJNP
6yAibpgZyCYfBh9CCKEZNXXwcfljzhl3OCeaDD5d5Z5MPmPSsckp8JTJFJTXeeVC
gquWIgYfQgihmTB18DGZXYJl3JoEn5mfrfbdm5wmGFDIMgdeuw4GH0IIoRkyfYsv
H9LCuCmDjxLBjPHpL08Smdp3L3bfeAXs6kQIITQ7/ohRnfnh5wfxt54guPbmUxh8
CCGEZsYfGXzKuO0ns4t+/dlE9X1y+sbRGHwIIYRmyb8g+P7YV8DgQwghNDsw+BBC
CM0VDD6EEEJz5ZsIPpzOgBBCaGZg8CGEEJor2NWJEEJorlwUfP8/xbvNoEM2QKkA
AAAASUVORK5CYII=">
<img style="position:absolute;top:365pt;left:98pt;width:442pt;height:118pt" src="data:image/png;base64,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">
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">127</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:303pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 14</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Efficacy Response in Placebo-Controlled Period for Study nr-axSpA II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:74pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Double-Blind</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:74pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Response at Week 68</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:386pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:10.08pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:389pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:10.08pt">N=153</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:477pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:10.08pt">Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:480pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:10.08pt">N=152</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:116pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a,b</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">47.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">70.4%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:130pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a,b</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.8%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:143pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Partial Remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">26.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:474pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">42.1%**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASDAS</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Inactive Disease</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">57.2%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Partial Flare</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40.8%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Assessment of SpondyloArthritis international Society</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Baseline is defined as open label baseline when patients have active disease.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Ankylosing Spondylitis Disease Activity Score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Partial flare is defined as ASDAS &#x2265; 1.3 but &lt; 2.1 at 2 consecutive visits.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">***, ** Statistically significant at p &lt; 0.001 and &lt; 0.01, respectively, for all comparisons between </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira and placebo.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Psoriatic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira, 40 mg every other week, was studied in patients with moderately to severely active psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis in two placebo-controlled studies, PsA studies I and II.  PsA study I with 24 week duration, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated 313 adult patients who had an inadequate response to non-steroidal anti-inflammatory drug therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and of these, approximately 50% were taking methotrexate. PsA study II with 12-week duration, treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">100 patients who had an inadequate response to DMARD therapy. Upon completion of both studies, 383 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients enrolled in an open-label extension study, in which 40 mg Humira was administered every other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is insufficient evidence of the efficacy of Humira in patients with ankylosing spondylitis-like </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriatic arthropathy due to the small number of patients studied. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 15</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:155pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">ACR Response in Placebo-Controlled Psoriatic Arthritis Studies</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:258pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(Percent of Patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:256pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PsA Study I</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:387pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PsA Study II</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:132pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:233pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:235pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:299pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:301pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=151</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:365pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:370pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=49</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:437pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=51</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:132pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:240pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:301pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:372pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:437pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:240pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:301pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">57%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N/A</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:440pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N/A</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:132pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:243pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:301pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:375pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:434pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:243pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:301pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N/A</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:440pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N/A</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:132pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:243pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:301pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:375pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:436pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14%</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:243pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:301pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N/A</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:440pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N/A</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:132pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.001 for all comparisons between Humira and placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:132pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.05 for all comparisons between Humira and placebo  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:132pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N/A  not applicable</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR responses in PsA study I were similar with and without concomitant methotrexate therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR responses were maintained in the open-label extension study for up to 136 weeks.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">128</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Radiographic changes were assessed in the psoriatic arthritis studies. Radiographs of hands, wrists, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">feet were obtained at baseline and Week 24 during the double-blind period when patients were on Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or placebo and at Week 48 when all patients were on open-label Humira. A modified Total Sharp Score </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(mTSS), which included distal interphalangeal joints (i.e. not identical to the TSS used for rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis), was used.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treatment reduced the rate of progression of peripheral joint damage compared with placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment as measured by change from baseline in mTSS  (mean &#xb1; SD) 0.8 &#xb1; 2.5 in the placebo group (at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24) compared with 0.0 &#xb1; 1.9; (p&lt; 0.001) in the Humira group (at Week 48).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In subjects treated with Humira with no radiographic progression from baseline to Week 48 (n=102), 84% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued to show no radiographic progression through 144 weeks of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treated patients demonstrated statistically significant improvement in physical function as assessed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">by HAQ and Short Form Health Survey (SF 36) compared to placebo at Week 24. Improved physical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">function continued during the open label extension up to Week 136.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were studied in adult patients with chronic plaque psoriasis (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 10% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BSA involvement and Psoriasis Area and Severity Index (PASI) </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 12 or</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 10) who were candidates for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">systemic therapy or phototherapy in randomised, double-blind studies. 73% of patients enrolled in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Studies I and II had received prior systemic therapy or phototherapy. The safety and efficacy of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira were also studied in adult patients with moderate to severe chronic plaque psoriasis with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant hand and/or foot psoriasis who were candidates for systemic therapy in a randomised double-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blind study (Psoriasis Study III).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Study I (REVEAL) evaluated 1,212 patients within three treatment periods. In period A, patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received placebo or Humira at an initial dose of 80 mg followed by 40 mg every other week starting one </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">week after the initial dose. After 16 weeks of therapy, patients who achieved at least a PASI 75 response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(PASI score improvement of at least 75% relative to baseline), entered period B and received open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg Humira every other week. Patients who maintained </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75 response at Week 33 and were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">originally randomised to active therapy in Period A, were re-randomised in period C to receive 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira every other week or placebo for an additional 19 weeks. Across all treatment groups, the mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">baseline PASI score was 18.9 and the baseline Physician&#x2019;s Global Assessment (PGA) score ranged from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x201c;moderate&#x201d; (53% of subjects included) to &#x201c;severe&#x201d; (41%) to &#x201c;very severe&#x201d; (6%).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Study II (CHAMPION) compared the efficacy and safety of Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> methotrexate and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo in 271 patients. Patients received placebo, an initial dose of MTX 7.5 mg and thereafter dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increases up to Week 12, with a maximum dose of 25 mg or an initial dose of 80 mg Humira followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week (starting one week after the initial dose) for 16 weeks. There are no data available </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparing Humira and MTX beyond 16 weeks of therapy. Patients receiving MTX who achieved a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 50 response at Week 8 and/or 12 did not receive further dose increases. Across all treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">groups, the mean baseline PASI score was 19.7 and the baseline PGA score ranged from &#x201c;mild&#x201d; (&lt;1%) to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x201c;moderate&#x201d; (48%) to &#x201c;severe&#x201d; (46%) to &#x201c;very severe&#x201d; (6%).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients participating in all Phase 2 and Phase 3 psoriasis studies were eligible to enrol into an open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension trial, where Humira was given for at least an additional 108 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Psoriasis Studies I and II, a primary endpoint was the proportion of patients who achieved a PASI 75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response from baseline at Week 16 (see Tables 16 and 17).</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">129</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 16</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:180pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Ps Study I (REVEAL)  - Efficacy Results at 16 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:303pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:306pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=398</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:307pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:376pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:405pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=814</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    </span></b><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PASI 75</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:304pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">26 (6.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">578 (70.9)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    PASI 100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 (0.8)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">163 (20.0)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    PGA: Clear/minimal</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:304pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17 (4.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">506 (62.2)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Percent of patients achieving PASI75 response was calculated as centre-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adjusted rate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p&lt;0.001, Humira vs. Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 17</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:176pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Ps Study II (CHAMPION) Efficacy Results at 16 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:235pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:240pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=53</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:240pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:315pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:313pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=110</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:315pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:406pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=108</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:408pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:135pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    </span></b><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PASI 75</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:233pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 (18.9)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39 (35.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">86 (79.6)</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a, b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:135pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    PASI 100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:238pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 (1.9)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:314pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8 (7.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18 (16.7)</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c, d</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:135pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    PGA: </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:135pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Clear/minimal</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 (11.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33 (30.0)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">79 (73.1)</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a, b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:135pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p&lt;0.001 Humira vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:135pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p&lt;0.001 Humira vs. methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:135pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p&lt;0.01 Humira vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:135pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p&lt;0.05 Humira vs. methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Psoriasis Study I, 28% of patients who were PASI 75 responders and were re-randomised to placebo at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 33 compared to 5% continuing on Humira, p&lt;0.001, experienced &#x201c;loss of adequate response&#x201d; (PASI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score after Week 33 and on or before Week 52 that resulted in a &lt;PASI 50 response relative to baseline </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with a minimum of a 6-point increase in PASI score relative to Week 33). Of the patients who lost </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adequate response after re-randomisation to placebo who then enrolled into the open-label extension trial, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38% (25/66) and 55% (36/66) regained PASI 75 response after 12 and 24 weeks of re-treatment, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A total of 233 PASI 75 responders at Week 16 and Week 33 received continuous Humira therapy for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52 weeks in Psoriasis Study I, and continued Humira in the open-label extension trial.  PASI 75 and PGA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of clear or minimal response rates in these patients were 74.7% and 59.0%, respectively, after an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">additional 108 weeks of open-label therapy (total of 160 weeks). In an analysis in which all patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dropped out of the study for adverse events or lack of efficacy, or who dose-escalated, were considered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">non-responders, PASI 75 and PGA of clear or minimal response rates in these patients were 69.6% and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">55.7%, respectively, after an additional 108 weeks of open-label therapy (total of 160 weeks).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A total of 347 stable responders participated in a withdrawal and retreatment evaluation in an open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension study. During the withdrawal period, symptoms of psoriasis returned over time with a median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">time to relapse (decline to PGA &#x201c;moderate&#x201d; or worse) of approximately 5 months. None of these patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced rebound during the withdrawal period. A total of 76.5% (218/285) of patients who entered the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">retreatment period had a response of PGA &#x201c;clear&#x201d; or &#x201c;minimal&#x201d; after 16 weeks of retreatment, irrespective </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of whether they relapsed during withdrawal (69.1%[123/178] and 88.8% [95/107] for patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">relapsed and who did not relapse during the withdrawal period, respectively).  A similar safety profile was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed during retreatment as before withdrawal.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">130</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Significant improvements at Week 16 from baseline compared to placebo (Studies I and II) and MTX </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(Study II) were demonstrated in the DLQI (Dermatology Life Quality Index). In Study I, improvements in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the physical and mental component summary scores of the SF-36 were also significant compared to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an open-label extension study, for patients who dose escalated from 40 mg every other week to 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly due to a PASI response below 50%, 26.4% (92/349) and 37.8% (132/349) of patients achieved </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75 response at Week 12 and 24, respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Study III (REACH) compared the efficacy and safety of Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo in 72 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with moderate to severe chronic plaque psoriasis and hand and/or foot psoriasis. Patients received an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initial dose of 80 mg Humira followed by 40 mg every other week (starting one week after the initial dose) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or placebo for 16 weeks. At Week 16, a statistically significantly greater proportion of patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received Humira achieved PGA of &apos;clear&apos; or &apos;almost clear&apos; for the hands and/or feet compared to patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who received placebo (30.6% versus 4.3%, respectively [P = 0.014]).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Study IV compared efficacy and safety of Humira versus placebo in 217 adult patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">moderate to severe nail psoriasis. Patients received an initial dose of 80 mg Humira followed by 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every other week (starting one week after the initial dose) or placebo for 26 weeks followed by open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treatment for an additional 26 weeks. Nail psoriasis assessments included the Modified Nail </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Severity Index (mNAPSI), the Physician&#x2019;s Global Assessment of Fingernail Psoriasis (PGA-F) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and the Nail Psoriasis Severity Index (NAPSI) (see Table 18). Humira demonstrated a treatment benefit in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">nail psoriasis patients with different extents of skin involvement (BSA&#x2265;10% (60% of patients) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BSA&lt;10% and &#x2265;5% (40% of patients)).    </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 18</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:183pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Ps Study IV Efficacy Results at 16, 26 and 52 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Endpoint</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:245pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 16</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:222pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo-Controlled</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:360pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 26</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo-Controlled</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:473pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Open-label</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:216pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:218pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=108</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:275pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:267pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg eow </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:276pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=109</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:332pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=108</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:387pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg eow </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:389pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=109</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg eow </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:480pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=80</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; mNAPSI 75 (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">26.0</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:341pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:393pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46.6</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:483pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PGA-F clear/minimal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265;2-grade improvement (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29.7</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:341pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:393pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">48.9</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:483pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">61.3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Percent Change in Total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fingernail NAPSI (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:224pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-7.8</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:278pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-44.2</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-11.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-56.2</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:481pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-72.2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p&lt;0.001, Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">vs.</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treated patients showed statistically significant improvements at Week 26 compared with placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in the DLQI. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Hidradenitis suppurativa</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in randomised, double-blind, placebo-controlled studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and an open-label extension study in adult patients with moderate to severe hidradenitis suppurativa (HS) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who were intolerant, had a contraindication or an inadequate response to at least a 3-month trial of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">systemic antibiotic therapy. The patients in HS-I and HS-II had Hurley Stage II or III disease with at least </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 abscesses or inflammatory nodules.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study HS-I (PIONEER I) evaluated 307 patients with 2 treatment periods. In Period A, patients received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo or Humira at an initial dose of 160 mg at Week 0, 80 mg at Week 2, and 40 mg every week </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">131</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting at Week 4 to Week 11. Concomitant antibiotic use was not allowed during the study.  After </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 weeks of therapy, patients who had received Humira in Period A were re-randomised in Period B to 1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of 3 treatment groups (Humira 40 mg every week, Humira 40 mg every other week, or placebo from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 12 to Week 35). Patients who had been randomised to placebo in Period A were assigned to receive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg every week in Period B.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study HS-II (PIONEER II) evaluated 326 patients with 2 treatment periods. In Period A, patients received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo or Humira at an initial dose of 160 mg at Week 0 and 80 mg at Week 2 and 40 mg every week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting at Week 4 to Week 11. 19.3% of patients had continued baseline oral antibiotic therapy during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study. After 12 weeks of therapy, patients who had received Humira in Period A were re-randomised in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Period B to 1 of 3 treatment groups (Humira 40 mg every week, Humira 40 mg every other week, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo from Week 12 to Week 35). Patients who had been randomised to placebo in Period A were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assigned to receive placebo in Period B.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients participating in Studies HS-I and HS-II were eligible to enrol into an open-label extension study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in which Humira 40mg was administered every week. Mean exposure in all adalimumab population was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">762 days. Throughout all 3 studies patients used topical antiseptic wash daily.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Clinical Response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reduction of inflammatory lesions and prevention of worsening of abscesses and draining fistulas was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assessed using Hidradenitis Suppurativa Clinical Response (HiSCR; at least a 50% reduction in total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">abscess and inflammatory nodule count with no increase in abscess count and no increase in draining </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fistula count relative to Baseline). Reduction in HS-related skin pain was assessed using a Numeric Rating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Scale in patients who entered the study with an initial baseline score of 3 or greater on a 11 point scale. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 12, a significantly higher proportion of patients treated with Humira versus placebo achieved </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HiSCR.   At Week 12, a significantly higher proportion of patients in Study HS-II experienced a clinically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">relevant decrease in HS-related skin pain (see Table 19). Patients treated with Humira had significantly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reduced risk of disease flare during the initial 12 weeks of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:174pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 19:  Efficacy Results at 12 Weeks, HS Studies I and II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:269pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HS Study I</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:428pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HS Study II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:233pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:297pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:313pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weekly</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:392pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:457pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:474pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weekly</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hidradenitis Suppurativa </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical Response (HiSCR)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:233pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 154</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:227pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 (26.0%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:313pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 153</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:303pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64 (41.8%) </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:395pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=163</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:385pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45 (27.6%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=163</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:460pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">96 (58.9%) </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265;30% Reduction in Skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pain</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:233pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 109</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:227pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">27 (24.8%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:313pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 122</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34 (27.9%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:395pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=111</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:385pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23 (20.7%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=105</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:460pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">48 (45.7%) </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">* </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">P</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> &lt; 0.05, ***</span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">P </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001, Humira versus placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">a</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among all randomised patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">b</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients with baseline HS-related skin pain assessment &#x2265; 3, based on Numeric Rating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Scale 0 &#x2013; 10; 0 = no skin pain, 10 = skin pain as bad as you can imagine.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Humira 40 mg every week significantly reduced the risk of worsening of abscesses and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:647pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">draining fistulas. Approximately twice the proportion of patients in the placebo group in the first 12 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of Studies HS-I and HS-II, compared with those in the Humira group experienced worsening of abscesses </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(23.0% vs 11.4%, respectively) and draining fistulas (30.0% vs 13.9%, respectively).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Greater improvements at Week 12 from baseline compared to placebo were demonstrated in skin-specific </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">health-related quality of life, as measured by the Dermatology Life Quality Index (DLQI; Studies HS-I </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">132</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and HS-II), patient global satisfaction with medication treatment as measured by the Treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Satisfaction Questionnaire - medication (TSQM; Studies HS-I and HS-II), and physical health as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">measured by the physical component summary score of the SF-36 (Study HS-I).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with at least a partial response to Humira 40 mg weekly at Week 12, the HiSCR rate at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 36 was higher in patients who continued weekly Humira than in patients in whom dosing frequency </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was reduced to every other week, or in whom treatment was withdrawn (see Table 20).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:109pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 20:</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:154pt;left:184pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Proportion of Patients</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Achieving HiSCR</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b </span></b></sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">at Weeks 24 and 36 After </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:181pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Treatment Reassignment from Weekly Humira at Week 12</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:220pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(treatment </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:217pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">withdrawal)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:230pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 73</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:310pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:305pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">every other week</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:329pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 70</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:406pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:424pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">weekly</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:425pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 70</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:130pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:221pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 (32.9%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36 (51.4%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 (57.1%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:130pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 36</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:221pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22 (30.1%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28 (40.0%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39 (55.7%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:130pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">a</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:142pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients with at least a partial response to Humira 40 mg weekly after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:142pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 weeks of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:130pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">b</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:143pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients meeting protocol-specified criteria for loss of response or no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:143pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement were required to discontinue from the studies and were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:143pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">counted as nonresponders.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients who were at least partial responders at Week 12, and who received continuous weekly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira therapy, the HiSCR rate at Week 48 was 68.3% and at Week 96 was 65.1%. Longer term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment with Humira 40 mg weekly for 96 weeks identified no new safety findings.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients whose Humira treatment was withdrawn at Week 12 in Studies HS-I and HS-II, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HiSCR rate 12 weeks after re-introduction of Humira 40 mg weekly returned to levels similar to that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed before withdrawal (56.0 %).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Crohn&#x2019;s disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in over 1500 patients with moderately to severely active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Crohn&#x2019;s disease (Crohn&#x2019;s Disease Activity Index (CDAI) </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 220 and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 450) in randomised, double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:500pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo-controlled studies. Concomitant stable doses of aminosalicylates, corticosteroids, and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunomodulatory agents were permitted and 80% of patients continued to receive at least one of these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">medications. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Induction of clinical remission (defined as CDAI &lt; 150) was evaluated in two studies, CD Study I </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(CLASSIC I) and CD Study II (GAIN). In CD Study I, 299 TNF-antagonist naive patients were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised to one of four treatment groups; placebo at Weeks 0 and 2, 160 mg Humira at Week 0 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg at Week 2, 80 mg at Week 0 and 40 mg at Week 2, and 40 mg at Week 0 and 20 mg at Week 2. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">CD Study II, 325 patients who had lost response or were intolerant to infliximab were randomised to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receive either 160 mg Humira at Week 0 and 80 mg at Week 2 or placebo at Weeks 0 and 2. The primary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">non-responders were excluded from the studies and therefore these patients were not further evaluated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Maintenance of clinical remission was evaluated in CD study III (CHARM).  In CD Study III, 854 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received open-label 80 mg at Week 0 and 40 mg at Week 2. At Week 4 patients were randomised to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week, 40 mg every week, or placebo with a total study duration of 56 weeks. Patients in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical response (decrease in CDAI &#x2265; 70) at Week 4 were stratified and analysed separately from those </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">not in clinical response at Week 4. Corticosteroid taper was permitted after Week 8. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">133</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">CD study I and CD study II induction of remission and response rates are presented in Table 21.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:281pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 21</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:193pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Induction of Clinical Remission and Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:111pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(Percent of Patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:128pt;left:191pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CD Study I: Infliximab Naive </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:140pt;left:191pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patients</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:128pt;left:372pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CD Study II: Infliximab </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:140pt;left:372pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Experienced Patients</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:197pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:203pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=74</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:258pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:255pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">80/40 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:261pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 75</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:318pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:313pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">160/80 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:324pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=76</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:385pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:388pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=166</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:468pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:462pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">160/80 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:471pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=159</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:201pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:205pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:266pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:217pt;left:325pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:217pt;left:475pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">21%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response (CR-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">100)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:205pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:266pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">37%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">**</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:394pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:473pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">**</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All p-values are pairwise comparisons of proportions for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.01</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Similar remission rates were observed for the 160/80 mg and 80/40 mg induction regimens by Week 8 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adverse events were more frequently noted in the 160/80 mg group.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In CD Study III, at Week 4, 58% (499/854) of patients were in clinical response and were assessed in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">primary analysis. Of those in clinical response at Week 4, 48% had been previously exposed to other TNF-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antagonists. Maintenance of remission and response rates are presented in Table 22.  Clinical remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">results remained relatively constant irrespective of previous TNF-antagonist exposure.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Disease-related hospitalisations and surgeries were statistically significantly reduced with adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared with placebo at Week 56.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">134</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:281pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 22</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maintenance of Clinical Remission and Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:86pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(Percent of Patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:283pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:359pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">40 mg Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:115pt;left:353pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">every other week</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:450pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">40 mg Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:115pt;left:458pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">every week</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 26</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:286pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=170</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:378pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=172</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:468pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=157</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:291pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">47%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:164pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response (CR-100)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:164pt;left:291pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">27%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:164pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:164pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:180pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in steroid-free remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:192pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for &gt;=90 days</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:279pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3% (2/66)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:360pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">19% (11/58)**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15% (11/74)**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 56</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:286pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=170</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:378pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=172</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:468pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=157</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:291pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response (CR-100)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:291pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">48%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in steroid-free remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for &gt;=90 days</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:279pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5% (3/66)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:363pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29% (17/58)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20% (15/74)**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.001 for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo pairwise comparisons   of proportions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">** p &lt; 0.02 for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo pairwise comparisons of proportions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of those receiving corticosteroids at baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients who were not in response at Week 4, 43% of Humira maintenance patients responded by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 12 compared to 30% of placebo maintenance patients. These results suggest that some patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have not responded by Week 4 benefit from continued maintenance therapy through Week 12. Therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued beyond 12 weeks did not result in significantly more responses (see section 4.2).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">117/276 patients from CD study I and 272/777 patients from CD studies II and III were followed through </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at least 3 years of open-label adalimumab therapy. 88 and 189 patients, respectively, continued to be in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical remission. Clinical response (CR-100) was maintained in 102 and 233 patients, respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of life</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In CD Study I and CD Study II, statistically significant improvement in the disease-specific inflammatory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bowel disease questionnaire (IBDQ) total score was achieved at Week 4 in patients randomised to Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80/40 mg and 160/80 mg compared to placebo and was seen at Weeks 26 and 56 in CD Study III as well </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">among the adalimumab treatment groups compared to the placebo group.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Ulcerative colitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of multiple doses of Humira were assessed in adult patients with moderately to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">severely active ulcerative colitis (Mayo score 6 to 12 with endoscopy subscore of 2 to 3) in randomised, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">double-blind, placebo-controlled studies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:621pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study UC-I, 390 TNF-antagonist na&#xef;ve patients were randomised to receive either placebo at Weeks 0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and 2, 160 mg Humira at Week 0  followed by 80 mg at Week 2,  or 80 mg Humira at Week 0  followed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">by 40 mg at Week 2. After Week 2, patients in both adalimumab arms received 40 mg eow. Clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission (defined as Mayo score &#x2264; 2 with no subscore &gt; 1) was assessed at Week 8. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study UC-II, 248 patients received 160 mg of Humira at Week 0, 80 mg at Week 2 and 40 mg eow </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">thereafter, and 246 patients received placebo. Clinical results were assessed for induction of remission at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 8 and for maintenance of remission at Week 52. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">135</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients induced with 160/80 mg Humira achieved clinical remission versus placebo at Week 8 in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">statistically significantly greater percentages in study UC-I (18% vs. 9% respectively, p=0.031) and study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">UC-II (17% vs. 9% respectively, p=0.019). In study UC-II, among those treated with Humira who were in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission at Week 8, 21/41 (51%) were in remission at Week 52.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Results from the overall UC-II study population are shown in Table 23.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:153pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 23</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:169pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Response, Remission and Mucosal Healing in Study UC-II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:192pt;left:258pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(Percent of Patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:318pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:384pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:410pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:320pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=246</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:404pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=248</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Clinical Response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:403pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   30%</span><span style="font-family:TimesNewRoman,serif;font-size:10.08pt">*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Clinical Remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:402pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   17%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Mucosal Healing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:402pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   25%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Steroid-free remission for &#x2265; 90 days</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:317pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N=140)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:398pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     13% *</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:400pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N=150)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 8 and 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Sustained Response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:357pt;left:400pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   24%**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Sustained Remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   8%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Sustained Mucosal Healing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">11%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:404pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  19%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission is Mayo score &#x2264; 2 with no subscore &gt; 1;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response is decrease from baseline in Mayo score &#x2265;3 points and &#x2265;30% plus a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">decrease in the rectal bleeding subscore [RBS] &#x2265;1 or an absolute RBS of 0 or 1;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:7.92pt">*</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p&lt;0.05 for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">vs.</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo pairwise comparison of proportions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:10.08pt">**</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p&lt;0.001 for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">vs.</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo pairwise comparison of proportions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Of those receiving corticosteroids at baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of those patients who had a response at Week 8, 47% were in response, 29% were in remission, 41% had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mucosal healing, and 20% were in steroid-free remission for &#x2265; 90 days at Week 52.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Approximately 40% of patients in study UC-II had failed prior anti-TNF treatment with infliximab. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">efficacy of adalimumab in those patients was reduced compared to that in anti-TNF na&#xef;ve patients.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients who had failed prior anti-TNF treatment, Week 52 remission was achieved by 3% on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo and 10% on adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients from studies UC-I and UC-II had the option to roll over into an open-label long-term extension </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study (UC III). Following 3 years of adalimumab therapy, 75% (301/402) continued to be in clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission per partial Mayo score. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Hospitalisation rates</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During 52 weeks of studies UC-I and UC-II, lower rates of all-cause hospitalisations and UC-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hospitalisations were observed for the adalimumab-treated arm compared to the placebo arm. The number </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of all cause hospitalisations in the adalimumab treatment group was 0.18 per patient year </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">vs</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">. 0.26 per </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">136</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient year in the placebo group and the corresponding figures for UC-related hospitalisations were 0.12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">per patient year </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">vs.</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.22 per patient year.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of life</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study UC-II, treatment with adalimumab resulted in improvements in the Inflammatory Bowel Disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Questionnaire (IBDQ) score.   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Uveitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in adult patients with non-infectious intermediate, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">posterior, and panuveitis, excluding patients with isolated anterior uveitis, in two randomised, double-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">masked, placebo-controlled studies (UV I and II). Patients received placebo or Humira at an initial dose of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg followed by 40 mg every other week starting one week after the initial dose. Concomitant stable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">doses of one non-biologic immunosuppressant were permitted. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV I evaluated 217 patients with active uveitis despite treatment with corticosteroids (oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">prednisone at a dose of 10 to 60 mg/day). All patients received a 2-week standardised dose of prednisone </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60 mg/day at study entry followed by a mandatory taper schedule, with complete corticosteroid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">discontinuation by Week 15. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV II evaluated 226 patients with inactive uveitis requiring chronic corticosteroid treatment (oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">prednisone 10 to 35 mg/day) at baseline to control their disease. Patients subsequently underwent a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mandatory taper schedule, with complete corticosteroid discontinuation by Week 19. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary efficacy endpoint in both studies was &#xb4;time to treatment failure&#xb4;. Treatment failure was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined by a multi-component outcome based on inflammatory chorioretinal and/or inflammatory retinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vascular lesions, anterior chamber (AC) cell grade, vitreous haze (VH) grade and best corrected visual </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">acuity (BCVA). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who completed Studies UV I and UV II were eligible to enroll in an uncontrolled long-term</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension study with an originally planned duration of 78 weeks. Patients were allowed to continue on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study medication beyond Week 78 until they had access to Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Clinical Response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with Humira versus patients receiving placebo (See Table 24). Both studies demonstrated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">an early and sustained effect of Humira on the treatment failure rate versus placebo (see Figure 2). </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">137</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 24</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:180pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Time to Treatment Failure in Studies UV I and UV II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:75pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Analysis</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:103pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Treatment</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:189pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:225pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Failure</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:225pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:283pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Median Time to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:283pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Failure (months)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:378pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HR</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:414pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CI 95% </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:414pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">for HR</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:472pt"><b><i><span style="font-family:TimesNewRoman,BoldItalic,serif;font-size:11.04pt">P</span></i></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> Value</span></b><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:75pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Time to Treatment Failure At or After Week 6 in Study UV I  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Primary analysis (ITT)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">107</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">84 (78.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:472pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">110</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60 (54.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.36, 0.70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:472pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:75pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Time to Treatment Failure At or After Week 2 in Study UV II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Primary analysis (ITT)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">111</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">61 (55.0)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8.3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:472pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">115</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45 (39.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NE</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.57</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.39, 0.84</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:472pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.004</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note:  Treatment failure at or after Week 6 (Study UV I), or at or after Week 2 (Study UV II), was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">counted as event. Drop outs due to reasons other than treatment failure were censored at the time of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dropping out.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">a</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HR of adalimumab vs placebo from proportional hazards regression with treatment as factor.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">b</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2-sided </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">P</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> value from log rank test.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">c</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NE = not estimable. Fewer than half of at-risk subjects had an event. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Figure 2: Kaplan-Meier Curves Summarizing Time to Treatment Failure on or after Week 6 (Study </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:233pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">UV I) or Week 2 (Study UV II)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TREATMENT FAILURE RATE (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:270pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TIME (MONTHS)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:100pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV I                        Treatment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:445pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<img style="position:absolute;top:366pt;left:100pt;width:432pt;height:174pt" src="data:image/png;base64,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">
<img style="position:absolute;top:552pt;left:291pt;width:31pt;height:14pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABcAAAAICAAAAAA3wTsyAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAR0lEQVR4nGP8z4AVMGKK/2eEioMZaDIg8X8fGRmAFEyWiYEPov75
fqAwTPQ/8z8+n39MEPP//2dk/A+V+8+EsBfDBmzuAQMAmYsaASeQxO8AAAAASUVO
RK5CYII=">
<img style="position:absolute;top:552pt;left:401pt;width:43pt;height:14pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABcAAAAGCAIAAACnwpLJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAqElEQVR4nGP8//8/A8WAEW4KkMHIyEhQA1ZlCFN+//79/ft3Pj6+
9+/f83Bzs7Cyfvz4kZ+fHygI1MTKxvblyxcBAQEgyczExMnF9eHDByAX3ZSbN2/e
vn3b29t7+fLlFhYWQON27twZHR29Y8cOUVFROTm5vXv3RkREbNu2DWi0qanJ+vUb
/Hx9gcahmAJxLUgIycHI7v/37x8TExNWKUaSQhctUOBcAGVhWfUkQWeYAAAAAElF
TkSuQmCC">
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">138</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:64pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TREATMENT FAILURE RATE (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:270pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TIME (MONTHS)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:100pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV II                       Treatment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:445pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note: P# = Placebo (Number of Events/Number at Risk); A# = HUMIRA (Number of</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Events/Number at Risk).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Study UV I statistically significant differences in favour of adalimumab versus placebo were observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for each component of treatment failure.  In Study UV II, statistically significant differences were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed for visual acuity only, but the other components were numerically in favour of adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of the 424 subjects included in the uncontrolled long-term extension of Studies UV I and UV II, 60</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subjects were regarded ineligible (e.g. due to deviations or due to complications secondary to diabetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">retinopathy, due to cataract surgery or vitrectomy) and were excluded from the primary analysis of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">efficacy. Of the 364 remaining patients, 269 evaluable patients (74%) reached 78 weeks of open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab treatment. Based on the observed data approach, 216 (80.3%) were in quiescence (no active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inflammatory lesions, AC cell grade &#x2264; 0.5+, VH grade &#x2264; 0.5+) with a concomitant steroid dose &#x2264; 7.5 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">per day, and 178 (66.2%) were in steroid-free quiescence. BCVA was either improved or maintained (&lt; 5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">letters deterioration) in 88.6% of the eyes at week 78. Data beyond Week 78 were generally consistent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with these results but the number of enrolled subjects declined after this time. Overall, among the patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who discontinued the study, 18% discontinued due to adverse events, and 8% due to insufficient response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to adalimumab treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of Life</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patient reported outcomes regarding vision-related functioning were measured in both clinical studies, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using the NEI VFQ-25. Humira was numerically favoured for the majority of subscores with statistically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significant mean differences for general vision, ocular pain, near vision, mental health, and total score in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV I, and for general vision and mental health in Study UV II. Vision related effects were not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">numerically in favour of Humira for colour vision in Study UVI and for colour vision, peripheral vision </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and near vision in Study UV II.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immunogenicity  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Formation of anti-adalimumab antibodies is associated with increased clearance and reduced efficacy of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab. There is no apparent correlation between the presence of anti-adalimumab antibodies and the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurrence of adverse events.</span></p>
<img style="position:absolute;top:78pt;left:100pt;width:432pt;height:171pt" src="data:image/png;base64,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">
<img style="position:absolute;top:263pt;left:291pt;width:31pt;height:14pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABcAAAAICAAAAAA3wTsyAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAR0lEQVR4nGP8z4AVMGKK/2eEioMZaDIg8X8fGRmAFEyWiYEPov75
fqAwTPQ/8z8+n39MEPP//2dk/A+V+8+EsBfDBmzuAQMAmYsaASeQxO8AAAAASUVO
RK5CYII=">
<img style="position:absolute;top:263pt;left:401pt;width:43pt;height:14pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABcAAAAGCAIAAACnwpLJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAqElEQVR4nGP8//8/A8WAEW4KkMHIyEhQA1ZlCFN+//79/ft3Pj6+
9+/f83Bzs7Cyfvz4kZ+fHygI1MTKxvblyxcBAQEgyczExMnF9eHDByAX3ZSbN2/e
vn3b29t7+fLlFhYWQON27twZHR29Y8cOUVFROTm5vXv3RkREbNu2DWi0qanJ+vUb
/Hx9gcahmAJxLUgIycHI7v/37x8TExNWKUaSQhctUOBcAGVhWfUkQWeYAAAAAElF
TkSuQmCC">
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">139</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in rheumatoid arthritis studies I, II and III were tested at multiple time points for anti-adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies during the 6 to 12 month period. In the pivotal trials, anti-adalimumab antibodies were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">identified in 5.5% (58/1053) of patients treated with adalimumab, compared to 0.5% (2/370) on placebo.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients not given concomitant methotrexate, the incidence was 12.4%, compared to 0.6% when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab was used as add-on to methotrexate.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with polyarticular juvenile idiopathic arthritis who were 4 to 17 years, anti-adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies were identified in 15.8% (27/171) of patients treated with adalimumab. In patients not given </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant methotrexate, the incidence was 25.6% (22/86) compared to 5.9% (5/85) when adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was used as add-on to methotrexate. In patients with polyarticular juvenile idiopathic arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 to &lt;4 years old or aged 4 and above weighing &lt;15 kg, anti-adalimumab antibodies were identified in 7% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(1/15) of patients, and the one patient was receiving concomitant methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with enthesitis-related arthritis, anti-adalimumab antibodies were identified in 10.9% (5/46) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with adalimumab. In patients not given concomitant methotrexate, the incidence was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13.6% (3/22), compared to 8.3% (2/24) when adalimumab was used as add-on to methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with psoriatic arthritis, anti-adalimumab antibodies were identified in 38/376 subjects (10%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with adalimumab. In patients not given concomitant methotrexate, the incidence was 13.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(24/178 subjects), compared to 7% (14 of 198 subjects) when adalimumab was used as add-on to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with ankylosing spondylitis anti-adalimumab antibodies were identified in 17/204 subjects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(8.3%) treated with adalimumab. In patients not given concomitant methotrexate, the incidence was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16/185 (8.6%), compared to 1/19 (5.3%) when adalimumab was used as add-on to methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with non-radiographic axial spondyloarthritis, anti-adalimumab antibodies were identified in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8/152 subjects (5.3%) who were treated continuously with adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with Crohn&#x2019;s disease, anti-adalimumab antibodies were identified in 7/269 subjects (2.6%) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in 19/487 subjects (3.9%) with ulcerative colitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with psoriasis, anti-adalimumab antibodies were identified in 77/920 subjects (8.4%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with adalimumab monotherapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult plaque psoriasis patients on long term adalimumab monotherapy who participated in a withdrawal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and retreatment study, the rate of antibodies to adalimumab after retreatment (11 of 482 subjects, 2.3%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was similar to the rate observed prior to withdrawal (11 of 590 subjects, 1.9%).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with paediatric psoriasis, anti-adalimumab antibodies were identified in 5/38 subjects (13%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with 0.8 mg/kg adalimumab monotherapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with moderate to severe hidradenitis suppurativa, anti-adalimumab antibodies were identified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in 10/99 subjects (10.1%) treated with adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with moderately to severely active paediatric Crohn&#x2019;s disease, the rate of anti-adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibody development in patients receiving adalimumab was 3.3%. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with non-infectious uveitis, anti-adalimumab antibodies were identified in 4.8% (12/249) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of patients treated with adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with moderately to severely active paediatric ulcerative colitis, the rate of anti-adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibody development in patients receiving adalimumab was 3%.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">140</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Because immunogenicity analyses are product-specific, comparison of antibody rates with those from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other products is not appropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Juvenile idiopathic arthritis (JIA)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Polyarticular juvenile idiopathic arthritis (pJIA)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira was assessed in two studies (pJIA I and II) in children with active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">polyarticular or polyarticular course juvenile idiopathic arthritis, who had a variety of JIA onset types </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(most frequently rheumatoid-factor negative or positive polyarthritis and extended oligoarthritis).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pJIA I</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:256pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in a multicentre, randomised, double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">parallel &#x2212; group study in 171 children (4-17 years old) with polyarticular JIA. In the open-label lead in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">phase (OL LI) patients were stratified into two groups, MTX (methotrexate)-treated or non-MTX-treated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who were in the non-MTX stratum were either na&#xef;ve to or had been withdrawn from MTX at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:306pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">least two weeks prior to study drug administration. Patients remained on stable doses of NSAIDs and or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">prednisone (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.2 mg /kg/day or 10 mg/day maximum). In the OL LI phase all patients received 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2 </span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">up to a maximum of 40 mg Humira every other week for 16 weeks. The distribution of patients by age </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and minimum, median and maximum dose received during the OL LI phase is presented in Table 25.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:370pt;left:287pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 25</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:104pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Distribution of patients by age and adalimumab dose received during the OL LI phase</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Age Group</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Number of patients at Baseline </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Minimum, median and maximum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 to 7 years</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">31 (18.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10, 20 and 25 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8 to 12 years</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">71 (41.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20, 25 and 40 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13 to 17 years</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">69 (40.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25, 40 and 40 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients demonstrating a Paediatric ACR 30 response at Week 16 were eligible to be randomised into the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">double blind (DB) phase and received either Humira 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2 </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">up to a maximum of 40 mg, or placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every other week for an additional 32 weeks or until disease flare. Disease flare criteria were defined as a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">worsening of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% from baseline in </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 3 of 6 Paediatric ACR core criteria, </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 2 active joints, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf03e;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% in no more than 1 of the 6 criteria.  After 32 weeks or at disease flare, patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were eligible to enrol into the open label extension phase.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">141</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:287pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 26</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:213pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Ped ACR 30 Responses in the JIA study</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Stratum</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:270pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:419pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Without MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Phase</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:123pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">OL-LI 16 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ped ACR 30 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response (n/N)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:252pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">94.1% (80/85)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">74.4% (64/86)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">                                                           Efficacy Outcomes</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Double Blind 32 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira /MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N = 38)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo / MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N = 37)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N = 30)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:461pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:461pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N = 28)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Disease flares at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the end of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">32 weeks</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n/N)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36.8% (14/38)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64.9% (24/37)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">43.3% (13/30)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:461pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">71.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:461pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(20/28)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Median time to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease flare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&gt;32 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&gt;32 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:461pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ped ACR 30/50/70 responses Week 48 significantly greater than those of placebo treated patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p = 0.015</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p = 0.031</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Amongst those who responded at Week 16 (n=144), the Paediatric ACR 30/50/70/90 responses were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintained for up to six years in the OLE phase in patients who received Humira throughout the study.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Over all 19 subjects, of which 11 of the baseline age group 4 to 12 and 8 of the baseline age group 13 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17 years were treated 6 years or longer.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Overall responses were generally better and, fewer patients developed antibodies when treated with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination of Humira and MTX compared to Humira alone. Taking these results into consideration, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is recommended for use in combination with MTX and for use as monotherapy in patients for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">whom MTX use is not appropriate (see section 4.2).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pJIA II</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira was assessed in an open-label, multicentre study in 32 children (2 -</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt;4 years old or aged 4 and above weighing &lt; 15 kg) with moderately to severely active polyarticular JIA. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The patients received 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body surface area (BSA) of Humira up to a maximum of 20 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week as a single dose via SC injection for at least 24 weeks. During the study, most subjects used </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant MTX, with fewer reporting use of corticosteroids or NSAIDs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 12 and Week 24, PedACR30 response was 93.5% and 90.0%, respectively, using the observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">data approach. The proportions of subjects with PedACR50/70/90 at Week 12 and Week 24 were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">90.3%/61.3%/38.7% and 83.3%/73.3%/36.7%, respectively. Amongst those who responded (Paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 30) at Week 24 (n=27 out of 30 patients), the Paediatric ACR 30 responses were maintained for up </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 60 weeks in the OLE phase in patients who received Humira throughout this time period. Overall, 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subjects were treated for 60 weeks or longer.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Enthesitis-related arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in a multicentre, randomised, double-blind study in 46 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients (6 to 17 years old) with moderate enthesitis-related arthritis. Patients were randomised </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to receive either 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body surface area (BSA) of Humira up to a maximum of 40 mg, or placebo </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">142</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every other week for 12 weeks. The double-blind period is followed by an open-label (OL) period during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:65pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">which patients received 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BSA of Humira up to a maximum of 40 mg every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneously for up to an additional 192 weeks. The primary endpoint was the percent change from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline to Week 12 in the number of active joints with arthritis (swelling not due to deformity or joints </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with loss of motion plus pain and/or tenderness), which was achieved with mean percent decrease of -</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">62.6% (median percent change -88.9%) in patients in the Humira group compared to -11.6% (median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">percent change -50.0%) in patients in the placebo group. Improvement in number of active joints with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis was maintained during the OL period through Week 156 for the 26 of 31 (84%) patients in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira group who remained in the study. Although not statistically significant, the majority of patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demonstrated clinical improvement in secondary endpoints such as number of sites of enthesitis, tender </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joint count (TJC), swollen joint count (SJC), Paediatric ACR 50 response, and Paediatric ACR 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Humira was assessed in a randomised, double-blind, controlled study of 114 paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients from 4 years of age with severe chronic plaque psoriasis (as defined by a PGA &#x2265; 4 or &gt; 20% BSA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">involvement or &gt; 10% BSA involvement with very thick lesions or PASI &#x2265; 20 or &#x2265; 10 with clinically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">relevant facial, genital, or hand/ foot involvement) who were inadequately controlled with topical therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and heliotherapy or phototherapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients received Humira 0.8 mg/kg eow (up to 40 mg), 0.4 mg/kg eow (up to 20 mg), or methotrexate 0.1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2013; 0.4 mg/kg weekly (up to 25 mg).   At Week 16, more patients randomised to Humira 0.8 mg/kg had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">positive efficacy responses (e.g., PASI 75) than those randomised to 0.4 mg/kg eow or MTX.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:149pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 27: Paediatric Plaque Psoriasis Efficacy Results at 16 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:300pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:301pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=37 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:385pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 0.8 mg/kg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:423pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=38 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:289pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 (32.4%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22 (57.9%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PGA: Clear/minimal</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:289pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15 (40.5%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23 (60.5%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX = methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> P=0.027, Humira 0.8 mg/kg versus MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> P=0.083, Humira 0.8 mg/kg versus MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who achieved PASI 75 and PGA clear or minimal were withdrawn from treatment for up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36 weeks and monitored for loss of disease control (i.e. a worsening of PGA by at least 2 grades).  Patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were then re-treated with adalimumab 0.8 mg/kg eow for an additional 16 weeks and response rates </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed during retreatment were similar to the previous double-blind period:  PASI 75 response of 78.9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(15 of 19 subjects) and PGA clear or minimal of 52.6% (10 of 19 subjects).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open label period of the study, PASI 75 and PGA clear or minimal responses were maintained for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">up to an additional 52 weeks with no new safety findings.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:628pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adolescent hidradenitis suppurativa</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There are no clinical trials with Humira in adolescent patients with HS. Efficacy of adalimumab for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment of adolescent patients with HS is predicted based on the demonstrated efficacy and exposure-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response relationship in adult HS patients and the likelihood that the disease course, pathophysiology, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">drug effects are substantially similar to that of adults at the same exposure levels. Safety of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:704pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recommended adalimumab dose in the adolescent HS population is based on cross-indication safety </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">143</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">profile of adalimumab in both adults and paediatric patients at similar or more frequent doses (see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.2).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric Crohn&#x2019;s disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira was assessed in a multicentre, randomised, double-blind clinical trial designed to evaluate the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:129pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">efficacy and safety of induction and maintenance treatment with doses dependent on body weight </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:142pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&lt; 40 kg or &#x2265; 40 kg) in 192 paediatric subjects between the ages of 6 and 17 (inclusive) years, with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:155pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">moderate to severe Crohn&#xb4;s disease (CD) defined as Paediatric Crohn&apos;s Disease Activity Index (PCDAI) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:167pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score &gt; 30. Subjects had to have failed conventional therapy (including a corticosteroid and/or an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:180pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunomodulator) for CD. Subjects may also have previously lost response or been intolerant to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:192pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infliximab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All subjects received open-label induction therapy at a dose based on their Baseline body weight: 160 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:230pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at Week 0 and 80 mg at Week 2 for subjects &#x2265; 40 kg, and 80 mg and 40 mg, respectively, for subjects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:243pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 4, subjects were randomised 1:1 based on their body weight at the time to either the Low Dose or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Standard Dose maintenance regimens as shown in Table 28.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:306pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 28</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:319pt;left:254pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maintenance regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:226pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:226pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:275pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Low dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:336pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Standard </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:336pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:275pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 mg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:275pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Efficacy results</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary endpoint of the study was clinical remission at Week 26, defined as PCDAI score </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 10.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline) rates are presented in Table 29. Rates of discontinuation of corticosteroids or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunomodulators are presented in Table 30.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">144</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 29</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:257pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Paediatric CD Study</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:210pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PCDAI Clinical Remission and Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:261pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Standard Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:264pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">40/20 mg eow </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:280pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 93</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Low Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:344pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">20/10 mg eow </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:360pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 95</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:424pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">P value</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 26</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:361pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.075</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   Clinical response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:361pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">48.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.073</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 52</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:361pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.100</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   Clinical response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:361pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.038</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">* p value for Standard Dose </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Low Dose comparison.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 30</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:257pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Paediatric CD Study</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:267pt;left:116pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Discontinuation of Corticosteroids or Immunomodulators and Fistula Remission</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:303pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Standard Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:306pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">40/20 mg eow </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:396pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Low Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:388pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">20/10 mg eow </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:469pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">P value</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">1</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:95pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Discontinued corticosteroids</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:324pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N= 33</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=38</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 26</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">84.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.066</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">69.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.420</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:95pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Discontinuation of Immunomodulators</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">2</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:325pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=60</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=57</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">30.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.983</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:95pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Fistula remission</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">3</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:325pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=15</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=21</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 26</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.608</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.303</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  p value for Standard Dose </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Low Dose comparison.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Immunosuppressant therapy could only be discontinued at or after Week 26 at the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">investigator&apos;s discretion if the subject met the clinical response criterion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">3</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> defined as a closure of all fistulas that were draining at Baseline for at least 2 consecutive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">post-Baseline visits</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Statistically significant increases (improvement) from Baseline to Week 26 and 52 in Body Mass Index </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and height velocity were observed for both treatment groups.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Statistically and clinically significant improvements from Baseline were also observed in both treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">groups for quality of life parameters (including IMPACT III).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">One hundred patients (n=100) from the Paediatric CD Study continued in an open-label long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension study.  After 5 years of adalimumab therapy, 74.0% (37/50) of the 50 patients remaining in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study continued to be in clinical remission, and 92.0% (46/50) of patients continued to be in clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response per PCDAI.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric ulcerative colitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira was assessed in a multicenter, randomized, double-blind, trial in 93 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients from 5 to 17 years of age with moderate to severe ulcerative colitis (Mayo score 6 to 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with endoscopy subscore of 2 to 3 points, confirmed by centrally read endoscopy) who had an inadequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response or intolerance to conventional therapy. Approximately 16% of patients in the study had failed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">prior anti-TNF treatment. Patients who received corticosteroids at enrollment were allowed to taper their </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">corticosteroid therapy after Week 4.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">145</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the induction period of the study, 77 patients were randomized 3:2 to receive double-blind treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Humira at an induction dose of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2; or an induction dose of 2.4 mg/kg (maximum of 160 mg) at Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0, placebo at Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2. Both groups received 0.6 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(maximum of 40 mg) at Week 4 and Week 6. Following an amendment to the study design, the remaining </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16 patients who enrolled in the induction period received open-label treatment with Humira at the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">induction dose of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 mg/kg (maximum of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg) at Week 2.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 8, 62 patients who demonstrated clinical response per Partial Mayo Score (PMS; defined as a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">decrease in PMS &#x2265; 2 points and &#x2265; 30% from Baseline) were randomized equally to receive double-blind </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintenance treatment with Humira at a dose of 0.6 mg/kg (maximum of 40 mg) every week (ew), or a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintenance dose of 0.6 mg/kg (maximum of 40 mg) every other week (eow). Prior to an amendment to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the study design, 12 additional patients who demonstrated clinical response per PMS were randomized to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receive placebo but were not included in the confirmatory analysis of efficacy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Disease flare was defined as an increase in PMS of at least 3 points (for patients with PMS of 0 to 2 at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 8), at least 2 points (for patients with PMS of 3 to 4 at Week 8), or at least 1 point (for patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PMS of 5 to 6 at Week 8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who met criteria for disease flare at or after Week 12 were randomized to receive a re-induction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose of 2.4 mg/kg (maximum of 160 mg) or a dose of 0.6 mg/kg (maximum of 40 mg) and continued to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receive their respective maintenance dose regimen afterwards.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Efficacy Results</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The co-primary endpoints of the study were clinical remission per PMS (defined as PMS &#x2264; 2 and no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:420pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">individual subscore &gt; 1) at Week 8, and clinical remission per FMS (Full Mayo Score) (defined as a Mayo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:433pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Score &#x2264; 2 and no individual subscore &gt; 1) at Week 52 in patients who achieved clinical response per PMS </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at Week 8.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:471pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission rates per PMS at Week 8 for patients in each of the Humira double-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:484pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blind induction groups are presented in Table 31.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:509pt;left:189pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 31: Clinical Remission per PMS at 8 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:269pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:221pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 160 mg at Week </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:239pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">0 / Placebo at Week 1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:278pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=30</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:415pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b, c</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:371pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 160 mg at Week </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">0 and Week 1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:428pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=47</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:118pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:259pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13/30 (43.3%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:409pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28/47 (59.6%)</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">146</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:118pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 2.4 mg/kg (maximum of 160 mg) at Week 0, placebo at Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:118pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:118pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:118pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:104pt;left:118pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Not including open-label Induction dose of Humira 2.4 mg/kg (maximum of 160 mg) at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:118pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 0 and Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:118pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note 1: Both induction groups received 0.6 mg/kg (maximum of 40 mg) at Week 4 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:118pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:118pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note 2: Patients with missing values at Week 8 were considered as not having met the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:118pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endpoint</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 52, clinical remission per FMS in Week 8 responders, clinical response per FMS (defined as a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">decrease in Mayo Score &#x2265; 3 points and &#x2265; 30% from Baseline) in Week 8 responders, mucosal healing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(defined as Mayo endoscopy subscore &#x2264; 1) in Week 8 responders, clinical remission per FMS in Week 8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remitters, and the proportion of subjects in corticosteroid-free remission per FMS in Week 8 responders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were assessed in patients who received Humira at the double-blind maximum 40 mg eow (0.6 mg/kg) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum 40 mg ew (0.6 mg/kg) maintenance doses (Table 32).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:213pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 32: Efficacy Results at 52 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:279pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:245pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 40 mg eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:405pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:373pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 40 mg ew</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:416pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission in Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8 PMS responders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:272pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9/31 (29.0%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:397pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14/31 (45.2%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response in Week 8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PMS responders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:269pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">19/31 (61.3%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:395pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">21/31 (67.7%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mucosal healing in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 8 PMS responders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:269pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12/31 (38.7%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:395pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16/31 (51.6%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission in Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8 PMS remitters</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:272pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9/21 (42.9%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:395pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10/22 (45.5%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Corticosteroid-free </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission in Week 8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PMS responders</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:272pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4/13 (30.8%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:398pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5/16 (31.3%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 0.6 mg/kg (maximum of 40 mg) every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 0.6 mg/kg (maximum of 40 mg) every week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> In patients receiving concomitant corticosteroids at baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note: Patients with missing values at Week 52 or who were randomized to receive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">re-induction or maintenance treatment were considered non-responders for Week 52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:559pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endpoints</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Additional exploratory efficacy endpoints included clinical response per the Paediatric Ulcerative Colitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Activity Index (PUCAI) (defined as a decrease in PUCAI &#x2265; 20 points from Baseline) and clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:610pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission per PUCAI (defined as PUCAI &lt; 10) at Week 8 and Week 52 (Table 33). </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">147</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:152pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 33: Exploratory Endpoints Results per PUCAI</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:332pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:269pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:235pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 160 mg at </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:224pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 0 / Placebo at Week 1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:277pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=30</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:399pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b,c</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:368pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 160 mg at </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:375pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 0 and Week 1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=47</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission per PUCAI</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:258pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10/30 (33.3%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22/47 (46.8%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:151pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response per PUCAI</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:151pt;left:258pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15/30 (50.0%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:151pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">32/47 (68.1%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:164pt;left:330pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 52</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:269pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">d</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:233pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 40 mg eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:277pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:402pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">e</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:368pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 40 mg ew</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission per PUCAI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in Week 8 PMS responders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:258pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14/31 (45.2%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18/31 (58.1%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response per PUCAI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in Week 8 PMS responders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:258pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18/31 (58.1%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16/31 (51.6%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Humira 2.4 mg/kg (maximum of 160 mg) at Week 0, placebo at Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Not including open-label Induction dose of Humira 2.4 mg/kg (maximum of 160 mg) at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 0 and Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Humira 0.6 mg/kg (maximum of 40 mg) every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">e</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Humira 0.6 mg/kg (maximum of 40 mg) every week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note 1: Both induction groups received 0.6 mg/kg (maximum of 40 mg) at Week 4 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note 2: Patients with missing values at Week 8 were considered as not having met the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:407pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endpoints</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note 3: Patients with missing values at Week 52 or who were randomized to receive re-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">induction or maintenance treatment were considered non-responders for Week 52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endpoints</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of the Humira-treated patients who received re-induction treatment during the maintenance period, 2/6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(33%) achieved clinical response per FMS at Week 52.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of life</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinically meaningful improvements from Baseline were observed in IMPACT III and the caregiver Work </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Productivity and Activity Impairment (WPAI) scores for the groups treated with Humira. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:571pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinically meaningful increases (improvement) from Baseline in height velocity were observed for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">groups treated with adalimumab, and clinically meaningful increases (improvement) from Baseline in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Body Mass Index were observed for subjects on the high maintenance dose of maximum 40 mg (0.6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg) ew. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric Uveitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira was assessed in a randomized, double-masked, controlled study of 90 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients from 2 to &lt; 18 years of age with active JIA-associated noninfectious anterior uveitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who were refractory to at least 12 weeks of methotrexate treatment.  Patients received either placebo or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg adalimumab (if &lt; 30 kg) or 40 mg adalimumab (if &#x2265; 30 kg) every other week in combination with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">their baseline dose of methotrexate. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">148</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary endpoint was &#x2018;time to treatment failure&#x2019;. The criteria determining treatment failure were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">worsening or sustained non-improvement in ocular inflammation, partial improvement with development </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of sustained ocular co-morbidities or worsening of ocular co-morbidities, non-permitted use of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant medications, and suspension of treatment for an extended period of time.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Clinical Response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab significantly delayed the time to treatment failure, as compared to placebo (See Figure 3, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">P &lt; 0.0001 from log rank test).The median time to treatment failure was 24.1 weeks for subjects treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with placebo, whereas the median time to treatment failure was not estimable for subjects treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab because less than one-half of these subjects experienced treatment failure.  Adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significantly decreased the risk of treatment failure by 75% relative to placebo, as shown by the hazard </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ratio (HR = 0.25 [95% CI:  0.12, 0.49]).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Figure 3: Kaplan-Meier Curves Summarizing Time to Treatment Failure in the Paediatric Uveitis </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:292pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Study</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PROBABILITY OF FAILING TREATMENT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:274pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TIME (WEEKS)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:445pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note: P = Placebo (Number at Risk); H = HUMIRA (Number at Risk).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacokinetic properties</span></b></p>
<img style="position:absolute;top:295pt;left:99pt;width:432pt;height:358pt" src="data:image/png;base64,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">
<img style="position:absolute;top:670pt;left:280pt;width:36pt;height:9pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAEwAAAAMCAAAAADtpASbAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAA2UlEQVR4nI2SPQ7CMAyF7bCzICYkJBaExMghkLgA5+BKcJDeoBsS
B+jUzoiJmDglrknSEk/x36f36iKBC0KYjN++y/pCvIb2DyfDGJKIhiXKCHlADVmT
7XlYwiJANZ28HACE4RNRxm+9EaMV49u1OHwynxtlk9qGxPd6yfT7S0SaAyOeD2vC
0GLD3Ka1gQbbeVCGUFeiA497t4XXTgp0QQfrboR29kb2tzvxUlV7knE1OK8wKJuO
6HBiLvKYg+X/oNxMmo0oUweBHDe9f6HN/sLK2KjwIlhpfAC8cXABl3kQ5QAAAABJ
RU5ErkJggg==">
<img style="position:absolute;top:671pt;left:401pt;width:35pt;height:6pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAFIAAAANCAIAAAC1lq7uAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAApElEQVR4nOWVzRGEIAxGE4qgDVy7oirdZmjAtQa6AHXirBHRkz9j
eAcmcsqbLwaMMQLAeCIiLySxlULSFk9ivmjLy/mvtvXCZMjFwI2o5jerIQ8hKKUe
6PEy9nZWfshFhk8FeaUrjT699333u7+5c5lnG0FrbYzJpw0sZOfct2nvb/QKRqmq
/lhr+e9dygPGmeTL0d7d5HD41r2U7HouKG1OodoDHdh+5CqIp8EAAAAASUVORK5CYII=">
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">149</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Absorption and distribution</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After subcutaneous administration of a single 40 mg dose, absorption and distribution of adalimumab was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">slow, with peak serum concentrations being reached about 5 days after administration. The average </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">absolute bioavailability of adalimumab estimated from three studies following a single 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous dose was 64%. After single intravenous doses ranging from 0.25 to 10 mg/kg, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentrations were dose proportional. After doses of 0.5 mg/kg (~40 mg), clearances ranged from 11 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15 ml/hour, the distribution volume (V</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">ss</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">) ranged from 5 to 6 litres and the mean terminal phase half-life </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was approximately two weeks. Adalimumab concentrations in the synovial fluid from several rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients ranged from 31-96% of those in serum.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following subcutaneous administration of 40 mg of adalimumab every other week in adult rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis (RA) patients the mean steady-state trough concentrations were approximately 5</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml (without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant methotrexate) and 8 to 9</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml (with concomitant methotrexate), respectively.  The serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab trough levels at steady-state increased roughly proportionally with dose following 20, 40 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg subcutaneous dosing every other week and every week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following the administration of 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(maximum of 40 mg) subcutaneously every other week to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with polyarticular juvenile idiopathic arthritis (JIA) who were 4 to 17 years the mean trough </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">steady-state (values measured from Week 20 to 48) serum adalimumab concentration was 5.6 &#xb1; 5.6 &#xb5;g/ml </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(102% CV) for adalimumab without concomitant methotrexate and 10.9 &#xb1; 5.2 &#xb5;g/ml (47.7% CV) with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with polyarticular JIA who were 2 to &lt;4 years old or aged 4 and above weighing &lt;15 kg dosed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:370pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with adalimumab 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">, the mean trough steady-state serum adalimumab concentrations was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.0 &#xb1; 6.1 &#xb5;g/ml (101% CV) for adalimumab without concomitant methotrexate and 7.9 &#xb1; 5.6 &#xb5;g/ml </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(71.2% CV) with concomitant methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following the administration of 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(maximum of 40 mg) subcutaneously every other week to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with enthesitis-related arthritis who were 6 to 17 years, the mean trough steady-state (values </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">measured at Week 24) serum adalimumab concentrations were 8.8 &#xb1; 6.6 &#x3bc;g/ml for adalimumab without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant methotrexate and 11.8 &#xb1; 4.3 &#x3bc;g/ml with concomitant methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:493pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following subcutaneous administration of 40 mg of adalimumab every other week in adult non-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">radiographic axial spondyloarthritis patients, the mean (&#xb1;SD) trough steady-state concentration at Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">68 was 8.0 &#xb1; 4.6</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with psoriasis, the mean steady-state trough concentration was 5</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab 40 mg every other week monotherapy treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following the administration of 0.8 mg/kg (maximum of 40 mg) subcutaneously every other week to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients with chronic plaque psoriasis, the mean &#xb1; SD steady-state adalimumab trough </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentration was approximately 7.4 &#xb1; 5.8 &#xb5;g/ml (79% CV).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with hidradenitis suppurativa, a dose of 160 mg Humira on Week 0 followed by 80 mg on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:647pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 2 achieved serum adalimumab trough concentrations of approximately 7 to 8 &#x3bc;g/ml at Week 2 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 4.  The mean steady-state trough concentration at Week 12 through Week 36 were approximately 8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 10 &#x3bc;g/ml during adalimumab 40 mg every week treatment.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab exposure in adolescent HS patients was predicted using population pharmacokinetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">modelling and simulation based on cross-indication pharmacokinetics in other paediatric patients </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">150</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn&#x2019;s disease, and enthesitis-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis). The recommended adolescent HS dosing schedule is 40 mg every other week. Since exposure to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab can be affected by body size, adolescents with higher body weight and inadequate response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">may benefit from receiving the recommended adult dose of 40 mg every week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with Crohn&#x2019;s disease, the loading dose of 80 mg Humira on Week 0 followed by 40 mg Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">on Week 2 achieves serum adalimumab trough concentrations of approximately 5.5</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">induction period. A loading dose of 160 mg Humira on Week 0 followed by 80 mg Humira on Week 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">achieves serum adalimumab trough concentrations of approximately 12</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml during the induction period. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mean steady-state trough levels of approximately 7</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml were observed in Crohn&#x2019;s disease patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received a maintenance dose of 40 mg Humira every other week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In paediatric patients with moderate to severe CD, the open-label adalimumab induction dose was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">160/80 mg or 80/40 mg at Weeks 0 and 2, respectively, dependent on a body weight cut-off of 40 kg.  At </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 4, patients were randomised 1:1 to either the Standard Dose (40/20 mg eow) or Low Dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(20/10 mg eow) maintenance treatment groups based on their body weight. The mean (&#xb1;SD) serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab trough concentrations achieved at Week 4 were 15.7&#xb1;6.6</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml for patients &#x2265; 40 kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(160/80 mg) and 10.6&#xb1;6.1</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml for patients &lt; 40 kg (80/40 mg). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For patients who stayed on their randomised therapy, the mean (&#xb1;SD) adalimumab trough concentrations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at Week 52 were 9.5&#xb1;5.6</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml for the Standard Dose group and 3.5&#xb1;2.2</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml for the Low Dose group.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The mean trough concentrations were maintained in patients who continued to receive adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment eow for 52 weeks. For patients who dose escalated from eow to weekly regimen, the mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&#xb1;SD) serum concentrations of adalimumab at Week 52 were 15.3&#xb1;11.4 &#x3bc;g/ml (40/20 mg, weekly) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.7&#xb1;3.5 &#x3bc;g/ml (20/10 mg, weekly).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with ulcerative colitis, a loading dose of 160 mg Humira on Week 0 followed by 80 mg Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">on Week 2 achieves serum adalimumab trough concentrations of approximately 12</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">induction period.  Mean steady-state trough levels of approximately 8</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml were observed in ulcerative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">colitis patients who received a maintenance dose of 40 mg Humira every other week. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following the subcutaneous administration of body weight-based dosing of 0.6 mg/kg (maximum of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg) every other week to paediatric patients with ulcerative colitis, the mean trough steady-state serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab concentration was 5.01&#xb1;3.28 &#xb5;g/ml at Week 52. For patients who received 0.6 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:493pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(maximum of 40 mg) every week, the mean (&#xb1;SD) trough steady-state serum adalimumab concentration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was 15.7&#xb1;5.60 &#x3bc;g/ml at Week 52.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with uveitis, a loading dose of 80 mg adalimumab on Week 0 followed by 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab every other week starting at Week 1, resulted in mean steady-state concentrations of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 8 to 10</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab exposure in paediatric uveitis patients was predicted using population pharmacokinetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">modelling and simulation based on cross-indication pharmacokinetics in other paediatric patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn&#x2019;s disease, and enthesitis-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:621pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis). No clinical exposure data are available on the use of a loading dose in children &lt; 6 years. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">predicted exposures indicate that in the absence of methotrexate, a loading dose may lead to an initial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increase in systemic exposure.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Population pharmacokinetic and pharmacokinetic/pharmacodynamic modelling and simulation predicted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparable adalimumab exposure and efficacy in patients treated with 80 mg every other week when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared with 40 mg every week (including adult patients with RA, HS, UC, CD or Ps, patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adolescent HS, and paediatric patients &#x2265; 40 kg with CD and UC).</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">151</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Exposure-response relationship in paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">On the basis of clinical trial data in patients with JIA (pJIA and ERA), an exposure-response relationship </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was established between plasma concentrations and PedACR 50 response. The apparent adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">plasma concentration that produces half the maximum probability of PedACR 50 response (EC50) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 &#x3bc;g/ml (95% CI: 1-6 &#x3bc;g/ml). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Exposure-response relationships between adalimumab concentration and efficacy in paediatric patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with severe chronic plaque psoriasis were established for PASI 75 and PGA clear or minimal, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively. PASI 75 and PGA clear or minimal increased with increasing adalimumab concentrations, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">both with a similar apparent EC50 of approximately 4.5 &#x3bc;g/ml (95% CI 0.4-47.6 and 1.9-10.5, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elimination</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Population pharmacokinetic analyses with data from over 1,300 RA patients revealed a trend toward </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher apparent clearance of adalimumab with increasing body weight. After adjustment for weight </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">differences, gender and age appeared to have a minimal effect on adalimumab clearance.  The serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">levels of free adalimumab (not bound to anti-adalimumab antibodies, AAA) were observed to be lower in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with measurable AAA.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatic or renal impairment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has not been studied in patients with hepatic or renal impairment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Preclinical safety data </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Non-clinical data reveal no special hazard for humans based on studies of single dose toxicity, repeated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose toxicity, and genotoxicity.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">An embryo-foetal developmental toxicity/perinatal developmental study has been performed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cynomolgus monkeys at 0, 30 and 100 mg/kg (9-17 monkeys/group) and has revealed no evidence of harm </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to the foetuses due to adalimumab. Neither carcinogenicity studies, nor a standard assessment of fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibody with limited cross-reactivity to rodent TNF and to the development of neutralising antibodies in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rodents. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">List of excipients </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mannitol</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Citric acid monohydrate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium citrate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium dihydrogen phosphate dihydrate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Disodium phosphate dihydrate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium chloride</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Polysorbate 80</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sodium hydroxide</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Water for injections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Incompatibilities </span></b></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">152</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">products.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Shelf life </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 years</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for storage </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Store in a refrigerator (2</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C &#x2013; 8</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C). Do not freeze. Keep the pre-filled syringe or pre-filled pen in its outer </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">carton in order to protect from light.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A single Humira pre-filled syringe or pre-filled pen may be stored at temperatures up to a maximum of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25&#xb0;C for a period of up to 14 days. The syringe or pen must be protected from light, and discarded if not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">used within the 14-day period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Nature and contents of container  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in pre-filled syringe </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in single-use pre-filled syringe (type I glass) with a plunger stopper </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(bromobutyl rubber) and a needle with a needle shield (thermoplastic elastomer).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Packs of:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 pre-filled syringe (0.8 ml sterile solution) with 1 alcohol pad in a blister. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 pre-filled syringes (0.8 ml sterile solution), each with 1 alcohol pad, in a blister. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 pre-filled syringes (0.8 ml sterile solution), each with 1 alcohol pad, in a blister. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 pre-filled syringes (0.8 ml sterile solution), each with 1 alcohol pad, in a blister.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in pre-filled syringe with needle guard </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in single-use pre-filled syringe (type I glass) with needle guard for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hospital and caregiver use. The syringe is made from type 1 glass with a plunger stopper (bromobutyl </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rubber) and a needle with a needle shield (thermoplastic elastomer).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Packs of:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 pre-filled syringe with needle guard (0.8 ml sterile solution) in a blister, and 1 alcohol pad.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in pre-filled pen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in single-use pre-filled pen for patient use containing a pre-filled </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">syringe. The syringe inside the pen is made from type 1 glass with a plunger stopper (bromobutyl rubber) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and a needle with a needle shield (thermoplastic elastomer).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Packs of:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:88pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:106pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 pre-filled pen (0.8 ml sterile solution), with 2 alcohol pads in a blister. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:88pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:106pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 pre-filled pens (0.8 ml sterile solution), each with 1 alcohol pad, in a blister. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:88pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:106pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 pre-filled pens (0.8 ml sterile solution), each with 1 alcohol pad, in a blister. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:88pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:106pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 pre-filled pens (0.8 ml sterile solution), each with 1 alcohol pad, in a blister.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not all presentations or pack sizes may be marketed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for disposal</span></b></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">153</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requirements.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">7.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">AbbVie Deutschland GmbH &amp; Co. KG</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Knollstrasse</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">67061 Ludwigshafen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Germany</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">8.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBERS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in pre-filled syringe </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/002</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/003</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/004</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/005</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in pre-filled syringe with needle guard </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/006</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in pre-filled pen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/007</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/008</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/009</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/010</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">9.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of first authorisation:  08 September 2003</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of latest renewal: 08 September 2008 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">10.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Agency </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000ff">http://www.ema.europa.eu</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">154</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">1.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in pre-filled syringe</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in pre-filled pen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">2.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in pre-filled syringe </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each 0.4 ml single dose pre-filled syringe contains 40 mg of adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in pre-filled pen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each 0.4 ml single dose pre-filled pen contains 40 mg of adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary cells.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For the full list of excipients, see section 6.1.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">3.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL FORM </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Solution for injection. (injection)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clear, colourless solution. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CLINICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Therapeutic indications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rheumatoid arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira in combination with methotrexate, is indicated for:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:Wingdings,sans-serif;font-size:11.04pt">&#xf0a7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:Wingdings,sans-serif;font-size:11.04pt">&#xf0a7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with methotrexate is inappropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has been shown to reduce the rate of progression of joint damage as measured by X-ray and to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improve physical function, when given in combination with methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Juvenile idiopathic arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Polyarticular juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira in combination with methotrexate is indicated for the treatment of active polyarticular juvenile </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more disease-modifying anti-rheumatic drugs (DMARDs). Humira can be given as monotherapy in case </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">155</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">efficacy in monotherapy see section 5.1). Humira has not been studied in patients aged less than 2 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Enthesitis-related arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Axial spondyloarthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Ankylosing spondylitis (AS)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inadequate response to conventional therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Axial spondyloarthritis without radiographic evidence of AS</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">evidence of AS but with objective signs of inflammation by elevated CRP and / or MRI, who have had an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriatic arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of active and progressive psoriatic arthritis in adults when the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. Humira has </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with polyarticular symmetrical subtypes of the disease (see Section 5.1) and to improve physical function.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are candidates for systemic therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric plaque psoriasis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and phototherapies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hidradenitis suppurativa (HS)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy (see sections 5.1 and 5.2).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Crohn&#x2019;s disease</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for treatment of moderately to severely active Crohn&#x2019;s disease, in adult patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have not responded despite a full and adequate course of therapy with a corticosteroid and/or an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">156</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric Crohn&apos;s disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of moderately to severely active Crohn&apos;s disease in paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (from 6 years of age) who have had an inadequate response to conventional therapy including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have contraindications for such therapies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ulcerative colitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric ulcerative colitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (from 6 years of age) who have had an inadequate response to conventional therapy including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">medical contraindications for such therapies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uveitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sparing, or in whom corticosteroid treatment is inappropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric Uveitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">whom conventional therapy is inappropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Posology and method of administration  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treatment should be initiated and supervised by specialist physicians experienced in the diagnosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and treatment of conditions for which Humira is indicated. Ophthalmologists are advised to consult with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">an appropriate specialist before initiation of treatment with Humira (see section 4.4). Patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira should be given the Patient Reminder Card.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After proper training in injection technique, patients may self-inject with Humira if their physician </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">determines that it is appropriate and with medical follow-up as necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During treatment with Humira, other concomitant therapies (e.g., corticosteroids and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunomodulatory agents) should be optimised.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Posology</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Rheumatoid arthritis</span></i></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">157</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for adult patients with rheumatoid arthritis is 40 mg adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered every other week as a single dose via subcutaneous injection. Methotrexate should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued during treatment with Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Glucocorticoids, salicylates, non-steroidal anti-inflammatory drugs, or analgesics can be continued during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment with Humira.  Regarding combination with disease modifying anti-rheumatic drugs other than </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate see sections 4.4 and 5.1.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In monotherapy, some patients who experience a decrease in their response to Humira 40 mg every other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">week may benefit from an increase in dosage to 40 mg adalimumab every week or 80 mg every other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">week. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Available data suggest that the clinical response is usually achieved within 12 weeks of treatment.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy should be reconsidered in a patient not responding within this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Dose interruption</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There may be a need for dose interruption, for instance before surgery or if a serious infection occurs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Available data suggest that re-introduction of Humira after discontinuation for 70 days or longer resulted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in the same magnitudes of clinical response and similar safety profile as before dose interruption.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS and psoriatic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for patients with ankylosing spondylitis, axial spondyloarthritis without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">radiographic evidence of AS and for patients with psoriatic arthritis is 40 mg adalimumab administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every other week as a single dose via subcutaneous injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Available data suggest that the clinical response is usually achieved within 12 weeks of treatment.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy should be reconsidered in a patient not responding within this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for adult patients is an initial dose of 80 mg administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneously, followed by 40 mg subcutaneously given every other week starting one week after the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initial dose.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy beyond 16 weeks should be carefully reconsidered in a patient not responding within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Beyond 16 weeks, patients with inadequate response to Humira 40 mg every other week may benefit from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">an increase in dosage to 40 mg every week or 80 mg every other week. The benefits and risks of continued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg weekly or 80 mg every other week therapy should be carefully reconsidered in a patient with an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inadequate response after the increase in dosage (see section 5.1).  If adequate response is achieved with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every week or 80 mg every other week, the dosage may subsequently be reduced to 40 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">158</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Hidradenitis suppurativa</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended Humira dose regimen for adult patients with hidradenitis suppurativa (HS) is 160 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initially at Day 1 (given as four 40 mg injections in one day or as two 40 mg injections per day for two </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">consecutive days), followed by 80 mg two weeks later at Day 15 (given as two 40 mg injections in one </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">day). Two weeks later (Day 29) continue with a dose of 40 mg every week or 80 mg every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(given as two 40 mg injections in one day). Antibiotics may be continued during treatment with Humira if </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">necessary. It is recommended that the patient should use a topical antiseptic wash on their HS lesions on a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">daily basis during treatment with Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy beyond 12 weeks should be carefully reconsidered in a patient with no improvement </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">within this time period.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Should treatment be interrupted, Humira 40 mg every week or 80 mg every other week may be re-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">introduced (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The benefit and risk of continued long-term treatment should be periodically evaluated (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Crohn&#x2019;s disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended Humira induction dose regimen for adult patients with moderately to severely active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Crohn&#x2019;s disease is 80 mg at Week 0 followed by 40 mg at Week 2. In case there is a need for a more rapid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response to therapy, the regimen 160 mg at Week 0 (given as four 40 mg injections in one day or as two </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg injections per day for two consecutive days), followed by 80 mg at Week 2 (given as two 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injections in one day), can be used with the awareness that the risk for adverse events is higher during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">induction.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After induction treatment, the recommended dose is 40 mg every other week via subcutaneous injection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Alternatively, if a patient has stopped Humira and signs and symptoms of disease recur, Humira may be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">re-administered. There is little experience from re-administration after more than 8 weeks since the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">previous dose.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During maintenance treatment, corticosteroids may be tapered in accordance with clinical practice </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">guidelines.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Some patients who experience decrease in their response to Humira 40 mg every other week may benefit </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">from an increase in dosage to 40 mg Humira every week or 80 mg every other week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Some patients who have not responded by Week 4 may benefit from continued maintenance therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">through Week 12. Continued therapy should be carefully reconsidered in a patient not responding within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Ulcerative colitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended Humira induction dose regimen for adult patients with moderate to severe ulcerative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">colitis is 160 mg at Week 0 (given as four 40 mg injections in one day or as two 40 mg injections per day </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">159</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for two consecutive days) and 80 mg at Week 2 (given as two 40 mg injections in one day). After </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">induction treatment, the recommended dose is 40 mg every other week via subcutaneous injection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During maintenance treatment, corticosteroids may be tapered in accordance with clinical practice </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">guidelines. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Some patients who experience decrease in their response to 40 mg every other week may benefit from an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increase in dosage to 40 mg Humira every week or 80 mg every other week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Available data suggest that clinical response is usually achieved within 2-8 weeks of treatment.  Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy should not be continued in patients failing to respond within this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Uveitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for adult patients with uveitis is an initial dose of 80 mg, followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg given every other week starting one week after the initial dose. There is limited experience in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initiation of treatment with Humira alone. Treatment with Humira can be initiated in combination with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">corticosteroids and/or with other non-biologic immunomodulatory agents. Concomitant corticosteroids </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">may be tapered in accordance with clinical practice starting two weeks after initiating treatment with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira.   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">It is recommended that the benefit and risk of continued long-term treatment should be evaluated on a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">yearly basis (see section 5.1).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Special populations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elderly</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose adjustment is required.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal and/or hepatic impairment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has not been studied in these patient populations. No dose recommendations can be made.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Juvenile idiopathic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Polyarticular juvenile idiopathic arthritis from 2 years of age</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for patients with polyarticular juvenile idiopathic arthritis from 2 years </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of age is based on body weight (Table 1). Humira is administered every other week via subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:112pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 1. Humira Dose for Patients with Polyarticular Juvenile Idiopathic Arthritis </span></b></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">160</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:59pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:59pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dosing Regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:75pt;left:185pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 kg to &lt; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:75pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:92pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Available data suggest that clinical response is usually achieved within 12 weeks of treatment. Continued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy should be carefully reconsidered in a patient not responding within this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in patients aged less than 2 years for this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Enthesitis-related arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for patients with enthesitis-related arthritis from 6 years of age is based </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">on body weight (Table 2). Humira is administered every other week via subcutaneous injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:147pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 2. Humira Dose for Patients with Enthesitis-Related Arthritis </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dosing Regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:185pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15 kg to &lt; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:344pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has not been studied in patients with enthesitis-related arthritis aged less than 6 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Psoriatic arthritis and axial spondyloarthritis including ankylosing spondyliti</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">s</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in the paediatric population for the indications of ankylosing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spondylitis and psoriatic arthritis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended Humira dose for patients with plaque psoriasis from 4 to 17 years of age is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body weight (Table 3). Humira is administered via subcutaneous injection.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">161</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:148pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 3. Humira Dose for Paediatric Patients with Plaque Psoriasis </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dosing Regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:185pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15 kg to &lt; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:100pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Initial dose of 20 mg, followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:113pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg given every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:318pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting one week after the initial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:153pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:153pt;left:316pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Initial dose of 40 mg, followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:165pt;left:324pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg given every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:177pt;left:318pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting one week after the initial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:217pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy beyond 16 weeks should be carefully considered in a patient not responding within this </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If retreatment with Humira is indicated, the above guidance on dose and treatment duration should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:267pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">followed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety of Humira in paediatric patients with plaque psoriasis has been assessed for a mean of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13 months.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 4 years for this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adolescent hidradenitis suppurativa (from 12 years of age, weighing at least 30 kg)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There are no clinical trials with Humira in adolescent patients with HS.  The posology of Humira in these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients has been determined from pharmacokinetic modelling and simulation (see section 5.2).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:457pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended Humira dose is 80 mg at Week 0 followed by 40 mg every other week starting at Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 via subcutaneous injection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adolescent patients with inadequate response to Humira 40 mg every other week, an increase in dosage</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 40 mg every week or 80 mg every other week may be considered.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Antibiotics may be continued during treatment with Humira if necessary.  It is recommended that the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient should use a topical antiseptic wash on their HS lesions on a daily basis during treatment with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy beyond 12 weeks should be carefully reconsidered in a patient with no improvement </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">within this time period.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Should treatment be interrupted, Humira may be re-introduced as appropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:647pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The benefit and risk of continued long-term treatment should be periodically evaluated (see adult data in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">section 5.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 12 years in this indication.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric Crohn&apos;s disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for patients with Crohn&#x2019;s disease from 6 to 17 years of age is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body weight (Table 4). Humira is administered via subcutaneous injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 4. Humira Dose for Paediatric Patients with Crohn&#x2019;s disease</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:78pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:78pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:255pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Induction Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:471pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maintenance </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:490pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:476pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Starting at </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:484pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:78pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:126pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 40 mg at week 0 and 20 mg at week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In case there is a need for a more rapid response to therapy with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">awareness that the risk for adverse events may be higher with use of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher induction dose, the following dose may be used:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:126pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 80 mg at week 0 and 40 mg at week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:474pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:477pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:78pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:126pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 80 mg at week 0 and 40 mg at week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In case there is a need for a more rapid response to therapy with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:369pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">awareness that the risk for adverse events may be higher with use of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher induction dose, the following dose may be used:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:126pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 160 mg at week 0 and 80 mg at week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:474pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:477pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who experience insufficient response may benefit from an increase in dosage:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg: 20 mg every week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 40 kg: 40 mg every week or 80 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy should be carefully considered in a subject not responding by week 12.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 6 years for this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric ulcerative colitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for patients from 6 to 17 years of age with ulcerative colitis is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body weight (Table 5). Humira is administered via subcutaneous injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:146pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 5. Humira Dose for Paediatric Patients with Ulcerative Colitis </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:102pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:234pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Induction Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:395pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maintenance Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:392pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Starting at Week 4*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:120pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:192pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 80 mg at Week 0 (given as two 40 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg injections in one day) and</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:192pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 40 mg at Week 2 (given as one 40 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg injection)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:365pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 40 mg every other week</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">163</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:120pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:192pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 160 mg at Week 0 (given as four </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg injections in one day or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">two 40 mg injections per day for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">two consecutive days) and</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:192pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 80 mg at Week 2 (given as two 40 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg injections in one day)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:365pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 80 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:91pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">* </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric patients who turn 18 years of age while on Humira should continue their prescribed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:91pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintenance dose.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:177pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy beyond 8 weeks should be carefully considered in patients not showing signs of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response within this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 6 years in this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in different strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric Uveitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for paediatric patients with uveitis from 2 years of age is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body weight (Table 6). Humira is administered via subcutaneous injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In paediatric uveitis, there is no experience in the treatment with Humira without concomitant treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:170pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 6. Humira Dose for Paediatric Patients with Uveitis</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:407pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:407pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dosing Regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:332pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg every other week in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:322pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination with methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:332pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:322pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination with methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">When Humira therapy is initiated, a loading dose of 40 mg for patients &lt; 30 kg or 80 mg for patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 30 kg may be administered one week prior to the start of maintenance therapy. No clinical data are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">available on the use of a Humira loading dose in children &lt; 6 years of age (see section 5.2).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 2 years in this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">It is recommended that the benefit and risk of continued long-term treatment should be evaluated on a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">yearly basis (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Method of administration</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is administered by subcutaneous injection. Full instructions for use are provided in the package </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">leaflet.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:707pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is available in other strengths and presentations.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">164</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Contraindications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Active tuberculosis or other severe infections such as sepsis, and opportunistic infections (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Moderate to severe heart failure (NYHA class III/IV) (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special warnings and precautions for use</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Traceability </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In order to improve traceability of biological medicinal products, the name and the batch number of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered product should be clearly recorded.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Infections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients taking TNF-antagonists are more susceptible to serious infections. Impaired lung function may </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increase the risk for developing infections. Patients must therefore be monitored closely for infections, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">including tuberculosis, before, during and after treatment with Humira.  Because the elimination of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab may take up to four months, monitoring should be continued throughout this period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Humira should not be initiated in patients with active infections including chronic or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">localised infections until infections are controlled. In patients who have been exposed to tuberculosis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who have travelled in areas of high risk of tuberculosis or endemic mycoses, such as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">histoplasmosis, coccidioidomycosis, or blastomycosis, the risk and benefits of treatment with Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be considered prior to initiating therapy (see </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Other opportunistic infections</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who develop a new infection while undergoing treatment with Humira should be monitored </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">closely and undergo a complete diagnostic evaluation. Administration of Humira should be discontinued if </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be initiated until the infection is controlled.  Physicians should exercise caution when considering </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the use of Humira in patients with a history of recurring infection or with underlying conditions which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">may predispose patients to infections, including the use of concomitant immunosuppressive medications.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Serious infections</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious infections, including sepsis, due to bacterial, mycobacterial, invasive fungal, parasitic, viral, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other opportunistic infections such as listeriosis, legionellosis and pneumocystis have been reported in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients receiving Humira.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Other serious infections seen in clinical trials include pneumonia, pyelonephritis, septic arthritis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">septicaemia. Hospitalisation or fatal outcomes associated with infections have been reported. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Tuberculosis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tuberculosis, including reactivation and new onset of tuberculosis, has been reported in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira.  Reports included cases of pulmonary and extra-pulmonary (i.e. disseminated) tuberculosis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Before initiation of therapy with Humira, all patients must be evaluated for both active or inactive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&#x201c;latent&#x201d;) tuberculosis infection.  This evaluation should include a detailed medical assessment of patient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">history of tuberculosis or possible previous exposure to people with active tuberculosis and previous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and/or current immunosuppressive therapy.  Appropriate screening tests (i.e. tuberculin skin test and chest </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">165</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">X-ray) should be performed in all patients (local recommendations may apply).  It is recommended that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the conduct and results of these tests are recorded in the Patient Reminder Card.  Prescribers are reminded </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunocompromised. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If active tuberculosis is diagnosed, Humira therapy must not be initiated (see section 4.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In all situations described below, the benefit/risk balance of therapy should be very carefully considered.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">consulted.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosis prophylaxis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment before the initiation of Humira, and in accordance with local recommendations. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Use of anti-tuberculosis prophylaxis treatment should also be considered before the initiation of Humira in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with several or significant risk factors for tuberculosis despite a negative test for tuberculosis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cannot be confirmed.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have occurred in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with Humira. Some patients who have been successfully treated for active tuberculosis have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">redeveloped tuberculosis while being treated with Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients should be instructed to seek medical advice if signs/symptoms suggestive of a tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infection (e.g., persistent cough, wasting/weight loss, low grade fever, listlessness) occur during or after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy with Humira. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Other opportunistic infections</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Opportunistic infections, including invasive fungal infections have been observed in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira. These infections have not consistently been recognised in patients taking TNF-antagonists and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">this has resulted in delays in appropriate treatment, sometimes resulting in fatal outcomes. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dyspnoea, and/or pulmonary infiltrates or other serious systemic illness with or without concomitant shock </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">an invasive fungal infection should be suspected and administration of Humira should be promptly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">discontinued.  Diagnosis and administration of empiric antifungal therapy in these patients should be made </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in consultation with a physician with expertise in the care of patients with invasive fungal infections. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatitis B reactivation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reactivation of hepatitis B has occurred in patients receiving a TNF-antagonist including Humira, who are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chronic carriers of this virus (i.e. surface antigen positive).  Some cases have had a fatal outcome. Patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be tested for HBV infection before initiating treatment with Humira. For patients who test positive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for hepatitis B infection, consultation with a physician with expertise in the treatment of hepatitis B is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recommended.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Carriers of HBV who require treatment with Humira should be closely monitored for signs and symptoms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of active HBV infection throughout therapy and for several months following termination of therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adequate data from treating patients who are carriers of HBV with anti-viral therapy in conjunction with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonist therapy to prevent HBV reactivation are not available. In patients who develop HBV </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">166</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactivation, Humira should be stopped and effective anti-viral therapy with appropriate supportive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment should be initiated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neurological events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonists including Humira have been associated in rare instances with new onset or exacerbation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">including multiple sclerosis and optic neuritis, and peripheral demyelinating disease, including Guillain-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Barr&#xe9; syndrome. Prescribers should exercise caution in considering the use of Humira in patients with pre-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">existing or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira should be considered if any of these disorders develop. There is a known association between </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intermediate uveitis and central demyelinating disorders. Neurologic evaluation should be performed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with non-infectious intermediate uveitis prior to the initiation of Humira therapy and regularly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">during treatment to assess for pre-existing or developing central demyelinating disorders. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Allergic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious allergic reactions associated with Humira were rare during clinical trials. Non-serious allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactions associated with Humira were uncommon during clinical trials. Reports of serious allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactions including anaphylaxis have been received following Humira administration. If an anaphylactic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reaction or other serious allergic reaction occurs, administration of Humira should be discontinued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immediately and appropriate therapy initiated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immunosuppression</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a study of 64 patients with rheumatoid arthritis that were treated with Humira, there was no evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enumeration of effector T-, B-, NK-cells, monocyte/macrophages, and neutrophils.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the controlled portions of clinical trials of TNF-antagonists, more cases of malignancies including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lymphoma have been observed among patients receiving a TNF-antagonist compared with control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients. However, the occurrence was rare. In the post marketing setting, cases of leukaemia have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reported in patients treated with a TNF-antagonist. There is an increased background risk for lymphoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">which complicates the risk estimation. With the current knowledge, a possible risk for the development of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lymphomas, leukaemia, and other malignancies in patients treated with a TNF-antagonist cannot be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">excluded.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22 years of age) treated with TNF-antagonists (initiation of therapy &#x2264; 18 years of age), including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab in the post marketing setting. Approximately half the cases were lymphomas. The other cases </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">represented a variety of different malignancies and included rare malignancies usually associated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunosuppression. A risk for the development of malignancies in children and adolescents treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonists cannot be excluded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare postmarketing cases of hepatosplenic T-cell lymphoma have been identified in patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab. This rare type of T-cell lymphoma has a very aggressive disease course and is usually fatal. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Some of these hepatosplenic T-cell lymphomas with Humira have occurred in young adult patients on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant treatment with azathioprine or 6-mercaptopurine used for inflammatory bowel disease. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">potential risk with the combination of azathioprine or 6-mercaptopurine and Humira should be carefully </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">167</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered. A risk for the development of hepatosplenic T-cell lymphoma in patients treated with Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cannot be excluded (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No studies have been conducted that include patients with a history of malignancy or in whom treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Humira is continued following development of malignancy.  Thus, additional caution should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exercised in considering Humira treatment of these patients (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis patients with a history of PUVA treatment should be examined for the presence of non-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">melanoma skin cancer prior to and during treatment with Humira.  Melanoma and Merkel cell carcinoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have also been reported in patients treated with TNF-antagonists including adalimumab (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an exploratory clinical trial evaluating the use of another TNF-antagonist, infliximab, in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies, mostly in the lung </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or head and neck, were reported in infliximab-treated patients compared with control patients. All patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had a history of heavy smoking. Therefore, caution should be exercised when using any TNF-antagonist in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">COPD patients, as well as in patients with increased risk for malignancy due to heavy smoking.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">With current data it is not known if adalimumab treatment influences the risk for developing dysplasia or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">colon cancer.  All patients with ulcerative colitis who are at increased risk for dysplasia or colon </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">carcinoma (for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or who had a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intervals before therapy and throughout their disease course. This evaluation should include colonoscopy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and biopsies per local recommendations.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Haematologic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare reports of pancytopenia including aplastic anaemia have been reported with TNF-antagonists.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adverse events of the haematologic system, including medically significant cytopenia (e.g. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">thrombocytopenia, leukopenia) have been reported with Humira. All patients should be advised to seek </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">persistent fever, bruising, bleeding, pallor) while on Humira. Discontinuation of Humira therapy should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered in patients with confirmed significant haematologic abnormalities.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vaccinations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Similar antibody responses to the standard 23-valent pneumococcal vaccine and the influenza trivalent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">virus vaccination were observed in a study in 226 adult subjects with rheumatoid arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with adalimumab or placebo. No data are available on the secondary transmission of infection by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">live vaccines in patients receiving Humira.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">agreement with current immunisation guidelines prior to initiating Humira therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients on Humira may receive concurrent vaccinations, except for live vaccines. Administration of live </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vaccines (e.g., BCG vaccine) to infants exposed to adalimumab in utero is not recommended for 5 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">following the mother&#x2019;s last adalimumab injection during pregnancy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Congestive heart failure</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a clinical trial with another TNF-antagonist worsening congestive heart failure and increased mortality </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">due to congestive heart failure have been observed. Cases of worsening congestive heart failure have also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been reported in patients receiving Humira. Humira should be used with caution in patients with mild </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">168</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">heart failure (NYHA class I/II). Humira is contraindicated in moderate to severe heart failure (see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.3). Treatment with Humira must be discontinued in patients who develop new or worsening symptoms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of congestive heart failure.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Autoimmune processes</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Humira may result in the formation of autoimmune antibodies. The impact of long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment with Humira on the development of autoimmune diseases is unknown. If a patient develops </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms suggestive of a lupus-like syndrome following treatment with Humira and is positive for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies against double-stranded DNA, further treatment with Humira should not be given (see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent administration of biologic DMARDS or TNF-antagonists</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious infections were seen in clinical studies with concurrent use of anakinra and another </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonist, etanercept, with no added clinical benefit compared to etanercept alone. Because of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">nature of the adverse events seen with the combination of etanercept and anakinra therapy, similar </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">toxicities may also result from the combination of anakinra and other TNF-antagonists. Therefore, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination of adalimumab and anakinra is not recommended. (See section 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concomitant administration of adalimumab with other biologic DMARDS (e.g, anakinra and abatacept) or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other TNF-antagonists is not recommended based upon the possible increased risk for infections, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">including serious infections and other potential pharmacological interactions. (See section 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Surgery</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is limited safety experience of surgical procedures in patients treated with Humira. The long half-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">life of adalimumab should be taken into consideration if a surgical procedure is planned.  A patient who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requires surgery while on Humira should be closely monitored for infections, and appropriate actions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be taken. There is limited safety experience in patients undergoing arthroplasty while receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Small bowel obstruction</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Failure to respond to treatment for Crohn&#x2019;s disease may indicate the presence of fixed fibrotic stricture </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">that may require surgical treatment. Available data suggest that Humira does not worsen or cause </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">strictures.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elderly</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The frequency of serious infections among Humira treated subjects over 65 years of age (3.7%) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher than for those under 65 years of age (1.5%). Some of those had a fatal outcome. Particular attention </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">regarding the risk for infection should be paid when treating the elderly.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">See Vaccinations above.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has been studied in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients taking Humira as monotherapy and those taking concomitant methotrexate.  Antibody </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">formation was lower when Humira was given together with methotrexate in comparison with use as </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">169</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy. Administration of Humira without methotrexate resulted in increased formation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies, increased clearance and reduced efficacy of adalimumab (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The combination of Humira and anakinra is not recommended (see section 4.4 &#x201c;Concurrent administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of biologic DMARDS or TNF-antagonists&#x201d;). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The combination of Humira and abatacept is not recommended (see section 4.4 &#x201c;Concurrent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration of biologic DMARDS or TNF-antagonists&#x201d;).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Fertility, pregnancy and lactation</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential should consider the use of adequate contraception to prevent pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and continue its use for at least five months after the last Humira treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pregnancy</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A large number (approximately 2100) of prospectively collected pregnancies exposed to adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">resulting in live birth with known outcomes, including more than 1500 exposed during the first trimester, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">does not indicate an increase in the rate of malformation in the newborn.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a prospective cohort registry, 257 women with rheumatoid arthritis (RA) or Crohn&#x2019;s disease (CD) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with adalimumab at least during the first trimester and 120 women with RA or CD not treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab were enrolled.  The primary endpoint was the birth prevalence of major birth defects. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rate of pregnancies ending with at least one live born infant with a major birth defect was 6/69 (8.7%) in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the adalimumab-treated women with RA and 5/74 (6.8%) in the untreated women with RA (unadjusted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">OR 1.31, 95% CI 0.38-4.52) and 16/152 (10.5%) in the adalimumab-treated women with CD and 3/32 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(9.4%) in the untreated women with CD (unadjusted OR 1.14, 95% CI 0.31-4.16). The adjusted OR </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(accounting for baseline differences) was 1.10 (95% CI 0.45-2.73) with RA and CD combined. There were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">no distinct differences between adalimumab-treated and untreated women for the secondary endpoints </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spontaneous abortions, minor birth defects, preterm delivery, birth size and serious or opportunistic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections and no stillbirths or malignancies were reported. The interpretation of data may be impacted due </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to methodological limitations of the study, including small sample size and non-randomized design.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a developmental toxicity study conducted in monkeys, there was no indication of maternal toxicity, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">embryotoxicity or teratogenicity. Preclinical data on postnatal toxicity of adalimumab are not available </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(see section 5.3).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Due to its inhibition of TNF</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf061;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">, adalimumab administered during pregnancy could affect normal immune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responses in the newborn. Adalimumab should only be used during pregnancy if clearly needed.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab may cross the placenta into the serum of infants born to women treated with adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">during pregnancy. Consequently, these infants may be at increased risk for infection. Administration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">live vaccines (e.g., BCG vaccine) to infants exposed to adalimumab in utero is not recommended for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5 months following the mother&#x2019;s last adalimumab injection during pregnancy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Breast-feeding</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Limited information from the published literature indicates that adalimumab is excreted in breast milk at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">very low concentrations with the presence of adalimumab in human milk at concentrations of 0.1% to 1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of the maternal serum level. Given orally, immunoglobulin G proteins undergo intestinal proteolysis and </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">170</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have poor bioavailability. No effects on the breastfed newborns/infants are anticipated. Consequently, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira can be used during breastfeeding.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fertility</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Preclinical data on fertility effects of adalimumab are not available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.7</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Effects on ability to drive and use machines </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may have a minor influence on the ability to drive and use machines. Vertigo and visual </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">impairment may occur following administration of Humira (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Undesirable effects</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Summary of the safety profile</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira was studied in 9,506 patients in pivotal controlled and open label trials for up to 60 months or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more.  These trials included rheumatoid arthritis patients with short term and long standing disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis) as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">well as axial spondyloarthritis (ankylosing spondylitis and axial spondyloarthritis without radiographic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">evidence of AS), psoriatic arthritis, Crohn&#x2019;s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and uveitis patients. The pivotal controlled studies involved 6,089 patients receiving Humira and 3,801 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients receiving placebo or active comparator during the controlled period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The proportion of patients who discontinued treatment due to adverse events during the double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">controlled portion of pivotal studies was 5.9% for patients taking Humira and 5.4% for control treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The most commonly reported adverse reactions are infections (such as nasopharyngitis, upper respiratory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tract infection and sinusitis), injection site reactions (erythema, itching, haemorrhage, pain or swelling), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">headache and musculoskeletal pain.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious adverse reactions have been reported for Humira. TNF-antagonists, such as Humira affect the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immune system and their use may affect the body&#x2019;s defence against infection and cancer.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fatal and life-threatening infections (including sepsis, opportunistic infections and TB), HBV reactivation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and various malignancies (including leukaemia, lymphoma and HSTCL) have also been reported with use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious haematological, neurological and autoimmune reactions have also been reported. These include </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rare reports of pancytopenia, aplastic anaemia, central and peripheral demyelinating events and reports of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lupus, lupus-related conditions and Stevens-Johnson syndrome.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In general, the adverse events in paediatric patients were similar in frequency and type to those seen in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adult patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tabulated list of adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The following list of adverse reactions is based on experience from clinical trials and on postmarketing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experience and are displayed by system organ class and frequency in Table 7 below: very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1/10); common (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1/100 to &lt; 1/10); uncommon (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1/1,000 to &lt; 1/100); rare (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1/10,000 to &lt; 1/1,000); </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and not known (cannot be estimated from the available data). Within each frequency grouping, </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">171</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">undesirable effects are presented in order of decreasing seriousness. The highest frequency seen among the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">various indications has been included. An asterisk (*) appears in the SOC column if further information is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">found elsewhere in sections 4.3, 4.4 and 4.8.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:288pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 7</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:259pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Undesirable Effects</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:152pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:152pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:152pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Infections and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infestations*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Respiratory tract infections (including lower and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">upper respiratory tract infection, pneumonia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sinusitis, pharyngitis, nasopharyngitis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pneumonia herpes viral)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:244pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Systemic infections (including sepsis, candidiasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and influenza),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:266pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intestinal infections (including gastroenteritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">viral),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">skin and soft tissue infections (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paronychia, cellulitis, impetigo, necrotising </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:317pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fasciitis and herpes zoster),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ear infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">oral infections (including herpes simplex, oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">herpes and tooth infections), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:367pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reproductive tract infections (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vulvovaginal mycotic infection), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">urinary tract infections (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pyelonephritis),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fungal infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joint infections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neurological infections (including viral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">meningitis),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">opportunistic infections and tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(including coccidioidomycosis, histoplasmosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and mycobacterium avium complex infection), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bacterial infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">eye infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">diverticulitis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neoplasms benign, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">malignant and unspecified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(including cysts and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:624pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">polyps)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Skin cancer excluding melanoma (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">basal cell carcinoma and squamous cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">carcinoma),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">benign neoplasm</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Lymphoma**, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">solid organ neoplasm (including breast cancer, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lung neoplasm and thyroid neoplasm), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">melanoma**</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">172</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Leukaemia</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:116pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatosplenic T-cell lymphoma</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Merkel cell carcinoma (neuroendocrine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">carcinoma of the skin)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Kaposi&#x2019;s sarcoma</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:193pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Blood and the lymphatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">system disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:193pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:193pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Leukopenia (including neutropenia and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">agranulocytosis), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anaemia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Leucocytosis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">thrombocytopenia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Idiopathic thrombocytopenic purpura</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pancytopenia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immune system disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypersensitivity,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">allergies (including seasonal allergy)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sarcoidosis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vasculitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Anaphylaxis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Metabolism and nutrition </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Lipids increased</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypokalaemia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">uric acid increased, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blood sodium abnormal,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hypocalcaemia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hyperglycaemia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hypophosphatemia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dehydration</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psychiatric disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mood alterations (including depression), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anxiety,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">insomnia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Nervous system disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:700pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Headache</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">173</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paraesthesias (including hypoesthesia),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">migraine,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">nerve root compression</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cerebrovascular accident</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tremor,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">neuropathy  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Multiple sclerosis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demyelinating disorders (e.g. optic neuritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Guillain-Barr&#xe9; syndrome)</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Eye disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Visual impairment,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conjunctivitis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blepharitis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">eye swelling</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Diplopia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ear and labyrinth </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vertigo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Deafness, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tinnitus</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cardiac disorders* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tachycardia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Myocardial infarction</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arrhythmia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">congestive heart failure</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cardiac arrest</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vascular disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypertension, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">flushing, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">haematoma</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Aortic aneurysm,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vascular arterial occlusion,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">thrombophlebitis   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Respiratory, thoracic and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mediastinal disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Asthma,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dyspnoea,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cough</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">174</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pulmonary embolism</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interstitial lung disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chronic obstructive pulmonary disease,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pneumonitis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pleural effusion</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pulmonary fibrosis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Gastrointestinal disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Abdominal pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">nausea and vomiting</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:232pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">GI haemorrhage, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dyspepsia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">gastroesophageal reflux disease,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sicca syndrome</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pancreatitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dysphagia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">face oedema</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Intestinal perforation</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepato-biliary disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:382pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elevated liver enzymes</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cholecystitis and cholelithiasis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hepatic steatosis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bilirubin increased</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactivation of hepatitis B</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1) </span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoimmune hepatitis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Liver failure</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Skin and subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tissue disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:557pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rash (including exfoliative rash)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Worsening or new onset of psoriasis(including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">palmoplantar pustular psoriasis)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">urticaria,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bruising (including purpura), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dermatitis (including eczema),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:648pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">onychoclasis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hyperhidrosis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">alopecia</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pruritus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Night sweats,</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">175</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">scar</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:111pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:110pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erythema multiforme</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:126pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Stevens-Johnson syndrome</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:142pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">angioedema</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cutaneous vasculitis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lichenoid skin reaction</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:205pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Worsening of symptoms of dermatomyositis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Musculoskeletal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">connective tissue disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Musculoskeletal pain</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Muscle spasms (including blood creatine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">phosphokinase increased)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rhabdomyolysis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">systemic lupus erythematosus</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Lupus-like syndrome</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal and urinary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal impairment,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">haematuria</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Nocturia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reproductive system and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">breast disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erectile dysfunction</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">General disorders and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:496pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration site </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conditions*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Injection site reaction (including injection site </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:496pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">erythema)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Chest pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">oedema,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pyrexia</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Inflammation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Investigations*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Coagulation and bleeding disorders (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">activated partial thromboplastin time prolonged), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoantibody test positive (including double </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">stranded DNA antibody), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blood lactate dehydrogenase increased</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Weight increased</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Injury, poisoning and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">procedural complications</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Impaired healing</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">176</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:68pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">* further information is found elsewhere in sections 4.3, 4.4 and 4.8</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:81pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">** including open label extension studies</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:89pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> including spontaneous reporting data</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2)</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> The mean weight change from baseline for adalimumab ranged from 0.3 kg to 1.0 kg across adult </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">indications compared to (minus) -0.4 kg to 0.4 kg for placebo over a treatment period of 4-6 months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Weight increase of 5-6 kg has also been observed in long-term extension studies with mean exposures of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 1-2 years without control group, particularly in patients with Crohn&#x2019;s disease and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ulcerative colitis. The mechanism behind this effect is unclear but could be associated with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anti-inflammatory effect of adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hidradenitis suppurativa</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety profile for patients with HS treated with Humira weekly was consistent with the known safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">profile of Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uveitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety profile for patients with uveitis treated with Humira every other week was consistent with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">known safety profile of Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Description of selected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Injection site reactions</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the pivotal controlled trials in adults and children, 12.9% of patients treated with Humira developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection site reactions (erythema and/or itching, haemorrhage, pain or swelling), compared to 7.2% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients receiving placebo or active control. Injection site reactions generally did not necessitate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">discontinuation of the medicinal product.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Infections </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the pivotal controlled trials in adults and children, the rate of infection was 1.51 per patient year in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treated patients and 1.46 per patient year in the placebo and active control-treated patients. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections consisted primarily of nasopharyngitis, upper respiratory tract infection, and sinusitis. Most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients continued on Humira after the infection resolved.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The incidence of serious infections was 0.04 per patient year in Humira treated patients and 0.03 per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient year in placebo and active control &#x2212; treated patients.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled and open label adult and paediatric studies with Humira, serious infections (including fatal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections, which occurred rarely) have been reported, which include reports of tuberculosis (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extrapulmonary histoplasmosis, blastomycosis, coccidioidomycosis, pneumocystis, candidiasis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">aspergillosis and listeriosis). Most of the cases of tuberculosis occurred within the first eight months after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initiation of therapy and may reflect recrudescence of latent disease.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No malignancies were observed in 249 paediatric patients with an exposure of 655.6 patient years during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira trials in patients with juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enthesitis-related arthritis). In addition, no malignancies were observed in 192 paediatric patients with an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exposure of 498.1 patient years during Humira trials in paediatric patients with Crohn&#x2019;s disease. No </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">177</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">malignancies were observed in 77 paediatric patients with an exposure of 80.0 patient years during a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira trial in paediatric patients with chronic plaque psoriasis. No malignancies were observed in 93</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients with an exposure of 65.3 patient years during a Humira trial in paediatric patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ulcerative colitis. No malignancies were observed in 60 paediatric patients with an exposure of 58.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient years during a Humira trial in paediatric patients with uveitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During the controlled portions of pivotal Humira trials in adults of at least 12 weeks in duration in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">without radiographic evidence of AS,  psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease, ulcerative colitis and uveitis, malignancies, other than lymphoma and non-melanoma skin cancer, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were observed at a rate (95% confidence interval) of 6.8 (4.4, 10.5)  per 1,000 patient-years among 5,291 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treated patients </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a rate of 6.3 (3.4, 11.8) per 1,000 patient-years among 3,444 control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (median duration of treatment was 4.0 months for Humira and 3.8 months for control-treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients). The rate (95% confidence interval) of non-melanoma skin cancers was 8.8 (6.0, 13.0) per 1,000 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient-years among Humira-treated patients and 3.2 (1.3, 7.6) per 1,000 patient-years among control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients. Of these skin cancers, squamous cell carcinomas occurred at rates (95% confidence interval) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.7 (1.4, 5.4) per 1,000 patient-years among Humira-treated patients and 0.6 (0.1, 4.5) per 1,000 patient-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">years among control patients. The rate (95% confidence interval) of lymphomas was 0.7 (0.2, 2.7) per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1,000 patient-years among Humira-treated patients and 0.6 (0.1, 4.5) per 1,000 patient-years among </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">control patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">When combining controlled portions of these trials and ongoing and completed open label extension </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies with a median duration of approximately 3.3 years including 6,427 patients and over 26,439 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient-years of therapy, the observed rate of malignancies, other than lymphoma and non-melanoma skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cancers is approximately 8.5 per 1,000 patient years. The observed rate of non-melanoma skin cancers is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 9.6 per 1,000 patient years, and the observed rate of lymphomas is approximately 1.3 per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1,000 patient years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In post-marketing experience from January 2003 to December 2010, predominantly in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rheumatoid arthritis, the reported rate of malignancies is approximately 2.7 per 1,000 patient treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">years. The reported rates for non-melanoma skin cancers and lymphomas are approximately 0.2 and 0.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">per 1,000 patient treatment years, respectively (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare post-marketing cases of hepatosplenic T-cell lymphoma have been reported in patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Autoantibodies </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients had serum samples tested for autoantibodies at multiple time points in rheumatoid arthritis studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">I &#x2212; V. In these trials, 11.9% of patients treated with Humira and 8.1% of placebo and active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">control &#x2212; treated patients that had negative baseline anti-nuclear antibody titres reported positive titres at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24. Two patients out of 3,441 treated with Humira in all rheumatoid arthritis and psoriatic arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies developed clinical signs suggestive of new-onset lupus-like syndrome. The patients improved </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">following discontinuation of therapy. No patients developed lupus nephritis or central nervous system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">178</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Hepato-biliary events</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled Phase 3 trials of Humira in patients with rheumatoid arthritis and psoriatic arthritis with a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">control period duration ranging from 4 to 104 weeks, ALT elevations &#x2265; 3 x ULN occurred in 3.7% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira-treated patients and 1.6% of control-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled Phase 3 trials of Humira in patients with polyarticular juvenile idiopathic arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 to 17 years and enthesitis-related arthritis who were 6 to 17 years, ALT elevations &#x2265; 3 x ULN occurred </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in 6.1% of Humira-treated patients and 1.3% of control-treated patients. Most ALT elevations occurred </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with concomitant methotrexate use. No ALT elevations &#x2265; 3 x ULN occurred in the Phase 3 trial of Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients with polyarticular juvenile idiopathic arthritis who were 2 to &lt; 4 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled Phase 3 trials of Humira in patients with Crohn&#x2019;s disease and ulcerative colitis with a control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">period ranging from 4 to 52 weeks. ALT elevations &#x2265; 3 x ULN occurred in 0.9% of Humira-treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients and 0.9% of controlled-treated patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the Phase 3 trial of Humira in patients with paediatric Crohn&#x2019;s disease which evaluated efficacy and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">safety of two body weight adjusted maintenance dose regimens following body weight adjusted induction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy up to 52 weeks of treatment, ALT elevations &#x2265; 3 x ULN occurred in 2.6% (5/192) of patients of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">whom 4 were receiving concomitant immunosuppressants at baseline.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled Phase 3 trials of Humira in patients with plaque psoriasis with a control period duration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ranging from 12 to 24 weeks, ALT elevations &#x2265; 3 x ULN occurred in 1.8% of Humira-treated patients and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.8% of control-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No ALT elevations &#x2265; 3 X ULN occurred in the Phase 3 trial of Humira in paediatric patients with plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled trials of Humira (initial doses of 160 mg at Week 0 and 80 mg at Week 2, followed by 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every week starting at Week 4), in patients with hidradenitis suppurativa with a control period duration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ranging from 12 to 16 weeks, ALT elevations &#x2265; 3 x ULN occurred in 0.3% of Humira-treated patients and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.6% of control-treated patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled trials of Humira (initial doses of 80 mg at Week 0 followed by 40 mg every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting at Week 1) in adult patients with uveitis up to 80 weeks with a median exposure of 166.5 days and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">105.0 days in Humira-treated and control-treated patients, respectively, ALT elevations &#x2265; 3 x ULN </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurred in 2.4% of Humira-treated patients and 2.4% of control-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the controlled Phase 3 trial of Humira in patients with paediatric ulcerative colitis (N=93) which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">evaluated efficacy and safety of a maintenance dose of 0.6 mg/kg (maximum of 40 mg) every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N=31) and a maintenance dose of 0.6 mg/kg (maximum of 40 mg) every Week (N=32), following body </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weight adjusted induction dosing of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2 (N=63), or an induction dose of 2.4 mg/kg (maximum of 160 mg) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at Week 0, placebo at Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2 (N=30), ALT elevations &#x2265; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 X ULN occurred in 1.1% (1/93) of patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Across all indications in clinical trials patients with raised ALT were asymptomatic and in most cases </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">elevations were transient and resolved on continued treatment.  However, there have also been post-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">marketing reports of liver failure as well as less severe liver disorders that may precede liver failure, such </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as hepatitis including autoimmune hepatitis in patients receiving adalimumab.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">179</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with azathioprine/6-mercaptopurine</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult Crohn&#x2019;s disease studies, higher incidences of malignant and serious infection-related adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">events were seen with the combination of Humira and azathioprine/6-mercaptopurine compared with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira alone.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting of suspected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important.  It allows </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued monitoring of the benefit/risk balance of the medicinal product.  Healthcare professionals are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">asked to report any suspected adverse reactions via the national reporting system listed in </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000ff">Appendix V.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Overdose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose-limiting toxicity was observed during clinical trials. The highest dose level evaluated has been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">multiple intravenous doses of 10 mg/kg, which is approximately 15 times the recommended dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacodynamic properties</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-&#x3b1;) inhibitors. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ATC code: L04AB04</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mechanism of action</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab binds specifically to TNF and neutralises the biological function of TNF by blocking its </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interaction with the p55 and p75 cell surface TNF receptors.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with an IC</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> of 0.1-0.2 nM). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharmacodynamic effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After treatment with Humira, a rapid decrease in levels of acute phase reactants of inflammation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and serum cytokines (IL-6) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed, compared to baseline in patients with rheumatoid arthritis. Serum levels of matrix </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">destruction were also decreased after Humira administration. Patients treated with Humira usually </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced improvement in haematological signs of chronic inflammation.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A rapid decrease in CRP levels was also observed in patients with polyarticular juvenile idiopathic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis, Crohn&#x2019;s disease, ulcerative colitis and hidradenitis suppurativa after treatment with Humira. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with Crohn&#x2019;s disease, a reduction of the number of cells expressing inflammatory markers in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">colon including a significant reduction of expression of TNF&#x3b1; was seen. Endoscopic studies in intestinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mucosa have shown evidence of mucosal healing in adalimumab treated patients.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">180</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical efficacy and safety</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Rheumatoid arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira was evaluated in over 3,000 patients in all rheumatoid arthritis clinical trials. The efficacy and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">safety of Humira were assessed in five randomised, double-blind and well-controlled studies. Some </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients were treated for up to 120 months duration. Injection site pain of Humira 40 mg/0.4 ml was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assessed in two randomised, active control, single-blind, two-period crossover studies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study I evaluated 271 patients with moderately to severely active rheumatoid arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 years old, had failed therapy with at least one disease-modifying, anti rheumatic drug and had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">insufficient efficacy with methotrexate at doses of 12.5 to 25 mg (10 mg if methotrexate-intolerant) every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">week and whose methotrexate dose remained constant at 10 to 25 mg every week. Doses of 20, 40 or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg of Humira or placebo were given every other week for 24 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study II evaluated 544 patients with moderately to severely active rheumatoid arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 years old and had failed therapy with at least one disease-modifying, anti-rheumatic drugs.  Doses of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 or 40 mg of Humira were given by subcutaneous injection every other week with placebo on alternative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks or every week for 26 weeks; placebo was given every week for the same duration.  No other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease-modifying anti-rheumatic drugs were allowed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study III evaluated 619 patients with moderately to severely active rheumatoid arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 years old, and who had an ineffective response to methotrexate at doses of 12.5 to 25 mg or have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been intolerant to 10 mg of methotrexate every week. There were three groups in this study.  The first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received placebo injections every week for 52 weeks. The second received 20 mg of Humira every week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for 52 weeks. The third group received 40 mg of Humira every other week with placebo injections on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">alternate weeks. Upon completion of the first 52 weeks, 457 patients enrolled in an open-label extension </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">phase in which 40 mg of Humira/MTX was administered every other week up to 10 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study IV primarily assessed safety in 636 patients with moderately to severely active rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis who were </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 years old. Patients were permitted to be either disease-modifying, anti-rheumatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">drug-na&#xef;ve or to remain on their pre-existing rheumatologic therapy provided that therapy was stable for a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">minimum of 28 days. These therapies include methotrexate, leflunomide, hydroxychloroquine, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sulfasalazine and/or gold salts. Patients were randomised to 40 mg of Humira or placebo every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for 24 weeks.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study V evaluated 799 methotrexate-na&#xef;ve, adult patients with moderate to severely active early </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rheumatoid arthritis (mean disease duration less than 9 months). This study evaluated the efficacy of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg every other week/methotrexate combination therapy, Humira 40 mg every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and methotrexate monotherapy in reducing the signs and symptoms and rate of progression </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of joint damage in rheumatoid arthritis for 104 weeks. Upon completion of the first 104 weeks, 497 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients enrolled in an open-label extension phase in which 40 mg of Humira was administered every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week up to 10 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA studies VI and VII each evaluated 60 patients with moderately to severely active rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who were &#x2265; 18 years old. Enrolled patients were either current users of Humira 40 mg/0.8 ml and rated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">their average injection site pain as at least 3 cm (on a 0-10 cm VAS) or were biologic-na&#xef;ve subjects who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were starting Humira 40 mg/0.8 ml. Patients were randomised to receive a single dose of Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg/0.8 ml or Humira 40 mg/0.4 ml, followed by a single injection of the opposite treatment at their </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">next dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary end point in RA studies I, II and III and the secondary endpoint in RA study IV was the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">percent of patients who achieved an ACR 20 response at Week 24 or 26. The primary endpoint in RA </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">181</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study V was the percent of patients who achieved an ACR 50 response at Week 52. RA studies III and V </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had an additional primary endpoint at 52 weeks of retardation of disease progression (as detected by X-ray </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">results). RA study III also had a primary endpoint of changes in quality of life. The primary endpoint in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA studies VI and VII was injection site pain immediately after injection as measured by a 0-10 cm VAS.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">ACR response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The percent of Humira-treated patients achieving ACR 20, 50 and 70 responses was consistent across RA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies I, II and III. The results for the 40 mg every other week dose are summarised in Table 8. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:197pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">ACR Responses in Placebo-Controlled Trials</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:255pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(Percent of Patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:169pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA Study I</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:298pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA Study II</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:428pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA Study III</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:144pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:149pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:151pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=60</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:194pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">/ MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:218pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=63</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:287pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=110</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:346pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:350pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=113</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=200</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:460pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">/ MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=207</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:149pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:215pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:287pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">19.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:350pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">63.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:222pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:293pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:356pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:151pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:215pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:350pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:222pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:293pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:356pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:151pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:215pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:350pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:222pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:293pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:356pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> RA study I at 24 weeks, RA study II at 26 weeks, and RA study III at 24 and 52 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 40 mg Humira administered every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> MTX = methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**p &lt; 0.01, Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA studies I-IV, all individual components of the ACR response criteria (number of tender and swollen </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joints, physician and patient assessment of disease activity and pain, disability index (HAQ) scores and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">CRP (mg/dl) values) improved at 24 or 26 weeks compared to placebo. In RA study III, these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvements were maintained throughout 52 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension for RA study III, most patients who were ACR responders maintained </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response when followed for up to 10 years. Of 207 patients who were randomised to Humira 40 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week, 114 patients continued on Humira 40 mg every other week for 5 years. Among those, 86 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (75.4%) had ACR 20 responses; 72 patients (63.2%) had ACR 50 responses; and 41 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(36%) had ACR 70 responses. Of 207 patients, 81 patients continued on Humira 40 mg every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for 10 years. Among those, 64 patients (79.0%) had ACR 20 responses; 56 patients (69.1%) had ACR 50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responses; and 43 patients (53.1%) had ACR 70 responses.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study IV, the ACR 20 response of patients treated with Humira plus standard of care was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">statistically significantly better than patients treated with placebo plus standard of care (p &lt; 0.001).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA studies I-IV, Humira-treated patients achieved statistically significant ACR 20 and 50 responses </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared to placebo as early as one to two weeks after initiation of treatment.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">182</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study V with early rheumatoid arthritis patients who were methotrexate na&#xef;ve, combination therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Humira and methotrexate led to faster and significantly greater ACR responses than methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and Humira monotherapy at Week 52 and responses were sustained at Week 104 (see Table </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:288pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:233pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">ACR Responses in RA Study V</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:258pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(percent of patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:178pt;left:79pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:172pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:170pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n=257</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:232pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:236pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n=274</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:290pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira/MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:308pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n=268</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:371pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">p-value</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:427pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">p-value</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:487pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">p-value</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">c</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">62.6%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">54.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">72.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:377pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.013</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.043</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">56.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">69.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:377pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.002</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.140</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">61.6%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.317</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">42.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">27.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.656</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46.6%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.864</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:80pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a. p-value is from the pairwise comparison of methotrexate monotherapy and Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy using the Mann-Whitney U test.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:80pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b. p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy using the Mann-Whitney U test</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:80pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">c.   p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using the Mann-Whitney U test</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:480pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension for RA study V, ACR response rates were maintained when followed for up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:493pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 years. Of 542 patients who were randomised to Humira 40 mg every other week, 170 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued on Humira 40 mg every other week for 10 years. Among those, 154 patients (90.6%) had ACR </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 responses; 127 patients (74.7%) had ACR 50 responses; and 102 patients (60.0%) had ACR 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responses.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 52, 42.9% of patients who received Humira/methotrexate combination therapy achieved clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission (DAS28 (CRP) &lt; 2.6) compared to 20.6% of patients receiving methotrexate monotherapy and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.4% of patients receiving Humira monotherapy. Humira/methotrexate combination therapy was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinically and statistically superior to methotrexate (p &lt; 0.001) and Humira monotherapy (p &lt; 0.001) in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">achieving a low disease state in patients with recently diagnosed moderate to severe rheumatoid arthritis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The response for the two monotherapy arms was similar (p = 0.447).  Of 342 subjects originally </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomized to Humira monotherapy or Humira/methotrexate combination therapy who entered the open-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">label extension study, 171 subjects completed 10 years of Humira treatment. Among those, 109 subjects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(63.7%) were reported to be in remission at 10 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Radiographic response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study III, where Humira treated patients had a mean duration of rheumatoid arthritis of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 11 years, structural joint damage was assessed radiographically and expressed as change in </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">183</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">modified Total Sharp Score (TSS) and its components, the erosion score and joint space narrowing score.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira/methotrexate patients demonstrated significantly less radiographic progression than patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving methotrexate alone at 6 and 12 months (see Table 10).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension of RA Study III, the reduction in rate of progression of structural damage is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintained for 8 and 10 years in a subset of patients. At 8 years, 81 of 207 patients originally treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg Humira every other week were evaluated radiographically. Among those, 48 patients showed no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">progression of structural damage defined by a change from baseline in the mTSS of 0.5 or less. At </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 years, 79 of 207 patients originally treated with 40 mg Humira every other week were evaluated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">radiographically. Among those, 40 patients showed no progression of structural damage defined by a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">change from baseline in the mTSS of 0.5 or less.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:271pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:147pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Radiographic Mean Changes Over 12 Months in RA Study III</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:180pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo/</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:180pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:260pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira/MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:263pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:266pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:352pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo/MTX-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:342pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira/MTX (95% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:360pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:365pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Interval</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:458pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Sharp Score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:284pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:357pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.6 (1.4, 3.8) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:456pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:92pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erosion score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:284pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:357pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.6 (0.9, 2.2)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:457pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">JSN</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:284pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:357pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.9 (0.3, 1.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:459pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  0.002</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">95% confidence intervals for the differences in change scores between methotrexate and Humira. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Based on rank analysis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Joint Space Narrowing</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study V, structural joint damage was assessed radiographically and expressed as change in modified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Sharp Score (see Table 11).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:278pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 11</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:164pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  Radiographic Mean Changes at Week 52 in RA Study V</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:173pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=257</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(95% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:162pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:167pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interval)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:244pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:247pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=274</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:249pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(95% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:237pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:242pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interval)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:305pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira/MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=268</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(95% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:311pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:317pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interval)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:379pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:428pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:478pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:85pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Sharp </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:158pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.7 (4.2-7.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0 (1.7-4.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.3 (0.5-2.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0020</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:479pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erosion score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:158pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.7 (2.7-4.7)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.7 (1.0-2.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.8 (0.4-1.2)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0082</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:479pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:89pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">JSN score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:158pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.0 (1.2-2.8)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.3 (0.5-2.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:312pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.5 (0-1.0)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0037</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:484pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.151</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value is from the pairwise comparison of methotrexate monotherapy and Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy using the Mann-Whitney U test.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy using the Mann-Whitney U test </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using the Mann-Whitney U test</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following 52 weeks and 104 weeks of treatment, the percentage of patients without progression (change </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">from baseline in modified Total Sharp Score </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.5) was significantly higher with Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy (63.8% and 61.2% respectively) compared to methotrexate monotherapy (37.4% and </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">184</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33.5% respectively, p &lt; 0.001) and Humira monotherapy (50.7%, p &lt; 0.002 and 44.5%, p &lt; 0.001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension of RA study V, the mean change from baseline at Year 10 in the modified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Sharp Score was 10.8, 9.2 and 3.9 in patients originally randomized to methotrexate monotherapy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira monotherapy and Humira/methotrexate combination therapy, respectively. The corresponding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">proportions of patients with no radiographic progression were 31.3%, 23.7% and 36.7% respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of life and physical function </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Health-related quality of life and physical function were assessed using the disability index of the Health </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Assessment Questionnaire (HAQ) in the four original adequate and well-controlled trials, which was a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pre-specified primary endpoint at Week 52 in RA study III. All doses/schedules of Humira in all four </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies showed statistically significantly greater improvement in the disability index of the HAQ from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">baseline to Month 6 compared to placebo and in RA study III the same was seen at Week 52. Results from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the Short Form Health Survey (SF 36) for all doses/schedules of Humira in all four studies support these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">findings, with statistically significant physical component summary (PCS) scores, as well as statistically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significant pain and vitality domain scores for the 40 mg every other week dose. A statistically significant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">decrease in fatigue as measured by functional assessment of chronic illness therapy (FACIT) scores was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">seen in all three studies in which it was assessed (RA studies I, III, IV).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study III, most subjects who achieved improvement in physical function and continued treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintained improvement through Week 520 (120 months) of open-label treatment. Improvement in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">quality of life was measured up to Week 156 (36 months) and improvement was maintained through that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">time.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study V, the improvement in the HAQ disability index and the physical component of the SF 36 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">showed greater improvement (p &lt; 0.001) for Humira/methotrexate combination therapy </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate monotherapy and Humira monotherapy at Week 52, which was maintained through </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 104. Among the 250 subjects who completed the open-label extension study, improvements in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">physical function were maintained through 10 years of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Injection site pain</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For the pooled crossover RA studies VI and VII, a statistically significant difference for injection site pain </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immediately after dosing was observed between Humira 40 mg/0.8 ml and Humira 40 mg/0.4 ml (mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">VAS of 3.7 cm versus 1.2 cm, scale of 0-10 cm, P &lt; 0.001). This represented an 84% median reduction in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection site pain.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Axial spondyloarthritis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Ankylosing spondylitis (AS)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg every other week was assessed in 393 patients in two randomised, 24 week double &#x2212; blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo &#x2212; controlled studies in patients with active ankylosing spondylitis (mean baseline score of disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.3 in all groups) who have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had an inadequate response to conventional therapy. Seventy-nine (20.1%) patients were treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitantly with disease modifying anti &#x2212; rheumatic drugs, and 37 (9.4%) patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">glucocorticoids. The blinded period was followed by an open &#x2212; label period during which patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received Humira 40 mg every other week subcutaneously for up to an additional 28 weeks. Subjects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n=215, 54.7%) who failed to achieve ASAS 20 at Weeks 12, or 16 or 20 received early escape open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab 40 mg every other week subcutaneously and were subsequently treated as non-responders in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the double-blind statistical analyses.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">185</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the larger AS study I with 315 patients, results showed statistically significant improvement of the signs </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and symptoms of ankylosing spondylitis in patients treated with Humira compared to placebo.  Significant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response was first observed at Week 2 and maintained through 24 weeks (Table 12). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 12</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:163pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Efficacy Responses in Placebo-Controlled AS Study &#x2013; Study I</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:225pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Reduction of Signs and Symptoms</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:127pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:294pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:298pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=107</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:404pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:408pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=208</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:192pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">             Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:303pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">42%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:303pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">21%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:303pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">19%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">51%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">             Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:303pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:303pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">11%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">35%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:302pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">             Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7%**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:342pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BASDAI</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">             Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:303pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:407pt;left:163pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:407pt;left:303pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:407pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">42%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:420pt;left:120pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">***,** Statistically significant at p &lt; 0.001, &lt; 0.01 for all comparisons between Humira and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:433pt;left:120pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo at Weeks 2, 12 and  24</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:120pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Assessments in Ankylosing Spondylitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:120pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Bath Ankylosing Spondylitis Disease Activity Index</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:484pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treated patients had significantly greater improvement at Week 12 which was maintained through </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:496pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24 in both the SF36 and Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Similar trends (not all statistically significant) were seen in the smaller randomised, double &#x2212; blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo controlled AS study II of 82 adult patients with active ankylosing spondylitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Axial spondyloarthritis without radiographic evidence of AS</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in two randomized, double-blind placebo controlled </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies in patients with non-radiographic axial spondyloarthritis (nr-axSpA). Study nr-axSpA I evaluated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:610pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with active nr-axSpA. Study nr-axSpA II was a treatment withdrawal study in active nr-axSpA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who achieved remission during open-label treatment with Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:648pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study nr-axSpA I</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Study nr-axSpA I, Humira 40 mg every other week was assessed in 185 patients in a randomised, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 week double - blind, placebo - controlled study in patients with active nr-axSpA (mean baseline score </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.4 for patients </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">186</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with Humira and 6.5 for those on placebo) who have had an inadequate response to or intolerance </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1 NSAIDs, or a contraindication for NSAIDs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Thirty-three (18%)  patients were treated concomitantly with disease modifying anti-rheumatic drugs, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">146 (79%) patients with NSAIDs at baseline. The double-blind period was followed by an open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">period during which patients receive Humira 40 mg every other week subcutaneously for up to an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">additional 144 weeks. Week 12 results showed statistically significant improvement of the signs and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms of active nr-axSpA in patients treated with Humira compared to placebo (Table 13).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 13</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:167pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Efficacy Response in Placebo-Controlled Study nr-axSpA I</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:74pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Double-Blind</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:74pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Response at Week 12</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:381pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:10.08pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:386pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:10.08pt">N=94</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:474pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:10.08pt">Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:480pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:10.08pt">N=91</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:231pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:473pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">31%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:475pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52%**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS 5/6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:473pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">31%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS Partial Remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:475pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  16%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BASDAI</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   35%**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASDAS</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c,d,e</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:389pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-0.3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:474pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-1.0***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASDAS Inactive Disease</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:390pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:473pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hs-CRP</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d,f,g</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:389pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-0.3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:474pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-4.7***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">SPARCC</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">h</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MRI Sacroiliac Joints</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d,i</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:389pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-0.6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:477pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-3.2**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">SPARCC MRI Spine</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d,j</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:389pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-0.2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:477pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-1.8**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Assessment of SpondyloArthritis international Society</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Bath Ankylosing Spondylitis Disease Activity Index</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Ankylosing Spondylitis Disease Activity Score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> mean change from baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">e</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> n=91 placebo and n=87 Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">f</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> high sensitivity C-Reactive Protein (mg/L)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">g</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> n=73 placebo and n=70 Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">h</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Spondyloarthritis Research Consortium of Canada</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">i</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> n=84 placebo and Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">j</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> n=82 placebo and n=85 Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">***, **, * Statistically significant at p &lt; 0.001, &lt; 0.01, and &lt; 0.05, respectively, for all comparisons </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">between Humira and placebo.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension, improvement in the signs and symptoms was maintained with Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy through Week 156.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Inhibition of inflammation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#221e1f">Significant improvement of signs of inflammation as measured by hs-CRP and MRI of both Sacroiliac </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#221e1f">Joints and the Spine was maintained in Humira-treated patients through Week 156 and Week 104, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:622pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#221e1f">respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:647pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Quality of life and physical function</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Health-related quality of life and physical function were assessed using the HAQ-S and the SF-36 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">questionnaires. Humira showed statistically significantly greater improvement in the HAQ-S total score </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and the SF-36 Physical Component Score (PCS) from baseline to Week 12 compared to placebo. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">187</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Improvement in health-related quality of life and physical function was maintained during the open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension through Week 156.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study nr-axSpA II</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">673 patients with active nr-axSpA (mean baseline disease activity [BASDAI] was 7.0) who had an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inadequate response to </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 2 NSAIDs, or an intolerance to or a contraindication for NSAIDs enrolled into </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the open-label period of Study nr-axSpA II during which they received Humira 40 mg eow for 28 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">These patients also had objective evidence of inflammation in the sacroiliac joints or spine on MRI or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">elevated hs-CRP. Patients who achieved sustained remission for at least 12 weeks (N=305) (ASDAS &lt; 1.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at Weeks 16, 20, 24, and 28) during the open-label period were then randomized to receive either </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued treatment with Humira 40 mg eow (N=152) or placebo (N=153) for an additional 40 weeks in a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">double-blind, placebo-controlled period (total study duration 68 weeks). Subjects who flared during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">double-blind period were allowed Humira 40 mg eow rescue therapy for at least 12 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary efficacy endpoint was the proportion of patients with no flare by Week 68 of the study. Flare </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was defined as ASDAS &#x2265; 2.1 at two consecutive visits four weeks apart. A greater proportion of patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">on Humira had no disease flare during the double-blind period, when compared with those on placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(70.4% vs. 47.1%, p&lt;0.001) (Figure 1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:158pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Figure 1: Kaplan-Meier Curves Summarizing Time to Flare in</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:262pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Study nr-axSpA II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:10.08pt">                   PROBABILITY OF NO FLARE</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:281pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:10.08pt">TIME (WEEKS)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:10.08pt">                                  Treatment      </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:252pt"><span style="font-family:TimesNewRoman,serif;font-size:10.08pt">Placebo     </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:331pt"><span style="font-family:TimesNewRoman,serif;font-size:10.08pt">Humira     &#x2206; Censored</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note: P = Placebo (Number at Risk (flared)); A = HUMIRA (Number at Risk (flared)).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among the 68 patients who flared in the group allocated to treatment withdrawal, 65 completed 12 weeks </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:647pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of rescue therapy with Humira, out of which 37 (56.9%) had regained remission (ASDAS &lt; 1.3) after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 weeks of restarting the open-label treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">By Week 68, patients receiving continuous Humira treatment showed statistically significant greater</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement of the signs and symptoms of active nr-axSpA as compared to patients allocated to treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">withdrawal during the double-blind period of the study (Table 14).</span></p>
<img style="position:absolute;top:336pt;left:98pt;width:442pt;height:118pt" src="data:image/png;base64,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">
<img style="position:absolute;top:454pt;left:98pt;width:442pt;height:118pt" src="data:image/png;base64,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">
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">188</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:303pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 14</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:158pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Efficacy Response in Placebo-Controlled Period for Study nr-axSpA II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:74pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Double-Blind</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:74pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Response at Week 68</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:386pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:10.08pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:389pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:10.08pt">N=153</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:477pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:10.08pt">Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:119pt;left:480pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:10.08pt">N=152</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:129pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a,b</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">47.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">70.4%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:142pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a,b</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.8%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:156pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASAS</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Partial Remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">26.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:474pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">42.1%**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ASDAS</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Inactive Disease</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">57.2%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Partial Flare</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:388pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40.8%***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:74pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Assessment of SpondyloArthritis international Society</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Baseline is defined as open label baseline when patients have active disease.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:220pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Ankylosing Spondylitis Disease Activity Score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Partial flare is defined as ASDAS &#x2265; 1.3 but &lt; 2.1 at 2 consecutive visits.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">***, ** Statistically significant at p &lt; 0.001 and &lt; 0.01, respectively, for all comparisons between </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira and placebo.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Psoriatic arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira, 40 mg every other week, was studied in patients with moderately to severely active psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis in two placebo-controlled studies, PsA studies I and II.  PsA study I with 24 week duration, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated 313 adult patients who had an inadequate response to non-steroidal anti-inflammatory drug therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and of these, approximately 50% were taking methotrexate. PsA study II with 12-week duration, treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">100 patients who had an inadequate response to DMARD therapy. Upon completion of both studies, 383 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients enrolled in an open-label extension study, in which 40 mg Humira was administered every other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is insufficient evidence of the efficacy of Humira in patients with ankylosing spondylitis-like </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriatic arthropathy due to the small number of patients studied. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 15</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:155pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">ACR Response in Placebo-Controlled Psoriatic Arthritis Studies</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:258pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(Percent of Patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:256pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PsA Study I</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:387pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PsA Study II</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:132pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:233pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:235pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:299pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:301pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=151</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:365pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:370pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=49</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:437pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=51</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:132pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:240pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:301pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:372pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:437pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:240pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:301pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">57%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N/A</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:440pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N/A</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:132pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:243pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:301pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:375pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:434pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:243pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:301pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N/A</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:440pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N/A</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:132pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 12</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:243pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:301pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:375pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:436pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14%</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:243pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:301pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N/A</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:440pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N/A</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:132pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">***</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.001 for all comparisons between Humira and placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:132pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:160pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.05 for all comparisons between Humira and placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:132pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N/A  not applicable</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR responses in PsA study I were similar with and without concomitant methotrexate therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR responses were maintained in the open-label extension study for up to 136 weeks.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">189</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Radiographic changes were assessed in the psoriatic arthritis studies. Radiographs of hands, wrists, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">feet were obtained at baseline and Week 24 during the double-blind period when patients were on Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or placebo and at Week 48 when all patients were on open-label Humira. A modified Total Sharp Score </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(mTSS), which included distal interphalangeal joints (i.e. not identical to the TSS used for rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis), was used.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treatment reduced the rate of progression of peripheral joint damage compared with placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment as measured by change from baseline in mTSS  (mean &#xb1; SD) 0.8 &#xb1; 2.5 in the placebo group (at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24) compared with 0.0 &#xb1; 1.9; (p&lt; 0.001) in the Humira group (at Week 48).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In subjects treated with Humira with no radiographic progression from baseline to Week 48 (n=102), 84% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued to show no radiographic progression through 144 weeks of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treated patients demonstrated statistically significant improvement in physical function as assessed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">by HAQ and Short Form Health Survey (SF 36) compared to placebo at Week 24. Improved physical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">function continued during the open label extension up to Week 136.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Psoriasis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were studied in adult patients with chronic plaque psoriasis (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 10% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BSA involvement and Psoriasis Area and Severity Index (PASI) </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 12 or </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 10) who were candidates for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">systemic therapy or phototherapy in randomised, double-blind studies. 73% of patients enrolled in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Studies I and II had received prior systemic therapy or phototherapy.  The safety and efficacy of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira were also studied in adult patients with moderate to severe chronic plaque psoriasis with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant hand and/or foot psoriasis who were candidates for systemic therapy in a randomised double-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blind study (Psoriasis Study III).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Study I (REVEAL) evaluated 1,212 patients within three treatment periods.  In period A, patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received placebo or Humira at an initial dose of 80 mg followed by 40 mg every other week starting one </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">week after the initial dose. After 16 weeks of therapy, patients who achieved at least a PASI 75 response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(PASI score improvement of at least 75% relative to baseline), entered period B and received open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg Humira every other week. Patients who maintained </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75 response at Week 33 and were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">originally randomised to active therapy in Period A, were re-randomised in period C to receive 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira every other week or placebo for an additional 19 weeks. Across all treatment groups, the mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">baseline PASI score was 18.9 and the baseline Physician&#x2019;s Global Assessment (PGA) score ranged from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x201c;moderate&#x201d; (53% of subjects included) to &#x201c;severe&#x201d; (41%) to &#x201c;very severe&#x201d; (6%).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Study II (CHAMPION) compared the efficacy and safety of Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> methotrexate and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo in 271 patients. Patients received placebo, an initial dose of MTX 7.5 mg and thereafter dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increases up to Week 12, with a maximum dose of 25 mg or an initial dose of 80 mg Humira followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week (starting one week after the initial dose) for 16 weeks. There are no data available </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparing Humira and MTX beyond 16 weeks of therapy. Patients receiving MTX who achieved a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 50 response at Week 8 and/or 12 did not receive further dose increases. Across all treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:603pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">groups, the mean baseline PASI score was 19.7 and the baseline PGA score ranged from &#x201c;mild&#x201d; (&lt;1%) to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x201c;moderate&#x201d; (48%) to &#x201c;severe&#x201d; (46%) to &#x201c;very severe&#x201d; (6%).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients participating in all Phase 2 and Phase 3 psoriasis studies were eligible to enrol into an open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension trial, where Humira was given for at least an additional 108 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Psoriasis Studies I and II, a primary endpoint was the proportion of patients who achieved a PASI 75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response from baseline at Week 16 (see Tables 16 and 17).</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">190</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 16</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:180pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Ps Study I (REVEAL)  - Efficacy Results at 16 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:303pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:306pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=398</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:307pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:376pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:405pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=814</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    </span></b><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> PASI 75</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:304pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">26 (6.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">578 (70.9)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    PASI 100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 (0.8)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">163 (20.0)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    PGA: Clear/minimal</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:304pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17 (4.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">506 (62.2)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Percent of patients achieving PASI75 response was calculated as centre-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adjusted rate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p &lt; 0.001, Humira vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 17</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:176pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Ps Study II (CHAMPION) Efficacy Results at 16 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:235pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:240pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=53</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:240pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:315pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:313pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=110</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:315pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:406pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=108</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:408pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:135pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    </span></b><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> PASI 75</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:233pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 (18.9)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39 (35.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">86 (79.6)</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a, b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:135pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    PASI 100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:238pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 (1.9)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:314pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8 (7.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18 (16.7)</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c, d</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:135pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    PGA: </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:135pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Clear/minimal</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 (11.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33 (30.0)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">79 (73.1)</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a, b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:135pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p &lt; 0.001 Humira vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:135pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p &lt; 0.001 Humira vs. methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:135pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p &lt; 0.01 Humira vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:135pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p &lt; 0.05 Humira vs. methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Psoriasis Study I, 28% of patients who were PASI 75 responders and were re-randomised to placebo at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 33 compared to 5% continuing on Humira, p &lt; 0.001, experienced &#x201c;loss of adequate response&#x201d;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:428pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(PASI score after Week 33 and on or before Week 52 that resulted in a &lt;PASI 50 response relative to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">baseline with a minimum of a 6-point increase in PASI score relative to Week 33). Of the patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lost adequate response after re-randomisation to placebo who then enrolled into the open-label extension </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trial, 38% (25/66) and 55% (36/66) regained PASI 75 response after 12 and 24 weeks of re-treatment, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A total of 233 PASI 75 responders at Week 16 and Week 33 received continuous Humira therapy for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52 weeks in Psoriasis Study I, and continued Humira in the open-label extension trial.  PASI 75 and PGA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:529pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of clear or minimal response rates in these patients were 74.7% and 59.0%, respectively, after an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">additional 108 weeks of open-label therapy (total of 160 weeks). In an analysis in which all patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dropped out of the study for adverse events or lack of efficacy, or who dose-escalated, were considered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">non-responders, PASI 75 and PGA of clear or minimal response rates in these patients were 69.6% and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">55.7%, respectively, after an additional 108 weeks of open-label therapy (total of 160 weeks).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A total of 347 stable responders participated in a withdrawal and retreatment evaluation in an open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension study. During the withdrawal period, symptoms of psoriasis returned over time with a median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">time to relapse (decline to PGA &#x201c;moderate&#x201d; or worse) of approximately 5 months. None of these patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced rebound during the withdrawal period. A total of 76.5% (218/285) of patients who entered the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">retreatment period had a response of PGA &#x201c;clear&#x201d; or &#x201c;minimal&#x201d; after 16 weeks of retreatment, irrespective </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of whether they relapsed during withdrawal (69.1%[123/178] and 88.8% [95/107] for patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">relapsed and who did not relapse during the withdrawal period, respectively).  A similar safety profile was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed during retreatment as before withdrawal.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">191</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Significant improvements at Week 16 from baseline compared to placebo (Studies I and II) and MTX </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(Study II) were demonstrated in the DLQI (Dermatology Life Quality Index). In Study I, improvements in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the physical and mental component summary scores of the SF-36 were also significant compared to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an open-label extension study, for patients who dose escalated from 40 mg every other week to 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly due to a PASI response below 50%, 26.4% (92/349) and 37.8% (132/349) of patients achieved </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75 response at Week 12 and 24, respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Study III (REACH) compared the efficacy and safety of Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo in 72 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with moderate to severe chronic plaque psoriasis and hand and/or foot psoriasis. Patients received an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initial dose of 80 mg Humira followed by 40 mg every other week (starting one week after the initial dose) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or placebo for 16 weeks. At Week 16, a statistically significantly greater proportion of patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received Humira achieved PGA of &apos;clear&apos; or &apos;almost clear&apos; for the hands and/or feet compared to patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who received placebo (30.6% versus 4.3%, respectively [P = 0.014]).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Study IV compared efficacy and safety of Humira versus placebo in 217 adult patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">moderate to severe nail psoriasis. Patients received an initial dose of 80 mg Humira followed by 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every other week (starting one week after the initial dose) or placebo for 26 weeks followed by open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treatment for an additional 26 weeks. Nail psoriasis assessments included the Modified Nail </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Severity Index (mNAPSI), the Physician&#x2019;s Global Assessment of Fingernail Psoriasis (PGA-F) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and the Nail Psoriasis Severity Index (NAPSI) (see Table 18). Humira demonstrated a treatment benefit in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">nail psoriasis patients with different extents of skin involvement (BSA&#x2265;10% (60% of patients) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BSA&lt;10% and &#x2265;5% (40% of patients)).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:160pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 18: Ps Study IV Efficacy Results at 16, 26 and 52 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Endpoint</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:245pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 16</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:222pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo-Controlled</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:360pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 26</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo-Controlled</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:473pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Open-label</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:216pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:218pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=108</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:275pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:267pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg eow </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:276pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=109</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:332pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=108</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:387pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg eow </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:389pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=109</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg eow </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:480pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=80</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; mNAPSI 75 (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">26.0</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:341pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:393pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46.6</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:483pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PGA-F clear/minimal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265;2-grade improvement (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29.7</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:341pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:393pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">48.9</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:483pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">61.3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Percent Change in Total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fingernail NAPSI (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:224pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-7.8</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:278pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-44.2</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-11.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-56.2</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:481pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-72.2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p&lt;0.001, Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">vs.</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treated patients showed statistically significant improvements at Week 26 compared with placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in the DLQI. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Hidradenitis suppurativa</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in randomised, double-blind, placebo-controlled studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and an open-label extension study in adult patients with moderate to severe hidradenitis suppurativa (HS) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who were intolerant, had a contraindication or an inadequate response to at least a 3-month trial of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">systemic antibiotic therapy.  The patients in HS-I and HS-II had Hurley Stage II or III disease with at least </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 abscesses or inflammatory nodules.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study HS-I (PIONEER I) evaluated 307 patients with 2 treatment periods.  In Period A, patients received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo or Humira at an initial dose of 160 mg at Week 0, 80 mg at Week 2, and 40 mg every week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting at Week 4 to Week 11.  Concomitant antibiotic use was not allowed during the study.  After </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">192</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 weeks of therapy, patients who had received Humira in Period A were re-randomised in Period B to 1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of 3 treatment groups (Humira 40 mg every week, Humira 40 mg every other week, or placebo from Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 to Week 35).  Patients who had been randomised to placebo in Period A were assigned to receive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg every week in Period B.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study HS-II (PIONEER II) evaluated 326 patients with 2 treatment periods.  In Period A, patients received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo or Humira at an initial dose of 160 mg at Week 0 and 80 mg at Week 2 and 40 mg every week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting at Week 4 to Week 11.  19.3% of patients had continued baseline oral antibiotic therapy during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study.  After 12 weeks of therapy, patients who had received Humira in Period A were re-randomised in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Period B to 1 of 3 treatment groups (Humira 40 mg every week, Humira 40 mg every other week, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo from Week 12 to Week 35).  Patients who had been randomised to placebo in Period A were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assigned to receive placebo in Period B.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients participating in Studies HS-I and HS-II were eligible to enrol into an open-label extension study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in which Humira 40mg was administered every week. Mean exposure in all adalimumab population was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">762 days.  Throughout all 3 studies patients used topical antiseptic wash daily.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Clinical Response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reduction of inflammatory lesions and prevention of worsening of abscesses and draining fistulas was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assessed using Hidradenitis Suppurativa Clinical Response (HiSCR; at least a 50% reduction in total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">abscess and inflammatory nodule count with no increase in abscess count and no increase in draining </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fistula count relative to Baseline).  Reduction in HS-related skin pain was assessed using a Numeric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rating Scale in patients who entered the study with an initial baseline score of 3 or greater on a 11 point </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">scale. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 12, a significantly higher proportion of patients treated with Humira versus placebo achieved </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HiSCR.   At Week 12, a significantly higher proportion of patients in Study HS-II experienced a clinically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">relevant decrease in HS-related skin pain (see Table 19).  Patients treated with Humira had significantly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reduced risk of disease flare during the initial 12 weeks of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:174pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 19:  Efficacy Results at 12 Weeks, HS Studies I and II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:269pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HS Study I</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:428pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HS Study II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:233pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:297pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:313pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weekly</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:392pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:457pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:491pt;left:474pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weekly</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hidradenitis Suppurativa </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical Response (HiSCR)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:233pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 154</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:227pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 (26.0%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:313pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 153</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:303pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64 (41.8%) </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:395pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=163</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:385pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45 (27.6%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=163</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:460pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">96 (58.9%) </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265;30% Reduction in Skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pain</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:233pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 109</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:227pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">27 (24.8%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:313pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 122</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34 (27.9%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:395pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=111</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:385pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23 (20.7%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=105</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:460pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">48 (45.7%) </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:569pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">* </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">P</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> &lt; 0.05, ***</span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">P </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001, Humira versus placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">a</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:582pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among all randomised patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">b</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients with baseline HS-related skin pain assessment &#x2265; 3, based on Numeric Rating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Scale 0 &#x2013; 10; 0 = no skin pain, 10 = skin pain as bad as you can imagine.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Humira 40 mg every week significantly reduced the risk of worsening of abscesses and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:647pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">draining fistulas.  Approximately twice the proportion of patients in the placebo group in the first 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks of Studies HS-I and HS-II, compared with those in the Humira group experienced worsening of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">abscesses (23.0% vs 11.4%, respectively) and draining fistulas (30.0% vs 13.9%, respectively).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Greater improvements at Week 12 from baseline compared to placebo were demonstrated in skin-specific </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">health-related quality of life, as measured by the Dermatology Life Quality Index (DLQI; Studies HS-I </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">193</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and HS-II), patient global satisfaction with medication treatment as measured by the Treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Satisfaction Questionnaire - medication (TSQM; Studies HS-I and HS-II), and physical health as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">measured by the physical component summary score of the SF-36 (Study HS-I).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with at least a partial response to Humira 40 mg weekly at Week 12, the HiSCR rate at Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36 was higher in patients who continued weekly Humira than in patients in whom dosing frequency was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reduced to every other week, or in whom treatment was withdrawn (see Table 20).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:109pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 20:</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:153pt;left:184pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Proportion of Patients</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Achieving HiSCR</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b </span></b></sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">at Weeks 24 and 36 After </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:181pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Treatment Reassignment from Weekly Humira at Week 12</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:220pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(treatment </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:217pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">withdrawal)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:230pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 73</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:310pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:305pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">every other week</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:329pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 70</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:406pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:424pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">weekly</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:425pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 70</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:130pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:221pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 (32.9%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36 (51.4%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 (57.1%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:130pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 36</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:221pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22 (30.1%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28 (40.0%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39 (55.7%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:130pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:142pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients with at least a partial response to Humira 40 mg weekly after 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:283pt;left:142pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:130pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Patients meeting protocol-specified criteria for loss of response or no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:142pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement were required to discontinue from the studies and were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:142pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">counted as nonresponders.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients who were at least partial responders at Week 12, and who received continuous weekly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira therapy, the HiSCR rate at Week 48 was 68.3% and at Week 96 was 65.1%. Longer term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment with Humira 40 mg weekly for 96 weeks identified no new safety findings.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients whose Humira treatment was withdrawn at Week 12 in Studies HS-I and HS-II, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HiSCR rate 12 weeks after re-introduction of Humira 40 mg weekly returned to levels similar to that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:422pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed before withdrawal (56.0 %).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Crohn&#x2019;s disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in over 1500 patients with moderately to severely active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Crohn&#x2019;s disease (Crohn&#x2019;s Disease Activity Index (CDAI) </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 220 and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 450) in randomised, double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo-controlled studies. Concomitant stable doses of aminosalicylates, corticosteroids, and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunomodulatory agents were permitted and 80% of patients continued to receive at least one of these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">medications. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Induction of clinical remission (defined as CDAI &lt; 150) was evaluated in two studies, CD Study I </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(CLASSIC I) and CD Study II (GAIN). In CD Study I, 299 TNF-antagonist naive patients were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised to one of four treatment groups; placebo at Weeks 0 and 2, 160 mg Humira at Week 0 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg at Week 2, 80 mg at Week 0 and 40 mg at Week 2, and 40 mg at Week 0 and 20 mg at Week 2. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">CD Study II, 325 patients who had lost response or were intolerant to infliximab were randomised to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receive either 160 mg Humira at Week 0 and 80 mg at Week 2 or placebo at Weeks 0 and 2. The primary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">non-responders were excluded from the studies and therefore these patients were not further evaluated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Maintenance of clinical remission was evaluated in CD study III (CHARM).  In CD Study III, 854 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received open-label 80 mg at Week 0 and 40 mg at Week 2.  At Week 4 patients were randomised to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week, 40 mg every week, or placebo with a total study duration of 56 weeks. Patients in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical response (decrease in CDAI &#x2265; 70) at Week 4 were stratified and analysed separately from those </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">not in clinical response at Week 4.  Corticosteroid taper was permitted after Week 8. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">194</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">CD study I and CD study II induction of remission and response rates are presented in Table 21.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:281pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 21</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:193pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Induction of Clinical Remission and Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:111pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(Percent of Patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:128pt;left:191pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CD Study I: Infliximab Naive </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:140pt;left:191pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patients</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:128pt;left:372pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CD Study II: Infliximab </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:140pt;left:372pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Experienced Patients</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:197pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:203pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=74</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:258pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:255pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">80/40 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:261pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 75</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:318pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:313pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">160/80 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:324pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=76</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:385pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:388pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=166</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:468pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:462pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">160/80 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:471pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=159</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:201pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:205pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:266pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:217pt;left:325pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:217pt;left:475pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">21%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response (CR-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">100)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:205pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:266pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">37%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">**</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:394pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:473pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">**</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All p-values are pairwise comparisons of proportions for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:276pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.01</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Similar remission rates were observed for the 160/80 mg and 80/40 mg induction regimens by Week 8 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adverse events were more frequently noted in the 160/80 mg group.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In CD Study III, at Week 4, 58% (499/854) of patients were in clinical response and were assessed in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">primary analysis. Of those in clinical response at Week 4, 48% had been previously exposed to other TNF-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antagonists. Maintenance of remission and response rates are presented in Table 22.  Clinical remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">results remained relatively constant irrespective of previous TNF-antagonist exposure.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Disease-related hospitalisations and surgeries were statistically significantly reduced with adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared with placebo at Week 56.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">195</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:281pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 22</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maintenance of Clinical Remission and Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:99pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(Percent of Patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:115pt;left:283pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:115pt;left:359pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">40 mg Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:353pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">every other week</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:115pt;left:450pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">40 mg Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:458pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">every week</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 26</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:286pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=170</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:378pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=172</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:468pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=157</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:291pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">47%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:177pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response (CR-100)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:177pt;left:291pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">27%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:177pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:177pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:193pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in steroid-free remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:204pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for &gt;=90 days</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:193pt;left:279pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3% (2/66)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:193pt;left:360pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">19% (11/58)**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:193pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15% (11/74)**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 56</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:286pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=170</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:378pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=172</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:468pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=157</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:291pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response (CR-100)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:291pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">48%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in steroid-free remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for &gt; = 90 days</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:279pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5% (3/66)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:363pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29% (17/58)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20% (15/74)**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.001 for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo pairwise comparisons of proportions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:314pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">** p &lt; 0.02 for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo pairwise comparisons of proportions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of those receiving corticosteroids at baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients who were not in response at Week 4, 43% of Humira maintenance patients responded by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 12 compared to 30% of placebo maintenance patients. These results suggest that some patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have not responded by Week 4 benefit from continued maintenance therapy through Week 12.  Therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:393pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued beyond 12 weeks did not result in significantly more responses (see section 4.2).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">117/276 patients from CD study I and 272/777 patients from CD studies II and III were followed through </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:431pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at least 3 years of open-label adalimumab therapy.  88 and 189 patients, respectively, continued to be in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical remission.  Clinical response (CR-100) was maintained in 102 and 233 patients, respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of life</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In CD Study I and CD Study II, statistically significant improvement in the disease-specific inflammatory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bowel disease questionnaire (IBDQ) total score was achieved at Week 4 in patients randomised to Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80/40 mg and 160/80 mg compared to placebo and was seen at Weeks 26 and 56 in CD Study III as well </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">among the adalimumab treatment groups compared to the placebo group.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Ulcerative colitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of multiple doses of Humira were assessed in adult patients with moderately to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">severely active ulcerative colitis (Mayo score 6 to 12 with endoscopy subscore of 2 to 3) in randomised, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">double-blind, placebo-controlled studies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study UC-I, 390 TNF-antagonist na&#xef;ve patients were randomised to receive either placebo at Weeks 0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and 2, 160 mg Humira at Week 0 followed by 80 mg at Week 2, or 80 mg Humira at Week 0 followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg at Week 2.  After Week 2, patients in both adalimumab arms received 40 mg eow.  Clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission (defined as Mayo score &#x2264; 2 with no subscore &gt; 1) was assessed at Week 8. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study UC-II, 248 patients received 160 mg of Humira at Week 0, 80 mg at Week 2 and 40 mg eow </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">thereafter, and 246 patients received placebo. Clinical results were assessed for induction of remission at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:722pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 8 and for maintenance of remission at Week 52. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">196</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients induced with 160/80 mg Humira achieved clinical remission versus placebo at Week 8 in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">statistically significantly greater percentages in study UC-I (18% vs. 9% respectively, p=0.031) and study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">UC-II (17% vs. 9% respectively, p=0.019). In study UC-II, among those treated with Humira who were in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission at Week 8, 21/41 (51%) were in remission at Week 52.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Results from the overall UC-II study population are shown in Table 23.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 23</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:169pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Response, Remission and Mucosal Healing in Study UC-II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:258pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(Percent of Patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:318pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:385pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:410pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:320pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=246</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:404pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=248</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Clinical Response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:253pt;left:403pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   30%</span><span style="font-family:TimesNewRoman,serif;font-size:10.08pt">*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:267pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Clinical Remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:267pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:267pt;left:402pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   17%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Mucosal Healing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:402pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   25%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Steroid-free remission for &#x2265; 90 days</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:317pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N=140)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:398pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     13% *</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:308pt;left:400pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N=150)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 8 and 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Sustained Response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:400pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   24%**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Sustained Remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   8%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Sustained Mucosal Healing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">11%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:404pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  19%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:392pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission is Mayo score &#x2264; 2 with no subscore &gt; 1;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response is decrease from baseline in Mayo score &#x2265; 3 points and &#x2265; 30% plus a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">decrease in the rectal bleeding subscore [RBS] &#x2265; 1 or an absolute RBS of 0 or 1;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:7.92pt">*</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.05 for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">vs.</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo pairwise comparison of proportions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:445pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:10.08pt">**</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.001 for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">vs.</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo pairwise comparison of proportions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Of those receiving corticosteroids at baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of those patients who had a response at Week 8, 47% were in response, 29% were in remission, 41% had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:497pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mucosal healing, and 20% were in steroid-free remission for &#x2265; 90 days at Week 52.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:522pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Approximately 40% of patients in study UC-II had failed prior anti-TNF treatment with infliximab. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">efficacy of adalimumab in those patients was reduced compared to that in anti-TNF na&#xef;ve patients.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:548pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients who had failed prior anti-TNF treatment, Week 52 remission was achieved by 3% on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo and 10% on adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients from studies UC-I and UC-II had the option to roll over into an open-label long-term extension </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study (UC III). Following 3 years of adalimumab therapy, 75% (301/402) continued to be in clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission per partial Mayo score. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Hospitalisation rates</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During 52 weeks of studies UC-I and UC-II, lower rates of all-cause hospitalisations and UC-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hospitalisations were observed for the adalimumab-treated arm compared to the placebo arm. The number </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of all cause hospitalisations in the adalimumab treatment group was 0.18 per patient year </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">vs</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">. 0.26 per </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">197</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient year in the placebo group and the corresponding figures for UC-related hospitalisations were 0.12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">per patient year </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">vs.</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.22 per patient year.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of life</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study UC-II, treatment with adalimumab resulted in improvements in the Inflammatory Bowel Disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Questionnaire (IBDQ) score.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Uveitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in adult patients with non-infectious intermediate, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">posterior, and panuveitis, excluding patients with isolated anterior uveitis, in two randomised, double-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">masked, placebo-controlled studies (UV I and II). Patients received placebo or Humira at an initial dose of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg followed by 40 mg every other week starting one week after the initial dose. Concomitant stable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">doses of one non-biologic immunosuppressant were permitted. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV I evaluated 217 patients with active uveitis despite treatment with corticosteroids (oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">prednisone at a dose of 10 to 60 mg/day). All patients received a 2-week standardised dose of prednisone </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60 mg/day at study entry followed by a mandatory taper schedule, with complete corticosteroid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">discontinuation by Week 15. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV II evaluated 226 patients with inactive uveitis requiring chronic corticosteroid treatment (oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">prednisone 10 to 35 mg/day) at baseline to control their disease. Patients subsequently underwent a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mandatory taper schedule, with complete corticosteroid discontinuation by Week 19. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary efficacy endpoint in both studies was &#xb4;time to treatment failure&#xb4;. Treatment failure was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined by a multi-component outcome based on inflammatory chorioretinal and/or inflammatory retinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vascular lesions, anterior chamber (AC) cell grade, vitreous haze (VH) grade and best corrected visual </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">acuity (BCVA). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who completed Studies UV I and UV II were eligible to enroll in an uncontrolled long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension study with an originally planned duration of 78 weeks. Patients were allowed to continue on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study medication beyond Week 78 until they had access to Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Clinical Response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with Humira versus patients receiving placebo (See Table 24). Both studies demonstrated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">an early and sustained effect of Humira on the treatment failure rate versus placebo (see Figure 2). </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">198</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 24</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:180pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Time to Treatment Failure in Studies UV I and UV II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:75pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Analysis</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:103pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Treatment</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:189pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:225pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Failure</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:225pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:283pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Median Time to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:283pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Failure (months)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:378pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HR</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:414pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CI 95% </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:414pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">for HR</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:94pt;left:472pt"><b><i><span style="font-family:TimesNewRoman,BoldItalic,serif;font-size:11.04pt">P</span></i></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> Value</span></b><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:75pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Time to Treatment Failure At or After Week 6 in Study UV I  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Primary analysis (ITT)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">107</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">84 (78.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:472pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">110</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60 (54.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.36, 0.70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:472pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:75pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Time to Treatment Failure At or After Week 2 in Study UV II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Primary analysis (ITT)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">111</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">61 (55.0)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8.3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:472pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">115</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45 (39.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NE</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.57</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.39, 0.84</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:472pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.004</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note:  Treatment failure at or after Week 6 (Study UV I), or at or after Week 2 (Study UV II), was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">counted as event. Drop outs due to reasons other than treatment failure were censored at the time of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dropping out.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">a</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HR of adalimumab vs placebo from proportional hazards regression with treatment as factor.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">b</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2-sided </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">P</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> value from log rank test.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">c</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NE = not estimable. Fewer than half of at-risk subjects had an event. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Figure 2: Kaplan-Meier Curves Summarizing Time to Treatment Failure on or after Week 6 (Study </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:233pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">UV I) or Week 2 (Study UV II)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TREATMENT FAILURE RATE (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:270pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TIME (MONTHS)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:100pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV I                        Treatment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:445pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<img style="position:absolute;top:366pt;left:100pt;width:432pt;height:174pt" src="data:image/png;base64,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">
<img style="position:absolute;top:552pt;left:291pt;width:31pt;height:14pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABcAAAAICAAAAAA3wTsyAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAR0lEQVR4nGP8z4AVMGKK/2eEioMZaDIg8X8fGRmAFEyWiYEPov75
fqAwTPQ/8z8+n39MEPP//2dk/A+V+8+EsBfDBmzuAQMAmYsaASeQxO8AAAAASUVO
RK5CYII=">
<img style="position:absolute;top:552pt;left:401pt;width:43pt;height:14pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABcAAAAGCAIAAACnwpLJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAqElEQVR4nGP8//8/A8WAEW4KkMHIyEhQA1ZlCFN+//79/ft3Pj6+
9+/f83Bzs7Cyfvz4kZ+fHygI1MTKxvblyxcBAQEgyczExMnF9eHDByAX3ZSbN2/e
vn3b29t7+fLlFhYWQON27twZHR29Y8cOUVFROTm5vXv3RkREbNu2DWi0qanJ+vUb
/Hx9gcahmAJxLUgIycHI7v/37x8TExNWKUaSQhctUOBcAGVhWfUkQWeYAAAAAElF
TkSuQmCC">
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">199</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:64pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TREATMENT FAILURE RATE (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:270pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TIME (MONTHS)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:100pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV II                       Treatment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:445pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note: P# = Placebo (Number of Events/Number at Risk); A# = HUMIRA (Number of</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Events/Number at Risk).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Study UV I statistically significant differences in favour of adalimumab versus placebo were observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for each component of treatment failure.  In Study UV II, statistically significant differences were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed for visual acuity only, but the other components were numerically in favour of adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of the 424 subjects included in the uncontrolled long-term extension of Studies UV I and UV II, 60</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subjects were regarded ineligible (e.g. due to deviations or due to complications secondary to diabetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">retinopathy, due to cataract surgery or vitrectomy) and were excluded from the primary analysis of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">efficacy. Of the 364 remaining patients, 269 evaluable patients (74%) reached 78 weeks of open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab treatment. Based on the observed data approach, 216 (80.3%) were in quiescence (no active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inflammatory lesions, AC cell grade  &#x2264; 0.5+, VH grade &#x2264; 0.5+) with a concomitant steroid dose &#x2264; 7.5 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">per day, and 178 (66.2%) were in steroid-free quiescence. BCVA was either improved or maintained (&lt; 5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">letters deterioration) in 88.6% of the eyes at week 78. Data beyond Week 78 were generally consistent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with these results but the number of enrolled subjects declined after this time. Overall, among the patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who discontinued the study, 18% discontinued due to adverse events, and 8% due to insufficient response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to adalimumab treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of Life</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patient reported outcomes regarding vision-related functioning were measured in both clinical studies, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using the NEI VFQ-25. Humira was numerically favoured for the majority of subscores with statistically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significant mean differences for general vision, ocular pain, near vision, mental health, and total score in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV I, and for general vision and mental health in Study UV II. Vision related effects were not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">numerically in favour of Humira for colour vision in Study UVI and for colour vision, peripheral vision </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and near vision in Study UV II.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immunogenicity</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Formation of anti-adalimumab antibodies is associated with increased clearance and reduced efficacy of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab. There is no apparent correlation between the presence of anti-adalimumab antibodies and the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurrence of adverse events.</span></p>
<img style="position:absolute;top:78pt;left:100pt;width:432pt;height:171pt" src="data:image/png;base64,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">
<img style="position:absolute;top:263pt;left:291pt;width:31pt;height:14pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABcAAAAICAAAAAA3wTsyAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAR0lEQVR4nGP8z4AVMGKK/2eEioMZaDIg8X8fGRmAFEyWiYEPov75
fqAwTPQ/8z8+n39MEPP//2dk/A+V+8+EsBfDBmzuAQMAmYsaASeQxO8AAAAASUVO
RK5CYII=">
<img style="position:absolute;top:263pt;left:401pt;width:43pt;height:14pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABcAAAAGCAIAAACnwpLJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAqElEQVR4nGP8//8/A8WAEW4KkMHIyEhQA1ZlCFN+//79/ft3Pj6+
9+/f83Bzs7Cyfvz4kZ+fHygI1MTKxvblyxcBAQEgyczExMnF9eHDByAX3ZSbN2/e
vn3b29t7+fLlFhYWQON27twZHR29Y8cOUVFROTm5vXv3RkREbNu2DWi0qanJ+vUb
/Hx9gcahmAJxLUgIycHI7v/37x8TExNWKUaSQhctUOBcAGVhWfUkQWeYAAAAAElF
TkSuQmCC">
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">200</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in rheumatoid arthritis studies I, II and III were tested at multiple time points for anti-adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies during the 6 to 12 month period. In the pivotal trials, anti-adalimumab antibodies were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">identified in 5.5% (58/1053) of patients treated with adalimumab, compared to 0.5% (2/370) on placebo.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients not given concomitant methotrexate, the incidence was 12.4%, compared to 0.6% when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab was used as add-on to methotrexate.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with polyarticular juvenile idiopathic arthritis who were 4 to 17 years, anti-adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies were identified in 15.8% (27/171) of patients treated with adalimumab. In patients not given </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant methotrexate, the incidence was 25.6% (22/86) compared to 5.9% (5/85) when adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was used as add-on to methotrexate. In patients with polyarticular juvenile idiopathic arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 to &lt;4 years old or aged 4 and above weighing &lt;15 kg, anti-adalimumab antibodies were identified in 7% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(1/15) of patients, and the one patient was receiving concomitant methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with enthesitis-related arthritis, anti-adalimumab antibodies were identified in 10.9% (5/46) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with adalimumab. In patients not given concomitant methotrexate, the incidence was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13.6% (3/22), compared to 8.3% (2/24) when adalimumab was used as add-on to methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with psoriatic arthritis, anti-adalimumab antibodies were identified in 38/376 subjects (10%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with adalimumab. In patients not given concomitant methotrexate, the incidence was 13.5% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(24/178 subjects), compared to 7% (14 of 198 subjects) when adalimumab was used as add-on to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with ankylosing spondylitis anti-adalimumab antibodies were identified in 17/204 subjects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(8.3%) treated with adalimumab. In patients not given concomitant methotrexate, the incidence was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16/185 (8.6%), compared to 1/19 (5.3%) when adalimumab was used as add-on to methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with non-radiographic axial spondyloarthritis, anti-adalimumab antibodies were identified in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8/152 subjects (5.3%) who were treated continuously with adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with Crohn&#x2019;s disease, anti-adalimumab antibodies were identified in 7/269 subjects (2.6%) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in 19/487 subjects (3.9%) with ulcerative colitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with psoriasis, anti-adalimumab antibodies were identified in 77/920 subjects (8.4%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with adalimumab monotherapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult plaque psoriasis patients on long term adalimumab monotherapy who participated in a withdrawal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and retreatment study, the rate of antibodies to adalimumab after retreatment (11 of 482 subjects, 2.3%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was similar to the rate observed prior to withdrawal (11 of 590 subjects, 1.9%).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with paediatric psoriasis, anti-adalimumab antibodies were identified in 5/38 subjects (13%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with 0.8 mg/kg adalimumab monotherapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with moderate to severe hidradenitis suppurativa, anti-adalimumab antibodies were identified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in 10/99 subjects (10.1%) treated with adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with moderately to severely active paediatric Crohn&#x2019;s disease, the rate of anti-adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibody development in patients receiving adalimumab was 3.3%. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with non-infectious uveitis, anti-adalimumab antibodies were identified in 4.8% (12/249) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of patients treated with adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with moderately to severely active paediatric ulcerative colitis, the rate of anti-adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibody development in patients receiving adalimumab was 3%.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">201</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Because immunogenicity analyses are product-specific, comparison of antibody rates with those from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other products is not appropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Juvenile idiopathic arthritis (JIA)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Polyarticular juvenile idiopathic arthritis (pJIA)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira was assessed in two studies (pJIA I and II) in children with active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">polyarticular or polyarticular course juvenile idiopathic arthritis, who had a variety of JIA onset types </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(most frequently rheumatoid-factor negative or positive polyarthritis and extended oligoarthritis).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pJIA I</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:256pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in a multicentre, randomised, double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">parallel &#x2212; group study in 171 children (4-17 years old) with polyarticular JIA. In the open-label lead in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">phase (OL LI) patients were stratified into two groups, MTX (methotrexate)-treated or non-MTX-treated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who were in the non-MTX stratum were either na&#xef;ve to or had been withdrawn from MTX at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:306pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">least two weeks prior to study drug administration. Patients remained on stable doses of NSAIDs and or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">prednisone (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.2 mg/kg/day or 10 mg/day maximum). In the OL LI phase all patients received 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2 </span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">up to a maximum of 40 mg Humira every other week for 16 weeks.  The distribution of patients by age </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and minimum, median and maximum dose received during the OL LI phase is presented in Table 25.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:370pt;left:287pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 25</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:104pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Distribution of patients by age and adalimumab dose received during the OL LI phase</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Age Group</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Number of patients at Baseline </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Minimum, median and maximum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 to 7 years</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">31 (18.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10, 20 and 25 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8 to 12 years</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">71 (41.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:455pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20, 25 and 40 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13 to 17 years</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">69 (40.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25, 40 and 40 mg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients demonstrating a Paediatric ACR 30 response at Week 16 were eligible to be randomised into the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">double blind (DB) phase and received either Humira 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2 </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">up to a maximum of 40 mg, or placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every other week for an additional 32 weeks or until disease flare. Disease flare criteria were defined as a</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">worsening of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% from baseline in </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 3 of 6 Paediatric ACR core criteria, </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 2 active joints, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement of </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf03e;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 30% in no more than 1 of the 6 criteria. After 32 weeks or at disease flare, patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were eligible to enrol into the open label extension phase. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">202</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:287pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 26</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:213pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Ped ACR 30 Responses in the JIA study</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Stratum</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:270pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:419pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Without MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Phase</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">OL-LI 16 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ped ACR 30 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response (n/N)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:252pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">94.1% (80/85)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">74.4% (64/86)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">                                                           Efficacy Outcomes</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Double Blind 32 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira /MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N = 38)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo / MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N = 37)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N = 30)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:461pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:186pt;left:461pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N = 28)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Disease flares at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the end of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">32 weeks</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(n/N)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36.8% (14/38)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64.9% (24/37)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">43.3% (13/30)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:461pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">71.4% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:461pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(20/28)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Median time to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:109pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease flare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:202pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&gt;32 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&gt;32 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:461pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ped ACR 30/50/70 responses Week 48 significantly greater than those of placebo treated patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p = 0.015</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p = 0.031</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:341pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Amongst those who responded at Week 16 (n=144), the Paediatric ACR 30/50/70/90 responses were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintained for up to six years in the OLE phase in patients who received Humira throughout the study.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:366pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Over all 19 subjects, of which 11 of the baseline age group 4 to 12 and 8 of the baseline age group 13 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:379pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17 years were treated 6 years or longer.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Overall responses were generally better and, fewer patients developed antibodies when treated with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination of Humira and MTX compared to Humira alone. Taking these results into consideration, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is recommended for use in combination with MTX and for use as monotherapy in patients for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">whom MTX use is not appropriate (see section 4.2).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pJIA II</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira was assessed in an open-label, multicentre study in 32 children </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(2 - &lt; 4 years old or aged 4 and above weighing &lt; 15 kg) with moderately to severely active polyarticular </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">JIA. The patients received 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body surface area (BSA) of Humira up to a maximum of 20 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every other week as a single dose via SC injection for at least 24 weeks. During the study, most subjects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">used concomitant MTX, with fewer reporting use of corticosteroids or NSAIDs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 12 and Week 24, PedACR30 response was 93.5% and 90.0%, respectively, using the observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">data approach. The proportions of subjects with PedACR50/70/90 at Week 12 and Week 24 were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">90.3%/61.3%/38.7% and 83.3%/73.3%/36.7%, respectively. Amongst those who responded (Paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 30) at Week 24 (n=27 out of 30 patients), the Paediatric ACR 30 responses were maintained for up </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 60 weeks in the OLE phase in patients who received Humira throughout this time period. Overall, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 subjects were treated for 60 weeks or longer.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Enthesitis-related arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in a multicentre, randomised, double-blind study in 46 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients (6 to 17 years old) with moderate enthesitis-related arthritis. Patients were randomised </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to receive either 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body surface area (BSA) of Humira up to a maximum of 40 mg, or placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every other week for 12 weeks. The double-blind period is followed by an open-label (OL) period during </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">203</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:52pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">which patients received 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BSA of Humira up to a maximum of 40 mg every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneously for up to an additional 192 weeks. The primary endpoint was the percent change from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline to Week 12 in the number of active joints with arthritis (swelling not due to deformity or joints </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with loss of motion plus pain and/or tenderness), which was achieved with mean percent decrease of -</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">62.6% (median percent change -88.9%) in patients in the Humira group compared to -11.6% (median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">percent change -50.0%) in patients in the placebo group. Improvement in number of active joints with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis was maintained during the OL period through Week 156 for the 26 of 31 (84%) patients in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira group who remained in the study. Although not statistically significant, the majority of patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demonstrated clinical improvement in secondary endpoints such as number of sites of enthesitis, tender </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joint count (TJC), swollen joint count (SJC), Paediatric ACR 50 response, and Paediatric ACR 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The efficacy of Humira was assessed in a randomised, double-blind, controlled study of 114 paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients from 4 years of age with severe chronic plaque psoriasis (as defined by a PGA &#x2265; 4 or &gt; 20% BSA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">involvement or &gt; 10% BSA involvement with very thick lesions or PASI &#x2265; 20 or &#x2265; 10 with clinically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">relevant facial, genital, or hand/ foot involvement) who were inadequately controlled with topical therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and heliotherapy or phototherapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients received Humira 0.8 mg/kg eow (up to 40 mg), 0.4 mg/kg eow (up to 20 mg), or methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.1- 0.4 mg/kg weekly (up to 25 mg).   At Week 16, more patients randomised to Humira 0.8 mg/kg had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">positive efficacy responses (e.g., PASI 75) than those randomised to 0.4 mg/kg eow or MTX.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:147pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 27: Paediatric Plaque Psoriasis Efficacy Results at 16 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:300pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:301pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=37 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:385pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 0.8 mg/kg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:423pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=38 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:289pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 (32.4%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22 (57.9%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PGA: Clear/minimal</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:289pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15 (40.5%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:411pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23 (60.5%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX = methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> P=0.027, Humira 0.8 mg/kg versus MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> P=0.083, Humira 0.8 mg/kg versus MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who achieved PASI 75 and PGA clear or minimal were withdrawn from treatment for up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36 weeks and monitored for loss of disease control (i.e. a worsening of PGA by at least 2 grades).  Patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were then re-treated with adalimumab 0.8 mg/kg eow for an additional 16 weeks and response rates </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed during retreatment were similar to the previous double-blind period:  PASI 75 response of 78.9% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(15 of 19 subjects) and PGA clear or minimal of 52.6% (10 of 19 subjects).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open label period of the study, PASI 75 and PGA clear or minimal responses were maintained for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">up to an additional 52 weeks with no new safety findings.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:599pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adolescent hidradenitis suppurativa</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There are no clinical trials with Humira in adolescent patients with HS.  Efficacy of adalimumab for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment of adolescent patients with HS is predicted based on the demonstrated efficacy and exposure-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:650pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response relationship in adult HS patients and the likelihood that the disease course, pathophysiology, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:663pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">drug effects are substantially similar to that of adults at the same exposure levels. Safety of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recommended adalimumab dose in the adolescent HS population is based on cross-indication safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">profile of adalimumab in both adults and paediatric patients at similar or more frequent doses (see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:701pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.2).</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">204</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric Crohn&#x2019;s disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:79pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira was assessed in a multicentre, randomised, double-blind clinical trial designed to evaluate the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:91pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">efficacy and safety of induction and maintenance treatment with doses dependent on body weight (&lt; 40 kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:104pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or &#x2265; 40 kg) in 192 paediatric subjects between the ages of 6 and 17 (inclusive) years, with moderate to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">severe Crohn&#xb4;s disease (CD) defined as Paediatric Crohn&apos;s Disease Activity Index (PCDAI) score &gt; 30.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:129pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Subjects had to have failed conventional therapy (including a corticosteroid and/or an immunomodulator) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:142pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for CD. Subjects may also have previously lost response or been intolerant to infliximab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:167pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All subjects received open-label induction therapy at a dose based on their Baseline body weight: 160 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:180pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at Week 0 and 80 mg at Week 2 for subjects &#x2265; 40 kg, and 80 mg and 40 mg, respectively, for subjects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:192pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:218pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 4, subjects were randomised 1:1 based on their body weight at the time to either the Low Dose or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:230pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Standard Dose maintenance regimens as shown in Table 28.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:256pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 28</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:254pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maintenance regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:226pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:226pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:275pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Low dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:336pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Standard </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:336pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:275pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 mg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:275pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Efficacy results</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary endpoint of the study was clinical remission at Week 26, defined as PCDAI score </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 10.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline) rates are presented in Table 29. Rates of discontinuation of corticosteroids or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunomodulators are presented in Table 30.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 29</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:257pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Paediatric CD Study</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:210pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PCDAI Clinical Remission and Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:261pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Standard Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:264pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">40/20 mg eow </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:280pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 93</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Low Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:344pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">20/10 mg eow </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:360pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 95</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:424pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">P value</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 26</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:361pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.075</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   Clinical response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:361pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">48.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.073</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 52</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:361pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.100</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   Clinical response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:361pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.038</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">* p value for Standard Dose </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Low Dose comparison.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">205</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 30</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:257pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Paediatric CD Study</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:116pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Discontinuation of Corticosteroids or Immunomodulators and Fistula Remission</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:303pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Standard Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:306pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">40/20 mg eow </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:396pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Low Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:388pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">20/10 mg eow </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:469pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">P value</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">1</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:95pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Discontinued corticosteroids</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:324pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N= 33</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=38</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 26</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">84.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:136pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.066</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">69.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.420</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:161pt;left:95pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Discontinuation of Immunomodulators</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">2</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:325pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=60</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=57</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">30.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.983</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:188pt;left:95pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Fistula remission</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">3</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:325pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=15</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=21</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 26</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.608</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.303</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  p value for Standard Dose </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Low Dose comparison.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Immunosuppressant therapy could only be discontinued at or after Week 26 at the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">investigator&apos;s discretion if the subject met the clinical response criterion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">3</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> defined as a closure of all fistulas that were draining at Baseline for at least 2 consecutive</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">post-Baseline visits</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Statistically significant increases (improvement) from Baseline to Week 26 and 52 in Body Mass Index </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and height velocity were observed for both treatment groups.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Statistically and clinically significant improvements from Baseline were also observed in both treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">groups for quality of life parameters (including IMPACT III).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">One hundred patients (n=100) from the Paediatric CD Study continued in an open-label long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension study.  After 5 years of adalimumab therapy, 74.0% (37/50) of the 50 patients remaining in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study continued to be in clinical remission, and 92.0% (46/50) of patients continued to be in clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response per PCDAI.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric ulcerative colitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira was assessed in a multicenter, randomized, double-blind, trial in 93 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients from 5 to 17 years of age with moderate to severe ulcerative colitis (Mayo score 6 to 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with endoscopy subscore of 2 to 3 points, confirmed by centrally read endoscopy) who had an inadequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response or intolerance to conventional therapy. Approximately 16% of patients in the study had failed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">prior anti-TNF treatment. Patients who received corticosteroids at enrollment were allowed to taper their </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">corticosteroid therapy after Week 4.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the induction period of the study, 77 patients were randomized 3:2 to receive double-blind treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:571pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Humira at an induction dose of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2; or an induction dose of 2.4 mg/kg (maximum of 160 mg) at Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0, placebo at Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2. Both groups received 0.6 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(maximum of 40 mg) at Week 4 and Week 6. Following an amendment to the study design, the remaining </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:621pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16 patients who enrolled in the induction period received open-label treatment with Humira at the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">induction dose of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 mg/kg (maximum of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:647pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg) at Week 2.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 8, 62 patients who demonstrated clinical response per Partial Mayo Score (PMS; defined as a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">decrease in PMS &#x2265; 2 points and &#x2265; 30% from Baseline) were randomized equally to receive double-blind </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintenance treatment with Humira at a dose of 0.6 mg/kg (maximum of 40 mg) every week (ew), or a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:710pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintenance dose of 0.6 mg/kg (maximum of 40 mg) every other week (eow). Prior to an amendment to </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">206</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the study design, 12 additional patients who demonstrated clinical response per PMS were randomized to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receive placebo but were not included in the confirmatory analysis of efficacy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Disease flare was defined as an increase in PMS of at least 3 points (for patients with PMS of 0 to 2 at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 8), at least 2 points (for patients with PMS of 3 to 4 at Week 8), or at least 1 point (for patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PMS of 5 to 6 at Week 8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who met criteria for disease flare at or after Week 12 were randomized to receive a re-induction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose of 2.4 mg/kg (maximum of 160 mg) or a dose of 0.6 mg/kg (maximum of 40 mg) and continued to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receive their respective maintenance dose regimen afterwards.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Efficacy Results</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:231pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The co-primary endpoints of the study were clinical remission per PMS (defined as PMS &#x2264; 2 and no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:243pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">individual subscore &gt; 1) at Week 8, and clinical remission per FMS (Full Mayo Score) (defined as a Mayo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:256pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Score &#x2264; 2 and no individual subscore &gt; 1) at Week 52 in patients who achieved clinical response per PMS </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at Week 8.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission rates per PMS at Week 8 for patients in each of the Humira double-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blind induction groups are presented in Table 31.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:189pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 31: Clinical Remission per PMS at 8 Weeks </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:257pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:210pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 160 mg at Week </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:228pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">0 / Placebo at Week 1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:266pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=30</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:404pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b, c</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:360pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 160 mg at Week </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:396pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">0 and Week 1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:417pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=47</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:247pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13/30 (43.3%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:397pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28/47 (59.6%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 2.4 mg/kg (maximum of 160 mg) at Week 0, placebo at Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Not including open-label Induction dose of Humira 2.4 mg/kg (maximum of 160 mg) at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 0 and Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note 1: Both induction groups received 0.6 mg/kg (maximum of 40 mg) at Week 4 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:537pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note 2: Patients with missing values at Week 8 were considered as not having met the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endpoint</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 52, clinical remission per FMS in Week 8 responders, clinical response per FMS (defined as a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">decrease in Mayo Score &#x2265; 3 points and &#x2265; 30% from Baseline) in Week 8 responders, mucosal healing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(defined as Mayo endoscopy subscore &#x2264; 1) in Week 8 responders, clinical remission per FMS in Week 8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remitters, and the proportion of subjects in corticosteroid-free remission per FMS in Week 8 responders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were assessed in patients who received Humira at the double-blind maximum 40 mg eow (0.6 mg/kg) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum 40 mg ew (0.6 mg/kg) maintenance doses (Table 32).</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">207</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:213pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 32: Efficacy Results at 52 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:73pt;left:279pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:87pt;left:245pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 40 mg eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:99pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:73pt;left:405pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:87pt;left:373pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 40 mg ew</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:99pt;left:416pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:118pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission in Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8 PMS responders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:272pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9/31 (29.0%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:125pt;left:397pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14/31 (45.2%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response in Week 8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PMS responders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:153pt;left:269pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">19/31 (61.3%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:153pt;left:395pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">21/31 (67.7%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mucosal healing in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 8 PMS responders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:269pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12/31 (38.7%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:395pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16/31 (51.6%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission in Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:213pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8 PMS remitters</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:272pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9/21 (42.9%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:395pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10/22 (45.5%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:226pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Corticosteroid-free </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission in Week 8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PMS responders</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:272pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4/13 (30.8%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:239pt;left:398pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5/16 (31.3%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 0.6 mg/kg (maximum of 40 mg) every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:277pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 0.6 mg/kg (maximum of 40 mg) every week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> In patients receiving concomitant corticosteroids at baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:303pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note: Patients with missing values at Week 52 or who were randomized to receive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:316pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">re-induction or maintenance treatment were considered non-responders for Week 52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:328pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endpoints</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:354pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Additional exploratory efficacy endpoints included clinical response per the Paediatric Ulcerative Colitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:367pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Activity Index (PUCAI) (defined as a decrease in PUCAI &#x2265; 20 points from Baseline) and clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission per PUCAI (defined as PUCAI &lt; 10) at Week 8 and Week 52 (Table 33). </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">208</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:181pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 33: Exploratory Endpoints Results per PUCAI</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:361pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:298pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:264pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 160 mg at </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 0 / Placebo at Week 1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=30</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:428pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b,c</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:397pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 160 mg at </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:404pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 0 and Week 1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:439pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=47</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission per PUCAI</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:286pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10/30 (33.3%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22/47 (46.8%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:151pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response per PUCAI</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:151pt;left:286pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15/30 (50.0%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:151pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">32/47 (68.1%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:164pt;left:359pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 52</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:297pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">d</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:262pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 40 mg eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:431pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">e</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:397pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 40 mg ew</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:439pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission per PUCAI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in Week 8 PMS responders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:286pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14/31 (45.2%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18/31 (58.1%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response per PUCAI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in Week 8 PMS responders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:286pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18/31 (58.1%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16/31 (51.6%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Humira 2.4 mg/kg (maximum of 160 mg) at Week 0, placebo at Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Not including open-label Induction dose of Humira 2.4 mg/kg (maximum of 160 mg) at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 0 and Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Humira 0.6 mg/kg (maximum of 40 mg) every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">e</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Humira 0.6 mg/kg (maximum of 40 mg) every week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note 1: Both induction groups received 0.6 mg/kg (maximum of 40 mg) at Week 4 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note 2: Patients with missing values at Week 8 were considered as not having met the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:407pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endpoints</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note 3: Patients with missing values at Week 52 or who were randomized to receive re-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">induction or maintenance treatment were considered non-responders for Week 52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endpoints</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of the Humira-treated patients who received re-induction treatment during the maintenance period, 2/6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(33%) achieved clinical response per FMS at Week 52.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of life</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinically meaningful improvements from Baseline were observed in IMPACT III and the caregiver Work </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Productivity and Activity Impairment (WPAI) scores for the groups treated with Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:571pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinically meaningful increases (improvement) from Baseline in height velocity were observed for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">groups treated with adalimumab, and clinically meaningful increases (improvement) from Baseline in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Body Mass Index were observed for subjects on the high maintenance dose of maximum 40 mg (0.6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg) ew. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric Uveitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira was assessed in a randomized, double-masked, controlled study of 90 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients from 2 to &lt; 18 years of age with active JIA-associated noninfectious anterior uveitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who were refractory to at least 12 weeks of methotrexate treatment.  Patients received either placebo or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg adalimumab (if &lt; 30 kg) or 40 mg adalimumab (if &#x2265; 30 kg) every other week in combination with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">their baseline dose of methotrexate. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">209</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary endpoint was &#x2018;time to treatment failure&#x2019;. The criteria determining treatment failure were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">worsening or sustained non-improvement in ocular inflammation, partial improvement with development </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of sustained ocular co-morbidities or worsening of ocular co-morbidities, non-permitted use of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant medications, and suspension of treatment for an extended period of time.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Clinical Response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab significantly delayed the time to treatment failure, as compared to placebo (See Figure 3, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">P &lt; 0.0001 from log rank test).The median time to treatment failure was 24.1 weeks for subjects treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with placebo, whereas the median time to treatment failure was not estimable for subjects treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab because less than one-half of these subjects experienced treatment failure.  Adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significantly decreased the risk of treatment failure by 75% relative to placebo, as shown by the hazard </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ratio (HR = 0.25 [95% CI:  0.12, 0.49]).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Figure 3: Kaplan-Meier Curves Summarizing Time to Treatment Failure in the Paediatric Uveitis </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:267pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Study</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PROBABILITY OF FAILING TREATMENT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:274pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TIME (WEEKS)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:445pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note: P = Placebo (Number at Risk); H = HUMIRA (Number at Risk).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacokinetic properties</span></b></p>
<img style="position:absolute;top:295pt;left:99pt;width:432pt;height:358pt" src="data:image/png;base64,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">
<img style="position:absolute;top:670pt;left:280pt;width:36pt;height:9pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAEwAAAAMCAAAAADtpASbAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAA2UlEQVR4nI2SPQ7CMAyF7bCzICYkJBaExMghkLgA5+BKcJDeoBsS
B+jUzoiJmDglrknSEk/x36f36iKBC0KYjN++y/pCvIb2DyfDGJKIhiXKCHlADVmT
7XlYwiJANZ28HACE4RNRxm+9EaMV49u1OHwynxtlk9qGxPd6yfT7S0SaAyOeD2vC
0GLD3Ka1gQbbeVCGUFeiA497t4XXTgp0QQfrboR29kb2tzvxUlV7knE1OK8wKJuO
6HBiLvKYg+X/oNxMmo0oUweBHDe9f6HN/sLK2KjwIlhpfAC8cXABl3kQ5QAAAABJ
RU5ErkJggg==">
<img style="position:absolute;top:671pt;left:401pt;width:35pt;height:6pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAFIAAAANCAIAAAC1lq7uAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAApElEQVR4nOWVzRGEIAxGE4qgDVy7oirdZmjAtQa6AHXirBHRkz9j
eAcmcsqbLwaMMQLAeCIiLySxlULSFk9ivmjLy/mvtvXCZMjFwI2o5jerIQ8hKKUe
6PEy9nZWfshFhk8FeaUrjT699333u7+5c5lnG0FrbYzJpw0sZOfct2nvb/QKRqmq
/lhr+e9dygPGmeTL0d7d5HD41r2U7HouKG1OodoDHdh+5CqIp8EAAAAASUVORK5CYII=">
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">210</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Absorption and distribution</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After subcutaneous administration of a single 40 mg dose, absorption and distribution of adalimumab was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">slow, with peak serum concentrations being reached about 5 days after administration. The average </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">absolute bioavailability of adalimumab estimated from three studies following a single 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous dose was 64%. After single intravenous doses ranging from 0.25 to 10 mg/kg, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentrations were dose proportional. After doses of 0.5 mg/kg (~40 mg), clearances ranged from 11 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15 ml/hour, the distribution volume (V</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">ss</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">) ranged from 5 to 6 litres and the mean terminal phase half-life </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was approximately two weeks. Adalimumab concentrations in the synovial fluid from several rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients ranged from 31-96% of those in serum.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following subcutaneous administration of 40 mg of adalimumab every other week in adult rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis (RA) patients the mean steady-state trough concentrations were approximately 5</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml (without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant methotrexate) and 8 to 9</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml (with concomitant methotrexate), respectively.  The serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab trough levels at steady-state increased roughly proportionally with dose following 20, 40 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg subcutaneous dosing every other week and every week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following the administration of 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(maximum of 40 mg) subcutaneously every other week to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with polyarticular juvenile idiopathic arthritis (JIA) who were 4 to 17 years the mean trough </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">steady-state (values measured from Week 20 to 48) serum adalimumab concentration was 5.6 &#xb1; 5.6 &#xb5;g/ml </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(102% CV) for adalimumab without concomitant methotrexate and 10.9 &#xb1; 5.2 &#xb5;g/ml (47.7% CV) with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with polyarticular JIA who were 2 to &lt; 4 years old or aged 4 and above weighing &lt; 15 kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:370pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dosed with adalimumab 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">, the mean trough steady-state serum adalimumab concentrations was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.0 &#xb1; 6.1 &#xb5;g/ml (101% CV) for adalimumab without concomitant methotrexate and 7.9 &#xb1; 5.6 &#xb5;g/ml </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(71.2% CV) with concomitant methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following the administration of 24 mg/m</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(maximum of 40 mg) subcutaneously every other week to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with enthesitis-related arthritis who were 6 to 17 years, the mean trough steady-state (values </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">measured at Week 24) serum adalimumab concentrations were 8.8 &#xb1; 6.6 &#x3bc;g/ml for adalimumab without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant methotrexate and 11.8 &#xb1; 4.3 &#x3bc;g/ml with concomitant methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following subcutaneous administration of 40 mg of adalimumab every other week in adult non-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">radiographic axial spondyloarthritis patients, the mean (&#xb1;SD) trough steady-state concentration at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 68 was 8.0 &#xb1; 4.6</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with psoriasis, the mean steady-state trough concentration was 5</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab 40 mg every other week monotherapy treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following the administration of 0.8 mg/kg (maximum of 40 mg) subcutaneously every other week to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients with chronic plaque psoriasis, the mean &#xb1; SD steady-state adalimumab trough </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentration was approximately 7.4 &#xb1; 5.8 &#xb5;g/ml (79% CV).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with hidradenitis suppurativa, a dose of 160 mg Humira on Week 0 followed by 80 mg on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 2 achieved serum adalimumab trough concentrations of approximately 7 to 8 &#x3bc;g/ml at Week 2 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 4.  The mean steady-state trough concentration at Week 12 through Week 36 were approximately 8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 10 &#x3bc;g/ml during adalimumab 40 mg every week treatment.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab exposure in adolescent HS patients was predicted using population pharmacokinetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">modelling and simulation based on cross-indication pharmacokinetics in other paediatric patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn&#x2019;s disease, and enthesitis-related </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">211</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis). The recommended adolescent HS dosing schedule is 40 mg every other week. Since exposure to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab can be affected by body size, adolescents with higher body weight and inadequate response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">may benefit from receiving the recommended adult dose of 40 mg every week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with Crohn&#x2019;s disease, the loading dose of 80 mg Humira on Week 0 followed by 40 mg Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">on Week 2 achieves serum adalimumab trough concentrations of approximately 5.5</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">induction period. A loading dose of 160 mg Humira on Week 0 followed by 80 mg Humira on Week 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">achieves serum adalimumab trough concentrations of approximately 12</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml during the induction period. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mean steady-state trough levels of approximately 7</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml were observed in Crohn&#x2019;s disease patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received a maintenance dose of 40 mg Humira every other week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In paediatric patients with moderate to severe CD, the open-label adalimumab induction dose was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">160/80 mg or 80/40 mg at Weeks 0 and 2, respectively, dependent on a body weight cut-off of 40 kg.  At </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 4, patients were randomised 1:1 to either the Standard Dose (40/20 mg eow) or Low Dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(20/10 mg eow) maintenance treatment groups based on their body weight. The mean (&#xb1;SD) serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:249pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab trough concentrations achieved at Week 4 were 15.7 &#xb1; 6.6</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml for patients &#x2265; 40 kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(160/80 mg) and 10.6 &#xb1; 6.1</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml for patients &lt; 40 kg (80/40 mg). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:289pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For patients who stayed on their randomised therapy, the mean (&#xb1;SD) adalimumab trough concentrations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at Week 52 were 9.5 &#xb1; 5.6</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml for the Standard Dose group and 3.5 &#xb1; 2.2</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml for the Low Dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:315pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">group.  The mean trough concentrations were maintained in patients who continued to receive adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:327pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment eow for 52 weeks. For patients who dose escalated from eow to weekly regimen, the mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:340pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&#xb1;SD) serum concentrations of adalimumab at Week 52 were 15.3 &#xb1; 11.4 &#x3bc;g/ml (40/20 mg, weekly) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:353pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.7 &#xb1; 3.5 &#x3bc;g/ml (20/10 mg, weekly).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:378pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with ulcerative colitis, a loading dose of 160 mg Humira on Week 0 followed by 80 mg Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">on Week 2 achieves serum adalimumab trough concentrations of approximately 12</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">induction period.  Mean steady-state trough levels of approximately 8</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml were observed in ulcerative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">colitis patients who received a maintenance dose of 40 mg Humira every other week. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following the subcutaneous administration of body weight-based dosing of 0.6 mg/kg (maximum of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg) every other week to paediatric patients with ulcerative colitis, the mean trough steady-state serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:468pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab concentration was 5.01&#xb1;3.28 &#xb5;g/ml at Week 52. For patients who received 0.6 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:481pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(maximum of 40 mg) every week, the mean (&#xb1;SD) trough steady-state serum adalimumab concentration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:493pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was 15.7&#xb1;5.60 &#x3bc;g/ml at Week 52. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with uveitis, a loading dose of 80 mg adalimumab on Week 0 followed by 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:531pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab every other week starting at Week 1, resulted in mean steady-state concentrations of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:544pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 8 to 10</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab exposure in paediatric uveitis patients was predicted using population pharmacokinetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">modelling and simulation based on cross-indication pharmacokinetics in other paediatric patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn&#x2019;s disease, and enthesitis-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis). No clinical exposure data are available on the use of a loading dose in children &lt; 6 years. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:621pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">predicted exposures indicate that in the absence of methotrexate, a loading dose may lead to an initial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increase in systemic exposure.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:659pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Population pharmacokinetic and pharmacokinetic/pharmacodynamic modelling and simulation predicted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparable adalimumab exposure and efficacy in patients treated with 80 mg every other week when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:684pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared with 40 mg every week (including adult patients with RA, HS, UC, CD or Ps, patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adolescent HS, and paediatric patients &#x2265; 40 kg with CD and UC).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:722pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Exposure-response relationship in paediatric population</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">212</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">On the basis of clinical trial data in patients with JIA (pJIA and ERA), an exposure-response relationship </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was established between plasma concentrations and PedACR 50 response. The apparent adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">plasma concentration that produces half the maximum probability of PedACR 50 response (EC50) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 &#x3bc;g/ml (95% CI: 1-6 &#x3bc;g/ml). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Exposure-response relationships between adalimumab concentration and efficacy in paediatric patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with severe chronic plaque psoriasis were established for PASI 75 and PGA clear or minimal, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively. PASI 75 and PGA clear or minimal increased with increasing adalimumab concentrations, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">both with a similar apparent EC50 of approximately 4.5 &#x3bc;g/ml (95% CI 0.4-47.6 and 1.9-10.5, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elimination</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Population pharmacokinetic analyses with data from over 1,300 RA patients revealed a trend toward </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher apparent clearance of adalimumab with increasing body weight. After adjustment for weight </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">differences, gender and age appeared to have a minimal effect on adalimumab clearance.  The serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">levels of free adalimumab (not bound to anti-adalimumab antibodies, AAA) were observed to be lower in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with measurable AAA.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatic or renal impairment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has not been studied in patients with hepatic or renal impairment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Preclinical safety data </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Non-clinical data reveal no special hazard for humans based on studies of single dose toxicity, repeated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose toxicity, and genotoxicity.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">An embryo-foetal developmental toxicity/perinatal developmental study has been performed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cynomolgus monkeys at 0, 30 and 100 mg/kg (9-17 monkeys/group) and has revealed no evidence of harm </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to the foetuses due to adalimumab. Neither carcinogenicity studies, nor a standard assessment of fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibody with limited cross-reactivity to rodent TNF and to the development of neutralising antibodies in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rodents. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">List of excipients </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mannitol</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Polysorbate 80</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Water for injections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Incompatibilities </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">products.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Shelf life </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 years</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">213</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for storage </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Store in a refrigerator (2</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C &#x2013; 8</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C). Do not freeze. Keep the pre-filled syringe or pre-filled pen in its outer </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">carton in order to protect from light.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A single Humira pre-filled syringe or pre-filled pen may be stored at temperatures up to a maximum of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25&#xb0;C for a period of up to 14 days. The syringe or pen must be protected from light, and discarded if not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">used within the 14-day period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Nature and contents of container</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in pre-filled syringe</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in single-use pre-filled syringe (type I glass) with a plunger stopper </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(bromobutyl rubber) and a needle with a needle shield (thermoplastic elastomer). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Packs of:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 pre-filled syringe (0.4 ml sterile solution) with 1 alcohol pad in a blister.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 pre-filled syringes (0.4 ml sterile solution), each with 1 alcohol pad, in a blister.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 pre-filled syringes (0.4 ml sterile solution), each with 1 alcohol pad, in a blister.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:301pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 pre-filled syringes (0.4 ml sterile solution), each with 1 alcohol pad, in a blister.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:326pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in pre-filled pen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in single-use pre-filled pen for patient use containing a pre-filled </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">syringe. The syringe inside the pen is made from type 1 glass with a plunger stopper (bromobutyl rubber) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and a needle with a needle shield (thermoplastic elastomer).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Packs of:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:88pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:106pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 pre-filled pen (0.4 ml sterile solution), with 2 alcohol pads in a blister.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:88pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:106pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 pre-filled pens (0.4 ml sterile solution), each with 1 alcohol pad, in a blister.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:429pt;left:88pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:106pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 pre-filled pens (0.4 ml sterile solution), each with 1 alcohol pad, in a blister.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:442pt;left:88pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:106pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 pre-filled pens (0.4 ml sterile solution), each with 1 alcohol pad, in a blister.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not all presentations or pack sizes may be marketed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for disposal</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:532pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requirements.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">7.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:595pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">AbbVie Deutschland GmbH &amp; Co. KG</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Knollstrasse</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:621pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">67061 Ludwigshafen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Germany</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">214</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">8.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBERS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in pre-filled syringe</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/012</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/013</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/014</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/015</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg solution for injection in pre-filled pen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/016</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/017</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/018</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/019</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">9.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of first authorisation: 08 September 2003</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of latest renewal: 08 September 2008 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">10.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Agency </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000ff">http://www.ema.europa.eu</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">215</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Error! Hyperlink reference not valid.1.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:286pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">NAME OF THE MEDICINAL PRODUCT </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 80 mg solution for injection in pre-filled syringe</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 80 mg solution for injection in pre-filled pen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">2.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">QUALITATIVE AND QUANTITATIVE COMPOSITION </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 80 mg solution for injection in pre-filled syringe </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each 0.8 ml single dose pre-filled syringe contains 80 mg of adalimumab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 80 mg solution for injection in pre-filled pen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Each 0.8 ml single dose pre-filled pen contains 80 mg of adalimumab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary cells.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For the full list of excipients, see section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">3.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL FORM </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Solution for injection. (injection)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clear, colourless solution. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CLINICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Therapeutic indications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rheumatoid arthritis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira in combination with methotrexate, is indicated for:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:Wingdings,sans-serif;font-size:11.04pt">&#xf0a7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:Wingdings,sans-serif;font-size:11.04pt">&#xf0a7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with methotrexate is inappropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has been shown to reduce the rate of progression of joint damage as measured by X-ray and to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improve physical function, when given in combination with methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">are candidates for systemic therapy.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">216</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hidradenitis suppurativa (HS)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy (see sections 5.1 and 5.2).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Crohn&#x2019;s disease</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for treatment of moderately to severely active Crohn&#x2019;s disease, in adult patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have not responded despite a full and adequate course of therapy with a corticosteroid and/or an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric Crohn&apos;s disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of moderately to severely active Crohn&apos;s disease in paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (from 6 years of age) who have had an inadequate response to conventional therapy including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have contraindications for such therapies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ulcerative colitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric ulcerative colitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (from 6 years of age) who have had an inadequate response to conventional therapy including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">medical contraindications for such therapies.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uveitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sparing, or in whom corticosteroid treatment is inappropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric Uveitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">whom conventional therapy is inappropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Posology and method of administration  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treatment should be initiated and supervised by specialist physicians experienced in the diagnosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and treatment of conditions for which Humira is indicated. Ophthalmologists are advised to consult with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">an appropriate specialist before initiation of treatment with Humira (see section 4.4). Patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira should be given the Patient Reminder Card.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">217</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After proper training in injection technique, patients may self-inject with Humira if their physician </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">determines that it is appropriate and with medical follow-up as necessary. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During treatment with Humira, other concomitant therapies (e.g., corticosteroids and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunomodulatory agents) should be optimised.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Posology</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Rheumatoid arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for adult patients with rheumatoid arthritis is 40 mg adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered every other week as a single dose via subcutaneous injection. Methotrexate should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued during treatment with Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Glucocorticoids, salicylates, non-steroidal anti-inflammatory drugs (NSAIDs), or analgesics can be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued during treatment with Humira.  Regarding combination with disease modifying anti-rheumatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">drugs other than methotrexate see sections 4.4 and 5.1.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In monotherapy, some patients who experience a decrease in their response to Humira 40 mg every other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">week may benefit from an increase in dosage to 40 mg adalimumab every week or 80 mg every other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">week. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Available data suggest that the clinical response is usually achieved within 12 weeks of treatment.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy should be reconsidered in a patient not responding within this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for adult patients is an initial dose of 80 mg administered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneously, followed by 40 mg subcutaneously given every other week starting one week after the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initial dose. Humira 40 mg solution for injection in pre-filled syringe and/or pre-filled pen is available for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the maintenance dose.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy beyond 16 weeks should be carefully reconsidered in a patient not responding within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Beyond 16 weeks, patients with inadequate response to Humira 40 mg every other week may benefit from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">an increase in dosage to 40 mg every week or 80 mg every other week. The benefits and risks of continued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg weekly or 80 mg every other week therapy should be carefully reconsidered in a patient with an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inadequate response after the increase in dosage (see section 5.1). If adequate response is achieved with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every week or 80 mg every other week, the dosage may subsequently be reduced to 40 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Hidradenitis suppurativa</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended Humira dose regimen for adult patients with hidradenitis suppurativa (HS) is 160 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initially at Day 1 (given as two 80 mg injections in one day or as one 80 mg injection per day for two </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">consecutive days), followed by 80 mg two weeks later at Day 15. Two weeks later (Day 29) continue with </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">218</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a dose of 40 mg every week or 80 mg every other week. Antibiotics may be continued during treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Humira if necessary. It is recommended that the patient should use a topical antiseptic wash on their </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HS lesions on a daily basis during treatment with Humira. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy beyond 12 weeks should be carefully reconsidered in a patient with no improvement </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">within this time period.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Should treatment be interrupted, Humira 40 mg every week or 80 mg every other week may be re-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">introduced (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The benefit and risk of continued long-term treatment should be periodically evaluated (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Crohn&#x2019;s disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended Humira induction dose regimen for adult patients with moderately to severely active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Crohn&#x2019;s disease is 80 mg at Week 0 followed by 40 mg at Week 2. In case there is a need for a more rapid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response to therapy, the regimen 160 mg at Week 0 (given as two 80 mg injections in one day or as one </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg injection per day for two consecutive days), followed by 80 mg at Week 2, can be used with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">awareness that the risk for adverse events is higher during induction.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After induction treatment, the recommended dose is 40 mg every other week via subcutaneous injection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Alternatively, if a patient has stopped Humira and signs and symptoms of disease recur, Humira may be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">re-administered. There is little experience from re-administration after more than 8 weeks since the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">previous dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During maintenance treatment, corticosteroids may be tapered in accordance with clinical practice </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">guidelines.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Some patients who experience decrease in their response to Humira 40 mg every other week may benefit </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">from an increase in dosage to 40 mg Humira every week or 80 mg every other week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Some patients who have not responded by Week 4 may benefit from continued maintenance therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">through Week 12. Continued therapy should be carefully reconsidered in a patient not responding within </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Ulcerative colitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended Humira induction dose regimen for adult patients with moderate to severe ulcerative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">colitis is 160 mg at Week 0 (given as two 80 mg injections in one day or as one 80 mg injection per day </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for two consecutive days) and 80 mg at Week 2. After induction treatment, the recommended dose is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week via subcutaneous injection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During maintenance treatment, corticosteroids may be tapered in accordance with clinical practice </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">guidelines. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Some patients who experience decrease in their response to 40 mg every other week may benefit from an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increase in dosage to 40 mg Humira every week or 80 mg every other week.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">219</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Available data suggest that clinical response is usually achieved within 2-8 weeks of treatment.  Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy should not be continued in patients failing to respond within this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Uveitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for adult patients with uveitis is an initial dose of 80 mg, followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg given every other week starting one week after the initial dose. Humira 40 mg solution for injection </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in pre-filled syringe and/or pre-filled pen is available for the maintenance dose. There is limited </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experience in the initiation of treatment with Humira alone. Treatment with Humira can be initiated in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination with corticosteroids and/or with other non-biologic immunomodulatory agents. Concomitant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">corticosteroids may be tapered in accordance with clinical practice starting two weeks after initiating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment with Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">It is recommended that the benefit and risk of continued long-term treatment should be evaluated on a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">yearly basis (see section 5.1).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Special populations</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elderly</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose adjustment is required.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal and/or hepatic impairment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has not been studied in these patient populations. No dose recommendations can be made.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric plaque psoriasis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira in children aged 4-17 years have been established for plaque psoriasis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended Humira dose is up to a maximum of 40 mg per dose.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adolescent hidradenitis suppurativa (from 12 years of age, weighing at least 30 kg)</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There are no clinical trials with Humira in adolescent patients with HS.  The posology of Humira in these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients has been determined from pharmacokinetic modelling and simulation (see section 5.2).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended Humira dose is 80 mg at Week 0 followed by 40 mg every other week starting at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 1 via subcutaneous injection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adolescent patients with inadequate response to Humira 40 mg every other week, an increase in dosage</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 40 mg every week or 80 mg every other week may be considered. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">220</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Antibiotics may be continued during treatment with Humira if necessary. It is recommended that the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient should use a topical antiseptic wash on their HS lesions on a daily basis during treatment with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy beyond 12 weeks should be carefully reconsidered in a patient with no improvement </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">within this time period.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Should treatment be interrupted, Humira may be re-introduced as appropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The benefit and risk of continued long-term treatment should be periodically evaluated (see adult data in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">section 5.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 12 years in this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric Crohn&apos;s disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for patients with Crohn&#x2019;s disease from 6 to 17 years of age is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body weight (Table 1). Humira is administered via subcutaneous injection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:150pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 1. Humira Dose for Paediatric Patients with Crohn&#x2019;s disease</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:78pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:78pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:255pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Induction Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:471pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maintenance </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:490pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:476pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Starting at </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:484pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:78pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:126pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 40 mg at Week 0 and 20 mg at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:441pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In case there is a need for a more rapid response to therapy with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">awareness that the risk for adverse events may be higher with use of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher induction dose, the following dose may be used:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:126pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 80 mg at Week 0 and 40 mg at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:474pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:477pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:78pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:126pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 80 mg at Week 0 and 40 mg at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In case there is a need for a more rapid response to therapy with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">awareness that the risk for adverse events may be higher with use of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:127pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher induction dose, the following dose may be used:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:126pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 160 mg at Week 0 and 80 mg at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:494pt;left:474pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:477pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:586pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who experience insufficient response may benefit from an increase in dosage:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:598pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg: 20 mg every week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 40 kg: 40 mg every week or 80 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy should be carefully considered in a subject not responding by Week 12.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 6 years for this indication.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">221</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric ulcerative colitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for patients from 6 to 17 years of age with ulcerative colitis is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body weight (Table 2). Humira is administered via subcutaneous injection. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:146pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 2. Humira Dose for Paediatric Patients with Ulcerative Colitis </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:141pt;left:102pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:141pt;left:234pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Induction Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:395pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maintenance Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:392pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Starting at Week 4*</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:120pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:192pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 80 mg at Week 0 (given as one 80 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg injection) and</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:187pt;left:192pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 40 mg at Week 2 (given as one 40 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg injection)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:365pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 40 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:120pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:192pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 160 mg at Week 0 (given as two </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:227pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg injections in one day or one </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:240pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg injection per day for two </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">consecutive days) and</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:192pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 80 mg at Week 2 (given as one 80 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg injection)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:365pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2022; 80 mg every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:91pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">* </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric patients who turn 18 years of age while on Humira should continue their prescribed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:91pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintenance dose.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Continued therapy beyond 8 weeks should be carefully considered in patients not showing signs of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response within this time period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 6 years in this indication.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in different strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric Uveitis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:460pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The recommended dose of Humira for paediatric patients with uveitis from 2 years of age is based on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">body weight (Table 3). Humira is administered via subcutaneous injection.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In paediatric uveitis, there is no experience in the treatment with Humira without concomitant treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with methotrexate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:170pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 3. Humira Dose for Paediatric Patients with Uveitis</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Dosing Regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:332pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg every other week in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:322pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination with methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:204pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 30 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:332pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:322pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination with methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:648pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">When Humira therapy is initiated, a loading dose of 40 mg for patients &lt; 30 kg or 80 mg for patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 30 kg may be administered one week prior to the start of maintenance therapy. No clinical data are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">available on the use of a Humira loading dose in children &lt; 6 years of age (see section 5.2).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is no relevant use of Humira in children aged less than 2 years in this indication.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">222</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">It is recommended that the benefit and risk of continued long-term treatment should be evaluated on a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">yearly basis (see section 5.1).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may be available in other strengths and/or presentations depending on the individual treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">needs.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Method of administration</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is administered by subcutaneous injection. Full instructions for use are provided in the package </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">leaflet.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira is available in other strengths and presentations.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Contraindications </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Active tuberculosis or other severe infections such as sepsis, and opportunistic infections (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Moderate to severe heart failure (NYHA class III/IV) (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special warnings and precautions for use</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Traceability </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In order to improve traceability of biological medicinal products, the name and the batch number of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administered product should be clearly recorded.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Infections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients taking TNF-antagonists are more susceptible to serious infections. Impaired lung function may </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increase the risk for developing infections. Patients must therefore be monitored closely for infections, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">including tuberculosis, before, during and after treatment with Humira.  Because the elimination of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab may take up to four months, monitoring should be continued throughout this period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Humira should not be initiated in patients with active infections including chronic or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">localised infections until infections are controlled. In patients who have been exposed to tuberculosis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients who have travelled in areas of high risk of tuberculosis or endemic mycoses, such as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">histoplasmosis, coccidioidomycosis, or blastomycosis, the risk and benefits of treatment with Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be considered prior to initiating therapy (see </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Other opportunistic infections</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:574pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who develop a new infection while undergoing treatment with Humira should be monitored </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:587pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">closely and undergo a complete diagnostic evaluation. Administration of Humira should be discontinued if </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:612pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be initiated until the infection is controlled.  Physicians should exercise caution when considering </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:625pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the use of Humira in patients with a history of recurring infection or with underlying conditions which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:637pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">may predispose patients to infections, including the use of concomitant immunosuppressive medications.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">223</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Serious infections</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious infections, including sepsis, due to bacterial, mycobacterial, invasive fungal, parasitic, viral, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other opportunistic infections such as listeriosis, legionellosis and pneumocystis have been reported in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients receiving Humira.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Other serious infections seen in clinical trials include pneumonia, pyelonephritis, septic arthritis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">septicaemia. Hospitalisation or fatal outcomes associated with infections have been reported. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Tuberculosis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tuberculosis, including reactivation and new onset of tuberculosis, has been reported in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira.  Reports included cases of pulmonary and extra-pulmonary (i.e. disseminated) tuberculosis. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Before initiation of therapy with Humira, all patients must be evaluated for both active or inactive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&#x201c;latent&#x201d;) tuberculosis infection.  This evaluation should include a detailed medical assessment of patient </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">history of tuberculosis or possible previous exposure to people with active tuberculosis and previous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and/or current immunosuppressive therapy.  Appropriate screening tests (i.e. tuberculin skin test and chest </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">X-ray) should be performed in all patients (local recommendations may apply).  It is recommended that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the conduct and results of these tests are recorded in the Patient Reminder Card.  Prescribers are reminded </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunocompromised. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If active tuberculosis is diagnosed, Humira therapy must not be initiated (see section 4.3). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In all situations described below, the benefit/risk balance of therapy should be very carefully considered.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">consulted.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">If latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosis prophylaxis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment before the initiation of Humira, and in accordance with local recommendations. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Use of anti-tuberculosis prophylaxis treatment should also be considered before the initiation of Humira in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with several or significant risk factors for tuberculosis despite a negative test for tuberculosis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cannot be confirmed.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have occurred in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with Humira. Some patients who have been successfully treated for active tuberculosis have</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">redeveloped tuberculosis while being treated with Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients should be instructed to seek medical advice if signs/symptoms suggestive of a tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infection (e.g., persistent cough, wasting/weight loss, low grade fever, listlessness) occur during or after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy with Humira. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Other opportunistic infections</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Opportunistic infections, including invasive fungal infections have been observed in patients receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira. These infections have not consistently been recognised in patients taking TNF-antagonists and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">this has resulted in delays in appropriate treatment, sometimes resulting in fatal outcomes. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">224</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dyspnoea, and/or pulmonary infiltrates or other serious systemic illness with or without concomitant shock </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">an invasive fungal infection should be suspected and administration of Humira should be promptly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">discontinued.  Diagnosis and administration of empiric antifungal therapy in these patients should be made </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in consultation with a physician with expertise in the care of patients with invasive fungal infections. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatitis B reactivation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reactivation of hepatitis B has occurred in patients receiving a TNF-antagonist including Humira, who are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chronic carriers of this virus (i.e. surface antigen positive).  Some cases have had a fatal outcome. Patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be tested for HBV infection before initiating treatment with Humira. For patients who test positive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for hepatitis B infection, consultation with a physician with expertise in the treatment of hepatitis B is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recommended.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Carriers of HBV who require treatment with Humira should be closely monitored for signs and symptoms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of active HBV infection throughout therapy and for several months following termination of therapy. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adequate data from treating patients who are carriers of HBV with anti-viral therapy in conjunction with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonist therapy to prevent HBV reactivation are not available. In patients who develop HBV </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactivation, Humira should be stopped and effective anti-viral therapy with appropriate supportive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment should be initiated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neurological events </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonists including Humira have been associated in rare instances with new onset or exacerbation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">including multiple sclerosis and optic neuritis, and peripheral demyelinating disease, including Guillain-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Barr&#xe9; syndrome. Prescribers should exercise caution in considering the use of Humira in patients with pre-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">existing or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira should be considered if any of these disorders develop. There is a known association between </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intermediate uveitis and central demyelinating disorders. Neurologic evaluation should be performed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with non-infectious intermediate uveitis prior to the initiation of Humira therapy and regularly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">during treatment to assess for pre-existing or developing central demyelinating disorders. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Allergic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious allergic reactions associated with Humira were rare during clinical trials. Non-serious allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactions associated with Humira were uncommon during clinical trials. Reports of serious allergic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactions including anaphylaxis have been received following Humira administration. If an anaphylactic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reaction or other serious allergic reaction occurs, administration of Humira should be discontinued </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immediately and appropriate therapy initiated. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immunosuppression</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a study of 64 patients with rheumatoid arthritis that were treated with Humira, there was no evidence of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enumeration of effector T-, B-, NK-cells, monocyte/macrophages, and neutrophils.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the controlled portions of clinical trials of TNF-antagonists, more cases of malignancies including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lymphoma have been observed among patients receiving a TNF-antagonist compared with control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients. However, the occurrence was rare. In the post marketing setting, cases of leukaemia have been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reported in patients treated with a TNF-antagonist. There is an increased background risk for lymphoma </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">225</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">which complicates the risk estimation. With the current knowledge, a possible risk for the development of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lymphomas, leukaemia, and other malignancies in patients treated with a TNF-antagonist cannot be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">excluded.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22 years of age) treated with TNF-antagonists (initiation of therapy &#x2264; 18 years of age), including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab in the post marketing setting. Approximately half the cases were lymphomas. The other cases </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">represented a variety of different malignancies and included rare malignancies usually associated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunosuppression. A risk for the development of malignancies in children and adolescents treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonists cannot be excluded. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare postmarketing cases of hepatosplenic T-cell lymphoma have been identified in patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab. This rare type of T-cell lymphoma has a very aggressive disease course and is usually fatal. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Some of these hepatosplenic T-cell lymphomas with Humira have occurred in young adult patients on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant treatment with azathioprine or 6-mercaptopurine used for inflammatory bowel disease. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">potential risk with the combination of azathioprine or 6-mercaptopurine and Humira should be carefully </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered. A risk for the development of hepatosplenic T-cell lymphoma in patients treated with Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cannot be excluded (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No studies have been conducted that include patients with a history of malignancy or in whom treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Humira is continued following development of malignancy.  Thus, additional caution should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exercised in considering Humira treatment of these patients (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis patients with a history of PUVA treatment should be examined for the presence of non-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">melanoma skin cancer prior to and during treatment with Humira.  Melanoma and Merkel cell carcinoma </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have also been reported in patients treated with TNF-antagonists including adalimumab (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an exploratory clinical trial evaluating the use of another TNF-antagonist, infliximab, in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies, mostly in the lung </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or head and neck, were reported in infliximab-treated patients compared with control patients. All patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had a history of heavy smoking. Therefore, caution should be exercised when using any TNF-antagonist in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">COPD patients, as well as in patients with increased risk for malignancy due to heavy smoking.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">With current data it is not known if adalimumab treatment influences the risk for developing dysplasia or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">colon cancer.  All patients with ulcerative colitis who are at increased risk for dysplasia or colon </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">carcinoma (for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or who had a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intervals before therapy and throughout their disease course. This evaluation should include colonoscopy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and biopsies per local recommendations.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Haematologic reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare reports of pancytopenia including aplastic anaemia have been reported with TNF-antagonists.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adverse events of the haematologic system, including medically significant cytopenia (e.g. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">thrombocytopenia, leukopenia) have been reported with Humira. All patients should be advised to seek </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">persistent fever, bruising, bleeding, pallor) while on Humira. Discontinuation of Humira therapy should be </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">considered in patients with confirmed significant haematologic abnormalities.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vaccinations </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">226</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Similar antibody responses to the standard 23-valent pneumococcal vaccine and the influenza trivalent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">virus vaccination were observed in a study in 226 adult subjects with rheumatoid arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with adalimumab or placebo. No data are available on the secondary transmission of infection by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">live vaccines in patients receiving Humira.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">agreement with current immunisation guidelines prior to initiating Humira therapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients on Humira may receive concurrent vaccinations, except for live vaccines. Administration of live </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vaccines (e.g., BCG vaccine) to infants exposed to adalimumab in utero is not recommended for 5 months </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">following the mother&#x2019;s last adalimumab injection during pregnancy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Congestive heart failure</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a clinical trial with another TNF-antagonist worsening congestive heart failure and increased mortality </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">due to congestive heart failure have been observed. Cases of worsening congestive heart failure have also </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been reported in patients receiving Humira. Humira should be used with caution in patients with mild </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">heart failure (NYHA class I/II). Humira is contraindicated in moderate to severe heart failure (see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.3). Treatment with Humira must be discontinued in patients who develop new or worsening symptoms </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of congestive heart failure.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Autoimmune processes</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Humira may result in the formation of autoimmune antibodies. The impact of long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment with Humira on the development of autoimmune diseases is unknown. If a patient develops </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms suggestive of a lupus-like syndrome following treatment with Humira and is positive for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies against double-stranded DNA, further treatment with Humira should not be given (see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent administration of biologic DMARDS or TNF-antagonists</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious infections were seen in clinical studies with concurrent use of anakinra and another </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">TNF-antagonist, etanercept, with no added clinical benefit compared to etanercept alone. Because of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">nature of the adverse events seen with the combination of etanercept and anakinra therapy, similar </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">toxicities may also result from the combination of anakinra and other TNF-antagonists. Therefore, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination of adalimumab and anakinra is not recommended. (See section 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concomitant administration of adalimumab with other biologic DMARDS (e.g, anakinra and abatacept) or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other TNF-antagonists is not recommended based upon the possible increased risk for infections, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">including serious infections and other potential pharmacological interactions. (See section 4.5).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Surgery</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There is limited safety experience of surgical procedures in patients treated with Humira. The long half-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">life of adalimumab should be taken into consideration if a surgical procedure is planned.  A patient who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requires surgery while on Humira should be closely monitored for infections, and appropriate actions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">should be taken. There is limited safety experience in patients undergoing arthroplasty while receiving </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">227</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Small bowel obstruction</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Failure to respond to treatment for Crohn&#x2019;s disease may indicate the presence of fixed fibrotic stricture </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">that may require surgical treatment. Available data suggest that Humira does not worsen or cause </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">strictures.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elderly</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The frequency of serious infections among Humira treated subjects over 65 years of age (3.7%) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher than for those under 65 years of age (1.5%). Some of those had a fatal outcome. Particular attention </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">regarding the risk for infection should be paid when treating the elderly.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">See Vaccinations above.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Interaction with other medicinal products and other forms of interaction </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has been studied in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients taking Humira as monotherapy and those taking concomitant methotrexate.  Antibody </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">formation was lower when Humira was given together with methotrexate in comparison with use as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy. Administration of Humira without methotrexate resulted in increased formation of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies, increased clearance and reduced efficacy of adalimumab (see section 5.1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The combination of Humira and anakinra is not recommended (see section 4.4 &#x201c;Concurrent administration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of biologic DMARDS or TNF-antagonists&#x201d;). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The combination of Humira and abatacept is not recommended (see section 4.4 &#x201c;Concurrent </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration of biologic DMARDS or TNF-antagonists&#x201d;).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Fertility, pregnancy and lactation</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Women of childbearing potential should consider the use of adequate contraception to prevent pregnancy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and continue its use for at least five months after the last Humira treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pregnancy</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A large number (approximately 2100) of prospectively collected pregnancies exposed to adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">resulting in live birth with known outcomes, including more than 1500 exposed during the first trimester, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">does not indicate an increase in the rate of malformation in the newborn.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a prospective cohort registry, 257 women with rheumatoid arthritis (RA) or Crohn&#x2019;s disease (CD) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with adalimumab at least during the first trimester and 120 women with RA or CD not treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab were enrolled.  The primary endpoint was the birth prevalence of major birth defects. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rate of pregnancies ending with at least one live born infant with a major birth defect was 6/69 (8.7%) in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the adalimumab-treated women with RA and 5/74 (6.8%) in the untreated women with RA (unadjusted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">OR 1.31, 95% CI 0.38-4.52) and 16/152 (10.5%) in the adalimumab-treated women with CD and 3/32 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(9.4%) in the untreated women with CD (unadjusted OR 1.14, 95% CI 0.31-4.16). The adjusted OR </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(accounting for baseline differences) was 1.10 (95% CI 0.45-2.73) with RA and CD combined. There were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">no distinct differences between adalimumab-treated and untreated women for the secondary endpoints </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">spontaneous abortions, minor birth defects, preterm delivery, birth size and serious or opportunistic </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">228</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections and no stillbirths or malignancies were reported. The interpretation of data may be impacted due </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to methodological limitations of the study, including small sample size and non-randomized design.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In a developmental toxicity study conducted in monkeys, there was no indication of maternal toxicity, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">embryotoxicity or teratogenicity. Preclinical data on postnatal toxicity of adalimumab are not available </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(see section 5.3).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Due to its inhibition of TNF</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf061;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">, adalimumab administered during pregnancy could affect normal immune </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responses in the newborn. Adalimumab should only be used during pregnancy if clearly needed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab may cross the placenta into the serum of infants born to women treated with adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">during pregnancy. Consequently, these infants may be at increased risk for infection. Administration of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">live vaccines (e.g., BCG vaccine) to infants exposed to adalimumab in utero is not recommended for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5 months following the mother&#x2019;s last adalimumab injection during pregnancy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Breast-feeding</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Limited information from the published literature indicates that adalimumab is excreted in breast milk at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">very low concentrations with the presence of adalimumab in human milk at concentrations of 0.1% to 1% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of the maternal serum level. Given orally, immunoglobulin G proteins undergo intestinal proteolysis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have poor bioavailability. No effects on the breastfed newborns/infants are anticipated. Consequently, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira can be used during breastfeeding.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fertility</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Preclinical data on fertility effects of adalimumab are not available.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.7</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Effects on ability to drive and use machines </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira may have a minor influence on the ability to drive and use machines. Vertigo and visual </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">impairment may occur following administration of Humira (see section 4.8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Undesirable effects</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Summary of the safety profile</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira was studied in 9,506 patients in pivotal controlled and open label trials for up to 60 months or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">more.  These trials included rheumatoid arthritis patients with short term and long standing disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis) as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">well as axial spondyloarthritis (ankylosing spondylitis and axial spondyloarthritis without radiographic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">evidence of AS), psoriatic arthritis, Crohn&#x2019;s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and uveitis patients. The pivotal controlled studies involved 6,089 patients receiving Humira and 3,801 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients receiving placebo or active comparator during the controlled period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The proportion of patients who discontinued treatment due to adverse events during the double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">controlled portion of pivotal studies was 5.9% for patients taking Humira and 5.4% for control treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The most commonly reported adverse reactions are infections (such as nasopharyngitis, upper respiratory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tract infection and sinusitis), injection site reactions (erythema, itching, haemorrhage, pain or swelling), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">headache and musculoskeletal pain.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">229</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious adverse reactions have been reported for Humira. TNF-antagonists, such as Humira affect the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immune system and their use may affect the body&#x2019;s defence against infection and cancer.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fatal and life-threatening infections (including sepsis, opportunistic infections and TB), HBV reactivation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and various malignancies (including leukaemia, lymphoma and HSTCL) have also been reported with use </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Serious haematological, neurological and autoimmune reactions have also been reported. These include </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rare reports of pancytopenia, aplastic anaemia, central and peripheral demyelinating events and reports of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lupus, lupus-related conditions and Stevens-Johnson syndrome.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In general, the adverse events in paediatric patients were similar in frequency and type to those seen in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adult patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tabulated list of adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The following list of adverse reactions is based on experience from clinical trials and on postmarketing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experience and are displayed by system organ class and frequency in Table 4 below: very common </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1/10); common (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1/100 to &lt; 1/10); uncommon (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1/1,000 to &lt; 1/100); rare (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 1/10,000 to &lt; 1/1,000); </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and not known (cannot be estimated from the available data). Within each frequency grouping, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">undesirable effects are presented in order of decreasing seriousness. The highest frequency seen among the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">various indications has been included. An asterisk (*) appears in the SOC column if further information is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">found elsewhere in sections 4.3, 4.4 and 4.8.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:288pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:259pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Undesirable Effects</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:418pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Infections and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infestations*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Respiratory tract infections (including lower and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">upper respiratory tract infection, pneumonia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sinusitis, pharyngitis, nasopharyngitis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pneumonia herpes viral)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Systemic infections (including sepsis, candidiasis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and influenza),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">intestinal infections (including gastroenteritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:545pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">viral),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">skin and soft tissue infections (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:570pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paronychia, cellulitis, impetigo, necrotising </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:583pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fasciitis and herpes zoster),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ear infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:608pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">oral infections (including herpes simplex, oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:621pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">herpes and tooth infections), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reproductive tract infections (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:646pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vulvovaginal mycotic infection), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">urinary tract infections (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:675pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pyelonephritis),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fungal infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:706pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joint infections</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">230</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neurological infections (including viral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">meningitis),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">opportunistic infections and tuberculosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(including coccidioidomycosis, histoplasmosis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and mycobacterium avium complex infection), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bacterial infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">eye infections,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:170pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">diverticulitis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Neoplasms benign, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">malignant and unspecified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(including cysts and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:238pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">polyps)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:200pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Skin cancer excluding melanoma (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">basal cell carcinoma and squamous cell </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:225pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">carcinoma),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">benign neoplasm</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Lymphoma**, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:282pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">solid organ neoplasm (including breast cancer, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lung neoplasm and thyroid neoplasm), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">melanoma**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Leukaemia</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:367pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatosplenic T-cell lymphoma</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Merkel cell carcinoma (neuroendocrine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">carcinoma of the skin)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Kaposi&#x2019;s sarcoma</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Blood and the lymphatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">system disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Leukopenia (including neutropenia and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">agranulocytosis), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anaemia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Leucocytosis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">thrombocytopenia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Idiopathic thrombocytopenic purpura</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pancytopenia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immune system disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypersensitivity,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:610pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">allergies (including seasonal allergy)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Sarcoidosis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vasculitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:688pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Anaphylaxis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Metabolism and nutrition </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:721pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Lipids increased</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">231</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypokalaemia, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:117pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">uric acid increased, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blood sodium abnormal,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:149pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hypocalcaemia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:164pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hyperglycaemia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:180pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hypophosphatemia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:195pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dehydration</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psychiatric disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mood alterations (including depression), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:252pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anxiety,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:268pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">insomnia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Nervous system disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Headache</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:331pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paraesthesias (including hypoesthesia),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">migraine,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">nerve root compression</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:391pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:390pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cerebrovascular accident</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:404pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tremor,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:417pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">neuropathy  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Multiple sclerosis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:458pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">demyelinating disorders (e.g. optic neuritis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Guillain-Barr&#xe9; syndrome)</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Eye disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:503pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Visual impairment,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conjunctivitis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blepharitis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">eye swelling</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Diplopia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ear and labyrinth </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:620pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vertigo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Deafness, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:649pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tinnitus</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cardiac disorders* </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Tachycardia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Myocardial infarction</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">232</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arrhythmia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">congestive heart failure</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:130pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:130pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cardiac arrest</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Vascular disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hypertension, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">flushing, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">haematoma</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Aortic aneurysm,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:231pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vascular arterial occlusion,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:244pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">thrombophlebitis   </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Respiratory, thoracic and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mediastinal disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Asthma,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dyspnoea,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:304pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cough</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:333pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:332pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pulmonary embolism</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interstitial lung disease, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">chronic obstructive pulmonary disease,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:371pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pneumonitis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pleural effusion</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pulmonary fibrosis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Gastrointestinal disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Abdominal pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">nausea and vomiting</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">GI haemorrhage, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dyspepsia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">gastroesophageal reflux disease,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sicca syndrome</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pancreatitis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:559pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dysphagia,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">face oedema</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Intestinal perforation</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepato-biliary disorders*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elevated liver enzymes</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:661pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Cholecystitis and cholelithiasis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hepatic steatosis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bilirubin increased</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:715pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatitis</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">233</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reactivation of hepatitis B</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1) </span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:100pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoimmune hepatitis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:130pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:129pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Liver failure</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Skin and subcutaneous </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:174pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">tissue disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rash (including exfoliative rash)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Worsening or new onset of psoriasis (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">palmoplantar pustular psoriasis)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">urticaria,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bruising (including purpura), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dermatitis (including eczema),</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">onychoclasis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:266pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hyperhidrosis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:278pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">alopecia</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pruritus </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:318pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Night sweats,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">scar</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:359pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:358pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erythema multiforme</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Stevens-Johnson syndrome</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">angioedema</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:405pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cutaneous vasculitis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:420pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lichenoid skin reaction</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Worsening of symptoms of dermatomyositis</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Musculoskeletal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:498pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">connective tissue disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:485pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Musculoskeletal pain</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:517pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Muscle spasms (including blood creatine </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">phosphokinase increased)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:558pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rhabdomyolysis,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:571pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">systemic lupus erythematosus</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:596pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Lupus-like syndrome</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal and urinary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:638pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disorders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Renal impairment,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">haematuria</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Nocturia</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reproductive system and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:712pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">breast disorders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erectile dysfunction</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">234</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:88pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">System Organ Class</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Frequency</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:63pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Adverse Reaction</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">General disorders and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:98pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">administration site </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:111pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">conditions*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Very Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:85pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Injection site reaction (including injection site </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:98pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">erythema)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Chest pain, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:140pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">oedema,</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:151pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pyrexia</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:178pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uncommon</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:178pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Inflammation</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Investigations*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Coagulation and bleeding disorders (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">activated partial thromboplastin time prolonged), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">autoantibody test positive (including double </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">stranded DNA antibody), </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blood lactate dehydrogenase increased</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:295pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not known</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Weight increased</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2)</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Injury, poisoning and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">procedural complications</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:206pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Common</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Impaired healing</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:352pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">* further information is found elsewhere in sections 4.3, 4.4 and 4.8</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">** including open label extension studies</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1)</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> including spontaneous reporting data</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2)</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> The mean weight change from baseline for adalimumab ranged from 0.3 kg to 1.0 kg across adult </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:402pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">indications compared to (minus) -0.4 kg to 0.4 kg for placebo over a treatment period of 4-6 months. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:415pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Weight increase of 5-6 kg has also been observed in long-term extension studies with mean exposures of</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 1-2 years without control group, particularly in patients with Crohn&#x2019;s disease and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Ulcerative colitis. The mechanism behind this effect is unclear but could be associated with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">anti-inflammatory effect of adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hidradenitis suppurativa</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:504pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety profile for patients with HS treated with Humira weekly was consistent with the known safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">profile of Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Uveitis</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety profile for patients with uveitis treated with Humira every other week was consistent with the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">known safety profile of Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Description of selected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Injection site reactions</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the pivotal controlled trials in adults and children, 12.9% of patients treated with Humira developed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:668pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection site reactions (erythema and/or itching, haemorrhage, pain or swelling), compared to 7.2% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients receiving placebo or active control. Injection site reactions generally did not necessitate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">discontinuation of the medicinal product.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">235</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Infections </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the pivotal controlled trials in adults and children, the rate of infection was 1.51 per patient year in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treated patients and 1.46 per patient year in the placebo and active control-treated patients. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections consisted primarily of nasopharyngitis, upper respiratory tract infection, and sinusitis. Most </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients continued on Humira after the infection resolved.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The incidence of serious infections was 0.04 per patient year in Humira treated patients and 0.03 per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient year in placebo and active control &#x2212; treated patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled and open label adult and paediatric studies with Humira, serious infections (including fatal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">infections, which occurred rarely) have been reported, which include reports of tuberculosis (including </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extrapulmonary histoplasmosis, blastomycosis, coccidioidomycosis, pneumocystis, candidiasis, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">aspergillosis and listeriosis). Most of the cases of tuberculosis occurred within the first eight months after </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initiation of therapy and may reflect recrudescence of latent disease.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Malignancies and lymphoproliferative disorders</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No malignancies were observed in 249 paediatric patients with an exposure of 655.6 patient years during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira trials in patients with juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">enthesitis-related arthritis). In addition, no malignancies were observed in 192 paediatric patients with an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">exposure of 498.1 patient years during Humira trials in paediatric patients with Crohn&#x2019;s disease. No </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">malignancies were observed in 77 paediatric patients with an exposure of 80.0 patient years during a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira trial in paediatric patients with chronic plaque psoriasis. No malignancies were observed in 93 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients with an exposure of 65.3 patient years during a Humira trial in paediatric patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ulcerative colitis. No malignancies were observed in 60 paediatric patients with an exposure of 58.4 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient years during a Humira trial in paediatric patients with uveitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During the controlled portions of pivotal Humira trials in adults of at least 12 weeks in duration in patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">without radiographic evidence of AS,  psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn&#x2019;s </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease, ulcerative colitis and uveitis, malignancies, other than lymphoma and non-melanoma skin cancer, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were observed at a rate (95% confidence interval) of 6.8 (4.4, 10.5)  per 1,000 patient-years among 5,291 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treated patients </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a rate of 6.3 (3.4, 11.8) per 1,000 patient-years among 3,444 control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (median duration of treatment was 4.0 months for Humira and 3.8 months for control-treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients). The rate (95% confidence interval) of non-melanoma skin cancers was 8.8 (6.0, 13.0) per 1,000 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient-years among Humira-treated patients and 3.2 (1.3, 7.6) per 1,000 patient-years among control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients. Of these skin cancers, squamous cell carcinomas occurred at rates (95% confidence interval) of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.7 (1.4, 5.4) per 1,000 patient-years among Humira-treated patients and 0.6 (0.1, 4.5) per 1,000 patient-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">years among control patients. The rate (95% confidence interval) of lymphomas was 0.7 (0.2, 2.7) per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1,000 patient-years among Humira-treated patients and 0.6 (0.1, 4.5) per 1,000 patient-years among </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">control patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">When combining controlled portions of these trials and ongoing and completed open label extension </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies with a median duration of approximately 3.3 years including 6,427 patients and over 26,439 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient-years of therapy, the observed rate of malignancies, other than lymphoma and non-melanoma skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cancers is approximately 8.5 per 1,000 patient years. The observed rate of non-melanoma skin cancers is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 9.6 per 1,000 patient years, and the observed rate of lymphomas is approximately 1.3 per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1,000 patient years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In post-marketing experience from January 2003 to December 2010, predominantly in patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rheumatoid arthritis, the reported rate of malignancies is approximately 2.7 per 1,000 patient treatment </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">236</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">years. The reported rates for non-melanoma skin cancers and lymphomas are approximately 0.2 and 0.3 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">per 1,000 patient treatment years, respectively (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rare post-marketing cases of hepatosplenic T-cell lymphoma have been reported in patients treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab (see section 4.4).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Autoantibodies </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients had serum samples tested for autoantibodies at multiple time points in rheumatoid arthritis studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">I &#x2212; V. In these trials, 11.9% of patients treated with Humira and 8.1% of placebo and active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">control &#x2212; treated patients that had negative baseline anti-nuclear antibody titres reported positive titres at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24. Two patients out of 3,441 treated with Humira in all rheumatoid arthritis and psoriatic arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies developed clinical signs suggestive of new-onset lupus-like syndrome. The patients improved </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">following discontinuation of therapy. No patients developed lupus nephritis or central nervous system </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">symptoms.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Hepato-biliary events</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled Phase 3 trials of Humira in patients with rheumatoid arthritis and psoriatic arthritis with a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">control period duration ranging from 4 to 104 weeks, ALT elevations &#x2265; 3 x ULN occurred in 3.7% of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira-treated patients and 1.6% of control-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled Phase 3 trials of Humira in patients with polyarticular juvenile idiopathic arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4 to 17 years and enthesitis-related arthritis who were 6 to 17 years, ALT elevations &#x2265; 3 x ULN occurred </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in 6.1% of Humira-treated patients and 1.3% of control-treated patients. Most ALT elevations occurred </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with concomitant methotrexate use. No ALT elevations &#x2265; 3 x ULN occurred in the Phase 3 trial of Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in patients with polyarticular juvenile idiopathic arthritis who were 2 to &lt; 4 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled Phase 3 trials of Humira in patients with Crohn&#x2019;s disease and ulcerative colitis with a control </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">period ranging from 4 to 52 weeks. ALT elevations &#x2265; 3 x ULN occurred in 0.9% of Humira-treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:436pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients and 0.9% of controlled-treated patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the Phase 3 trial of Humira in patients with paediatric Crohn&#x2019;s disease which evaluated efficacy and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">safety of two body weight adjusted maintenance dose regimens following body weight adjusted induction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">therapy up to 52 weeks of treatment, ALT elevations &#x2265; 3 x ULN occurred in 2.6% (5/192) of patients of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">whom 4 were receiving concomitant immunosuppressants at baseline.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled Phase 3 trials of Humira in patients with plaque psoriasis with a control period duration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ranging from 12 to 24 weeks, ALT elevations &#x2265; 3 x ULN occurred in 1.8% of Humira-treated patients and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.8% of control-treated patients. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No ALT elevations &#x2265; 3 X ULN occurred in the Phase 3 trial of Humira in paediatric patients with plaque </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">psoriasis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled trials of Humira (initial doses of 160 mg at Week 0 and 80 mg at Week 2, followed by 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every week starting at Week 4), in patients with hidradenitis suppurativa with a control period duration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ranging from 12 to 16 weeks, ALT elevations &#x2265; 3 x ULN occurred in 0.3% of Humira-treated patients and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.6% of control-treated patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:677pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In controlled trials of Humira (initial doses of 80 mg at Week 0 followed by 40 mg every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting at Week 1) in adult patients with uveitis up to 80 weeks with a median exposure of 166.5 days and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">105.0 days in Humira-treated and control-treated patients, respectively, ALT elevations &#x2265; 3 x ULN </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurred in 2.4% of Humira-treated patients and 2.4% of control-treated patients. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">237</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the controlled Phase 3 trial of Humira in patients with paediatric ulcerative colitis (N=93) which </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">evaluated efficacy and safety of a maintenance dose of 0.6 mg/kg (maximum of 40 mg) every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N=31) and a maintenance dose of 0.6 mg/kg (maximum of 40 mg) every Week (N=32), following body </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weight adjusted induction dosing of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2 (N=63), or an induction dose of 2.4 mg/kg (maximum of 160 mg) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at Week 0, placebo at Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2 (N=30), ALT elevations &#x2265; </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 X ULN occurred in 1.1% (1/93) of patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Across all indications in clinical trials patients with raised ALT were asymptomatic and in most cases </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">elevations were transient and resolved on continued treatment.  However, there have also been post-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">marketing reports of liver failure as well as less severe liver disorders that may precede liver failure, such </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">as hepatitis including autoimmune hepatitis in patients receiving adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Concurrent treatment with azathioprine/6-mercaptopurine</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult Crohn&#x2019;s disease studies, higher incidences of malignant and serious infection-related adverse </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">events were seen with the combination of Humira and azathioprine/6-mercaptopurine compared with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira alone.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting of suspected adverse reactions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reporting suspected adverse reactions after authorisation of the medicinal product is important.  It allows </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued monitoring of the benefit/risk balance of the medicinal product.  Healthcare professionals are </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">asked to report any suspected adverse reactions via the national reporting system listed in </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000ff">Appendix V.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">4.9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:106pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Overdose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">No dose-limiting toxicity was observed during clinical trials. The highest dose level evaluated has been </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">multiple intravenous doses of 10 mg/kg, which is approximately 15 times the recommended dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACOLOGICAL PROPERTIES</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacodynamic properties</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-&#x3b1;) inhibitors. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:525pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ATC code: L04AB04</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mechanism of action</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab binds specifically to TNF and neutralises the biological function of TNF by blocking its </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interaction with the p55 and p75 cell surface TNF receptors.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:639pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with an IC</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">50</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> of 0.1-0.2 nM). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pharmacodynamic effects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After treatment with Humira, a rapid decrease in levels of acute phase reactants of inflammation </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:702pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and serum cytokines (IL-6) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed, compared to baseline in patients with rheumatoid arthritis. Serum levels of matrix </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">238</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">destruction were also decreased after Humira administration. Patients treated with Humira usually </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced improvement in haematological signs of chronic inflammation.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A rapid decrease in CRP levels was also observed in patients with polyarticular juvenile idiopathic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis, Crohn&#x2019;s disease, ulcerative colitis and hidradenitis suppurativa after treatment with Humira. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with Crohn&#x2019;s disease, a reduction of the number of cells expressing inflammatory markers in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">colon including a significant reduction of expression of TNF&#x3b1; was seen. Endoscopic studies in intestinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mucosa have shown evidence of mucosal healing in adalimumab treated patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical efficacy and safety</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Rheumatoid arthritis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira was evaluated in over 3,000 patients in all rheumatoid arthritis clinical trials. The efficacy and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">safety of Humira were assessed in five randomised, double-blind and well-controlled studies. Some </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients were treated for up to 120 months duration. Injection site pain of Humira 40 mg/0.4 ml was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assessed in two randomised, active control, single-blind, two-period crossover studies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study I evaluated 271 patients with moderately to severely active rheumatoid arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 years old, had failed therapy with at least one disease-modifying, anti rheumatic drug and had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">insufficient efficacy with methotrexate at doses of 12.5 to 25 mg (10 mg if methotrexate-intolerant) every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">week and whose methotrexate dose remained constant at 10 to 25 mg every week. Doses of 20, 40 or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg of Humira or placebo were given every other week for 24 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study II evaluated 544 patients with moderately to severely active rheumatoid arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 years old and had failed therapy with at least one disease-modifying, anti-rheumatic drugs.  Doses of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 or 40 mg of Humira were given by subcutaneous injection every other week with placebo on alternative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks or every week for 26 weeks; placebo was given every week for the same duration.  No other </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">disease-modifying anti-rheumatic drugs were allowed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study III evaluated 619 patients with moderately to severely active rheumatoid arthritis who were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 years old, and who had an ineffective response to methotrexate at doses of 12.5 to 25 mg or have </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">been intolerant to 10 mg of methotrexate every week. There were three groups in this study.  The first </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received placebo injections every week for 52 weeks. The second received 20 mg of Humira every week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for 52 weeks. The third group received 40 mg of Humira every other week with placebo injections on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">alternate weeks. Upon completion of the first 52 weeks, 457 patients enrolled in an open-label extension </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">phase in which 40 mg of Humira/MTX was administered every other week up to 10 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study IV primarily assessed safety in 636 patients with moderately to severely active rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis who were </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 18 years old. Patients were permitted to be either disease-modifying, anti-rheumatic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">drug-na&#xef;ve or to remain on their pre-existing rheumatologic therapy provided that therapy was stable for a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">minimum of 28 days. These therapies include methotrexate, leflunomide, hydroxychloroquine, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">sulfasalazine and/or gold salts. Patients were randomised to 40 mg of Humira or placebo every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for 24 weeks.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA study V evaluated 799 methotrexate-na&#xef;ve, adult patients with moderate to severely active early </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rheumatoid arthritis (mean disease duration less than 9 months). This study evaluated the efficacy of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg every other week/methotrexate combination therapy, Humira 40 mg every other week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and methotrexate monotherapy in reducing the signs and symptoms and rate of progression </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of joint damage in rheumatoid arthritis for 104 weeks. Upon completion of the first 104 weeks, 497 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients enrolled in an open-label extension phase in which 40 mg of Humira was administered every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week up to 10 years.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">239</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA studies VI and VII each evaluated 60 patients with moderately to severely active rheumatoid arthritis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who were &#x2265; 18 years old. Enrolled patients were either current users of Humira 40 mg/0.8 ml and rated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">their average injection site pain as at least 3 cm (on a 0-10 cm VAS) or were biologic-na&#xef;ve subjects who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were starting Humira 40 mg/0.8 ml. Patients were randomised to receive a single dose of Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg/0.8 ml or Humira 40 mg/0.4 ml, followed by a single injection of the opposite treatment at their </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">next dose. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary end point in RA studies I, II and III and the secondary endpoint in RA study IV was the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">percent of patients who achieved an ACR 20 response at Week 24 or 26. The primary endpoint in RA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study V was the percent of patients who achieved an ACR 50 response at Week 52. RA studies III and V </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">had an additional primary endpoint at 52 weeks of retardation of disease progression (as detected by X-ray </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">results). RA study III also had a primary endpoint of changes in quality of life. The primary endpoint in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA studies VI and VII was injection site pain immediately after injection as measured by a 0-10 cm VAS.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">ACR response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The percent of Humira-treated patients achieving ACR 20, 50 and 70 responses was consistent across RA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies I, II and III. The results for the 40 mg every other week dose are summarised in Table 5. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:197pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">ACR Responses in Placebo-Controlled Trials</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:255pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(Percent of Patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:169pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA Study I</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:298pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA Study II</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:428pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">RA Study III</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:144pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:149pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:151pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=60</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:194pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">/ MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:218pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=63</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:287pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=110</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:346pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:350pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=113</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:410pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo/ </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=200</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:460pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">/ MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=207</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:149pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:215pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:287pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">19.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:350pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">63.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:222pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:293pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:356pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">58.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:151pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:215pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:350pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:222pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:293pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:356pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:151pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:215pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:350pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 months</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:155pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:222pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:293pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:356pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NA</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:482pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> RA study I at 24 weeks, RA study II at 26 weeks , and RA study III at 24 and 52 weeks</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 40 mg Humira administered every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:561pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> MTX = methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">**p &lt; 0.01, Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA studies I-IV, all individual components of the ACR response criteria (number of tender and swollen </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">joints, physician and patient assessment of disease activity and pain, disability index (HAQ) scores and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">CRP (mg/dl) values) improved at 24 or 26 weeks compared to placebo. In RA study III, these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvements were maintained throughout 52 weeks. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension for RA study III, most patients who were ACR responders maintained </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:680pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response when followed for up to 10 years. Of 207 patients who were randomised to Humira 40 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week, 114 patients continued on Humira 40 mg every other week for 5 years. Among those, 86 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients (75.4%) had ACR 20 responses; 72 patients (63.2%) had ACR 50 responses; and 41 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(36%) had ACR 70 responses. Of 207 patients, 81 patients continued on Humira 40 mg every other week </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">240</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for 10 years. Among those, 64 patients (79.0%) had ACR 20 responses; 56 patients (69.1%) had ACR 50 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responses; and 43 patients (53.1%) had ACR 70 responses.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study IV, the ACR 20 response of patients treated with Humira plus standard of care was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">statistically significantly better than patients treated with placebo plus standard of care (p &lt; 0.001).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA studies I-IV, Humira-treated patients achieved statistically significant ACR 20 and 50 responses </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared to placebo as early as one to two weeks after initiation of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study V with early rheumatoid arthritis patients who were methotrexate na&#xef;ve, combination therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Humira and methotrexate led to faster and significantly greater ACR responses than methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">monotherapy and Humira monotherapy at Week 52 and responses were sustained at Week 104 (see Table </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:288pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:233pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">ACR Responses in RA Study V</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:258pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(percent of patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:291pt;left:79pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:172pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:170pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n=257</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:232pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:236pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n=274</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:290pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira/MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:308pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n=268</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:371pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">p-value</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:427pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">p-value</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:290pt;left:487pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">p-value</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">c</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 20</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">62.6%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">54.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">72.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:377pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.013</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.043</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">56.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">69.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:377pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.002</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.140</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">61.6%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.317</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">42.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.162</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ACR 70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:466pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">27.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:453pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.656</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:108pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:492pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">104</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:170pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:309pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46.6%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:373pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:430pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:494pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.864</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:505pt;left:80pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">a. p-value is from the pairwise comparison of methotrexate monotherapy and Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:518pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy using the Mann-Whitney U test.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:530pt;left:80pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">b. p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:543pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy using the Mann-Whitney U test</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:80pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">c.   p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:568pt;left:96pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using the Mann-Whitney U test</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension for RA study V, ACR response rates were maintained when followed for up to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 years. Of 542 patients who were randomised to Humira 40 mg every other week, 170 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:619pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued on Humira 40 mg every other week for 10 years. Among those, 154 patients (90.6%) had ACR </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 responses; 127 patients (74.7%) had ACR 50 responses; and 102 patients (60.0%) had ACR 70 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">responses.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 52, 42.9% of patients who received Humira/methotrexate combination therapy achieved clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission (DAS28 (CRP) &lt; 2.6) compared to 20.6% of patients receiving methotrexate monotherapy and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.4% of patients receiving Humira monotherapy. Humira/methotrexate combination therapy was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinically and statistically superior to methotrexate (p &lt; 0.001) and Humira monotherapy (p &lt; 0.001) in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">achieving a low disease state in patients with recently diagnosed moderate to severe rheumatoid arthritis. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">241</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The response for the two monotherapy arms was similar (p = 0.447).  Of 342 subjects originally </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomized to Humira monotherapy or Humira/methotrexate combination therapy who entered the open-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">label extension study, 171 subjects completed 10 years of Humira treatment. Among those, 109 subjects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(63.7%) were reported to be in remission at 10 years.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Radiographic response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study III, where Humira treated patients had a mean duration of rheumatoid arthritis of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 11 years, structural joint damage was assessed radiographically and expressed as change in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">modified Total Sharp Score (TSS) and its components, the erosion score and joint space narrowing score.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira/methotrexate patients demonstrated significantly less radiographic progression than patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receiving methotrexate alone at 6 and 12 months (see Table 7).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension of RA Study III, the reduction in rate of progression of structural damage is </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintained for 8 and 10 years in a subset of patients. At 8 years, 81 of 207 patients originally treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg Humira every other week were evaluated radiographically. Among those, 48 patients showed no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">progression of structural damage defined by a change from baseline in the mTSS of 0.5 or less. At </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 years, 79 of 207 patients originally treated with 40 mg Humira every other week were evaluated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">radiographically. Among those, 40 patients showed no progression of structural damage defined by a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">change from baseline in the mTSS of 0.5 or less.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:274pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 7</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:147pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Radiographic Mean Changes Over 12 Months in RA Study III</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:180pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo/</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:180pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:260pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira/MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:263pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:266pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:352pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo/MTX-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:342pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira/MTX (95% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:360pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:365pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Interval</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:458pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:82pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Sharp Score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.7</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:284pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:357pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.6 (1.4, 3.8) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:456pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:92pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erosion score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:284pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:357pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.6 (0.9, 2.2)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:457pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:434pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">JSN</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span></sup><sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> </span></sup><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:203pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:284pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.1</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:357pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.9 (0.3, 1.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:459pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  0.002</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">95% confidence intervals for the differences in change scores between methotrexate and Humira. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Based on rank analysis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Joint Space Narrowing</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study V, structural joint damage was assessed radiographically and expressed as change in modified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Sharp Score (see Table 8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:281pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:164pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">  Radiographic Mean Changes at Week 52 in RA Study V</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:173pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:171pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=257</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:174pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(95% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:162pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:167pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interval)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:244pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:247pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=274</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:249pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(95%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:237pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:242pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interval)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:305pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira/MTX</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:321pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">n=268</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(95% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:311pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">confidence </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:317pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">interval)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:379pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:428pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:478pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:85pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Sharp </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:158pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.7 (4.2-7.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0 (1.7-4.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.3 (0.5-2.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0020</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:655pt;left:479pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Erosion score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:158pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.7 (2.7-4.7)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.7 (1.0-2.4)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.8 (0.4-1.2)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0082</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:479pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:89pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">JSN score</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:158pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.0 (1.2-2.8)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:234pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1.3 (0.5-2.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:312pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.5 (0-1.0)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.0037</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:694pt;left:484pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.151</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">242</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:56pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p-value is from the pairwise comparison of methotrexate monotherapy and Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy using the Mann-Whitney U test.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:78pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy using the Mann-Whitney U test </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:103pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using the Mann-Whitney U test</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following 52 weeks and 104 weeks of treatment, the percentage of patients without progression (change </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">from baseline in modified Total Sharp Score </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.5) was significantly higher with Humira/methotrexate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">combination therapy (63.8% and 61.2% respectively) compared to methotrexate monotherapy (37.4% and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33.5% respectively, p &lt; 0.001) and Humira monotherapy (50.7%, p &lt; 0.002 and 44.5%, p &lt; 0.001 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the open-label extension of RA study V, the mean change from baseline at Year 10 in the modified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Total Sharp Score was 10.8, 9.2 and 3.9 in patients originally randomized to methotrexate monotherapy, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira monotherapy and Humira/methotrexate combination therapy, respectively. The corresponding </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">proportions of patients with no radiographic progression were 31.3%, 23.7% and 36.7% respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of life and physical function </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Health-related quality of life and physical function were assessed using the disability index of the Health </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Assessment Questionnaire (HAQ) in the four original adequate and well-controlled trials, which was a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">pre-specified primary endpoint at Week 52 in RA study III. All doses/schedules of Humira in all four </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">studies showed statistically significantly greater improvement in the disability index of the HAQ from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">baseline to Month 6 compared to placebo and in RA study III the same was seen at Week 52. Results from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the Short Form Health Survey (SF 36) for all doses/schedules of Humira in all four studies support these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">findings, with statistically significant physical component summary (PCS) scores, as well as statistically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significant pain and vitality domain scores for the 40 mg every other week dose. A statistically significant </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">decrease in fatigue as measured by functional assessment of chronic illness therapy (FACIT) scores was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">seen in all three studies in which it was assessed (RA studies I, III, IV).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study III, most subjects who achieved improvement in physical function and continued treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintained improvement through Week 520 (120 months) of open-label treatment. Improvement in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">quality of life was measured up to Week 156 (36 months) and improvement was maintained through that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">time.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In RA study V, the improvement in the HAQ disability index and the physical component of the SF 36 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">showed greater improvement (p &lt; 0.001) for Humira/methotrexate combination therapy </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">methotrexate monotherapy and Humira monotherapy at Week 52, which was maintained through </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:552pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 104. Among the 250 subjects who completed the open-label extension study, improvements in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">physical function were maintained through 10 years of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Injection site pain</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:615pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For the pooled crossover RA studies VI and VII, a statistically significant difference for injection site pain </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:627pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immediately after dosing was observed between Humira 40 mg/0.8 ml and Humira 40 mg/0.4 ml (mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">VAS of 3.7 cm versus 1.2 cm, scale of 0-10 cm, P &lt; 0.001). This represented an 84% median reduction in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">injection site pain.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Psoriasis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were studied in adult patients with chronic plaque psoriasis (</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 10% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BSA involvement and Psoriasis Area and Severity Index (PASI) </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 12 or </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 10) who were candidates for </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">243</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">systemic therapy or phototherapy in randomised, double-blind studies. 73% of patients enrolled in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Studies I and II had received prior systemic therapy or phototherapy.  The safety and efficacy of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira were also studied in adult patients with moderate to severe chronic plaque psoriasis with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant hand and/or foot psoriasis who were candidates for systemic therapy in a randomised double-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blind study (Psoriasis Study III).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:132pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Study I (REVEAL) evaluated 1,212 patients within three treatment periods.  In period A, patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:144pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received placebo or Humira at an initial dose of 80 mg followed by 40 mg every other week starting one </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">week after the initial dose. After 16 weeks of therapy, patients who achieved at least a PASI 75 response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(PASI score improvement of at least 75% relative to baseline), entered period B and received open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:182pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg Humira every other week. Patients who maintained </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75 response at Week 33 and were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">originally randomised to active therapy in Period A, were re-randomised in period C to receive 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira every other week or placebo for an additional 19 weeks. Across all treatment groups, the mean </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">baseline PASI score was 18.9 and the baseline Physician&#x2019;s Global Assessment (PGA) score ranged from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x201c;moderate&#x201d; (53% of subjects included) to &#x201c;severe&#x201d; (41%) to &#x201c;very severe&#x201d; (6%).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Study II (CHAMPION) compared the efficacy and safety of Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> methotrexate and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:271pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo in 271 patients. Patients received placebo, an initial dose of MTX 7.5 mg and thereafter dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increases up to Week 12, with a maximum dose of 25 mg or an initial dose of 80 mg Humira followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week (starting one week after the initial dose) for 16 weeks. There are no data available </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparing Humira and MTX beyond 16 weeks of therapy. Patients receiving MTX who achieved a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:322pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 50 response at Week 8 and/or 12 did not receive further dose increases. Across all treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">groups, the mean baseline PASI score was 19.7 and the baseline PGA score ranged from &#x201c;mild&#x201d; (&lt;1%) to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x201c;moderate&#x201d; (48%) to &#x201c;severe&#x201d; (46%) to &#x201c;very severe&#x201d; (6%).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients participating in all Phase 2 and Phase 3 psoriasis studies were eligible to enrol into an open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension trial, where Humira was given for at least an additional 108 weeks.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Psoriasis Studies I and II, a primary endpoint was the proportion of patients who achieved a PASI 75 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response from baseline at Week 16 (see Tables 9 and 10).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:288pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 9</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:180pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Ps Study I (REVEAL)  - Efficacy Results at 16 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:303pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:306pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=398</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:307pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:376pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:405pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=814</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    </span></b><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> PASI 75</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:514pt;left:304pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">26 (6.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">578 (70.9)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    PASI 100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 (0.8)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">163 (20.0)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:137pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    PGA: Clear/minimal</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:304pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17 (4.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">506 (62.2)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Percent of patients achieving PASI75 response was calculated as centre-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:567pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adjusted rate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:137pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p &lt; 0.001, Humira vs. Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:605pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 10</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:176pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Ps Study II (CHAMPION) Efficacy Results at 16 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:235pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:240pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=53</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:240pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:315pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MTX</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:313pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=110</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:315pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:643pt;left:377pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:656pt;left:406pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=108</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:669pt;left:408pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">n (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:135pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    </span></b><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> PASI 75</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:233pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 (18.9)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:682pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39 (35.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:681pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">86 (79.6)</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a, b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:135pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    PASI 100</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:238pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 (1.9)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:696pt;left:314pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8 (7.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18 (16.7)</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c, d</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:135pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">    PGA: </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:722pt;left:135pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Clear/minimal</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:236pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6 (11.3)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:308pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33 (30.0)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">79 (73.1)</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a, b</span></sup></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">244</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:53pt;left:135pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p &lt; 0.001 Humira vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:66pt;left:135pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p &lt; 0.001 Humira vs. methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:78pt;left:135pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p &lt; 0.01 Humira vs. placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:91pt;left:135pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p &lt; 0.05 Humira vs. methotrexate</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:121pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Psoriasis Study I, 28% of patients who were PASI 75 responders and were re-randomised to placebo at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 33 compared to 5% continuing on Humira, p &lt; 0.001, experienced &#x201c;loss of adequate response&#x201d;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(PASI score after Week 33 and on or before Week 52 that resulted in a &lt;PASI 50 response relative to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">baseline with a minimum of a 6-point increase in PASI score relative to Week 33). Of the patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">lost adequate response after re-randomisation to placebo who then enrolled into the open-label extension </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">trial, 38% (25/66) and 55% (36/66) regained PASI 75 response after 12 and 24 weeks of re-treatment, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A total of 233 PASI 75 responders at Week 16 and Week 33 received continuous Humira therapy for </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52 weeks in Psoriasis Study I, and continued Humira in the open-label extension trial.  PASI 75 and PGA </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of clear or minimal response rates in these patients were 74.7% and 59.0%, respectively, after an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">additional 108 weeks of open-label therapy (total of 160 weeks). In an analysis in which all patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dropped out of the study for adverse events or lack of efficacy, or who dose-escalated, were considered </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">non-responders, PASI 75 and PGA of clear or minimal response rates in these patients were 69.6% and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">55.7%, respectively, after an additional 108 weeks of open-label therapy (total of 160 weeks).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A total of 347 stable responders participated in a withdrawal and retreatment evaluation in an open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension study. During the withdrawal period, symptoms of psoriasis returned over time with a median </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">time to relapse (decline to PGA &#x201c;moderate&#x201d; or worse) of approximately 5 months. None of these patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:361pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">experienced rebound during the withdrawal period. A total of 76.5% (218/285) of patients who entered the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">retreatment period had a response of PGA &#x201c;clear&#x201d; or &#x201c;minimal&#x201d; after 16 weeks of retreatment, irrespective </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of whether they relapsed during withdrawal (69.1%[123/178] and 88.8% [95/107] for patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">relapsed and who did not relapse during the withdrawal period, respectively).  A similar safety profile was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed during retreatment as before withdrawal.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Significant improvements at Week 16 from baseline compared to placebo (Studies I and II) and MTX </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:450pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(Study II) were demonstrated in the DLQI (Dermatology Life Quality Index). In Study I, improvements in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the physical and mental component summary scores of the SF-36 were also significant compared to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:475pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In an open-label extension study, for patients who dose escalated from 40 mg every other week to 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weekly due to a PASI response below 50%, 26.4% (92/349) and 37.8% (132/349) of patients achieved </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PASI 75 response at Week 12 and 24, respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:551pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Study III (REACH) compared the efficacy and safety of Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo in 72 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with moderate to severe chronic plaque psoriasis and hand and/or foot psoriasis. Patients received an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">initial dose of 80 mg Humira followed by 40 mg every other week (starting one week after the initial dose) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or placebo for 16 weeks. At Week 16, a statistically significantly greater proportion of patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:602pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received Humira achieved PGA of &apos;clear&apos; or &apos;almost clear&apos; for the hands and/or feet compared to patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who received placebo (30.6% versus 4.3%, respectively [P = 0.014]).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Study IV compared efficacy and safety of Humira versus placebo in 217 adult patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">moderate to severe nail psoriasis. Patients received an initial dose of 80 mg Humira followed by 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:665pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">every other week (starting one week after the initial dose) or placebo for 26 weeks followed by open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treatment for an additional 26 weeks. Nail psoriasis assessments included the Modified Nail </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Psoriasis Severity Index (mNAPSI), the Physician&#x2019;s Global Assessment of Fingernail Psoriasis (PGA-F) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and the Nail Psoriasis Severity Index (NAPSI) (see Table 11). Humira demonstrated a treatment benefit in </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">245</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">nail psoriasis patients with different extents of skin involvement (BSA&#x2265;10% (60% of patients) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">BSA&lt;10% and &#x2265;5% (40% of patients)).    </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 11</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:183pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Ps Study IV Efficacy Results at 16, 26 and 52 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Endpoint</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:245pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 16</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:222pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo-Controlled</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:360pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 26</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:337pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo-Controlled</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:473pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Open-label</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:216pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:218pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=108</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:275pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:267pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg eow </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:276pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=109</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:330pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:332pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=108</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:387pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg eow </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:389pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=109</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:146pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:468pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg eow </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:480pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=80</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; mNAPSI 75 (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">26.0</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:341pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:184pt;left:393pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46.6</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:483pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PGA-F clear/minimal and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:211pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265;2-grade improvement (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29.7</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:341pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.9</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:393pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">48.9</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:483pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">61.3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Percent Change in Total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Fingernail NAPSI (%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:224pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-7.8</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:278pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-44.2</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-11.5</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:223pt;left:391pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-56.2</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:481pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">-72.2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:76pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> p&lt;0.001, Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">vs.</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:275pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira treated patients showed statistically significant improvements at Week 26 compared with placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:288pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in the DLQI. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Hidradenitis suppurativa</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in randomised, double-blind, placebo-controlled studies </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and an open-label extension study in adult patients with moderate to severe hidradenitis suppurativa (HS) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:364pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who were intolerant, had a contraindication or an inadequate response to at least a 3-month trial of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:377pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">systemic antibiotic therapy.  The patients in HS-I and HS-II had Hurley Stage II or III disease with at least </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:389pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 abscesses or inflammatory nodules.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study HS-I (PIONEER I) evaluated 307 patients with 2 treatment periods.  In Period A, patients received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:427pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo or Humira at an initial dose of 160 mg at Week 0, 80 mg at Week 2, and 40 mg every week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:440pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting at Week 4 to Week 11.  Concomitant antibiotic use was not allowed during the study.  After </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:452pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 weeks of therapy, patients who had received Humira in Period A were re-randomised in Period B to 1 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:465pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of 3 treatment groups (Humira 40 mg every week, Humira 40 mg every other week, or placebo from Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12 to Week 35).  Patients who had been randomised to placebo in Period A were assigned to receive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 40 mg every week in Period B.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study HS-II (PIONEER II) evaluated 326 patients with 2 treatment periods.  In Period A, patients received </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo or Humira at an initial dose of 160 mg at Week 0 and 80 mg at Week 2 and 40 mg every week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">starting at Week 4 to Week 11.  19.3% of patients had continued baseline oral antibiotic therapy during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:554pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study.  After 12 weeks of therapy, patients who had received Humira in Period A were re-randomised in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Period B to 1 of 3 treatment groups (Humira 40 mg every week, Humira 40 mg every other week, or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:579pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo from Week 12 to Week 35).  Patients who had been randomised to placebo in Period A were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assigned to receive placebo in Period B.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients participating in Studies HS-I and HS-II were eligible to enrol into an open-label extension study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in which Humira 40mg was administered every week. Mean exposure in all adalimumab population was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:642pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">762 days.  Throughout all 3 studies patients used topical antiseptic wash daily.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Clinical Response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:693pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Reduction of inflammatory lesions and prevention of worsening of abscesses and draining fistulas was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">assessed using Hidradenitis Suppurativa Clinical Response (HiSCR; at least a 50% reduction in total </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:718pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">abscess and inflammatory nodule count with no increase in abscess count and no increase in draining </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">246</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">fistula count relative to Baseline).  Reduction in HS-related skin pain was assessed using a Numeric </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Rating Scale in patients who entered the study with an initial baseline score of 3 or greater on a 11 point </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">scale. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 12, a significantly higher proportion of patients treated with Humira versus placebo achieved </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HiSCR.   At Week 12, a significantly higher proportion of patients in Study HS-II experienced a clinically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">relevant decrease in HS-related skin pain (see Table 12).  Patients treated with Humira had significantly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reduced risk of disease flare during the initial 12 weeks of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:173pt;left:174pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 12:  Efficacy Results at 12 Weeks, HS Studies I and II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:269pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HS Study I</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:428pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HS Study II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:233pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:297pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:313pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weekly</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:392pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:457pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:229pt;left:474pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weekly</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hidradenitis Suppurativa </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical Response (HiSCR)</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:233pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 154</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:227pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 (26.0%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:313pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 153</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:303pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">64 (41.8%) </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:395pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=163</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:385pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45 (27.6%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=163</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:460pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">96 (58.9%) </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265;30% Reduction in Skin </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Pain</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:233pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 109</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:227pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">27 (24.8%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:313pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N = 122</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">34 (27.9%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:395pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=111</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:385pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23 (20.7%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=105</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:460pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">48 (45.7%) </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">***</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:306pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">* </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">P</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> &lt; 0.05, ***</span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">P </span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001, Humira versus placebo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">a</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among all randomised patients.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:79pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">b</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients with baseline HS-related skin pain assessment &#x2265; 3, based on Numeric Rating </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:97pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Scale 0 &#x2013; 10; 0 = no skin pain, 10 = skin pain as bad as you can imagine.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment with Humira 40 mg every week significantly reduced the risk of worsening of abscesses and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:385pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">draining fistulas.  Approximately twice the proportion of patients in the placebo group in the first 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:397pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks of Studies HS-I and HS-II, compared with those in the Humira group experienced worsening of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:410pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">abscesses (23.0% vs 11.4%, respectively) and draining fistulas (30.0% vs 13.9%, respectively).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:435pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Greater improvements at Week 12 from baseline compared to placebo were demonstrated in skin-specific </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:448pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">health-related quality of life, as measured by the Dermatology Life Quality Index (DLQI; Studies HS-I </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and HS-II), patient global satisfaction with medication treatment as measured by the Treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:473pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Satisfaction Questionnaire - medication (TSQM; Studies HS-I and HS-II), and physical health as </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">measured by the physical component summary score of the SF-36 (Study HS-I).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:511pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with at least a partial response to Humira 40 mg weekly at Week 12, the HiSCR rate at Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36 was higher in patients who continued weekly Humira than in patients in whom dosing frequency was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:536pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">reduced to every other week, or in whom treatment was withdrawn (see Table 13).</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">247</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:109pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 13:</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:52pt;left:184pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Proportion of Patients</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> </span></b></sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Achieving HiSCR</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b </span></b></sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">at Weeks 24 and 36 After</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:181pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Treatment Reassignment from Weekly Humira at Week 12</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:84pt;left:227pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:220pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(treatment </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:217pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">withdrawal)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:230pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 73</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:310pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:305pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">every other week</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:329pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 70</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:406pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:424pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">weekly</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:425pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 70</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:130pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 24</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:221pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24 (32.9%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36 (51.4%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 (57.1%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:153pt;left:130pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 36</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:153pt;left:221pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22 (30.1%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:153pt;left:320pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28 (40.0%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:153pt;left:415pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">39 (55.7%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:168pt;left:129pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:169pt;left:147pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients with at least a partial response to Humira 40 mg weekly after 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:181pt;left:147pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">weeks of treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:130pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Patients meeting protocol-specified criteria for loss of response or no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:207pt;left:142pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">improvement were required to discontinue from the studies and were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:219pt;left:142pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">counted as nonresponders.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:245pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients who were at least partial responders at Week 12, and who received continuous weekly </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:258pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira therapy, the HiSCR rate at Week 48 was 68.3% and at Week 96 was 65.1%. Longer term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:270pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment with Humira 40 mg weekly for 96 weeks identified no new safety findings.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients whose Humira treatment was withdrawn at Week 12 in Studies HS-I and HS-II, the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:309pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HiSCR rate 12 weeks after re-introduction of Humira 40 mg weekly returned to levels similar to that </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:321pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed before withdrawal (56.0 %).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Crohn&#x2019;s disease</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in over 1500 patients with moderately to severely active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:384pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Crohn&#x2019;s disease (Crohn&#x2019;s Disease Activity Index (CDAI) </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 220 and </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 450) in randomised, double-blind, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo-controlled studies. Concomitant stable doses of aminosalicylates, corticosteroids, and/or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunomodulatory agents were permitted and 80% of patients continued to receive at least one of these </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:423pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">medications. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Induction of clinical remission (defined as CDAI &lt; 150) was evaluated in two studies, CD Study I </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(CLASSIC I) and CD Study II (GAIN). In CD Study I, 299 TNF-antagonist naive patients were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">randomised to one of four treatment groups; placebo at Weeks 0 and 2, 160 mg Humira at Week 0 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:486pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg at Week 2, 80 mg at Week 0 and 40 mg at Week 2, and 40 mg at Week 0 and 20 mg at Week 2. In </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">CD Study II, 325 patients who had lost response or were intolerant to infliximab were randomised to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receive either 160 mg Humira at Week 0 and 80 mg at Week 2 or placebo at Weeks 0 and 2. The primary </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:524pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">non-responders were excluded from the studies and therefore these patients were not further evaluated.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Maintenance of clinical remission was evaluated in CD study III (CHARM).  In CD Study III, 854 patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:562pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received open-label 80 mg at Week 0 and 40 mg at Week 2.  At Week 4 patients were randomised to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:575pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg every other week, 40 mg every week, or placebo with a total study duration of 56 weeks. Patients in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical response (decrease in CDAI &#x2265; 70) at Week 4 were stratified and analysed separately from those </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:600pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">not in clinical response at Week 4.  Corticosteroid taper was permitted after Week 8. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">CD study I and CD study II induction of remission and response rates are presented in Table 14.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">248</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:281pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 14</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:193pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Induction of Clinical Remission and Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:86pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(Percent of Patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:191pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CD Study I: Infliximab Naive </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:115pt;left:191pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patients</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:102pt;left:372pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CD Study II: Infliximab </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:115pt;left:372pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Experienced Patients</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:197pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:203pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=74</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:258pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:255pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">80/40 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:261pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 75</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:318pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:313pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">160/80 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:157pt;left:324pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=76</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:385pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:388pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=166</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:131pt;left:468pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:462pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">160/80 mg</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:471pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=159</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 4</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:192pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:192pt;left:205pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:192pt;left:266pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:325pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:192pt;left:396pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:191pt;left:475pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">21%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response (CR-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">100)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:205pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">24%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:266pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">37%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">49%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">**</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:394pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:208pt;left:473pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38%</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">**</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All p-values are pairwise comparisons of proportions for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:251pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:265pt;left:93pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.01</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:293pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Similar remission rates were observed for the 160/80 mg and 80/40 mg induction regimens by Week 8 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adverse events were more frequently noted in the 160/80 mg group.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In CD Study III, at Week 4, 58% (499/854) of patients were in clinical response and were assessed in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">primary analysis. Of those in clinical response at Week 4, 48% had been previously exposed to other TNF-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:356pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antagonists. Maintenance of remission and response rates are presented in Table 15.  Clinical remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">results remained relatively constant irrespective of previous TNF-antagonist exposure.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Disease-related hospitalisations and surgeries were statistically significantly reduced with adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:406pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared with placebo at Week 56.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:433pt;left:281pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 15</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:186pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maintenance of Clinical Remission and Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:461pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(Percent of Patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:478pt;left:283pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:359pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">40 mg Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:353pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">every other week</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:450pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">40 mg Humira</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:458pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">every week</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 26</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:286pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=170</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:378pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=172</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:468pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=157</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:291pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:523pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">47%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response (CR-100)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:291pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">27%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">52%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in steroid-free remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for &gt;=90 days</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:279pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3% (2/66)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:360pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">19% (11/58)**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:556pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15% (11/74)**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:81pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 56</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:286pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=170</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:378pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=172</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:468pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=157</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:291pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">36%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response (CR-100)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:291pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">17%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:380pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:471pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">48%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:633pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in steroid-free remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for &gt; = 90 days</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:279pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5% (3/66)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:363pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29% (17/58)*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:634pt;left:451pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20% (15/74)**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:662pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.001 for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo pairwise comparisons of proportions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:676pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">** p &lt; 0.02 for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo pairwise comparisons of proportions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:81pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:690pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of those receiving corticosteroids at baseline</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">249</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients who were not in response at Week 4, 43% of Humira maintenance patients responded by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 12 compared to 30% of placebo maintenance patients. These results suggest that some patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">have not responded by Week 4 benefit from continued maintenance therapy through Week 12.  Therapy </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">continued beyond 12 weeks did not result in significantly more responses (see section 4.2).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">117/276 patients from CD study I and 272/777 patients from CD studies II and III were followed through </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at least 3 years of open-label adalimumab therapy.  88 and 189 patients, respectively, continued to be in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">clinical remission.  Clinical response (CR-100) was maintained in 102 and 233 patients, respectively.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of life</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In CD Study I and CD Study II, statistically significant improvement in the disease-specific inflammatory </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">bowel disease questionnaire (IBDQ) total score was achieved at Week 4 in patients randomised to Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80/40 mg and 160/80 mg compared to placebo and was seen at Weeks 26 and 56 in CD Study III as well </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">among the adalimumab treatment groups compared to the placebo group.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Ulcerative colitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of multiple doses of Humira were assessed in adult patients with moderately to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">severely active ulcerative colitis (Mayo score 6 to 12 with endoscopy subscore of 2 to 3) in randomised, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">double-blind, placebo-controlled studies. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study UC-I, 390 TNF-antagonist na&#xef;ve patients were randomised to receive either placebo at Weeks 0 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and 2, 160 mg Humira at Week 0 followed by 80 mg at Week 2, or 80 mg Humira at Week 0 followed by </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg at Week 2.  After Week 2, patients in both adalimumab arms received 40 mg eow.  Clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission (defined as Mayo score &#x2264; 2 with no subscore &gt; 1) was assessed at Week 8. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study UC-II, 248 patients received 160 mg of Humira at Week 0, 80 mg at Week 2 and 40 mg eow </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">thereafter, and 246 patients received placebo. Clinical results were assessed for induction of remission at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 8 and for maintenance of remission at Week 52. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients induced with 160/80 mg Humira achieved clinical remission versus placebo at Week 8 in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">statistically significantly greater percentages in study UC-I (18% vs. 9% respectively, p=0.031) and study </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">UC-II (17% vs. 9% respectively, p=0.019). In study UC-II, among those treated with Humira who were in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:487pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission at Week 8, 21/41 (51%) were in remission at Week 52.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Results from the overall UC-II study population are shown in Table 16.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 16</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:169pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Response, Remission and Mucosal Healing in Study UC-II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:258pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">(Percent of Patients)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:318pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Placebo</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:385pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira 40 mg </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:590pt;left:410pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:320pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=246</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:617pt;left:404pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=248</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Clinical Response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:631pt;left:403pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   30%</span><span style="font-family:TimesNewRoman,serif;font-size:10.08pt">*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Clinical Remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:402pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   17%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Mucosal Healing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:402pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   25%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:673pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Steroid-free remission for &#x2265; 90 days</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6% </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:317pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N=140)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:398pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">     13% *</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:686pt;left:400pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(N=150)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:713pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 8 and 52</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">250</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Sustained Response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:400pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   24%**</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Sustained Remission </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:329pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:72pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   8%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:86pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Sustained Mucosal Healing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:86pt;left:326pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">11%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:86pt;left:404pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  19%*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission is Mayo score &#x2264; 2 with no subscore &gt; 1;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:114pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response is decrease from baseline in Mayo score &#x2265; 3 points and &#x2265; 30% plus a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:127pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">decrease in the rectal bleeding subscore [RBS] &#x2265; 1 or an absolute RBS of 0 or 1;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:139pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:7.92pt">*</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.05 for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">vs.</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo pairwise comparison of proportions </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:154pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:10.08pt">**</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">p &lt; 0.001 for Humira </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">vs.</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> placebo pairwise comparison of proportions</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:166pt;left:72pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Of those receiving corticosteroids at baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:193pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of those patients who had a response at Week 8, 47% were in response, 29% were in remission, 41% had </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:206pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mucosal healing, and 20% were in steroid-free remission for &#x2265; 90 days at Week 52.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:231pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Approximately 40% of patients in study UC-II had failed prior anti-TNF treatment with infliximab. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:244pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">efficacy of adalimumab in those patients was reduced compared to that in anti-TNF na&#xef;ve patients.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:257pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Among patients who had failed prior anti-TNF treatment, Week 52 remission was achieved by 3% on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:269pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">placebo and 10% on adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients from studies UC-I and UC-II had the option to roll over into an open-label long-term extension </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study (UC III). Following 3 years of adalimumab therapy, 75% (301/402) continued to be in clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission per partial Mayo score. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:345pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Hospitalisation rates</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:370pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">During 52 weeks of studies UC-I and UC-II, lower rates of all-cause hospitalisations and UC-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:383pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">hospitalisations were observed for the adalimumab-treated arm compared to the placebo arm. The number </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:396pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of all cause hospitalisations in the adalimumab treatment group was 0.18 per patient year </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">vs</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">. 0.26 per </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patient year in the placebo group and the corresponding figures for UC-related hospitalisations were 0.12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:421pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">per patient year </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">vs.</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 0.22 per patient year.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of life</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:472pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In study UC-II, treatment with adalimumab resulted in improvements in the Inflammatory Bowel Disease </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:484pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Questionnaire (IBDQ) score.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:510pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Uveitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:535pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira were assessed in adult patients with non-infectious intermediate, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:547pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">posterior, and panuveitis, excluding patients with isolated anterior uveitis, in two randomised, double-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:560pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">masked, placebo-controlled studies (UV I and II). Patients received placebo or Humira at an initial dose of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:573pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg followed by 40 mg every other week starting one week after the initial dose. Concomitant stable </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:585pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">doses of one non-biologic immunosuppressant were permitted. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:611pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV I evaluated 217 patients with active uveitis despite treatment with corticosteroids (oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">prednisone at a dose of 10 to 60 mg/day). All patients received a 2-week standardised dose of prednisone </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60 mg/day at study entry followed by a mandatory taper schedule, with complete corticosteroid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:648pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">discontinuation by Week 15. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:674pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV II evaluated 226 patients with inactive uveitis requiring chronic corticosteroid treatment (oral </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:687pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">prednisone 10 to 35 mg/day) at baseline to control their disease. Patients subsequently underwent a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:699pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mandatory taper schedule, with complete corticosteroid discontinuation by Week 19. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">251</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary efficacy endpoint in both studies was &#xb4;time to treatment failure&#xb4;. Treatment failure was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">defined by a multi-component outcome based on inflammatory chorioretinal and/or inflammatory retinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">vascular lesions, anterior chamber (AC) cell grade, vitreous haze (VH) grade and best corrected visual </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">acuity (BCVA). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who completed Studies UV I and UV II were eligible to enroll in an uncontrolled long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension study with an originally planned duration of 78 weeks. Patients were allowed to continue on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study medication beyond Week 78 until they had access to Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Clinical Response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients treated with Humira versus patients receiving placebo (See Table 17). Both studies demonstrated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">an early and sustained effect of Humira on the treatment failure rate versus placebo (see Figure 1). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 17</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:180pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Time to Treatment Failure in Studies UV I and UV II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:75pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Analysis</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:103pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Treatment</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:189pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:225pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Failure</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:225pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:283pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Median Time to </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:283pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Failure (months)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:378pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">HR</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:414pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">CI 95% </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:296pt;left:414pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">for HR</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:472pt"><b><i><span style="font-family:TimesNewRoman,BoldItalic,serif;font-size:11.04pt">P</span></i></b><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt"> Value</span></b><span style="font-family:TimesNewRoman,serif;font-size:6.96pt"> </span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:311pt;left:75pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Time to Treatment Failure At or After Week 6 in Study UV I  </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:324pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Primary analysis (ITT)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">107</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">84 (78.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3.0</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:336pt;left:472pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">110</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60 (54.5)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.50</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.36, 0.70</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:349pt;left:472pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 0.001</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:75pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Time to Treatment Failure At or After Week 2 in Study UV II</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Primary analysis (ITT)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">111</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">61 (55.0)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8.3</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:472pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">--</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:103pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:189pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">115</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:225pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">45 (39.1)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:283pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NE</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:378pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.57</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:414pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.39, 0.84</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:472pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.004</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note:  Treatment failure at or after Week 6 (Study UV I), or at or after Week 2 (Study UV II), was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">counted as event. Drop outs due to reasons other than treatment failure were censored at the time of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dropping out.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:454pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">a</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">HR of adalimumab vs placebo from proportional hazards regression with treatment as factor.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:467pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">b</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2-sided </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">P</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> value from log rank test.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:479pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:5.04pt">c</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:476pt;left:88pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">NE = not estimable. Fewer than half of at-risk subjects had an event. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">252</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:71pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Figure 1: Kaplan-Meier Curves Summarizing Time to Treatment Failure on or after Week 6 (Study </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:233pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">UV I) or Week 2 (Study UV II)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:101pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TREATMENT FAILURE RATE (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:285pt;left:270pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TIME (MONTHS)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:100pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV I                        Treatment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:445pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TREATMENT FAILURE RATE (%)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:506pt;left:270pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TIME (MONTHS)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:100pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV II                       Treatment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:519pt;left:445pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note: P# = Placebo (Number of Events/Number at Risk); A# = HUMIRA (Number of</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:75pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Events/Number at Risk).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:581pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In Study UV I statistically significant differences in favour of adalimumab versus placebo were observed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:594pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for each component of treatment failure.  In Study UV II, statistically significant differences were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:607pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">observed for visual acuity only, but the other components were numerically in favour of adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:632pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of the 424 subjects included in the uncontrolled long-term extension of Studies UV I and UV II, 60</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:645pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subjects were regarded ineligible (e.g. due to deviations or due to complications secondary to diabetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:657pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">retinopathy, due to cataract surgery or vitrectomy) and were excluded from the primary analysis of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:670pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">efficacy. Of the 364 remaining patients, 269 evaluable patients (74%) reached 78 weeks of open-label </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab treatment. Based on the observed data approach, 216 (80.3%) were in quiescence (no active </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:695pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">inflammatory lesions, AC cell grade &#x2264; 0.5+, VH grade &#x2264; 0.5+) with a concomitant steroid dose &#x2264; 7.5 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:708pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">per day, and 178 (66.2%) were in steroid-free quiescence. BCVA was either improved or maintained (&lt; 5 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:720pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">letters deterioration) in 88.6% of the eyes at week 78. Data beyond Week 78 were generally consistent </span></p>
<img style="position:absolute;top:111pt;left:100pt;width:432pt;height:174pt" src="data:image/png;base64,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">
<img style="position:absolute;top:297pt;left:291pt;width:31pt;height:14pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABcAAAAICAAAAAA3wTsyAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAR0lEQVR4nGP8z4AVMGKK/2eEioMZaDIg8X8fGRmAFEyWiYEPov75
fqAwTPQ/8z8+n39MEPP//2dk/A+V+8+EsBfDBmzuAQMAmYsaASeQxO8AAAAASUVO
RK5CYII=">
<img style="position:absolute;top:297pt;left:401pt;width:43pt;height:14pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABcAAAAGCAIAAACnwpLJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAqElEQVR4nGP8//8/A8WAEW4KkMHIyEhQA1ZlCFN+//79/ft3Pj6+
9+/f83Bzs7Cyfvz4kZ+fHygI1MTKxvblyxcBAQEgyczExMnF9eHDByAX3ZSbN2/e
vn3b29t7+fLlFhYWQON27twZHR29Y8cOUVFROTm5vXv3RkREbNu2DWi0qanJ+vUb
/Hx9gcahmAJxLUgIycHI7v/37x8TExNWKUaSQhctUOBcAGVhWfUkQWeYAAAAAElF
TkSuQmCC">
<img style="position:absolute;top:334pt;left:100pt;width:432pt;height:171pt" src="data:image/png;base64,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">
<img style="position:absolute;top:519pt;left:291pt;width:31pt;height:14pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABcAAAAICAAAAAA3wTsyAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAR0lEQVR4nGP8z4AVMGKK/2eEioMZaDIg8X8fGRmAFEyWiYEPov75
fqAwTPQ/8z8+n39MEPP//2dk/A+V+8+EsBfDBmzuAQMAmYsaASeQxO8AAAAASUVO
RK5CYII=">
<img style="position:absolute;top:519pt;left:401pt;width:43pt;height:14pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAABcAAAAGCAIAAACnwpLJAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAqElEQVR4nGP8//8/A8WAEW4KkMHIyEhQA1ZlCFN+//79/ft3Pj6+
9+/f83Bzs7Cyfvz4kZ+fHygI1MTKxvblyxcBAQEgyczExMnF9eHDByAX3ZSbN2/e
vn3b29t7+fLlFhYWQON27twZHR29Y8cOUVFROTm5vXv3RkREbNu2DWi0qanJ+vUb
/Hx9gcahmAJxLUgIycHI7v/37x8TExNWKUaSQhctUOBcAGVhWfUkQWeYAAAAAElF
TkSuQmCC">
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">253</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with these results but the number of enrolled subjects declined after this time. Overall, among the patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who discontinued the study, 18% discontinued due to adverse events, and 8% due to insufficient response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to adalimumab treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of Life</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patient reported outcomes regarding vision-related functioning were measured in both clinical studies, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">using the NEI VFQ-25. Humira was numerically favoured for the majority of subscores with statistically </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significant mean differences for general vision, ocular pain, near vision, mental health, and total score in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Study UV I, and for general vision and mental health in Study UV II. Vision related effects were not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">numerically in favour of Humira for colour vision in Study UVI and for colour vision, peripheral vision </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and near vision in Study UV II.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Immunogenicity</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Formation of anti-adalimumab antibodies is associated with increased clearance and reduced efficacy of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab. There is no apparent correlation between the presence of anti-adalimumab antibodies and the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">occurrence of adverse events.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients in rheumatoid arthritis studies I, II and III were tested at multiple time points for anti-adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibodies during the 6 to 12 month period. In the pivotal trials, anti-adalimumab antibodies were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">identified in 5.5% (58/1053) of patients treated with adalimumab, compared to 0.5% (2/370) on placebo.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients not given concomitant methotrexate, the incidence was 12.4%, compared to 0.6% when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab was used as add-on to methotrexate.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with Crohn&#x2019;s disease, anti-adalimumab antibodies were identified in 7/269 subjects (2.6%) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in 19/487 subjects (3.9%) with ulcerative colitis.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:411pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with psoriasis, anti-adalimumab antibodies were identified in 77/920 subjects (8.4%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treated with adalimumab monotherapy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult plaque psoriasis patients on long term adalimumab monotherapy who participated in a withdrawal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:462pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and retreatment study, the rate of antibodies to adalimumab after retreatment (11 of 482 subjects, 2.3%) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was similar to the rate observed prior to withdrawal (11 of 590 subjects, 1.9%).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:499pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with moderate to severe hidradenitis suppurativa, anti-adalimumab antibodies were identified </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:512pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in 10/99 subjects (10.1%) treated with adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with moderately to severely active paediatric Crohn&#x2019;s disease, the rate of anti-adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:550pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibody development in patients receiving adalimumab was 3.3%. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:576pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with non-infectious uveitis, anti-adalimumab antibodies were identified in 4.8% (12/249) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:588pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of patients treated with adalimumab.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:613pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with moderately to severely active paediatric ulcerative colitis, the rate of anti-adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:626pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibody development in patients receiving adalimumab was 3%.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:651pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Because immunogenicity analyses are product-specific, comparison of antibody rates with those from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:664pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">other products is not appropriate.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:689pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:714pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Adolescent hidradenitis suppurativa</span></i></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">254</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">There are no clinical trials with Humira in adolescent patients with HS.  Efficacy of adalimumab for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment of adolescent patients with HS is predicted based on the demonstrated efficacy and exposure-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response relationship in adult HS patients and the likelihood that the disease course, pathophysiology, and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">drug effects are substantially similar to that of adults at the same exposure levels. Safety of the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">recommended adalimumab dose in the adolescent HS population is based on cross-indication safety </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">profile of adalimumab in both adults and paediatric patients at similar or more frequent doses (see section </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5.2).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric Crohn&#x2019;s disease </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira was assessed in a multicentre, randomised, double-blind clinical trial designed to evaluate the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">efficacy and safety of induction and maintenance treatment with doses dependent on body weight (&lt; 40 kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">or &#x2265; 40 kg) in 192 paediatric subjects between the ages of 6 and 17 (inclusive) years, with moderate to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">severe Crohn&#xb4;s disease (CD) defined as Paediatric Crohn&apos;s Disease Activity Index (PCDAI) score &gt; 30.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Subjects had to have failed conventional therapy (including a corticosteroid and/or an immunomodulator) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">for CD. Subjects may also have previously lost response or been intolerant to infliximab. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">All subjects received open-label induction therapy at a dose based on their Baseline body weight: 160 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at Week 0 and 80 mg at Week 2 for subjects &#x2265; 40 kg, and 80 mg and 40 mg, respectively, for subjects </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 4, subjects were randomised 1:1 based on their body weight at the time to either the Low Dose or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Standard Dose maintenance regimens as shown in Table 18.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 18</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:386pt;left:254pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maintenance regimen</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:226pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Patient </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:226pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Weight</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:275pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Low dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:399pt;left:336pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Standard </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:412pt;left:336pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&lt; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:275pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10 mg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:226pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">&#x2265; 40 kg</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:275pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:438pt;left:336pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg eow</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Efficacy results</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary endpoint of the study was clinical remission at Week 26, defined as PCDAI score </span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0a3;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> 10.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Baseline) rates are presented in Table 19. Rates of discontinuation of corticosteroids or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">immunomodulators are presented in Table 20.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">255</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:58pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 19</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:257pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Paediatric CD Study</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:210pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PCDAI Clinical Remission and Response</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:261pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Standard Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:264pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">40/20 mg eow </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:280pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 93</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:352pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Low Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:344pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">20/10 mg eow </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:360pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N = 95</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:424pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">P value</span></b><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">*</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:135pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 26</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:361pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:148pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.075</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   Clinical response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">59.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:361pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">48.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:162pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.073</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:175pt;left:140pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 52</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">33.3%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:361pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.2%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:189pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.100</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">   Clinical response</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:281pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">41.9%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:361pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28.4%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:202pt;left:432pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.038</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:215pt;left:140pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">* p value for Standard Dose </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Low Dose comparison.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:242pt;left:285pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 20</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:255pt;left:257pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Paediatric CD Study</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:267pt;left:116pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Discontinuation of Corticosteroids or Immunomodulators and Fistula Remission</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:303pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Standard Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:306pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">40/20 mg eow </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:281pt;left:396pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Low Dose</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:294pt;left:388pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">20/10 mg eow </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:279pt;left:469pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">P value</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">1</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:95pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Discontinued corticosteroids</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:324pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N= 33</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:307pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=38</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 26</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">84.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">65.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:320pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.066</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">69.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">60.5%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:334pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.420</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:346pt;left:95pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Discontinuation of Immunomodulators</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">2</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:325pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=60</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:347pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=57</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">30.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">29.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.983</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:372pt;left:95pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Fistula remission</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">3</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:325pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=15</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:407pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">N=21</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 26</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">46.7%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">38.1%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.608</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 52</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:323pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40.0%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:405pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">23.8%</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:476pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0.303</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">1</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  p value for Standard Dose </span><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">versus</span></i><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Low Dose comparison.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">2</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">  Immunosuppressant therapy could only be discontinued at or after Week 26 at the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">investigator&apos;s discretion if the subject met the clinical response criterion </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:447pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">3</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> defined as a closure of all fistulas that were draining at Baseline for at least 2 consecutive</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:95pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">post-Baseline visits</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:490pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Statistically significant increases (improvement) from Baseline to Week 26 and 52 in Body Mass Index </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and height velocity were observed for both treatment groups.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Statistically and clinically significant improvements from Baseline were also observed in both treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">groups for quality of life parameters (including IMPACT III).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:566pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">One hundred patients (n=100) from the Paediatric CD Study continued in an open-label long-term </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">extension study.  After 5 years of adalimumab therapy, 74.0% (37/50) of the 50 patients remaining in the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">study continued to be in clinical remission, and 92.0% (46/50) of patients continued to be in clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:604pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response per PCDAI.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric ulcerative colitis</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira was assessed in a multicenter, randomized, double-blind, trial in 93 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:667pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients from 5 to 17 years of age with moderate to severe ulcerative colitis (Mayo score 6 to 12 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with endoscopy subscore of 2 to 3 points, confirmed by centrally read endoscopy) who had an inadequate </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">response or intolerance to conventional therapy. Approximately 16% of patients in the study had failed </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:705pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">prior anti-TNF treatment. Patients who received corticosteroids at enrollment were allowed to taper their </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">corticosteroid therapy after Week 4.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">256</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the induction period of the study, 77 patients were randomized 3:2 to receive double-blind treatment </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with Humira at an induction dose of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2; or an induction dose of 2.4 mg/kg (maximum of 160 mg) at Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">0, placebo at Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2. Both groups received 0.6 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(maximum of 40 mg) at Week 4 and Week 6. Following an amendment to the study design, the remaining </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16 patients who enrolled in the induction period received open-label treatment with Humira at the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">induction dose of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 mg/kg (maximum of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg) at Week 2.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 8, 62 patients who demonstrated clinical response per Partial Mayo Score (PMS; defined as a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">decrease in PMS &#x2265; 2 points and &#x2265; 30% from Baseline) were randomized equally to receive double-blind </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:209pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintenance treatment with Humira at a dose of 0.6 mg/kg (maximum of 40 mg) every week (ew), or a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maintenance dose of 0.6 mg/kg (maximum of 40 mg) every other week (eow). Prior to an amendment to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">the study design, 12 additional patients who demonstrated clinical response per PMS were randomized to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:246pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receive placebo but were not included in the confirmatory analysis of efficacy.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:272pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Disease flare was defined as an increase in PMS of at least 3 points (for patients with PMS of 0 to 2 at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 8), at least 2 points (for patients with PMS of 3 to 4 at Week 8), or at least 1 point (for patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PMS of 5 to 6 at Week 8).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:323pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Patients who met criteria for disease flare at or after Week 12 were randomized to receive a re-induction </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose of 2.4 mg/kg (maximum of 160 mg) or a dose of 0.6 mg/kg (maximum of 40 mg) and continued to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:348pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">receive their respective maintenance dose regimen afterwards.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Efficacy Results</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:408pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The co-primary endpoints of the study were clinical remission per PMS (defined as PMS &#x2264; 2 and no </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:420pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">individual subscore &gt; 1) at Week 8, and clinical remission per FMS (Full Mayo Score) (defined as a Mayo </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:433pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Score &#x2264; 2 and no individual subscore &gt; 1) at Week 52 in patients who achieved clinical response per PMS </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:446pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at Week 8.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:471pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission rates per PMS at Week 8 for patients in each of the Humira double-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:484pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">blind induction groups are presented in Table 21.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:521pt;left:189pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 21: Clinical Remission per PMS at 8 Weeks </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:257pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:210pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 160 mg at Week </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:228pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">0 / Placebo at Week 1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:266pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=30</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:549pt;left:404pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b, c</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:563pt;left:360pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 160 mg at Week </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:578pt;left:396pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">0 and Week 1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:592pt;left:417pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=47</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:247pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">13/30 (43.3%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:397pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">28/47 (59.6%)</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">257</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 2.4 mg/kg (maximum of 160 mg) at Week 0, placebo at Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:71pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:104pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Not including open-label Induction dose of Humira 2.4 mg/kg (maximum of 160 mg) at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 0 and Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note 1: Both induction groups received 0.6 mg/kg (maximum of 40 mg) at Week 4 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:147pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note 2: Patients with missing values at Week 8 were considered as not having met the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:107pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endpoint</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:199pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">At Week 52, clinical remission per FMS in Week 8 responders, clinical response per FMS (defined as a </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:212pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">decrease in Mayo Score &#x2265; 3 points and &#x2265; 30% from Baseline) in Week 8 responders, mucosal healing </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:224pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(defined as Mayo endoscopy subscore &#x2264; 1) in Week 8 responders, clinical remission per FMS in Week 8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:237pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remitters, and the proportion of subjects in corticosteroid-free remission per FMS in Week 8 responders </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:250pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">were assessed in patients who received Humira at the double-blind maximum 40 mg eow (0.6 mg/kg) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:262pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">maximum 40 mg ew (0.6 mg/kg) maintenance doses (Table 22).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:213pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 22: Efficacy Results at 52 Weeks</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:279pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:245pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 40 mg eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:290pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:329pt;left:405pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:343pt;left:373pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 40 mg ew</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:355pt;left:416pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:374pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission in Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:387pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8 PMS responders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:272pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9/31 (29.0%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:380pt;left:397pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14/31 (45.2%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:403pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response in Week 8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:416pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PMS responders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:269pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">19/31 (61.3%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:409pt;left:395pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">21/31 (67.7%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:430pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mucosal healing in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:443pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 8 PMS responders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:269pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">12/31 (38.7%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:437pt;left:395pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16/31 (51.6%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:456pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission in Week </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:469pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">8 PMS remitters</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:272pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">9/21 (42.9%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:395pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10/22 (45.5%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:482pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Corticosteroid-free </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission in Week 8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:507pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">PMS responders</span><sup><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:272pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">4/13 (30.8%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:495pt;left:398pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">5/16 (31.3%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:520pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 0.6 mg/kg (maximum of 40 mg) every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:533pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 0.6 mg/kg (maximum of 40 mg) every week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:542pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> In patients receiving concomitant corticosteroids at baseline</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:559pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note: Patients with missing values at Week 52 or who were randomized to receive </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:572pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">re-induction or maintenance treatment were considered non-responders for Week 52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:117pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endpoints</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:610pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Additional exploratory efficacy endpoints included clinical response per the Paediatric Ulcerative Colitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:623pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Activity Index (PUCAI) (defined as a decrease in PUCAI &#x2265; 20 points from Baseline) and clinical </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:636pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">remission per PUCAI (defined as PUCAI &lt; 10) at Week 8 and Week 52 (Table 23). </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">258</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:181pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Table 23: Exploratory Endpoints Results per PUCAI</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:70pt;left:361pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 8</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:298pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">a</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:264pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 160 mg at </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:253pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 0 / Placebo at Week 1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=30</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:428pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">b,c</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:97pt;left:397pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 160 mg at </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:109pt;left:404pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 0 and Week 1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:122pt;left:439pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=47</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission per PUCAI</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:286pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">10/30 (33.3%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:137pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">22/47 (46.8%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:151pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response per PUCAI</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:151pt;left:286pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15/30 (50.0%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:151pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">32/47 (68.1%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:164pt;left:359pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Week 52</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:297pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">d</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:262pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 40 mg eow</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:306pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:176pt;left:431pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Humira</span></b><sup><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:6.96pt">e</span></b></sup></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:190pt;left:397pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Maximum of 40 mg ew</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:203pt;left:439pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">N=31</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical remission per PUCAI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:228pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in Week 8 PMS responders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:286pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">14/31 (45.2%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:216pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18/31 (58.1%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinical response per PUCAI </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:254pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">in Week 8 PMS responders</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:286pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">18/31 (58.1%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:241pt;left:420pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">16/31 (51.6%)</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:263pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">a</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Humira 2.4 mg/kg (maximum of 160 mg) at Week 0, placebo at Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:280pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:292pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">b </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:305pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:313pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">c</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Not including open-label Induction dose of Humira 2.4 mg/kg (maximum of 160 mg) at </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:330pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 0 and Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:339pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">d</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Humira 0.6 mg/kg (maximum of 40 mg) every other week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:351pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">e</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt"> Humira 0.6 mg/kg (maximum of 40 mg) every week</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:368pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note 1: Both induction groups received 0.6 mg/kg (maximum of 40 mg) at Week 4 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:381pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 6</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:394pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note 2: Patients with missing values at Week 8 were considered as not having met the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:407pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endpoints</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:419pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note 3: Patients with missing values at Week 52 or who were randomized to receive re-</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:432pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">induction or maintenance treatment were considered non-responders for Week 52 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:444pt;left:104pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">endpoints</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:470pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Of the Humira-treated patients who received re-induction treatment during the maintenance period, 2/6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:483pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(33%) achieved clinical response per FMS at Week 52.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:508pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Quality of life</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:534pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinically meaningful improvements from Baseline were observed in IMPACT III and the caregiver Work </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:546pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Productivity and Activity Impairment (WPAI) scores for the groups treated with Humira.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:571pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Clinically meaningful increases (improvement) from Baseline in height velocity were observed for the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:584pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">groups treated with adalimumab, and clinically meaningful increases (improvement) from Baseline in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:597pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Body Mass Index were observed for subjects on the high maintenance dose of maximum 40 mg (0.6 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:609pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">mg/kg) ew. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:635pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Paediatric Uveitis </span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:660pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The safety and efficacy of Humira was assessed in a randomized, double-masked, controlled study of 90 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:672pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">paediatric patients from 2 to &lt; 18 years of age with active JIA-associated noninfectious anterior uveitis </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:685pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">who were refractory to at least 12 weeks of methotrexate treatment.  Patients received either placebo or </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:698pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">20 mg adalimumab (if &lt; 30 kg) or 40 mg adalimumab (if &#x2265; 30 kg) every other week in combination with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:711pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">their baseline dose of methotrexate. </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">259</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">The primary endpoint was &#x2018;time to treatment failure&#x2019;. The criteria determining treatment failure were </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">worsening or sustained non-improvement in ocular inflammation, partial improvement with development </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">of sustained ocular co-morbidities or worsening of ocular co-morbidities, non-permitted use of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant medications, and suspension of treatment for an extended period of time.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><i><span style="font-family:TimesNewRoman,Italic,serif;font-size:11.04pt">Clinical Response</span></i></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:159pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab significantly delayed the time to treatment failure, as compared to placebo (See Figure 2, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">P &lt; 0.0001 from log rank test).The median time to treatment failure was 24.1 weeks for subjects treated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with placebo, whereas the median time to treatment failure was not estimable for subjects treated with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:197pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab because less than one-half of these subjects experienced treatment failure.  Adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">significantly decreased the risk of treatment failure by 75% relative to placebo, as shown by the hazard </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:222pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">ratio (HR = 0.25 [95% CI:  0.12, 0.49]).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Figure 2: Kaplan-Meier Curves Summarizing Time to Treatment Failure in the Paediatric Uveitis </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:264pt;left:292pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Study</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:365pt;left:76pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PROBABILITY OF FAILING TREATMENT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:274pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">TIME (WEEKS)</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Treatment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:333pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Placebo</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:445pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:679pt;left:99pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Note: P = Placebo (Number at Risk); H = HUMIRA (Number at Risk).</span></p>
<img style="position:absolute;top:295pt;left:99pt;width:432pt;height:358pt" src="data:image/png;base64,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">
<img style="position:absolute;top:670pt;left:280pt;width:36pt;height:9pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAEwAAAAMCAAAAADtpASbAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAA2UlEQVR4nI2SPQ7CMAyF7bCzICYkJBaExMghkLgA5+BKcJDeoBsS
B+jUzoiJmDglrknSEk/x36f36iKBC0KYjN++y/pCvIb2DyfDGJKIhiXKCHlADVmT
7XlYwiJANZ28HACE4RNRxm+9EaMV49u1OHwynxtlk9qGxPd6yfT7S0SaAyOeD2vC
0GLD3Ka1gQbbeVCGUFeiA497t4XXTgp0QQfrboR29kb2tzvxUlV7knE1OK8wKJuO
6HBiLvKYg+X/oNxMmo0oUweBHDe9f6HN/sLK2KjwIlhpfAC8cXABl3kQ5QAAAABJ
RU5ErkJggg==">
<img style="position:absolute;top:671pt;left:401pt;width:35pt;height:6pt" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAFIAAAANCAIAAAC1lq7uAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAApElEQVR4nOWVzRGEIAxGE4qgDVy7oirdZmjAtQa6AHXirBHRkz9j
eAcmcsqbLwaMMQLAeCIiLySxlULSFk9ivmjLy/mvtvXCZMjFwI2o5jerIQ8hKKUe
6PEy9nZWfshFhk8FeaUrjT699333u7+5c5lnG0FrbYzJpw0sZOfct2nvb/QKRqmq
/lhr+e9dygPGmeTL0d7d5HD41r2U7HouKG1OodoDHdh+5CqIp8EAAAAASUVORK5CYII=">
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">260</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Pharmacokinetic properties</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Absorption and distribution</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">After subcutaneous administration of a single 40 mg dose, absorption and distribution of adalimumab was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">slow, with peak serum concentrations being reached about 5 days after administration. The average </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">absolute bioavailability of adalimumab estimated from three studies following a single 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">subcutaneous dose was 64%. After single intravenous doses ranging from 0.25 to 10 mg/kg, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concentrations were dose proportional. After doses of 0.5 mg/kg (~40 mg), clearances ranged from 11 to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">15 ml/hour, the distribution volume (V</span><span style="font-family:TimesNewRoman,serif;font-size:6.96pt">ss</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">) ranged from 5 to 6 litres and the mean terminal phase half-life </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was approximately two weeks. Adalimumab concentrations in the synovial fluid from several rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis patients ranged from 31-96% of those in serum.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:221pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following subcutaneous administration of 40 mg of adalimumab every other week in adult rheumatoid </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:233pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis (RA) patients the mean steady-state trough concentrations were approximately 5</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml (without </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:247pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">concomitant methotrexate) and 8 to 9</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml (with concomitant methotrexate), respectively.  The serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab trough levels at steady-state increased roughly proportionally with dose following 20, 40 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:274pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">80 mg subcutaneous dosing every other week and every week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:298pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with psoriasis, the mean steady-state trough concentration was 5</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml during </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab 40 mg every other week monotherapy treatment.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with hidradenitis suppurativa, a dose of 160 mg Humira on Week 0 followed by 80 mg on </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 2 achieved serum adalimumab trough concentrations of approximately 7 to 8 &#x3bc;g/ml at Week 2 and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:363pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 4.  The mean steady-state trough concentration at Week 12 through Week 36 were approximately 8 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to 10 &#x3bc;g/ml during adalimumab 40 mg every week treatment.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab exposure in adolescent HS patients was predicted using population pharmacokinetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">modelling and simulation based on cross-indication pharmacokinetics in other paediatric patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:426pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn&#x2019;s disease, and enthesitis-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis). The recommended adolescent HS dosing schedule is 40 mg every other week. Since exposure to </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab can be affected by body size, adolescents with higher body weight and inadequate response </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">may benefit from receiving the recommended adult dose of 40 mg every week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with Crohn&#x2019;s disease, the loading dose of 80 mg Humira on Week 0 followed by 40 mg Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:502pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">on Week 2 achieves serum adalimumab trough concentrations of approximately 5.5</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:516pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">induction period. A loading dose of 160 mg Humira on Week 0 followed by 80 mg Humira on Week 2 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:528pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">achieves serum adalimumab trough concentrations of approximately 12</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml during the induction period. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:541pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mean steady-state trough levels of approximately 7</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml were observed in Crohn&#x2019;s disease patients who </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:555pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">received a maintenance dose of 40 mg Humira every other week.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:580pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In paediatric patients with moderate to severe CD, the open-label adalimumab induction dose was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:593pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">160/80 mg or 80/40 mg at Weeks 0 and 2, respectively, dependent on a body weight cut-off of 40 kg.  At </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:606pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Week 4, patients were randomised 1:1 to either the Standard Dose (40/20 mg eow) or Low Dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:618pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(20/10 mg eow) maintenance treatment groups based on their body weight. The mean (&#xb1;SD) serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:630pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab trough concentrations achieved at Week 4 were 15.7 &#xb1; 6.6</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml for patients &#x2265; 40 kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:644pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(160/80 mg) and 10.6 &#xb1; 6.1</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml for patients &lt; 40 kg (80/40 mg). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:671pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">For patients who stayed on their randomised therapy, the mean (&#xb1;SD) adalimumab trough concentrations </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:683pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">at Week 52 were 9.5 &#xb1; 5.6</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml for the Standard Dose group and 3.5 &#xb1; 2.2</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml for the Low Dose </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:697pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">group.  The mean trough concentrations were maintained in patients who continued to receive adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:709pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">treatment eow for 52 weeks. For patients who dose escalated from eow to weekly regimen, the mean </span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">261</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:57pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(&#xb1;SD) serum concentrations of adalimumab at Week 52 were 15.3 &#xb1; 11.4 &#x3bc;g/ml (40/20 mg, weekly) and </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">6.7 &#xb1; 3.5 &#x3bc;g/ml (20/10 mg, weekly).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In patients with ulcerative colitis, a loading dose of 160 mg Humira on Week 0 followed by 80 mg Humira </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:107pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">on Week 2 achieves serum adalimumab trough concentrations of approximately 12</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml during the </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:120pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">induction period.  Mean steady-state trough levels of approximately 8</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml were observed in ulcerative </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">colitis patients who received a maintenance dose of 40 mg Humira every other week. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Following the subcutaneous administration of body weight-based dosing of 0.6 mg/kg (maximum of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:172pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">40 mg) every other week to paediatric patients with ulcerative colitis, the mean trough steady-state serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab concentration was 5.01&#xb1;3.28 &#xb5;g/ml at Week 52. For patients who received 0.6 mg/kg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(maximum of 40 mg) every week, the mean (&#xb1;SD) trough steady-state serum adalimumab concentration </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:210pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was 15.7&#xb1;5.60 &#x3bc;g/ml at Week 52.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:236pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In adult patients with uveitis, a loading dose of 80 mg adalimumab on Week 0 followed by 40 mg </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:248pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adalimumab every other week starting at Week 1, resulted in mean steady-state concentrations of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:260pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">approximately 8 to 10</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt"> &#xf06d;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">g/ml.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:287pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Adalimumab exposure in paediatric uveitis patients was predicted using population pharmacokinetic </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:300pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">modelling and simulation based on cross-indication pharmacokinetics in other paediatric patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:312pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn&#x2019;s disease, and enthesitis-related </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:325pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">arthritis). No clinical exposure data are available on the use of a loading dose in children &lt; 6 years. The </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:338pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">predicted exposures indicate that in the absence of methotrexate, a loading dose may lead to an initial </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:350pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">increase in systemic exposure.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:376pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Population pharmacokinetic and pharmacokinetic/pharmacodynamic modelling and simulation predicted </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:388pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">comparable adalimumab exposure and efficacy in patients treated with 80 mg every other week when </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:401pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">compared with 40 mg every week (including adult patients with RA, HS, UC, CD or Ps, patients with </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:414pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">adolescent HS, and paediatric patients &#x2265; 40 kg with CD and UC).</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:439pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Exposure-response relationship in paediatric population</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:451pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">On the basis of clinical trial data in patients with JIA (pJIA and ERA), an exposure-response relationship </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:464pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">was established between plasma concentrations and PedACR 50 response. The apparent adalimumab </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:477pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">plasma concentration that produces half the maximum probability of PedACR 50 response (EC50) was </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:489pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 &#x3bc;g/ml (95% CI: 1-6 &#x3bc;g/ml). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:515pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Exposure-response relationships between adalimumab concentration and efficacy in paediatric patients </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:527pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">with severe chronic plaque psoriasis were established for PASI 75 and PGA clear or minimal, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:540pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively. PASI 75 and PGA clear or minimal increased with increasing adalimumab concentrations, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:553pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">both with a similar apparent EC50 of approximately 4.5 &#x3bc;g/ml (95% CI 0.4-47.6 and 1.9-10.5, </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:565pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">respectively).  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:591pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Elimination</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:616pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Population pharmacokinetic analyses with data from over 1,300 RA patients revealed a trend toward </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:629pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">higher apparent clearance of adalimumab with increasing body weight. After adjustment for weight </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:641pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">differences, gender and age appeared to have a minimal effect on adalimumab clearance.  The serum </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:654pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">levels of free adalimumab (not bound to anti-adalimumab antibodies, AAA) were observed to be lower in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:666pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">patients with measurable AAA.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:692pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Hepatic or renal impairment</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:717pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira has not been studied in patients with hepatic or renal impairment.</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">262</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">5.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Preclinical safety data </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Non-clinical data reveal no special hazard for humans based on studies of single dose toxicity, repeated </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:108pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">dose toxicity, and genotoxicity.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:133pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">An embryo-foetal developmental toxicity/perinatal developmental study has been performed in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:145pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">cynomolgus monkeys at 0, 30 and 100 mg/kg (9-17 monkeys/group) and has revealed no evidence of harm </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:158pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">to the foetuses due to adalimumab. Neither carcinogenicity studies, nor a standard assessment of fertility </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:171pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:183pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">antibody with limited cross-reactivity to rodent TNF and to the development of neutralising antibodies in </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:196pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">rodents. </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:234pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">PHARMACEUTICAL PARTICULARS</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.1</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:259pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">List of excipients </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:284pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Mannitol</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:297pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Polysorbate 80</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:310pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Water for injections</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.2</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:335pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Incompatibilities </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:360pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:373pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">products.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.3</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:398pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Shelf life </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:424pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">2 years</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.4</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:449pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for storage </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:474pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Store in a refrigerator (2</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C &#x2013; 8</span><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b0;</span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">C). Do not freeze. Keep the pre-filled syringe or pre-filled pen in its outer </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">carton in order to protect from light.  </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:513pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">A single Humira pre-filled syringe or pre-filled pen may be stored at temperatures up to a maximum of </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:526pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">25&#xb0;C for a period of up to 14 days. The syringe or pen must be protected from light, and discarded if not </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:538pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">used within the 14-day period.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.5</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Nature and contents of container</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:589pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 80 mg solution for injection in pre-filled syringe</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:601pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 80 mg solution for injection in single-use pre-filled syringe (type I glass) with a plunger stopper </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:614pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">(bromobutyl rubber) and a needle with a needle shield (thermoplastic elastomer). </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:640pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Packs of:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:652pt;left:70pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:653pt;left:98pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 pre-filled syringe (0.8 ml sterile solution) with 1 alcohol pad in a blister.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:678pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 80 mg solution for injection in pre-filled pen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:691pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 80 mg solution for injection in single-use pre-filled pen for patient use containing a pre-filled </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:703pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">syringe. The syringe inside the pen is made from type 1 glass with a plunger stopper (bromobutyl rubber) </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:716pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">and a needle with a needle shield (thermoplastic elastomer).</span></p>
</div>
<div id="page0" style="position:relative;width:612pt;height:792pt;background-color:white">
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:747pt;left:296pt"><span style="font-family:Arial,sans-serif;font-size:7.92pt">263</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:69pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Packs of:</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:82pt;left:88pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:83pt;left:106pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">1 pre-filled pen (0.8 ml sterile solution), with 2 alcohol pads in a blister.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:95pt;left:88pt"><span style="font-family:Symbol,sans-serif;font-size:11.04pt">&#xf0b7;</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:96pt;left:106pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">3 pre-filled pens (0.8 ml sterile solution), with 4 alcohol pads in a blister.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:134pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Not all presentations or pack sizes may be marketed.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">6.6</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:160pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">Special precautions for disposal</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:185pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Any unused medicinal product or waste material should be disposed of in accordance with local </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:198pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">requirements.</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">7.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:235pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION HOLDER </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:261pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">AbbVie Deutschland GmbH &amp; Co. KG</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:273pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Knollstrasse</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:286pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">67061 Ludwigshafen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:299pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Germany</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">8.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:337pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">MARKETING AUTHORISATION NUMBERS </span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:362pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 80 mg solution for injection in pre-filled syringe</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:375pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/020</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:400pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Humira 80 mg solution for injection in pre-filled pen</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:413pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/021</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:425pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">EU/1/03/256/027</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">9.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:463pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:488pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of first authorisation: 08 September 2003</span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:501pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Date of latest renewal: 08 September 2008 </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:70pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">10.</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:539pt;left:98pt"><b><span style="font-family:TimesNewRoman,Bold,serif;font-size:11.04pt">DATE OF REVISION OF THE TEXT</span></b></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:564pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Detailed information on this medicinal product is available on the website of the European Medicines </span></p>
<p style="position:absolute;white-space:pre;margin:0;padding:0;top:577pt;left:70pt"><span style="font-family:TimesNewRoman,serif;font-size:11.04pt">Agency </span><span style="font-family:TimesNewRoman,serif;font-size:11.04pt;color:#0000ff">http://www.ema.europa.eu</span></p>
</div>


























































































































































































































</body>
</html> 

